<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23829369</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4286</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>13</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Current pharmaceutical design</Title><ISOAbbreviation>Curr Pharm Des</ISOAbbreviation></Journal><ArticleTitle>Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies.</ArticleTitle><Pagination><StartPage>2114</StartPage><EndPage>2125</EndPage><MedlinePgn>2114-25</MedlinePgn></Pagination><Abstract><AbstractText>Smoking cannabis produces a diverse range of effects, including impairments in learning and memory. These effects are exerted through action on the endocannabinoid system, which suggests involvement of this system in human cognition. Learning and memory deficits are core symptoms of psychiatric and neurological disorders such as schizophrenia and Alzheimer's disease, and may also be related to endocannabinoid dysfunction in these disorders. However, before new research can focus on potential treatments that work by manipulating the endocannabinoid system, it needs to be elucidated how this system is involved in symptoms of psychiatric disorders. Here we review neuroimaging studies that investigated acute and non-acute effects of cannabis on human learning and memory function, both in adults and in adolescents. Overall, results of these studies show that cannabis use is associated with a pattern of increased activity and a higher level of deactivation in different memory-related areas. This could reflect either increased neural effort ('neurophysiological inefficiency') or a change in strategy to maintain good task performance. However, the interpretation of these findings is significantly hampered by large differences between study populations in cannabis use in terms of frequency, age of onset, and time that subjects were abstinent from cannabis. Future neuroimaging studies should take these limitations into account, and should focus on the potential of cannabinoid compounds for treatment of cognitive symptoms in psychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bossong</LastName><ForeName>Matthijs G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Jager</LastName><ForeName>Gerry</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bhattacharyya</LastName><ForeName>Sagnik</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Department of Psychosis Studies (PO67), King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom. matthijs.bossong@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0501775</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>NIHR-CS-011-001</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J012149/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Pharm Des</MedlineTA><NlmUniqueID>9602487</NlmUniqueID><ISSNLinking>1381-6128</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002188" MajorTopicYN="N">Cannabis</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23829369</ArticleId><ArticleId IdType="doi">10.2174/13816128113199990436</ArticleId><ArticleId IdType="pii">CPD-EPUB-06-05-07-2013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29213845</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1980-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Dementia &amp; neuropsychologia</Title><ISOAbbreviation>Dement Neuropsychol</ISOAbbreviation></Journal><ArticleTitle>Neurobiology of neuropsychiatric symptoms in Alzheimer's disease: A critical review with a focus on neuroimaging.</ArticleTitle><Pagination><StartPage>236</StartPage><EndPage>243</EndPage><MedlinePgn>236-243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1980-57642013DN70300002</ELocationID><Abstract><AbstractText>The objective of this critical review of the literature was to reveal the neural circuits involved in the occurrence of neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) patients through the association of these symptoms with neuroimaging findings. The search for articles was performed on PUBMED from January 2000 to May 2013, using the key words: Dementia AND BPSD; Dementia AND Neuropsychiatric Symptoms; and Dementia AND Psychosis, Delusions, Hallucinations, Agitation, Depression, Anxiety, Apathy, Euphoria, Disinhibition, Irritability, Aberrant Motor Behavior, Sleep or Eating Disorders. Forty-six articles were reviewed and important contributions, especially regarding the psychopathological concepts discussed, were also considered even if not included in this time period. The available evidence suggests the three most relevant neurobiological models for neuropsychiatric symptoms in Alzheimer's disease are the frontal-subcortical circuits, the cortico-cortical networks, and the monoaminergic system. We discussed the association of the individual symptoms or syndromes with these models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tascone</LastName><ForeName>Lyssandra Dos Santos</ForeName><Initials>LDS</Initials><AffiliationInfo><Affiliation>Old Age Research Group, Institute of Psychiatry, University of S&#xe3;o Paulo, S&#xe3;o Paulo SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottino</LastName><ForeName>C&#xe1;ssio Machado de Campos</ForeName><Initials>CMC</Initials><AffiliationInfo><Affiliation>Old Age Research Group, Institute of Psychiatry, University of S&#xe3;o Paulo, S&#xe3;o Paulo SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Dement Neuropsychol</MedlineTA><NlmUniqueID>101506587</NlmUniqueID><ISSNLinking>1980-5764</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="por"><AbstractText>O objetivo dessa revis&#xe3;o cr&#xed;tica da literatura &#xe9; investigar os circuitos neurais envolvidos na ocorr&#xea;ncia dos sintomas neuropsiqui&#xe1;tricos nos pacientes com doen&#xe7;a de Alzheimer atrav&#xe9;s da associa&#xe7;&#xe3;o destes sintomas com achados de neuroimagem. A procura dos artigos foi feita no PUBMED de Janeiro de 2000 a Maio de 2013, usando as palavraschave: Dem&#xea;ncia E BPSD; Dem&#xea;ncia E Sintomas Neuropsiqui&#xe1;tricos; e Dem&#xea;ncia E Psicose, Del&#xed;rios, Alucina&#xe7;&#xf5;es, Agita&#xe7;&#xe3;o, Depress&#xe3;o, Anxiedade, Apatia, Euforia, Desinibi&#xe7;&#xe3;o, Irritabilidade, Comportamento Motor Aberrante, Dist&#xfa;rbios do Sono ou Apetite. Quarenta e seis artigos foram revisados e contribui&#xe7;&#xf5;es importantes, especialmente considerando os conceitos psicopatol&#xf3;gicos discutidos, foram tamb&#xe9;m discutidos, mesmo se n&#xe3;o inclu&#xed;dos neste periodo de tempo. As evid&#xea;ncias dispon&#xed;veis sugerem que os tr&#xea;s modelos neurobiol&#xf3;gicos mais relevantes para os sintomas neuropsiqui&#xe1;tricos na doen&#xe7;a de Alzheimer s&#xe3;o os circuitos frontal-subcorticais, as redes cortico-corticais, e o sistema monoamin&#xe9;rgico. N&#xf3;s discutimos a associa&#xe7;&#xe3;o dos sintomas individuais ou s&#xed;ndromes com esses modelos.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">BPSD</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">neuroimaging</Keyword><Keyword MajorTopicYN="N">neuropsychiatric symptoms</Keyword></KeywordList><CoiStatement>Disclosure: The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29213845</ArticleId><ArticleId IdType="pmc">PMC5619193</ArticleId><ArticleId IdType="doi">10.1590/S1980-57642013DN70300002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McIlroy S, Craig D. Neurobiology and Genetics of Behavioural Syndromes of Alzheimer's disease. Curr Alzheimer Res. 2004;1:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15975078</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinosaki K, Nishikawa T, Takeda M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin Neurosci. 2000;54:111&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145458</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Baldinetti F, Buccione I, et al. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. J Neurol. 2004;251:688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruen PB, McGeown WJ, Sanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's Disease. Brain. 2008;131:2455&#x2013;2463.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669506</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova MF, Starkstein SE, Jellinger KA. Clinicopathologic correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011;122:117&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">21455688</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Jack CR, Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology. 2000;54:581&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680786</ArticleId></ArticleIdList></Reference><Reference><Citation>Horinek D, Petrovicky P, Hort J, et al. Amygdalar volume and psychiatric symptoms in Alzheimer's disease: an MRI analysis. Acta Neurol Scand. 2006;113:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16367898</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlow YA, Wells WM, Ellison JM, Sung YH, Renshaw PF, Harper DG. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25:780&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975914</ArticleId><ArticleId IdType="pubmed">19946864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinno H, Inagaki T, Miyaoka T, et al. A decrease in N-acetylaspartate and an increase in the anterior cingulated gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. J Neurol Sci. 2007;206:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">17540407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M. Behavioral neuroanatomy: large-scale networks, association cortex, frontal syndromes, the limbic system, and hemispheric specializations. New York: Oxford University Press; 2000. Principles of behavioral neurology; pp. 1&#x2013;120.</Citation></Reference><Reference><Citation>Ismail Z, Nguyen M-Q, Fischer CE, Schweizer TA, Mulsant BH, Mamo D. Neurobiology of Delusions in Alzheimer's Disease. Curr Psychiatry Rep. 2011;13:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">21404128</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry. 1990;157:72&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatsuka M, Meguro K, Tsuboi H, Nakamura K, Akanuma K, Yamaguchi S. Content of delusional thoughts in Alzheimer's disease and assessment of content-specific brain dysfunctions with BEHAVE-AD-FW and SPECT. Int Psychogeriatr. 2013;25:939&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">23433495</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves SJ, Goulda RL, Powell JF, Howard RJ. Origins of delusions in Alzheimer's disease. Neurosci Biobehav Rev. 2012;36:2274&#x2013;2287.</Citation><ArticleIdList><ArticleId IdType="pubmed">22910677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2000;69:167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737034</ArticleId><ArticleId IdType="pubmed">10896687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Meguro K, Hashimoto R, et al. Confabulations in episodic memory are associated with delusions in Alzheimer's disease. J Geriatr Psychiatry Neurol. 2007;20:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341769</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaniyappan L, Balain V, Liddle PF. The neuroanatomy of psychotic diathesis: A meta-analytic review. J Psychiatr Res. 2012;46:1249&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">22790253</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaniyappan L, Liddle PF. Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry Neurosci. 2012;37:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244495</ArticleId><ArticleId IdType="pubmed">21693094</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaniyappan L, Mallikarjun P, Joseph V, Liddle PF. Appreciating symptoms and deficits in schizophrenia: Right posterior insula and poor insight. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">21182887</ArticleId></ArticleIdList></Reference><Reference><Citation>Northoff G, Heinzel A, de Greck M, Bermpohl F. Self-referential processing in our brain. A meta-analysis of imaging studies on the self. NeuroImage. 2006;31:440&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">16466680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail Z, Nguyen M-Q, Fischer CE, Schweizer TA, Mulsant BH. Neuroimaging of delusions in Alzheimer's disease. Psychiatry Res: Neuroimaging. 2012;202:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22703622</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra L, Perri R, Cercignani M, et al. Are the Behavioral Symptoms of Alzheimer's Disease Directly Associated with Neurodegeneration? J Alzeimers Dis. 2010;21:627&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">20555138</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead D, Tunnard C, Hurt C, et al. Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's disease. Int Psychogeriatr. 2012;24:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">21740613</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwood NJ, Howard RJ, Bentall RP, Murray RM. Cognitive neuropsychiatric models of persecutory delusions. Am J Psychiatry. 2001;158:527&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282685</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx M, Rosenthal A. A description of agitation in a nursing home. J Gerontol. 1989;44:M77&#x2013;M84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto T, Lanct&#xf4;t L, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia Alzheimer's type. Ageing Res Rev. 2011;10:404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">21292041</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane SD, Kjome KL, Moeller FG. Neuropsychiatry of Aggression. Neurol Clin. 2011;29:49&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053027</ArticleId><ArticleId IdType="pubmed">21172570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and Anterior Cingulate Cortex Neurofibrillary Tangle Burden Is Associated with Agitation in Alzheimer Disease. Ann Neurol. 2001;49:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging. 2000;21:845&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Ishii K, et al. Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology. 1998;50:380&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484357</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. Neuropsychiatry Clin Neurosci. 1998;10:314&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">9706539</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2522333</ArticleId><ArticleId IdType="pubmed">18704495</ArticleId></ArticleIdList></Reference><Reference><Citation>Naismith SL, Norrie LM, Mowszowski L, Hickie IB. The neurobiology of depression in later-life: Clinical, neuropsychological, neuroimaging and pathophysiological features. Prog Neurobiol. 2012;98:99&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609700</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigs M, Grafman J. The functional neuroanatomy of depression: Distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res. 2009;201:239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680780</ArticleId><ArticleId IdType="pubmed">19428640</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreescu C, Butters MA, Begley A, et al. Gray Matter Changes in Late Life Depression - a Structural MRI Analysis. Neuropsychopharmacology. 2008;33:2566&#x2013;2572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872084</ArticleId><ArticleId IdType="pubmed">18075490</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Tol MJ, van der Wee NJA, van den Heuvel OA, et al. Regional Brain Volume in Depression and anxiety disorders. Arch Gen Psychiatry. 2010;67:1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">20921116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprengelmeyer R, Steele D, Mwangi D, Kumar P. The insular cortex and the neuroanatomy of major depression. J Affect Disord. 2011;133:120&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">21531027</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, Byrum CE, McQuoid DR, et al. Hippocampal Volume in Geriatric Depression. Biol Psychiatry. 2000;48:301&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">10960161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballmaier M, Narr KL, Toga AW, et al. Hippocampal Morphology and Distinguishing Late-Onset From Early-Onset Elderly Depression. Am J Psychiatry. 2008;165:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834288</ArticleId><ArticleId IdType="pubmed">17986679</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Yu SC, McQuoid DR, et al. Reduction of dorsolateral prefrontal cortex gray matter in late-life depression. Psychiatry Res. 2011;193:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3105213</ArticleId><ArticleId IdType="pubmed">21596532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballmaier M, Sowell ER, Thompson PM, et al. Mapping Brain Size and Cortical Gray Matter Changes in Elderly Depression. Biol Psychiatry. 2004;55:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HK, Jung WS, Ahn KJ, et al. Regional cortical thickness and subcortical volume changes are associated with cognitive impairments in the drug-naive patients with late-onset depression. Neuropsychopharmacology. 2012;37:838&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3260976</ArticleId><ArticleId IdType="pubmed">22048467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Zivkovic S, Smith G, et al. Psychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2001;13:56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto H, Monserratt L, Nguyen P, et al. Anxiety and regional cortical glucose metabolism in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2006;18:521&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135378</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter V, Buxton W, Fairbanks LA, et al. Frequency and Characteristics of Anxiety among patients with Alzheimer's disease and disorders related. J Neuropsychiatry Clin Neurosci. 2003;15:180&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">12724459</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkstein SE, Jorge R, Petracca G, Robinson R. The Construct of Generalized Anxiety Disorder in Alzheimer Disease. Am J Geriatr Psychiatry. 2007;15:42&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">17194814</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hn S, Schubert F, Gallinat J. Structural correlates of trait anxiety: Reduced thickness in medial orbitofrontal cortex accompanied by volume increase in nucleus accumbens. J Affect Disord. 2011;134:315&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">21705088</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">2403472</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Akopyan GG, Partiali N, et al. Structural Correlates of Apathy in Alzheimer's Disease. Dement Geriatr Cogn Disord. 2007;24:91&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570907</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy R, Dubois B. Apathy and the Functional Anatomy of the Prefrontal Cortex--Basal Ganglia Circuits. Cereb Cortex. 2006;16:916&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207933</ArticleId></ArticleIdList></Reference><Reference><Citation>Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ. The integration of negative affect, pain and cognitive control in the cingulate cortex. Nat Rev Neurosci. 2011;12:154&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044650</ArticleId><ArticleId IdType="pubmed">21331082</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es HC, Levy R, Teixeira AL, Beato RG, Caramelli P. Neurobiology of apathy in Alzheimer's disease. Arq Neuropsiquiatr. 2008;66:436&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">18641892</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain. 2005;128:2612&#x2013;2625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820861</ArticleId><ArticleId IdType="pubmed">16195246</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res. 2002;53:647&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Moskvina V, et al. Four Components Describe Behavioral Symptoms in 1, 120 Individuals with Late-Onset Alzheimer's Disease. J Am Geriatr Soc. 2006;54:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970641</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FRJ, Boziki M, et al. Neuropsychiatric syndromes in dementia Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JME, Steinberg M, et al. Neuropsychiatric disturbances in Alzheimer's disease clusters into three groups: the cache county study. Int J Geriatr Psych. 2001;16:1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter ML, Vogt B, Frisch S, et al. Dissociating behavioral disorders in early dementia-An FDG-PET study. Psychiatry Res. 2011;194:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">22044532</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata T, Shinagawa S, Ochiai Y, et al. Relationship of frontal lobe dysfunction and aberrant motor behaviors in patients with Alzheimer's disease. Int Psychogeriatr. 2010;22:463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">20003629</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert PH, Verhey FRJ, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20:490&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310680</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Kozauer N, Rabins PV. Psychiatric manifestations of neurologic disease: where are we headed? Dialogues Clin Neurosci. 2007;9:111&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687521</ArticleId><ArticleId IdType="pubmed">17726911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Brown J, Holland A J, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;73:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738075</ArticleId><ArticleId IdType="pubmed">12235302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton EC, Parkinson JA, Holland AJ, Arana FS, Roberts AC, Owen AM. Neural contributions to the motivational control of appetite in humans. Eur J Neurosci. 2004;20:1411&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pubmed">15341613</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KL, Greenwood CE. Weight Loss and Nutritional Considerations in Alzheimer Disease. J Nutr Elder. 2008;27:381&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">19042581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23800465</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><PubDate><Year>2013</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2013.06.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(13)00121-8</ELocationID><Abstract><AbstractText>Administration of NMDA receptor antagonists, such as ketamine and MK-801, may induce psychotic-like behaviors in preclinical models of schizophrenia. Ketamine has also been observed to exacerbate psychotic symptoms in schizophrenia patients. However, memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease and proposed for antipsychotic augmentation, may challenge this view. To date, the molecular mechanisms by which these NMDA receptor antagonists cause different neurochemical, behavioral, and clinical effects are still a matter of debate. Here, we investigated by molecular imaging whether these agents could differently modulate gene expression and topographical distribution of glutamatergic postsynaptic density (PSD) proteins. We focused on Homer1a/Homer1b/PSD-95 signaling network, which may be implicated in glutamate-dependent synaptic plasticity, as well as in psychosis pathophysiology and treatment. Ketamine (25 and 50mg/kg) and MK-801 (0.8mg/kg) significantly induced the transcripts of immediate-early genes (Arc, c-fos, and Homer1a) in cortical regions compared to vehicle, whereas they reduced Homer1b and PSD-95 expression in cortical and striatal regions. Differently, memantine (5mg/kg) did not increase Homer1a signal compared to vehicle, whereas it induced c-fos in the somatosensory and in the medial agranular cortices. Moreover, memantine did not affect Homer1b and PSD-95 expression. When compared to ketamine and MK-801, memantine significantly increased the expression of c-fos, Homer1b and PSD-95. Overall, ketamine and MK-801 prominently increased Homer1a/Homer1b expression ratio, whereas memantine elicited the opposite effect. These data may support the view that ketamine, MK-801 and memantine exert divergent effects on PSD transcripts, which may contribute to their partially different behavioral and clinical effects.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Bartolomeis</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, University School of Medicine "Federico II", Naples, Italy. Electronic address: adebarto@unina.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarappa</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Buonaguro</LastName><ForeName>Elisabetta F</ForeName><Initials>EF</Initials></Author><Author ValidYN="Y"><LastName>Marmo</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Eramo</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tomasetti</LastName><ForeName>Carmine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Iasevoli</LastName><ForeName>Felice</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501444">DLG4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606614">HOMER1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072233">Homer Scaffolding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606624">Homer1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6LR8C1B66Q</RegistryNumber><NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072233" MajorTopicYN="N">Homer Scaffolding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="N">Ketamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACC</Keyword><Keyword MajorTopicYN="N">ANOVA</Keyword><Keyword MajorTopicYN="N">Antipsychotics</Keyword><Keyword MajorTopicYN="N">Arc</Keyword><Keyword MajorTopicYN="N">BDNF</Keyword><Keyword MajorTopicYN="N">DEPC</Keyword><Keyword MajorTopicYN="N">Dopamine</Keyword><Keyword MajorTopicYN="N">EDTA</Keyword><Keyword MajorTopicYN="N">Glutamate</Keyword><Keyword MajorTopicYN="N">HSP70</Keyword><Keyword MajorTopicYN="N">Homer1</Keyword><Keyword MajorTopicYN="N">IC</Keyword><Keyword MajorTopicYN="N">MAC</Keyword><Keyword MajorTopicYN="N">MC</Keyword><Keyword MajorTopicYN="N">N-methyl-d-aspartate</Keyword><Keyword MajorTopicYN="N">NMDA</Keyword><Keyword MajorTopicYN="N">PBS</Keyword><Keyword MajorTopicYN="N">PSD</Keyword><Keyword MajorTopicYN="N">PSD-95</Keyword><Keyword MajorTopicYN="N">ROIs</Keyword><Keyword MajorTopicYN="N">S.E.M</Keyword><Keyword MajorTopicYN="N">SS</Keyword><Keyword MajorTopicYN="N">SSC</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword><Keyword MajorTopicYN="N">TdT</Keyword><Keyword MajorTopicYN="N">activity-related cytoplasmic protein</Keyword><Keyword MajorTopicYN="N">anterior cingulate cortex</Keyword><Keyword MajorTopicYN="N">brain-derived neurotrophic factor</Keyword><Keyword MajorTopicYN="N">core</Keyword><Keyword MajorTopicYN="N">core of the nucleus accumbens</Keyword><Keyword MajorTopicYN="N">diethylpyrocarbonate</Keyword><Keyword MajorTopicYN="N">dlCP</Keyword><Keyword MajorTopicYN="N">dmCP</Keyword><Keyword MajorTopicYN="N">dorsolateral caudate putamen</Keyword><Keyword MajorTopicYN="N">dorsomedial caudate putamen</Keyword><Keyword MajorTopicYN="N">ethylene-diamine-tetra-acetic acid</Keyword><Keyword MajorTopicYN="N">heat shock protein of 70kDa</Keyword><Keyword MajorTopicYN="N">insular cortex</Keyword><Keyword MajorTopicYN="N">mGluR5</Keyword><Keyword MajorTopicYN="N">medial agranular cortex</Keyword><Keyword MajorTopicYN="N">motor cortex</Keyword><Keyword MajorTopicYN="N">one-way analysis of variance</Keyword><Keyword MajorTopicYN="N">phosphate buffered saline</Keyword><Keyword MajorTopicYN="N">postsynaptic density</Keyword><Keyword MajorTopicYN="N">regions of interest</Keyword><Keyword MajorTopicYN="N">saline sodium citrate solution</Keyword><Keyword MajorTopicYN="N">shell</Keyword><Keyword MajorTopicYN="N">shell of the nucleus accumbens</Keyword><Keyword MajorTopicYN="N">somatosensory cortex</Keyword><Keyword MajorTopicYN="N">standard error mean</Keyword><Keyword MajorTopicYN="N">terminal deoxytransferase</Keyword><Keyword MajorTopicYN="N">type 5 metabotropic glutamate receptors</Keyword><Keyword MajorTopicYN="N">ventrolateral caudate putamen</Keyword><Keyword MajorTopicYN="N">ventromedial caudate putamen</Keyword><Keyword MajorTopicYN="N">vlCP</Keyword><Keyword MajorTopicYN="N">vmCP</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23800465</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2013.06.010</ArticleId><ArticleId IdType="pii">S0278-5846(13)00121-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23772215</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-0640</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Frontiers in psychiatry</Title><ISOAbbreviation>Front Psychiatry</ISOAbbreviation></Journal><ArticleTitle>NMDA Receptor Activity in Neuropsychiatric Disorders.</ArticleTitle><Pagination><StartPage>52</StartPage><MedlinePgn>52</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">52</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2013.00052</ELocationID><Abstract><AbstractText>N-Methyl-d-aspartate (NMDA) receptors play a variety of physiologic roles and their proper signaling is essential for cellular homeostasis. Any disruption in this pathway, leading to either enhanced or decreased activity, may result in the manifestation of neuropsychiatric pathologies such as schizophrenia, mood disorders, substance induced psychosis, Huntington's disease, Alzheimer's disease, and neuropsychiatric systemic lupus erythematosus. Here, we explore the notion that the overlap in activity of at least one biochemical pathway, the NMDA receptor pathway, may be the link to understanding the overlap in psychotic symptoms between diseases. This review intends to present a broad overview of those neuropsychiatric disorders for which alternations in NMDA receptor activity is prominent thus suggesting that continued direction of pharmaceutical intervention to this pathway may present a viable option for managing symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lakhan</LastName><ForeName>Shaheen E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Biosciences Department, Global Neuroscience Initiative Foundation , Beverly Hills, CA , USA ; Neurological Institute, Cleveland Clinic , Cleveland, OH , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caro</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hadzimichalis</LastName><ForeName>Norell</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Psychiatry</MedlineTA><NlmUniqueID>101545006</NlmUniqueID><ISSNLinking>1664-0640</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">NMDA</Keyword><Keyword MajorTopicYN="N">mood disorders</Keyword><Keyword MajorTopicYN="N">neuropsychiatric systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">psychiatry</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword><Keyword MajorTopicYN="N">substance induced psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23772215</ArticleId><ArticleId IdType="pmc">PMC3677126</ArticleId><ArticleId IdType="doi">10.3389/fpsyt.2013.00052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreasen J. T., Gynther M., Rygaard A., B&#xf8;gelund T., Nielsen S. D., Clausen R. P., et al. (2013). Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neurosci. Lett. 10.1016/j.neulet.2013.04.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2013.04.045</ArticleId><ArticleId IdType="pubmed">23643996</ArticleId></ArticleIdList></Reference><Reference><Citation>Basselin M., Chang L., Bell J. M., Rapoport S. I. (2006). Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31, 1659&#x2013;167410.1038/sj.npp.1300920</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1300920</ArticleId><ArticleId IdType="pubmed">16292331</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. (1986). Replication of the neurochemical characteristics of Huntington&#x2019;s disease by quinolinic acid. Nature 321, 168&#x2013;17110.1038/321168a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/321168a0</ArticleId><ArticleId IdType="pubmed">2422561</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulay D., Bergis O., Avenet P., Griebel G. (2010). The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35, 416&#x2013;42710.1038/npp.2009.144</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2009.144</ArticleId><ArticleId IdType="pmc">PMC3055391</ArticleId><ArticleId IdType="pubmed">19759529</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan R. W., Javitt D. C., Marder S. R., Schooler N. R., Gold J. M., Mcmahon R. P., et al. (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164, 1593&#x2013;160210.1176/appi.ajp.2007.06081358</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2007.06081358</ArticleId><ArticleId IdType="pubmed">17898352</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield D. A., Pocernich C. B. (2003). The glutamatergic system and Alzheimer&#x2019;s disease: therapeutic implications. CNS Drugs 17, 641&#x2013;65210.2165/00023210-200317090-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00023210-200317090-00004</ArticleId><ArticleId IdType="pubmed">12828500</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael J., Chatellier J., Woolfson A., Milstein C., Fersht A. R., Rubinsztein D. C. (2000). Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 97, 9701&#x2013;970510.1073/pnas.170280697</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.170280697</ArticleId><ArticleId IdType="pmc">PMC16928</ArticleId><ArticleId IdType="pubmed">10920207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M., Halabisky B., Harris J., Devidze N., Dubal D. B., Sun B., et al. (2011). Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47&#x2013;5210.1038/nature09635</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09635</ArticleId><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle J. T., Schwarcz R. (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington&#x2019;s chorea. Nature 263, 244&#x2013;24610.1038/263244a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/263244a0</ArticleId><ArticleId IdType="pubmed">8731</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle J. T., Tsai G., Goff D. (2003). Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 1003, 318&#x2013;32710.1196/annals.1300.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1300.020</ArticleId><ArticleId IdType="pubmed">14684455</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies S., Ramsden D. B. (2001). Huntington&#x2019;s disease. Mol. Pathol. 54, 409&#x2013;413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187131</ArticleId><ArticleId IdType="pubmed">11724916</ArticleId></ArticleIdList></Reference><Reference><Citation>Dongen A. M. V. (2009). Biology of the NMDA Receptor. Boca Raton, FL: CRC Press</Citation></Reference><Reference><Citation>D&#x2019;Souza D. C., Singh N., Elander J., Carbuto M., Pittman B., de Haes J., et al. (2012). Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 37, 1036&#x2013;104610.1038/npp.2011.295</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2011.295</ArticleId><ArticleId IdType="pmc">PMC3280648</ArticleId><ArticleId IdType="pubmed">22113087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald L. W., Deutch A. Y., Gasic G., Heinemann S. F., Nestler E. J. (1995). Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15, 2453&#x2013;2461</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578121</ArticleId><ArticleId IdType="pubmed">7891180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischhacker W. W. (1995). New drugs for the treatment of schizophrenic patients. Acta Psychiatr. Scand. Suppl. 388, 24&#x2013;3010.1111/j.1600-0447.1995.tb05941.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1995.tb05941.x</ArticleId><ArticleId IdType="pubmed">7604735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaynes B. N., Rush A. J., Trivedi M. H., Wisniewski S. R., Balasubramani G. K., Mcgrath P. J., et al. (2008). Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR&#x2217;D. J. Gen. Intern. Med. 23, 551&#x2013;56010.1007/s11606-008-0522-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-008-0522-3</ArticleId><ArticleId IdType="pmc">PMC2324144</ArticleId><ArticleId IdType="pubmed">18247097</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaynor B., Putterman C., Valadon P., Spatz L., Scharff M. D., Diamond B. (1997). Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc. Natl. Acad. Sci. U.S.A. 94, 1955&#x2013;196010.1073/pnas.94.5.1955</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.5.1955</ArticleId><ArticleId IdType="pmc">PMC20024</ArticleId><ArticleId IdType="pubmed">9050886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmour G., Dix S., Fellini L., Gastambide F., Plath N., Steckler T., et al. (2012). NMDA receptors, cognition and schizophrenia &#x2013; testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 62, 1401&#x2013;141210.1016/j.neuropharm.2011.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2011.03.015</ArticleId><ArticleId IdType="pubmed">21420987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogas K. R. (2006). Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 6, 68&#x2013;7410.1016/j.coph.2005.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2005.11.001</ArticleId><ArticleId IdType="pubmed">16376149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon-Krajcer W., Salinska E., Lazarewicz J. W. (2002). N-methyl-d-aspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro &#x2013; superfusion study. Folia Neuropathol. 40, 13&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pubmed">12121034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusella J. F., Wexler N. S., Conneally P. M., Naylor S. L., Anderson M. A., Tanzi R. E., et al. (1983). A polymorphic DNA marker genetically linked to Huntington&#x2019;s disease. Nature 306, 234&#x2013;23810.1038/306234a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/306234a0</ArticleId><ArticleId IdType="pubmed">6316146</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Duff K., Hardy K. G., Perez-Tur J., Hutton M. (1998). Genetic dissection of Alzheimer&#x2019;s disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1, 355&#x2013;35810.1038/3743</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3743</ArticleId><ArticleId IdType="pubmed">10196523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D. J. (2002). The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;35610.1126/science.1072994</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal N., van Praag H. M. (1995). The role of serotonin in schizophrenia. Eur. Neuropsychopharmacol. 5(Suppl.), 11&#x2013;2310.1016/0924-977X(95)00027-M</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0924-977X(95)00027-M</ArticleId><ArticleId IdType="pubmed">8775754</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz J. B., Limpanasithikul W., Diamond B. (1994). Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med. 180, 925&#x2013;93210.1084/jem.180.3.925</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.180.3.925</ArticleId><ArticleId IdType="pmc">PMC2191646</ArticleId><ArticleId IdType="pubmed">8064241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp J. A., McKernan R. M. (2002). NMDA receptor pathways as drug targets. Nat. Neurosci. 5(Suppl.), 1039&#x2013;104210.1038/nn936</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn936</ArticleId><ArticleId IdType="pubmed">12403981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. S., Kornhuber H. H., Schmid-Burgk W., Holzmuller B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379&#x2013;38210.1016/0304-3940(80)90178-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(80)90178-0</ArticleId><ArticleId IdType="pubmed">6108541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal C., Degiorgio L. A., Lee J. Y., Edgar M. A., Huerta P. T., Volpe B. T., et al. (2006). Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U.S.A. 103, 19854&#x2013;1985910.1073/pnas.0608397104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0608397104</ArticleId><ArticleId IdType="pmc">PMC1702320</ArticleId><ArticleId IdType="pubmed">17170137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowal C., Degiorgio L. A., Nakaoka T., Hetherington H., Huerta P. T., Diamond B., et al. (2004). Cognition and immunity; antibody impairs memory. Immunity 21, 179&#x2013;18810.1016/j.immuni.2004.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2004.07.011</ArticleId><ArticleId IdType="pubmed">15308099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretschmer B. D. (1999). Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors. J. Neurochem. 73, 839&#x2013;84810.1046/j.1471-4159.1999.0730839.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0730839.x</ArticleId><ArticleId IdType="pubmed">10428083</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal J. H., Karper L. P., Seibyl J. P., Freeman G. K., Delaney R., Bremner J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199&#x2013;21410.1001/archpsyc.1994.03950030035004</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1994.03950030035004</ArticleId><ArticleId IdType="pubmed">8122957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahti A. C., Holcomb H. H., Medoff D. R., Tamminga C. A. (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6, 869&#x2013;87210.1097/00001756-199504190-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199504190-00011</ArticleId><ArticleId IdType="pubmed">7612873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner S. M. (2006). Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr. Opin. Pharmacol. 6, 75&#x2013;8110.1016/j.coph.2005.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2005.11.002</ArticleId><ArticleId IdType="pubmed">16376148</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine M. S., Klapstein G. J., Koppel A., Gruen E., Cepeda C., Vargas M. E., et al. (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington&#x2019;s disease. J. Neurosci. Res. 58, 515&#x2013;53210.1002/(SICI)1097-4547(19991115)58:4&lt;515::AID-JNR5&gt;3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19991115)58:4&lt;515::AID-JNR5&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10533044</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinson D. F. (1991). Pharmacologic treatment of schizophrenia. Clin. Ther. 13, 326&#x2013;352</Citation><ArticleIdList><ArticleId IdType="pubmed">1683269</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Tsien J. Z. (2009). Memory and the NMDA receptors. N. Engl. J. Med. 361, 302&#x2013;30310.1056/NEJMcibr0902052</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr0902052</ArticleId><ArticleId IdType="pmc">PMC3703758</ArticleId><ArticleId IdType="pubmed">19605837</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N., Lee B., Liu R. J., Banasr M., Dwyer J. M., Iwata M., et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959&#x2013;96410.1126/science.1190287</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1190287</ArticleId><ArticleId IdType="pmc">PMC3116441</ArticleId><ArticleId IdType="pubmed">20724638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman J. A., Stroup T. S., Mcevoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209&#x2013;122310.1056/NEJMoa051688</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051688</ArticleId><ArticleId IdType="pubmed">16172203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenmayer J. P. (1995). New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. Suppl. 388, 15&#x2013;1910.1111/j.1600-0447.1995.tb05939.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1995.tb05939.x</ArticleId><ArticleId IdType="pubmed">7541598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton S. A., Rosenberg P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613&#x2013;62210.1056/NEJM199403033300907</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300907</ArticleId><ArticleId IdType="pubmed">7905600</ArticleId></ArticleIdList></Reference><Reference><Citation>Long K. D., Mastropaolo J., Rosse R. B., Manaye K. F., Deutsch S. I. (2006). Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain. Brain Res. Bull. 69, 626&#x2013;63010.1016/j.brainresbull.2006.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2006.03.007</ArticleId><ArticleId IdType="pubmed">16716829</ArticleId></ArticleIdList></Reference><Reference><Citation>Luby E. D., Cohen B. D., Rosenbaum G., Gottlieb J. S., Kelley R. (1959). Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 81, 363&#x2013;36910.1001/archneurpsyc.1959.02340150095011</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurpsyc.1959.02340150095011</ArticleId><ArticleId IdType="pubmed">13626287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A., Ho R. C. M., Lau C. S. (2009). Clinical implications of neuropsychiatric systemic lupus erythematosus. Adv. Psychiatr. Treat. 15, 451&#x2013;45810.1192/apt.bp.108.005785</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/apt.bp.108.005785</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R. (2012). New developments on the role of NMDA receptors in Alzheimer&#x2019;s disease. Curr. Opin. Neurobiol. 22, 559&#x2013;56310.1016/j.conb.2011.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2011.09.001</ArticleId><ArticleId IdType="pmc">PMC3405538</ArticleId><ArticleId IdType="pubmed">21962484</ArticleId></ArticleIdList></Reference><Reference><Citation>Martucci L., Wong A. H., De Luca V., Likhodi O., Wong G. W., King N., et al. (2006). N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: polymorphisms and mRNA levels. Schizophr. Res. 84, 214&#x2013;22110.1016/j.schres.2006.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2006.02.001</ArticleId><ArticleId IdType="pubmed">16549338</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters C. L., Simms G., Weinman N. A., Multhaup G., Mcdonald B. L., Beyreuther K. (1985). Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82, 4245&#x2013;424910.1073/pnas.82.12.4245</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.12.4245</ArticleId><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer H. Y., Stahl S. M. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2, 19&#x2013;7610.1093/schbul/2.1.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/2.1.19</ArticleId><ArticleId IdType="pubmed">779020</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael N., Erfurth A., Ohrmann P., Gossling M., Arolt V., Heindel W., et al. (2003). Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl.) 168, 344&#x2013;34610.1007/s00213-003-1440-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-003-1440-z</ArticleId><ArticleId IdType="pubmed">12684737</ArticleId></ArticleIdList></Reference><Reference><Citation>Millan M. J. (2005). N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl.) 179, 30&#x2013;5310.1007/s00213-005-2199-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-005-2199-1</ArticleId><ArticleId IdType="pubmed">15761697</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi-Pynttari J. A., Sund R., Putkonen H., Vorma H., Wahlbeck K., Pirkola S. P. (2013). Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J. Clin. Psychiatry 74, e94&#x2013;e9910.4088/JCP.12m07822</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.12m07822</ArticleId><ArticleId IdType="pubmed">23419236</ArticleId></ArticleIdList></Reference><Reference><Citation>NLM (2013). ClinicalTrials.gov. Available at: http://ClinicalTrials.gov [accessed]</Citation></Reference><Reference><Citation>Nolt M. J., Lin Y., Hruska M., Murphy J., Sheffler-Colins S. I., Kayser M. S., et al. (2011). EphB controls NMDA receptor function and synaptic targeting in a subunit-specific manner. J. Neurosci. 31, 5353&#x2013;536410.1523/JNEUROSCI.0282-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0282-11.2011</ArticleId><ArticleId IdType="pmc">PMC3147026</ArticleId><ArticleId IdType="pubmed">21471370</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P., Neyton J. (2007). NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 7, 39&#x2013;4710.1016/j.coph.2006.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2006.08.011</ArticleId><ArticleId IdType="pubmed">17088105</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Naqibuddin M., Sampedro M., Omdal R., Carson K. A. (2011). Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin. Arthritis Rheum. 41, 194&#x2013;20210.1016/j.semarthrit.2011.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.02.005</ArticleId><ArticleId IdType="pmc">PMC3153605</ArticleId><ArticleId IdType="pubmed">21458845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinard E., Alanine A., Alberati D., Bender M., Borroni E., Bourdeaux P., et al. (2010). Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J. Med. Chem. 53, 4603&#x2013;461410.1021/jm100210p</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm100210p</ArticleId><ArticleId IdType="pubmed">20491477</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu A., Kao A. H. (2011). Neuropsychiatric systemic lupus erythematosus. Curr. Neuropharmacol. 9, 449&#x2013;45710.2174/157015911796557984</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157015911796557984</ArticleId><ArticleId IdType="pmc">PMC3151599</ArticleId><ArticleId IdType="pubmed">22379459</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabe-Jablonska J., Mirek M., Pawelczyk T. (2012). Risk factors of schizophrenia development in patients with amphetamines dependence and psychosis (amphetamine-induced psychosis and schizophrenia), and without psychosis. Psychiatr. Pol. 46, 571&#x2013;584</Citation><ArticleIdList><ArticleId IdType="pubmed">23214160</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport S. I., Bosetti F. (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592&#x2013;59610.1001/archpsyc.59.7.592</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.59.7.592</ArticleId><ArticleId IdType="pubmed">12090811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora G., Zarate C. A., Krystal J. H., Manji H. K. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7, 426&#x2013;43710.1038/nrd2462</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2462</ArticleId><ArticleId IdType="pmc">PMC2715836</ArticleId><ArticleId IdType="pubmed">18425072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler T., Mesic I., Madry C., Bartholomaus I., Laube B. (2008). Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly. J. Biol. Chem. 283, 37&#x2013;4610.1074/jbc.M703539200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M703539200</ArticleId><ArticleId IdType="pubmed">17959602</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz T. L., Sachdeva S., Stahl S. M. (2012). Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 3:19510.3389/fphar.2012.00195</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2012.00195</ArticleId><ArticleId IdType="pmc">PMC3505861</ArticleId><ArticleId IdType="pubmed">23189055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner R., Kleiner G., Turken A., Papazian L., Diamond B. (1991). A novel class of anti-DNA antibodies identified in BALB/c mice. J. Exp. Med. 173, 287&#x2013;29610.1084/jem.173.2.287</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.173.2.287</ArticleId><ArticleId IdType="pmc">PMC2118791</ArticleId><ArticleId IdType="pubmed">1988536</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl S. M. (2008). Depression and Bipolar Disorder: Stahl&#x2019;s Essential Psychopharmacology. Cambridge: Cambridge University Press</Citation></Reference><Reference><Citation>Stephenson F. A., Cousins S. L., Kenny A. V. (2008). Assembly and forward trafficking of NMDA receptors (review). Mol. Membr. Biol. 25, 311&#x2013;32010.1080/09687680801971367</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09687680801971367</ArticleId><ArticleId IdType="pubmed">18446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Savanenin A., Reddy P. H., Liu Y. F. (2001). Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713&#x2013;2471810.1074/jbc.M103501200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M103501200</ArticleId><ArticleId IdType="pubmed">11319238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsapakis E. M., Travis M. J. (2002). Glutamate and psychiatric disorders. Adv. Psychiatr. Treat. 8, 189&#x2013;19710.1192/apt.8.3.189</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/apt.8.3.189</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate C. A., Jr., Singh J. B., Carlson P. J., Brutsche N. E., Ameli R., Luckenbaugh D. A., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856&#x2013;86410.1001/archpsyc.63.8.856</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.8.856</ArticleId><ArticleId IdType="pubmed">16894061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23746276</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-533X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>24</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Current medicinal chemistry</Title><ISOAbbreviation>Curr Med Chem</ISOAbbreviation></Journal><ArticleTitle>n-3 fatty acids: role in neurogenesis and neuroplasticity.</ArticleTitle><Pagination><StartPage>2953</StartPage><EndPage>2963</EndPage><MedlinePgn>2953-63</MedlinePgn></Pagination><Abstract><AbstractText>Omega-3 polyunsaturated fatty acids (PUFA) are essential unsaturated fatty acids with a double bond (C=C) starting after the third carbon atom from the end of the carbon chain. They are important nutrients but, unfortunately, mammals cannot synthesize them, whereby they must be obtained from food sources or from supplements. Amongst nutritionally important polyunsaturated n-3 fatty acids, &#x3b1;-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are highly concentrated in the brain and have anti-oxidative stress, anti-inflammatory and antiapoptotic effects. They are involved in many bodily processes and may reportedly lead to neuron protection in neurological diseases. aged or damaged neurons and in Alzheimer's disease. Their effect in cognitive and behavioral functions and in several neurological and psychiatric disorders has been also proven. The dentate gyrus (DG), a sub-region of hippocampus, is implicated in cognition and mood regulation. The hippocampus represents one of the two areas in the mammalian brain in which adult neurogenesis occurs. This process is associated with beneficial effects on cognition, mood and chronic pharmacological treatment. The exposure to n-3 fatty acids enhances adult hippocampal neurogenesis associated with cognitive and behavioral processes, promotes synaptic plasticity by increasing long-term potentiation and modulates synaptic protein expression to stimulate the dendritic arborization and new spines formation. On this basis we review the effect of n-3 fatty acids on adult hippocampal neurogenesis and neuroplasticity. Moreover their possible use as a new therapeutic approach for neurodegenerative diseases is pointed out.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crupi</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology, School of Medicine, University of Messina, Policlinico Universitario, Torre Biologica 98123 Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cuzzocrea</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Med Chem</MedlineTA><NlmUniqueID>9440157</NlmUniqueID><ISSNLinking>0929-8673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23746276</ArticleId><ArticleId IdType="doi">10.2174/09298673113209990140</ArticleId><ArticleId IdType="pii">CMC-EPUB-20130531-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23715298</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders.</ArticleTitle><Pagination><StartPage>e263</StartPage><MedlinePgn>e263</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/tp.2013.42</ELocationID><Abstract><AbstractText>The db/db mouse is a widely used preclinical model in diabetes research. Recent studies have shown that these mice also display aspects of psychosis and depression-like behaviors as seen in some psychiatric disorders. Here, we have performed multiplex immunoassay and liquid chromatography mass spectrometry profiling of the plasma and brain samples from db/db and control mice to identify altered pathways, which could be related to these behavioral abnormalities. This is the first study to carry out profiling of the brain proteome in this model. Plasma from the db/db mice had increased levels of leptin and insulin, decreased levels of peptide YY, glucagon and prolactin and alterations in inflammation-related proteins, compared with control mice. Frontal cortex tissue from the db/db mice showed changes in proteins involved in energy metabolism, cellular structure and neural functioning, and the hippocampus had changes in proteins involved in the same pathways, with additional effects on cellular signalling proteins. The overlap of these findings with effects seen in type 2 diabetes, schizophrenia, major depressive disorder and Alzheimer's disease might contribute to a common endophenotype seen in metabolic and neurological disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>A N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Elased</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Guest</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Rahmoune</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL093567</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008401" MajorTopicYN="N">Gas Chromatography-Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23715298</ArticleId><ArticleId IdType="pmc">PMC3669927</ArticleId><ArticleId IdType="doi">10.1038/tp.2013.42</ArticleId><ArticleId IdType="pii">tp201342</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep. 2012;4:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388805</ArticleId><ArticleId IdType="pubmed">22802875</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008;101:273&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673564</ArticleId><ArticleId IdType="pubmed">18258416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2008;160:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562574</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry. 2010;15:118&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">20098438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Forte TM, Taniguchi S, Ishida BY, Oka K, Chan L. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism. 2000;49:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10647060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science. 1966;153:1127&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">5918576</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman DL. A historical perspective on leptin. Nat Med. 2010;16:1097&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinel AL, Andre C, Aubert A, Ferreira G, Laye S, Castanon N. Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome. PLoS One. 2011;6:e24325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174932</ArticleId><ArticleId IdType="pubmed">21949705</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375373</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Ittner LM, Lim YA. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci. 2009;66:1321&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131449</ArticleId><ArticleId IdType="pubmed">19266159</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience. 2002;113:607&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">12150780</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AN, Elased KM, Garrett TL, Lucot JB. Neurobehavioral deficits in db/db diabetic mice. Physiol Behav. 2010;101:381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098504</ArticleId><ArticleId IdType="pubmed">20637218</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AN, Elased KM, Lucot JB. Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice. J Psychopharmacol. 2012;26:724&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331176</ArticleId></ArticleIdList></Reference><Reference><Citation>Trayhurn P. Thermoregulation in the diabetic-obese (db/db) mouse. The role of non-shivering thermogenesis in energy balance. Pflugers Arch. 1979;380:227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">573463</ArticleId></ArticleIdList></Reference><Reference><Citation>Taicher GZ, Tinsley FC, Reiderman A, Heiman ML. Quantitative magnetic resonance (QMR) method for bone and whole-body-composition analysis. Anal Bioanal Chem. 2003;377:990&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">13680051</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17:494&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">21483431</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy D, Levin Y, Harris LW, Umrania Y, Bahn S, Guest PC. Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics. 2011;11:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">21268279</ArticleId></ArticleIdList></Reference><Reference><Citation>le Roux CW, Bloom SR. Peptide YY, appetite and food intake. Proc Nutr Soc. 2005;64:213&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">15960866</ArticleId></ArticleIdList></Reference><Reference><Citation>Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res. 1988;22:69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">3397912</ArticleId></ArticleIdList></Reference><Reference><Citation>Benker G, Jaspers C, Hausler G, Reinwein D. Control of prolactin secretion. Klin Wochenschr. 1990;68:1157&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">2126309</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlton PL, Manowitz P. Dopamine and schizophrenia: an analysis of the theory. Neurosci Biobehav Rev. 1984;8:137&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">6145134</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system. Diabetologia. 1998;41:1241&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794114</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnadas R, Cavanagh J. Depression: an inflammatory illness. J Neurol Neurosurg Psychiatry. 2012;83:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">22423117</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh VK. Studies of neuroimmune markers in Alzheimer's disease. Mol Neurobiol. 1994;9:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534089</ArticleId></ArticleIdList></Reference><Reference><Citation>Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43:157&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">19908934</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68:437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">11037963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA. 2006;103:1593&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360555</ArticleId><ArticleId IdType="pubmed">16423896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst A, Ma D, Garcia-Perez I, Tsang TM, Kluge W, Schwarz E, et al. Molecular validation of the acute phencyclidine rat model for schizophrenia: identification of translational changes in energy metabolism and neurotransmission. J Proteome Res. 2012;11:3704&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pubmed">22613019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Yu X, Zhang B, Yuan Y, Xu Q, Shen Y. An association study between polymorphisms in three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family and paranoid schizophrenia in northern Chinese population. Eur Psychiatry. 2004;19:377&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15363479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah PS, Ramshaw HS, Thomas PQ, Toyo-Oka K, Xu X, Martin S, et al. Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3zeta deficiency. Mol Psychiatry. 2012;17:451&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">22124272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira L, Matthes J, Schuster I, Valdivia HH, Herzig S, Richard S, et al. Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes. 2006;55:608&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MD, Misbahuddin A, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord. 2012;27:1522&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">22956510</ArticleId></ArticleIdList></Reference><Reference><Citation>Morishita T, Hidaka T, Sugahara K, Noguchi T. Leptin changes Ca2+/calmodulin-dependent response and up-regulates the gene expression of calcineurin in rat hypothalamus. Life Sci. 1998;63:PL311&#x2013;PL315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9820130</ArticleId></ArticleIdList></Reference><Reference><Citation>Govoni S, Amadio M, Battaini F, Pascale A. Senescence of the brain: focus on cognitive kinases. Curr Pharm Des. 2010;16:660&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">20388076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno K, Giese KP. Hippocampus-dependent memory formation: do memory type-specific mechanisms exist. J Pharmacol Sci. 2005;98:191&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">15968141</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G, Seeman P, Tallerico T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse. 2006;59:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247765</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23707254</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3405</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>13</Issue><PubDate><Year>2013</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Bioorganic &amp; medicinal chemistry letters</Title><ISOAbbreviation>Bioorg Med Chem Lett</ISOAbbreviation></Journal><ArticleTitle>Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.</ArticleTitle><Pagination><StartPage>3822</StartPage><EndPage>3825</EndPage><MedlinePgn>3822-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2013.04.082</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0960-894X(13)00572-6</ELocationID><Abstract><AbstractText>Synthetic derivatives of phenothiazine have been used for over a century as well-tolerated drugs against a variety of human ailments from psychosis to cancer. This implies a considerable diversity in the mechanisms of action produced by structural changes to the phenothiazine scaffold. For example, chlorpromazine treatment of psychosis is related to its interaction with dopaminergic receptors. On the other hand, antagonistic action of such drugs on cholinergic receptor systems would be counter-productive for treatment of Alzheimer's disease. In a search for phenothiazines that are inhibitors of cholinesterases, especially butyrylcholinesterase, with potential to treat Alzheimer's disease, we wished to ascertain that such molecules could be devoid of neurotransmitter receptor interactions. To that end, a number of our synthetic N-10-carbonyl phenothiazine derivatives, with cholinesterase inhibitory activity, were tested for interaction with a variety of neurotransmitter receptor systems. We demonstrate that phenothiazines can be prepared without significant neurotransmitter receptor interactions while retaining high potency as cholinesterase ligands for treatment of Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Darvesh</LastName><ForeName>Sultan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine (Neurology and Geriatric Medicine), Dalhousie University, 5850 College Street, Halifax, Nova Scotia, Canada B3H 4R2. sultan.darvesh@dal.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Earl</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HHSN-271-2008-00025-C</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioorg Med Chem Lett</MedlineTA><NlmUniqueID>9107377</NlmUniqueID><ISSNLinking>0960-894X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010640">Phenothiazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.8</RegistryNumber><NameOfSubstance UI="D002091">Butyrylcholinesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>GS9EX7QNU6</RegistryNumber><NameOfSubstance UI="C031637">phenothiazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002091" MajorTopicYN="N">Butyrylcholinesterase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010640" MajorTopicYN="N">Phenothiazines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23707254</ArticleId><ArticleId IdType="doi">10.1016/j.bmcl.2013.04.082</ArticleId><ArticleId IdType="pii">S0960-894X(13)00572-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23687507</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Print">1664-5464</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders extra</Title><ISOAbbreviation>Dement Geriatr Cogn Dis Extra</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms in elderly inpatients: a multicenter cross-sectional study.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>130</EndPage><MedlinePgn>123-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000350805</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">We determined the prevalence of neuropsychiatric symptoms in geriatric rehabilitation patients to compare neuropsychiatric symptoms between patients with and without dementia, and to evaluate associations linking severity of cognitive impairment and neuropsychiatric symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In February 2009, we studied patients aged 75 years or older who had been admitted to four geriatric rehabilitation units in the Paris area. The twelve Neuropsychiatric Inventory items and four neuropsychiatric subsyndromes defined by the European Alzheimer's Disease Consortium were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 194 patients, 149 (76.8%) had dementia, and 154 (79.4%) had exhibited at least one neuropsychiatric symptom during the past week. Agitation was the most common neuropsychiatric symptom in the group with dementia (36.9%) and depression in the group without dementia (35.6%). The dementia group had significantly higher prevalences of hyperactivity (p &lt; 0.001) and delusions (p = 0.01) than the non-dementia group. In the dementia group, severity of cognitive impairment was associated with hyperactivity (p = 0.01) and psychosis (p = 0.02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prevalence of neuropsychiatric symptoms among geriatric rehabilitation patients was high but not higher than in elderly outpatients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M&#xe9;zi&#xe8;re</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Soins de Suite et R&#xe9;adaptation G&#xe9;riatrique, Fondation d'Heur et Chemin Delatour, GH La Piti&#xe9; Salp&#xea;tri&#xe8;re-Charles Foix, Assistance Publique-H&#xf4;pitaux de Paris, Ivry-sur-Seine, Paris ; Service de G&#xe9;riatrie, H&#xf4;pital Albert Chenevier, Assistance Publique-H&#xf4;pitaux de Paris, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blachier</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Verny</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Herbaud</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bouillanne</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Le Thuaut</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Canou&#xef;-Poitrine</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Paillaud</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Dis Extra</MedlineTA><NlmUniqueID>101564825</NlmUniqueID><ISSNLinking>1664-5464</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dementia and neuropsychology</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric symptoms</Keyword><Keyword MajorTopicYN="N">Rehabilitation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23687507</ArticleId><ArticleId IdType="pmc">PMC3656668</ArticleId><ArticleId IdType="doi">10.1159/000350805</ArticleId><ArticleId IdType="pii">dee-0003-0123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fernandez Martinez M, Castro Flores J, Perez de las Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Imirizaldu JJ. Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain) Dement Geriatr Cogn Disord. 2008;25:103&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Voisin T, Sourdet S, Cantet C, Andrieu S, Vellas B. Descriptive analysis of hospitalizations of patients with Alzheimer's disease: a two-year prospective study of 686 patients from the REAL.FR study. J Nutr Health Aging. 2009;13:890&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">19924349</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59:473&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088883</ArticleId><ArticleId IdType="pubmed">21391937</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai WY. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277:806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FR, Boziki M, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Girtler N, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium (EADC): part I. Dement Geriatr Cogn Disord. 2007;24:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert PH, Medecin I, Vincent S, et al. L'inventaire neuropsychiatrique: validation de la version fran&#xe7;aise d'un instrument destin&#xe9; &#xe0; &#xe9;valuer les troubles du comportement chez les sujets d&#xe9;ments. L'Ann&#xe9;e G&#xe9;rontologique. 1998;5:63&#x2013;87.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x2018;Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Derouesne C, Poitreneau J, Hugonot L, Kalafat M, Dubois B, Laurent B. Mini-Mental State Examination: a useful method for the evaluation of the cognitive status of patients by the clinician. Consensual French version (in French). Presse Med. 1999;28:1141&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399508</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, de Vugt M, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005;20:523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920712</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit M, Staccini P, Brocker P, Benhamidat T, Bertogliati C, Lechowski L, Tortrat D, Robert PH. Behavioral and psychological symptoms in Alzheimer's disease: results of the REAL. FR study (in French). Rev Med Interne. 2003;24:319s&#x2013;324s.</Citation><ArticleIdList><ArticleId IdType="pubmed">14710451</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH. Consistency of neuropsychiatric syndromes across dementia: results from the European Alzheimer Disease Consortium (EADC) Part II. Dement Geriatr Cogn Disord. 2008;25:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18025783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Moskvina V, Dowzell K, Moore PJ, Foy C, Archer N, Lynch A, Lovestone S, Brayne C, Rubinsztein DC, Lawlor B, Gill M, Owen MJ, Williams J. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc. 2006;54:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang JP, Yang CH, Tsai SJ, Liu KM. Behavioural disturbances in psychiatric inpatients with dementia of the Alzheimer's type in Taiwan. Int J Geriat Psychiatry. 1997;12:902&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">9309467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23686054</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Season>Spring</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reversible parietal hypometabolism in late-onset psychosis.</ArticleTitle><Pagination><StartPage>E32</StartPage><EndPage>E33</EndPage><MedlinePgn>E32-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.12040092</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Poeck</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Van Laere</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Vandenbulcke</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008659" MajorTopicYN="N">Metabolic Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23686054</ArticleId><ArticleId IdType="doi">10.1176/appi.neuropsych.12040092</ArticleId><ArticleId IdType="pii">1688323</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23681754</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>159</EndPage><MedlinePgn>153-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.3980</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Knowledge of potentially modifiable risk factors for neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) is important. This study longitudinally explores modifiable vascular risk factors for NPS in AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants enrolled in the Cache County Study on Memory in Aging with no dementia at baseline were subsequently assessed over three additional waves, and those with incident (new onset) dementia were invited to join the Dementia Progression Study for longitudinal follow-up. A total of 327 participants with incident AD were identified and assessed for the following vascular factors: atrial fibrillation, hypertension, diabetes mellitus, angina, coronary artery bypass surgery, myocardial infarction, cerebrovascular accident, and use of antihypertensive or diabetes medicines. A vascular index (VI) was also calculated. NPS were assessed over time using the Neuropsychiatric Inventory (NPI). Affective and Psychotic symptom clusters were assessed separately. The association between vascular factors and change in NPI total score was analyzed using linear mixed model and in symptom clusters using a random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No individual vascular risk factors or the VI significantly predicted change in any individual NPS. The use of antihypertensive medications more than four times per week was associated with higher total NPI and Affective cluster scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of antihypertensive medication was associated with higher total NPI and Affective cluster scores. The results of this study do not otherwise support vascular risk factors as modifiers of longitudinal change in NPS in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Corcoran</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Breitner</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Leoutsakos</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tschanz</LastName><ForeName>Joann</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG21136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG11380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011380</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">neuropsychiatric</Keyword><Keyword MajorTopicYN="N">vascular</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23681754</ArticleId><ArticleId IdType="mid">NIHMS482882</ArticleId><ArticleId IdType="pmc">PMC3883945</ArticleId><ArticleId IdType="doi">10.1002/gps.3980</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arbus C, Gardette V, Cantet CE, Andrieu S, Nourhashemi F, Schmitt L, Vellas B REAL.FR Group. Incidence and predictive factors of depressive symptoms in Alzheimer&#x2019;s disease: the REAL.FR study. J Nutr Health Aging. 2011;15:609&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21968854</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer N, Brown RG, Reeves SJ, Boothby H, Nicholas H, Foy C, Williams J, Lovestone S. Premorbid personality and behavioral and psychological symptoms in probable Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2007;15:202&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">17322133</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, del Valle M. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry. 2009;24:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18727132</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O&#x2019;Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomized, multicenter, double-blind, placebo-controlled trial. Lancet. 2011;378:403&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">21764118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Steinberg M, Warren A, Rosenblatt A, Baker A, Lyketsos C. Delusions and hallucinations in Alzheimer&#x2019;s disease: prevalence and clinical correlates. Int J Geriatr Psychiatry. 2000;15:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679840</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer&#x2019;s disease patients. Int J Geriatr Psychiatry. 2002;17:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994927</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlow YA, Wells YM, Ellison JM, Sung YH, Renshaw PF, Harper DG. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2010;25:780&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975914</ArticleId><ArticleId IdType="pubmed">19946864</ArticleId></ArticleIdList></Reference><Reference><Citation>Black BS, Johnston D, Morrison A, Rabins PV, Lyketsos CG, Samus QM. Quality of life of community-residing persons with dementia based on self-rated and caregiver-rated measures. Qual Life Res. 2012;21:1379&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296880</ArticleId><ArticleId IdType="pubmed">22038392</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Malloy PF. Treating apathy in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2004;17:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">14564128</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, Tschanz JT, Plassman BL, Meyer MR, Skoog I, Khachaturian A. APOE-epsilon 4 count predicts age when prevalence of Alzheimer&#x2019;s disease increases, then declines: the Cache County Study. Neurology. 1999;53:321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430421</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropath. 2011;122:117&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">21455688</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunter J, Albert M. Psychiatric symptomatology and prodromal Alzheimer&#x2019;s disease. Alzheimer Dis Assoc Disord. 2003;17:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621314</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2005;13:460&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956265</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Finklel S. Introduction to behavioural and psychological symptoms of dementia (BPSD) Int J Geriatr Psychiatry. 2000;15(Suppl 1):S2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10767742</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Salvador MT, Arango C, Lyketsos CG, Barba AC. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry. 1999;14:701&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">10479740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, Bell CM, Lee PE, Fischer HD, Herrmann N, Gurwitz JH, Rochon PA. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548409</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Barker WW, Ownby RL, Duara R. Prevalence and correlates of Capgras syndrome in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1999;6:415&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">10398349</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Barker WW, Ownby RL, Duara R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2000;15:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822237</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzer R, Tang MX, Devanand DP, Albert SM, Wegesin DJ, Marder K, Bell K, Albert M, Brandt J, Stern Y. Psychopathological features in Alzheimer&#x2019;s disease: course and relationship with cognitive status. J Am Geriatr Soc. 2003;51:953&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">12834515</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. ANCP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharm. 2008;33:957&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553721</ArticleId><ArticleId IdType="pubmed">17637610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, Blow FC. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164:1568&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Arch Neurol. 1994;51:901&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">8080390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos C, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer&#x2019;s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV. Treating depression in Alzheimer&#x2019;s disease: efficacy and safety of sertraline therapy and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;7:737&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">12860778</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R, Lyketsos CG. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007;69:1850&#x2013;1858.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi R, Starkstein SE, Jorge R, Robinson RG. Phenomenology and clinical correlates of delusions in Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2006;14:573&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">16816010</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien J, Perry R, Barber R, Gholkar A, Thomas A. The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Ann NY Acad Sci. 2000;903:482&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818542</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer K, Lupo F, Perri R, Salamone G, Fadda L, Caltagirone C, Musicco M, Cravello L. Predicting disease progression in Alzheimer&#x2019;s disease: the role of neuropsychiatric syndromes on functional and cognitive decline. J Alzheimers Dis. 2011;24:35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21157019</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Sarwari A, Wattmo C, Bronge L, Zhang Y, Wahlund LO, Nagga K. Association between subcortical lesions and behavioral and psychological symptoms in patients with Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2011;33:417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">22343788</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Lyketsos CG, Steele CD. Practical Dementia Care. New York: Oxford University Press; 1999.</Citation></Reference><Reference><Citation>Rao V, Spiro JR, Rosenberg PB, Lee HB, Rosenblatt A, Lyketsos CG. An open-label study of escitalopram (Lexapro) for the treatment of &#x2018;Depression of Alzheimer&#x2019;s disease&#x2019; (dAD) Int J Geriatr Psychiatry. 2006;21:273&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">16477587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, Zandi PP, Breitner JC, Norton MC, Welsh-Bohmer KA, Zukderman IH, Rattinger GB, Green RC, Corcoran C, Tschanz JT. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2012 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448859</ArticleId><ArticleId IdType="pubmed">22374884</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. N Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer&#x2019;s disease. Am J Psychiatry. 2001;158:872&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">11384893</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2006;77:8&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117400</ArticleId><ArticleId IdType="pubmed">16361584</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JCS, Steffens DC, Tschanz JT. Cache County Investigators. 2008. Point and Five-year Period Prevalence of Neuropsychiatric Symptoms in Dementia: The Cache County Study. Int J Geriatr Psychiatry. 23:170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932652</ArticleId><ArticleId IdType="pubmed">17607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SB, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Treiber KA, Lyketsos CG, Corcoran C, Steinberg M, Norton M, Green RC, Rabins P, Stein DM, Welsh-Bohmer KA, Breitner JC, Tschanz JT. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer&#x2019;s disease: the Cache County Study. Int Psychogeriatr. 2008;20:538&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692675</ArticleId><ArticleId IdType="pubmed">18289451</ArticleId></ArticleIdList></Reference><Reference><Citation>Truelsen T, Lindenstrom E, Boysen G. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke. 1994;25:802&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">8160224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai SJ, Hwang JP, Yang CH, Liu KM. Physical aggression and associated factors in probable Alzheimer&#x2019;s disease. Azheimer Dis Assoc Disord. 1996;10:82&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8727169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschanz JT, Welsh-Bohmer KA, Plassman BL, Norton MC, Wyse BW, Breitner JC The Cache County Study Group. An adaptation of the Modified Mini-Mental State Examination: analysis of demographic influences and normative date: The Cache County Study. Neuropsychiatry, Neuropsychol Behav Neurol. 2002;15:28&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11877549</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins P, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer&#x2019;s disease: the Cache County Dementia Progression study. 2011;19:532&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101372</ArticleId><ArticleId IdType="pubmed">21606896</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek DE, van Riezen J, de Boer RA, van Melle JP, de Jonge P. A review of the putative association between beta-blockers and depression. Heart Fail Clin. 2011;7:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21109212</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease: week 24 outcomes. Am J Geriatr Psychiatry. 2010;18:332&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849739</ArticleId><ArticleId IdType="pubmed">20220589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23672944</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative.</ArticleTitle><Pagination><StartPage>698</StartPage><EndPage>707</EndPage><MedlinePgn>698-707</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2012.10.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(12)00102-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">An ascendant body of evidence suggests that Alzheimer disease with psychosis (AD+P) is a distinct variant of illness with its own genetic diathesis and a unique clinical course. Impaired frontal lobe function has been previously implicated in AD+P. The current exploratory study, presented in two parts, evaluates both the regional brain metabolic and psychometric correlates of psychosis in a longitudinal sample of subjects with AD, made available by the Alzheimer's Disease Neuroimaging Initiative (ADNI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In Part 1 of the study, 21 ADNI participants with AD who developed psychotic symptoms during the study but were not psychotic at baseline were matched with 21 participants with AD who never became psychotic during the study period, and mean brain [F(18)]fluorodeoxyglucose positron emission tomography (FDG-PET) Cerebral metabolic rate for glucose (CMRgl) by regions of interest (ROIs) were compared Additionally, 39 participants with active psychosis at the time of image acquisition were matched with 39 participants who were never psychotic during the study period, and mean brain FDG-PET CMRgl by sROI were compared. In Part 2 of the study, 354 ADNI participants with AD who were followed for 24 months with serial psychometric testing were identified, and cognitive performance and decline were evaluated for correlation with psychotic symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Part 1: There were no regional brain metabolic differences between those with AD destined to become psychotic and those who did not become psychotic. There was a significant reduction in mean orbitofrontal brain metabolism in those with active psychosis. Part 2: Over the course of study follow-up, psychosis was associated with accelerated decline in functional performance as measured by the Functional Assessment Questionnaire, the Mini-Mental State Examination, and Forward Digit Span.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a sample drawn from the ADNI dataset, our exploratory FDG-PET findings and longitudinal cognitive outcomes support the hypofrontality model of AD+P. Focal frontal vulnerability may mediate the accelerated decline seen in AD+P.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koppel</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Litwin Zucker Alzheimer's Research Center, Manhasset, NY. Electronic address: jkoppel@nshs.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunday</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Litwin Zucker Alzheimer's Research Center, Manhasset, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Terry E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Litwin Zucker Alzheimer's Research Center, Manhasset, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Litwin Zucker Alzheimer's Research Center, Manhasset, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christen</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Litwin Zucker Alzheimer's Research Center, Manhasset, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwald</LastName><ForeName>Blaine S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Litwin Zucker Alzheimer's Research Center, Manhasset, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="Y">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">frontal</Keyword><Keyword MajorTopicYN="N">hypofrontality</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword><Keyword MajorTopicYN="N">working memory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23672944</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2012.10.028</ArticleId><ArticleId IdType="pii">S1064-7481(12)00102-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23671016</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Insight in Alzheimer's disease and its relation to psychiatric and behavioral disturbances.</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>84</EndPage><MedlinePgn>77-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.3972</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Individuals suffering from Alzheimer's disease (AD) often have impaired awareness or a lack of insight into their cognitive deficits and functional abilities, especially in the later stages of the disease. Previous research has documented a relationship between depression and insight in AD, such that greater awareness of one's disease has been associated with a higher degree of depression. However, little is known about the relationship between insight, cognitive decline, and other psychiatric or behavioral problems associated with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study included 107 outpatients who met criteria for probable AD. Instruments included the Neurobehavioral Rating Scale, the Apathy Evaluation Scale, and the mini mental state exam. A series of hierarchical regression analyses were conducted to determine the relationship between insight and depressed mood, anxiety, psychosis, apathy, agitation, and behavioral retardation in AD patients after controlling for cognitive skills.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Insight was found to significantly predict depressed mood, anxiety, and apathy even after controlling for global cognition. Greater insight was found to be associated with depressed mood and anxiety. However, impaired insight was associated with higher levels of apathy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Insight may be differentially related to mood symptoms and apathy within AD, such that patients with intact insight are more depressed, whereas patients with impaired insight are more apathetic. This suggests that assessment of insight in AD may complement the clinical evaluation of depression and apathy in AD and help guide the most appropriate interventions. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.</AbstractText><CopyrightInformation>Published 2013. This article is a U.S. Government work and is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horning</LastName><ForeName>Sheena M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Brain, Behavior, and Aging Research Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melrose</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH056031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH56031</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="N">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">apathy</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">insight</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23671016</ArticleId><ArticleId IdType="mid">NIHMS482478</ArticleId><ArticleId IdType="pmc">PMC3796120</ArticleId><ArticleId IdType="doi">10.1002/gps.3972</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Arlington, VA: American Psychiatric Association; 2000. text revision.</Citation></Reference><Reference><Citation>Arkin S, Mahendra N. Insight in Alzheimer&#x2019;s patients: Results of a longitudinal study using three assessment methods. American Journal of Alzheimer&#x2019;s Disease and Other Dementias. 2001;16(4):211&#x2013;224. doi: 10.1177/153331750101600401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/153331750101600401</ArticleId><ArticleId IdType="pmc">PMC10833994</ArticleId><ArticleId IdType="pubmed">11501343</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy for Depression. New York, NY: The Guilford Press; 1979.</Citation></Reference><Reference><Citation>Bombardier CH, D&#x2019;Amico C, Jordon JS. The relationship of appraisal and coping to chronic illness and adjustment. Behav Re and Ther. 1990;26(4):297&#x2013;304. doi: 10.1016/0005-7967(90)90081-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-7967(90)90081-S</ArticleId><ArticleId IdType="pubmed">2222387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. A power primer. Psychol Bull. 1992;112(1):155&#x2013;159. doi: 10.1037/0033-2909.112.1.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-2909.112.1.155</ArticleId><ArticleId IdType="pubmed">19565683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Cole G. Alzheimer&#x2019;s disease. JAMA. 2002;287(18):2335&#x2013;2338. doi: 10.1001/jama.287.18.2335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.18.2335</ArticleId><ArticleId IdType="pubmed">11988038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Ross W, Absher J, Gornbein J, Hadjiaghai L. Depressive symptoms in Alzheimer disease: Assessment and determinants. Alzheimer Dis Assoc Disord. 1995;9(2):87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">7662328</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State:&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes HC, Levy R, Teixeira AL, Beato RG, Caramelli P. Neurobiology of apathy in Alzheimer&#x2019;s disease. Arq Neuro-Psiquiatr. 2008;66(n.2b):436&#x2013;443. doi: 10.1590/S0004-282X2008000300035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0004-282X2008000300035</ArticleId><ArticleId IdType="pubmed">18641892</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Sultzer DL, Feil D, Monserratt L, Freedman E, Mandelkern MA. Frontal lobe hypometabolism and impaired insight in Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 2005;13(11):934&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286436</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Sultzer DL, Wheatley MV. Impaired insight in Alzheimer disease: Association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13(2):83&#x2013;88. AN: 00010291-200013020-00002.</Citation><ArticleIdList><ArticleId IdType="pubmed">10780626</ArticleId></ArticleIdList></Reference><Reference><Citation>Haupt M, Kurz A. Predictors of nursing home placement in patients with Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1993;8:741&#x2013;746. AN:12103247.</Citation></Reference><Reference><Citation>Kashiwa Y, Kitabayashi Y, Narumoto J, Nakamura K, Ueda H, Fukui K. Anosognosia in Alzheimer&#x2019;s disease: Association with patient characteristics, psychiatric symptoms, and cognitive deficits. Psychiatry Clin Neurosci. 2005;59:697&#x2013;704. doi: 10.1111/j.1440-1819.2005.01439.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1819.2005.01439.x</ArticleId><ArticleId IdType="pubmed">16401246</ArticleId></ArticleIdList></Reference><Reference><Citation>Landes AM, Sperry SD, Strauss ME, Geldmatcher DS. Apathy in Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2001;49:1700&#x2013;1707. doi: 10.1046/j.1532-5415.2001.49282.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2001.49282.x</ArticleId><ArticleId IdType="pubmed">11844006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus R, Folkman S. Stress, Appraisal, and Coping. New York, NY: Springer Publishing Company, Inc; 1984.</Citation></Reference><Reference><Citation>Levin HS, High WM, Goethe KE, Sisson RA, Overall JE, Gary HE. The Neurobehavioral Rating Scale: Assessment of the behavioral sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry. 1987;50:183&#x2013;193. doi: 10.1136/jnnp.50.2.183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.50.2.183</ArticleId><ArticleId IdType="pmc">PMC1031490</ArticleId><ArticleId IdType="pubmed">3572433</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 1998;153:1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Olin J. Depression in Alzheimer&#x2019;s disease: Overview and treatment. Biol Psychiatry. 2002;52:243&#x2013;252. doi: 10.1016/S0006-3223(02)01348-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3223(02)01348-3</ArticleId><ArticleId IdType="pubmed">12182930</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">2403472</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143&#x2013;162. 0.1016/0165-1781(91)90040-V.</Citation><ArticleIdList><ArticleId IdType="pubmed">1754629</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: A treatable syndrome. J Neuropsychiatry Clin Neurosci. 1995;7:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7711487</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2006;21(3):144&#x2013;147. doi: 10.1159/000090674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000090674</ArticleId><ArticleId IdType="pubmed">16391476</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer&#x2019;s disease. Neurology. 1996;46:130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/01.wnl.0000400650.92875.cf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000400650.92875.cf</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Phelps CH. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Association workgroup. Alzheimer&#x2019;s &amp; Dementia. 2011:1&#x2013;7. doi: 10.1016/j.jalz.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen R, Howard R, David A, Levy R. Insight in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1996;11:645&#x2013;651. AN:14150318.</Citation></Reference><Reference><Citation>Ott BR, LaFleche G, Whelihan WM, Buongiorno GW, Albert MS, Fogel BS. Impaired awareness of deficits in Alzheimer&#x2019;s disease. Alzheimer Dis Assoc Disord. 1996;10(2):68&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8727167</ArticleId></ArticleIdList></Reference><Reference><Citation>Padala PR, Burke WJ, Bhatia SC, Petty F. Treatment of apathy with methylphendidate. J Neuropsychiatry Clin Neurosci. 2007;19:81&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308232</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon E, Perani D, Herholz K, Marique P, Kalbe E, Garraux G. Neural correlates of anosognosia for cognitive impairment in Alzheimer&#x2019;s disease. Hum Brain Mapp. 2005;27:558&#x2013;597. doi: 10.1002/hbm.20203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20203</ArticleId><ArticleId IdType="pmc">PMC6871369</ArticleId><ArticleId IdType="pubmed">16247783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevush S, Leve N. Denial of memory deficit in Alzheimer&#x2019;s disease. Am Journal of Psychiatry. 1993;150(5):748&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">8480820</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CA, Henderson VW, McCleary CA, Murdock GA, Buckwalker JG. Anosognosia and Alzheimer&#x2019;s disease: The role of depressive symptoms in mediating impaired insight. J Clin and Exp Neuropsychol. 2000;22(4):437&#x2013;444. doi: 10.1076/1380-3395(200008)22:4;1-0;FT437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/1380-3395(200008)22:4;1-0;FT437</ArticleId><ArticleId IdType="pubmed">10923053</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkstein SE, Brockman S, Bruce D, Petracca G. Anosognosia is a significant predictor of apathy in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2010;22(4):378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">21037121</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 1990;147(8):1049&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuss DT, Knight RT, editors. Principles of Frontal Lobe Function. New York, NY: Oxford University Press, Inc; 2002.</Citation></Reference><Reference><Citation>Sultzer DL, Berisford MA, Gunay I. The Neurobehavioral Rating Scale: Reliability in patients with dementia. J Psychiatr Res. 1995;29:185&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">7473295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: The Neurobehavioral Rating Scale. J Am Geriatr Soc. 1992;40:549&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">1587970</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Ferretti LE, Gibbons LE, Logsdon RG, McCurry SM, Kukull WA, Larson EB. Anxiety in Alzheimer&#x2019;s disease: Prevalence and Comorbidity. Journal of Gerontology: Medical Sciences. 1999;54A(7):M348&#x2013;352. AN:2695357.</Citation><ArticleIdList><ArticleId IdType="pubmed">10462166</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies W, Bleiler L. 2011 Alzheimer&#x2019;s disease facts and figures. Alzheimer&#x2019;s &amp; Dementia. 2011;7(2):208&#x2013;244. doi: 10.1016/j.jalz.2011.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.02.004</ArticleId><ArticleId IdType="pubmed">21414557</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson S, Herrmann N, Rapoport MJ, Lanctot KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer&#x2019;s disease: A metaanalysis. Can J Psychiatry. 2007;52(4):248&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">17500306</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunnard C, Whitehead D, Hurt C, Wahlunds LO, Mecocci P, Simmons A. apathy and cortical atrophy in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2011;26(7):741&#x2013;748. doi: 10.1002/gps.2603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2603</ArticleId><ArticleId IdType="pubmed">20872914</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhey FRJ, Rozendall N, Ponds RWHM, Jolles J. Dementia, awareness and depression. Int J Geriatr Psychiatry. 1993;8:851&#x2013;856. AN:12115445.</Citation></Reference><Reference><Citation>Verkaik R, van Weert JCM, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: A systematic review. Int J Geriatr Psychiatry. 2005;20:301&#x2013;314. doi: 10.1002/gps.1279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1279</ArticleId><ArticleId IdType="pubmed">15799081</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A, Waldorff FB, Waldemar G. Impaired awareness of deficits in neuropsychiatric symptoms in early Alzheimer&#x2019;s disease: The Danish Alzheimer Intervention Study (DAISY) J Neuropsychiatry Clin Neurosci. 2010;22(1):93&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23659787</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1948-7193</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>ACS chemical neuroscience</Title><ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation></Journal><ArticleTitle>Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.</ArticleTitle><Pagination><StartPage>1026</StartPage><EndPage>1048</EndPage><MedlinePgn>1026-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/cn400086m</ELocationID><Abstract><AbstractText>Since the cholinergic hypothesis of memory dysfunction was first reported, extensive research efforts have focused on elucidating the mechanisms by which this intricate system contributes to the regulation of processes such as learning, memory, and higher executive function. Several cholinergic therapeutic targets for the treatment of cognitive deficits, psychotic symptoms, and the underlying pathophysiology of neurodegenerative disorders, such as Alzheimer's disease and schizophrenia, have since emerged. Clinically approved drugs now exist for some of these targets; however, they all may be considered suboptimal therapeutics in that they produce undesirable off-target activity leading to side effects, fail to address the wide variety of symptoms and underlying pathophysiology that characterize these disorders, and/or afford little to no therapeutic effect in subsets of patient populations. A promising target for which there are presently no approved therapies is the M1 muscarinic acetylcholine receptor (M1 mAChR). Despite avid investigation, development of agents that selectively activate this receptor via the orthosteric site has been hampered by the high sequence homology of the binding site between the five muscarinic receptor subtypes and the wide distribution of this receptor family in both the central nervous system (CNS) and the periphery. Hence, a plethora of ligands targeting less structurally conserved allosteric sites of the M1 mAChR have been investigated. This Review aims to explain the rationale behind allosterically targeting the M1 mAChR, comprehensively summarize and critically evaluate the M1 mAChR allosteric ligand literature to date, highlight the challenges inherent in allosteric ligand investigation that are impeding their clinical advancement, and discuss potential methods for resolving these issues.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davie</LastName><ForeName>Briana J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopoulos</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Scammells</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Chem Neurosci</MedlineTA><NlmUniqueID>101525337</NlmUniqueID><ISSNLinking>1948-7193</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23659787</ArticleId><ArticleId IdType="pmc">PMC3715844</ArticleId><ArticleId IdType="doi">10.1021/cn400086m</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Koppen C. J.; Kaiser B. (2003) Regulation of muscarinic acetylcholine receptor signaling. Pharmacol. Ther. 98, 197&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725869</ArticleId></ArticleIdList></Reference><Reference><Citation>Canals M.; Sexton P. M.; Christopoulos A. (2011) Allostery in GPCRs: &#x201c;MWC&#x201d; revisited. Trends Biochem. Sci. 36, 663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">21920759</ArticleId></ArticleIdList></Reference><Reference><Citation>Caulfield M. P. (1993) Muscarinic Receptors-Characterization, Coupling and Function. Pharmacol. Ther. 58, 319&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504306</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N. M. (2008) Synthesis, trafficking and localization of muscarinic acetylcholine receptors. Pharmacol. Ther. 119, 33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579790</ArticleId><ArticleId IdType="pubmed">18558434</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A. (2008) M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer&#x2019;s Disease - The Pivotal Role of Brain M1 Receptors. Neurodegener. Dis. 5, 237&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322400</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead C. J.; Watson J.; Reavill C. (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117, 232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082893</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.; Yan J.; Zhou P.; Li J.; Gao H.; Xia Y.; Wang Q. (2012) Neurotransmitter receptors and cognitive dysfunction in Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. Prog. Neurobiol. 97, 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371373</ArticleId><ArticleId IdType="pubmed">22387368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wess J. (2004) Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications. Annu. Rev. Pharmacol. Toxicol. 44, 423&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick N. C.; Offen W. W.; Levey A. I.; Cutler N. R.; Gauthier S. G.; Satlin A.; Shannon H. E.; Tollefson G. D.; Rasmussen K.; Bymaster F. P.; Hurley D. J.; Potter W. Z.; Paul S. M. (1997) Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease. Arch. Neurol. 54, 465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Digby G. J.; Shirey J. K.; Conn P. J. (2010) Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol. BioSyst. 6, 1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780333</ArticleId><ArticleId IdType="pubmed">20582339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus R. T.; Dean R. L.; Beer B.; Lippa A. S. (1982) The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 217, 408&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">7046051</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse P. J.; Price D. L.; Struble R. G.; Clark A. W.; Coyle J. T.; Delon M. R. (1982) Alzheimer&#x2019;s disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">7058341</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis P. T.; Palmer A. M.; Snape M.; Wilcock G. K. (1999) The cholinergic hypothesis of Alzheimer&#x2019;s disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736202</ArticleId><ArticleId IdType="pubmed">10071091</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E. (2000) Cholinesterase Inhibitors Stabilize Alzheimer&#x2019;s Disease. Ann. N.Y. Acad. Sci. 920, 321&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza N. R.; Peters D.; Sparks R. G. (2003) Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists. CNS Drug Rev. 9, 159&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741650</ArticleId><ArticleId IdType="pubmed">12847557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster F. P.; Whitesitt C. A.; Shannon H. E.; DeLapp N.; Ward J. S.; Calligaro D. O.; Shipley L. A.; Buelke-Sam J. L.; Bodick N. C.; Farde L.; Sheardown M. J.; Olesen P. H.; Hansen K. T.; Suzdak P. D.; Swedberg M. D. B.; Sauerberg P.; Mitch C. H. (1997) Xanomeline: A Selective Muscarinic Agonist for the Treatment of Alzheimer&#x2019;s Disease. Drug Dev. Res. 40, 158&#x2013;170.</Citation></Reference><Reference><Citation>Bymaster F. P.; McKinzie D. L.; Felder C. C.; Wess J. (2003) Use of M1-M5 Muscarinic Receptor Knockout Mice as Novel Tools to Delineate the Physiological Roles of the Muscarinic Cholinergic System. Neurochem. Res. 28, 437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">12675128</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon H. E.; Rasmussen K.; Bymaster F. P.; Hart J. C.; Peters S. C.; Swedberg M. D. B.; Jeppeson L.; Sheardown M. J.; Sauerberg P.; Fink-Jensen A. (2000) Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr. Res. 42, 249&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785583</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar A.; Potter W. Z.; Lightfoot J.; Lienemann J.; Dube S.; Mallinckrodt C.; Bymaster F. P.; McKinzie D. L.; Felder C. C. (2008) Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia. Am. J. Psychiatry 165, 1033&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593778</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley M. L.; Carter H. J.; Gartlon J. E.; Watson J. M.; Dawson L. A. (2009) Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur. J. Pharmacol. 603, 147&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">19111716</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzavara E. T.; Bymaster F. P.; Davis R. J.; Wade M. R.; Perry K. W.; Wess J.; McKinzie D. L.; Felder C.; Nomikos G. G. (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies. FASEB J. 18, 1410&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">15231726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood M. D.; Murkitt K. L.; Ho M.; Watson J. M.; Brown F.; Hunter A. J.; Middlemiss D. N. (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br. J. Pharmacol. 126, 1620&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565933</ArticleId><ArticleId IdType="pubmed">10323594</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrell M.; Roth B. L. (2010) Allosteric Antipsychotics: M4Muscarinic Potentiatiors as Novel Treatments for Schizophrenia. Neuropsychopharmacology 35, 851&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055359</ArticleId><ArticleId IdType="pubmed">20145632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang S. W. Y.; Pomakian J.; Marshall G. A.; Vinters H. V.; Cummings J. L.; Chen C. P. L.-H.; Wong P. T.-H.; Lai M. K. P. (2007) Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer&#x2019;s disease. Neurobiol. Aging 28, 1381&#x2013;1387.</Citation><ArticleIdList><ArticleId IdType="pubmed">16828202</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A. (2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer&#x2019;s disease. J. Neurochem. 120, 22&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122190</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M. J.; Rouse S. T.; Levey A. I.; Potter L. T.; Conn P. J. (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. U.S.A. 95, 11465&#x2013;11470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21666</ArticleId><ArticleId IdType="pubmed">9736760</ArticleId></ArticleIdList></Reference><Reference><Citation>Collingridge G. L.; Volianskis A.; Bannister N.; France G.; Hanna L.; Mercier M.; Tidball P.; Fang G.; Irvine M. W.; Costa B. M.; Monaghan D. T.; Bortolotto Z. A.; Molnar E.; Lodge D.; Jane D. E. (2013) The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 64, 13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4696548</ArticleId><ArticleId IdType="pubmed">22796429</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P.; Maloney A. J. F. (1976) Selective Loss of Central Cholinergic Neurons in Alzheimer&#x2019;s Disease. Lancet 2, 1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">63862</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn D. D.; Ferrari-DiLeo G.; Mash D. C.; Levey A. I. (1995) Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer&#x2019;s Disease. J. Neurochem. 64, 1888&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">7891119</ArticleId></ArticleIdList></Reference><Reference><Citation>Overk C. R.; Felder C. C.; Tu Y.; Schober D. A.; Bales K. R.; Wuu J.; Mufson E. J. (2010) Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer&#x2019;s disease. J. Chem. Neuroanat. 40, 63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864794</ArticleId><ArticleId IdType="pubmed">20347961</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner P. R.; O&#x2019;Connor K.; Tate W. P.; Abraham W. C. (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 70, 1&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C.; Maddalena A.; Raschig A.; Muller-Spahn F.; Eschweiler G.; Hager K.; Heuser I.; Hampel H.; Muller-Thomsen T.; Oertel W.; Wienrich M.; Signorell A.; Gonzalez-Agosti C.; Nitsch R. M. (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Ab42 in patients with Alzheimer&#x2019;s disease. Amyloid 10, 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12762134</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A.; Michaelson D. M.; Brandeis R.; Haring R.; Chapman S.; Pittel Z. (2000) M1Muscarinic Agonists as Potential Disease-Modifying Agents in Alzheimer&#x2019;s Disease: Rationale and Perspectives. Ann. N.Y. Acad. Sci. 920, 315&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193170</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J. D.; Gandy S. E.; Cicchetti P.; Ehrlich M. E.; Czernik A. J.; Fracasso R. P.; Ramabhadran T. V.; Unterbeck A. J.; Greengard P. (1990) Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 87, 6003&#x2013;6006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54458</ArticleId><ArticleId IdType="pubmed">2116015</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A.; Oddo S.; Billings L. M.; Green K. N.; Martinez-Coria H.; Fisher A.; LaFerla F. M. (2006) M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. Neuron 49, 671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Farde L.; Nordstrom A.-L.; Wiesel F.-A.; Pauli S.; Halldin C.; Sedvall G. (1992) Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine. Arch. Gen. Psychiatry 49, 538&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">1352677</ArticleId></ArticleIdList></Reference><Reference><Citation>Serretti A.; De Ronchi D.; Lorenzi C.; Berardi D. (2004) New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects. Curr. Med. Chem. 11, 343&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">14965236</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLeon A.; Patel N. C.; Crismon M. L. (2004) Aripiprazole: A Comprehensive Review of Its Pharmacology, Clinical Efficacy, and Tolerability. Clin. Ther. 26, 649&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220010</ArticleId></ArticleIdList></Reference><Reference><Citation>Minzenberg M. J.; Carter C. S. (2012) Developing treatments for impaired cognition in schizophrenia. Trends Cognit. Sci. 16, 35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22178120</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder C. C.; Bymaster F. P.; DeLapp N. (2000) Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System. J. Med. Chem. 43, 4333&#x2013;4353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087557</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook J. M.; Tomaskovic-Crook E.; Copolov D. L.; Dean B. (2000) Decreased Muscarinic Receptor Binding in Subjects with Schizophrenia: A Study of the Human Hippocampal Formation. Biol. Psychiatry 48, 381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978721</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook J. M.; Tomaskovic-Crook E.; Copolov D. L.; Dean B. (2001) Low Muscarinic Receptor Binding in Prefrontal Cortex From Subjects With Schizophrenia: A Study of Brodmann&#x2019;s Areas 8, 9, 10 and 46 and the Effects of Neuroleptic Drug Treatment. Am. J. Psychiatry 158, 918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">11384900</ArticleId></ArticleIdList></Reference><Reference><Citation>Raedler T. J.; Bymaster F. P.; Tandon R.; Copolov D.; Dean B. (2007) Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 12, 232&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17146471</ArticleId></ArticleIdList></Reference><Reference><Citation>Korczyn A. D. (2000) Muscarinic M1 agonists in the treament of Alzheimer&#x2019;s disease. Expert Opin. Invest. Drug 9, 2259&#x2013;2267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060805</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn D. D.; Weinstein D. A.; Mash D. C. (1991) Loss of High-Affinity Agonist Binding to M1Muscarinic Receptors in Alzheimer&#x2019;s Disease: Implications for the Failure of Cholinergic Replacement Therapies. Ann. Neurol. 29, 256&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">2042942</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead C. J.; Christopoulos A. (2006) Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol. Sci. 27, 475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">16889837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenakin T. P. (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165, 1659&#x2013;1669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372820</ArticleId><ArticleId IdType="pubmed">22023017</ArticleId></ArticleIdList></Reference><Reference><Citation>May L. T.; Leach K.; Sexton P. M.; Christopoulos A. (2007) Allosteric Modulation of G Protein-Coupled Receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17009927</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong B. J. (2005) Cinacalcet: An Oral Calcimimetic Agent for the Management of Hyperparathyroidism. Clin. Ther. 27, 1725&#x2013;1751.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368445</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Perez J.; Rueda P.; Staropoli I.; Kellenberger E.; Alcami J.; Arenzana-Seisdedos F.; Lagane B. (2011) New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection. J. Biol. Chem. 286, 4978&#x2013;4990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037610</ArticleId><ArticleId IdType="pubmed">21118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlert F. J.; Roeske W. R.; Gee K. W.; Yamamura H. I. (1983) An Allosteric Model For Benzodiazepine Receptor Function. Biochem. Pharmacol. 32, 2375&#x2013;2383.</Citation><ArticleIdList><ArticleId IdType="pubmed">6311215</ArticleId></ArticleIdList></Reference><Reference><Citation>Christopoulos A. (2002) Allosteric Binding Sites On Cell-Surface Receptors: Novel Targets For Drug Discovery. Nat. Rev. Drug Discovery 1, 198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12120504</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn P. J.; Jones C. K.; Lindsley C. W. (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30, 148&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907736</ArticleId><ArticleId IdType="pubmed">19201489</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenakin T. (2005) New Concepts In Drug Discovery: Collateral Efficacy And Permissive Antagonism. Nat. Rev. Drug Discovery 4, 919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">16264435</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenakin T. (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24, 346&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871667</ArticleId></ArticleIdList></Reference><Reference><Citation>Keov P.; Sexton P. M.; Christopoulos A. (2011) Allosteric modulation of G protein-coupled receptors: A pharmacological perspective. Neuropharmacology 60, 24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">20637785</ArticleId></ArticleIdList></Reference><Reference><Citation>Leach K.; Loiacono R. E.; Felder C. C.; McKinzie D. L.; Mogg A.; Shaw D. B.; Sexton P. M.; Christopoulos A. (2010) Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties. Neuropsychopharmacology 35, 855&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055367</ArticleId><ArticleId IdType="pubmed">19940843</ArticleId></ArticleIdList></Reference><Reference><Citation>Canals M.; Lane J. R.; Wen A.; Scammells P. J.; Sexton P. M.; Christopoulos A. (2012) A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation. J. Biol. Chem. 287, 650&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249119</ArticleId><ArticleId IdType="pubmed">22086918</ArticleId></ArticleIdList></Reference><Reference><Citation>Palczewski K.; Kumasaka T.; Hori T.; Behnke C. A.; Motoshima H.; Fox B. A.; Le Trong I.; Teller D. C.; Okada T.; Stenkamp R. E.; Yamamoto M.; Miyano M. (2000) Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 289, 739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">10926528</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen S. G. F.; Choi H.-J.; Rosenbaum D. M.; Kobilka T. S.; Thian F. S.; Edwards P. C.; Burghammer M.; Ratnala V. R. P.; Sanishvili R.; Fischetti R. F.; Schertler G. F. X.; Weis W. I.; Kobilka B. K. (2007) Crystal structure of the human b2 adrenergic G-protein-coupled receptor. Nature 450, 383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">17952055</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaakola V.-P.; Griffith M. T.; Hanson M. A.; Cherezov V.; Chien E. Y. T.; Lane J. R.; Ijzerman A. P.; Stevens R. C. (2008) The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science 322, 1211&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586971</ArticleId><ArticleId IdType="pubmed">18832607</ArticleId></ArticleIdList></Reference><Reference><Citation>Strotmann R.; Schrock K.; Boselt I.; Staubert C.; Russ A.; Schoneberg T. (2011) Evolution of GPCR: Change and continuity. Mol. Cell. Endocrinol. 331, 170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">20708652</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga K.; Kruse A. C.; Asada H.; Yurugi-Kobayashi T.; Shiroishi M.; Zhang C.; Weis W. I.; Okada T.; Kobilka B. K.; Haga T.; Kobayashi T. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345277</ArticleId><ArticleId IdType="pubmed">22278061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse A. C.; Hu J.; Pan A. C.; Arlow D. H.; Rosenbaum D. M.; Rosemond E.; Green H. F.; Liu T.; Chae P. S.; Dror R. O.; Shaw D. E.; Weis W. I.; Wess J.; Kobilka B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529910</ArticleId><ArticleId IdType="pubmed">22358844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme E. C.; Birdsall N. J. M.; Buckley N. J. (1990) Muscarinic Receptor Subtypes. Annu. Rev. Pharmacol. Toxicol. 30, 633&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">2188581</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding T. A.; Birdsall N. J. M.; Curtis C. A. M.; Hulme E. C. (1994) Acetylcholine Mustard Labels the Binding Site Aspartate in Muscarinic Acetylcholine Receptors. J. Biol. Chem. 269, 4092&#x2013;4097.</Citation><ArticleIdList><ArticleId IdType="pubmed">8307968</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin J. A.; Hulme E. C.; Langmead C. J.; Tehan B. G. (2007) Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands. Mol. Pharmacol. 72, 1484&#x2013;1496.</Citation><ArticleIdList><ArticleId IdType="pubmed">17848601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis J. (1997) Allosteric Binding Sites on Muscarinic Receptors. Drug Dev. Res. 40, 193&#x2013;204.</Citation></Reference><Reference><Citation>Wess J. (2005) Allosteric Binding Sites on Muscarinic Acetylcholine Receptors. Mol. Pharmacol. 68, 1506&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gnagey A. L.; Seidenberg M.; Ellis J. (1999) Site-Directed Mutagenesis Reveals Two Epitopes Involved in the Subtype Selectivity of the Allosteric Interactions of Gallamine at Muscarinic Acetylcholine Receptors. Mol. Pharmacol. 56, 1245&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">10570052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazareno S.; Popham A.; Birdsall N. J. M. (2000) Allosteric Interactions of Staurosporine and Other Indolocarbazoles with N-[methyl-3H]Scopolamine and Acetylcholine at Muscarinic Receptor Subtypes: Identification of a Second Allosteric Site. Mol. Pharmacol. 58, 194&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860942</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdsall N. J. M.; Lazareno S.; Popham A.; Saldanha J. (2001) Multiple allosteric sites on muscarinic receptors. Life Sci. 68, 2517&#x2013;2524.</Citation><ArticleIdList><ArticleId IdType="pubmed">11392621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazareno S.; Popham A.; Birdsall N. J. M. (2002) Analogs of WIN 62,577 Define a Second Allosteric Site on Muscarinic Receptors. Mol. Pharmacol. 62, 1492&#x2013;1505.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435818</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza-Fonseca L. M.; Trujillo-Ferrara J. G. (2006) The existence of a second allosteric site on the M1 muscarinic acetylcholine receptor and its implications for drug design. Bioorg. Med. Chem. Lett. 16, 1217&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenakin T.; Christopoulos A. (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discovery 12, 205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411724</ArticleId></ArticleIdList></Reference><Reference><Citation>Valant C.; Felder C. C.; Sexton P. M.; Christopoulos A. (2012) Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects. Mol. Pharmacol. 81, 41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989256</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan W. Y.; McKinzie D. L.; Bose S.; Mitchell S. N.; Witkin J. M.; Thompson R. C.; Christopoulos A.; Lazareno S.; Birdsall N. J. M.; Bymaster F. P.; Felder C. C. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 105, 10978&#x2013;10983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495016</ArticleId><ArticleId IdType="pubmed">18678919</ArticleId></ArticleIdList></Reference><Reference><Citation>Suratman S.; Leach K.; Sexton P. M.; Felder C. C.; Loiacono R. E.; Christopoulos A. (2011) Impact of species variability and &#x2019;probe dependence&#x2019; on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br. J. Pharmacol. 162, 1659&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057301</ArticleId><ArticleId IdType="pubmed">21198541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzafame A.; Christopoulos A.; Mitchelson F. (1997) Three Allosteric Modulators Act at a Common Site, Distinct from that of Competitive Antagonists, at Muscarinic Acetylcholine M2 Receptors. J. Pharmacol. Exp. Ther. 282, 278&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">9223565</ArticleId></ArticleIdList></Reference><Reference><Citation>May L. T.; Avlani V. A.; Langmead C. J.; Herdon H. J.; Wood M. D.; Sexton P. M.; Christopoulos A. (2007) Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors. Mol. Pharmacol. 72, 463&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">17525129</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony J.; Kellershohn K.; Mohr-Andra M.; Kebig A.; Prilla S.; Muth M.; Heller E.; Disingrini T.; Dallanoce C.; Bertoni S.; Schrobang J.; Trankle C.; Kostenis E.; Christopoulos A.; Holtje H.-D.; Barocelli E.; De Amici M.; Holzgrabe U.; Mohr K. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 23, 442&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">18842964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane J. R.; Sexton P. M.; Christopoulos A. (2013) Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol. Sci. 34, 59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23177916</ArticleId></ArticleIdList></Reference><Reference><Citation>Valant C.; Sexton P. M.; Christopoulos A. (2009) Orthosteric/Allosteric Bitopic Ligands - Going Hybrid at GPCRs. Mol. Interventions 9, 125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">19592673</ArticleId></ArticleIdList></Reference><Reference><Citation>Valant C.; Gregory K. J.; Hall N. E.; Scammells P. J.; Lew M. J.; Sexton P. M.; Christopoulos A. (2008) A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity - Muscarinic Partial Agonist McN-A-343 As A Bitopic Orthosteric/Allosteric Ligand. J. Biol. Chem. 283, 29312&#x2013;29321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662018</ArticleId><ArticleId IdType="pubmed">18723515</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdsall N. J. M.; Burgen A. S. V.; Hulme E. C.; Stockton J. M.; Zigmond M. J. (1983) The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart. Br. J. Pharmacol. 78, 257&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2044719</ArticleId><ArticleId IdType="pubmed">6187403</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazareno S.; Birdsall N. J. M. (1995) Detection, Quantitation, and Verification of Allosteric Interactions of Agents with Labeled and Unlabeled Ligands at G Protein-Coupled Receptors: Interactions of Strychnine and Acetylcholine at Muscarinic Receptors. Mol. Pharmacol. 48, 362&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651370</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdsall N. J. M.; Farries T.; Gharagozloo P.; Kobayashi S.; Kuonen D.; Lazareno S.; Popham A.; Sugimoto M. (1997) Selective Allosteric Enhancement of the Binding and Actions of Acetylcholine at Muscarinic Receptor Subtypes. Life Sci. 60, 1047&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9121346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L.; Seager M. A.; Wittman M.; Jacobson M.; Bickel D.; Burno M.; Jones K.; Graufelds V. K.; Xu G.; Pearson M.; McCampbell A.; Gaspar R.; Shughrue P.; Danziger A.; Regan C.; Flick R.; Pascarella D.; Garson S.; Doran S.; Kreatsoulas C.; Veng L.; Lindsley C. W.; Shipe W.; Kuduk S.; Sur C.; Kinney G.; Seabrook G. R.; Ray W. J. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl. Acad. Sci. U.S.A. 106, 15950&#x2013;15955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732705</ArticleId><ArticleId IdType="pubmed">19717450</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T.; Yamada M.; Duttaroy A.; Wess J. (2001) Hyperactivity and Intact Hippocampus-Dependent Learning in Mice Lacking the M1 Muscarinic Acetylcholine Receptor. J. Neurosci. 21, 5239&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762828</ArticleId><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouse S. T.; Hamilton S. E.; Potter L. T.; Nathanson N. M.; Conn P. J. (2000) Muscarinic-induced modulation of potassium conductances is unchanged in mouse hippocampal pyramidal cells that lack functional M1 receptors. Neurosci. Lett. 278, 61&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">10643801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirey J. K.; Brady A. E.; Jones P. J.; Davis A. A.; Bridges T. M.; Kennedy J. P.; Jadhav S. B.; Menon U. N.; Xiang Z.; Watson M. L.; Christian E. P.; Doherty J. J.; Quirk M. C.; Snyder D. H.; Lah J. J.; Levey A. I.; Nicolle M. M.; Lindsley C. W.; Conn P. J. (2009) A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. J. Neurosci. 29, 14271&#x2013;14286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811323</ArticleId><ArticleId IdType="pubmed">19906975</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruana D. A.; Warburton E. C.; Bashir Z. I. (2011) Induction of Activity-Dependent LTD Requires Muscarinic Receptor Activation in Medial Prefrontal Cortex. J. Neurosci. 31, 18464&#x2013;18478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623881</ArticleId><ArticleId IdType="pubmed">22171048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambon C.; Jatzke C.; Wegener N.; Gravius A.; Danysz W. (2012) Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication. Eur. J. Pharmacol. 697, 73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">23085025</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambon C.; Wegener N.; Gravius A.; Danysz W. (2011) A new automated method to assess the rat recognition memory: Validation of the method. Behav. Brain Res. 222, 151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">21421012</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichel A. (2006) The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry. Curr. Drug Metab. 7, 183&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F. V.; Shipe W. D.; Bunda J. L.; Nolt M. B.; Wisnoski D. D.; Zhao Z.; Barrow J. C.; Ray W. J.; Ma L.; Wittman M.; Seager M. A.; Koeplinger K. A.; Hartman G. D.; Lindsley C. W. (2010) Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators. Bioorg. Med. Chem. Lett. 20, 531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">20004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Chang R. K.; Di Marco C. N.; Ray W. J.; Ma L.; Wittman M.; Seager M. A.; Koeplinger K. A.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2010) Quinolizidinone Carboxylic Acids as CNS Penetrant, Selective M1 Allosteric Muscarinic Receptor Modulators. ACS Med. Chem. Lett. 1, 263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007972</ArticleId><ArticleId IdType="pubmed">24900206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Chang R. K.; Di Marco C. N.; Ray W. J.; Ma L.; Wittman M.; Seager M. A.; Koeplinger K. A.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2011) Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series. Bioorg. Med. Chem. Lett. 21, 1710&#x2013;1715.</Citation><ArticleIdList><ArticleId IdType="pubmed">21324684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Di Marco C. N.; Chang R. K.; Ray W. J.; Ma L.; Wittman M.; Seager M. A.; Koeplinger K. A.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2010) Heterocyclic fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorg. Med. Chem. Lett. 20, 2533&#x2013;2537.</Citation><ArticleIdList><ArticleId IdType="pubmed">20303264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Di Marco C. N.; Cofre V.; Pitts D. R.; Ray W. J.; Ma L.; Wittman M.; Seager M.; Koeplinger K.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2010) Pyridine containing M1 positive allosteric modulators with reduced plasma protein binding. Bioorg. Med. Chem. Lett. 20, 657&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">19962304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Di Marco C. N.; Cofre V.; Pitts D. R.; Ray W. J.; Ma L.; Wittman M.; Veng L.; Seager M. A.; Koeplinger K.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2010) N-Heterocyclic derived M1 positive allosteric modulators. Bioorg. Med. Chem. Lett. 20, 1334&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pubmed">20097564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Di Marco C. N.; Cofre V.; Ray W. J.; Ma L.; Wittman M.; Seager M. A.; Koeplinger K. A.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2011) Fused heterocyclic M1 positive allosteric modulators. Bioorg. Med. Chem. Lett. 21, 2769&#x2013;2772.</Citation><ArticleIdList><ArticleId IdType="pubmed">21055928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; DiPardo R. M.; Beshore D. C.; Ray W. J.; Ma L.; Wittman M.; Seager M. A.; Koeplinger K. A.; Thompson C. D.; Hartman G. D.; Bilodeau M. T. (2010) Hydroxy cycloalkyl fused pyridone carboxylic acid M1 positive allosteric modulators. Bioorg. Med. Chem. Lett. 20, 2538&#x2013;2541.</Citation><ArticleIdList><ArticleId IdType="pubmed">20346667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Chang R. K.; Greshock T. J.; Ray W. J.; Ma L.; Wittmann M.; Koeplinger K. A.; Seager M. A.; Thompson C. D.; Hartman G.; Bilodeau M. T. (2012) Identification of Amides as Carboxylic Acid Surrogates for Quinolizidinone-Based M1 Positive Allosteric Modulators. ACS Med. Chem. Lett. 3, 1070&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4025801</ArticleId><ArticleId IdType="pubmed">24900430</ArticleId></ArticleIdList></Reference><Reference><Citation>Uslaner J. M.; Eddins D.; Puri V.; Cannon C. E.; Sutcliffe J.; Chew C. S.; Pearson M.; Vivian J. A.; Chang R. K.; Ray W. J.; Kuduk S. D.; Wittmann M. (2013) The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology 225, 21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22825578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuduk S. D.; Beshore D. C. (2012) Novel M1 allosteric ligands: a patent review. Expert Opin. Ther. Pat. 22, 1385&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">23092292</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlo J. E.; Niswender C. M.; Days E. L.; Bridges T. M.; Xiang Y.; Rodriguez A. L.; Shirey J. K.; Brady A. E.; Nalywajko T.; Luo Q.; Austin C. A.; Baxter Williams M.; Kim K.; Williams R.; Orton D.; Brown H. A.; Lindsley C. W.; Weaver C. D.; Conn P. J. (2009) Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity. Mol. Pharmacol. 75, 577&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684909</ArticleId><ArticleId IdType="pubmed">19047481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges T. M.; Kennedy J. P.; Noetzel M. J.; Breininger M. L.; Gentry P. R.; Conn P. J.; Lindsley C. W. (2010) Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM. Bioorg. Med. Chem. Lett. 20, 1972&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834874</ArticleId><ArticleId IdType="pubmed">20156687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges T. M.; Kennedy J. P.; Cho H. P.; Breininger M. L.; Gentry P. R.; Hopkins C. R.; Conn P. J.; Lindsley C. W. (2010) Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. Bioorg. Med. Chem. Lett. 20, 558&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Melancon B. J.; Poslusney M. S.; Gentry P. R.; Tarr J. C.; Sheffler D. J.; Mattmann M. E.; Bridges T. M.; Utley T. J.; Daniels J. S.; Niswender C. M.; Conn P. J.; Lindsley C. W.; Wood M. R. (2013) Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: Continued optimization of an MLPCN probe molecule. Bioorg. Med. Chem. Lett. 23, 412&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534865</ArticleId><ArticleId IdType="pubmed">23237839</ArticleId></ArticleIdList></Reference><Reference><Citation>Poslusney M. S.; Melancon B. J.; Gentry P. R.; Sheffler D. J.; Bridges T. M.; Utley T. J.; Daniels J. S.; Niswender C. M.; Conn P. J.; Lindsley C. W.; Wood M. R. (2013) Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule. Bioorg. Med. Chem. Lett. 23, 1860&#x2013;1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3594472</ArticleId><ArticleId IdType="pubmed">23416001</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid P. R.; Bridges T. M.; Sheffler D. J.; Cho H. P.; Lewis L. M.; Days E.; Daniels J. S.; Jones C. K.; Niswender C. M.; Weaver C. D.; Conn P. J.; Lindsley C. W.; Wood M. R. (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe. Bioorg. Med. Chem. Lett. 21, 2697&#x2013;2701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082000</ArticleId><ArticleId IdType="pubmed">21194936</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarr J. C.; Turlington M. L.; Reid P. R.; Utley T. J.; Sheffler D. J.; Cho H. P.; Klar R.; Pancani T.; Klein M. T.; Bridges T. M.; Morrison R. D.; Blobaum A. L.; Xiang Z.; Daniels J. S.; Niswender C. M.; Conn P. J.; Wood M. R.; Lindsley C. W. (2012) Targeting Selective Activation of M1 for the Treatment of Alzheimer&#x2019;s Disease: Further Chemical Optimization and Pharmacological Characterization of the M1 Positive Allosteric Modulator ML169. ACS Chem. Neurosci. 3, 884&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503349</ArticleId><ArticleId IdType="pubmed">23173069</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding T. A.; Trotter C.; Skjaerbaek N.; Messier T. L.; Currier E. A.; Burstein E. S.; Li D.; Hacksell U.; Brann M. R. (2002) Discovery of an Ectopic Activation Site on the M1 Muscarinic Receptor. Mol. Pharmacol. 61, 1297&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021390</ArticleId></ArticleIdList></Reference><Reference><Citation>Avlani V. A.; Langmead C. J.; Guida E.; Wood M. D.; Tehan B. G.; Herdon H. J.; Watson J. M.; Sexton P. M.; Christopoulos A. (2010) Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor. Mol. Pharmacol. 78, 94&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">20413650</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead C. J.; Fry V. A. H.; Forbes I. T.; Branch C. L.; Christopoulos A.; Wood M. D.; Herdon H. J. (2006) Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist. Mol. Pharmacol. 69, 236&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207821</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding T. A.; Ma J.-N.; Ott T. R.; Friberg M.; Bajpai A.; Bradley S. R.; Davis R. E.; Brann M. R.; Burstein E. S. (2006) Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation. Mol. Pharmacol. 70, 1974&#x2013;1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M. A.; O&#x2019;Brien J. A.; Pascarella D.; Mallorga P. J.; Scolnick E. M.; Sur C. (2004) Mapping the interaction site of M1 muscarinic receptor allosteric agonists. Soc. Neurosci. Abstr. 30, 846.16.</Citation></Reference><Reference><Citation>Thomas R. L.; Mistry R.; Langmead C. J.; Wood M. D.; Challiss R. A. J. (2008) G Protein Coupling and Signaling Pathway Activation by M1 Muscarinic Acetylcholine Receptor Orthosteric and Allosteric Agonists. J. Pharmacol. Exp. Ther. 327, 365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">18664591</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas R. L.; Langmead C. J.; Wood M. D.; Challiss R. A. J. (2009) Contrasting Effects of Allosteric and Orthosteric Agonists on M1 Muscarinic Acetylcholine Receptor Internalization and Down-regulation. J. Pharmacol. Exp. Ther. 331, 1086&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784718</ArticleId><ArticleId IdType="pubmed">19767446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebon G.; Langmead C. J.; Tehan B. G.; Hulme E. C. (2009) Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors. Mol. Pharmacol. 75, 331&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684897</ArticleId><ArticleId IdType="pubmed">19001633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S. R.; Lameh J.; Ohrmund L.; Son T.; Bajpai A.; Nguyen D.; Friberg M.; Burstein E. S.; Spalding T. A.; Ott T. R.; Schiffer H. H.; Tabatabaei A.; McFarland K.; Davis R. E.; Bonhaus D. W. (2010) AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58, 365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">19835892</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanover K. E.; Veinbergs I.; Davis R. E. (2008) Antipsychotic-Like Behavioural Effects and Cognitive Enhancement by a Potent and Selective Muscarinic M1 Receptor Agonist AC-260584. Behav. Neurosci. 122, 570&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">18513127</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead C. J.; Austin N. E.; Branch C. L.; Brown J. T.; Buchanan K. A.; Davies C. H.; Forbes I. T.; Fry V. A. H.; Hagan J. J.; Herdon H. J.; Jones G. A.; Jeggo R.; Kew J. N. C.; Mazzali A.; Melarange R.; Patel N.; Pardoe J.; Randall A. D.; Roberts C.; Roopun A.; Starr K. R.; Teriakidis A.; Wood M. D.; Whittington M.; Wu Z.; Watson J. (2008) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 154, 1104&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2451039</ArticleId><ArticleId IdType="pubmed">18454168</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan K. A.; Petrovic M. M.; Chamberlain S. E. L.; Marrion N. V.; Mellor J. R. (2010) Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors Is Mediated by Inhibition of SK Channels. Neuron 68, 948&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003154</ArticleId><ArticleId IdType="pubmed">21145007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroki T.; Nagao N.; Nakahara T. (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 172, 199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18772034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sur C.; Mallorga P. J.; Wittmann M.; Jacobson M. A.; Pascarella D.; Williams J. B.; Brandish P. E.; Pettibone D. J.; Scolnick E. M.; Conn P. J. (2003) N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U.S.A. 100, 13674&#x2013;13679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263872</ArticleId><ArticleId IdType="pubmed">14595031</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D. R.; Dada A.; Jones G. A.; Deisz R. A.; Gigout S.; Langmead C. J.; Werry T. D.; Hendry N.; Hagan J. J.; Davies C. H.; Watson J. M. (2010) N-Desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor. Neuropharmacology 58, 1206&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">20206188</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones C. K.; Brady A. E.; Davis A. A.; Xiang Z.; Bubser M.; Noor Tantawy M.; Kane A. S.; Bridges T. M.; Kennedy J. P.; Bradley S. R.; Peterson T. E.; Ansari M. S.; Baldwin R. M.; Kessler R. M.; Deutch A. Y.; Lah J. J.; Levey A. I.; Lindsley C. W.; Conn P. J. (2008) Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats. J. Neurosci. 28, 10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges T. M.; Brady A. E.; Kennedy J. P.; Daniels R. N.; Miller N. R.; Kim K.; Breininger M. L.; Gentry P. R.; Brogan J. T.; Jones C. K.; Conn P. J.; Lindsley C. W. (2008) Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorg. Med. Chem. Lett. 18, 5439&#x2013;5442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177598</ArticleId><ArticleId IdType="pubmed">18805692</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller N. R.; Daniels R. N.; Bridges T. M.; Brady A. E.; Conn P. J.; Lindsley C. W. (2008) Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas-The effect of capping the distal basic piperidine nitrogen. Bioorg. Med. Chem. Lett. 18, 5443&#x2013;5447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177607</ArticleId><ArticleId IdType="pubmed">18829311</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffler D. J.; Sevel C.; Le U.; Lovett K. M.; Tarr J. C.; Carrington S. J. S.; Cho H. P.; Digby G. J.; Niswender C. M.; Conn P. J.; Hopkins C. R.; Wood M. R.; Lindsley C. W. (2013) Further exploration of M1 allosteric agonists: Subtle structural changes abolish M1 allosteric agonism and result in pan-mAChR orthosteric antagonism. Bioorg. Med. Chem. Lett. 23, 223&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3525729</ArticleId><ArticleId IdType="pubmed">23200253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebois E. P.; Bridges T. M.; Lewis L. M.; Dawson E. S.; Kane A. S.; Xiang Z.; Jadhav S. B.; Yin H.; Kennedy J. P.; Meiler J.; Niswender C. M.; Jones C. K.; Conn P. J.; Weaver C. D.; Lindsley C. W. (2010) Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M1 Receptor Function in the Central Nervous System. ACS Chem. Neurosci. 1, 104&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180826</ArticleId><ArticleId IdType="pubmed">21961051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebois E. P.; Digby G. J.; Sheffler D. J.; Melancon B. J.; Tarr J. C.; Cho H. P.; Miller N. R.; Morrison R.; Bridges T. M.; Xiang Z.; Daniels J. S.; Wood M. R.; Conn P. J.; Lindsley C. W. (2011) Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg. Med. Chem. Lett. 21, 6451&#x2013;6455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190051</ArticleId><ArticleId IdType="pubmed">21930376</ArticleId></ArticleIdList></Reference><Reference><Citation>Melancon B. J.; Gogliotti R. D.; Tarr J. C.; Saleh S. A.; Chauder B. A.; Lebois E. P.; Cho H. P.; Utley T. J.; Sheffler D. J.; Bridges T. M.; Morrison R. D.; Daniels J. S.; Niswender C. M.; Conn P. J.; Lindsley C. W.; Wood M. R. (2012) Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Bioorg. Med. Chem. Lett. 22, 3467&#x2013;3472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348459</ArticleId><ArticleId IdType="pubmed">22507963</ArticleId></ArticleIdList></Reference><Reference><Citation>Digby G. J.; Noetzel M. J.; Bubser M.; Utley T. J.; Walker A. G.; Byun N. E.; Lebois E. P.; Xiang Z.; Sheffler D. J.; Cho H. P.; Davis A. A.; Nemirovsky N. E.; Mennenga S. E.; Camp B. W.; Bimonte-Nelson H. A.; Bode J.; Italiano K.; Morrison R.; Daniels J. S.; Niswender C. M.; Olive M. F.; Lindsley C. W.; Jones C. K.; Conn P. J. (2012) Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioural Effects in Animal Models. J. Neurosci. 32, 8532&#x2013;8544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3398407</ArticleId><ArticleId IdType="pubmed">22723693</ArticleId></ArticleIdList></Reference><Reference><Citation>Digby G. J.; Utley T. J.; Lamsal A.; Sevel C.; Sheffler D. J.; Lebois E. P.; Bridges T. M.; Wood M. R.; Niswender C. M.; Lindsley C. W.; Conn P. J. (2012) Chemical Modification of the M1 Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode. ACS Chem. Neurosci. 3, 1025&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526969</ArticleId><ArticleId IdType="pubmed">23259038</ArticleId></ArticleIdList></Reference><Reference><Citation>Sams A. G.; Hentzer M.; Mikkelsen G. K.; Larsen K.; Bundgaard C.; Plath N.; Christoffersen C. T.; Bang-Andersen B. (2010) Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M1 Receptor Agonist with Unprecedented Selectivity and Procognitive Potential. J. Med. Chem. 53, 6386&#x2013;6397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20684563</ArticleId></ArticleIdList></Reference><Reference><Citation>Sams A. G.; Larsen K.; Mikkelsen G. K.; Hentzer M.; Christoffersen C. T.; Jensen K. G.; Frederiksen K.; Bang-Andersen B. (2012) Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential. Bioorg. Med. Chem. Lett. 22, 5134&#x2013;5140.</Citation><ArticleIdList><ArticleId IdType="pubmed">22677319</ArticleId></ArticleIdList></Reference><Reference><Citation>Budzik B.; Garzya V.; Shi D.; Foley J. J.; Rivero R. A.; Langmead C. J.; Watson J.; Wu Z.; Forbes I. T.; Jin J. (2010) 2&#x2032; Biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR. Bioorg. Med. Chem. Lett. 20, 3540&#x2013;3544.</Citation><ArticleIdList><ArticleId IdType="pubmed">20483611</ArticleId></ArticleIdList></Reference><Reference><Citation>Budzik B.; Garzya V.; Shi D.; Walker G.; Lauchart Y.; Lucas A. J.; Rivero R. A.; Langmead C. J.; Watson J.; Wu Z.; Forbes I. T.; Jin J. (2010) 2&#x2032; Biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling. Bioorg. Med. Chem. Lett. 20, 3545&#x2013;3549.</Citation><ArticleIdList><ArticleId IdType="pubmed">20483599</ArticleId></ArticleIdList></Reference><Reference><Citation>Budzik B.; Garzya V.; Shi D.; Walker G.; Woolley-Roberts M.; Pardoe J.; Lucas A.; Tehan B.; Rivero R. A.; Langmead C. J.; Watson J.; Wu Z.; Forbes I. T.; Jin J. (2010) Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists. ACS Med. Chem. Lett. 1, 244&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007837</ArticleId><ArticleId IdType="pubmed">24900202</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D. J.; Forbes I. T.; Watson S. P.; Garzya V.; Stevenson G. I.; Walker G. R.; Mudhar H. S.; Flynn S. T.; Wyman P. A.; Smith P. W.; Murkitt G. S.; Lucas A. J.; Mookherjee C. R.; Watson J. M.; Gartlon J. E.; Bradford A. M.; Brown F. (2010) The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. Bioorg. Med. Chem. Lett. 20, 5434&#x2013;5438.</Citation><ArticleIdList><ArticleId IdType="pubmed">20709550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan P. J.; Watson J.; Lund J.; Davies C. H.; Peters G.; Dodds C. M.; Swirski B.; Lawrence P.; Bentley G. D.; O&#x2019;Neill B. V.; Robertson J.; Watson S.; Jones G. A.; Maruff P.; Croft R. J.; Laruelle M.; Bullmore E. T. (2013) The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int. J. Neuropsychopharmacol. 16, 721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">22932339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23597931</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).</ArticleTitle><Pagination><StartPage>908</StartPage><EndPage>916</EndPage><MedlinePgn>908-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2012.08.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(13)00108-5</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the proportion of elderly people with a first psychotic episode actually suffering from dementia, especially Alzheimer disease (AD), by using cerebrospinal fluid (CSF) biomarkers.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective case-control study.</AbstractText><AbstractText Label="SETTING AND PARTICIPANTS" NlmCategory="METHODS">Sixty-six patients age 65 years and older with recent psychotic symptoms and 12 comparison subjects with chronic schizophrenia over 10 years that were referred to acute old age psychiatry, in-ward treatment.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Concentration levels of CSF A&#x3b2;42, tau and p-tau-181 measured by ELISA compared to clinical diagnosis made by a multiprofessional team of one neurologist and several psychiatrists.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The CSF specimen was obtained from 51 (65.4%) of the patients. In five subjects out of 13 with a clinical diagnosis of AD, all the CSF biomarkers (A&#x3b2;42, tau and p-tau) were normal. Only one patient out of 25 with a psychiatric diagnosis and none out of the comparison group with schizophrenia showed a CSF profile typical of AD. Three patients with an AD diagnosis, four patients with a psychiatric diagnosis and one patient with schizophrenia had a low A&#x3b2;42 concentration with normal levels of tau or p-tau. The patients with AD had lower CSF A&#x3b2;42 levels than other patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The CSF biomarkers are important and useful as part of the diagnostic procedure for detecting AD and other dementia in elderly patients displaying psychotic symptoms. The accuracy of AD diagnosis encounters problems due to atypical behavioural symptoms in psychiatric settings and thus the differential diagnostics can be improved by using CSF biomarkers of AD more frequently.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sepp&#xe4;l&#xe4;</LastName><ForeName>Toni T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. Electronic address: toni.seppala@fimnet.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louhija</LastName><ForeName>Ulla-Marja</ForeName><Initials>UM</Initials><AffiliationInfo><Affiliation>Unit of Psychogeriatrics, Division of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appelberg</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit of Psychogeriatrics, Division of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Neurology of NeuroCenter, Kuopio University Hospital, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juva</LastName><ForeName>Kati</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Unit of Psychogeriatrics, Division of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">Late-onset psychosis</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23597931</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2012.08.020</ArticleId><ArticleId IdType="pii">S1064-7481(13)00108-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23582751</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias.</ArticleTitle><Pagination><StartPage>580</StartPage><EndPage>586</EndPage><MedlinePgn>580-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2012.11.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(12)00063-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether the 5HTTLPR serotonin transporter polymorphism is associated with delusions and hallucinations in people with dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 187 individuals, recruited from centres in Norway, Sweden, and the United Kingdom were included in this study; 97 with clinically or neuropathologically diagnosed DLB/PDD and 90 cognitively normal individuals as a comparison group.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">All participants with dementia underwent serial evaluation of neuropsychiatric symptoms to assess the presence of persistent delusions and hallucinations using the Columbia University Scale for Psychopathology in Alzheimer disease, the Neuropsychiatric Inventory, or the Present Behavioural Examination. Severity of cognitive impairment was measured using the Mini Mental State Examination (MMSE). Individuals were genotyped for the 5HTTLPR polymorphism.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Logistic regression demonstrated that homozygosity for the L/L genotype and lower MMSE were associated with an increased risk for delusions (odds ratio: 11.5 and 1.16, respectively). Neither was significantly associated with hallucinations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study is the first to demonstrate the 5HTTLPR polymorphism is associated with delusions in Lewy body dementias, with important implications regarding the mechanisms underlying this symptom across the AD/DLB/PDD spectrum. Further studies are warranted to investigate this relationship further and examine treatment opportunities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Creese</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; Department of Geriatric Medicine, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Londos</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Sciences Unit, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, United Kingdom. Electronic address: emma.3.jones@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">5HTTLPR</Keyword><Keyword MajorTopicYN="N">Parkinson disease dementia</Keyword><Keyword MajorTopicYN="N">SLC6A4</Keyword><Keyword MajorTopicYN="N">dementia with Lewy bodies</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23582751</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2012.11.001</ArticleId><ArticleId IdType="pii">S1064-7481(12)00063-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23567389</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Attributional style and theory of mind in people with Alzheimer disease and persecutory delusions.</ArticleTitle><Pagination><StartPage>898</StartPage><EndPage>905</EndPage><MedlinePgn>898-905</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2013.01.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(13)00025-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Between 7% and 40% of people with Alzheimer disease (AD) experience persecutory delusions (PDs) during the course of their dementia. Although attributional style and theory of mind processes have been linked with PDs in people with psychosis, they have not yet been examined in those with AD and PDs. The objective of this study was, hence, to explore the role of these cognitive processes in groups of participants with AD with and without PDs, as well as a nonclinical comparison group.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Measures of attributional style and theory of mind were administered to three groups: people with AD and PDs (n = 22), people with AD without PDs (n = 22), and a nonclinical group (n = 23).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although no clear differences in attributional style between the three groups were found, the group with AD and PDs were found to perform worse on the first-order (but not second-order) theory of mind task than the other two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Interventions designed to enhance theory of mind skills might be beneficial for individuals with AD and PDs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rowse</LastName><ForeName>Georgina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Psychology Unit, The University of Sheffield, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy-Jones</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Corcoran</LastName><ForeName>Rhiannon</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bentall</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012938" MajorTopicYN="Y">Social Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056345" MajorTopicYN="N">Theory of Mind</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">attribution</Keyword><Keyword MajorTopicYN="N">delusions</Keyword><Keyword MajorTopicYN="N">persecutory</Keyword><Keyword MajorTopicYN="N">theory of mind</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23567389</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2013.01.020</ArticleId><ArticleId IdType="pii">S1064-7481(13)00025-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23567373</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptom clusters of Alzheimer disease in Hong Kong Chinese: correlates with caregiver burden and depression.</ArticleTitle><Pagination><StartPage>1029</StartPage><EndPage>1037</EndPage><MedlinePgn>1029-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2013.01.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(13)00046-8</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the relative effects of different neuropsychiatric syndromes of Alzheimer disease (AD) on caregiver burden and depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred forty-two Chinese family carers of persons with AD were individually interviewed using Neuropsychiatric Inventory (NPI), Revised Memory and Behavior Problems Checklist (RMBPC), Zarit Burden Interview, Pearlin's measure of role overload, Hamilton Depression Rating Scale, and other relevant measures (e.g., caregiving hours per week, relationship to care recipient [CR], CR's functional impairment). CRs were administered the Cantonese version of the Mini-Mental State Examination. AD severity was determined by Clinical Dementia Rating. NPI and RMBPC items were scored according to syndromal classifications (NPI: behavior problems, psychosis, mood disturbance, euphoria; RMBPC: disruptive behaviors, depression, memory-related problems). Data were analyzed using multiple regression, with caregiver gender, caregiving hours per week, and CR's functional impairment as covariates. The analysis with Hamilton depression as the outcome variable also included Zarit burden and role overload as predictors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">NPI behavior and NPI mood were consistent predictors of Zarit burden and role overload. RMBPC memory predicted Zarit burden. No other neuropsychiatric syndromes had independent effects on burden and overload. After partializing out the effects of burden, overload, and other covariates, NPI behavior was the only syndrome that predicted caregiver depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Not all neuropsychiatric symptoms affected caregiver burden and depression, and overt behavior problems and mood disturbances were consistent predictors of burden.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Sheung-Tak</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Psychological Studies and Center for Psychosocial Health and Aging, Hong Kong Institute of Education, Hong Kong. Electronic address: takcheng@ied.edu.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Linda C W</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="Y">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">caregiver burden</Keyword><Keyword MajorTopicYN="N">caregiver depression</Keyword><Keyword MajorTopicYN="N">neuropsychiatric symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23567373</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2013.01.041</ArticleId><ArticleId IdType="pii">S1064-7481(13)00046-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23567368</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality.</ArticleTitle><Pagination><StartPage>1135</StartPage><EndPage>1143</EndPage><MedlinePgn>1135-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2013.01.051</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(13)00056-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To establish the prevalence, incidence, persistence, risk factors, and mortality risk increase of psychosis of Alzheimer disease (PoAD) in a clinical sample.</AbstractText><AbstractText Label="DESIGN, PARTICIPANTS, AND MEASUREMENTS" NlmCategory="METHODS">Cross-sectional, observational study of 491 patients with probable AD who, at baseline visit, were evaluated with the Cambridge Examination for Mental Disorders of the Elderly, the Neuropsychiatric Inventory-10, the Rapid Disability Rating Scale-2, and the Zarit Burden Interview. All participants were reevaluated at 6, 12, 18, and 24 months. PoAD diagnoses were made using specific criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PoAD prevalence was 7.3%, and the cumulative incidence at 6, 12, 18, and 24 months was 5.8%, 10.6%, 13.5%, and 15.1%, respectively. After 1 year, psychotic symptoms persisted in 68.7% of the patients with initial PoAD. At baseline, patients with PoAD scored lower in the Cambridge Cognitive Examination and Mini-Mental State Examination and higher in the Rapid Disability Rating Scale-2 and Zarit Burden Interview tests. Both low scores in the Cambridge Cognitive Examination subscale of learning memory (hazard ratio [HR] = 0.874; 95% CI: 0.788-0.969; Wald &#x3c7;2 = 6.515; df = 1) and perception (HR = 0.743; 95% CI: 0.610-0.904; Wald &#x3c7;2 = 8.778; df = 1), and high scores in expressive language (HR = 1.179; 95% CI: 1.024-1.358; Wald &#x3c7;2 = 5.261; df = 1) and calculation skills (HR = 1.763; 95% CI: 1.067-2.913; Wald &#x3c7;2 = 4.905; df = 1) were found to be associated with PoAD. PoAD leads to a faster functional impairment, and it increases mortality risk (HR = 2.191; 95% CI: 1.136-4.228; Wald &#x3c7;2 = 5.471; df = 1) after controlling for age, gender, cognitive and functional disability, general health status, and antipsychotic treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PoAD seems to define a phenotype of AD of greater severity, with worsened functional progression and increased mortality risk.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilalta-Franch</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit, Institut d'Assist&#xe8;ncia Sanit&#xe0;ria, Salt, Spain; Dementia Unit, Hospital de Santa Caterina, Salt, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Pousa</LastName><ForeName>Secundino</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Calv&#xf3;-Perxas</LastName><ForeName>Laia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Garre-Olmo</LastName><ForeName>Josep</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer disease</Keyword><Keyword MajorTopicYN="N">cohort studies</Keyword><Keyword MajorTopicYN="N">delusions</Keyword><Keyword MajorTopicYN="N">hallucinations</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">psychotic disorders</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23567368</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2013.01.051</ArticleId><ArticleId IdType="pii">S1064-7481(13)00056-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23562430</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future.</ArticleTitle><Pagination><StartPage>602</StartPage><EndPage>608</EndPage><MedlinePgn>602-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2012.12.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(12)02570-8</ELocationID><Abstract><AbstractText>Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling. This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented with emotional distress and delusions of infidelity/excessive jealousy, followed by cognitive symptoms. Being cognizant of this, in 2010 the Alzheimer's Association convened a research roundtable on the topic of NPS in AD. A major outcome of the roundtable was the founding of a Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART). The NPS-PIA has prepared a series of documents that are intended to summarize the literature and provide more detailed specific recommendations for NPS research. This overview paper is the first of these living documents that will be updated periodically as the science advances. The overview is followed by syndrome-specific synthetic reviews and recommendations prepared by NPS-PIA workgroups on depression, apathy, sleep, agitation, and psychosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, College of Medicine, Mayo Clinic, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Gitlin</LastName><ForeName>Laura N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Gwenn S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Jovier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lanct&#xf4;t</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Paul T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Padala</LastName><ForeName>Prasad P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadikaobi U</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Luis Ag&#xfc;era</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Ancoli-Israel</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bliwise</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Vitiello</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zee</LastName><ForeName>Phyllis C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Khin</LastName><ForeName>Ni A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Alfaro</LastName><ForeName>Cara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Patrick S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><CollectiveName>Neuropsychiatric Syndromes Professional Interest Area of ISTAART</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R24 MH074779</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041633</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038893</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01-MH68351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH079814</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024150</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR024150</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24-MH074779</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1-MH090770-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH068351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022254</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR014200</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 MH090770</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Agitation/aggression</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Apathy</Keyword><Keyword MajorTopicYN="N">Behavioral and psychological symptoms of dementia</Keyword><Keyword MajorTopicYN="N">Delusions</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Hallucinations</Keyword><Keyword MajorTopicYN="N">Mild behavioral impairment</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric symptoms</Keyword><Keyword MajorTopicYN="N">Psychosis</Keyword><Keyword MajorTopicYN="N">Sleep disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23562430</ArticleId><ArticleId IdType="mid">NIHMS465719</ArticleId><ArticleId IdType="pmc">PMC3766403</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2012.12.001</ArticleId><ArticleId IdType="pii">S1552-5260(12)02570-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Martin JB. The integration of neurology, psychiatry, and neuroscience in the 21st century. Am J Psychiatry. 2002;159:695&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">11986119</ArticleId></ArticleIdList></Reference><Reference><Citation>Price BH, Adams RD, Coyle JT. Neurology and psychiatry: closing the great divide. Neurology. 2000;54:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10636118</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. Uber eine eigenartige erkrankung der hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin. 1907;64:146&#x2013;148.</Citation></Reference><Reference><Citation>American Psychiatric Association. American Psychiatric Association . Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed American Psychiatric Association; Washington, DC: 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984:34.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS. Organising the language of Alzheimer&#x2019;s disease in light of biomarkers. Lancet Neurol. 2010;9:1044&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934913</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol. 2010;9:1118&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. From sensation to cognition. Brain. 1998;121:1013&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:532&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299979</ArticleId><ArticleId IdType="pubmed">21889116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer&#x2019;s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23:271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821241</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Werner P, Marx MS. An observational study of agitation in agitated nursing home residents. Int Psychogeriatr. 1989;1:153&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2491142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer&#x2019;s disease. Am J Psychiatry. 1989;146:577&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, et al. The consortium to establish a registry for Alzheimer&#x2019;s disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer&#x2019;s disease. Neurology. 1993;43:2457&#x2013;2465.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799&#x2013;812.</Citation></Reference><Reference><Citation>Wilkinson IM, Graham-White J. Psychogeriatric dependency rating scales (PGDRS): a method of assessment for use by nurses. Br J Psychiatry. 1980;137:558&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pubmed">6452189</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmes E, Csapo KG, Short JA. Standardization and validation of the Multidimensional Observation Scale for Elderly Subjects (MOSES) J Gerontol. 1987;42:395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">3598087</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Truax P, Logsdon R, Uomoto J, Zarit S, Vitaliano PP. Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist. Psychol Aging. 1992;7:622&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">1466831</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, et al. Scales as outcome measures for Alzheimer&#x2019;s disease. Alzheimers Dement. 2009;5:324&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560103</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739066</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer&#x2019;s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry. 2008;23:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">17879256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. N Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord. 2004;18:17&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Ozsarfati Y, Beard CM, O&#x2019;Brien PC, Rocca WA. Impact of referral bias on clinical and epidemiological studies of Alzheimer&#x2019;s disease. J Clin Epidemiol. 1996;49:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Kukull W, Sheppard L, Barnhart RL, Peskind E, Edland SD, et al. Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer&#x2019;s disease samples. J Am Geriatr Soc. 1996;44:704&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">8642164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer&#x2019;s disease clusters into three groups: the Cache County study. [see comments.] Int J Geriatr Psychiatry. 2001;16:1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002;288:1475&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJ, Pankratz VS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65:1193&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575648</ArticleId><ArticleId IdType="pubmed">18838636</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone C, et al. Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer&#x2019;s disease: the role of depression and apathy. J Alzheimers Dis. 2010;20:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22:984&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314709</ArticleId><ArticleId IdType="pubmed">20594384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranzler HR, Kadden RM, Babor TF, Rounsaville BJ. Longitudinal, expert, all data procedure for psychiatric diagnosis in patients with psychoactive substance use disorders. J Nerv Ment Dis. 1994;182:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678309</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2009;21:144&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622685</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. &#x2019;Vascular depression&#x2019; hypothesis. Arch Gen Psychiatry. 1997;54:915&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">9337771</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS. The vascular depression hypothesis: 10 years later. Biol Psychiatry. 2006;60:1304&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">17157096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol. 1990;47:209&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">1689144</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, &#x201c;prefrontal&#x201d; and &#x201c;limbic&#x201d; functions. Prog Brain Res. 1990;85:119&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">2094891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50:873&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">8352676</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch EE. Basic Neurosciences with Clinical Applications. Butterworth Heinemann/Elsevier; Philadelphia: 2006.</Citation></Reference><Reference><Citation>Geschwind N, Kaplan E. A human cerebral deconnection syndrome. A preliminary report. Neurology. 1962;12:675&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">13898109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Principles of Behavioral Neurology. F.A. Davis; Philadelphia: 1985.</Citation></Reference><Reference><Citation>Mesulam MM. Principles of Behavioral and Cognitive Neurology. 2nd ed Oxford University Press; Oxford; New York: 2000. pp. 1&#x2013;120.</Citation></Reference><Reference><Citation>Mesulam MM. Large-scale neurocognitive networks and distributed processing for attention, language, and memory. Ann Neurol. 1990;28:597&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">2260847</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GS, Kramer E, Hermann C, Ma Y, Dhawan V, Chaly T, et al. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry. 2009;66:259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706292</ArticleId><ArticleId IdType="pubmed">19368900</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GS, Kramer E, Ma Y, Hermann CR, Dhawan V, Chaly T, et al. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer&#x2019;s disease. Brain. 2009;132:392&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640217</ArticleId><ArticleId IdType="pubmed">19153152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer&#x2019;s disease. Am J Psychiatry. 2003;160:341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562582</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology. 2009;72:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818181</ArticleId><ArticleId IdType="pubmed">19204262</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64:1015&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620493</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GS, Gunning-Dixon FM, Lotrich FE, Taylor WD, Evans JD. Translational research in late-life mood disorders: implications for future intervention and prevention research. Neuropsychopharmacology. 2007;32:1857&#x2013;1875.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. 2001;13:401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">12003247</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer&#x2019;s disease: a review. J Alzheimers Dis. 2010;19:761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord. 2008;22:261&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636843</ArticleId><ArticleId IdType="pubmed">18580591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Psychiatric history and related exposures as risk factors for Alzheimer&#x2019;s disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20:S43&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">1917269</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm A, van Duijn C, Chandra V, Fratiglioni L, Graves A, Heyman A, et al. Psychiartric history and related exposures as risk factors for Alzheimer&#x2019;s disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20:S43&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pubmed">1917269</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006;63:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">16533972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015810</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58:1465&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955191</ArticleId><ArticleId IdType="pubmed">20662955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalon L, Gum AM, Feliciano L, Arean PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166:2182&#x2013;2188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101935</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003;290:2015&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Nonpharmacological interventions for persons with dementia. Alzheimers Care Today. 2005;6:129&#x2013;145.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23543555</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.</ArticleTitle><Pagination><StartPage>CD007726</StartPage><MedlinePgn>CD007726</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD007726.pub2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antipsychotic agents are often used to treat neuropsychiatric symptoms (NPS) in dementia, although the literature is sceptical about their long-term use for this indication. Their effectiveness is limited and there is concern about adverse effects, including higher mortality with long-term use. When behavioural strategies have failed and drug therapy is instituted, regular attempts to withdraw these drugs are recommended. Physicians, nurses and families of older people with dementia are often reluctant to try to stop antipsychotics, fearing deterioration of NPS. Strategies to reduce antipsychotic use have been proposed, but a systematic review of interventions aimed at withdrawal of antipsychotic agents in older people with dementia has not yet been performed.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate whether withdrawal of antipsychotic agents is successful in older people with dementia in community or nursing home settings, to list the different strategies for withdrawal of antipsychotic agents in older people with dementia and NPS, and to measure the effects of withdrawal of antipsychotic agents on behaviour.</AbstractText><AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">ALOIS, the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, clinical trials registries and grey literature sources were searched on 23 November 2012. The search included the following terms: antipsychotic* or neuroleptic* or phenothiazines or butyrophenones or risperidone or olanzapine or haloperidol or prothipendyl or methotrimeprazine or clopenthixol or flupenthixol or clothiapine or metylperon or droperidol or pipamperone or benperidol or bromperidol or fluspirilene or pimozide or penfluridol or sulpiride or veralipride or levosulpiride or sultopride or aripiprazole or clozapine or quetiapine or thioridazine combined wither terms such as discontinu* or withdraw* or cessat* or reduce* or reducing or reduct* or taper* or stop*.ALOIS contains records from all major healthcare databases (The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), as well as from many clinical trials registries and grey literature sources.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised, placebo-controlled trials comparing an antipsychotic withdrawal strategy to continuation of antipsychotics in people with dementia.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Review authors independently assessed trials for inclusion, rated their risk of bias and extracted data.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included nine trials with 606 randomised participants. Seven trials were conducted in nursing homes, one trial in an outpatient setting and one in both settings. In these trials, different types of antipsychotics prescribed at different doses were withdrawn. Both abrupt and gradual withdrawal schedules were used. The risk of bias of the included studies was generally low regarding blinding and outcome reporting and unclear for randomisation procedures and recruitment of participants.There was a wide variety of outcome measures. Our primary efficacy outcomes were success of withdrawal (i.e. remaining in study off antipsychotics) and NPS. Eight of nine trials reported no overall significant difference between groups on the primary outcomes, although in one pilot study of people with psychosis and agitation that had responded to haloperidol, time to relapse was significantly shorter in the discontinuation group (Chi(2) = 4.1, P value = 0.04). The ninth trial included people with psychosis or agitation who had responded well to risperidone therapy for four to eight months and reported that discontinuation led to an increased risk of relapse, that is, increase in the Neuropsychiatric Inventory (NPI)-core score of 30% or greater (P value = 0.004, hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.09 to 3.45 at four months). The only outcome that could be pooled was the full NPI-score, used in two studies. For this outcome there was no significant difference between people withdrawn from and those continuing on antipsychotics at three months (mean difference (MD) -1.49, 95% CI -5.39 to 2.40). These two studies reported subgroup analyses according to baseline NPI-score (14 or less versus &gt; 14). In one study, those with milder symptoms at baseline were significantly less agitated at three months in the discontinuation group (NPI-agitation, Mann-Whitney U test z = 2.4, P value = 0.018). In both studies, there was evidence of significant behavioural deterioration in people with more severe baseline NPS who were withdrawn from antipsychotics (Chi(2) = 6.8; P value = 0.009 for the marked symptom score in one study).Individual studies did not report significant differences between groups on any other outcome except one trial that found a significant difference in a measure of verbal fluency, favouring discontinuation. Most trials lacked power to detect clinically important differences between groups.Adverse events were not systematically assessed. In one trial there was a non-significant increase in mortality in people who continued antipsychotic treatment (5% to 8% greater than placebo, depending on the population analysed, measured at 12 months). This trend became significant three years after randomisation, but due to dropout and uncertainty about the use of antipsychotics in this follow-up period this result should be interpreted with caution.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that many older people with Alzheimer's dementia and NPS can be withdrawn from chronic antipsychotic medication without detrimental effects on their behaviour. It remains uncertain whether withdrawal is beneficial for cognition or psychomotor status, but the results of this review suggest that discontinuation programmes could be incorporated into routine practice. However, two studies of people whose agitation or psychosis had previously responded well to antipsychotic treatment found an increased risk of relapse or shorter time to relapse after discontinuation. Two other studies suggest that people with more severe NPS at baseline could benefit from continuing their antipsychotic medication. In these people, withdrawal might not be recommended.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Declercq</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Practice and Primary Health Care, Ghent University, Ghent, Belgium. tomrw.declercq@ugent.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovic</LastName><ForeName>Mirko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Azermai</LastName><ForeName>Majda</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vander Stichele</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>De Sutter</LastName><ForeName>An I M</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>van Driel</LastName><ForeName>Mieke L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Christiaens</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2013 Aug;16(3):81. doi: 10.1136/eb-2013-101372</RefSource><PMID Version="1">23766414</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23543555</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD007726.pub2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23504051</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>260</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study.</ArticleTitle><Pagination><StartPage>1859</StartPage><EndPage>1865</EndPage><MedlinePgn>1859-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-013-6893-3</ELocationID><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD) represent common manifestations among patients affected by Alzheimer's disease (AD). Some reports have recently classified BPSD into specific clusters/subsyndromes exploring the internal structure of the Neuropsychiatric Inventory (NPI). We evaluated whether specific behavioral subsyndromes are associated with worsening cognitive function. Mild to moderate AD patients were recruited from the cohort of the Impact of Cholinergic Treatment USe (ICTUS) study. Neuropsychiatric symptoms were classified in three subsyndromes, identified at baseline, grouping different combinations of NPI items: (1) "psychotic" ("delusions" and/or "hallucinations"); (2) "affective" ("agitation" and/or "depression" and/or "anxiety" and/or "irritability"); and (3) "behavioral" ("euphoria" and/or "apathy" and/or "disinhibition" and/or "aberrant motor behavior"). Mixed model analyses were performed to measure six-monthly changes in the ADAS-Cog score over a follow-up of 2 years, according to these subsyndromes. All analyses were stratified according to AD severity as defined by the Clinical Dementia Rating (CDR). A total of 1,375 AD subjects were recruited. No NPI cluster was found to significantly (p &lt; 0.05) affect the rate of cognitive decline across the 3 CDR classes. Our results suggest that the cognitive course of AD is not substantially influenced by the presence of specific neuropsychiatric phenotypes. Further studies are needed to extend the present findings and identify possible biological and clinical bases for behavioral subsyndromes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canevelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Clinic, Department of Neurology and Psychiatry, "Sapienza" University, Viale dell'Universit&#xe0; 30, 00185 Rome, Italy. marco.canevelli@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adali</LastName><ForeName>Nawal</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Cantet</LastName><ForeName>Christelle</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Andrieu</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cesari</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><CollectiveName>ICTUS/DSA Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Vellas</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynish</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ousset</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrieu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frisoni</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salmon</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zekry</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boada</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dartigues</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olde-Rikkert</LastName><ForeName>M G M</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rigaud</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winblad</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malick</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinclair</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheltens</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ribera</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touchon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salva</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waldmar</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bullock</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costa-Tsolaki</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spiru</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stiens</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoppe</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eriksdotter J&#xf6;nhagen</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherubini</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lage</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camus</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ag&#xfc;era-Morales</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrieu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantet</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coley</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23504051</ArticleId><ArticleId IdType="doi">10.1007/s00415-013-6893-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int Psychogeriatr. 2010 Mar;22(2):281-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19781112</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1963 Sep 21;185:914-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14044222</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2010 Mar;6(2):98-103</Citation><ArticleIdList><ArticleId IdType="pubmed">20298969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1969 Autumn;9(3):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Health Aging. 2010 Apr;14(4):288-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20305996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;17(1):105-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19494435</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):8-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16361584</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroepidemiology. 2007;29(1-2):29-38</Citation><ArticleIdList><ArticleId IdType="pubmed">17898521</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1993 Nov;43(11):2412-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Jan;19(1):85-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14716704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 1996;8 Suppl 3:497-500</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;22(4):1157-67</Citation><ArticleIdList><ArticleId IdType="pubmed">20930289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10026387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2010 Jan;6(1):39-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19592311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1980 Dec;20(6):649-55</Citation><ArticleIdList><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2005 Nov;20(7):490-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16310680</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Sep 25;288(12):1475-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2011 May;19(5):403-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21522049</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2007 Sep;22(9):896-901</Citation><ArticleIdList><ArticleId IdType="pubmed">17343292</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2011 Aug;122(2):117-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21455688</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Nov;141(11):1356-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Feb 28;66(4):523-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16505306</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 May;48(5 Suppl 6):S10-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2007;24(6):457-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2010 Mar;22(2):300-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19906327</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2008;25(6):564-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18544978</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 Jun;20(6):523-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15920712</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2011 Sep;68(9):1124-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21911694</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2004 Jan;38(1):105-11</Citation><ArticleIdList><ArticleId IdType="pubmed">14690773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23456959</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4421</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</Title><ISOAbbreviation>Gesundheitswesen</ISOAbbreviation></Journal><ArticleTitle>[Social and economic consequences of night-time aircraft noise in the vicinity of Frankfurt/Main airport].</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>133</EndPage><MedlinePgn>127-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0033-1333785</ELocationID><Abstract><AbstractText>A prospective calculation of disease-related social and economic costs due to night-time aircraft noise in the vicinity of Frankfurt/Main airport was performed for the calendar years 2012-2021. It was based on risk estimates for a variety of diagnostic entities (cardiovascular disease, depression, psychosis, diabetes mellitus, dementia and Alzheimer's disease, all cancers except malignancies of the respiratory system) from a previous case-control study on more than 1 million persons enrolled in compulsory sickness funds in the vicinity of the Cologne-Bonn airport, on disease-related cost estimates performed by the German Federal Statistical Office for the calender years 2002-2008, and calculations of the population exposed to night-time aircraft noise in the vicinity of Frankfurt/Main airport (2005 aircraft routes and flight frequencies). Total estimated costs came to more than 1.5 billion &#x20ac; with an excess of 23 400 cases of diseases treated in hospitals and of 3 400 subsequent deaths.</AbstractText><CopyrightInformation>&#xa9; Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greiser</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Abteilung Gesundheits&#xf6;konomie, Gesundheitspolitik und Versorgungsforschung, Zentrum f&#xfc;r Sozialpolitik, Universit&#xe4;t Bremen, Germany. Eberhard.greiser@zes.uni-bremen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaeske</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Soziale und &#xf6;konomische folgen n&#xe4;chtlichen flugl&#xe4;rms im umfeld des flughafens Frankfurt/Main.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Gesundheitswesen</MedlineTA><NlmUniqueID>9204210</NlmUniqueID><ISSNLinking>0941-3790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000401" MajorTopicYN="N">Aircraft</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059028" MajorTopicYN="N">Airports</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004777" MajorTopicYN="N">Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009622" MajorTopicYN="Y">Noise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018582" MajorTopicYN="N">Sick Leave</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23456959</ArticleId><ArticleId IdType="doi">10.1055/s-0033-1333785</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23430276</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1463</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neural transmission (Vienna, Austria : 1996)</Title><ISOAbbreviation>J Neural Transm (Vienna)</ISOAbbreviation></Journal><ArticleTitle>The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient.</ArticleTitle><Pagination><StartPage>649</StartPage><EndPage>653</EndPage><MedlinePgn>649-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00702-013-0994-0</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) has been described as an age-related disease. Ageing significantly increases the risk of psychosis and dementia. Older patients often have a complex mixture of delirium, psychosis, dementia, gait and balance problems and other comorbidities which can cause significant management problems. There are concerns about the safety and tolerability of the treatments for psychosis and dementia. Delirium is common in older Parkinson's patients and must be assessed and managed carefully. The aetiology of psychosis in Parkinson's is complex and often associated with the development of cognitive impairment. Initial adjustments of Parkinson's drugs should be considered if symptoms are intrusive. Where drug therapy is required, evidence suggests that quetiapine may be a safe initial option. There is no contraindication to the use of clozapine in older patients, with the required blood monitoring. Dementia is almost inevitable with very advanced disease and increasing age, and is associated with a marked cholinergic deficit in the brain. Cholinesterase inhibitors may be more effective in PD than in Alzheimer's disease and appear relatively safe with appropriate monitoring of the pulse. There is much less evidence for the use of memantine. There is no current evidence for the use of specific non-pharmacological therapies in the management of psychosis or dementia in PD. Due to the associated gait and balance problems, older Parkinson's patients benefit from comprehensive multi-disciplinary assessment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hindle</LastName><ForeName>John V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, Bangor University, Bangor, UK. j.v.hindle@bangor.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm (Vienna)</MedlineTA><NlmUniqueID>9702341</NlmUniqueID><ISSNLinking>0300-9564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23430276</ArticleId><ArticleId IdType="doi">10.1007/s00702-013-0994-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brain. 2007 Jul;130(Pt 7):1787-98</Citation><ArticleIdList><ArticleId IdType="pubmed">17535834</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2009 May 11;169(9):867-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19433698</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Pharmacother. 2010 Aug;8(4):316-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20869621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Oct;20(10):1255-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16041803</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2010 Sep;11(6):788-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20586532</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1093-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20571039</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Nov;21(11):1899-907</Citation><ArticleIdList><ArticleId IdType="pubmed">16960863</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2011 Jul;68(7):899-904</Citation><ArticleIdList><ArticleId IdType="pubmed">21747029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2012 Mar;60(3):420-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22329464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2008 Apr 30;23(6):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2010 Nov 27;376(9755):1829-37</Citation><ArticleIdList><ArticleId IdType="pubmed">21056464</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2011 Oct;17(5):428-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21951368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2010 Oct;9(10):969-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20729148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2009 Jun 15;24(8):1217-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19370737</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2005 Sep;11(6):387-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16111911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Dec;22(16):2314-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18098298</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Sep;22 Suppl 17:S374-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18175399</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2010 Mar;39(2):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20051606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504</Citation><ArticleIdList><ArticleId IdType="pubmed">22419314</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):443-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22009228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Pharmacol. 2006 Jul;58(7):871-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16805946</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2006 Jun;60(6):639-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16805745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 2008 Sep;65(3):249-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18707947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2009 Jul;8(7):613-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19520613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2011 Dec;26(14):2496-503</Citation><ArticleIdList><ArticleId IdType="pubmed">21898597</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2012 Feb 23;344:e977</Citation><ArticleIdList><ArticleId IdType="pubmed">22362541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2013 Jul;28(8):1034-49</Citation><ArticleIdList><ArticleId IdType="pubmed">23426759</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2003 Dec;60(12):1745-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14676050</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2010 Aug;67(8):996-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">20697051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1318-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18586866</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Toxicol. 2010 Dec;10(4):306-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20865460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2011 Jun;59(6):1019-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21649634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23425341</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1364-6915</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Aging &amp; mental health</Title><ISOAbbreviation>Aging Ment Health</ISOAbbreviation></Journal><ArticleTitle>The influences of psychotic symptoms on the activities of daily living of individuals with Alzheimer disease: a longitudinal analysis.</ArticleTitle><Pagination><StartPage>738</StartPage><EndPage>747</EndPage><MedlinePgn>738-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13607863.2013.770446</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Psychotic symptoms associated with Alzheimer Disease (AD) contribute to excess functional dependence. Longitudinal studies have generally examined the association between rates of functional decline and the occurrence of psychotic symptoms from either a single evaluation or from multiple evaluations rather than through changes in frequency and severity of symptoms. Although the presence or absence of psychotic symptoms at initial or follow-up examinations may be associated with changes in functional status, the nature of the relationship between changes in these domains cannot be inferred. We examine the association between changes in the frequency of psychotic symptoms and changes in dependence in activities of daily living (ADL) over a period ranging from 1 to 74 months (median = 17.7).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Data from a cohort of 234 individuals referred to a memory clinic were analyzed using multilevel linear regression. Information on ADL, behavioral and psychological symptoms, depression, and cognition was collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">An increase in the frequency of psychotic symptoms had a unique influence on the deterioration of basic ADL, after controlling for demographic variables, changes in cognition, depression, and other behavioral and psychological symptoms (B = -.017, p = .003). However, changes in psychotic symptoms did not significantly contribute to declines in the ability to perform instrumental ADL (B = -.008, p = .439).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Changes in psychotic symptoms may influence basic but not instrumental ADL over time. These findings may have ramifications for studies and treatment plans for individuals with AD who demonstrate psychotic symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Complex Care Services, St. Joseph's Care Group, Thunder Bay, Ontario, Canada. tranm@tbh.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xe9;dard</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Molloy</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Ment Health</MedlineTA><NlmUniqueID>9705773</NlmUniqueID><ISSNLinking>1360-7863</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23425341</ArticleId><ArticleId IdType="doi">10.1080/13607863.2013.770446</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23421098</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2240</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>10</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Przeglad lekarski</Title><ISOAbbreviation>Przegl Lek</ISOAbbreviation></Journal><ArticleTitle>[Marihuana and cannobinoids as medicaments].</ArticleTitle><Pagination><StartPage>1095</StartPage><EndPage>1097</EndPage><MedlinePgn>1095-7</MedlinePgn></Pagination><Abstract><AbstractText>Biological activity of cannabinoids is caused by binding to two cannabinoid receptors CB1 and CB2. Psychoactive is not only tetrahydrocannabinol (THC) but also: cannabidiol, cannabigerol or cannabichromen. Formerly, the usefulness of hemp was assessed in the relation to temporary appeasement of the symptoms of some ailments as nausea or vomiting. Present discoveries indicates that cannabis-based drugs has shown ability to alleviate of autoimmunological disorders such as: Multiple sclerosis (MS), Rheumatoid arthritis (RA) or inflammatory bowel disease. Another studies indicates that cannabinoids play role in treatment of neurological disorders like Alzheimer disease or Amyotrophic lateral sclerosis (ALS) or even can reduce spreading of tumor cells. Cannabinoids stand out high safety profile considering acute toxicity, it is low possibility of deadly overdosing and side-effects are comprise in range of tolerated side-effects of other medications. In some countries marinol and nabilone are used as anti vomiting and nausea drug. First cannabis-based drug containg naturally occurring cannabinoids is Sativex. Sativex is delivered in an mucosal spray for patients suffering from spasticity in MS, pain relevant with cancer and neuropathic pain of various origin. Despite the relatively low acute toxicity of cannabinoids they should be avoid in patients with psychotic disorders, pregnant or breastfeeding woman. Cannabinoids prolong a time of reaction and decrease power of concentration that's why driving any vehicles is forbidden. Cannabis side-effects varies and depend from several factors like administrated dose, rout of administration and present state of mind. After sudden break from long-lasting use, withdrawal symptoms can appear, although they entirely disappear after a week or two.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tkaczyk</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Krakowska Wyzsza Szko&#x142;a Promocji Zdrowia, Krak&#xf3;w.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florek</LastName><ForeName>Ewa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Piekoszewski</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Marihuana i kanabinoidy jako leki.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Przegl Lek</MedlineTA><NlmUniqueID>19840720R</NlmUniqueID><ISSNLinking>0033-2240</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002186">Cannabinoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>19GBJ60SN5</RegistryNumber><NameOfSubstance UI="D002185">Cannabidiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>2N4O9L084N</RegistryNumber><NameOfSubstance UI="C011941">nabilone</NameOfSubstance></Chemical><Chemical><RegistryNumber>7J8897W37S</RegistryNumber><NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance></Chemical><Chemical><RegistryNumber>K4H93P747O</RegistryNumber><NameOfSubstance UI="C587251">nabiximols</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002185" MajorTopicYN="N">Cannabidiol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002186" MajorTopicYN="N">Cannabinoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002188" MajorTopicYN="N">Cannabis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075202" MajorTopicYN="N">Contraindications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009128" MajorTopicYN="N">Muscle Spasticity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014839" MajorTopicYN="N">Vomiting</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23421098</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23418130</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0193</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Human brain mapping</Title><ISOAbbreviation>Hum Brain Mapp</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network.</ArticleTitle><Pagination><StartPage>1237</StartPage><EndPage>1246</EndPage><MedlinePgn>1237-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hbm.22248</ELocationID><Abstract><AbstractText>Neuropsychiatric syndromes are highly prevalent in Alzheimer's disease (AD), but their neurobiology is not completely understood. New methods in functional magnetic resonance imaging, such as intrinsic functional connectivity or "resting-state" analysis, may help to clarify this issue. Using such approaches, alterations in the default-mode and salience networks (SNs) have been described in Alzheimer's, although their relationship with specific symptoms remains unclear. We therefore carried out resting-state functional connectivity analysis with 20 patients with mild to moderate AD, and correlated their scores on neuropsychiatric inventory syndromes (apathy, hyperactivity, affective syndrome, and psychosis) with maps of connectivity in the default mode network and SN. In addition, we compared network connectivity in these patients with that in 17 healthy elderly control subjects. All analyses were controlled for gray matter density and other potential confounds. Alzheimer's patients showed increased functional connectivity within the SN compared with controls (right anterior cingulate cortex and left medial frontal gyrus), along with reduced functional connectivity in the default-mode network (bilateral precuneus). A correlation between increased connectivity in anterior cingulate cortex and right insula areas of the SN and hyperactivity syndrome (agitation, irritability, aberrant motor behavior, euphoria, and disinhibition) was found. These findings demonstrate an association between specific network changes in AD and particular neuropsychiatric symptom types. This underlines the potential clinical significance of resting state alterations in future diagnosis and therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Balthazar</LastName><ForeName>Marcio L F</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Neuroimaging Laboratory, Department of Neurology, Medical Sciences School, University of Campinas (UNICAMP), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Fabr&#xed;cio R S</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>T&#xe1;tila M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Elvis L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Coan</LastName><ForeName>Ana Carolina</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Brunno M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Niall W</ForeName><Initials>NW</Initials></Author><Author ValidYN="Y"><LastName>Stella</LastName><ForeName>Florindo</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Northoff</LastName><ForeName>Georg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Damasceno</LastName><ForeName>Benito P</ForeName><Initials>BP</Initials></Author><Author ValidYN="Y"><LastName>Cendes</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Brain Mapp</MedlineTA><NlmUniqueID>9419065</NlmUniqueID><ISSNLinking>1065-9471</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036421" MajorTopicYN="N">Nerve Fibers, Unmyelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">default mode network</Keyword><Keyword MajorTopicYN="N">functional connectivity</Keyword><Keyword MajorTopicYN="N">neuropsychiatric symptoms</Keyword><Keyword MajorTopicYN="N">salience network</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23418130</ArticleId><ArticleId IdType="pmc">PMC6868965</ArticleId><ArticleId IdType="doi">10.1002/hbm.22248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Girtler N, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH (2007): Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: Part I. Dement Geriatr Cogn Disord 24:457&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MJ, Robinson J (2001): Permutation tests for linear models. Aust NZ J Stat 43:75&#x2013;78.</Citation></Reference><Reference><Citation>Ashburner J, Friston KJ (2000): Voxel&#x2010;based morphometry&#x2014;The methods. Neuroimage 11(6 Pt 1):805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, Smith SM (2004): Probabilistic independent component analysis for functional magnetic resonance imaging. IEEE Trans Med Imaging 23:137&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">14964560</ArticleId></ArticleIdList></Reference><Reference><Citation>Brucki SM, Nitrini R, Caramelli P, Bertolucci PH, Okamoto IH (2003): [Suggestions for utilization of the mini&#x2010;mental state examination in Brazil]. Arq Neuropsiquiatr 61:777&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595482</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruen PD, McGeown WJ, Shanks MF, Venneri A (2008): Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain 131(Pt 9):2455&#x2013;2463.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669506</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews&#x2010;Hanna JR, Schacter DL (2008): The brain's default network: Anatomy, function, and relevance to disease. Ann NY Acad Sci 1124:1&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore ET, Suckling J, Overmeyer S, Rabe&#x2010;Hesketh S, Taylor E, Brammer MJ (1999): Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 18:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193695</ArticleId></ArticleIdList></Reference><Reference><Citation>Carhart&#x2010;Harris RL, Friston KJ (2010). The default&#x2010;mode, ego&#x2010;functions and free&#x2010;energy: A neurobiological account of Freudian ideas. Brain 133:1265&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850580</ArticleId><ArticleId IdType="pubmed">20194141</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA (2006): Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: An independent component analysis. J Neurosci 26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen A&#x2010;L.1975. Luria's Neuropsychological Investigation, Manual and Test Material, 4th ed Copenhagen:Munksgaard.</Citation></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg&#x2010;Thompson S, Carusi DA, Gornbein J (1994): The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL (2000): Cognitive and behavioral heterogeneity in Alzheimer's disease: Seeking the neurobiological basis. Neurobiol Aging 21:845&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124429</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande G, Kerssens C, Sebel PS, Hu X (2010): Altered local coherence in the default mode network due to sevoflurane anesthesia. Brain Res 1318:110&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845285</ArticleId><ArticleId IdType="pubmed">20059988</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR (1975): &#x201c;Mini&#x2010;mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME (2005): The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME (2007): Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Wirth Y, Mobius HJ (2005): Effects of memantine on behavioural symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 20:459&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852444</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C (2010): Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 22:346&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20096151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gili T, Cercignani M, Serra L, Perri R, Giove F, Maraviglia B, Caltagirone C, Bozzali M (2011): Regional brain atrophy and functional disconnection across Alzheimer's disease evolution. J Neurol Neurosurg Psychiatry 82:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639384</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS (2001): A voxel&#x2010;based morphometric study of ageing in 465 normal adult human brains. Neuroimage 14(1 Pt 1):21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V (2003): Functional connectivity in the resting brain: A network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A 100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V (2004): Default&#x2010;mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI. Proc Natl Acad Sci U S A 101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y (2011): A general probabilistic model for group independent component analysis and its estimation methods. Biometrics 67:1532&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412593</ArticleId><ArticleId IdType="pubmed">21517789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayasaka S, Nichols TE (2003): Validating cluster size inference: Random field and permutation methods. Neuroimage 20:2343&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pubmed">14683734</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Rabheru K, Wang J, Binder C (2005): Galantamine treatment of problematic behavior in Alzheimer disease: Post&#x2010;hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 13:527&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956273</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M, Smith S (2002): Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Smith S (2001): A global optimisation method for robust affine registration of brain images. Med Image Anal 5:143&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan EF, Goodglass H, Weintraub S (1983). The Boston Naming Test, 2nd ed Philadelphia:Lea &amp; Febiger.</Citation></Reference><Reference><Citation>Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS (2011): Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer Dement 7:532&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299979</ArticleId><ArticleId IdType="pubmed">21889116</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Jones DT, Vemuri P, McDade E, Avula R, Przybelski S, Boeve BF, Knopman DS, Petersen RC, Jack CR Jr (2011): Effect of APOE epsilon4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol 68:1131&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392960</ArticleId><ArticleId IdType="pubmed">21555604</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984): Clinical diagnosis of Alzheimer's disease: Report of the NINCDS&#x2010;ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon V (2011): Large&#x2010;scale brain networks and psychopathology: A unifying triple network model. Trends Cogn Sci 15:483&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">21908230</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP (2002): Nonparametric permutation tests for functional neuroimaging: A primer with examples. Hum Brain Mapp 15:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterrieth PA (1944). [The test of copying a complex figure: A contribution to the study of perception and memory]. Arch Psychol 30:286&#x2013;356.</Citation></Reference><Reference><Citation>Palaniyappan L, Liddle PF (2012): Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry Neurosci 37:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244495</ArticleId><ArticleId IdType="pubmed">21693094</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus MP, Stein MB (2006). An insular view of anxiety. Biol Psychiatry 60:383&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">16780813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliff G (1979): Spatial thought, mental rotation and the right cerebral hemisphere. Neuropsychologia 17:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">431809</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A.1964. [Clinical examination in psychology]. Paris:Press Universitaire de France.</Citation></Reference><Reference><Citation>Rolland Y, Payoux P, Lauwers&#x2010;Cances V, Voisin T, Esquerre JP, Vellas B (2005): A SPECT study of wandering behavior in Alzheimer's disease. Int J Geriatr Psychiatry 20:816&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116584</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD (2007): Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 27:2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009): Neurodegenerative diseases target large&#x2010;scale human brain networks. Neuron 62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD (2012): Decoding subject driven cognitive states with whole&#x2010;brain connectivity patterns. Cereb Cortex 22:158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236795</ArticleId><ArticleId IdType="pubmed">21616982</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM (2002): Fast robust automated brain extraction. Hum Brain Mapp 17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen&#x2010;Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004): Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23(Suppl 1):S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridharan D, Levitin DJ, Menon V (2008): A critical role for the right fronto&#x2010;insular cortex in switching between central&#x2010;executive and default&#x2010;mode networks. Proc Natl Acad Sci U S A 105:12569&#x2013;12574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527952</ArticleId><ArticleId IdType="pubmed">18723676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, Cummings JL (2001): Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 49:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261510</ArticleId></ArticleIdList></Reference><Reference><Citation>Thivard L, Lehericy S, Krainik A, Adam C, Dormont D, Chiras J, Baulac M, Dupont S (2005): Diffusion tensor imaging in medial temporal lobe epilepsy with hippocampal sclerosis. Neuroimage 28:682&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">16084113</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, Hulshoff Pol HE (2010): Exploring the brain network: A review on resting&#x2010;state fMRI functional connectivity. Eur Neuropsychopharmacol 20:519&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">20471808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D (1987). Manual for the Wechsler Memory Scale&#x2010;Revised (WMS&#x2010;R). San Antonio:The Psychological Corporation.</Citation></Reference><Reference><Citation>Westlye ET, Lundervold A, Rootwelt H, Lundervold AJ, Westlye LT (2011): Increased hippocampal default mode synchronization during rest in middle&#x2010;aged and elderly APOE epsilon4 carriers: Relationships with memory performance. J Neurosci 31:7775&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633142</ArticleId><ArticleId IdType="pubmed">21613490</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn JC, Lee DY, Jhoo JH, Kim KW, Choo IH, Woo JI (2011): Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD). Arch Gerontol Geriatr 52:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20537736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HY, Wang SJ, Liu B, Ma ZL, Yang M, Zhang ZJ, Teng GJ (2010): Resting brain connectivity: Changes during the progress of Alzheimer disease. Radiology 256:598&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">20656843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Brady M, Smith S (2001): Segmentation of brain MR images through a hidden Markov random field model and the expectation&#x2010;maximization algorithm. IEEE Trans Med Imaging 20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, Kramer JH, Weiner M, Miller BL, Seeley WW (2010): Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 133(Pt 5):1352&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912696</ArticleId><ArticleId IdType="pubmed">20410145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23415840</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-9375</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of the American Medical Directors Association</Title><ISOAbbreviation>J Am Med Dir Assoc</ISOAbbreviation></Journal><ArticleTitle>Two cases of loss of consciousness after long-term memantine treatment.</ArticleTitle><Pagination><StartPage>375</StartPage><EndPage>376</EndPage><MedlinePgn>375-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jamda.2013.01.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-8610(13)00032-7</ELocationID><Abstract><AbstractText>Memantine is approved for treatment of moderate to severe Alzheimer disease (AD) but is also investigated as a treatment option for a number of different conditions, and even though there are reports of a number of adverse effects, including new-onset seizures and psychosis, it is considered to be generally well tolerated. We report two cases of repeated loss of consciousness after long-term memantine treatment in patients with AD, which resolved after its discontinuation. The possible changes in the central nervous system after prolonged memantine use for AD are briefly discussed, as well as its capacity to facilitate and/or change the expression of seizure activities. Presented cases indicate the need for increased caution and careful weighing of benefits and risks of prolonged treatment with memantine in patients with AD, as well as for careful evaluation of risks of combining memantine with other medications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savi&#x107;</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Psychiatric Hospital Vrap&#x10d;e, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia. aleks.bos@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mimica</LastName><ForeName>Ninoslav</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Med Dir Assoc</MedlineTA><NlmUniqueID>100893243</NlmUniqueID><ISSNLinking>1525-8610</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014474" MajorTopicYN="N">Unconsciousness</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23415840</ArticleId><ArticleId IdType="doi">10.1016/j.jamda.2013.01.010</ArticleId><ArticleId IdType="pii">S1525-8610(13)00032-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23409724</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7658</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Expert opinion on investigational drugs</Title><ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation></Journal><ArticleTitle>5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.</ArticleTitle><Pagination><StartPage>411</StartPage><EndPage>421</EndPage><MedlinePgn>411-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/13543784.2013.769957</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">5-Hydroxytryptamine 2A receptors (5-HT2A-Rs) are widely expressed in the brain and have been implicated in mood and behavior. Based on the use of atypical antipsychotics in schizophrenia, antagonism of 5-HT2A-Rs initially emerged as a potential intervention capable of reducing the incidence of extrapyramidal symptoms, while exerting an effective antipsychotic action. More recently, highly selective 5-HT2A-R antagonists have been evaluated in the treatment of a wide range of other psychiatric disorders.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">The aim of the current review is to present important clinical studies investigating the potential therapeutic effects of 5-HT2A-R antagonists in both primary psychiatric disorders, such as schizophrenia and mood disorders, as well as in psychiatric manifestations of neurodegenerative disorders. We present an overview of 5-HT2A-Rs in normal brain function and the rationale for use in (neuro) psychiatric disease based on significant findings from genetic association studies, neuroimaging data and postmortem studies. The majority of the studies relate to schizophrenia, depression, anxiety, obsessive compulsive disorder and psychosis in Parkinson's disease and Alzheimer's disease. To date, there is sparse literature on 5-HT2A-Rs in Gilles de la Tourette syndrome, attention deficit hyperactivity disorder, eating disorders and autism spectrum disorders. The authors conclude by reviewing recent clinical trials investigating highly selective 5-HT2A-R antagonists in schizophrenia, psychosis in Parkinson's disease, insomnia and generalized anxiety.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Despite the potential, to date, 5-HT2A-R antagonists have not made an impact in the management of psychiatric disorders and psychiatric symptoms of neurodegenerative conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mestre</LastName><ForeName>Tiago A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>University of Toronto, Toronto Western Hospital and Division of Neurology, Movement Disorders Centre, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zurowski</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Susan H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Investig Drugs</MedlineTA><NlmUniqueID>9434197</NlmUniqueID><ISSNLinking>1354-3784</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23409724</ArticleId><ArticleId IdType="doi">10.1517/13543784.2013.769957</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23392273</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>3-4</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Cognitive impairment in studies of 5HTTLPR and psychosis in Alzheimer's disease: a systematic review.</ArticleTitle><Pagination><StartPage>155</StartPage><EndPage>164</EndPage><MedlinePgn>155-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000346733</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Cognitive impairment is a well-established correlate of psychotic symptoms in Alzheimer's disease (AD-P). We review whether this relationship has confounded previous genetic association studies of 5HTTLPR and AD-P.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed all studies on 5HTTLPR and conducted a semi-quantitative analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three out of 4 studies with low MMSE reported a significant association, while 1 out of 4 with high MMSE reported a significant association.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Variation in cognitive impairment in past studies has contributed to the inconsistency in findings. The findings presented here bring a greater clarity to our understanding of the role of 5HTTLPR in AD-P.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Creese</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23392273</ArticleId><ArticleId IdType="doi">10.1159/000346733</ArticleId><ArticleId IdType="pii">000346733</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23387851</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7674</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert opinion on therapeutic patents</Title><ISOAbbreviation>Expert Opin Ther Pat</ISOAbbreviation></Journal><ArticleTitle>Sigma receptor modulators: a patent review.</ArticleTitle><Pagination><StartPage>597</StartPage><EndPage>613</EndPage><MedlinePgn>597-613</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/13543776.2013.769522</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sigma receptors are involved in several central nervous system (CNS) disorders, including mood disorders (depression and anxiety), psychosis, schizophrenia, movement disorders (i.e., Parkinson's disease) and memory deficits (i.e., Alzheimer's disease). Recently, the involvement of sigma receptors in neuropathic pain and cancer has also been observed.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">This review aims at highlighting the research advancements published in the patent literature between 1986 and 2012, dividing patents according to both their time frame and applicants. The review especially focuses on the development of sigma receptor modulators and their application over the years with respect to CNS diseases, neuropathic pain and neurodegenerative pathologies. The literature was sought through Espacenet, Orbit, ISI Web and PubMed databases.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">In recent years, considerable progress in the knowledge of the biology and pharmacology of sigma receptors has encouraged research on the potential benefits of sigma modulators in a wide range of pathologies. So far, only few potent agonists and antagonists of sigma receptors are in clinical trial for acute and chronic neurodegenerative diseases (SA4503 and ANAVEX 2-73) or neuropathic pain (E-52862).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collina</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Pavia, Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, Pavia, Italy. simona.collina@unipv.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaggeri</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Negrinotti</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Negri</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Ther Pat</MedlineTA><NlmUniqueID>9516419</NlmUniqueID><ISSNLinking>1354-3776</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010330" MajorTopicYN="N">Patents as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="N">Receptors, sigma</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23387851</ArticleId><ArticleId IdType="doi">10.1517/13543776.2013.769522</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23378767</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1176-6328</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Neuropsychiatric disease and treatment</Title><ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation></Journal><ArticleTitle>Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: a case report and literature review of the evidence for use of these Kampo herbal formulae.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>155</EndPage><MedlinePgn>151-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/NDT.S38318</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Yokukan-san, a Japanese traditional herbal (Kampo) prescription, has recently gathered increasing attention due to accumulating reports showing its remarkable efficacy in treating a wide variety of diseases refractory to conventional medicine as well as the behavioral and psychological symptoms of dementia. As yokukan-san has become broadly integrated with conventional medicine, augmentation therapy with other Kampo prescriptions has become necessary when the yokukan-san has been only partially efficacious. In this paper, we report three cases in which the addition of orengedoku-to, another Kampo formula, to yokukan-san was remarkably effective.</AbstractText><AbstractText Label="CASES" NlmCategory="METHODS">Case 1 was an 85-year-old man with Alzheimer-type dementia who had become aggressive during the past 2 years. Three milligrams of aripiprazole completely suppressed his problematic behaviors but had to be stopped because of extrapyramidal symptoms. In the second case, a 44-year-old man with methamphetamine-induced psychosis had suffered from serious tardive dystonia for 2 years. No conventional approach had improved his tardive dystonia. The third case was a 29-year-old engineer who often failed to resist aggressive impulses and was diagnosed with intermittent explosive disorder. He was prescribed 5 mg of olanzapine, which did not suppress his extraordinary anger and caused somnolence even though the dose was low.</AbstractText><AbstractText Label="INTERVENTIONS AND OUTCOMES" NlmCategory="RESULTS">Yokukan-san was complementarily added to the patients' regular medication and exerted a definitive but partial effect in all cases. The addition of orengedoku-to to yokukan-san exerted the same efficacy as aripiprazole in controlling aggressiveness in Case 1, improved the tardive dystonia by 80% in Case 2, and was completely effective in controlling the patient's aggressive impulses in Case 3.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Together with empirical evidence demonstrating the effectiveness of both yokukansan and orengedoku-to in reducing irritability, impulsivity, and aggression, these three cases suggest that orengedoku-to augmentation can be an effective option in cases that are partially responsive to yokukan-san treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Japanese-Oriental (Kampo) Medicine, Chiba University Graduate School of Medicine, Chiba City, Japan;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chino</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hirasaki</LastName><ForeName>Yoshiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Keigo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Iyo</LastName><ForeName>Masaomi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Namiki</LastName><ForeName>Takao</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Neuropsychiatr Dis Treat</MedlineTA><NlmUniqueID>101240304</NlmUniqueID><ISSNLinking>1176-6328</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aggressiveness</Keyword><Keyword MajorTopicYN="N">intermittent explosive disorder</Keyword><Keyword MajorTopicYN="N">tardive dystonia</Keyword><Keyword MajorTopicYN="N">traditional medicine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23378767</ArticleId><ArticleId IdType="pmc">PMC3554226</ArticleId><ArticleId IdType="doi">10.2147/NDT.S38318</ArticleId><ArticleId IdType="pii">ndt-9-151</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Caires S, Steenkamp V. Use of Yokukansan (TJ-54) in the treatment of neurological disorders: a reviewPhytother Res 20102491265&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">20812276</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label studyClin Neuropharmacol 20093216&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19471183</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label studyProg Neuropsychopharmacol Biol Psychiatry 2008323761&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201810</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka T, Furuya M, Yasuda H, Hayashia M, Inagaki T, Horiguchi J.Yi-gan san for the treatment of borderline personality disorder: an open-label studyProg Neuropsychopharmacol Biol Psychiatry 2008321150&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765378</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, Takahashi T, Iwasaki K, et al. Traditional Chinese medicine on four patients with Huntington&#x2019;s disease. Mov Disord. 2009;24(3):453&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">19133663</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV; Fourth Edition. Arlington, VA: American Psychiatric Association; p. 1994.</Citation></Reference><Reference><Citation>Okamoto H. Reconsideration of Japanese traditional herbal medicine: new field of research and clinical medicine. Mini Rev Med Chem. 2006;6(5):543&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16719828</ArticleId></ArticleIdList></Reference><Reference><Citation>The Japan Society for Oriental Medicine Introduction to Kampo: Japanese Traditional Medicine. Tokyo: Elsevier Japan; p. 2005.</Citation></Reference><Reference><Citation>Terasawa K. Kampo. Tokyo: Standard McIntyre; 1993.</Citation></Reference><Reference><Citation>Ohta Y, Kobayashi T, Nishida K, Sasaki E, Ishiguro I. Preventive effect of Oren-gedoku-to (Huanglian-Jie-Du-Tang) extract on the development of stress-induced acute gastric mucosal lesions in rats. J Ethnopharmacol. 1999;67(3):377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617076</ArticleId></ArticleIdList></Reference><Reference><Citation>Monji A, Takita M, Samejima T, et al. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer&#x2019;s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):308&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Ishida Y, Inoue T, et al. Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):541&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184936</ArticleId></ArticleIdList></Reference><Reference><Citation>Okahara K, Ishida Y, Hayashi Y, et al. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer&#x2019;s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):532&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">20170698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer&#x2019;s disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis. 2010;22(1):257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">20847417</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23350964</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole in the treatment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>474</EndPage><MedlinePgn>459-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656566.2013.764989</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and caregiver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because of increased mortality associated with the use of these medications in dementia patients. Aripiprazole is a newer atypical antipsychotic drug with partial agonist activity at dopamine receptors and antagonist activity at 5-HT(2A) receptors, with a low side-effect profile.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">This descriptive review gives a short overview of the pathology and epidemiology of AD, including psychotic symptoms, and describes the mode of action of aripiprazole and results of preclinical studies. Finally, randomized controlled trials evaluating the use of aripiprazole in AD-related psychosis and agitation are discussed. Whenever relevant, meta-analytical data from literature are referred to.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">In randomized placebo-controlled clinical trials, aripiprazole shows modest efficacy in the treatment of AD-related psychosis. Neuropsychiatric symptoms alleviated were predominantly psychotic features and agitation. In individual trials, aripiprazole was generally well tolerated, serious side effects were seldom reported and included accidental injury and somnolence. Meta-analyses however demonstrated increased mortality as a class effect for atypical, but also for typical antipsychotics. No increased cardiovascular outcomes, cerebrovascular accidents, increased appetite or weight gain were demonstrated in meta-analyses for aripiprazole-treated patients with psychosis of dementia. Aripiprazole was found to induce sedation. Aripiprazole should only be used in selected patient populations resistant to non-pharmacological treatment with persisting or severe psychotic symptoms and/or agitation, and in which symptoms lead to significant morbidity, patient suffering and potential self-harm. The indication for continuing treatment should be revised regularly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Alzheimer Research Center, Department of Neurology, 9713 GZ Groningen, The Netherlands. p.p.de.deyn@umcg.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drenth</LastName><ForeName>Annemieke F J</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Kremer</LastName><ForeName>Berry P</ForeName><Initials>BP</Initials></Author><Author ValidYN="Y"><LastName>Oude Voshaar</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Van Dam</LastName><ForeName>Debby</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058830">Serotonin 5-HT2 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058830" MajorTopicYN="N">Serotonin 5-HT2 Receptor Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23350964</ArticleId><ArticleId IdType="doi">10.1517/14656566.2013.764989</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23343485</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive decline and dementia risk in older adults with psychotic symptoms: a prospective cohort study.</ArticleTitle><Pagination><StartPage>119</StartPage><EndPage>128</EndPage><MedlinePgn>119-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2012.10.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(12)00014-0</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To study the temporal association between psychotic symptoms with cognitive decline and incident dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Population-based prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">General population in England and Wales.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A subsample of 2,025 participants of the Medical Research Council Cognitive Function and Ageing Study, representing a study sample of 11,916 nondemented adults age 65 years or older.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Baseline presence of psychotic symptoms was assessed with the Geriatric Mental State. Cognitive decline (Cambridge Cognitive Examination) and incident dementia (Automated Geriatric Examination for Computer Assisted Taxonomy diagnosis) were evaluated at 2, 6, and 10 years from baseline.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 330 participants reported baseline symptoms of paranoid delusions, misidentification, or hallucinations, estimated to represent 13.4% of the older general population without dementia. Psychotic symptoms were cross-sectionally associated with worse cognitive functioning, and individuals with psychotic symptoms displayed more rapid cognitive decline from baseline to a 6-year follow-up, especially in nonmemory functions, than people without such symptoms. They further carried an increased overall risk of later dementia (odds ratio&#xa0;= 2.76, 95% confidence interval&#xa0;= 1.75-4.36). The risk increment was observed independently of baseline cognition, depression, anxiety, and vascular risk factors, increased with increasing numbers of psychotic symptoms, and was highest in people age 65-74 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Older adults with psychotic symptoms are vulnerable to develop dementia and might be a promising target for indicated prevention strategies. Their neuropsychological functioning should be evaluated on a regular basis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>K&#xf6;hler</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School for Mental Health and Neuroscience and Alzheimer Centre Limburg, Maastricht University Medical Centre, The Netherlands. s.koehler@maastrichtuniversity.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allardyce</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Fiona</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Savva</LastName><ForeName>George M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><CollectiveName>Medical Research Council Cognitive Function and Ageing Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105292687</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23343485</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2012.10.010</ArticleId><ArticleId IdType="pii">S1064-7481(12)00014-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23342234</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2040-6223</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Therapeutic advances in chronic disease</Title><ISOAbbreviation>Ther Adv Chronic Dis</ISOAbbreviation></Journal><ArticleTitle>Management of patients with Alzheimer's disease: pharmacological treatment and quality of life.</ArticleTitle><Pagination><StartPage>183</StartPage><EndPage>193</EndPage><MedlinePgn>183-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/2040622312452387</ELocationID><Abstract><AbstractText>A methodological approach to quality of life (QoL) assessment in Alzheimer's disease (AD) is challenging and few clinical trials have included it among outcomes, with conflicting results. In this review an indirect appraisal of evidence has been performed, searching the literature for the effect of drug treatments on determinants of QoL in AD. Among clinical factors associated with QoL, possible targets of drugs include cognition, which seems to be associated with QoL in early disease and can be positively affected by cholinesterase inhibitors (CIs) in this stage; functional decline, the risk of which can be decreased by CIs and memantine (MEM); behavioral and psychological symptoms, which can be reduced by MEM and atypical antipsychotics. Long-term observational studies have associated CIs and MEM treatment with a reduced institutionalization risk. According to the evidence, drug treatment of depression associated with AD should not be first choice from a QoL perspective, while treatment of pain can have beneficial effects on wellbeing indicators also in the late stages of the disease. Possible drug-related adverse events can affect QoL and should always be weighed against expected benefits from the patient's perspective. For this reason antipsychotic treatment is often problematic in AD and should be limited to severe psychosis and aggression, using the lowest effective doses for the shortest possible period. Conversely titration of CIs is necessary to reach the most effective dosages, although dose-related risk of adverse events has to be taken into account. Finally, CIs and MEM have been shown to reduce caregiver burden in randomized trials, possibly affecting caregivers' QoL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mossello</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unit of Gerontology and Geriatric Medicine, Viale G. Pieraccini 6, 50139 Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballini</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ther Adv Chronic Dis</MedlineTA><NlmUniqueID>101532140</NlmUniqueID><ISSNLinking>2040-6223</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">analgesics</Keyword><Keyword MajorTopicYN="N">antidepressive agents</Keyword><Keyword MajorTopicYN="N">antipsychotic agents</Keyword><Keyword MajorTopicYN="N">cholinesterase inhibitors</Keyword><Keyword MajorTopicYN="N">drug therapy</Keyword><Keyword MajorTopicYN="N">memantine</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList><CoiStatement><b>Conflict of interest statement:</b> EM has received lecture honoraria from Novartis, Lundbeck and Pfizer.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23342234</ArticleId><ArticleId IdType="pmc">PMC3539289</ArticleId><ArticleId IdType="doi">10.1177/2040622312452387</ArticleId><ArticleId IdType="pii">10.1177_2040622312452387</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arlt S., Hornung J., Eichenlaub M., Jahn H., Bullinger M., Petersen C. (2008) The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives. Int J Geriatr Psychiatry 23: 604&#x2013;610</Citation><ArticleIdList><ArticleId IdType="pubmed">18008392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C., Howard R. (2006) Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7: 492&#x2013;500</Citation><ArticleIdList><ArticleId IdType="pubmed">16715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Hellier J., Dewey M., Romeo R., Ballard C., Baldwin R., et al. (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378: 403&#x2013;411</Citation><ArticleIdList><ArticleId IdType="pubmed">21764118</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Samsi K., Petrie C., Alvir J., Treglia M., Schwam E., et al. (2009) What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry 24: 15&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">18727132</ArticleId></ArticleIdList></Reference><Reference><Citation>Barca M., Engedal K., Laks J., Selbaek G. (2011) Quality of life among elderly patients with dementia in institutions. Dement Geriatr Cogn Disord 31: 435&#x2013;442</Citation><ArticleIdList><ArticleId IdType="pubmed">21757909</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer C., Flicker L., Horner B., Bretland N., Scherer S., Lautenschlager N., et al. (2010) Factors associated with self and informant ratings of the quality of life of people with dementia living in care facilities: a cross sectional study. PLoS One 5: e15621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001486</ArticleId><ArticleId IdType="pubmed">21179448</ArticleId></ArticleIdList></Reference><Reference><Citation>Beusterien K., Thomas S., Gause D., Kimel M., Arcona S., Mirski D. (2004) Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 18: 1143&#x2013;1148</Citation><ArticleIdList><ArticleId IdType="pubmed">15581384</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J. (2006) Cholinesterase inhibitors for Alzheimer&#x2019;s disease. Cochrane Database Syst Rev 1: CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J., Grimley E., Iakovidou V., Tsolaki M., Holt F. (2009) Rivastigmine for Alzheimer&#x2019;s disease. Cochrane Database Syst Rev 4: CD001191</Citation><ArticleIdList><ArticleId IdType="pubmed">19370562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosboom P., Alfonso H., Eaton J., Almeida O. (2012) Quality of life in Alzheimer&#x2019;s disease: different factors associated with complementary ratings by patients and family carers. Int Psychogeriatr 24: 708&#x2013;721</Citation><ArticleIdList><ArticleId IdType="pubmed">22244307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwens S., van Heugten C., Verhey F. (2008) Review of goal attainment scaling as a useful outcome measure in psychogeriatric patients with cognitive disorders. Dement Geriatr Cogn Disord 26: 528&#x2013;540</Citation><ArticleIdList><ArticleId IdType="pubmed">19052453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brod M., Stewart A., Sands L., Walton P. (1999) Conceptualization and measurement of quality of life in dementia: the Dementia Quality of Life instrument (DQoL). Gerontologist 39: 25&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">10028768</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A., Perry E., Holmes C., Francis P., Morris J., Howes M., et al. (2011) A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord 31: 158&#x2013;164</Citation><ArticleIdList><ArticleId IdType="pubmed">21335973</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A., Spiegel R., Quarg P. (2004) Efficacy of rivastigmine in subjects with moderately severe Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry 19: 243&#x2013;249</Citation><ArticleIdList><ArticleId IdType="pubmed">15027039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibnall J., Tait R., Harman B., Luebbert R. (2005) Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia. J Am Geriatr Soc 53: 1921&#x2013;1929</Citation><ArticleIdList><ArticleId IdType="pubmed">16274373</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde-Sala J., Garre-Olmo J., Turro-Garriga O., Lopez-Pousa S., Vilalta-Franch J. (2009) Factors related to perceived quality of life in patients with Alzheimer&#x2019;s disease: the patient&#x2019;s perception compared with that of caregivers. Int J Geriatr Psychiatry 24: 585&#x2013;594</Citation><ArticleIdList><ArticleId IdType="pubmed">19031477</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordner Z., Blass D., Rabins P., Black B. (2010) Quality of life in nursing home residents with advanced dementia. J Am Geriatr Soc 58: 2394&#x2013;2400</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057956</ArticleId><ArticleId IdType="pubmed">21054329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettema T., Droes R., de Lange J., Mellenbergh G., Ribbe M. (2007) QUALIDEM: development and evaluation of a dementia specific quality of life instrument &#x2013; validation. Int J Geriatr Psychiatry 22: 424&#x2013;430</Citation><ArticleIdList><ArticleId IdType="pubmed">17044131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettema T., Droes R., de Lange J., Ooms M., Mellenbergh G., Ribbe M. (2005) The concept of quality of life in dementia in the different stages of the disease. Int Psychogeriatr 17: 353&#x2013;370</Citation><ArticleIdList><ArticleId IdType="pubmed">16252370</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H., Gauthier S., Hecker J., Vellas B., Emir B., Mastey V., et al. (2003) Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer&#x2019;s disease and the effect on caregiver burden. J Am Geriatr Soc 51: 737&#x2013;744</Citation><ArticleIdList><ArticleId IdType="pubmed">12757558</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuh J., Wang S. (2006) Assessing quality of life in Taiwanese patients with Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry 21: 103&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">16416471</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldmacher D., Provenzano G., McRae T., Mastey V., Ieni J. (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer&#x2019;s disease. J Am Geriatr Soc 51: 937&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">12834513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen R., Gartlehner G., Lohr K., Kaufer D. (2007) Functional outcomes of drug treatment in Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Drugs Aging 24: 155&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pubmed">17313203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe J., Hancock G., Livingston G., Orrell M. (2006) Quality of life of people with dementia in residential care homes. Br J Psychiatry 188: 460&#x2013;464</Citation><ArticleIdList><ArticleId IdType="pubmed">16648533</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe J., Katona C., Orrell M., Livingston G. (2007) Quality of life in dementia: care recipient and caregiver perceptions of quality of life in dementia: the LASER-AD study. Int J Geriatr Psychiatry 22: 1031&#x2013;1036</Citation><ArticleIdList><ArticleId IdType="pubmed">17380488</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley A., Volicer B., Hanrahan P., Houde S., Volicer L. (1992) Assessment of discomfort in advanced Alzheimer patients. Res Nurs Health 15: 369&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pubmed">1529121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurt C., Banerjee S., Tunnard C., Whitehead D., Tsolaki M., Mecocci P., et al. (2010) Insight, cognition and quality of life in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry 81: 331&#x2013;336</Citation><ArticleIdList><ArticleId IdType="pubmed">19828481</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish J., Casarett D., Klocinski J., Clark C. (2001) The relationship between caregivers&#x2019; global ratings of Alzheimer&#x2019;s disease patients&#x2019; quality of life, disease severity, and the caregiving experience. J Am Geriatr Soc 49: 1066&#x2013;1070</Citation><ArticleIdList><ArticleId IdType="pubmed">11555068</ArticleId></ArticleIdList></Reference><Reference><Citation>Karttunen K., Karppi P., Hiltunen A., Vanhanen M., Valimaki T., Martikainen J., et al. (2011) Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry 26: 473&#x2013;482</Citation><ArticleIdList><ArticleId IdType="pubmed">21445998</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi F., Onder G., Cesari M., Gambassi G., Steel K., Russo A., et al. (2001) Pain management in frail, community-living elderly patients. Arch Intern Med 161: 2721&#x2013;2724</Citation><ArticleIdList><ArticleId IdType="pubmed">11732938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton M. (1991) A multidimensional view of quality of life in frail elders. In: Birren J.E., Lubben J.E., Rowe J.C., Deutchman D.E. (Eds.), The Concept and Measurement of Quality of Life in the Frail Elderly, 3&#x2013;11 San Diego, CA: Academic Press</Citation></Reference><Reference><Citation>Lawton M. (1997) Assessing quality of life in Alzheimer disease research. Alzheimer Dis Assoc Disord 11(Suppl. 6): 91&#x2013;99</Citation><ArticleIdList><ArticleId IdType="pubmed">9437453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton M., Moss M., Kleban M., Glicksman A., Rovine M. (1991) A two-factor model of caregiving appraisal and psychological well-being. J Gerontol 46: 181&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pubmed">2071844</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon R., Gibbons L., McCurry S., Teri L. (2002) Assessing quality of life in older adults with cognitive impairment. Psychosom Med 64: 510&#x2013;519</Citation><ArticleIdList><ArticleId IdType="pubmed">12021425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez O., Becker J., Wahed A., Saxton J., Sweet R., Wolk D., et al. (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80: 600&#x2013;607</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823571</ArticleId><ArticleId IdType="pubmed">19204022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez O., Becker J., Wisniewski S., Saxton J., Kaufer D., DeKosky S. (2002) Cholinesterase inhibitor treatment alters the natural history of Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry 72: 310&#x2013;314</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737770</ArticleId><ArticleId IdType="pubmed">11861686</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R., Areosa S., Minakaran N. (2006) Memantine for dementia. Cochrane Database Syst Rev 2: CD003154.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed S., Rosenheck R., Lyketsos C., Kaczynski R., Sultzer D., Schneider L. (2012) Effect of second-generation antipsychotics on caregiver burden in Alzheimer&#x2019;s disease. J Clin Psychiatry 73: 121&#x2013;128</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4040971</ArticleId><ArticleId IdType="pubmed">21939611</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossello E., Boncinelli M., Caleri V., Cavallini M., Palermo E., Di Bari M., et al. (2008) Is antidepressant treatment associated with reduced cognitive decline in Alzheimer&#x2019;s disease? Dement Geriatr Cogn Disord 25: 372&#x2013;379</Citation><ArticleIdList><ArticleId IdType="pubmed">18354253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossello E., Tonon E., Caleri V., Tilli S., Cantini C., Cavallini M., et al. (2004) Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer&#x2019;s disease: a &#x2018;real world&#x2019; study. Arch Gerontol Geriatr Suppl 9: 297&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pubmed">15207427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mowla A., Mosavinasab M., Haghshenas H., Borhani H. (2007) Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer&#x2019;s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 27: 484&#x2013;487</Citation><ArticleIdList><ArticleId IdType="pubmed">17873681</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan S., Beusterien K., Thomas S., Musher J., Strunk B. (2006) Antipsychotic drug use among nursing home residents taking rivastigmine. J Am Med Dir Assoc 7: 12&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">16413429</ArticleId></ArticleIdList></Reference><Reference><Citation>Olazaran J., Reisberg B., Clare L., Cruz I., Pena-Casanova J., Del Ser T., et al. (2010) Nonpharmacological therapies in Alzheimer&#x2019;s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 30: 161&#x2013;178</Citation><ArticleIdList><ArticleId IdType="pubmed">20838046</ArticleId></ArticleIdList></Reference><Reference><Citation>Porzsolt F., Kojer M., Schmidl M., Greimel E., Sigle J., Richter J., et al. (2004) A new instrument to describe indicators of well-being in old-old patients with severe dementia &#x2013; the Vienna List. Health Qual Life Outcomes 2: 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395842</ArticleId><ArticleId IdType="pubmed">14975057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins P., Kasper J., Kleinman L., Black B., Patrick D. (1999) Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimer&#x2019;s disease. J Ment Health Aging 5: 33&#x2013;48</Citation></Reference><Reference><Citation>Raina P., Santaguida P., Ismaila A., Patterson C., Cowan D., Levine M., et al. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">18316756</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind M., Kumar V., Malaty L., Messina J., Hartman R., Anand R. (2000) Rivastigmine for Alzheimer&#x2019;s disease: improvement versus reduced worsening. Prim Care Companion J Clin Psychiatry 2: 134&#x2013;138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC181126</ArticleId><ArticleId IdType="pubmed">15014648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ready R., Ott B., Grace J., Fernandez I. (2002) The Cornell&#x2013;Brown Scale for Quality of Life in dementia. Alzheimer Dis Assoc Disord 16: 109&#x2013;115</Citation><ArticleIdList><ArticleId IdType="pubmed">12040306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie C., Ames D., Clayton T., Lai R. (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12: 358&#x2013;369</Citation><ArticleIdList><ArticleId IdType="pubmed">15249273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K., Fay S., Song X., MacKnight C., Gorman M. (2006) Attainment of treatment goals by people with Alzheimer&#x2019;s disease receiving galantamine: a randomized controlled trial. CMAJ 174: 1099&#x2013;1105</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421447</ArticleId><ArticleId IdType="pubmed">16554498</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers S., Doody R., Mohs R., Friedhoff L. (1998a) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158: 1021&#x2013;1031</Citation><ArticleIdList><ArticleId IdType="pubmed">9588436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers S., Farlow M., Doody R., Mohs R., Friedhoff L. (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer&#x2019;s disease. Donepezil Study Group. Neurology 50: 136&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">9443470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers S., Friedhoff L. (1996) The efficacy and safety of donepezil in patients with Alzheimer&#x2019;s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7: 293&#x2013;303</Citation><ArticleIdList><ArticleId IdType="pubmed">8915035</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothermund K., Brandtstadter J. (2003) Coping with deficits and losses in later life: from compensatory action to accommodation. Psychol Aging 18: 896&#x2013;905</Citation><ArticleIdList><ArticleId IdType="pubmed">14692874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L. (2004) AD2000: donepezil in Alzheimer&#x2019;s disease. Lancet 363: 2100&#x2013;2101</Citation><ArticleIdList><ArticleId IdType="pubmed">15220027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L., Dagerman K., Insel P. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934&#x2013;1943</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L., Tariot P., Dagerman K., Davis S., Hsiao J., Ismail M., et al. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. N Engl J Med 355: 1525&#x2013;1538</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;lzel-Dorenbos C., Ettema T., Bos J., Boelens-van der Knoop E., Gerritsen D., Hoogeveen F., et al. (2007a) Evaluating the outcome of interventions on quality of life in dementia: selection of the appropriate scale. Int J Geriatr Psychiatry 22: 511&#x2013;519</Citation><ArticleIdList><ArticleId IdType="pubmed">17133655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;lzel-Dorenbos C., van der Steen M., Engels L., Olde Rikkert M. (2007b) Assessment of quality of life as outcome in dementia and MCI intervention trials: a systematic review. Alzheimer Dis Assoc Disord 21: 172&#x2013;178</Citation><ArticleIdList><ArticleId IdType="pubmed">17545745</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S., Lamping D., Banerjee S., Harwood R., Foley B., Smith P., et al. (2005) Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 9: 1&#x2013;iv</Citation><ArticleIdList><ArticleId IdType="pubmed">15774233</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh D., Arcona S., Thomas S., Powers C., Rabinowicz A., Shin H., et al. (2004) Risk of antipsychotic drug use in patients with Alzheimer&#x2019;s disease treated with rivastigmine. Drugs Aging 21: 395&#x2013;403</Citation><ArticleIdList><ArticleId IdType="pubmed">15084141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer D., Davis S., Tariot P., Dagerman K., Lebowitz B., Lyketsos C., et al. (2008) Clinical symptom responses to atypical antipsychotic medications in Alzheimer&#x2019;s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165: 844&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A., Loveman E., Clegg A., Kirby J., Picot J., Payne E., et al. (2006) A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry 21: 17&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">16323253</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P., Lalloue F., Preux P., Hazif-Thomas C., Pariel S., Inscale R., et al. (2006) Dementia patients caregivers quality of life: the PIXEL study. Int J Geriatr Psychiatry 21: 50&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">16323256</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson S., Herrmann N., Rapoport M., Lanctot K. (2007) Efficacy and safety of antidepressants for treatment of depression in Alzheimer&#x2019;s disease: a metaanalysis. Can J Psychiatry 52: 248&#x2013;255</Citation><ArticleIdList><ArticleId IdType="pubmed">17500306</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigg R., Watts S., Jones R., Tod A. (2011) Predictors of quality of life ratings from persons with dementia: the role of insight. Int J Geriatr Psychiatry 26: 83&#x2013;91</Citation><ArticleIdList><ArticleId IdType="pubmed">21157853</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh N., Hoblyn J., Mohanty S., Yaffe K. (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 289: 210&#x2013;216</Citation><ArticleIdList><ArticleId IdType="pubmed">12517232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattmo C., Wallin A., Londos E., Minthon L. (2011) Risk factors for nursing home placement in Alzheimer&#x2019;s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist 51: 17&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">20562471</ArticleId></ArticleIdList></Reference><Reference><Citation>WHOQOL Group (1995) The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41: 1403&#x2013;1409</Citation><ArticleIdList><ArticleId IdType="pubmed">8560308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock G., Ballard C., Cooper J., Loft H. (2008) Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer&#x2019;s disease: a pooled analysis of 3 studies. J Clin Psychiatry 69: 341&#x2013;348</Citation><ArticleIdList><ArticleId IdType="pubmed">18294023</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson D., Andersen H. (2007) Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord 24: 138&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">17622761</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson D., Schindler R., Schwam E., Waldemar G., Jones R., Gauthier S., et al. (2009) Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord 28: 244&#x2013;251</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202931</ArticleId><ArticleId IdType="pubmed">19786776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson I., Cleary P. (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273: 59&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">7996652</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A., Winblad B., Stoffler A., Wirth Y., Mobius H. (2003) Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer&#x2019;s disease. Pharmacoeconomics 21: 327&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pubmed">12627986</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B., Grossberg G., Frolich L., Farlow M., Zechner S., Nagel J., et al. (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69: S14&#x2013;S22</Citation><ArticleIdList><ArticleId IdType="pubmed">17646619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23335160</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.</ArticleTitle><Pagination><StartPage>1045</StartPage><EndPage>1065</EndPage><MedlinePgn>1045-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-013-8404-z</ELocationID><Abstract><AbstractText>Arduous efforts have been made in the last three decades to elucidate the role of insulin in the brain. A growing number of evidences show that insulin is involved in several physiological function of the brain such as food intake and weight control, reproduction, learning and memory, neuromodulation and neuroprotection. In addition, it is now clear that insulin and insulin disturbances particularly diabetes mellitus may contribute or in some cases play the main role in development and progression of neurodegenerative and neuropsychiatric disorders. Focusing on the molecular mechanisms, this review summarizes the recent findings on the involvement of insulin dysfunction in neurological disorders like Alzheimer's disease, Parkinson's disease and Huntington's disease and also mental disorders like depression and psychosis sharing features of neuroinflammation and neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghasemi</LastName><ForeName>Rasoul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuroscience Research Center and Department of Physiology, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dargahi</LastName><ForeName>Leila</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Haeri</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moosavi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Zahurin</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Ahmadiani</LastName><ForeName>Abolhassan</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23335160</ArticleId><ArticleId IdType="doi">10.1007/s12035-013-8404-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nutrition. 2011 Feb;27(2):239-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20363589</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2012 Sep;97(9):3016-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22745234</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropeptides. 2009 Aug;43(4):283-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19541365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1996 Jan 17;777:374-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8624116</ArticleId></ArticleIdList></Reference><Reference><Citation>Peptides. 1997;18(9):1423-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9392846</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Dec 12;27(50):13635-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18077675</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1997 Mar;16(3):183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9138434</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2003 Feb 21;964(1):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12573518</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Aug 6;23(18):7084-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12904469</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1993 Jan 29;602(1):161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8448653</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15249677</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2005 Dec;54(12):3343-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16306348</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2005;29(4-5):891-909</Citation><ArticleIdList><ArticleId IdType="pubmed">15885777</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Aug 8;283(32):21934-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18550525</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2010 Aug 31;75(9):764-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20739649</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 1996 Jan;45(1):86-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8522065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Sep;16(9):889-902</Citation><ArticleIdList><ArticleId IdType="pubmed">21519341</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):7036-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20231468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2001 Apr 15;21(8):2561-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11306609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1994 Oct;63(4):1392-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7931291</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 1988;44(2):205-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3070584</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1986 Apr;17(4):1127-38</Citation><ArticleIdList><ArticleId IdType="pubmed">3520377</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 May 15;22(10):RC221</Citation><ArticleIdList><ArticleId IdType="pubmed">12006603</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 1999 Mar;48(3):491-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10078548</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16446752</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2011 Apr 25;8:40</Citation><ArticleIdList><ArticleId IdType="pubmed">21518436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2002 Aug-Oct;19(1-2):155-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12212773</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2005 Nov;49(3):618-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16269322</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Aug 14;388(6643):686-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9262404</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2008 Apr;65(4):476-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18413469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2009 Apr;8(4):382-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19296921</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2008 Mar;49(3):390-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18287270</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1996 Oct 14;736(1-2):54-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8930308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Life Sci. 2006 Jun;63(11):1226-35</Citation><ArticleIdList><ArticleId IdType="pubmed">16568235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiad Lek. 2007;60(9-10):449-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18350720</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1984 Mar 26;168(2):299-302</Citation><ArticleIdList><ArticleId IdType="pubmed">6373366</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1996 Aug;44(8):897-904</Citation><ArticleIdList><ArticleId IdType="pubmed">8708297</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetologia. 2006 May;49(5):837-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16520921</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2006 Jun;199(2):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16515786</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Feb 25;280(8):7377-87</Citation><ArticleIdList><ArticleId IdType="pubmed">15591071</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Jan;1802(1):2-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19853658</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2012 May;1820(5):553-64</Citation><ArticleIdList><ArticleId IdType="pubmed">21871538</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2010 Aug;117(8):971-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20571837</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2003 Nov;18(10):2731-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14656322</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2007 Mar;14(3):327-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17355556</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Mar;9(1):13-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16627931</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1993 Nov-Dec;14(6):523-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8295654</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2011 Apr 25;88(17-18):784-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21362433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;18(3):483-507</Citation><ArticleIdList><ArticleId IdType="pubmed">19542630</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1981 Nov 27;214(4524):1031-3</Citation><ArticleIdList><ArticleId IdType="pubmed">6458088</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2003 Aug;28(6):809-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12812866</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1980 Oct 31;96(4):1671-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7004443</ArticleId></ArticleIdList></Reference><Reference><Citation>Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):110-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18720742</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2009 Jul;132(Pt 7):1820-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19451179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Diabetes. 2010 Sep;11(6):417-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19912553</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2011 May;34(5):1102-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21411503</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 Jan;34(1):130-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19666048</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Neurosci. 1993 Dec;107(6):926-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8136068</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 Jul 10;284(28):18742-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19406747</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 2005 Oct;166(2):220-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16034568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Oct;111(1):242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19659459</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S49-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17478001</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2003 Apr;6(4):345-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12658281</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Pathol. 1993 Jul;30(4):317-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8212454</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Neurosci. 2009 Dec;123(6):1309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20001114</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Cogn. 2007 Jun;64(1):86-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17349729</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Apr 6;3(77):77sr1</Citation><ArticleIdList><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2010 May;10(5):703-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20420491</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol. 1991 Apr;260(4 Pt 2):R712-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2012243</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 1997 Mar-Apr;24(2):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15374119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2005 Feb;7(1):63-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15750215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1967 Sep 23;215(5108):1375-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6055448</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroendocrinology. 1998 Jul;68(1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9695934</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1991 Jun 21;552(1):175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1913176</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2004 Feb;53(2):474-81</Citation><ArticleIdList><ArticleId IdType="pubmed">14747300</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Sep 9;334(4):979-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16039605</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 2006 Apr;23(4):445-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16620276</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Regul Integr Comp Physiol. 2010 Oct;299(4):R1082-90</Citation><ArticleIdList><ArticleId IdType="pubmed">20702796</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 2002 Oct;53(4):907-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12377302</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1983 Jul 25;258(14):8527-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6345543</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 11;318(4):814-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15147943</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 May 22;423(6938):435-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12761548</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2006 May;24(5):563-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16713974</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Endocrinol Metab. 2011 Jan;22(1):16-23</Citation><ArticleIdList><ArticleId IdType="pubmed">20888253</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2000 May;14(7):1015-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10783157</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2001 Oct 25;32(2):177-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11683988</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 2000 Apr;83(4):2332-48</Citation><ArticleIdList><ArticleId IdType="pubmed">10758137</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Biochem Biophys. 2011 Apr 1;508(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">21176768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2009 Mar;20(5):1533-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19144826</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Med. 2000 Mar;93(3):147-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10741319</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1994 Jan 14;634(1):155-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8156386</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 1998;105(4-5):423-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9720972</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1999 Mar 26;263(2-3):161-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10213160</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2001 Aug 3;909(1-2):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11478935</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hypotheses. 2006;66(4):820-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16321476</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 1992 Mar;14(2):253-67</Citation><ArticleIdList><ArticleId IdType="pubmed">1572948</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2003 Aug;52(8):2129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">12882932</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Jan;50(1):164-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9443474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2000;107(4):445-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11215755</ArticleId></ArticleIdList></Reference><Reference><Citation>Peptides. 1998;19(5):883-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9663454</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin Med J (Engl). 2008 May 5;121(9):827-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18701049</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4162-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Physiol Pharmacol Latinoam. 1989;39(3):211-25</Citation><ArticleIdList><ArticleId IdType="pubmed">2534495</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2005 Apr;18(3):628-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15755688</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9873-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1658790</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Pharmacol. 2008 Jul;19(4):292-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18622176</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 1990 Jan;13(1):16-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2298111</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2001 Jun;24(6):1069-78</Citation><ArticleIdList><ArticleId IdType="pubmed">11375373</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1984 Aug 20;309(1):187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">6386100</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1981 Jul;109(1):310-2</Citation><ArticleIdList><ArticleId IdType="pubmed">6165572</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1994;87(4):343-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8017169</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1996 Feb 9;204(3):201-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8938265</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 1986 Apr;35(4):481-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3514326</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem. 1988;20(3):225-30</Citation><ArticleIdList><ArticleId IdType="pubmed">3281864</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2004 Apr 19;490(1-3):115-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15094078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2006 Jan;5(1):64-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2002 Sep;3(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12154357</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2006 Nov;113(11):1685-95</Citation><ArticleIdList><ArticleId IdType="pubmed">17036175</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2000 Oct;57(10):1439-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3100-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14981233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr. 2008 May;138(5):954-63</Citation><ArticleIdList><ArticleId IdType="pubmed">18424607</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2011 Aug;39(4):891-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21787319</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1994 Feb 4;636(1):9-27</Citation><ArticleIdList><ArticleId IdType="pubmed">8156415</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1997 Oct 25;315(7115):1045-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9366728</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2004 May;18(7):902-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2010 Nov 30;75(22):1982-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21115952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Endocrinol. 1995 Nov;147(2):321-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7490562</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2008 Nov 15;86(15):3265-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18627032</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1202-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20600470</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2011 Oct;231(2):314-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21763311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Jul;9(2):101-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16873957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pathol. 2011 Sep;225(1):54-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21598254</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1998 Dec 4;273(49):32730-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Cell. 2002 Jun;2(6):831-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12062094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Nov;10(11):975-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16077680</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Physiol. 2010;72:219-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20148674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2000;920:256-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11193160</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2005 Oct 1;39(7):876-89</Citation><ArticleIdList><ArticleId IdType="pubmed">16140208</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1996 Jan-Feb;17(1):123-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8786794</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;22(2):405-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20847404</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroendocrinology. 1992 Sep;56(3):415-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1436380</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Protein Chem Struct Biol. 2012;88:49-68</Citation><ArticleIdList><ArticleId IdType="pubmed">22814706</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2008 Oct;31(10):2003-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18599528</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2004 Jul;114(1):121-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2011 Jun;26(7):1198-1205</Citation><ArticleIdList><ArticleId IdType="pubmed">22046592</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1984 May;42(5):1354-62</Citation><ArticleIdList><ArticleId IdType="pubmed">6323631</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neurosci. 1993 Mar-Apr;69(1-4):125-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8082998</ArticleId></ArticleIdList></Reference><Reference><Citation>Anat Rec. 1983 Sep;207(1):69-77</Citation><ArticleIdList><ArticleId IdType="pubmed">6356989</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 2000 Feb;68(4):509-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10713291</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegener Dis. 2007;4(1):13-27</Citation><ArticleIdList><ArticleId IdType="pubmed">17429215</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2001 Jul-Aug;63(4):619-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11485116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1999 Dec 10;53(9):1937-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10599761</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biosyst. 2007 Nov;3(11):766-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17940659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1984 Aug 31;49(3):301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6493613</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 1999 Mar;48(3):649-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10078572</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroendocrinol. 2009 Sep;21(9):770-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19602103</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1972 Jun 24;1(7765):1356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4113563</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2001 Feb;8(1):162-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11162250</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2011 Aug;36(7):1092-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21251762</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2011 Apr;34(4):910-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21378214</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 2011 Nov 30;105(1):124-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21536059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Feb;15(2):118-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20098438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2002;14(2):77-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12145454</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2002 Sep;14(3):239-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12475085</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2007 Jul;56(7):1817-24</Citation><ArticleIdList><ArticleId IdType="pubmed">17456849</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Aug 1;272(31):19547-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9235959</ArticleId></ArticleIdList></Reference><Reference><Citation>Obes Rev. 2012 Feb;13(2):136-49</Citation><ArticleIdList><ArticleId IdType="pubmed">22034852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biochem. 1999 Sep;199(1-2):81-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10544955</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2011 May 30;85(3-4):231-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21440606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 2003 Sep;36 Suppl 2:S136-43</Citation><ArticleIdList><ArticleId IdType="pubmed">14574628</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 1997;60(16):1393-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9096260</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2007 Jan;56(1):211-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17192484</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2006 Nov;63(11):1551-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17101823</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Mar;38(2):280-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20558532</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2011 Sep;231(1):171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21703262</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2006 May 9;1088(1):176-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16626669</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2011 Apr;152(4):1314-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21266511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Dec 8;24(49):11120-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15590928</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2004 Jan;25(1):93-103</Citation><ArticleIdList><ArticleId IdType="pubmed">14675735</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1966 Mar;14(3):383-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4952826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Jul;9(2):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16873964</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1996 Jan 5;202(3):141-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8848251</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2004 Mar;111(3):367-86</Citation><ArticleIdList><ArticleId IdType="pubmed">14991460</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2009 May;1792(5):482-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19026743</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Cell. 2005 Feb;4(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15659208</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2012 May;26(5):1799-809</Citation><ArticleIdList><ArticleId IdType="pubmed">22278939</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Feb;160(2):284-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12562574</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 2007 May;24(5):481-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17381506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2010 Oct;62(4):308-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20561999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2008 Feb;93(2):572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18029467</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2007 Jun 15;257(1-2):206-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17316694</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006;9(3 Suppl):243-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16914862</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontology. 1977;23(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">136379</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1994 May 2;644(2):331-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8050044</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2009 Jun;5(6):305-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19498432</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1986 Apr;46(4):1068-72</Citation><ArticleIdList><ArticleId IdType="pubmed">2419504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2006 Sep;10(1):89-109</Citation><ArticleIdList><ArticleId IdType="pubmed">16988486</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Jul 23;28(30):7687-98</Citation><ArticleIdList><ArticleId IdType="pubmed">18650345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2008 Feb;118(2):403-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18246189</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2008 May 6;585(1):38-49</Citation><ArticleIdList><ArticleId IdType="pubmed">18407262</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2011 Nov;24(6):519-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21897249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 1991 Nov;11(6):1006-14</Citation><ArticleIdList><ArticleId IdType="pubmed">1939378</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Med. 2012 Jan 18;4(1):1</Citation><ArticleIdList><ArticleId IdType="pubmed">22257447</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Jan;33(1):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17882234</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Mar;29(3):461-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14628002</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 1991;36(5):343-62</Citation><ArticleIdList><ArticleId IdType="pubmed">1887067</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2006 May;51(6):382-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16786820</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2006 Feb 27;172(5):719-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16505167</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2000 Dec;24(8):855-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11118610</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1990 Jan;54(1):143-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2293606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2005 Mar 1;14(5):565-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15649949</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Oct 27;24(43):9632-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15509750</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2006 Jul 25;254-255:127-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16759792</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Oct;164(10):1557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17898347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2005 May;115(5):1111-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15864338</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2006 Dec;55(12):3320-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17130475</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 May 25;62(10):1869-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15159498</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2009 Dec;150(12):5294-301</Citation><ArticleIdList><ArticleId IdType="pubmed">19819959</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2012 May;26(5 Suppl):33-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22472311</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Ther Targets. 2012 Nov;16(11):1097-112</Citation><ArticleIdList><ArticleId IdType="pubmed">22925041</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 Dec 12;67(11):1960-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17159101</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 May;84(1):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16581231</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1979 Aug;64(2):636-42</Citation><ArticleIdList><ArticleId IdType="pubmed">156737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;16(4):741-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19387110</ArticleId></ArticleIdList></Reference><Reference><Citation>Regul Pept. 1993 Oct 20;48(1-2):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8265817</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2001 Sep;41(4):464-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11543766</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2012;970:493-516</Citation><ArticleIdList><ArticleId IdType="pubmed">22351070</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 1991 Nov;50(5):973-81</Citation><ArticleIdList><ArticleId IdType="pubmed">1725217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Oct;11(10):929-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16702975</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2007 Aug;42(8):762-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17592750</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2002 Feb 8;927(1):97-103</Citation><ArticleIdList><ArticleId IdType="pubmed">11814436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Diabetes Sci Technol. 2008 Nov;2(6):1101-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19885299</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2002 Dec;11(3):410-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12586550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2009 Oct 15;18(20):3942-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19628478</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 2004 Oct 30;83(1):47-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15501490</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Dec 15;64(12):1077-87</Citation><ArticleIdList><ArticleId IdType="pubmed">18973876</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2000 Sep;49(9):1525-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10969837</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabet Med. 2006 Nov;23(11):1165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17054590</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1994 Oct;94(4):1543-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7523453</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropeptides. 1986 Aug-Sep;8(2):93-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3531909</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2004 Nov;29(10):1326-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15288712</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2010 May;33(5):1128-33</Citation><ArticleIdList><ArticleId IdType="pubmed">20185745</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Dec;56(12):1135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10591291</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;16(4):763-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19387111</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Care. 2010 Jul;33(7):1471-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20368411</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2011 Apr;31(2):231-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21346605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2010 Jun;41(2-3):248-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20107928</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Jul;109(1-2):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18063093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2012 Mar;37(3):312-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22089194</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2005 Mar;21(6):1478-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15845076</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1985 Sep 16;343(1):190-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3899277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2011 Aug 05;8:91</Citation><ArticleIdList><ArticleId IdType="pubmed">21819568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1999;893:290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10672251</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):144-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17545740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurobiol. 1999 Jun 15;39(4):536-46</Citation><ArticleIdList><ArticleId IdType="pubmed">10380075</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroendocrinology. 2007;86(3):175-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17898535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Metab. 2009 Nov;10(5):419-29</Citation><ArticleIdList><ArticleId IdType="pubmed">19883619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1995 Dec 21-28;378(6559):785-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8524413</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2005 Aug;6(8):777-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16007092</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Nov;13(11):950-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16286438</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes. 2011 Oct;60(10):2474-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21911747</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1978 Nov;75(11):5737-41</Citation><ArticleIdList><ArticleId IdType="pubmed">364489</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2010 Nov 22;170(21):1884-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21098346</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Genet. 1985 Jan;27(1):62-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3156696</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2008 Oct;5(5):438-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18855585</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Oct 12;63(7):1181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15477535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2005 Feb;64(2):104-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15751224</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1978 Apr 27;272(5656):827-9</Citation><ArticleIdList><ArticleId IdType="pubmed">205798</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 2009 Feb;35(1):60-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18346114</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1985 Feb 4;53(3):235-40</Citation><ArticleIdList><ArticleId IdType="pubmed">3872424</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2005 Nov;33(Pt 5):1033-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16246039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23305525</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1752-1947</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><PubDate><Year>2013</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Delusional parasitosis with hyperthyroidism in an elderly woman: a case report.</ArticleTitle><Pagination><StartPage>17</StartPage><MedlinePgn>17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1752-1947-7-17</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Delusional parasitosis is a rare, monosymptomatic psychosis involving a delusion of being infested with parasites. It is commonly observed among female patients over the age of 50. It is classified as a 'delusional disorder' according to the 10th revision of the International Classification of Diseases and as a 'delusional disorder - somatic type' according to the Diagnostic and Statistical Manual, Fourth Edition. Delusional parasitosis was reported to be associated with physical disorders such as hypoparathyroidism, Huntington's chorea and Alzheimer's disease, among others. Other than vitamin deficiencies however, a causal relationship has not to date been identified. We present this case due to the rarity of Turkish patients with this condition, its duration of follow-up, and its temporal pattern of symptoms paralleling thyroid function tests.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">Our patient was a 70-year-old white Anatolian Turkish woman with primary school education who had been living alone for the past five years. She presented to our psychiatry department complaining of 'feeling large worms moving in her body'. The complaints started after she was diagnosed with hyperthyroidism, increased when she did not use her thyroid medications and remitted when she was compliant with treatment. She was treated with pimozide 2mg/day for 20 months and followed-up without any antipsychotic treatment for an additional nine months. At her last examination, she was euthyroid, not receiving antipsychotics and was not having any delusions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although endocrine disorders, including hyperthyroidism, are listed among the etiological factors contributing to secondary delusional parasitosis, as far as we are aware this is the first case demonstrating a temporal pattern of thyroid hyperfunction and delusions through a protracted period of follow-up. It may be that the treatment of delusional parasitosis depends on clarifying the etiology and that atypical antipsychotics may help in the management of primary delusional parasitosis. Further studies on the relationship between thyroid hormones and dopaminergic neurotransmission may be warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ozten</LastName><ForeName>Eylem</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Uskudar University Medical Faculty, Istanbul, Turkey. eylemozten@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tufan</LastName><ForeName>Ali Evren</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Cerit</LastName><ForeName>Cem</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sayar</LastName><ForeName>G&#xf6;kben H&#x131;zl&#x131;</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Ulubil</LastName><ForeName>Irem Yalug</ForeName><Initials>IY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23305525</ArticleId><ArticleId IdType="pmc">PMC3554433</ArticleId><ArticleId IdType="doi">10.1186/1752-1947-7-17</ArticleId><ArticleId IdType="pii">1752-1947-7-17</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Driscoll MS, Rothe MJ, Grant-Kels JM, Hale MS. Delusional parasitosis: a dermatologic, psychiatric and pharmacologic approach. J Am Acad Dermatol. 1993;29:1023&#x2013;1033. doi: 10.1016/0190-9622(93)70284-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0190-9622(93)70284-Z</ArticleId><ArticleId IdType="pubmed">7902366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford EB, Calfee DP, Pearson RD. Delusions of intestinal parasitosis. South Med J. 2001;94:545&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">11372814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ait-Ameur A, Bern P, Firoloni MP, Menecier P. [Delusional parasitosis or Ekbom&#x2019;s syndrome] Rev Med Interne. 2000;21:182&#x2013;186. doi: 10.1016/S0248-8663(00)88248-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0248-8663(00)88248-X</ArticleId><ArticleId IdType="pubmed">10703075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyell A. The Michelson lecture: delusions of parasitosis. Br J Dermatol. 1983;108:485&#x2013;499. doi: 10.1111/j.1365-2133.1983.tb04604.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.1983.tb04604.x</ArticleId><ArticleId IdType="pubmed">6838775</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med. 1999;130:910&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">10375340</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber M, Kirchler E, Karner M, Pycha R. Delusional parasitosis and the dopamine transporter. A new insight of etiology? Med Hypotheses. 2007;68:1351&#x2013;1358. doi: 10.1016/j.mehy.2006.07.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2006.07.061</ArticleId><ArticleId IdType="pubmed">17134847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepping P, Russel I, Freudenmann RW. Antipsychotic treatment of primary delusional parasitosis: systematic review. Br J Psychiatry. 2007;191:198&#x2013;205. doi: 10.1192/bjp.bp.106.029660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.106.029660</ArticleId><ArticleId IdType="pubmed">17766758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallucci G, Beard G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics. 1995;36:578&#x2013;580. doi: 10.1016/S0033-3182(95)71615-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0033-3182(95)71615-2</ArticleId><ArticleId IdType="pubmed">7501790</ArticleId></ArticleIdList></Reference><Reference><Citation>Le K, Gonski PN. Delusional parasitosis mimicking cutaneous infestation in elderly patients. Med J Aust. 2003;179:209&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12914513</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepping P, Gil-Candon R, Freudenmann RW. Delusional parasitosis treated with amisulpride. Prog Neurol Psychiatry. 2005;9:12&#x2013;16.</Citation></Reference><Reference><Citation>Catic AG. Identification and management of in- hospital drug- induced delirium in older patients. Drugs Aging. 2011;28(9):737&#x2013;748. doi: 10.2165/11592240-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11592240-000000000-00000</ArticleId><ArticleId IdType="pubmed">21913739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">23301740</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>368</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Discontinuation of risperidone in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>187</StartPage><MedlinePgn>187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1214030</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Shari M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Bonner</LastName><ForeName>Alice F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>McMullen</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058</RefSource><PMID Version="1">23075176</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):187-8. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301737</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23301740</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1214030</ArticleId><ArticleId IdType="pii">10.1056/NEJMc1214030#SA3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">23301739</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>368</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Discontinuation of risperidone in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>186</StartPage><EndPage>187</EndPage><MedlinePgn>186-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1214030</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Power</LastName><ForeName>G Allen</ForeName><Initials>GA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058</RefSource><PMID Version="1">23075176</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):187-8. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301737</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23301739</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1214030</ArticleId><ArticleId IdType="pii">10.1056/NEJMc1214030#SA2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">23301738</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>368</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Discontinuation of risperidone in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>186</StartPage><MedlinePgn>186</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1214030</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gnjidic</LastName><ForeName>Danijela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hilmer</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058</RefSource><PMID Version="1">23075176</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):187-8. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301737</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23301738</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1214030</ArticleId><ArticleId IdType="pii">10.1056/NEJMc1214030#SA1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">23301737</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>368</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Discontinuation of risperidone in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>188</EndPage><MedlinePgn>187-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMc1214030</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058</RefSource><PMID Version="1">23075176</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):186. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301738</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):186-7. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301739</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):187. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301740</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23301737</ArticleId><ArticleId IdType="doi">10.1056/NEJMc1214030</ArticleId><ArticleId IdType="pii">10.1056/NEJMc1214030#SA4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23293522</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1176-6328</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Neuropsychiatric disease and treatment</Title><ISOAbbreviation>Neuropsychiatr Dis Treat</ISOAbbreviation></Journal><ArticleTitle>Behavior management approach for agitated behavior in Japanese patients with dementia: a pilot study.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>14</EndPage><MedlinePgn>9-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/NDT.S38943</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Agitated behaviors are frequently observed in patients with dementia and can cause severe distress to caregivers. However, little evidence of the efficacy of nonpharmacological interventions for agitated behaviors exists for patients with dementia. The present pilot study aimed to evaluate a behavioral management program developed by the Seattle Protocols for patients with agitated behaviors in Japan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighteen patients with dementia (Alzheimer's disease, n = 14; dementia with Lewy bodies, n = 4) participated in an open study testing the effectiveness of a behavioral management program. The intervention consisted of 20 sessions over the course of 3 months. The primary outcomes were severity of agitation in dementia, as measured using the Agitated Behavior in Dementia scale (ABID) and the Cohen-Mansfield Agitation Inventory (CMAI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The behavioral management program resulted in significant reductions in total scores on both the ABID and CMAI. Although both physically agitated and verbally agitated behavior scores on the ABID improved significantly, symptoms of psychosis did not improve after the intervention.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The behavioral management technique may be beneficial to distressed caregivers of patients with dementia. In the future, a well designed study to develop the behavioral management program more fully is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaaki</LastName><ForeName>Shutaro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Katsuyoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Oka</LastName><ForeName>Mizuki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Negi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tatsumi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Narumoto</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Toshi A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Mimura</LastName><ForeName>Masaru</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Neuropsychiatr Dis Treat</MedlineTA><NlmUniqueID>101240304</NlmUniqueID><ISSNLinking>1176-6328</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Agitated Behavior in Dementia scale</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">agitated behavior</Keyword><Keyword MajorTopicYN="N">behavioral management</Keyword><Keyword MajorTopicYN="N">dementia with Lewy bodies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23293522</ArticleId><ArticleId IdType="pmc">PMC3533688</ArticleId><ArticleId IdType="doi">10.2147/NDT.S38943</ArticleId><ArticleId IdType="pii">ndt-9-009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hirono N, Mori E, Tanimukai S, et al. Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci. 1999;11(4):498&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">10570764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Kobayashi H, Mori E. Caregiver burden in dementia: evaluation with a Japanese version of the Zarit caregiver burden interview. No to Shinkei = Brain and Nerve. 1998;50(6):561&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">9656252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc. 1986;34(10):711&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer&#x2019;s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry. 2007;164(10):1568&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898349</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Logsdon RG, Peskind E, et al. Alzheimer&#x2019;s Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087767</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003;290(15):2015&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559955</ArticleId></ArticleIdList></Reference><Reference><Citation>McCurry SM, Gibbons LE, Logsdon RG, Vitiello MV, Teri L. Nighttime insomnia treatment and education for Alzheimer&#x2019;s disease: a randomized, controlled trial. J Am Geriatr Soc. 2005;53(5):793&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">15877554</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalon L, Gum AM, Feliciano L, Arean PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med. 2006;166(20):2182&#x2013;2188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101935</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, McCurry SM, Teri L. Evidence-based psychological treatments for disruptive behaviors in individuals with dementia. Psychol Aging. 2007;22(1):28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17385980</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck CK, Vogelpohl TS, Rasin JH, et al. Effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents. Nurs Res. 2002;51(4):219&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">12131234</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhr J, Anderson S, Tranel D. Progressive muscle relaxaion in the management of behvioral disturbance in Alzheimer&#x2019;s disease. Neuropsychol Rehabil. 1999;9:31&#x2013;44.</Citation></Reference><Reference><Citation>Cooper C, Mukadam N, Katona C, et al. Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia. Int Psychogeriatr. 2012;24(6):856&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">22244371</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallion P, Toseland RW, Freeman K. An evaluation of a family visit education program. J Am Geriatr Soc. 1999;47(2):203&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">9988292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA. 2010;304(9):983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4091681</ArticleId><ArticleId IdType="pubmed">20810376</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor R, Burns A, Powell HS, et al. Behavioural management in nursing and residential homes: a randomised controlled trial. Lancet. 1999;354(9172):26&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">10406361</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, McCurry SM, Logsdon R, Gibbons LE. Training community consultants to help family members improve dementia care: a randomized controlled trial. Gerontologist. 2005;45(6):802&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">16326662</ArticleId></ArticleIdList></Reference><Reference><Citation>Narumoto J, Miya H, Shibata K, et al. Challenging behavior of patients with frontal dysfunction managed successfully by behavioral intervention. Psychogeriatrics. 2009;9:147&#x2013;150.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services. Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, Teri L, Weiner MF, et al. Assessment of agitation in Alzheimer&#x2019;s disease: the agitated behavior in dementia scale. Alzheimer&#x2019;s Disease Cooperative Study. J Am Geriatr Soc. 1999;47(11):1354&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10573447</ArticleId></ArticleIdList></Reference><Reference><Citation>Torii K, Nakaaki S, Banno K, et al. Reliability and validity of the Japanese version of the Agitated Behaviour in Dementia Scale in Alzheimer&#x2019;s disease: three dimensions of agitated behaviour in dementia. Psychogeriatrics. 2011;11(4):212&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">22151240</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Werner P, Watson V, Pasis S. Agitation among elderly persons at adult day-care centers: the experiences of relatives and staff members. Int Psychogeriatr. 1995;7(3):447&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">8821352</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma A, Niina R, Ishii T, et al. Assessment of validity of a Japanese version of Cohen-Mansfield Agitation Inventory. Jpn J Geriatr Psychiatry. 2002;13(7):831&#x2013;835.</Citation></Reference><Reference><Citation>Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20(6):649&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L. Management and understaing behavior problems in Alzheimer&#x2019;s disease and related disorders Videotape training program. Seattle, WA: University of Washington; 1990.</Citation></Reference><Reference><Citation>Teri L, Logsdon RG. Assessment and management of behavioral disturbances in Alzheimer disease. Compr Ther. 2000;26(3):169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">10984821</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, de Vugt ME, Lousberg R, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord. 2003;15(2):99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566599</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt AE, Albert ML. Cognitive neuroscience of delusions in aging. Neuropsychiatr Dis Treat. 2006;2(2):181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671775</ArticleId><ArticleId IdType="pubmed">19412462</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Tractenberg RE, Sano M, et al. No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer&#x2019;s disease patients. J Geriatr Psychiatry Neurol. 2002;15(2):95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12083600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Agitation in the elderly definitional and theoretical conceptualizations. In: Hay DP, Klein DT, Hay LK, Grossberg GT, Kennedy JS, editors. Agitation in Patients with Dementia: A Practical Guide to Diagnosis and Management. Washington, DC: American Psychiatric Publishing Inc; 2003.</Citation></Reference><Reference><Citation>Molinari V, Edelstein BA. Commentary on the current status and the future of behavior therapy in long-term care settings. Behav Ther. 2011;42(1):59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">21292052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23270420</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1744-9081</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2012</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Behavioral and brain functions : BBF</Title><ISOAbbreviation>Behav Brain Funct</ISOAbbreviation></Journal><ArticleTitle>Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer's disease is dependent on the psychosis phenotype.</ArticleTitle><Pagination><StartPage>62</StartPage><MedlinePgn>62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1744-9081-8-62</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropsychiatric symptoms such as psychosis are prevalent in patients with probable Alzheimer's disease (AD) and are associated with increased morbidity and mortality. Because these disabling symptoms are generally not well tolerated by caregivers, patients with these symptoms tend to be institutionalized earlier than patients without them. The identification of protective and risk factors for neuropsychiatric symptoms in AD would facilitate the development of more specific treatments for these symptoms and thereby decrease morbidity and mortality in AD. The E4 allele of the apolipoprotein E (APOE) gene is a well-documented risk factor for the development of AD. However, genetic association studies of the APOE 4 allele and BPS in AD have produced conflicting findings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study investigates the association between APOE and neuropsychiatric symptoms in a large sample of clinically well-characterized subjects with probable AD (n=790) who were systematically evaluated using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Behavioral Rating Scale for Dementia (BRSD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our study found that hallucinations were significantly more likely to occur in subjects with no APO&#x395;4 alleles than in subjects with two &#x395;4 alleles (15% of subjects and 5% of subjects, respectively; p=.0066), whereas there was no association between the occurrence of delusions, aberrant motor behavior, or agitation and the number of &#x395;4 alleles. However, 94% of the subjects with hallucinations also had delusions (D+H).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings suggest that in AD the &#x395;4 allele is differentially associated with D+H but not delusions alone. This is consistent with the hypothesis that distinct psychotic subphenotypes may be associated with the APOE allele.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Christie</LastName><ForeName>Drew</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VISN-20 Mental Illness, Seattle, WA, USA. dwt1@uw.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shofer</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Millard</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Demichele-Sweet</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Debby</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS48595</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG10845</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG06781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065070</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Behav Brain Funct</MedlineTA><NlmUniqueID>101245751</NlmUniqueID><ISSNLinking>1744-9081</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23270420</ArticleId><ArticleId IdType="pmc">PMC3549850</ArticleId><ArticleId IdType="doi">10.1186/1744-9081-8-62</ArticleId><ArticleId IdType="pii">1744-9081-8-62</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer&#x2019;s disease: a review. Journal of Alzheimer&#x2019;s disease: JAD. 2010;19:761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer&#x2019;s disease. Am J Psychiatry. 1991;148:1159&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">1882992</ArticleId></ArticleIdList></Reference><Reference><Citation>Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol. 1996;9:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Frisardi V, Seripa D, D&#x2019;Onofrio G, Santamato A, Masullo C, Logroscino G, Solfrizzi V, Pilotto A. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer&#x2019;s disease. Ageing Res Rev. 2011;11:87&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, Stretton A, Jones N, Gerrish A, Chapman J. et al.Genome-wide association study of Alzheimer&#x2019;s disease with psychotic symptoms. Mol Psychiatry. 2011;17:1316&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272435</ArticleId><ArticleId IdType="pubmed">22005930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Kaufer DI, Hamilton RL, Sweet RA, Klunk W, DeKosky ST. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 2002;59:43&#x2013;46. doi: 10.1001/archneur.59.1.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.1.43</ArticleId><ArticleId IdType="pubmed">11790229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA. et al.The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack JL, Patterson MB, Tariot PN. Behavior Rating Scale for Dementia: development of test scales and presentation of data for 555 individuals with Alzheimer&#x2019;s disease. J Geriatr Psychiatry Neurol. 1999;12:211&#x2013;223. doi: 10.1177/089198879901200408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/089198879901200408</ArticleId><ArticleId IdType="pubmed">10616870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley. Colorado. Atherosclerosis. 1995;112:145&#x2013;159. doi: 10.1016/0021-9150(94)05409-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(94)05409-C</ArticleId><ArticleId IdType="pubmed">7772075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley TKR, Ma S. Relative Risk Regression in Medical Research: Models, Contrasts, Estimators, and Algorithm. UW Biostatistics Working Paper Series. 2006. Working Paper #293.</Citation></Reference><Reference><Citation>LA McNutt WC, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940&#x2013;943. doi: 10.1093/aje/kwg074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwg074</ArticleId><ArticleId IdType="pubmed">12746247</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE J. Regression Modeling Strategies: with Application to Linear Models, Logistic Regression and Survival Analysis. New York: Springer-Verlag; 2001.</Citation></Reference><Reference><Citation>Venables WN, Ripley BD. Modern applied statistics with S. 4th. New York: Springer; 2002.</Citation></Reference><Reference><Citation>R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.</Citation></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE. et al.Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer&#x2019;s disease: review of the brain decade. Psychosomatics. 2003;44:388&#x2013;401. doi: 10.1176/appi.psy.44.5.388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.psy.44.5.388</ArticleId><ArticleId IdType="pubmed">12954913</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichele-Sweet MA, Lopez OL, Sweet RA. Psychosis in Alzheimer&#x2019;s disease in the national Alzheimer&#x2019;s disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e. International journal of Alzheimer&#x2019;s disease. 2011;2011:926597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065057</ArticleId><ArticleId IdType="pubmed">21461363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer&#x2019;s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043&#x2013;1053. doi: 10.1002/gps.448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.448</ArticleId><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. Int Psychogeriatr. 2009;21:722&#x2013;728. doi: 10.1017/S1041610209009235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610209009235</ArticleId><ArticleId IdType="pubmed">19470200</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">23250689</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4413</ISSN><JournalIssue CitedMedium="Internet"><Volume>138</Volume><Issue>1-2</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Deutsche medizinische Wochenschrift (1946)</Title><ISOAbbreviation>Dtsch Med Wochenschr</ISOAbbreviation></Journal><ArticleTitle>[Longterm treatment with Risperidone in Alzheimer's disease? No justification for more "drug deaths" in nursing homes!].</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0032-1329031</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>F&#xf6;rstl</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><VernacularTitle>Langfristige Risperidongabe bei aggressiv-agitierten Demenzpatienten? - Keine Rechtfertigung f&#xfc;r weitere "Drogentote" in Altenpflegeheimen!</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Med Wochenschr</MedlineTA><NlmUniqueID>0006723</NlmUniqueID><ISSNLinking>0012-0472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>N Engl J Med. 2012 Oct 18;367(16):1497-507. doi: 10.1056/NEJMoa1114058</RefSource><PMID Version="1">23075176</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23250689</ArticleId><ArticleId IdType="doi">10.1055/s-0032-1329031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23113901</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Patterns of neuropsychiatric sub-syndromes in Brazilian and Norwegian patients with dementia.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>235</EndPage><MedlinePgn>228-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610212001640</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropsychiatric symptoms (NPS) affect the majority of patients who have dementia. Neuropsychiatric sub-syndromes with symptoms that occur together and have common neurobiological correlates have been identified. There are scarce data regarding the comparison of the pattern of the neuropsychiatric sub-syndromes in distinct ethnical and cultural populations. We aim at comparing the pattern of the NPS, and the factor analysis of the Neuropsychiatric Inventory (NPI-10) in two samples of outpatients with dementia living in Brazil and Norway.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a cross-sectional study. The sample consists of 168 Brazilian and 155 Norwegian demented patients from psychogeriatric facilities and community-based educational programs. Brazilian patients were diagnosed with Alzheimer's disease (63.7%), vascular dementia (15.5%), or mixed dementia (20.8%), whereas the diagnoses of Norwegian patients were Alzheimer's disease (97.4%) and mixed dementia (2.6%). Principal component analysis with the Varimax rotation was used for factor analysis of the NPI-10.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Apathy (80.4 %), agitation/aggression (45.8%), and aberrant motor behavior (45.8%) were the most common symptoms in the Brazilian sample. Apathy (72.3%), dysphoria (61.9%), and anxiety (52.3%) were the most frequent symptoms in the Norwegian sample. Factor analysis of the NPI-10 revealed three syndromes for the Brazilian (Psychosis, Mood, Psychomotor) and Norwegian (Psychosis, Mood, Frontal) groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The frequency of individual NPS may differ among distinct populations. However, Psychosis and Depression are common sub-syndromes in diverse ethnical and cultural patients with dementia. Our findings support the syndromic approach for the clinical assessment of the patients with dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Truzzi</LastName><ForeName>Annibal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Alzheimer&#xb4;s Disease, Institute of Psychiatry, Federal University of Rio de Janeiro, Brazil. atruzzi@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulstein</LastName><ForeName>Ingun</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Letice</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Engelhardt</LastName><ForeName>Eliasz</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Coutinho</LastName><ForeName>Evandro Silva Freire</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Laks</LastName><ForeName>Jerson</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Engedal</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="Y">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23113901</ArticleId><ArticleId IdType="doi">10.1017/S1041610212001640</ArticleId><ArticleId IdType="pii">S1041610212001640</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23083629</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1618-1433</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie</Title><ISOAbbreviation>Exp Toxicol Pathol</ISOAbbreviation></Journal><ArticleTitle>Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>694</EndPage><MedlinePgn>689-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.etp.2012.09.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0940-2993(12)00082-6</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is recognized as the second most common neurodegenerative disorder after Alzheimer's disease. PD is mainly characterized by a selective degeneration of the dopaminergic neurons in the substantia nigra. Also, it is observed imbalances in some nondopaminergic systems, including the serotonergic system. Serotonergic dysfunction appears to play a role in some parkinsonian symptoms, including motor function, L-dopa-induced dyskinesia, mood, psychosis, and constipation. The fact that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes a parkinsonian syndrome was discovered in 1982 and has been used extensively and successfully in various mammalian species, including monkeys and mice, to produce an experimental model of PD. Three common dosing regimens of the MPTP-induced mice model of PD were compared on dopaminergic neurotransmission and serotonin levels in various brain regions. Results showed that tyrosine hydroxylase activity and dopaminergic transporter density were reduced in striatum and substantia nigra of mice and that this reduction was dependent on the cumulative dose of MPTP injected. Furthermore, for the three protocols, a decrease of dopamine (DA) level was observed in striatum, associated with a significant diminution of DA concentration in frontal cortex only for the chronic treatment. Moreover, a decrease of serotonin level was observed in midbrain and hippocampus of acute and sub-acute intoxicated-mice. In all, the results suggested that dosing regimen should be carefully pre-considered. Furthermore, the acute and sub-acute MPTP protocols represent good models of early, subclinical stages of PD, ideal in the development of neuroprotective strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier GmbH. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pain</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>INSERM U1084, Universit&#xe9; de Poitiers, 1, rue Georges Bonnet, 86022 Poitiers, France. stephanie.pain@univ-poitiers.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gochard</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bodard</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gulhan</LastName><ForeName>Zuhal</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Prunier-Aesch</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chalon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Exp Toxicol Pathol</MedlineTA><NlmUniqueID>9208920</NlmUniqueID><ISSNLinking>0940-2993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="Y">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23083629</ArticleId><ArticleId IdType="doi">10.1016/j.etp.2012.09.001</ArticleId><ArticleId IdType="pii">S0940-2993(12)00082-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23075176</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>367</Volume><Issue>16</Issue><PubDate><Year>2012</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Relapse risk after discontinuation of risperidone in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1497</StartPage><EndPage>1507</EndPage><MedlinePgn>1497-507</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1114058</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse of psychosis or agitation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily). The severity of psychosis and agitation were reduced, although there was a mild increase in extrapyramidal signs; 112 patients met the criteria for response to treatment, of whom 110 underwent randomization. In the first 16 weeks after randomization, the rate of relapse was higher in the group that received placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33% [23 of 70 in groups 1 and 2]; P=0.004; hazard ratio with placebo, 1.94; 95% confidence interval [CI], 1.09 to 3.45; P=0.02). During the next 16 weeks, the rate of relapse was higher in the group that was switched from risperidone to placebo than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15% [2 of 13 in group 1]; P=0.02; hazard ratio, 4.88; 95% CI, 1.08 to 21.98; P=0.02). The rates of adverse events and death after randomization did not differ significantly among the groups, although comparisons were based on small numbers of patients, especially during the final 16 weeks.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with Alzheimer's disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00417482.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York, New York 10032, USA. dpd3@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Howard F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>de la Pena</LastName><ForeName>Danilo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Colon</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schimming</LastName><ForeName>Corbett</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00417482</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>N Engl J Med. 2012 Dec 20;367(25):2458</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Med Wochenschr. 2013 Jan;138(1-2):16. doi: 10.1055/s-0032-1329031</RefSource><PMID Version="1">23250689</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):187-8. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301737</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):186. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301738</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):186-7. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301739</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2013 Jan 10;368(2):187. doi: 10.1056/NEJMc1214030</RefSource><PMID Version="1">23301740</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23075176</ArticleId><ArticleId IdType="mid">NIHMS415940</ArticleId><ArticleId IdType="pmc">PMC3490406</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1114058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Devanand DP, Jacobs DM, Tang M-X, et al. The course of psychopathologic symptoms in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffans DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007;64:1755&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690610</ArticleId><ArticleId IdType="pubmed">18071039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz D, Mallya A. Discontinuation of a psychogeriatric program for nursing home residents: psychotropic medication changes and behavioral reactions. J Appl Gerontol. 1992;11:50&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10116945</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992;327:168&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608408</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm A, Michel M, Stern GA, et al. The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist. 1999;39:668&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650676</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovner BW, Steele CD, Shmuely Y, Folstein MF. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc. 1996;44:7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong EH, Evans LK, Guevara JP. Non-pharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13:512&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19629775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Brown R, Fossey J, et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial) Am J Geriatr Psychiatry. 2009;17:726&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700946</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359&#x2013;69. [Erratum, JAMA 2012;307:147.]</Citation><ArticleIdList><ArticleId IdType="pubmed">21954480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer&#x2019;s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10873925</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. N Engl J Med. 2006;355:1525&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer&#x2019;s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166:583&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891018</ArticleId><ArticleId IdType="pubmed">19369318</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitk&#xe4;l&#xe4; KH. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15:416&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463191</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17:417&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773714</ArticleId><ArticleId IdType="pubmed">19390299</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TC, Luk JK, Shea YF, et al. Continuous use of antipsychotics and its association with mortality and hospitalization in institutionalized Chinese older adults: an 18-month prospective cohort study. Int Psychogeriatr. 2011;23:1640&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21902863</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorr RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA. 1994;271:358&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8283585</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz GJ, Tariot PN, Mead K, Cox C. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry. 1995;3:290&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28531062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. J Am Geriatr Soc. 2004;52:1737&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Margallo LM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or stopping neuroleptics (the DART-AD trial) PLoS Med. 2008;5(4):e76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276521</ArticleId><ArticleId IdType="pubmed">18384230</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa PB, Meador KG, Gideon P, Fought RL, Ray WA. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc. 1994;42:280&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol. 1997;10:119&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9322135</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999;159:1733&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the Neuropsychiatric Inventory median cutoff is a predictor of clinical outcome. J Clin Psychol. 2004;65:114&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744180</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2011;26:937&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685500</ArticleId><ArticleId IdType="pubmed">21845596</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz I, de Deyn PP, Mintzer J, Green-span A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer&#x2019;s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22:475&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471598</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Mintzer J, Schultz S, et al. The Antipsychotic Discontinuation in Alzheimer Disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012;20:362&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146556</ArticleId><ArticleId IdType="pubmed">21407047</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer&#x2019;s disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168:831&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310182</ArticleId><ArticleId IdType="pubmed">21572163</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, Keene J, Gedling K, Fair-burn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ. 1997;314:266&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2125727</ArticleId><ArticleId IdType="pubmed">9022490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry. 2004;65:1708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15641877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer&#x2019;s disease: randomised double blind placebo controlled trial. BMJ. 2005;330:874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556156</ArticleId><ArticleId IdType="pubmed">15722369</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Schultz S. Consequences of antipsychotic medications for the dementia patient. Am J Psychiatry. 2011;168:767&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23069674</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7972</ISSN><JournalIssue CitedMedium="Internet"><Volume>531</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>4</EndPage><MedlinePgn>1-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neulet.2012.09.062</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0304-3940(12)01327-4</ELocationID><Abstract><AbstractText>We sought to determine whether the COMT val158met polymorphism (rs4680) is associated with delusions and hallucinations in people with dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). A total of 218 individuals, recruited from centres in Norway, Sweden and the UK were included in this study; 121 with clinically or neuropathologically diagnosed DLB/PDD and 97 age-matched, cognitively normal controls. All participants with dementia underwent serial evaluation of neuropsychiatric symptoms to assess the presence of persistent delusions and hallucinations using the Columbia University Scale for Psychopathology in Alzheimer's disease, the Neuropsychiatric Inventory or the Present Behavioural Examination. Severity of cognitive impairment was measured using the Mini Mental State Examination (MMSE). Both controls and participants with dementia were genotyped for rs4680. In contrast to previous findings, analysis by logistic regression failed to find any associations between rs4680 and psychotic symptoms. Larger studies in well characterised cohorts are warranted in order to investigate this relationship further.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Creese</LastName><ForeName>Byron</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Londos</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurosci Lett. 2014 Sep 19;580:178</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23069674</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2012.09.062</ArticleId><ArticleId IdType="pii">S0304-3940(12)01327-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23062764</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1968</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Neurologia (Barcelona, Spain)</Title><ISOAbbreviation>Neurologia</ISOAbbreviation></Journal><ArticleTitle>Inappropriate treatments for patients with cognitive decline.</ArticleTitle><Pagination><StartPage>523</StartPage><EndPage>532</EndPage><MedlinePgn>523-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nrl.2012.05.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0213-4853(12)00185-5</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Some treatments are inappropriate for patients with cognitive decline. We analyse their use in 500 patients and present a literature review.</AbstractText><AbstractText Label="DEVELOPMENT" NlmCategory="METHODS">Benzodiazepines produce dependence, and reduce attention, memory, and motor ability. They can cause disinhibition or aggressive behaviour, facilitate the appearance of delirium, and increase accident and mortality rates in people older than 60. In subjects over 65, low systolic blood pressure is associated with cognitive decline. Maintaining this figure between 130 and 140 mm Hg (145 in patients older than 80) is recommended. Hypocholesterolaemia &lt; 160 mg/dl is associated with increased morbidity and mortality, aggressiveness, and suicide; HDL-cholesterol&lt;40 mg/dl is associated with memory loss and increased vascular and mortality risks. Old age is a predisposing factor for developing cognitive disorders or delirium when taking opioids. The risks of prescribing anticholinesterases and memantine to patients with non-Alzheimer dementia that is not associated with Parkinson disease, mild cognitive impairment, or psychiatric disorders probably outweigh the benefits. Anticholinergic drugs acting preferentially on the peripheral system can also induce cognitive side effects. Practitioners should be aware of steroid-induced dementia and steroid-induced psychosis, and know that risk of delirium increases with polypharmacy. Of 500 patients with cognitive impairment, 70.4% were on multiple medications and 42% were taking benzodiazepines. Both conditions were present in 74.3% of all suspected iatrogenic cases.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Polypharmacy should be avoided, if it is not essential, especially in elderly patients and those with cognitive impairment. Benzodiazepines, opioids and anticholinergics often elicit cognitive and behavioural disorders. Moreover, systolic blood pressure must be kept above 130 mm Hg, total cholesterol levels over 160 mg/dl, and HDL-cholesterol over 40 mg/dl in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Sociedad Espa&#xf1;ola de Neurolog&#xed;a. Published by Elsevier Espana. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robles Bay&#xf3;n</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Neurolog&#xed;a Cognitiva, Hospital La Rosaleda, Santiago de Compostela, Espa&#xf1;a. Electronic address: alfredorobles@hospitalrosaleda.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gude Sampedro</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unidad de Epidemiolog&#xed;a Cl&#xed;nica, Hospital Cl&#xed;nico Universitario, Santiago de Compostela, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Neurologia</MedlineTA><NlmUniqueID>9005460</NlmUniqueID><ISSNLinking>0213-4853</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="Y">Polypharmacy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticholinergics</Keyword><Keyword MajorTopicYN="N">Anticholinesterases</Keyword><Keyword MajorTopicYN="N">Anticolinesterasas</Keyword><Keyword MajorTopicYN="N">Anticolin&#xe9;rgicos</Keyword><Keyword MajorTopicYN="N">Benzodiacepinas</Keyword><Keyword MajorTopicYN="N">Benzodiazepines</Keyword><Keyword MajorTopicYN="N">Memantina</Keyword><Keyword MajorTopicYN="N">Memantine</Keyword><Keyword MajorTopicYN="N">Opioides</Keyword><Keyword MajorTopicYN="N">Opioids</Keyword><Keyword MajorTopicYN="N">Polifarmacia</Keyword><Keyword MajorTopicYN="N">Polypharmacy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23062764</ArticleId><ArticleId IdType="doi">10.1016/j.nrl.2012.05.004</ArticleId><ArticleId IdType="pii">S0213-4853(12)00185-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23047785</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-1948</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Medical care</Title><ISOAbbreviation>Med Care</ISOAbbreviation></Journal><ArticleTitle>Use of antipsychotics among older residents in VA nursing homes.</ArticleTitle><Pagination><StartPage>954</StartPage><EndPage>960</EndPage><MedlinePgn>954-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MLR.0b013e31825fb21d</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antipsychotic medications are commonly prescribed to nursing home residents despite their well-established adverse event profiles. Because little is known about their use in Veterans Affairs (VA) nursing homes [ie, Community Living Centers (CLCs)], we assessed the prevalence and risk factors for antipsychotic use in older residents of VA CLCs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study included 3692 Veterans age 65 or older who were admitted between January 2004 and June 2005 to one of 133 VA CLCs and had a stay of &#x2265;90 days. We used VA Pharmacy Benefits Management data to examine antipsychotic use and VA Medical SAS datasets and the Minimum Data Set to identify evidence-based indications for antipsychotic use (eg, schizophrenia, dementia with psychosis). We used multivariable logistic regression and generalized estimating equations to identify factors independently associated with antipsychotic receipt.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 948/3692(25.7%) residents received an antipsychotic, of which 59.3% had an evidence-based indication for use. Residents with aggressive behavior [odds ratio (OR)=2.74, 95% confidence interval (CI), 2.04-3.67] and polypharmacy (9+ drugs; OR=1.84, 95% CI, 1.41-2.40) were more likely to receive antipsychotics, as were users of antidepressants (OR=1.37, 95% CI, 1.14-1.66), anxiolytic/hypnotics (OR=2.30, 95% CI, 1.64-3.23), or drugs for dementia (OR=1.52, 95% CI, 1.21-1.92). Those residing in Alzheimer/dementia special care units were also more likely to receive an antipsychotic (OR=1.66, 95% CI, 1.26-2.21). Veterans with dementia but no documented psychosis were as likely as those with an evidence-based indication to receive an antipsychotic (OR=1.10, 95% CI, 0.82-1.47).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Antipsychotic use is common among VA nursing home residents aged 65 and older, including those without a documented evidence-based indication for use. Further quality improvement efforts are needed to reduce potentially inappropriate antipsychotic prescribing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gellad</LastName><ForeName>Walid F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, 7180 Highland Drive, Pittsburgh, PA 15206, USA. walid.gellad@va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aspinall</LastName><ForeName>Sherrie L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Handler</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Roslyn A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Castle</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Semla</LastName><ForeName>Todd P</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Good</LastName><ForeName>Chester B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Fine</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Dysken</LastName><ForeName>Maurice</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hanlon</LastName><ForeName>Joseph T</ForeName><Initials>JT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH082682</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3U01 AG012553</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG034056</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG021885</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56AG027017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR010135</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K07AG033174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K07 AG033174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG027017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Care</MedlineTA><NlmUniqueID>0230027</NlmUniqueID><ISSNLinking>0025-7079</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014151" MajorTopicYN="N">Anti-Anxiety Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="N">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="N">United States Department of Veterans Affairs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23047785</ArticleId><ArticleId IdType="mid">NIHMS494977</ArticleId><ArticleId IdType="pmc">PMC3746977</ArticleId><ArticleId IdType="doi">10.1097/MLR.0b013e31825fb21d</ArticleId><ArticleId IdType="pii">00005650-201211000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011 Feb;68(2):190&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">21300946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005 Feb 2;293(5):596&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005 Jun 13;165(11):1280&#x2013;1285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KPA, Sherer J. Antipsychotic Drug Use Among Elderly Nursing Home Residents in the United States. Am J Geriatr Pharmacother. 2008 Oct;6(4):187&#x2013;197. 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028374</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010 Jan 11;170(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897009</ArticleId><ArticleId IdType="pubmed">20065204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008 Oct;6(4):187&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007 Apr 9;167(7):676&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420426</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010 Dec;18(12):1078&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009456</ArticleId><ArticleId IdType="pubmed">20808119</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle NG, Hanlon JT, Handler SM. Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. Am J Geriatr Pharmacother. 2009 Jun;7(3):143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867195</ArticleId><ArticleId IdType="pubmed">19616182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjia J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc. 2010 May;58(5):880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910133</ArticleId><ArticleId IdType="pubmed">20406320</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services Office of the Inspector General   [May 10, 2011];Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents. 2011 May;  http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf.</Citation></Reference><Reference><Citation>O'neil M, Freeman M, Christensen V, Telerant A, Addleman A, Kansagara D. Nonpharmacological Interventions for Behavioral Symptoms of Dementia: A Systematic Review of the Evidence. VA-ESP Project #05-225. 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">21634073</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc. 2010 Jun;58(6):1027&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">20487081</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 Oct 19;294(15):1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006 Oct 12;355(15):1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005 Sep 12;165(16):1882&#x2013;1888.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005 Aug;53(8):1374&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">16078964</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J. Health Aff (Millwood) 1. Vol. 14. Spring; 1995. Medication use and the elderly: current status and opportunities. pp. 276&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7657215</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J, Dreyer P, Connelly K, Soumerai SB. Use of psychoactive medication and the quality of care in rest homes. Findings and policy implications of a statewide study. N Engl J Med. 1989 Jan 26;320(4):227&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">2911307</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J, Gurwitz JH. Drug use in the nursing home. Ann Intern Med. 1995 Aug 1;123(3):195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">7598302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray WA, Blazer DG, 2nd, Schaffner W, Federspiel CF. Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit. Am J Public Health. 1987 Nov;77(11):1448&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1647107</ArticleId><ArticleId IdType="pubmed">2889382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009 Jan 15;360(3):225&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713724</ArticleId><ArticleId IdType="pubmed">19144938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health. 1980 May;70(5):485&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1619409</ArticleId><ArticleId IdType="pubmed">6103676</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv. 2009 Sep;60(9):1175&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pubmed">19723731</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DR, Safford MM, Pogach LM. Who Has Diabetes? Best Estimates of Diabetes Prevalence in the Department of Veterans Affairs Based on Computerized Patient Data. Diabetes Care. 2004 May 1;27(suppl_2):B10&#x2013;21. 2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Assistant Deputy Under Secretary for Health for Policy and Planning  . VHA Enrollment, Patients and Expenditures. U.S. Department of Veterans Affairs Intranet Site; Washington, D.C.: 2008.  [September 1, 2009].  Available at  http://vaww.va.gov/vhaopp/default.htm.</Citation></Reference><Reference><Citation>Government Accountability Office (GAO)   [May 1, 2011];VA Long-Term Care: Trends and Planning Challenges in Providing Nursing Home Care to Veterans. 2006 Jan;  http://www.gao.gov/new.items/d06333t.pdf.</Citation></Reference><Reference><Citation>Mor V. A comprehensive clinical assessment tool to inform policy and practice: applications of the minimum data set. Med Care. 2004 Apr;42(4 Suppl):III50&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">15026672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanlon JT, Wang X, Good CB, et al. Racial differences in medication use among older, long-stay Veterans Affairs nursing home care unit patients. Consult Pharm. 2009 Jun;24(6):439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734488</ArticleId><ArticleId IdType="pubmed">19555154</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607900</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell ES, Pieper CF, Sloane RJ, Branch LG. Effects of cognitive performance on change in physical function in long-stay nursing home residents. J Gerontol A Biol Sci Med Sci. 2002 Dec;57(12):M778&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">12456736</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan N, Lee TA, Valenstein M, Weiss KB. Effect of care setting on evidence-based depression treatment for veterans with COPD and comorbid depression. J Gen Intern Med. 2007 Oct;22(10):1447&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2305861</ArticleId><ArticleId IdType="pubmed">17687614</ArticleId></ArticleIdList></Reference><Reference><Citation>Plomondon ME, Ho PM, Wang L, et al. Severe mental illness and mortality of hospitalized ACS patients in the VHA. BMC Health Serv Res. 2007;7:146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2082028</ArticleId><ArticleId IdType="pubmed">17877804</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugh MJ, Fincke BG, Bierman AS, et al. Potentially inappropriate prescribing in elderly veterans: are we using the wrong drug, wrong dose, or wrong duration? J Am Geriatr Soc. 2005 Aug;53(8):1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16078952</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare and Medicaid Services (CMS)  State Operations Manual.  [May 1, 2011];Guidance to Surveyors for Long Term Care Facilities. Dec;15:2006.  http://www.cms.gov/manuals/Downloads/som107ap_pp_guidelines_ltcf.pdf.</Citation></Reference><Reference><Citation>Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988 Dec;44(4):1049&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pubmed">3233245</ArticleId></ArticleIdList></Reference><Reference><Citation>French DD, Campbell RR, Spehar AM, Rubenstein LZ, Cunningham FE. Drug costs and use in VHA nursing homes: a national overview of long-stay residents. J Am Med Dir Assoc. 2007 Oct;8(8):515&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">17931575</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin CM, McSpadden CS. Changes in the state operations manual: implications for consultant pharmacy practice. Consult Pharm. 2006 Dec;21(12):948&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass E, Putney K, Alvear M. Economic aspects of dementia special care units in Veterans Affairs nursing homes. J Am Med Dir Assoc. 2005 Jul-Aug;6(4):276&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005415</ArticleId></ArticleIdList></Reference><Reference><Citation>Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007 Jun;9(6):430&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17642388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007 Dec;5(4):345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">18179993</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992 Jul 16;327(3):168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608408</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcum ZA, Handler SM, Wright R, Hanlon JT. Interventions to improve suboptimal prescribing in nursing homes: A narrative review. Am J Geriatr Pharmacother. 2010 Jun;8(3):183&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925103</ArticleId><ArticleId IdType="pubmed">20624609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray WA, Taylor JA, Meador KG, et al. Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education. Arch Intern Med. 1993 Mar 22;153(6):713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">8447709</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlin BE, Teri L, McGee JS, et al. STAR-VA: Manual for VA Community Living Center Mental Health Providers. U.S. Department of Veterans Affairs; Washington, D.C.: 2011.</Citation></Reference><Reference><Citation>Teri L, Huda P, Gibbons L, Young H, van Leynseele J. STAR: a dementia-specific training program for staff in assisted living residences. Gerontologist. 2005;45(5):686&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">16199404</ArticleId></ArticleIdList></Reference><Reference><Citation>Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 Jun;68(6):826&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">17592905</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23036583</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>C9ORF72 repeat expansions not detected in a group of patients with schizophrenia.</ArticleTitle><Pagination><StartPage>1309.e9</StartPage><EndPage>1309.10</EndPage><MedlinePgn>1309.e9-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2012.08.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(12)00433-2</ELocationID><Abstract><AbstractText>A hexanucleotide repeat expansion in C9ORF72 was recently found to cause some cases of frontotemporal lobar degeneration, frontotemporal dementia (FTD)-amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. Patients with frontotemporal lobar degeneration with the C9ORF72 repeat expansion are more likely than those without to present with psychosis. In this study, we screened DNA samples from 192 unrelated subjects with schizophrenia for the C9ORF72 repeat expansion. None of the subjects with schizophrenia had the pathogenic expansion. C9ORF72 repeat expansions either do not cause schizophrenia, or do so rarely (less than 1% of cases).</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Columbia University, New York, NY 10032, USA. edh2126@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez-Murillo</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Manoochehri</LastName><ForeName>Masood</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Karayiorgou</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS076837</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS060766</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIA P01AG07232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH061399</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH061399</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIA R01AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>6. Disclosure statement. The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23036583</ArticleId><ArticleId IdType="mid">NIHMS412079</ArticleId><ArticleId IdType="pmc">PMC3584690</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.08.011</ArticleId><ArticleId IdType="pii">S0197-4580(12)00433-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Collins JS, Schwartz CE. Detecting polymorphisms and mutations in candidate genes. Am J Hum Genet. 2002;71:1251&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC385117</ArticleId><ArticleId IdType="pubmed">12452182</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni P, DeTucci K, Straub RE, Weinberger DR, Davies P, et al. Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia. Neurocase. 2010;16:273&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895558</ArticleId><ArticleId IdType="pubmed">20087814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurnberger JI, Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 1994;51:849&#x2013;59. discussion 63&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7944874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pick A. Ueber primare chronische Demenz (so. Dementia praecox) im jugendlichen Alter. Prager medicinische Wochenschrif. 1891;16:312&#x2013;5.</Citation></Reference><Reference><Citation>Rademakers R. C9orf72 repeat expansions in patients with ALS and FTD. Lancet Neurol. 2012;11:297&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114244</ArticleId><ArticleId IdType="pubmed">22406229</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoder D, Hannequin D, Martinaud O, Opolczynski G, Guyant-Marechal L, et al. Morbid risk for schizophrenia in first-degree relatives of people with frontotemporal dementia. Br J Psychiatry. 2010;197:28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592430</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135:693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Velakoulis D, Walterfang M, Mocellin R, Pantelis C, McLean C. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry. 2009;194:298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">19336778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziauddeen H, Dibben C, Kipps C, Hodges JR, McKenna PJ. Negative schizophrenic symptoms and the frontal lobe syndrome: one and the same? Eur Arch Psychiatry Clin Neurosci. 2011;261:59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">20711784</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23034079</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1758-9193</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease.</ArticleTitle><Pagination><StartPage>38</StartPage><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/alzrt141</ELocationID><Abstract><AbstractText>Earlier reports of chromosome 9p-linked frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS) kindreds observed psychosis as a prominent feature in some patients. Since the discovery of chromosome 9 open reading frame 72 (C9orf72) hexanucleotide expansions as a cause of FTD and ALS, research groups and consortia around the world have reported their respective observations of the clinical features associated with this mutation. We reviewed the recent literature on C9orf72-associated FTD and ALS with focus on the neuropsychiatric features associated with this mutation, as well as the experience at University of California, San Francisco. The results and methodologies varied greatly across studies, making comparison of results challenging. Four reports found that psychotic features (particularly delusions) were frequent among mutation carriers, particularly when present early during the disease course, suggesting that this symptom category may be a marker for the mutation. Disinhibition and apathy were the most commonly reported early behavioral symptoms, but these may not be helpful in distinguishing carriers and noncarriers because of the symptoms' frequency in sporadic behavioral variant FTD. Other neuropsychiatric features were reported in different frequencies across studies, suggesting either a similar behavioral phenotype in carriers and noncarriers or reflecting the heterogeneity in clinical presentation of behavioral variant FTD due to C9orf72 expansions. Further studies with larger cohorts will be necessary to determine the neuropsychiatric presentation associated with this mutation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takada</LastName><ForeName>Leonel T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>University of California, San Francisco Memory and Aging Center, Box 1207, San Francisco, CA 94143-1207, USA ; Department of Neurology, University of S&#xe3;o Paulo, Av. Dr. En&#xe9;as de Carvalho Aguiar, 255, room 5084, Sao Paulo, SP 05403-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sha</LastName><ForeName>Sharon J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>University of California, San Francisco Memory and Aging Center, Box 1207, San Francisco, CA 94143-1207, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23034079</ArticleId><ArticleId IdType="pmc">PMC3580395</ArticleId><ArticleId IdType="doi">10.1186/alzrt141</ArticleId><ArticleId IdType="pii">alzrt141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72:126&#x2013;133. doi: 10.4088/JCP.10m06382oli.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.10m06382oli</ArticleId><ArticleId IdType="pmc">PMC3076589</ArticleId><ArticleId IdType="pubmed">21382304</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung G-YR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE. et al.A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AMT, Jones M, Gerhard A, Davidson YS, Robinson A, Gibbons L, Hu Q, DuPlessis D, Neary D, Mann DMA, Pickering-Brown SM. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135:693&#x2013;708. doi: 10.1093/brain/awr355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha SJ, Takada LT, Rankin KP, Yokoyama JS, Rutherford NJ, Fong JC, Khan B, Karydas A, Baker MC, DeJesus-Hernandez M, Pribadi M, Coppola G, Geschwind DH, Rademakers R, Lee SE, Seeley W, Miller BL, Boxer AL. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012;79:1002&#x2013;1011. doi: 10.1212/WNL.0b013e318268452e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318268452e</ArticleId><ArticleId IdType="pmc">PMC3430713</ArticleId><ArticleId IdType="pubmed">22875087</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T, Yeatman T, Warrington EK, Schott JM, Fox NC, Rossor MN, Hardy J, Collinge J, Revesz T, Mead S, Warren JD. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012;135:736&#x2013;750. doi: 10.1093/brain/awr361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr361</ArticleId><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Boylan KB, Graff-Radford NR, DeJesus-Hernandez M, Knopman DS, Pedraza O, Vemuri P, Jones D, Lowe V, Murray ME, Dickson DW, Josephs KA, Rush BK, Machulda MM, Fields JA, Ferman TJ, Baker M, Rutherford NJ, Adamson J, Wszolek ZK, Adeli A, Savica R, Boot B, Kuntz KM, Gavrilova R, Reeves A, Whitwell J, Kantarci K, Jack CR, Parisi JE. et al.Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135:765&#x2013;783. doi: 10.1093/brain/aws004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws004</ArticleId><ArticleId IdType="pmc">PMC3286335</ArticleId><ArticleId IdType="pubmed">22366793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG, Duno M, Batbayli M, Puschmann A, Braendgaard H, Mardosiene S, Svenstrup K, Pinborg LH, Vestergaard K, Hjermind LE, Stokholm J, Andersen BB, Johannsen P, Nielsen JE. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet. 2012. in press doi: 10.1111/j.1399-0004.2012.01903.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, Wszolek ZK, Ferman TJ, Josephs KA, Boylan KB, Rademakers R, Dickson DW. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122:673&#x2013;690. doi: 10.1007/s00401-011-0907-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0907-y</ArticleId><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Dowd S, Curtin D, Waite AJ, Roberts K, Pender N, Reid V, O'Connell M, Williams NM, Morris HR, Traynor BJ, Lynch T. C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. Mov Disord. 2012;27:1072&#x2013;1074. doi: 10.1002/mds.25022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25022</ArticleId><ArticleId IdType="pmc">PMC3516857</ArticleId><ArticleId IdType="pubmed">22807188</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chi&#xf2; A, Restagno G, Nicolaou N, Sim&#xf3;n-S&#xe1;nchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pamphlett R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O. Chromosome 9-ALS/FTD Consortium; French Research Network on FTLD/FTLD/ALS; ITALSGEN Consortium. Hernandez DG, Arepalli S, Sabatelli M. et al.Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Mackenzie IR, Boeve BF, Baker M, Seeley WW, Crook R, Feldman H, Hsiung G-YR, Rutherford N, Laluz V, Whitwell J, Foti D, McDade E, Molano J, Karydas A, Wojtas A, Goldman J, Mirsky J, Sengdy P, Dearmond S, Miller BL, Rademakers R. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011;82:196&#x2013;203. doi: 10.1136/jnnp.2009.204081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.204081</ArticleId><ArticleId IdType="pmc">PMC3017222</ArticleId><ArticleId IdType="pubmed">20562461</ArticleId></ArticleIdList></Reference><Reference><Citation>Luty AA, Kwok JB, Thompson EM, Blumbergs P, Brooks WS, Loy CT, Dobson-Stone C, Panegyres PK, Hecker J, Nicholson GA, Halliday GM, Schofield PR. Pedigree with frontotemporal lobar degeneration - motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol. 2008;8:32. doi: 10.1186/1471-2377-8-32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-8-32</ArticleId><ArticleId IdType="pmc">PMC2553097</ArticleId><ArticleId IdType="pubmed">18755042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson JP, Williams NM, Majounie E, Waite A, Stott J, Newsway V, Murray A, Hernandez D, Guerreiro R, Singleton AB, Neal J, Morris HR. Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol. 2011;258:647&#x2013;655. doi: 10.1007/s00415-010-5815-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5815-x</ArticleId><ArticleId IdType="pmc">PMC4696389</ArticleId><ArticleId IdType="pubmed">21072532</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, Siddique T, Schelhaas HJ, Kusters B, Troost D, Baas F, de Jong V, Shaw CE. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain. 2006;129:868&#x2013;876. doi: 10.1093/brain/awl030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl030</ArticleId><ArticleId IdType="pubmed">16495328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-Sanchez J, Dopper EGP, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, de Graaf JRA, de Koning I, van Schoor NM, Deeg DJH, Smits M, Raaphorst J, van den Berg LH, Schelhaas HJ, De Die-Smulders CEM, Majoor-Krakauer D, Rozemuller AJM, Willemsen R, Pijnenburg YAL, Heutink P, Van Swieten JC. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135:723&#x2013;735. doi: 10.1093/brain/awr353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr353</ArticleId><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiung G-YR, DeJesus-Hernandez M, Feldman HH, Sengdy P, Bouchard-Kerr P, Dwosh E, Butler R, Leung B, Fok A, Rutherford NJ, Baker M, Rademakers R, Mackenzie IRA. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain. 2012;135:709&#x2013;722. doi: 10.1093/brain/awr354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr354</ArticleId><ArticleId IdType="pmc">PMC3286328</ArticleId><ArticleId IdType="pubmed">22344582</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O'Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240. doi: 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillo P, Garcin B, Hornberger M, Bak TH, Hodges JR. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010;67:826&#x2013;830. doi: 10.1001/archneurol.2010.146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.146</ArticleId><ArticleId IdType="pubmed">20625088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Borghero G, Restagno G, Mora G, Drepper C, Traynor BJ, Sendtner M, Brunetti M, Ossola I, Calvo A, Pugliatti M, Sotgiu MA, Murru MR, Marrosu MG, Marrosu F, Marinou K, Mandrioli J, Sola P, Caponnetto C, Mancardi G, Mandich P, La Bella V, Spataro R, Conte A, Monsurro MR, Tedeschi G, Pisano F, Bartolomei I, Salvi F, Lauria Pinter G. et al.Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135:784&#x2013;793. doi: 10.1093/brain/awr366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr366</ArticleId><ArticleId IdType="pmc">PMC3286333</ArticleId><ArticleId IdType="pubmed">22366794</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O'Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240. doi: 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314. doi: 10.1212/WNL.44.12.2308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-Sanchez J, Dopper EGP, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, de Graaf JRA, de Koning I, van Schoor NM, Deeg DJH, Smits M, Raaphorst J, van den Berg LH, Schelhaas HJ, De Die-Smulders CEM, Majoor-Krakauer D, Rozemuller AJM, Willemsen R, Pijnenburg YAL, Heutink P, van Swieten JC. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135:723&#x2013;735. doi: 10.1093/brain/awr353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr353</ArticleId><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-Sanchez J, Dopper EGP, Cohn-Hokke PE, Hukema RK, Nicolaou N, Seelaar H, de Graaf JRA, de Koning I, van Schoor NM, Deeg DJH, Smits M, Raaphorst J, van den Berg LH, Schelhaas HJ, De Die-Smulders CEM, Majoor-Krakauer D, Rozemuller AJM, Willemsen R, Pijnenburg YAL, Heutink P, Van Swieten JC. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135:723&#x2013;735. doi: 10.1093/brain/awr353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr353</ArticleId><ArticleId IdType="pubmed">22300876</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP. et al.Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Velakoulis D, Walterfang M, Mocellin R, Pantelis C, McLean C. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry. 2009;194:298&#x2013;305. doi: 10.1192/bjp.bp.108.057034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.108.057034</ArticleId><ArticleId IdType="pubmed">19336778</ArticleId></ArticleIdList></Reference><Reference><Citation>Grace J, Malloy P. Frontal Systems Behavior Scale: Professional Manual. Lutz, FL: Psychological Assessment Resources Inc; 2001.</Citation></Reference><Reference><Citation>Piguet O. Eating disturbance in behavioural-variant frontotemporal dementia. J Mol Neurosci. 2011;45:589&#x2013;593. doi: 10.1007/s12031-011-9547-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9547-x</ArticleId><ArticleId IdType="pubmed">21584651</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011;122:117&#x2013;135. doi: 10.1007/s00401-011-0821-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0821-3</ArticleId><ArticleId IdType="pubmed">21455688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Shapira JS, Woods RJ, Licht EA, Saul RE. Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord. 2008;25:206&#x2013;211. doi: 10.1159/000113418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000113418</ArticleId><ArticleId IdType="pubmed">18204254</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, Seelaar H, van Swieten JC, Brown JM, Johannsen P, Nielsen JE, Holm IE, FReJA Consortium, Dickson DW, Rademakers R, Graff-Radford NR, Parisi JE, Petersen RC, Hatanpaa KJ, White CL, Weiner MF, Geser F, Van Deerlin VM, Trojanowski JQ, Miller BL, Seeley WW, van der Zee J, Kumar-Singh S, Engelborghs S, De Deyn PP. et al.FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 2010;120:33&#x2013;41. doi: 10.1007/s00401-010-0698-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0698-6</ArticleId><ArticleId IdType="pmc">PMC2887939</ArticleId><ArticleId IdType="pubmed">20490813</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol J, Deramecourt V, Lejeune P, la Sayette de V, Belliard S, Vercelletto M, Meyrignac C, Van Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice A. French Research Network on FTD/FTD-MND. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain. 2008;131:732&#x2013;746. doi: 10.1093/brain/awn012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn012</ArticleId><ArticleId IdType="pubmed">18245784</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G, Karydas AM, Stewart H, Johnson N, Hsiung G-Y, Kelley B, Kuntz K, Steinbart E, Wood EM, Yu C-E, Josephs K, Sorenson E, Womack KB, Weintraub S, Pickering-Brown SM, Schofield PR, Brooks WS, Van Deerlin VM, Snowden J, Clark CM, Kertesz A, Boylan K, Ghetti B. et al.Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C&#x2192;T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007;6:857&#x2013;868. doi: 10.1016/S1474-4422(07)70221-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70221-1</ArticleId><ArticleId IdType="pubmed">17826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang Y-D, Calvo A, Mora G, Sabatelli M, Monsurr&#xf2; MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G. et al.Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Wijsman EM, Nochlin D, Leehey M, Sumi SM, Payami H, Poorkaj P, Nemens E, Rafkind M, Schellenberg GD. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology. 1997;48:949&#x2013;954. doi: 10.1212/WNL.48.4.949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.48.4.949</ArticleId><ArticleId IdType="pubmed">9109883</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Woolley JD, Chao S, See T, Karydas AM, Miller BL, Rankin KP. Schizophrenia or neurodegenerative disease prodrome? Outcome of a first psychotic episode in a 35-year-old woman. Psychosomatics. 2012;53:280&#x2013;284. doi: 10.1016/j.psym.2011.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psym.2011.04.005</ArticleId><ArticleId IdType="pmc">PMC3660996</ArticleId><ArticleId IdType="pubmed">22284422</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada LT, Pimentel MLV, DeJesus-Hernandez M, Fong JC, Yokoyama JS, Karydas A, Thibodeau M-P, Rutherford NJ, Baker MC, Lomen-Hoerth C, Rademakers R, Miller BL. Frontotemporal dementia in a Brazilian kindred with the C9orf72 mutation. Arch Neurol. 2012;69:1149&#x2013;1153. doi: 10.1001/archneurol.2012.650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.650</ArticleId><ArticleId IdType="pmc">PMC3625641</ArticleId><ArticleId IdType="pubmed">22964910</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, Sha SJ, Rutherford NJ, Fong JC, Karydas AM, Wu T, Ketelle RS, Baker MC, Hernandez M-D, Coppola G, Geschwind DH, Rademakers R, Lee SE, Rosen HJ, Rabinovici GD, Seeley WW, Rankin KP, Boxer AL, Miller BL. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012;83:358&#x2013;364. doi: 10.1136/jnnp-2011-301883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301883</ArticleId><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23027418</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2012</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0171-2004</ISSN><JournalIssue CitedMedium="Print"><Issue>213</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Handbook of experimental pharmacology</Title><ISOAbbreviation>Handb Exp Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Muscarinic mechanisms in psychotic disorders.</ArticleTitle><Pagination><StartPage>233</StartPage><EndPage>265</EndPage><MedlinePgn>233-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-642-25758-2_9</ELocationID><Abstract><AbstractText>Schizophrenia is a devastating disease with several broad symptom clusters and the current monoamine-based treatments do not adequately treat the disease, especially negative and cognitive symptoms. A proposed alternative approach for treating schizophrenia is through the use of compounds that activate certain muscarinic receptor subtypes, the so-called muscarinic cholinergic hypothesis theory. This theory has been revitalized with a number of recent and provocative findings including postmortem reports in schizophrenia patients showing decreased numbers of muscarinic M(1) and M(4) receptors in brain regions associated with schizophrenia as well as decreased muscarinic receptors in an in vivo imaging study. Studies with M(4) knockout mice have shown that there is a reciprocal relationship between M(4) and dopamine receptor function, and a number of muscarinic agonists have shown antidopaminergic activity in a variety of preclinical assays predictive of antipsychotic efficacy in the clinic. Furthermore, the M(1)/M(4) preferring partial agonist xanomeline has been shown to have antipsychotic-like and pro-cognitive activity in preclinical models and in clinical trials to decrease psychotic-like behaviors in Alzheimer's patients and positive, negative, and cognitive symptoms in patients with schizophrenia. Therefore, we propose that an agonist with M(1) and M(4) interactions would effectively treat core symptom clusters associated with schizophrenia. Currently, research is focused on developing subtype-selective muscarinic agonists and positive allosteric modulators that have reduced propensity for parasympathetic side-effects, but retain the therapeutic benefit observed with their less selective predecessors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKinzie</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN 46285, USA. dmckinzie@lilly.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bymaster</LastName><ForeName>Frank P</ForeName><Initials>FP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Handb Exp Pharmacol</MedlineTA><NlmUniqueID>7902231</NlmUniqueID><ISSNLinking>0171-2004</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23027418</ArticleId><ArticleId IdType="doi">10.1007/978-3-642-25758-2_9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">23035306</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK100899</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Center for Biotechnology Information (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="micad">Molecular Imaging and Contrast Agent Database (MICAD)</BookTitle><PubDate><Year>2004</Year></PubDate><BeginningDate><Year>2004</Year></BeginningDate><EndingDate><Year>2013</Year></EndingDate><Medium>Internet</Medium></Book><ArticleTitle book="micad" part="I125-E1">[<sup>125</sup>I](<i>E</i>)-<i>N</i>-1-(3'-iodoallyl)-<i>N</i>'-4-(3'',4''-dimethoxyphenethyl)-piperazine</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Center for Biotechnology Information, NLM, NIH</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>[<sup>125</sup>I](<i>E</i>)-<i>N</i>-1-(3'-iodoallyl)-<i>N</i>'-4-(3'',4''-dimethoxyphenethyl)-piperazine, abbreviated as [<sup>125</sup>I]<b><i>E</i>-1</b>, is a hybrid structure of two known ligands: TPCNE (1(<i>trans</i>-iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine) and SA4503 (1-[2-(3,4-dimethoxyphenethyl)]-4-(3-phenylpropyl)piperazine). [<sup>125</sup>I]<b><i>E</i>-1</b> was synthesized for use with single-photon emission computed tomography (SPECT) of sigma-1 (&#x3c3;1) receptors (1). &#x3c3;1 receptor is a protein that is widely distributed in both the central nervous system (CNS) and peripheral organs. There are at least two subtypes of &#x3c3; receptors, &#x3c3;1 receptor and &#x3c3;2 receptor. Although the functions of &#x3c3;2 receptor are poorly understood, &#x3c3;1 receptor is believed to act as a modulator of the signal transduction in neurotransmitter systems (2, 3). &#x3c3;1 receptor primarily resides at the interface between the endoplasmic reticulum and mitochondria, where it modulates Ca<sup>2+</sup> flux by acting as a molecular chaperone for type 3 inositol-1,4,5-triphosphate receptors. &#x3c3;1 receptor can also translocate to the plasma membrane, where it regulates the voltage-dependent Ca<sup>2+</sup> channels, K<sup>+</sup> channels, and other membrane-bound proteins (2, 4). Increasing evidence suggests that &#x3c3;1 receptor is involved in a range of CNS diseases such as affective disorders, psychosis, schizophrenia, substance abuse, Parkinson&#x2019;s disease, and Alzheimer&#x2019;s disease (4, 5). Studies on postmortem human brains have shown that the density of &#x3c3;1 receptor decreased in patients with schizophrenia and Alzheimer&#x2019;s disease (6). Discovery of specific ligands for &#x3c3;1 receptors has further prompted development of efficient imaging probes for neuropsychiatric diseases by targeting &#x3c3;1 receptor (3, 5). TPCNE and SA4503 are among the radiotracers investigated for &#x3c3; receptor imaging. TPCNE has an affinity of <i>K</i><sub>i</sub> = 0.67 nM (log <i>P</i> = 3.36) for &#x3c3;1 receptors, and SA4503 has an affinity of <i>K</i><sub>i</sub> = ~5 nM (log <i>P</i> = 2.52) for &#x3c3;1 receptors (7-9). Both exhibit good specific binding to &#x3c3;1 receptors in rat brains and in human brains. Lever et al. synthesized four hybrid structure&#x2013;related <i>N</i>-1-allyl-<i>N</i>'-4-phenethylpiperazines (<b><i>E</i>-1</b>, <b><i>Z</i>-1</b>, <b>2</b>, and <b>3</b>) from TPCNE and SA4503 on the basis of the hypothesis that hybrid structures might be suitable scaffolds for developing radioiodinated ligands that have high &#x3c3;1 receptor affinities and appropriate lipophilicities for <i>in vivo</i> studies (1). Lever et al. selected <b><i>E</i>-1</b> and <b><i>Z</i>-1</b> to probe the effect of geometric isomerism upon &#x3c3; receptor binding and to discriminate the contribution of the iodine atom through comparison with the allyl analog <b>2</b> (1). Compound <b>3</b>, which is a monomethyl analog and is likely to be a metabolite of <b><i>E</i>-1</b>, was used in the studies to determine the radiometabolites of [<sup>125</sup>I]<b><i>E</i>-1</b>. The results obtained by Lever et al. showed that [<sup>125</sup>I]<b><i>E</i>-1</b> was a selective &#x3c3;1 receptor antagonist that exhibited properties amenable to <i>in vitro</i> and <i>in vivo</i> studies, with possible extension to SPECT using iodine-123 (1).</AbstractText></Abstract><Sections><Section><SectionTitle book="micad" part="I125-E1" sec="I125-E1.Background">Background</SectionTitle></Section><Section><SectionTitle book="micad" part="I125-E1" sec="I125-E1.Synthesis">Synthesis</SectionTitle></Section><Section><SectionTitle book="micad" part="I125-E1" sec="I125-E1.In_Vitro_Studies_Testing_in_Cell"><i>In Vitro</i> Studies: Testing in Cells and Tissues</SectionTitle></Section><Section><SectionTitle book="micad" part="I125-E1" sec="I125-E1.Animal_Studies">Animal Studies</SectionTitle></Section><Section><SectionTitle book="micad" part="I125-E1" sec="I125-E1.Human_Studies">Human Studies</SectionTitle></Section><Section><SectionTitle book="micad" part="I125-E1" sec="I125-E1.References">References</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">[125I]E-1</Keyword><Keyword MajorTopicYN="N">Compounds</Keyword><Keyword MajorTopicYN="N">Sigma-1 (&#x3c3;1) receptor</Keyword><Keyword MajorTopicYN="N">Receptors</Keyword><Keyword MajorTopicYN="N">Single-photon emission computed tomography (SPECT)</Keyword><Keyword MajorTopicYN="N">125I</Keyword></KeywordList><ContributionDate><Year>2012</Year><Month>8</Month><Day>16</Day></ContributionDate><DateRevised><Year>2012</Year><Month>9</Month><Day>25</Day></DateRevised><ReferenceList><Reference><Citation>Lever S.Z., Xu R., Fan K.H., Fergason-Cantrell E.A., Carmack T.L., Watkinson L.D., Lever J.R. Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-N -4-phenethylpiperazine analogs. . Nucl Med Biol. 2012;39(3):401&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22172395</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz J.L., Zamanillo D., Corbera J., Baeyens J.M., Maldonado R., Pericas M.A., Vela J.M., Torrens A. Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. . Cent Nerv Syst Agents Med Chem. 2009;9(3):172&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021351</ArticleId></ArticleIdList></Reference><Reference><Citation>Berardi F., Abate C., Ferorelli S., Colabufo N.A., Perrone R. 1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (sigma1) and sigma-2 (sigma2) receptor ligands: a review. . Cent Nerv Syst Agents Med Chem. 2009;9(3):205&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021355</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa I.A., Banister S.D., Giboureau N., Meikle S.R., Kassiou M. Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel sigma1 receptor PET imaging agent. . Bioorg Med Chem Lett. 2011;21(22):6820&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21962578</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa I.A., Banister S.D., Beinat C., Giboureau N., Reynolds A.J., Kassiou M. Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. . J Med Chem. 2010;53(16):6228&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">20662542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen K.L., Faull R.L., Storey P., Leslie R.A. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. . Brain Res. 1993;623(2):299&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221112</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone J.M., Arstad E., Erlandsson K., Waterhouse R.N., Ell P.J., Pilowsky L.S. [123I]TPCNE--a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge. . Synapse. 2006;60(2):109&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16715498</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever J.R., Gustafson J.L., Xu R., Allmon R.L., Lever S.Z. Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. . Synapse. 2006;59(6):350&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16463398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura K., Ishiwata K., Tajima H., Ishii S., Matsuno K., Homma Y., Senda M. In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma(1) receptors. . Nucl Med Biol. 2000;27(3):255&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10832082</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse R.N., Mardon K., Giles K.M., Collier T.L., O'Brien J.C. Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]pip eri dine. . J Med Chem. 1997;40(11):1657&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9171875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobos E.J., Baeyens J.M., Del Pozo E. Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. . Synapse. 2005;55(3):192&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635593</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23035306</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22992546</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pharmacological treatment of dementia.</ArticleTitle><Pagination><StartPage>542</StartPage><EndPage>550</EndPage><MedlinePgn>542-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCO.0b013e328358e4f2</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">In this article, we discuss new data on currently licensed drugs for dementia and novel developments in the management of neuropsychiatric symptoms in patients with dementia.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">During the last years, a large body of evidence has been accumulated to support the use of antidementia medication in patients with severe Alzheimer's disease. Combination therapy with acetylcholinesterase inhibitors and memantine for Alzheimer's disease remains controversial, as controlled trials have yielded conflicting results. Memantine is not indicated in patients with mild Alzheimer's disease. Studies on memantine for Parkinson's disease dementia and dementia with Lewy bodies were inconclusive. In adult patients with dementia in the context of Down syndrome, memantine is not effective, and further studies on acetylcholinesterase inhibitors are warranted. There is still no treatment established for patients with vascular or frontotemporal dementia. The efficacy of antidepressants to treat depression associated with dementia is not proven. Treatment of agitation and psychosis in patients with dementia remains a challenge.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Recent systematic clinical reviews and new research on currently available treatment options provide valuable assistance for clinicians to deal with frequent clinical problems in the context of dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany. stefan.schwarz@zi-mannheim.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froelich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22992546</ArticleId><ArticleId IdType="doi">10.1097/YCO.0b013e328358e4f2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22989782</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev Neurol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Diagnosis of psychocognitive complaints or disorders after de novo consultation in a university hospital specialized memory unit].</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>107</EndPage><MedlinePgn>97-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2012.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0035-3787(12)00894-6</ELocationID><Abstract><AbstractText>Psychiatric diagnoses are frequent in memory units, but most neurologists do not feel comfortable about making the diagnosis of psychopathologic cognitive complaint or disorder. The full diagnosis usually requires careful history taking and a neuropsychological examination followed by a clear joint explanation to the patient. There are no good validated clinical signs to distinguish organic memory complaints from psychological disorders, but a nonorganic pattern, as seen in somatic conversion disorder, can be suggestive of a "cognitivoform" disorder. Cognitive doubt is a frequent symptom of anxiety. Bradypsychia is a frequent symptom of depression. We report 50 patients attending their first neurological memory consultation in university hospital for whom a de novo diagnosis of psychopathologic disorder was established on the basis of the clinical setting, observation, examination and neuropsychological tests. These psychopathologic disorders accounted for 40.3% of first-consultation diagnoses. In 76% of cases, the neuropsychological examination was normal. Nine subjects had mild cognitive impairment, concerning executive functions in six and several domains in three. Simulation with atypical neuropsychological pattern was distinguished in three patients. The diagnoses were:psychosis (n=9), traumatic stress (n=5), depression (n=7), anxiety or obsession/compulsion (n=13), hypochondria and "cognitivoform" disorders (n=13). In this study, few patients consulted with a known psychiatric diagnosis. Psychiatric co-morbidity was common. In the memory unit, listening carefully to ascertain the psychic, somatic and social situation of each individual patient appears to be as important as evaluating cognition. The neurologist can rule out organic disorders or an exaggeration of somatic symptoms and determine the precise etiology in order to build a rationale for treatment. The neurologist can also avert an overconsumption of complementary explorations. In conclusion, this study shows first that psychopathologic disorders are commonly encountered in a neurological memory unit, emphasizing the need for training for the neurologist and collaboration with a psychiatrist, and secondly that the role of the memory unit cannot be limited to the diagnosis of Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas-Ant&#xe9;rion</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de neuropsychologie-CM2R, CHU Nord, 25, boulevard Pasteur, 42100 Saint-&#xc9;tienne, France. catherine.thomas@chu-st-etienne.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard-Mornas</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Situations de plaintes ou de d&#xe9;ficits psychocognitifs observ&#xe9;es lors d'une premi&#xe8;re consultation de m&#xe9;moire en CM2R.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003291" MajorTopicYN="N">Conversion Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003953" MajorTopicYN="N">Diagnosis-Related Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006757" MajorTopicYN="Y">Hospital Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006998" MajorTopicYN="N">Hypochondriasis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22989782</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2012.05.011</ArticleId><ArticleId IdType="pii">S0035-3787(12)00894-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22975750</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Involvement in activities and wandering in nursing home residents with cognitive impairment.</ArticleTitle><Pagination><StartPage>272</StartPage><EndPage>277</EndPage><MedlinePgn>272-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0b013e31826d012e</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Analysis of a relationship between wandering and involvement in meaningful activities in nursing home residents with cognitive impairment.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional analysis of the minimum data set information.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The analyses were conducted on 8 nursing homes in the Netherlands.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The participants were residents aged 65 years and above with an evidence of cognitive impairment.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Items in the minimum data set related to wandering behavior, involvement in activities, presence of psychotic symptoms, and treatment with antipsychotics. Ambulatory residents who exhibited wandering were divided into: those whose behavior was easily altered [modifiable wandering (MW)] and those whose wandering behavior was not easily altered by the staff [nonmodifiable wandering (NMW)]. The duration of time for which they had opportunity to be involved in meaningful activities was estimated from involvement in activities of nonambulatory residents.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of wandering increased with severity of cognitive impairment. MW was present in 3.5% of total residents (8.5% of ambulatory), whereas NMW was present in 11.2% of the total ambulatory and nonambulatory residents (26.6% of ambulatory). The risk of NMW was increased with resistiveness to care and decreased with antipsychotic use. Individuals with NMW were less involved in activities. NMW was more prevalent in facilities in which residents were involved in activities for a shorter duration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Involvement of residents in meaningful activities should be tested for reducing the incidence of problematic wandering and for decrease in usage of antipsychotic medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volicer</LastName><ForeName>Ladislav</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Aging Studies, University of South Florida, Tampa, FL, USA. lvolicer@cas.usf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Steen</LastName><ForeName>Jenny T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Frijters</LastName><ForeName>Dinnus H M</ForeName><Initials>DH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055816" MajorTopicYN="Y">Wandering Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22975750</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e31826d012e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22952074</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study.</ArticleTitle><Pagination><StartPage>954</StartPage><EndPage>962</EndPage><MedlinePgn>954-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2012.11121815</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The trajectory of cognitive decline in patients with late-onset Alzheimer's disease varies widely. Genetic variations in CLU, PICALM, and CR1 are associated with Alzheimer's disease, but it is unknown whether they exert their effects by altering cognitive trajectory in elderly individuals at risk for the disease.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors developed a Bayesian model to fit cognitive trajectories in a cohort of elderly subjects and test for genetic effects. They first validated the model's ability to detect the previously established effects of APOE &#x3b5;4 alleles on age at cognitive decline and of psychosis on the rate of cognitive decline in 802 subjects from the Cardiovascular Health Cognition Study who did not have dementia at study entry and developed incident dementia during follow-up. The authors then evaluated the effects of CLU, PICALM, and CR1 on age and rate of decline in 1,831 subjects who did not have dementia at study entry and then did or did not develop incident dementia by study's end.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The model generated robust fits to the observed cognitive trajectory data, and validation analysis supported the model's utility. CLU and CR1 were associated with more rapid cognitive decline. PICALM was associated with an earlier age at midpoint of cognitive decline. Associations remained after accounting for the effects of APOE and demographic factors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Evaluation of cognitive trajectories provides a powerful approach to dissecting genetic effects on the processes leading to cognitive deterioration and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA. sweetra@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seltman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Emanuel</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Bis</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>DeMichele-Sweet</LastName><ForeName>Mary Ann A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lewis H</ForeName><Initials>LH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N0-1-HC-85239</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85085</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85081</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC015103</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC55222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85082</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85079</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC045133</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC035129</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85086</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-55222</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL087251</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85083</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-75150</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85080</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC75150</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85084</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509991">CR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034041">Monomeric Clathrin Assembly Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439003">PICALM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017463">Receptors, Complement 3b</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034041" MajorTopicYN="N">Monomeric Clathrin Assembly Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017463" MajorTopicYN="N">Receptors, Complement 3b</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest</b>: The authors have no conflict of interest to report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22952074</ArticleId><ArticleId IdType="mid">NIHMS444967</ArticleId><ArticleId IdType="pmc">PMC3610571</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2012.11121815</ArticleId><ArticleId IdType="pii">1356978</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den BH, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS. Evidence for Ordering of Alzheimer Disease Biomarkers. Arch. Neurol. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann. Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Wilkosz PA. In: Genetics in Textbook of Geriatric Psychiatry. Blazer DG, Steffens DC, editors. Arlington: American Psychiatric Publishing, Inc; 2009.</Citation></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol. Psychiatry. 2003;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am. J. Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, DeMichele-Sweet MA, Kuller L, Sweet RA. Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am. J. Geriatr. Psychiatry. 2011;19:160&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000865</ArticleId><ArticleId IdType="pubmed">20808116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, Sweet RA. Trajectories of cognitive decline in Alzheimer's disease. Int.Psychogeriatr. 2010;22:281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834298</ArticleId><ArticleId IdType="pubmed">19781112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashby D. Bayesian statistics in medicine: a 25 year review. Stat. Med. 2006;25:3589&#x2013;3631.</Citation><ArticleIdList><ArticleId IdType="pubmed">16947924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566948</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A. The Cardiovascular Health Study: design and rationale. Ann. Epidemiol. 1991;1:263&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann. Epidemiol. 1993;3:358&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275211</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, Walter S, Lunetta KL, Garcia ME, Slagboom PE, Christensen K, Arnold AM, Aspelund T, Aulchenko YS, Benjamin EJ, Christiansen L, D'Agostino RB, Sr, Fitzpatrick AL, Franceschini N, Glazer NL, Gudnason V, Hofman A, Kaplan R, Karasik D, Kelly-Hayes M, Kiel DP, Launer LJ, Marciante KD, Massaro JM, Miljkovic I, Nalls MA, Hernandez D, Psaty BM, Rivadeneira F, Rotter J, Seshadri S, Smith AV, Taylor KD, Tiemeier H, Uh HW, Uitterlinden AG, Vaupel JW, Walston J, Westendorp RG, Harris TB, Lumley T, van Duijn CM, Murabito JM. A meta-analysis of four genome-wide association studies of survival to age 90 years or older: the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. J. Gerontol. A Biol. Sci. Med. Sci. 2010;65:478&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854887</ArticleId><ArticleId IdType="pubmed">20304771</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J. Clin. Psychiatry. 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale Manual. New York: Psychological Corporation; 1955.</Citation></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Beck TL, Bienias JL, Bennett DA. Terminal cognitive decline: accelerated loss of cognition in the last years of life. Psychosom. Med. 2007;69:131&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327212</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Narasimhalu K, Gibbons LE, Mungas DM, Haneuse S, Larson EB, Kuller L, Hall K, van BG. Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. J. Clin. Epidemiol. 2008;61:1018&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762121</ArticleId><ArticleId IdType="pubmed">18455909</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Amieva H, Dartigues JF, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am. J. Epidemiol. 2007;165:344&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244646</ArticleId><ArticleId IdType="pubmed">17105962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, Mayeux R. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011;7:e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am. J. Hum. Genet. 2007;80:531&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1821115</ArticleId><ArticleId IdType="pubmed">17273975</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke GM, Cardon LR. Aspects of observing and claiming allele flips in association studies. Genet. Epidemiol. 2010;34:266&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20013941</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin B, Cook EH, Jr, Coon H, Dawson G, Grigorenko EL, McMahon W, Minshew N, Pauls D, Smith M, Spence MA, Rodier PM, Stodgell C, Schellenberg GD. Autism and the serotonin transporter: the long and short of it. Mol. Psychiatry. 2005;10:1110&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaykin DV, Shibata K. Genetic flip-flop without an accompanying change in linkage disequilibrium. Am. J. Hum. Genet. 2008;82:794&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427269</ArticleId><ArticleId IdType="pubmed">18319078</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res. Rev. 2009;61:89&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">19651157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry. 2010;67:739&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111021</ArticleId><ArticleId IdType="pubmed">20603455</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen AM, Stevens B. The role of the classical complement cascade in synapse loss during development and glaucoma. Adv. Exp. Med. Biol. 2010;703:75&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20711708</ArticleId></ArticleIdList></Reference><Reference><Citation>Krych-Goldberg M, Atkinson JP. Structure-function relationships of complement receptor type 1. Immunol. Rev. 2001;180:112&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414353</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Van CC, Engelborghs S, Lambert JC, Bettens K, Le BN, Pasquier F, Montoya AG, Peeters K, Mattheijssens M, Vandenberghe R, De Deyn PP, Cruts M, Amouyel P, Sleegers K, Van BC. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol. Psychiatry. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265835</ArticleId><ArticleId IdType="pubmed">21403675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, Hopkins CR, Evans PR, McMahon HT. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science. 2001;291:1051&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">11161218</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig S, Joseph SA, Tayler H, Abraham R, Owen MJ, Williams J, Kehoe PG, Love S. Distribution and expression of picalm in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2010;69:1071&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017341</ArticleId><ArticleId IdType="pubmed">20838239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch. Gen. Psychiatry. 2011;68:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">21300948</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22936268</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0172-780X</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Neuro endocrinology letters</Title><ISOAbbreviation>Neuro Endocrinol Lett</ISOAbbreviation></Journal><ArticleTitle>Transient psychosis due to caregiver burden in a patient caring for severely demented spouses.</ArticleTitle><Pagination><StartPage>372</StartPage><EndPage>374</EndPage><MedlinePgn>372-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Caring for demented people has been associated with negative effect on caregiver health. One or more severe stress factors can precipitate brief reactive psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 59-year-old Caucasian married woman with no prior psychosis has been caring for her severely demented husband for more than 3 years. She was treated for anxiety disorder and reaction to severe stress in our clinic for 1 year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five days after husband's nursing home placement our patient developed the abnormal thought, that someone might tell her neighbours of her laziness and failures. She believed that she was under constant surveillance. These ideas grew rapidly into delusions and hallucinations. She was diagnosed as having transient psychosis with associated acute stress and was treated with risperidone. The psychosis lasted for two months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Careful differential diagnosis is necessary in the cases of transient psychosis. Psychotic symptoms in overloaded individuals may be more common than was previously thought.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zverova</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Charles University, Prague, Czech Republic. Martina.Zverova@vfn.cz</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Neuro Endocrinol Lett</MedlineTA><NlmUniqueID>8008373</NlmUniqueID><ISSNLinking>0172-780X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018454" MajorTopicYN="N">Spouses</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22936268</ArticleId><ArticleId IdType="pii">NEL330412A01</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22903471</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1931-7565</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Brain imaging and behavior</Title><ISOAbbreviation>Brain Imaging Behav</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N&#x2009;=&#x2009;1345 young and elderly subjects.</ArticleTitle><Pagination><StartPage>102</StartPage><EndPage>115</EndPage><MedlinePgn>102-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11682-012-9199-7</ELocationID><Abstract><AbstractText>Deficits in lentiform nucleus volume and morphometry are implicated in a number of genetically influenced disorders, including Parkinson's disease, schizophrenia, and ADHD. Here we performed genome-wide searches to discover common genetic variants associated with differences in lentiform nucleus volume in human populations. We assessed structural MRI scans of the brain in two large genotyped samples: the Alzheimer's Disease Neuroimaging Initiative (ADNI; N&#x2009;=&#x2009;706) and the Queensland Twin Imaging Study (QTIM; N&#x2009;=&#x2009;639). Statistics of association from each cohort were combined meta-analytically using a fixed-effects model to boost power and to reduce the prevalence of false positive findings. We identified a number of associations in and around the flavin-containing monooxygenase (FMO) gene cluster. The most highly associated SNP, rs1795240, was located in the FMO3 gene; after meta-analysis, it showed genome-wide significant evidence of association with lentiform nucleus volume (P MA &#x2009;=&#x2009;4.79&#x2009;&#xd7;&#x2009;10(-8)). This commonly-carried genetic variant accounted for 2.68&#xa0;% and 0.84&#xa0;% of the trait variability in the ADNI and QTIM samples, respectively, even though the QTIM sample was on average 50&#xa0;years younger. Pathway enrichment analysis revealed significant contributions of this gene to the cytochrome P450 pathway, which is involved in metabolizing numerous therapeutic drugs for pain, seizures, mania, depression, anxiety, and psychosis. The genetic variants we identified provide replicated, genome-wide significant evidence for the FMO gene cluster's involvement in lentiform nucleus volume differences in human populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hibar</LastName><ForeName>Derrek P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Imaging Genetics Center at the Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E 635 Charles Young Drive, Los Angeles, CA, 90095-1769, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Ryles</LastName><ForeName>April B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Kohannim</LastName><ForeName>Omid</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Jahanshad</LastName><ForeName>Neda</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Medland</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Hansell</LastName><ForeName>Narelle K</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Katie L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>de Zubicaray</LastName><ForeName>Greig I</ForeName><Initials>GI</Initials></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Grant W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Nicholas G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Margaret J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB01651</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB008432</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG19771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30AG041681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM07356</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008281</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007356</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB007813</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB007813</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG041681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008042</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM005639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR019771</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008432</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EB008281</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>LM05639</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Imaging Behav</MedlineTA><NlmUniqueID>101300405</NlmUniqueID><ISSNLinking>1931-7557</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest</b> The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22903471</ArticleId><ArticleId IdType="mid">NIHMS439314</ArticleId><ArticleId IdType="pmc">PMC3779070</ArticleId><ArticleId IdType="doi">10.1007/s11682-012-9199-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abecasis GR, Li Y, Willer CJ, Ding J, Scheet P. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genetic Epidemiology. 2010;34(8):816&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175618</ArticleId><ArticleId IdType="pubmed">21058334</ArticleId></ArticleIdList></Reference><Reference><Citation>Annett M. A classification of hand preference by association analysis. British Journal of Psychology. 1970;61(3):303&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">5457503</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnone D, Cavanagh J, Gerber D, Lawrie SM, Ebmeier KP, McIntosh AM. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. [Meta-analysis Research Support, Non-U.S. Gov&#x2019;t Review] The British Journal of Psychiatry: The Journal of Mental Science. 2009;195(3):194&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">19721106</ArticleId></ArticleIdList></Reference><Reference><Citation>Athanasiu L, Mattingsdal M, Kahler AK, Brown A, Gustafsson O, Agartz I, et al. Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. Journal of Psychiatric Research. 2010;44(12):748&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224994</ArticleId><ArticleId IdType="pubmed">20185149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagwat SV, Bhamre S, Boyd MR, Ravindranath V. Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain. [In Vitro Research Support, Non-U.S. Gov&#x2019;t Research Support, U.S. Gov&#x2019;t, Non-P.H.S.] Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology. 1996;15(2):133&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">8840349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhamre S, Bhagwat SV, Shankar SK, Boyd MR, Ravindranath V. Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes. [Research Support, Non-U.S. Gov&#x2019;t] Brain Research. 1995;672(1-2):276&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">7749747</ArticleId></ArticleIdList></Reference><Reference><Citation>Bis JC, DeCarli CS, Smith AV, van der Lijn F, Crivello F, Fornage M, et al. Common variants at 12q14 and 12q24 are associated with hippocampal volume. Nature Genetics. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427729</ArticleId><ArticleId IdType="pubmed">22504421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobilya DJ, Gauthier NA, Karki S, Olley BJ, Thomas WK. Longitudinal changes in zinc transport kinetics, metallothionein and zinc transporter expression in a blood-brain barrier model in response to a moderately excessive zinc environment. [Research Support, N.I.H., Extramural] The Journal of Nutritional Biochemistry. 2008;19(2):129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2247408</ArticleId><ArticleId IdType="pubmed">18061429</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage. 2004;23(2):724&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascino GD, Adams RD. Brainstem auditory hallucinosis. Neurology. 1986;36(8):1042&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">3526177</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman JR, Zhang J. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metabolism and Disposition. 2002;30(10):1043&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">12228178</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP, et al. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Archives of General Psychiatry. 1996;53(7):607&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WM, Abecasis GR. Family-based association tests for genomewide association scans. American Journal of Human Genetics. 2007;81(5):913&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265659</ArticleId><ArticleId IdType="pubmed">17924335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CS, Chiang IC, Li CW, Lin WC, Lu CY, Hsieh TJ, Kuo YT. Proton magnetic resonance spectroscopy of late-life major depressive disorder. [Comparative Study Research Support, Non-U.S. Gov&#x2019;t] Psychiatry Research. 2009;172(3):210&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">19303260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Gutierrez ED, Thompson W, Panizzon MS, Jernigan TL, Eyler LT, Dale AM. Hierarchical genetic organization of human cortical surface area. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov&#x2019;t Research Support, U.S. Gov&#x2019;t, Non-P.H.S. Twin Study] Science. 2012;335(6076):1634&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690329</ArticleId><ArticleId IdType="pubmed">22461613</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, Barysheva M, McMahon KL, de Zubicaray GI, Johnson K, Montgomery GW, et al. Gene network effects on brain microstructure and intellectual performance identified in 472 twins. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. 2012;32(25):8732&#x2013;8745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3420968</ArticleId><ArticleId IdType="pubmed">22723713</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson&#x2019;s disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114(Pt 4):1953&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832073</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MC, Scheibel AB, Elson LM. The human brain coloring book. 1st ed. New York: Barnes &amp; Noble Books; 1985.</Citation></Reference><Reference><Citation>Durston S, Fossella JA, Casey BJ, Hulshoff Pol HE, Galvan A, Schnack HG, et al. Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. Molecular Psychiatry. 2005;10(7):678&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">15724142</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvernoy HM, Bourgouin P. The human brain: surface, three-dimensional sectional anatomy with MRI, and blood supply (2nd completely rev. and enl. ed.) Wien: Springer; 1999.</Citation></Reference><Reference><Citation>Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breier A. Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. The American Journal of Psychiatry. 1994;151(5):752&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison-Wright I, Ellison-Wright Z, Bullmore E. Structural brain change in attention deficit hyperactivity disorder identified by meta-analysis. BMC Psychiatry. 2008;8:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2453122</ArticleId><ArticleId IdType="pubmed">18590567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. The American Journal of Psychiatry. 2008;165(8):1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873788</ArticleId><ArticleId IdType="pubmed">18381902</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. American Journal of Human Genetics. 2011;88(5):586&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146723</ArticleId><ArticleId IdType="pubmed">21565292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines RN. Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert Opinion on Drug Metabolism &amp; Toxicology. 2006;2(1):41&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16863467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines RN, Hopp KA, Franco J, Saeian K, Begun FP. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Molecular Pharmacology. 2002;62(2):320&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines RN, Koukouritaki SB, Poch MT, Stephens MC. Regulatory polymorphisms and their contribution to in-terindividual differences in the expression of enzymes influencing drug and toxicant disposition. Drug Metabolism Reviews. 2008;40(2):263&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">18464046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Archives of General Psychiatry. 2008;65(9):1017&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Research. 2002;51(2):236&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">11809920</ArticleId></ArticleIdList></Reference><Reference><Citation>Koukouritaki SB, Poch MT, Henderson MC, Siddens LK, Krueger SK, VanDyke JE, et al. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. Journal of Pharmacology and Experimental Therapeutics. 2007;320(1):266&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">17050781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremen WS, Prom-Wormley E, Panizzon MS, Eyler LT, Fischl B, Neale MC, et al. Genetic and environmental influences on the size of specific brain regions in midlife: the VETSA MRI study. NeuroImage. 2010;49(2):1213&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397915</ArticleId><ArticleId IdType="pubmed">19786105</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacology and Therapeutics. 2005;106(3):357&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828602</ArticleId><ArticleId IdType="pubmed">15922018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265(5181):2037&#x2013;2048.</Citation><ArticleIdList><ArticleId IdType="pubmed">8091226</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MX, Sham PC, Cherny SS, Song YQ. A knowledge-based weighting framework to boost the power of genome-wide association studies. [Research Support, Non-U.S. Gov&#x2019;t] PLoS One. 2010;5(12):e14480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013112</ArticleId><ArticleId IdType="pubmed">21217833</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MX, Gui HS, Kwan JSH, Sham PC. GATES: a rapid and powerful gene-based association test using extended simes procedure. American Journal of Human Genetics. 2011;88(3):283&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059433</ArticleId><ArticleId IdType="pubmed">21397060</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsden CD, Obeso JA, Rothwell JC. Clinical neurophysiology of muscle jerks: myoclonus, chorea, and tics. Advances in Neurology. 1983;39:865&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">6229162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. [Research Support, Non-U.S. Gov&#x2019;t Research Support, U.S. Gov&#x2019;t, P.H.S.] Biological Psychiatry. 2000;48(8):830&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063978</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN. Genomewide association studies for complex traits: consensus, uncertainty and challenges. Nature Reviews Genetics. 2008;9(5):356&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">18398418</ArticleId></ArticleIdList></Reference><Reference><Citation>Morey RA, Selgrade ES, Wagner HR, 2nd, Huettel SA, Wang L, McCarthy G. Scan-rescan reliability of subcortical brain volumes derived from automated segmentation. Human Brain Mapping. 2010;31(11):1751&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782252</ArticleId><ArticleId IdType="pubmed">20162602</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale MC, Cardon LR North Atlantic Treaty Organization. Methodology for genetic studies of twins and families. Dordrecht: Kluwer Academic Publishers; 1992. Scientific Affairs Division.</Citation></Reference><Reference><Citation>Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW. Pathophysiology of the basal ganglia in Parkinson&#x2019;s disease. Trends in Neurosciences. 2000;23(10 Suppl):S8&#x2013;S19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11052215</ArticleId></ArticleIdList></Reference><Reference><Citation>Overby LH, Carver GC, Philpot RM. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chemico-Biological Interactions. 1997;106(1):29&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305407</ArticleId></ArticleIdList></Reference><Reference><Citation>Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov&#x2019;t] NeuroImage. 2011;56(3):907&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Peper JS, Brouwer RM, Boomsma DI, Kahn RS, Hulshoff Pol HE. Genetic influences on human brain structure: a review of brain imaging studies in twins. Human Brain Mapping. 2007;28(6):464&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871295</ArticleId><ArticleId IdType="pubmed">17415783</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Aging, mild cognitive impairment, and Alzheimer&#x2019;s disease. Neurologic Clinics. 2000;18(4):789&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072261</ArticleId></ArticleIdList></Reference><Reference><Citation>Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465(7301):1033&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206313</ArticleId><ArticleId IdType="pubmed">20577206</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Rodrigue KM, Kennedy KM, Head D, Gunning-Dixon F, Acker JD. Differential aging of the human striatum: longitudinal evidence. AJNR. American Journal of Neuro-radiology. 2003;24(9):1849&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7976312</ArticleId><ArticleId IdType="pubmed">14561615</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner A, Albin RL, Anderson KD, D&#x2019;Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(15):5733&#x2013;5737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281835</ArticleId><ArticleId IdType="pubmed">2456581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36(2):241&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">12383780</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Human Brain Mapping. 2002;17(3):143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 2004;23:S208&#x2013;S219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell RS. Clinical neuroanatomy. 7th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins; 2010.</Citation></Reference><Reference><Citation>Stein JL, Hua X, Morra JH, Lee S, Hibar DP, Ho AJ, et al. Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer&#x2019;s disease. NeuroImage. 2010;51(2):542&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856746</ArticleId><ArticleId IdType="pubmed">20197096</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein JL, Medland SE, Arias Vasquez A, Hibar D, Senstad RE, Winkler AM, et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics. 2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635491</ArticleId><ArticleId IdType="pubmed">22504417</ArticleId></ArticleIdList></Reference><Reference><Citation>Strakowski SM, DelBello MP, Sax KW, Zimmerman ME, Shear PK, Hawkins JM, Larson ER. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Archives of General Psychiatry. 1999;56(3):254&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078503</ArticleId></ArticleIdList></Reference><Reference><Citation>Toga AW, Thompson PM. Mapping brain asymmetry. Nature Reviews Neuroscience. 2003;4(1):37&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12511860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen YZ, Zheng LL, Liao JY, Wang MH, Wei Y, Guo XM, et al. Pseudogene-derived small interference RNAs regulate gene expression in African Trypanosoma brucei. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(20):8345&#x2013;8350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100955</ArticleId><ArticleId IdType="pubmed">21531904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wik G, Wiesel FA, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. [Research Support, Non-U.S. Gov&#x2019;t] Psychopharmacology. 1989;97(3):309&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">2497479</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition. 2004;32(11):1201&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304429</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SAK. Progressive lenticular degeneration. A familial nervous disease associated with cirrhosis of the liver. Lancet. 1912;1:1115&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung CK, Lang DH, Thummel KE, Rettie AE. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metabolism and Disposition. 2000;28(9):1107&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950857</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22892657</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-2731</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use.</ArticleTitle><Pagination><StartPage>468</StartPage><EndPage>473</EndPage><MedlinePgn>468-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1533317512456450</ELocationID><Abstract><AbstractText>Dementia with Lewy bodies (DLB) is commonly associated with excessive daytime somnolence (EDS). Modafinil is a wakefulness-promoting agent that is considered to have limited interaction with the dopaminergic system. As individuals with DLB are predisposed to psychotic symptoms that might be exacerbated by dopaminergic stimulation, modafinil is considered to be an attractive option for the treatment of EDS in DLB. We describe 2 cases in which administration of modafinil exacerbated agitation and hallucinations in DLB, and we also review data that may explain the mechanisms underlying this effect. In both cases, psychotic symptoms emerged concomitantly with modafinil administration and remitted following its discontinuation. Although definitive data regarding the benefits and adverse effects of modafinil for the treatment of EDS in DLB await controlled prospective randomized studies, our observations warrant caution regarding its use in this context.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prado</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, State University of Londrina, Brazil. eduardostp@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paholpak</LastName><ForeName>Pongsatorn</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ngo</LastName><ForeName>Myha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Verna</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Marrocos</LastName><ForeName>Rog&#xe9;rio</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG-16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>R3UK8X3U3D</RegistryNumber><NameOfSubstance UI="D000077408">Modafinil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017109" MajorTopicYN="Y">Akathisia, Drug-Induced</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006970" MajorTopicYN="N">Disorders of Excessive Somnolence</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077408" MajorTopicYN="N">Modafinil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="Y">Psychoses, Substance-Induced</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22892657</ArticleId><ArticleId IdType="mid">NIHMS574409</ArticleId><ArticleId IdType="pmc">PMC4005870</ArticleId><ArticleId IdType="doi">10.1177/1533317512456450</ArticleId><ArticleId IdType="pii">1533317512456450</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mosimann UP, McKeith IG. Dementia with Lewy bodies&#x2014;diagnosis and treatment. Swiss Med Weekly. 2003;133(9-10):131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707840</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44(10):1624&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">20736422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cephalon. Prescribing Information: Provigil (Modafinil) Tablets. Cephalon, Inc; Frazer, PA &#x2013; US; 1999.</Citation></Reference><Reference><Citation>Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson&#x2019;s disease with modafinil. Clin Neuropharmacol. 2002;25(2):111&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">11981239</ArticleId></ArticleIdList></Reference><Reference><Citation>Howcroft DJ, Jones RW. Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia? Int J Geriatr Psychiatry. 2005;20(5):492&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852440</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Dementia with lewy bodies: molecular pathogenesis and implications for classification. J Geriatr Psychiatry Neurol. 2004;17(3):112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312274</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004;17(suppl 1):3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676464</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson&#x2019;s disease. From description to etiology. J Neurol. 2005;252(7):753&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15999234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson&#x2019;s disease: a review. Drugs Aging. 2008;25(8):665&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045853</ArticleId><ArticleId IdType="pubmed">18665659</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson&#x2019;s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137166</ArticleId><ArticleId IdType="pubmed">17898337</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844739</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson&#x2019;s disease, and Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 1991;640:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">1723256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters EC. Intrinsic and extrinsic psychosis in Parkinson&#x2019;s disease. J Neurol. 2001;248(suppl 3):22&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11697684</ArticleId></ArticleIdList></Reference><Reference><Citation>Albasanz JL, Dalfo E, Ferrer I, Martin M. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer&#x2019;s disease and dementia with Lewy bodies correlates with stage of Alzheimer&#x2019;s-disease-related changes. Neurobiol Dis. 2005;20(3):685&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">15949941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17(5):436&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991954</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon P, Hemet C, Ramassamy C, Costentin J. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol. 1995;5(4):509&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">8998404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93:14128&#x2013;14133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19505</ArticleId><ArticleId IdType="pubmed">8943072</ArticleId></ArticleIdList></Reference><Reference><Citation>Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20(22):8620&#x2013;8628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773149</ArticleId><ArticleId IdType="pubmed">11069971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisor JP, Eriksson KS. Dopaminergic&#x2013;adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132(4):1027&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009;329:738&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672878</ArticleId><ArticleId IdType="pubmed">19197004</ArticleId></ArticleIdList></Reference><Reference><Citation>Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006;319(2):561&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">16885432</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrard P, Malcolm R. Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007;3(3):349&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654794</ArticleId><ArticleId IdType="pubmed">19300566</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou RH, Freeman C, Langley RW, Szabadi E, Bradshaw CM. Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers. Psychopharmacology (Berl). 2005;181(3):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">15983798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762940</ArticleId><ArticleId IdType="pubmed">11222668</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci. 2008;28(34):8462&#x2013;8469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671058</ArticleId><ArticleId IdType="pubmed">18716204</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696807</ArticleId><ArticleId IdType="pubmed">19293415</ArticleId></ArticleIdList></Reference><Reference><Citation>Spence SA, Green RD, Wilkinson ID, Hunter MD. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry. 2005;187:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15994572</ArticleId></ArticleIdList></Reference><Reference><Citation>Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry. 2002;59(3):292&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879175</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorspan F, Warot D, Consoli A, Cohen D, Mazet P. Mania in a boy treated with modafinil for narcolepsy. Am J Psychiatry. 2005;162(4):813&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">15800167</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry. 2005;162(10):1983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16199854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Jones S, Ryan CJ, Michail D, Robinson TD. Modafinil-induced psychosis. Intern Med J. 2008;38(8):677&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">18808567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadock BJ, Kaplan HI, Sadock VA. Kaplan &amp; Sadock's Synopsis of Psychiatry Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia, PA: Wolter Kluwer/Lippincott Williams &amp; Wilkins; 2007.</Citation></Reference><Reference><Citation>Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov Disord. 2000;15(6):1269&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">11104221</ArticleId></ArticleIdList></Reference><Reference><Citation>Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson&#x2019;s disease with modafinil. J Neurol. 2001;248(7):632&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">11518012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyne HL, Taylor J, Baker GA, Steiger MJ. Modafinil for Parkinson&#x2019;s disease fatigue. J Neurol. 2010;257(3):452&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">19842011</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson&#x2019;s disease. Mov Disord. 2003;18(3):287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">12621632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson&#x2019;s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokk J. Daytime sleepiness in elderly Parkinson&#x2019;s disease patients and treatment with the psychostimulant modafinil: a preliminary study. Neuropsychiatr Dis Treat. 2010;6:93&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854085</ArticleId><ArticleId IdType="pubmed">20396641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou JS, Dimitrova DM, Park BS, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol. 2009;32(6):305&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">19620846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson&#x2019;s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739456</ArticleId><ArticleId IdType="pubmed">16291885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22868934</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Interactive effect of apolipoprotein e genotype and age on hippocampal activation during memory processing in healthy adults.</ArticleTitle><Pagination><StartPage>804</StartPage><EndPage>813</EndPage><MedlinePgn>804-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2011.1893</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Although the apolipoprotein E (APOE) &#x3f5;4 allele is a major genetic risk factor for late-onset Alzheimer disease, its effect on hippocampal function during episodic memory is controversial because studies have yielded mixed results. The age of the studied cohorts may contribute to this apparent inconsistency: activation for &#x3f5;4 carriers tends to be increased in studies of older adults but decreased in some studies of younger adults. Consistent with differential age effects, research in transgenic mice suggests that the &#x3f5;4 allele may particularly affect the aging process.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To define the interactions of age and this allelic variation on brain activation during episodic memory across adult life in healthy individuals.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Functional magnetic resonance imaging (fMRI) using an episodic memory paradigm to test for differences in neuroactivation across APOE genotypes and age groups.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A federal research institute.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Healthy white volunteers (APOE &#x3f5;3 homozygotes and &#x3f5;2 and &#x3f5;4 heterozygotes) completed the fMRI task (133 volunteers aged 19-77 years).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Memory-related regional blood oxygenation level-dependent (BOLD) activation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Genotype affected the pattern of change in hippocampal BOLD activation across the adult lifespan: older age was associated with decreased activation in &#x3f5;2 carriers and, to a lesser extent, in &#x3f5;3 homozygotes, but this pattern was not observed in &#x3f5;4 carriers. Among young participants, &#x3f5;4 carriers had less hippocampal activation compared with &#x3f5;3 homozygotes despite similar task performance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings support the hypothesis that aging and APOE allele status have interacting effects on the neural substrate of episodic memory and lend clarification to disparities in the literature. The stepwise decrease in activation with age found among genotype groups resembles the order of susceptibility to Alzheimer disease, suggesting a compensatory neurobiological mechanism in older asymptomatic &#x3f5;4 carriers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Clinical Brain Disorders Branch, Genes, Cognition, and Psychosis Program, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masdeu</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mattay</LastName><ForeName>Venkata S</ForeName><Initials>VS</Initials></Author><Author ValidYN="Y"><LastName>Kohn</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sambataro</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kolachana</LastName><ForeName>Bhaskar</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Elvev&#xe5;g</LastName><ForeName>Brita</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kippenhan</LastName><ForeName>Shane</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Weinberger</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Karen F</ForeName><Initials>KF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2013 Jun;70(6):646-7. doi: 10.1001/jamapsychiatry.2013.865</RefSource><PMID Version="1">23740051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="Y">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="Y">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22868934</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.1893</ArticleId><ArticleId IdType="pii">1307557</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22851482</PMID><DateCompleted><Year>2012</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2012</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Actas espanolas de psiquiatria</Title><ISOAbbreviation>Actas Esp Psiquiatr</ISOAbbreviation></Journal><ArticleTitle>Vascular psychosis in the elderly: response to clozapine.</ArticleTitle><Pagination><StartPage>228</StartPage><EndPage>230</EndPage><MedlinePgn>228-30</MedlinePgn></Pagination><Abstract><AbstractText>Cerebrovascular disease is a cause of late-onset psychosis in the elderly more frequent, accompanied or not, multi-infarct dementia. In many cases the patient has adequate preservation of cognitive functions or in any case, no criteria for dementia. In those that do, is in vascular dementia where psychotic symptoms are more frequent, occurring in over half cases, compared to one third of patients with Alzheimer disease. A case of a 92 year-old woman with no somatic background -except for a bilateral progressive hearing loss-, who debuted at this age with psychotic delusions structured injury and auditory hallucinations. The CT scan showed signs of cortico-subcortical atrophy. Neuropsychological examinations showed some cognitive impairment but no clinical criteria for dementia. Was refractory to first-line atypical antipsychotics, remitting symptoms after administration of low doses of clozapine. We discuss the clinical features of this psychosis, as well as its therapeutic approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soriano-Barcel&#xf3;</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Psiquiatr&#xed;a, Complexo Hospitalario Universitario de Santiago de Compostela, Spain. jsorianobarcelo@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mota-Rodr&#xed;guez</LastName><ForeName>Ma Jes&#xfa;s</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ara&#xfa;xo</LastName><ForeName>Alberte</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Esp Psiquiatr</MedlineTA><NlmUniqueID>100886502</NlmUniqueID><ISSNLinking>1139-9287</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22851482</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22834095</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2012</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0546-1766</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>[Nihon koshu eisei zasshi] Japanese journal of public health</Title><ISOAbbreviation>Nihon Koshu Eisei Zasshi</ISOAbbreviation></Journal><ArticleTitle>[Suicide due to mental diseases based on the Vital Statistics Survey Death Form].</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>406</EndPage><MedlinePgn>399-406</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Mental diseases such as schizophrenia and depression put patients at risk for suicide. It is extremely important to understand that one way of preventing suicide is to determine the actual mental state of the individual. The purpose of this study was to analyze the true mental state of suicide victims reported in the vital statistics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study investigated the vital statistics of 30,299 suicide victims in Japan in 2008. The use of these basic statistics for non-statistical purposes was approved by the Japanese Ministry of Health, Labour and Welfare. The method involved reviewing the Vital Statistics Survey Death Form at the Ministry of Health, Labour and Welfare as well as analyzing their Online Reporting of Vital Statistics. Furthermore, this study was able to validate 29,799 of the 30,299 suicides (98.3%) that occurred in 2008. Mental diseases were validated not only from the "Cause of death" section as marked on the death certificate, but also by information found in sections for "Additional items for death by external cause" and "Other special remarks." RESULTS; From the Vital Statistics Survey Death Form and Online Reporting of Vital Statistics, 2964 individuals with either a mental disease or mental disorder were identified. Of the 2964 identified individuals, 55 had dementia (of which 13 were dementia in Alzheimer's disease), 116 had alcohol dependence/psychotic disorder, 550 had schizophrenia, 101 had bipolar affective disorder, 1,913 has had a depressive episode, 13 had obsessive-compulsive disorder, 22 had adjustment disorders, 14 had eating disorders, 49 had nonorganic sleep disorders, 24 had personality disorder, and 6 had pervasive developmental disorders. In addition, 125 individuals had more than one mental disease. The national police statistics from 2008 show that 1,368 suicide victims had schizophrenia and</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">6,490 had depression. These figures show quite a difference between the results of this study and the police statistics. Further, there have been controversies regarding autopsies of suicide victims. Thus, further investigation into the cause of death is of great importance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takizawa</LastName><ForeName>Tohru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Human Health, Hachinohe University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Koshu Eisei Zasshi</MedlineTA><NlmUniqueID>19130150R</NlmUniqueID><ISSNLinking>0546-1766</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014798" MajorTopicYN="N">Vital Statistics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22834095</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22784860</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Systematic reviews on behavioural and psychological symptoms in the older or demented population.</ArticleTitle><Pagination><StartPage>28</StartPage><MedlinePgn>28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/alzrt131</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We have undertaken a systematic review of reviews to give a broad overview of the prevalence, course, biological and psychosocial associations, care and outcomes of BPS in the older or demented population, and highlight limitations and gaps in existing research. Embase and Medline were searched for systematic reviews using search terms for BPS, dementia and ageing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-six reviews were identified. Most investigated the prevalence or course of symptoms, while few reviewed the effects of BPS on outcomes and care. BPS were found to occur in non-demented, cognitively impaired and demented people, but reported estimates vary widely. Biological factors associated with BPS in dementia include genetic factors, homocysteine levels and vascular changes. Psychosocial factors increase risk of BPS; however, across studies and between symptoms findings are inconsistent. BPS have been associated with burden of care, caregiver's general health and caregiver depression scores, but findings are limited regarding institutionalisation, quality of life and disease outcome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Limitations of reviews include a lack of high quality reviews, particularly of BPS other than depression. Limitations of original studies include heterogeneity in study design particularly related to measurement of BPS, level of cognitive impairment, population characteristics and participant recruitment. It is our recommendation that more high quality reviews, including all BPS, and longitudinal studies with larger sample sizes that use frequently cited instruments to measure BPS are undertaken. A better understanding of the risk factors and course of BPS will inform prevention, treatment and management and possibly improve quality of life for the patients and their carers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Linde</LastName><ForeName>Rianne M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care - Forvie Site, Institute of Public Health, University of Cambridge, Robinson Way, Cambridge CB2 0SR, UK. rmv23@medschl.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Blossom Cm</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Savva</LastName><ForeName>George M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Dening</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22784860</ArticleId><ArticleId IdType="pmc">PMC3506942</ArticleId><ArticleId IdType="doi">10.1186/alzrt131</ArticleId><ArticleId IdType="pii">alzrt131</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194:212&#x2013;219. doi: 10.1192/bjp.bp.108.049619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.108.049619</ArticleId><ArticleId IdType="pubmed">19252147</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Clinical Excellence. Dementia - Supporting people with Dementia and their Carers in Health and Social Care. 2006.</Citation></Reference><Reference><Citation>Department of Health (UK) Living Well with Dementia: A National Dementia Strategy. 2009.</Citation></Reference><Reference><Citation>Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011;11:15. doi: 10.1186/1471-2288-11-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-11-15</ArticleId><ArticleId IdType="pmc">PMC3039637</ArticleId><ArticleId IdType="pubmed">21291558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraepelin E. Psychiatrie: ein Lehrbuch f&#xfc;r studierende und &#xc4;rtze. Leipzig: J.A. Barth; 1896.</Citation></Reference><Reference><Citation>Roth M. The natural history of mental disorder in old age. J Ment Sci. 1955;101:281&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">13243044</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. &#xdc;ber einen eigenartigen schweren Er Krankungsprozeb der Himrinde. Neurol Zbl. 1906;23:1129&#x2013;1136.</Citation></Reference><Reference><Citation>Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48 Suppl:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3:e123&#x2013;e130. doi: 10.2174/1874306400903010123.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874306400903010123</ArticleId><ArticleId IdType="pmc">PMC3090117</ArticleId><ArticleId IdType="pubmed">21603045</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;15:7&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1810543</ArticleId><ArticleId IdType="pubmed">17302989</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013&#x2013;1020. doi: 10.1016/j.jclinepi.2008.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2008.10.009</ArticleId><ArticleId IdType="pubmed">19230606</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MG, Bellavance F. The prognosis of depression in old age. Am J Geriatr Psychiatry. 1997;5:4&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169240</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen H, Griffiths K, Mackinnon A, Jacomb P. A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Int Neuropsychol Soc. 1997;3:631&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">9448376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MG, Bellavance F. Depression in elderly medical inpatients: a meta-analysis of outcomes. Can Med Assoc J. 1997;157:1055&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1228261</ArticleId><ArticleId IdType="pubmed">9347776</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MG. Does depression in older medical inpatients predict mortality? A systematic review. Gen Hosp Psychiatry. 2007;29:425&#x2013;430. doi: 10.1016/j.genhosppsych.2007.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2007.07.002</ArticleId><ArticleId IdType="pubmed">17888809</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry JD, Crawford JR. A meta-analytic review of verbal fluency deficits in depression. J Clin Exp Neuropsychol. 2005;27:78&#x2013;101. doi: 10.1080/138033990513654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/138033990513654</ArticleId><ArticleId IdType="pubmed">15814444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima GA, Wenger NS. Quality indicators for the care of depression in vulnerable elders. J Am Geriatr Soc. 2007;55:S302&#x2013;S311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17910551</ArticleId></ArticleIdList></Reference><Reference><Citation>Savoie I, Morettin D, Green CJ, Kazanjian A. Systematic review of the role of gender as a health determinant of hospitalization for depression. Int J Technol Assess Health Care. 2004;20:115&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">15209172</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Copeland JR, Wei L. A meta-analysis of epidemiological studies in depression of older people in The People's Republic of China. Int J Geriatr Psychiatry. 1999;14:821&#x2013;830. doi: 10.1002/(SICI)1099-1166(199910)14:10&lt;821::AID-GPS21&gt;3.0.CO;2-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1099-1166(199910)14:10&lt;821::AID-GPS21&gt;3.0.CO;2-0</ArticleId><ArticleId IdType="pubmed">10521881</ArticleId></ArticleIdList></Reference><Reference><Citation>Monastero R, Mangialasche F, Camarda C, Ercolani S, Camarda R. A systematic review of neuropsychiatric symptoms in mild cognitive impairment. J Alzheimer's Dis. 2009;18:11&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542627</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: A systematic review of the literature. Dementia Geriatr Cogn Disord. 2008;25:115&#x2013;126. doi: 10.1159/000112509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000112509</ArticleId><ArticleId IdType="pubmed">18087152</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr. 2010;22:1025&#x2013;1039. doi: 10.1017/S1041610210000608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610210000608</ArticleId><ArticleId IdType="pubmed">20522279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007;20:41&#x2013;49. doi: 10.1177/0891988706292762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988706292762</ArticleId><ArticleId IdType="pubmed">17341770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shub D, Ball V, Abbas AAA, Gottumukkala A, Kunik ME. The link between psychosis and aggression in persons with dementia: a systematic review. Psychiatr Q. 2010;81:97&#x2013;110. doi: 10.1007/s11126-009-9121-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11126-009-9121-7</ArticleId><ArticleId IdType="pubmed">20058077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989;146:577&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030. doi: 10.1176/appi.ajp.162.11.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.162.11.2022</ArticleId><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, Weyerer S, Konig HH, Riedel-Heller SG. Age- and gender-specific prevalence of depression in latest-life - Systematic review and meta-analysis. J Affective Disord. 2012;136:212&#x2013;221. doi: 10.1016/j.jad.2010.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.11.033</ArticleId><ArticleId IdType="pubmed">21194754</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307&#x2013;311. doi: 10.1192/bjp.174.4.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.174.4.307</ArticleId><ArticleId IdType="pubmed">10533549</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeks TW, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in "a minor" can "b major": a review of epidemiology, illness course, and public health implications of subthreshold depression in older adults. J Affective Disord. 2011;129:126&#x2013;142. doi: 10.1016/j.jad.2010.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.09.015</ArticleId><ArticleId IdType="pmc">PMC3036776</ArticleId><ArticleId IdType="pubmed">20926139</ArticleId></ArticleIdList></Reference><Reference><Citation>Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006;113:372&#x2013;387. doi: 10.1111/j.1600-0447.2006.00770.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2006.00770.x</ArticleId><ArticleId IdType="pubmed">16603029</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwahhabi F. Anxiety symptoms and generalized anxiety disorder in the elderly: a review. Harv Rev Psychiatry. 2003;11:180&#x2013;193. doi: 10.1080/10673220303944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10673220303944</ArticleId><ArticleId IdType="pubmed">12944126</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Kokmen E, Kondo K, Mortimer JA, Rocca WA. et al.Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol. 1991;20(Suppl 2):S43&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pubmed">1917269</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkaik R, Nuyen J, Schellevis F, Francke A. The relationship between severity of Alzheimer's disease and prevalence of comorbid depressive symtoms and depression: a systematic review. Int J Geriatr Psychiatry. 2007;22:1063&#x2013;1086. doi: 10.1002/gps.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1809</ArticleId><ArticleId IdType="pubmed">17457960</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CQ, Wang ZR, Li YH, Xie YZ, Liu QX. Cognitive function and risk for depression in old age: a meta-analysis of published literature. Int Psychogeriatr. 2011;23:516&#x2013;525. doi: 10.1017/S1041610210000049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610210000049</ArticleId><ArticleId IdType="pubmed">20937170</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry. 2001;35:776&#x2013;781. doi: 10.1046/j.1440-1614.2001.00967.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1614.2001.00967.x</ArticleId><ArticleId IdType="pubmed">11990888</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF. Is depression a risk factor for dementia or cognitive decline? A review. Gerontology. 2000;46:219&#x2013;227. doi: 10.1159/000022163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000022163</ArticleId><ArticleId IdType="pubmed">10859462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27:1255&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15586779</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd JA, Janisse JJ, Jenuwine ES, Ager JW. Changes in REM-sleep percentage over the adult lifespan. Sleep. 2007;30:829&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978369</ArticleId><ArticleId IdType="pubmed">17682652</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd JA, Medler SM, Ager JW, Janisse JJ. Age-related changes in initiation and maintenance of sleep: a meta-analysis. Res Nurs Health. 2000;23:106&#x2013;117. doi: 10.1002/(SICI)1098-240X(200004)23:2&lt;106::AID-NUR3&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-240X(200004)23:2&lt;106::AID-NUR3&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">10782869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo HK, Sorond FA, Chen JH, Hashmi A, Milberg WP, Lipsitz LA. The role of homocysteine in multisystem age-related problems: A systematic review. J Gerontol Ser A Biol Sci Med Sci. 2005;60:1190&#x2013;1201. doi: 10.1093/gerona/60.9.1190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/60.9.1190</ArticleId><ArticleId IdType="pubmed">16183962</ArticleId></ArticleIdList></Reference><Reference><Citation>Flirski M, Sobow T, Kloszewska I. Behavioural genetics of Alzheimer's disease: A comprehensive review. Arch Med Sci. 2011;7:195&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258720</ArticleId><ArticleId IdType="pubmed">22291757</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CQ, Dong BR, Lu ZC, Yue JR, Liu QX. Chronic diseases and risk for depression in old age: a meta-analysis of published literature. Ageing Res Rev. 2010;9:131&#x2013;141. doi: 10.1016/j.arr.2009.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2009.05.005</ArticleId><ArticleId IdType="pubmed">19524072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang-Quan H, Xue-Mei Z, Bi-Rong D, Zhen-Chan L, Ji-Rong Y, Qing-Xiu L. Health status and risk for depression among the elderly: a meta-analysis of published literature. Age Ageing. 2010;39:23&#x2013;30. doi: 10.1093/ageing/afp187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afp187</ArticleId><ArticleId IdType="pubmed">19903775</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L. Homocysteine and depression in later life. Arch Gen Psychiatry. 2008;65:1286&#x2013;1294. doi: 10.1001/archpsyc.65.11.1286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.65.11.1286</ArticleId><ArticleId IdType="pubmed">18981340</ArticleId></ArticleIdList></Reference><Reference><Citation>Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. Psychosom Med. 2011;73:114&#x2013;126. doi: 10.1097/PSY.0b013e31820ad12b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PSY.0b013e31820ad12b</ArticleId><ArticleId IdType="pubmed">21257974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: Systematic review and meta-analysis. Lancet Neurol. 2005;4:371&#x2013;380. doi: 10.1016/S1474-4422(05)70099-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70099-5</ArticleId><ArticleId IdType="pubmed">15907742</ArticleId></ArticleIdList></Reference><Reference><Citation>Camus V, Kraehenbuhl H, Preisig M, Bula CJ, Waeber G. Geriatric depression and vascular diseases: what are the links? J Affective Disord. 2004;81:1&#x2013;16. doi: 10.1016/j.jad.2003.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2003.08.003</ArticleId><ArticleId IdType="pubmed">15183594</ArticleId></ArticleIdList></Reference><Reference><Citation>Vink D, Aartsen MJ, Schoevers RA. Risk factors for anxiety and depression in the elderly: a review. J Affective Disord. 2008;106:29&#x2013;44. doi: 10.1016/j.jad.2007.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2007.06.005</ArticleId><ArticleId IdType="pubmed">17707515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MG, Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry. 2003;160:1147&#x2013;1156. doi: 10.1176/appi.ajp.160.6.1147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.160.6.1147</ArticleId><ArticleId IdType="pubmed">12777274</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler JE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia. Med Care. 2009;47:191&#x2013;198. doi: 10.1097/MLR.0b013e31818457ce.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31818457ce</ArticleId><ArticleId IdType="pubmed">19169120</ArticleId></ArticleIdList></Reference><Reference><Citation>Black W, Almeida OP. A systematic review of the association between the Behavioral and Psychological Symptoms of Dementia and burden of care. Int Psychogeriatr. 2004;16:295&#x2013;315. doi: 10.1017/S1041610204000468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610204000468</ArticleId><ArticleId IdType="pubmed">15559754</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, de Valle M. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry. 2009;24:15&#x2013;24. doi: 10.1002/gps.2090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2090</ArticleId><ArticleId IdType="pubmed">18727132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Chodosh J. Dementia and life expectancy: what do we know? J Am Med Dir Assoc. 2009;10:466&#x2013;471. doi: 10.1016/j.jamda.2009.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2009.03.014</ArticleId><ArticleId IdType="pubmed">19716062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer CE, Verhoeff NP, Churchill K, Schweizer TA. Functional outcome in delusional Alzheimer disease patients: a systematic review. Dement Geriatr Cogn Disord. 2009;27:105&#x2013;110. doi: 10.1159/000194659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000194659</ArticleId><ArticleId IdType="pubmed">19169029</ArticleId></ArticleIdList></Reference><Reference><Citation>Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, Weyerer S, Konig HH, Riedel-Heller SG. Age- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysis. J Affect Disord. 2012;136:212&#x2013;221. doi: 10.1016/j.jad.2010.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2010.11.033</ArticleId><ArticleId IdType="pubmed">21194754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang-Quan H, Xue-Mei Z, Bi-Rong D, Zhen-Chan L, Ji-Rong Y, Qing-Xiu L. Health status and risk for depression among the elderly: a meta-analysis of published literature. Age Ageing. 2010;39:23&#x2013;30. doi: 10.1093/ageing/afp187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afp187</ArticleId><ArticleId IdType="pubmed">19903775</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307&#x2013;311. doi: 10.1192/bjp.174.4.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.174.4.307</ArticleId><ArticleId IdType="pubmed">10533549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030. doi: 10.1176/appi.ajp.162.11.2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.162.11.2022</ArticleId><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530&#x2013;538. doi: 10.1001/archpsyc.63.5.530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.63.5.530</ArticleId><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>International Psychogeriatric Association (IPA) Behavioral and Psychological Symptoms of Dementia (BPSD) Educational Pack. 2002.</Citation></Reference><Reference><Citation>Serra L, Perri R, Cercignani M, Spano B, Fadda L, Marra C, Carlesimo GA, Caltagirone C, Bozzali M. Are the behavioral symptoms of Alzheimer's disease directly associated with neurodegeneration? J Alzheimers Dis. 2010;21:627&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">20555138</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlow YA, Wells WM, Ellison JM, Sung YH, Renshaw PF, Harper DG. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25:780&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975914</ArticleId><ArticleId IdType="pubmed">19946864</ArticleId></ArticleIdList></Reference><Reference><Citation>Staekenborg SS, Gillissen F, Romkes R, Pijnenburg YA, Barkhof F, Scheltens P, van der Flier WM. Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23:387&#x2013;392. doi: 10.1002/gps.1891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1891</ArticleId><ArticleId IdType="pubmed">17907266</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3:e123&#x2013;e130. doi: 10.2174/1874306400903010123.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874306400903010123</ArticleId><ArticleId IdType="pmc">PMC3090117</ArticleId><ArticleId IdType="pubmed">21603045</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke L, Clarke M, Clarke T. How useful are Cochrane reviews in identifying research needs? J Health Serv Res Policy. 2007;12:101&#x2013;103. doi: 10.1258/135581907780279648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/135581907780279648</ArticleId><ArticleId IdType="pubmed">17407660</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen O, Middleton P, Ezzo J, Gotzsche PC, Hadhazy V, Herxheimer A, Kleijnen J, McIntosh H. Quality of Cochrane reviews: assessment of sample from 1998. BMJ. 2001;323:829&#x2013;832. doi: 10.1136/bmj.323.7317.829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.323.7317.829</ArticleId><ArticleId IdType="pmc">PMC57800</ArticleId><ArticleId IdType="pubmed">11597965</ArticleId></ArticleIdList></Reference><Reference><Citation>Schunemann H, Oxman A, Vist G, Higgins J, Deeks J, Glasziou P, Guyatt G. In: Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0) Higgins J, Green S, editor. Oxford: The Cochrane Collaboration; 2011. Chapter 12: Interpreting results and drawing conclusions; pp. 359&#x2013;388.</Citation></Reference><Reference><Citation>Robinson KA, Saldanha IJ, McKoy NA. Development of a framework to identify research gaps from systematic reviews. J Clin Epidemiol. 2011;64:1325&#x2013;1330. doi: 10.1016/j.jclinepi.2011.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.06.009</ArticleId><ArticleId IdType="pubmed">21937195</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314. doi: 10.1212/WNL.44.12.2308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2308</ArticleId><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN. CERAD behavior rating scale for dementia. Int Psychogeriatr. 1996;8(Suppl 3):317&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154581</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(Suppl 3):301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154579</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24:709&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22750845</PMID><DateCompleted><Year>2012</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5849</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Behavioural pharmacology</Title><ISOAbbreviation>Behav Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>426</StartPage><EndPage>433</EndPage><MedlinePgn>426-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/FBP.0b013e3283566082</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration in cognitive functioning. Overall, 25-50% of patients with AD also show symptoms of psychosis including hallucinations and delusions. As all available antipsychotic drugs have a 'black-box' warning for use in these patients because of increased mortality, no appropriate treatment for psychotic symptoms in AD currently exists. In the present study, we examined whether selective antagonism of 5-HT(2A) serotonin receptors has antipsychotic-like activity in an animal model of AD. Mice receiving an intracerebroventricular infusion of the amyloid &#x3b2;(25-35) peptide fragment showed AD-like histopathology and a psychosis-related behavioral phenotype with enhanced responses to the psychostimulants 2,5-dimethoxy-4-iodoamphetamine hydrochloride and amphetamine as well as disrupted prepulse inhibition. Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology. These data suggest that an infusion of amyloid &#x3b2; might induce alterations in serotonergic function that underlie a psychosis-like phenotype that can be normalized by treatment with a 5-HT(2A) inverse agonist. This in turn suggests that 5-HT(2A) inverse agonists, such as pimavanserin, might have therapeutic benefits in the treatment of psychosis in AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Diana L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>ACADIA Pharmaceuticals Inc., San Diego, California 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonhaus</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>McFarland</LastName><ForeName>Krista</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Behav Pharmacol</MedlineTA><NlmUniqueID>9013016</NlmUniqueID><ISSNLinking>0955-8810</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000662">Amphetamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058830">Serotonin 5-HT2 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical><Chemical><RegistryNumber>CK833KGX7E</RegistryNumber><NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>JZ963P0DIK</RegistryNumber><NameOfSubstance UI="C510793">pimavanserin</NameOfSubstance></Chemical><Chemical><RegistryNumber>OOM10GW9UE</RegistryNumber><NameOfSubstance UI="C015952">4-iodo-2,5-dimethoxyphenylisopropylamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000662" MajorTopicYN="N">Amphetamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054314" MajorTopicYN="N">Drug Inverse Agonism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058830" MajorTopicYN="N">Serotonin 5-HT2 Receptor Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22750845</ArticleId><ArticleId IdType="doi">10.1097/FBP.0b013e3283566082</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">22764387</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK98127</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Center for Biotechnology Information (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="micad">Molecular Imaging and Contrast Agent Database (MICAD)</BookTitle><PubDate><Year>2004</Year></PubDate><BeginningDate><Year>2004</Year></BeginningDate><EndingDate><Year>2013</Year></EndingDate><Medium>Internet</Medium></Book><ArticleTitle book="micad" part="C11-13">1-(Benzofuran-2-ylmethyl)-4-(4-[<sup>11</sup>C]methoxybenzyl)piperazine</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Center for Biotechnology Information, NLM, NIH</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>1-(Benzofuran-2-ylmethyl)-4-(4-[<sup>11</sup>C]methoxybenzyl)piperazine, abbreviated as [<sup>11</sup>C]<b>13</b>, is a piperazine derivative synthesized by Moussa et al. for positron emission tomography (PET) of sigma-1 (&#x3c3;1) receptor (1). &#x3c3;1 receptor is a protein that is widely distributed in both the central nervous system (CNS) and peripheral organs. There are at least two subtypes of &#x3c3; receptors, &#x3c3;1 and &#x3c3;2 receptors. Although the functions of &#x3c3;2 receptor are poorly understood, &#x3c3;1 receptor is believed to act as a modulator of the signal transduction in neurotransmitter systems (2, 3). &#x3c3;1 receptor primarily resides at the interface between the endoplasmic reticulum and mitochondria, where it modulates Ca<sup>2+</sup> flux by acting as a molecular chaperone for type 3 inositol-1,4,5-triphosphate receptors. &#x3c3;1 receptor can also translocate to the plasma membrane, where it regulates the voltage-dependent Ca<sup>2+</sup> channels, K<sup>+</sup> channels, and other membrane-bound proteins (2, 4). More and more evidence suggests that &#x3c3;1 receptor is involved in a range of CNS diseases such as affective disorders, psychosis, schizophrenia, substance abuse, Parkinson&#x2019;s disease, and Alzheimer&#x2019;s disease (1, 4). Studies on postmortem human brains have shown that the density of &#x3c3;1 receptor decreased in patients with schizophrenia and Alzheimer&#x2019;s disease (5). Discovery of specific ligands for &#x3c3;1 receptor has further prompted investigations in the imaging and treatment of neuropsychiatric diseases by targeting &#x3c3;1 receptor (1, 3). Noninvasive imaging of &#x3c3;1 receptor <i>in vivo</i> would enable better understanding of the pathogenesis of neuropsychiatric diseases as well as how the expression and function of &#x3c3;1 receptors change during disease progression (2). Early in 1998, Baziard-Mouysset et al. synthesized a series of disubstituted 1,4-piperazines, flanked by a chromene ring and a benzyl group (6). Of this series, the simplest compound that contained an unsubstituted benzyl ring displayed high affinity for &#x3c3; receptors (<i>K</i><sub>i</sub> = 3 nM) and negligible off-target activity. Substitution of the benzyl ring was generally detrimental to &#x3c3; binding, with the exception of 4-chloro or 4-methoxy substitution, which improved &#x3c3; receptor binding (<i>K</i><sub>i</sub> = 1 nM and 0.6 nM, respectively). The chromene ring was shown to have little effect on &#x3c3; binding, and it was well tolerated for substitution with a large number of alternative aromatic groups (7). With the 2-benzofurylmethyl group&#x2013;substituted compound as a lead compound, Moussa et al. generated a series of <i>N</i>-(2-benzofuranylmethyl)-<i>N</i>'-(alkoxybenzyl)piperazines as selective &#x3c3;1 receptor ligands (1, 4, 8). Two compounds in this series, <i>N</i>-(2-benzofuranylmethyl)-<i>N</i>'-[4-(2-fluoroethoxy)benzyl]piperazine (compound <b>6</b>) and <i>N</i>-(benzofuran-2-ylmethyl)-<i>N</i>'-(4'-methoxybenzyl)piperazine (compound <b>13</b>), were further radiolabeled and tested for their feasibilities as imaging probes for &#x3c3;1 receptors. This chapter summarizes the data obtained with [<sup>11</sup>C]<b>13</b>.</AbstractText></Abstract><Sections><Section><SectionTitle book="micad" part="C11-13" sec="C11-13.Background">Background</SectionTitle></Section><Section><SectionTitle book="micad" part="C11-13" sec="C11-13.Synthesis">Synthesis</SectionTitle></Section><Section><SectionTitle book="micad" part="C11-13" sec="C11-13.In_Vitro_Studies_Testing_in_Cells"><i>In Vitro</i> Studies: Testing in Cells and Tissues</SectionTitle></Section><Section><SectionTitle book="micad" part="C11-13" sec="C11-13.Animal_Studies">Animal Studies</SectionTitle></Section><Section><SectionTitle book="micad" part="C11-13" sec="C11-13.Human_Studies">Human Studies</SectionTitle></Section><Section><SectionTitle book="micad" part="C11-13" sec="C11-13.References">References</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">[11C]13</Keyword><Keyword MajorTopicYN="N">Compounds</Keyword><Keyword MajorTopicYN="N">Sigma-1 (&#x3c3;1) receptor</Keyword><Keyword MajorTopicYN="N">Receptors</Keyword><Keyword MajorTopicYN="N">Positron emission tomography (PET)</Keyword><Keyword MajorTopicYN="N">11C</Keyword></KeywordList><ContributionDate><Year>2012</Year><Month>5</Month><Day>10</Day></ContributionDate><DateRevised><Year>2012</Year><Month>6</Month><Day>27</Day></DateRevised><ReferenceList><Reference><Citation>Moussa I.A. et al. Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. . J Med Chem. 2010;53(16):6228&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">20662542</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz J.L. et al. Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. . Cent Nerv Syst Agents Med Chem. 2009;9(3):172&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021351</ArticleId></ArticleIdList></Reference><Reference><Citation>Berardi F. et al. 1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (sigma1) and sigma-2 (sigma2) receptor ligands: a review. . Cent Nerv Syst Agents Med Chem. 2009;9(3):205&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021355</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa I.A. et al. Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel sigma1 receptor PET imaging agent. . Bioorg Med Chem Lett. 2011;21(22):6820&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21962578</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen K.L. et al. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. . Brain Res. 1993;623(2):299&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221112</ArticleId></ArticleIdList></Reference><Reference><Citation>Baziard-Mouysset G. et al. Synthesis and structure-activity relationships of novel 2-amino alkyl chromones and related derivatives as s site-selective ligands. . Eur J Med Chem. 1998;33:339&#x2013;47.</Citation></Reference><Reference><Citation>Younes S. et al. Synthesis and structure-activity relationships of novel arylalkyl 4-benzyl piperazine derivatives as sigma site selective ligands. . Eur J Med Chem. 2000;35(1):107&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10733608</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa I.A. et al. Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine sigma(1) receptor ligands. . Bioorg Med Chem Lett. 2011;21(19):5707&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21871797</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22764387</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedBookArticle><BookDocument><PMID Version="1">22764386</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK98126</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Center for Biotechnology Information (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="micad">Molecular Imaging and Contrast Agent Database (MICAD)</BookTitle><PubDate><Year>2004</Year></PubDate><BeginningDate><Year>2004</Year></BeginningDate><EndingDate><Year>2013</Year></EndingDate><Medium>Internet</Medium></Book><ArticleTitle book="micad" part="F18-6">[<sup>18</sup>F]<i>N</i>-(2-benzofuranylmethyl)-<i>N</i>'-[4-(2-fluoroethoxy)benzyl]piperazine</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Center for Biotechnology Information, NLM, NIH</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>[<sup>18</sup>F]<i>N</i>-(2-benzofuranylmethyl)-<i>N</i>'-[4-(2-fluoroethoxy)benzyl]piperazine, abbreviated as [<sup>18</sup>F]<b>6</b>, is a piperazine derivative synthesized by Moussa et al. for positron emission tomography (PET) of sigma-1 (&#x3c3;1) receptor (1). &#x3c3;1 receptor is a protein that is widely distributed in both the central nervous system (CNS) and peripheral organs. There are at least two subtypes of &#x3c3; receptors, &#x3c3;1 and &#x3c3;2 receptors. Although the functions of &#x3c3;2 receptor are poorly understood, &#x3c3;1 receptor is believed to act as a modulator of the signal transduction in neurotransmitter systems (2, 3). &#x3c3;1 receptor primarily resides at the interface between the endoplasmic reticulum and mitochondria, where it modulates Ca<sup>2+</sup> flux by acting as a molecular chaperone for type 3 inositol-1,4,5-triphosphate receptors. &#x3c3;1 receptor can also translocate to the plasma membrane, where it regulates the voltage-dependent Ca<sup>2+</sup> channels, K<sup>+</sup> channels, and other membrane-bound proteins (1, 2). More and more evidence suggests that &#x3c3;1 receptor is involved in a range of CNS diseases such as affective disorders, psychosis, schizophrenia, substance abuse, Parkinson&#x2019;s disease, and Alzheimer&#x2019;s disease (1, 4). Studies on postmortem human brains have shown that the density of &#x3c3;1 receptor decreased in patients with schizophrenia and Alzheimer&#x2019;s disease (5). Discovery of specific ligands for &#x3c3;1 receptor has further prompted investigations in the imaging and treatment of neuropsychiatric diseases by targeting &#x3c3;1 receptor (3, 4). Noninvasive imaging of &#x3c3;1 receptor <i>in vivo</i> would enable better understanding of the pathogenesis of neuropsychiatric diseases as well as how the expression and function of &#x3c3;1 receptors change during disease progression (2). Early in 1998, Baziard-Mouysset et al. synthesized a series of disubstituted 1,4-piperazines, flanked by a chromene ring and a benzyl group (6). Of this series, the simplest compound that contained an unsubstituted benzyl ring displayed high affinity for &#x3c3; receptors (<i>K</i><sub>i</sub> = 3 nM) and negligible off-target activity. Substitution of the benzyl ring was generally detrimental to &#x3c3; binding, with the exception of 4-chloro or 4-methoxy substitution, which marginally improved &#x3c3; receptor binding (<i>K</i><sub>i</sub> = 1 nM and 0.6 nM, respectively). The chromene ring was shown to have little effect on &#x3c3; binding, and it was well tolerated for substitution with a large number of alternate aromatic groups (7). With the 2-benzofurylmethyl group&#x2013;substituted compound as a lead compound, Moussa et al. generated a series of <i>N</i>-(2-benzofuranylmethyl)-<i>N</i>'-(alkoxybenzyl)piperazines as selective &#x3c3;1 receptor ligands (1, 4, 8). Two compounds in this series, <i>N</i>-(2-benzofuranylmethyl)-<i>N</i>'-[4-(2-fluoroethoxy)benzyl]piperazine (compound <b>6</b>) and <i>N</i>-(benzofuran-2-ylmethyl)-<i>N</i>'-(4'-methoxybenzyl)piperazine (compound <b>13</b>), were further radiolabeled and tested for their feasibilities as imaging probes for &#x3c3;1 receptors. This chapter summarizes the data obtained with [<sup>18</sup>F]<b>6</b>.</AbstractText></Abstract><Sections><Section><SectionTitle book="micad" part="F18-6" sec="F18-6.Background">Background</SectionTitle></Section><Section><SectionTitle book="micad" part="F18-6" sec="F18-6.Synthesis">Synthesis</SectionTitle></Section><Section><SectionTitle book="micad" part="F18-6" sec="F18-6.In_Vitro_Studies_Testing_in_Cells"><i>In Vitro</i> Studies: Testing in Cells and Tissues</SectionTitle></Section><Section><SectionTitle book="micad" part="F18-6" sec="F18-6.Animal_Studies">Animal Studies</SectionTitle></Section><Section><SectionTitle book="micad" part="F18-6" sec="F18-6.Human_Studies">Human Studies</SectionTitle></Section><Section><SectionTitle book="micad" part="F18-6" sec="F18-6.References">References</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">[18F]6</Keyword><Keyword MajorTopicYN="N">Compounds</Keyword><Keyword MajorTopicYN="N">Sigma-1 (&#x3c3;1) receptor</Keyword><Keyword MajorTopicYN="N">Receptors</Keyword><Keyword MajorTopicYN="N">Positron emission tomography (PET)</Keyword><Keyword MajorTopicYN="N">18F</Keyword></KeywordList><ContributionDate><Year>2012</Year><Month>5</Month><Day>10</Day></ContributionDate><DateRevised><Year>2012</Year><Month>6</Month><Day>27</Day></DateRevised><ReferenceList><Reference><Citation>Moussa I.A. et al. Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel sigma1 receptor PET imaging agent. . Bioorg Med Chem Lett. 2011;21(22):6820&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21962578</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz J.L. et al. Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. . Cent Nerv Syst Agents Med Chem. 2009;9(3):172&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021351</ArticleId></ArticleIdList></Reference><Reference><Citation>Berardi F. et al. 1-Cyclohexylpiperazine and 3,3-dimethylpiperidine derivatives as sigma-1 (sigma1) and sigma-2 (sigma2) receptor ligands: a review. . Cent Nerv Syst Agents Med Chem. 2009;9(3):205&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">20021355</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa I.A. et al. Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. . J Med Chem. 2010;53(16):6228&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">20662542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen K.L. et al. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. . Brain Res. 1993;623(2):299&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">8221112</ArticleId></ArticleIdList></Reference><Reference><Citation>Baziard-Mouysset G. et al. Synthesis and structure-activity relationships of novel 2-amino alkyl chromones and related derivatives as s site-selective ligands. . Eur J Med Chem. 1998;33:339&#x2013;47.</Citation></Reference><Reference><Citation>Younes S. et al. Synthesis and structure-activity relationships of novel arylalkyl 4-benzyl piperazine derivatives as sigma site selective ligands. . Eur J Med Chem. 2000;35(1):107&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10733608</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa I.A. et al. Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine sigma(1) receptor ligands. . Bioorg Med Chem Lett. 2011;21(19):5707&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21871797</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22764386</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22723693</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>25</Issue><PubDate><Year>2012</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.</ArticleTitle><Pagination><StartPage>8532</StartPage><EndPage>8544</EndPage><MedlinePgn>8532-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0337-12.2012</ELocationID><Abstract><AbstractText>M(1) muscarinic acetylcholine receptors (mAChRs) represent a viable target for treatment of multiple disorders of the central nervous system (CNS) including Alzheimer's disease and schizophrenia. The recent discovery of highly selective allosteric agonists of M(1) receptors has provided a major breakthrough in developing a viable approach for the discovery of novel therapeutic agents that target these receptors. Here we describe the characterization of two novel M(1) allosteric agonists, VU0357017 and VU0364572, that display profound differences in their efficacy in activating M(1) coupling to different signaling pathways including Ca(2+) and &#x3b2;-arrestin responses. Interestingly, the ability of these agents to differentially activate coupling of M(1) to specific signaling pathways leads to selective actions on some but not all M(1)-mediated responses in brain circuits. These novel M(1) allosteric agonists induced robust electrophysiological effects in rat hippocampal slices, but showed lower efficacy in striatum and no measureable effects on M(1)-mediated responses in medial prefrontal cortical pyramidal cells in mice. Consistent with these actions, both M(1) agonists enhanced acquisition of hippocampal-dependent cognitive function but did not reverse amphetamine-induced hyperlocomotion in rats. Together, these data reveal that M(1) allosteric agonists can differentially regulate coupling of M(1) to different signaling pathways, and this can dramatically alter the actions of these compounds on specific brain circuits important for learning and memory and psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Digby</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noetzel</LastName><ForeName>Meredith J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Bubser</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Utley</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Adam G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Byun</LastName><ForeName>Nellie E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Lebois</LastName><ForeName>Evan P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Zixiu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Sheffler</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hyekyung P</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Albert A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Nemirovsky</LastName><ForeName>Natali E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Mennenga</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Camp</LastName><ForeName>Bryan W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Bimonte-Nelson</LastName><ForeName>Heather A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Bode</LastName><ForeName>Jacob</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Italiano</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>J Scott</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Niswender</LastName><ForeName>Colleen M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Olive</LastName><ForeName>M Foster</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Lindsley</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Carrie K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Conn</LastName><ForeName>P Jeffrey</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 EB001628</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065867</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MH084659</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS071746</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH065215</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073676</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32NS071746</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG029731</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 GM099650</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 MH087039</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH087956</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01 NS065867</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH086601</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH082867</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019390">Arrestins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C574616">VU0357017</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C574617">VU0364572</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019390" MajorTopicYN="N">Arrestins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22723693</ArticleId><ArticleId IdType="mid">NIHMS388035</ArticleId><ArticleId IdType="pmc">PMC3398407</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0337-12.2012</ArticleId><ArticleId IdType="pii">32/25/8532</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anagnostaras SG, Maren S, Fanselow MS. Scopolamine selectively disrupts the acquisition of contextual fear conditioning in rats. Neurobiol Learn Mem. 1995;64:191&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">8564372</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483218</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA, Werge T. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 2003;28:1168&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700711</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten AF. Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int J Dev Neurosci. 2011;29:215&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115784</ArticleId><ArticleId IdType="pubmed">21345366</ArticleId></ArticleIdList></Reference><Reference><Citation>Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">12450488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, Jones PJ, Lindsley CW, Olive MF, Conn PJ. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology. 2009;34:2057&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884290</ArticleId><ArticleId IdType="pubmed">19295507</ArticleId></ArticleIdList></Reference><Reference><Citation>Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald A, 3rd, Noll DC, Cohen JD. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry. 2001;58:280&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">11231835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 1997a;11(Suppl 4):S16&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997b;54:465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology. 2010;58:365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">19835892</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan KA, Petrovic MM, Chamberlain SE, Marrion NV, Mellor JR. Facilitation of long-term potentiation by muscarinic M(1) receptors is mediated by inhibition of SK channels. Neuron. 2010;68:948&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003154</ArticleId><ArticleId IdType="pubmed">21145007</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn PJ, Tamminga C, Schoepp DD, Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol Interv. 2008;8:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403654</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009;30:148&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907736</ArticleId><ArticleId IdType="pubmed">19201489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis J. Muscarinic receptors. In: Pangalos MN, Davis CH, editors. Understanding g protein-coupled receptors and their role in the CNS. London: Oxford UP; 2002.</Citation></Reference><Reference><Citation>Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem. 2000;43:4333&#x2013;4353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087557</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher SK, Snider RM. Differential receptor occupancy requirements for muscarinic cholinergic stimulation of inositol lipid hydrolysis in brain and in neuroblastomas. Mol Pharmacol. 1987;32:81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">3600615</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 1995;64:1888&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">7891119</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A. 2001;98:15312&#x2013;15317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65026</ArticleId><ArticleId IdType="pubmed">11752469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther. 2005;312:1055&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">15574685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci. 2008;28:10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead CJ, Starr KR, Teriakidis A, Wood MD, et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28&#x2013;1. Br J Pharmacol. 2008;154:1104&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2451039</ArticleId><ArticleId IdType="pubmed">18454168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci. 2010;1:104&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180826</ArticleId><ArticleId IdType="pubmed">21961051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, Miller NR, Morrison R, Bridges TM, Xiang Z, Scott Daniels J, Wood MR, Conn PJ, Lindsley CW. Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett. 2011;21:6451&#x2013;6455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190051</ArticleId><ArticleId IdType="pubmed">21930376</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1&#x2013;m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci. 1995;15:4077&#x2013;4092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578239</ArticleId><ArticleId IdType="pubmed">7751967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A. 2009;106:15950&#x2013;15955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732705</ArticleId><ArticleId IdType="pubmed">19717450</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A. 1998;95:11465&#x2013;11470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21666</ArticleId><ArticleId IdType="pubmed">9736760</ArticleId></ArticleIdList></Reference><Reference><Citation>Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol. 2010;8:69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866463</ArticleId><ArticleId IdType="pubmed">20808547</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MM, Moore-Kochlacs C, Gu X, Boyden ES, Han X, Kopell N. Striatal origin of the pathologic beta oscillations in Parkinson's disease. Proc Natl Acad Sci U S A. 2011;108:11620&#x2013;11625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136295</ArticleId><ArticleId IdType="pubmed">21697509</ArticleId></ArticleIdList></Reference><Reference><Citation>McCutchen E, Scheiderer CL, Dobrunz LE, McMahon LL. Coexistence of muscarinic long-term depression with electrically induced long-term potentiation and depression at CA3-CA1 synapses. J Neurophysiol. 2006;96:3114&#x2013;3121.</Citation><ArticleIdList><ArticleId IdType="pubmed">17005622</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci U S A. 1999;96:13591&#x2013;13593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33933</ArticleId><ArticleId IdType="pubmed">10570115</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci. 2001;21:5239&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762828</ArticleId><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP. The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry. 2001;49:716&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">11313039</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010;78:1105&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993468</ArticleId><ArticleId IdType="pubmed">20923853</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiderer CL, McCutchen E, Thacker EE, Kolasa K, Ward MK, Parsons D, Harrell LE, Dobrunz LE, McMahon LL. Sympathetic sprouting drives hippocampal cholinergic reinnervation that prevents loss of a muscarinic receptor-dependent long-term depression at CA3-CA1 synapses. J Neurosci. 2006;26:3745&#x2013;3756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674126</ArticleId><ArticleId IdType="pubmed">16597728</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785583</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dub&#xe9; S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W, Tian X, Day M, Ulrich S, Tkatch T, Nathanson NM, Surmeier DJ. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci. 2007;10:1458&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">17906621</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoe T, Matsui M, Taketo MM, Manabe T. Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci. 2005;25:11194&#x2013;11200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725656</ArticleId><ArticleId IdType="pubmed">16319319</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009;29:14271&#x2013;14286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811323</ArticleId><ArticleId IdType="pubmed">19906975</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther. 2001;299:782&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">11602695</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland RJ, Whishaw IQ, Regehr JC. Cholinergic receptor blockade impairs spatial localization by use of distal cues in the rat. J Comp Physiol Psychol. 1982;96:563&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">7119176</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas RL, Mistry R, Langmead CJ, Wood MD, Challis RA. G protein coupling and signaling pathway activation by m1 muscarinic receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther. 2008;327:365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">18664591</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanover KE, Veinbergs I, Davis RE. Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav Neurosci. 2008;122:570&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">18513127</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk LJ, Pfeiffer BE, Gibson JR, Huber KM. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci. 2007;27:11624&#x2013;11634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673232</ArticleId><ArticleId IdType="pubmed">17959805</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Thompson AD, Jones CK, Lindsley CW, Conn PJ. Roles of M1 muscarinic acetylcholine receptor subtype in regulation of basal ganglia function and implications for treatment of Parkinson's disease. J Pharmacol Exp Ther. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286317</ArticleId><ArticleId IdType="pubmed">22135383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22717370</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptom clusters of Alzheimer's disease in Hong Kong Chinese: prevalence and confirmatory factor analysis of the Neuropsychiatric Inventory.</ArticleTitle><Pagination><StartPage>1465</StartPage><EndPage>1473</EndPage><MedlinePgn>1465-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610212000609</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to investigate the clustering of symptoms on the Neuropsychiatric Inventory (NPI) and the relative prevalence of symptom clusters in mild and moderate Alzheimer's disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Confirmatory factor analysis (CFA) was performed on the polychoric correlation matrix of 12 NPI items (scored yes or no) using the weighted least squares with mean and variance adjustment (WLSMV) estimator in Mplus (N = 224 community-dwelling Chinese persons with mild/moderate AD). Severity of AD was determined by Clinical Dementia Rating scores. The relative model fit of three competing measurement models (also known as factor structures) was tested using a modified &#x3c7;2 difference test. Prevalence rates across mild and moderate stages were compared using &#x3c7;2 tests. Furthermore, the measurement model of choice was cross-validated in an independent sample of 181 community-dwelling persons with dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CFA supported a four-factor model, namely behavioral problems (agitation/aggressiveness, disinhibition, irritability, and aberrant motor behavior), psychosis (delusions and hallucinations), mood disturbance (depression, anxiety, sleep, appetite, and apathy), and euphoria (a stand-alone item that is equivalent to the factor). The most prevalent symptom clusters were behavioral (72%) and mood (69%) disturbances, followed by psychosis (45%). Euphoria was rare (6%). All syndromes were more prevalent in moderate than in mild stage, except for euphoria. In addition, the four-factor model was replicated in the cross-validation sample.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The four syndromes provide a parsimonious conceptualization of neuropsychiatric symptoms corresponding to clinical observations and neurochemical changes of the disease. The independent replication in the second sample supports generalization of the four-factor model in Chinese persons with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Sheung-Tak</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Psychological Studies, Hong Kong Institute of Education, Hong Kong, China. takcheng@ied.edu.hk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Linda C W</ForeName><Initials>LC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22717370</ArticleId><ArticleId IdType="doi">10.1017/S1041610212000609</ArticleId><ArticleId IdType="pii">S1041610212000609</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22703622</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>202</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Neuroimaging of delusions in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>89</StartPage><EndPage>95</EndPage><MedlinePgn>89-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pscychresns.2012.01.008</ELocationID><Abstract><AbstractText>MEDLINE, Embase and PsycINFO were searched using the keywords "imaging", "neuroimaging", "CT", "MRI", "PET", "SPECT", "Alzheimer's", "dementia", "delusions" and "psychosis" to find studies specifically assessing or reporting on neuroimaging of delusions in Alzheimer's Dementia (AD), separate from hallucinations or psychosis in general in AD. Twenty-five studies were found meeting criteria and are included in this review which reports on structural, regional perfusion, metabolic and receptor binding imaging modalities assessing delusions as a whole, as well as persecutory and misidentification delusional subtypes. The majority of studies implicate right-sided pathology, primarily frontal lobe. Left-frontal predominance and release, secondary to right-sided pathology, may create a hyperinferential state resulting in the formation of delusions. This perturbation and imbalance of normal networks is associated with delusional phenomenology. Temporal lobe structures are also important in misidentification syndromes, which have a different natural history than paranoid delusions. Consistent with the neuropathological and genetic literature, neuroimaging has shown that paranoid versus misidentification delusions are associated with different phenomenology and different neural substrates. Delusional subtype is an important factor in understanding the neurobiological underpinnings of delusions in dementia. We also discuss methodological issues related to neuroimaging of delusions in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Zahinoor</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario, Canada. zahinoor@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Minh-Quan</ForeName><Initials>MQ</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Corinne E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Schweizer</LastName><ForeName>Tom A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="Y">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22703622</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2012.01.008</ArticleId><ArticleId IdType="pii">S0925-4927(12)00028-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22697366</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Determinants of quality of life in Alzheimer's disease: perspective of patients, informal caregivers, and professional caregivers.</ArticleTitle><Pagination><StartPage>1805</StartPage><EndPage>1815</EndPage><MedlinePgn>1805-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610212001081</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is a chronic medical condition with symptoms that compromise patients' quality of life (QoL). The identification of the factor predicting QoL in AD is essential to develop more effective interventions. Recent research suggests that these factors could be different for the distinct informants. This study explores the QoL predictors considering three different sources of information: patients, caregivers, and healthcare staff.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, a sample of 102 patients, their primary caregivers, and 15 members of the healthcare staff evaluated patients' QoL (QoL-AD Scale). Patients' and caregivers' demographic and clinical data (cognitive function, neuropsychiatric symptoms, depression, and caregivers' burden) were considered as QoL predictors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In multivariate-adjusted linear regression analyses, we observed that patients' ratings were mainly affected by their mood whereas caregivers' ratings were also negatively influenced by patients' irritability and burden. According to staff ratings, both psychotic symptoms and neuroleptics were associated with lower QoL.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that depression is the main variable related to patients' QoL and that more careful management of neuropsychiatric disorders is necessary. Both proxies' ratings are not equivalent to patients' reports in terms of predictors but they are complementary. Thus, a thorough QoL assessment should consider separately the perspective of the different informants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;mez-Gallego</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, Catholic University of Murcia, Murcia, Spain. mgomezg@um.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Amor</LastName><ForeName>Jesus</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Garc&#xed;a</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016743" MajorTopicYN="Y">Mental Competency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018434" MajorTopicYN="N">Sickness Impact Profile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22697366</ArticleId><ArticleId IdType="doi">10.1017/S1041610212001081</ArticleId><ArticleId IdType="pii">S1041610212001081</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22672384</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2826</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neuroendocrinology</Title><ISOAbbreviation>J Neuroendocrinol</ISOAbbreviation></Journal><ArticleTitle>Androgen function in the pathophysiology and treatment of male Huntington's disease patients.</ArticleTitle><Pagination><StartPage>1275</StartPage><EndPage>1283</EndPage><MedlinePgn>1275-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2826.2012.02347.x</ELocationID><Abstract><AbstractText>Low concentrations of circulating testosterone have been associated with dementia manifesting with advancing age and in neurodegenerative conditions. Huntington's disease (HD) is a dominantly inherited neurodegenerative disease with an invariably fatal outcome. Severe motor symptoms, psychosis and dementia are symptomatic hallmarks of the progression of HD that result from the dysfunction and death of neocortical and basal ganglia neurones. Treatments are directed toward manifest symptoms, although they are largely ineffectual in slowing or preventing disease progression. Emerging data have identified hypothamic pathologies in HD that result in endocrine disturbances. Clinically defined primary or secondary hypogonadism elicit low circulating testosterone concentrations and have been linked to the development of Alzheimer's disease in men. Examining similar neuroendocrine dysfunction in HD including the nature of manifest hypogonadism in male patients could allow an elucidation of the complex pathophysiology of HD and provide an impetus for hitherto untested testosterone replacement therapy.</AbstractText><CopyrightInformation>&#xa9; 2012 Florey Neuroscience Institutes Journal of Neuroendocrinology &#xa9; 2012 British Society for Neuroendocrinology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ransome</LastName><ForeName>M I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Florey Neuroscience Institutes, Melbourne Brain Centre, University of Melbourne, Victoria, Australia. mark.ransome@florey.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuroendocrinol</MedlineTA><NlmUniqueID>8913461</NlmUniqueID><ISSNLinking>0953-8194</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000728">Androgens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000728" MajorTopicYN="N">Androgens</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007030" MajorTopicYN="N">Hypothalamo-Hypophyseal System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22672384</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2826.2012.02347.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22594761</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1758-9193</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Alzheimer's research &amp; therapy</Title><ISOAbbreviation>Alzheimers Res Ther</ISOAbbreviation></Journal><ArticleTitle>Factors that influence survival in a probable Alzheimer disease cohort.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/alzrt119</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This longitudinal study examined multiple factors that influence survival in a cohort of Alzheimer patients followed over two decades.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Time to death after symptom onset was determined in 641 probable AD patients who were evaluated annually until death or loss to follow-up, and information was entered into a longitudinal database. Date of death was available for everyone including those eventually lost. Baseline variables included age, sex, race, disease severity, a calculated index of rate of initial cognitive decline from symptom onset to cohort entry (pre-progression rate or PPR), years of education, and medical comorbidities (diabetes, hypertension, hyperlipidemia, coronary disease, cerebrovascular disease). Multivariable Cox proportional hazard regression analysis was used to analyze the baseline and/or time dependent association in Mini-mental Status Exam (MMSE) severity, Physical Self Maintenance Scale (PSMS), Persistency Index (PI) of exposure to antipsychotic and antidementia drugs, and psychotic symptoms (hallucinations, delusions) with mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline covariates significantly associated with increased survival were younger age (p = .0016), female sex (p = .0001), and a slower PPR (p &lt; .0001). Overall disease severity at baseline, medical comorbidities, and education did not influence time to death. Time-dependent changes in antipsychotic drug use, development of psychotic symptoms, antidementia drug use, and observed MMSE change were not predictive. In the final model the only time-dependent covariate that significantly decreased survival was worsening of functional ability on the PSMS (hazard ratio = 1.10; CI: 1.07-1.11).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large AD cohort survival is influenced by age, sex, and the development of functional disability during follow-up. The most important predictor of mortality was a faster rate of cognitive decline at the initial patient visit (PPR). The currently available antidementia drugs do not prolong survival in Alzheimer patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, 1977 Butler Boulevard, Suite E5,101, Houston, TX 77030, USA. rountree@bcm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Wenyaw</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Pavlik</LastName><ForeName>Valory N</ForeName><Initials>VN</Initials></Author><Author ValidYN="Y"><LastName>Darby</LastName><ForeName>Eveleen J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Alzheimers Res Ther</MedlineTA><NlmUniqueID>101511643</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22594761</ArticleId><ArticleId IdType="pmc">PMC3506931</ArticleId><ArticleId IdType="doi">10.1186/alzrt119</ArticleId><ArticleId IdType="pii">alzrt119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai WY. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277:806&#x2013;812. doi: 10.1001/jama.1997.03540340040030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1997.03540340040030</ArticleId><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci. 2005;229-230:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">15760618</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta KM, Yaffe K, Perez-Stable EJ, Stewart A, Barnes D, Kurland BF, Miller BL. Race/ethnic differences in AD survival in US Alzheimer's Disease Centers. Neurology. 2008;70:1163&#x2013;1170. doi: 10.1212/01.wnl.0000285287.99923.3c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285287.99923.3c</ArticleId><ArticleId IdType="pmc">PMC2830859</ArticleId><ArticleId IdType="pubmed">18003939</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Zdaniuk B, Belle SH, Czaja SJ, Michael Arrighi H, Zbrozek AS. Baseline differences and trajectories of change for deceased, placed, and community residing Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2010;24:143&#x2013;150. doi: 10.1097/WAD.0b013e3181b795b7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3181b795b7</ArticleId><ArticleId IdType="pmc">PMC2879087</ArticleId><ArticleId IdType="pubmed">20505432</ArticleId></ArticleIdList></Reference><Reference><Citation>Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, Bisanti L. Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31:218&#x2013;224. doi: 10.1159/000326213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000326213</ArticleId><ArticleId IdType="pubmed">21474930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional versus atypical antipsychotic medications. N Engl J Med. 2005;353:2335&#x2013;2341. doi: 10.1056/NEJMoa052827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa052827</ArticleId><ArticleId IdType="pubmed">16319382</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;1943. doi: 10.1001/jama.294.15.1934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.15.1934</ArticleId><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59:1764&#x2013;1767. doi: 10.1001/archneur.59.11.1764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.11.1764</ArticleId><ArticleId IdType="pubmed">12433264</ArticleId></ArticleIdList></Reference><Reference><Citation>Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:209&#x2013;221. doi: 10.1097/WAD.0b013e31816653bc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31816653bc</ArticleId><ArticleId IdType="pmc">PMC2718545</ArticleId><ArticleId IdType="pubmed">18580597</ArticleId></ArticleIdList></Reference><Reference><Citation>Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1:7. doi: 10.1186/alzrt7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt7</ArticleId><ArticleId IdType="pmc">PMC2874259</ArticleId><ArticleId IdType="pubmed">19845950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600&#x2013;607. doi: 10.1136/jnnp.2008.158964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.158964</ArticleId><ArticleId IdType="pmc">PMC2823571</ArticleId><ArticleId IdType="pubmed">19204022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310&#x2013;314. doi: 10.1136/jnnp.72.3.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.72.3.310</ArticleId><ArticleId IdType="pmc">PMC1737770</ArticleId><ArticleId IdType="pubmed">11861686</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc. 2003;51:937&#x2013;944. doi: 10.1046/j.1365-2389.2003.51306.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2389.2003.51306.x</ArticleId><ArticleId IdType="pubmed">12834513</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal JS, Lacombe JM, Dartigues JF, Pasquier F, Robert P, Tzourio C, Alperovitch A. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Alzheimer Dis Assoc Disord. 2008;22:125&#x2013;130. doi: 10.1097/WAD.0b013e31815a9e10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31815a9e10</ArticleId><ArticleId IdType="pubmed">18525283</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott B, Lapane K. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc. 2002;50:35&#x2013;40. doi: 10.1046/j.1532-5415.2002.50005.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2002.50005.x</ArticleId><ArticleId IdType="pubmed">12028244</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother. 2005;3:1&#x2013;7. doi: 10.1016/j.amjopharm.2005.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjopharm.2005.02.001</ArticleId><ArticleId IdType="pubmed">16089241</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Dunn JK, Huang E, Azher S, Kataki M. A method for estimating duration of illness in Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">14560058</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Massman P, Dunn JK. A method for estimating progression rates in Alzheimer disease. Arch Neurol. 2001;58:449&#x2013;454. doi: 10.1001/archneur.58.3.449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.58.3.449</ArticleId><ArticleId IdType="pubmed">11255449</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179&#x2013;186. doi: 10.1093/geront/9.3_Part_1.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/9.3_Part_1.179</ArticleId><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, Rockwood K, Hogan DB. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111&#x2013;1116. doi: 10.1056/NEJM200104123441501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200104123441501</ArticleId><ArticleId IdType="pubmed">11297701</ArticleId></ArticleIdList></Reference><Reference><Citation>Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y. Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology. 2008;71:1489&#x2013;1495. doi: 10.1212/01.wnl.0000334278.11022.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000334278.11022.42</ArticleId><ArticleId IdType="pmc">PMC2843528</ArticleId><ArticleId IdType="pubmed">18981370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruandet A, Richard F, Bombois S, Maurage CA, Masse I, Amouyel P, Pasquier F. Cognitive decline and survival in Alzheimer's disease according to education level. Dement Geriatr Cogn Disord. 2008;25:74&#x2013;80. doi: 10.1159/000111693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000111693</ArticleId><ArticleId IdType="pubmed">18042993</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody R, Pavlik V, Massman P, Kenan M, Yeh S, Powell S, Cooke N, Dyer C, Demirovic J, Waring S, Chan W. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord. 2005;20:198&#x2013;208. doi: 10.1159/000087300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000087300</ArticleId><ArticleId IdType="pubmed">16088145</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman A, Peterson B, Fillenbaum G, Pieper C. The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology. 1996;46:656&#x2013;660. doi: 10.1212/WNL.46.3.656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.46.3.656</ArticleId><ArticleId IdType="pubmed">8618662</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Alzheimers Res Ther. 2010;2:2. doi: 10.1186/alzrt25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt25</ArticleId><ArticleId IdType="pmc">PMC2874261</ArticleId><ArticleId IdType="pubmed">20178566</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, Kukull WA. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">15068977</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Brayne C, Matthews FE. Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ. 2008;336:258&#x2013;262. doi: 10.1136/bmj.39433.616678.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39433.616678.25</ArticleId><ArticleId IdType="pmc">PMC2223023</ArticleId><ArticleId IdType="pubmed">18187696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266&#x2013;1272. doi: 10.1001/archneur.56.10.1266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.10.1266</ArticleId><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert M, Brandt J, Jacobs DM, Tang MX, Marder K, Bell K, Sano M, Devanand DP, Bylsma F, Lafleche G. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994;44:2300&#x2013;2307. doi: 10.1212/WNL.44.12.2300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.44.12.2300</ArticleId><ArticleId IdType="pubmed">7991116</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JH, Klocinski JL, Merz J, Clark CM, Asch DA. Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology. 2000;55:1008&#x2013;1014. doi: 10.1212/WNL.55.7.1008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.7.1008</ArticleId><ArticleId IdType="pubmed">11061260</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattmo C, Wallin AK, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2011;25:63&#x2013;72. doi: 10.1097/WAD.0b013e3181f5dd97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3181f5dd97</ArticleId><ArticleId IdType="pubmed">20847636</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22581594</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3843</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Neurologia i neurochirurgia polska</Title><ISOAbbreviation>Neurol Neurochir Pol</ISOAbbreviation></Journal><ArticleTitle>Clinical application of the Polish adaptation of the Montreal Cognitive Assessment (MoCA) test in screening for cognitive impairment.</ArticleTitle><Pagination><StartPage>130</StartPage><EndPage>139</EndPage><MedlinePgn>130-9</MedlinePgn></Pagination><Abstract><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A group of 115 subjects (36 meeting DSM-IV criteria for Alzheimer disease (AD) [Clinical Dementia Rating (CDR) = 1], 42 meeting Petersen's criteria for MCI [CDR = 0.5], and 37 cognitively intact controls [CDR = 0]) was recruited for the study in the university-based Alzheimer out-patient clinic. All participants underwent general medical, neurological, and psychiatric examinations. The MoCA, the MMSE, CDR and the short (15-item) version of the Geriatric Depression Scale were also applied.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both MCI and AD groups exhibited impaired performance on MoCA compared to controls. Polish versions of the MMSE and MoCA tests were comparable in discriminating mild dementia from both MCI and control groups. The Polish version of the MoCA test performed marginally better than MMSE in discriminating MCI from controls. We propose to use the MoCA test to screen for MCI using an optimal cut-off score of 24 and to screen for dementia using a cut-off score of 19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Polish version of the MoCA seems effective in the detection of deteriorated cognitive performance and appropriate for differentiating impaired from preserved cognitive function in a Polish population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Magierska</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Czechoslowacka St. 8/10, 92-216 Lodz, Poland. r.magierski@csk.umed.lodz.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magierski</LastName><ForeName>Rados&#x142;aw</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fendler</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz M</ForeName><Initials>TM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Neurol Neurochir Pol</MedlineTA><NlmUniqueID>0101265</NlmUniqueID><ISSNLinking>0028-3843</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22581594</ArticleId><ArticleId IdType="doi">10.5114/ninp.2012.28255</ArticleId><ArticleId IdType="pii">S0028-3843(14)60327-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22574633</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1969</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Drugs &amp; aging</Title><ISOAbbreviation>Drugs Aging</ISOAbbreviation></Journal><ArticleTitle>How legislation on decisional capacity can negatively affect the feasibility of clinical trials in patients with dementia.</ArticleTitle><Pagination><StartPage>607</StartPage><EndPage>614</EndPage><MedlinePgn>607-14</MedlinePgn></Pagination><Abstract><AbstractText>Antipsychotic drugs are widely used to treat behavioural and psychological disturbances associated with Alzheimer's disease (AD), although only modest evidence from randomized controlled trials supports their efficacy, and increasing evidence from post-marketing surveillance shows serious adverse events associated with their use, including increased mortality. The AdCare study, a non-profit, randomized, placebo-controlled, double-blind, multicentre, pragmatic trial coordinated by the Italian National Institute of Health, aimed to evaluate the long-term safety and efficacy profiles of three atypical antipsychotic drugs (risperidone, olanzapine and quetiapine) and one conventional antipsychotic drug (haloperidol) in treating psychosis, aggression and agitation in outpatients with AD. The study was planned to be carried out in 19 clinical centres and to enrol 1000 outpatients. According to Italian law, in the case where a patient is considered unable to give informed consent, a legal representative designated by the court has to provide it. Because of difficulties in the informed consent procedure, the study had to be prematurely interrupted. From February 2009 to April 2010, 83 patients gave informed consent to participate in the trial. Fifty-six patients (68%) were included with consent given by a legal representative, while 27 patients (32%) were considered to provide personal informed consent on the basis of the results from a specifically built procedure. Patients and caregivers were offered the opportunity to participate in the trial before the occurrence of behavioural disturbances, in order to provide them with enough time to consider their participation in the study. Twenty-three patients experienced behavioural, clinically relevant symptoms and were randomized to the study drug; all randomized patients except one had consent for inclusion in the study given by legal representatives. After trial interruption, all patients taking an active drug continued treatment with the same molecule in clinical practice. Randomized controlled trials are acknowledged as the gold standard source of evidence on drug safety and efficacy. The AdCare study showed that an excessively rigid regulation can become a major obstacle while carrying out therapeutic research with incapacitated persons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galeotti</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institute of Health, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanacore</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gainotti</LastName><ForeName>Sabina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Izzicupo</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Menniti-Ippolito</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Petrini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chiarotti</LastName><ForeName>Flavia</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Chattat</LastName><ForeName>Rabih</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Raschetti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>AdCare Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs Aging</MedlineTA><NlmUniqueID>9102074</NlmUniqueID><ISSNLinking>1170-229X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="Y">Decision Making</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016743" MajorTopicYN="N">Mental Competency</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Popoli</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potenza</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tebano</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giubilei</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Locuratolo</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruno</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piacentini</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talarico</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasparini</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Re</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruni</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colao</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puccio</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curcio</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clodimiro</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caffarra</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Messa</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Concari</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pagliara</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fabbo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zucchi</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonora</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veschi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carbone</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ursino</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fatica</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Bonis</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gainotti</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marra</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quaranta</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zinno</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nobili</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbieri</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dessi</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzei</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnaldi</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brugnolo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clerici</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mariani</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maggiore</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomati</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padovani</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rozzini</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zanetti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinaglia</LastName><ForeName>C Negri</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engaddi</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Domenico</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savorgnan</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpino</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Civerchia</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raccichini</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Specchio</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goffredo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biancardi</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Putzu</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Araujo</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ballisai</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piras</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherchi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bagella</LastName><ForeName>C F</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deiana</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catania</LastName><ForeName>T M Vitrano</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bracco</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piccini</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mecocci</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feliziani</LastName><ForeName>F T</ForeName><Initials>FT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornacchiola</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gambina</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broggio</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sala</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22574633</ArticleId><ArticleId IdType="doi">10.1007/BF03262277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2008 Jul 19;372(9634):183-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18640439</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 May 23;54(10):1965-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2009 Nov;3(11):e1000131</Citation><ArticleIdList><ArticleId IdType="pubmed">19918557</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2006 Jan;5(1):64-74</Citation><ArticleIdList><ArticleId IdType="pubmed">16485346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Oct;59(10):550-61; quiz 562-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9818639</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychol Rev. 2004 Sep;14(3):131-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15673234</ArticleId></ArticleIdList></Reference><Reference><Citation>IRB. 2009 Jan-Feb;31(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19241733</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2001 Fall;9(4):346-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11739062</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1986 Oct;34(10):711-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2009 Feb;8(2):151-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19138567</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2010 Jan 11;170(1):96-103</Citation><ArticleIdList><ArticleId IdType="pubmed">20065205</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Aug;163(8):1323-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16877642</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2008 Oct 16;337:a1732</Citation><ArticleIdList><ArticleId IdType="pubmed">18927171</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2002 Mar-Apr;10(2):151-65</Citation><ArticleIdList><ArticleId IdType="pubmed">11925276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2010 Nov;21(11):2295</Citation><ArticleIdList><ArticleId IdType="pubmed">20855466</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 May;161(5):797-806</Citation><ArticleIdList><ArticleId IdType="pubmed">15121642</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2010 Jan;25(1):22-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19898244</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Jun 16;5(6):e11150</Citation><ArticleIdList><ArticleId IdType="pubmed">20585400</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2010 Jan;6(1):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20129322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yale J Health Policy Law Ethics. 2008 Winter;8(1):37-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18564493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioethics. 2012 Feb;26(2):60-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20497168</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2006 May 9;66(9):1367-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16682669</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2003 Dec 23;61(12):1649-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14694024</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Invest. 2010 Jan;40(1):69-86</Citation><ArticleIdList><ArticleId IdType="pubmed">20055898</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Nov 1;357(18):1834-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17978292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2002;(2):CD002852</Citation><ArticleIdList><ArticleId IdType="pubmed">12076456</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2006 Oct 12;355(15):1525-38</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16276663</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000;54(11 Suppl 5):S4-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10854354</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2008 Aug 26;179(5):438-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18725616</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2010 Mar;87(3):351-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20010554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22549770</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults.</ArticleTitle><Pagination><StartPage>265</StartPage><EndPage>275</EndPage><MedlinePgn>265-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.3820</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mild cognitive impairment (MCI) is a clinical concept that categorizes subjects who are in an intermediate cognitive state between normal aging and dementia. The aim of this study is to characterize behavior in MCI compared with Alzheimer's disease (AD) and healthy older patients.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A cross-sectional analysis of baseline data from a prospective, longitudinal study on behavioral symptoms of dementia and MCI was performed. The study population consisted of 270 MCI, 402 AD patients, and 108 healthy controls. Behavioral assessment was performed by means of Middelheim Frontality Score, Behavioral Pathology in Alzheimer's Disease Rating Scale, Cohen-Mansfield Agitation Inventory, and Cornell Scale for Depression in Dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Moderate-to-severe behavioral symptoms were present in 13% of MCI patients, as compared with 39% in AD patients and 3% in controls (p&#x2009;&lt;&#x2009;0.001). The general severity of behavioral symptoms was intermediate between controls and AD patients. The three most frequent symptoms in MCI patients were aggressiveness (49%), affective disturbance (45%), and anxiety (38%); in AD patients, the most frequent symptoms were aggressiveness (60%), activity disturbances (54%), and psychosis (40%). The prevalence and severity of frontal lobe symptoms, aggressiveness, activity disturbances, and delusions was intermediate between normal aging and AD. In addition, the severity of physically non-aggressive and verbally agitated behavior and the severity of depressive symptoms were also intermediate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The behavioral profile of MCI patients is characterized as an intermediate state between normal aging and AD for the prevalence and severity of certain behavioral symptoms. Follow-up is ongoing to test the hypothesis that behavioral disturbances in MCI predict progression to dementia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van der Mussele</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Bastard</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Vermeiren</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Saerens</LastName><ForeName>Jos</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Somers</LastName><ForeName>Nore</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mari&#xeb;n</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Goeman</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22549770</ArticleId><ArticleId IdType="doi">10.1002/gps.3820</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22527230</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>259</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach.</ArticleTitle><Pagination><StartPage>2299</StartPage><EndPage>2308</EndPage><MedlinePgn>2299-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-012-6490-x</ELocationID><Abstract><AbstractText>The neuropsychiatric symptoms and behavioral disorders affecting Parkinson's disease (PD) patients are common and disabling. A PD-specific interview-based 12-item scale, the Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease (SEND-PD), has been developed to assess the severity of neuropsychiatric manifestations. The present study is aimed at testing some basic psychometric attributes of this scale. A total of 633 consecutive patients and their caregivers were included in this cross-sectional, multicenter, observational study. In addition to the tested scale, the following assessments were applied: Hoehn and Yahr staging, Scales for Outcomes in Parkinson's Disease Motor and Psychiatric complications, MiniMental State Examination, Clinical Impression of Severity Index, and the Zarit Caregiver Burden Inventory. Patients in all stages of disease were included and 18.38 % were demented. The SEND-PD was responded by patients (86.16 %), caregivers (13.15 %), or both (0.69 %). Three factors (accounting for 66.63 % of the variance) were identified and considered as subscales: Psychotic symptoms, Mood/Apathy, and Impulse control disorders. The subscales showed satisfactory scaling assumptions (multitrait-item success rate 100 %) and internal consistency (alpha indices &gt;0.70). The convergent validity with other measures of psychiatric symptoms and the discriminant validity to distinguish between categories of patients' age, duration and severity of disease, and dopaminergic treatment were satisfactory. The precision of the scale dimensions was acceptable. The SEND-PD performed as an acceptable, consistent, valid, and precise scale for evaluation of neuropsychiatric symptoms in Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez-Martin</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Alzheimer Center Reina Sofia Foundation, C/. Valderrebollo, 5, 28031, Madrid, Spain. pmartinez@fundacioncien.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frades-Payo</LastName><ForeName>Belen</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ag&#xfc;era-Ortiz</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ayuga-Martinez</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22527230</ArticleId><ArticleId IdType="doi">10.1007/s00415-012-6490-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Qual Life Res. 2002 May;11(3):193-205</Citation><ArticleIdList><ArticleId IdType="pubmed">12074258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Dec;22(16):2314-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18098298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2009 Oct;62(10):1062-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19230609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2011 Sep;26(11):2110-3</Citation><ArticleIdList><ArticleId IdType="pubmed">21661056</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1998 Sep-Oct;21(5):280-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9789707</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):423-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10727476</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2002 Jan;8(3):193-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12039431</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2011 Sep;26(11):1976-84</Citation><ArticleIdList><ArticleId IdType="pubmed">21661054</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2005 Jul;58(7):674-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15939218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Jun 15;22(8):1077-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17394234</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1992 Jun;40(6):549-55</Citation><ArticleIdList><ArticleId IdType="pubmed">1587970</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2010 May;67(5):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20457959</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Aug 15;22(11):1623-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17546669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2010 Nov 15;25(15):2649-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21069833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2001 Dec;54(12):1204-17</Citation><ArticleIdList><ArticleId IdType="pubmed">11750189</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2010 Jul 30;25(10):1391-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20310036</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2005 Aug;20(8):958-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15800937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1999 Sep;52(9):861-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10529027</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 1995 Aug;4(4):293-307</Citation><ArticleIdList><ArticleId IdType="pubmed">7550178</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1979 Sep;17(9):902-21</Citation><ArticleIdList><ArticleId IdType="pubmed">480998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2009 Jan 30;24(2):211-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18973256</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1967 May;17(5):427-42</Citation><ArticleIdList><ArticleId IdType="pubmed">6067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2008 Oct 30;23(14):2004-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18709683</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2008 Mar 15;23(4):484-500</Citation><ArticleIdList><ArticleId IdType="pubmed">18175343</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Jan 15;34(2):714-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17113310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurol. 2004 Oct 1-15;39(7):639-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15490351</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsons Dis. 2011;2011:485063</Citation><ArticleIdList><ArticleId IdType="pubmed">21603184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2003 Sep;18 Suppl 6:S80-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14502660</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2012 Feb;20(2):123-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21617521</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2005 Sep;252(9):1060-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15789127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Feb;21(2):208-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16161158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 1980 Dec;20(6):649-55</Citation><ArticleIdList><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2005 Mar;9(10):1-93, iii-iv</Citation><ArticleIdList><ArticleId IdType="pubmed">15774233</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2009 May;8(5):464-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19375664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2004 Mar;19(3):312-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15022186</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):388-95</Citation><ArticleIdList><ArticleId IdType="pubmed">14966153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Nov 15;22(15):2221-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17712843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2008 Nov 15;23(15):2129-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19025984</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2006 Jul;63(7):969-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16831966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2006 Jul;21(7):916-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16547944</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):70-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8676165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2011 Feb 15;26(3):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">21264941</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2006 Aug 22;4:54</Citation><ArticleIdList><ArticleId IdType="pubmed">16925807</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 May 15;22(7):924-31; quiz 1060</Citation><ArticleIdList><ArticleId IdType="pubmed">17238193</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2001;10(7):571-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11822790</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinsonism Relat Disord. 2011 Sep;17(8):621-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21684792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2006 Mar;5(3):235-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16488379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurol (Paris). 2009 Nov;165(11):845-56</Citation><ArticleIdList><ArticleId IdType="pubmed">19683776</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1677-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16291893</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 1993 Dec;2(6):441-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8161978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Oct 15;22(13):1901-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17674410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol. 2005 Jul;252(7):753-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15999234</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2004 Apr;19(4):397-405</Citation><ArticleIdList><ArticleId IdType="pubmed">15077237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2008 Oct 30;23(14):2015-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18792121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jun 13;373(9680):2055-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19524782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2011 May;26(6):1022-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21626547</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Oct;13(10):844-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16223962</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Dec 11;57(11):2078-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11739829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22505366</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1509-572X</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>1</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Folia neuropathologica</Title><ISOAbbreviation>Folia Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer's disease: morphometric study and review of the literature.</ArticleTitle><Pagination><StartPage>74</StartPage><EndPage>84</EndPage><MedlinePgn>74-84</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Microglia are the resident immune cells of the CNS. They are involved in the pathogenesis of diverse neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease, prion diseases as well as multiple sclerosis, amyotrophic lateral sclerosis and AIDS dementia complex. Activated microglia up-regulate many surface receptors such as the major histocompatibility complex (MHC) or complement receptors and secrete a variety of soluble biologically active factors, which are either neurotrophic (e.g. Glia-Derived Neurotrophic Factor [GDNF]) or proinflammatory and neurotoxic (e.g. tumour necrosis factor alpha [TNF-&#x3b1;], interleukin 1&#x3b2; [IL-1&#x3b2;], nitric oxide [NO], superoxide, eicosanoids, quinolinic acid).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this work was to assess differences in the expression of microglial markers (ferritin, CD68, and HLA-DR) between AD and Creutzfeldt-Jakob disease (CJD) brains.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Analyses were performed on 65 slices derived from 26 brains [46 CJD (20 brains), 12 AD (4 brains) and 7 controls (2 brains)]. Slices were labelled immunohistochemically using anti-ferritin, anti-HLA-DR and anti-CD68 antibodies. The nonparametric Mann-Whitney U test was used to assess quantitative differences between groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The expression of microglia markers (HLA-DR and CD68) is more noticeable in CJD than in AD or control brains. There is no difference between AD and controls. The latter statement is only true in the case of using HLA-DR or CD-68 labelling. Furthermore, ferritin is not a recommended marker in this context.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CNS inflammation is more prominent in CJD than in AD or controls. The lack of differences between AD and controls may result from a relatively advanced neurodegeneration in AD brains. In late phases of AD, inflammation is no longer present, in contrast to the early stages of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wojtera</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, 8/10 Czechos&#x142;owacka st., 92-216 Lodz, Poland. voymart@wp.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawe&#x142; P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Sikorska</LastName><ForeName>Beata</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Folia Neuropathol</MedlineTA><NlmUniqueID>9437431</NlmUniqueID><ISSNLinking>1509-572X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007562" MajorTopicYN="N">Creutzfeldt-Jakob Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22505366</ArticleId><ArticleId IdType="pii">18392</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22492754</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1471-2970</ISSN><JournalIssue CitedMedium="Internet"><Volume>367</Volume><Issue>1594</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</Title><ISOAbbreviation>Philos Trans R Soc Lond B Biol Sci</ISOAbbreviation></Journal><ArticleTitle>Failures of metacognition and lack of insight in neuropsychiatric disorders.</ArticleTitle><Pagination><StartPage>1379</StartPage><EndPage>1390</EndPage><MedlinePgn>1379-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1098/rstb.2012.0002</ELocationID><Abstract><AbstractText>Lack of insight or unawareness of illness are the hallmarks of many psychiatric disorders, especially schizophrenia (SCZ) and other psychoses and could be conceived of as a failure in metacognition. Research in this area in the mental health field h as burgeoned with the development and widespread use of standard assessment instruments and the mapping out of the clinical and neuropsychological correlates of insight and its loss. There has been a growing appreciation of the multi-faceted nature of the concept and of the different 'objects' of insight, such as the general awareness that one is ill, to more specific metacognitive awareness of individual symptoms, impairments and performance. This in turn has led to the notion that insight may show modularity and may fractionate across different domains and disorders, supported by work that directly compares metacognition of memory deficits and illness awareness in patients with SCZ, Alzheimer's disease and brain injury. The focus of this paper will be on the varieties of metacognitive failure in psychiatry, particularly the psychoses. We explore cognitive models based on self-reflectiveness and their possible social and neurological bases, including data from structural and functional MRI. The medial frontal cortex appears to play an important role in self-appraisal in health and disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>David</LastName><ForeName>Anthony S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Section of Cognitive Neuropsychology, Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, London, SE5 8AF, UK. anthony.david@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedford</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wiffen</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gilleen</LastName><ForeName>James</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Philos Trans R Soc Lond B Biol Sci</MedlineTA><NlmUniqueID>7503623</NlmUniqueID><ISSNLinking>0962-8436</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22492754</ArticleId><ArticleId IdType="pmc">PMC3318769</ArticleId><ArticleId IdType="doi">10.1098/rstb.2012.0002</ArticleId><ArticleId IdType="pii">rstb.2012.0002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saxe R., Offen S. 2010. Seeing ourselves: what vision can teach us about metacognition. In Metacognition and severe adult mental disorders (eds Dimaggio G., Lysaker P. H.), pp. 13&#x2013;30 Hove, East Sussex: Routledge</Citation></Reference><Reference><Citation>Prigatano G. P. 2009. The study of anosognosia. New York, NY: Oxford University Press</Citation></Reference><Reference><Citation>David A. S.
1990. 
Insight and psychosis. Brit. J. Psychiat.
156, 798&#x2013;80810.1192/bjp.156.6.798 (doi:10.1192/bjp.156.6.798)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.156.6.798</ArticleId><ArticleId IdType="doi">10.1192/bjp.156.6.798</ArticleId><ArticleId IdType="pubmed">2207510</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador X. F., David A. S. (eds) 2004. Insight and psychosis: awareness of illness in schizophrenia and related disorders, 2nd edn Oxford, UK: Oxford University Press</Citation></Reference><Reference><Citation>Markova I. S. 2005. Insight in psychiatry. Cambridge, UK: Cambridge University Press</Citation></Reference><Reference><Citation>Amador X. F., Strauss D. H., Yale S. A., Gorman J. M. 1993. Assessment of insight in psychosis. Am. J. Psychiat. 150, 873&#x2013;879</Citation><ArticleIdList><ArticleId IdType="pubmed">8494061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiffen B. D. R., Rabinowitz J., Lex A., David A. S.
2010. 
Correlates, change and &#x2018;state or trait&#x2019; properties of insight in schizophrenia. Schizophr. Res.
122, 94&#x2013;10310.1016/j.schres.2010.03.005 (doi:10.1016/j.schres.2010.03.005)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2010.03.005</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2010.03.005</ArticleId><ArticleId IdType="pubmed">20382507</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz M., Constable G., Lopez-Ibor I., Kemp R., David A. S.
1998. 
A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol. Med.
28, 437&#x2013;44610.1017/S0033291797006296 (doi:10.1017/S0033291797006296)</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291797006296</ArticleId><ArticleId IdType="doi">10.1017/S0033291797006296</ArticleId><ArticleId IdType="pubmed">9572100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilleen J., Greenwood K., David A. S. 2009. Anosognosia in schizophrenia and other neuropsychiatric disorders: similarities and differences. In The study of anosognosia (ed. Prigatano G. P.), pp. 255&#x2013;290 Oxford, UK: Oxford University Press</Citation></Reference><Reference><Citation>Gilleen J., Greenwood K., David A. S. 2010. Lack of insight and awareness in schizophrenia and neuropsychiatric disorders. In Neuropsychiatric disorders (eds Myoshi K., Morimura Y., Maeda K.), pp. 33&#x2013;49 Tokyo, Japan: Springer</Citation></Reference><Reference><Citation>Rossell S. L., Coakes J., Shapleske J., Woodruff P. W. R. 2003. Insight: its relationship with cognitive function, brain volume and symptoms in schizophrenia. Psychol. Med. 33, 111&#x2013;119</Citation><ArticleIdList><ArticleId IdType="pubmed">12537042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher T. T. J., Koch K., Stottmeister F., Durst V.
2007. 
Metacognition and reflexivity in patients with schizophrenia. Psychopathology
40, 254&#x2013;26010.1159/000101730 (doi:10.1159/000101730)</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000101730</ArticleId><ArticleId IdType="doi">10.1159/000101730</ArticleId><ArticleId IdType="pubmed">17440288</ArticleId></ArticleIdList></Reference><Reference><Citation>Medalia A., Thysen J.
2008. 
Insight into neurocognitive dysfunction in schizophrenia. Schizophr. Bull.
34, 1221&#x2013;123010.1093/schbul/sbm144 (doi:10.1093/schbul/sbm144)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbm144</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbm144</ArticleId><ArticleId IdType="pmc">PMC2632502</ArticleId><ArticleId IdType="pubmed">18199632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayard S., Capdevielle D., Boulenger J.P., Raffard S.
2009. 
Dissociating self-reported cognitive complaint from clinical insight in schizophrenia. Eur. Psychiat.
24, 251&#x2013;25810.1016/j.eurpsy.2008.12.010 (doi:10.1016/j.eurpsy.2008.12.010)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eurpsy.2008.12.010</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2008.12.010</ArticleId><ArticleId IdType="pubmed">19324531</ArticleId></ArticleIdList></Reference><Reference><Citation>McGlynn S. M., Schacter D. L.
1989. 
Unawareness of deficits in neuropsychological syndromes. J. Clin. Exp. Neuropsychol.
11, 143&#x2013;20510.1080/01688638908400882 (doi:10.1080/01688638908400882)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01688638908400882</ArticleId><ArticleId IdType="doi">10.1080/01688638908400882</ArticleId><ArticleId IdType="pubmed">2647781</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasdale T. W., et al. 
1997. 
Subjective experience in brain injured patients and their close relatives: a European brain injury questionnaire study. Brain Injury
11, 543&#x2013;56410.1080/026990597123250 (doi:10.1080/026990597123250)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/026990597123250</ArticleId><ArticleId IdType="doi">10.1080/026990597123250</ArticleId><ArticleId IdType="pubmed">9251864</ArticleId></ArticleIdList></Reference><Reference><Citation>Clare L.
2004. 
Awareness in early-stage Alzheimer's disease: a review of methods and evidence. Brit. J. Clin. Psychol.
43, 177&#x2013;19610.1348/014466504323088042 (doi:10.1348/014466504323088042)</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/014466504323088042</ArticleId><ArticleId IdType="doi">10.1348/014466504323088042</ArticleId><ArticleId IdType="pubmed">15169617</ArticleId></ArticleIdList></Reference><Reference><Citation>Clare L.
2004. 
The construction of awareness in early-stage Alzheimer's disease: a review of concepts and models. Brit. J. Clin. Psychol.
43, 155&#x2013;17510.1348/014466504323088033 (doi:10.1348/014466504323088033)</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/014466504323088033</ArticleId><ArticleId IdType="doi">10.1348/014466504323088033</ArticleId><ArticleId IdType="pubmed">15169616</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasterling J. J., Seltzer B., Foss J. W., Vanderbrook V. 1995. Unawareness of deficit in Alzheimer's disease. Domain-specific differences and disease correlates. Neuropsychol. Neuropsychol. Behav. Neurol. 8, 26&#x2013;32</Citation></Reference><Reference><Citation>Gilleen J., Greenwood K., David A. S.
2011. 
Domains of awareness in schizophrenia. Schizophr. Bull.
37, 61&#x2013;7210.1093/schbul/sbq100 (doi:10.1093/schbul/sbq100)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbq100</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbq100</ArticleId><ArticleId IdType="pmc">PMC3004192</ArticleId><ArticleId IdType="pubmed">20851850</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess P. W., Alderman N., Emslie H., Evans J. J., Wilson B. A. 1996. The dysexecutive questionnaire. In Behavioural assessment of the dysexecutive syndrome. Bury St. Edmunds, UK: Thames Valley Test Company</Citation></Reference><Reference><Citation>Clare L., Wilson B. A., Carter G., Roth I., Hodges J. R.
2002. 
Assessing awareness in early-stage Alzheimer's disease: Development and piloting of the Memory Awareness Rating Scale. Neuropsychol. Rehab.
12, 341&#x2013;36210.1080/09602010244000129 (doi:10.1080/09602010244000129)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09602010244000129</ArticleId><ArticleId IdType="doi">10.1080/09602010244000129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Cockburn J., Baddeley A. 1985. The Rivermead behavioural memory test (RBMT). Reading, MA: Thames Valley Test Company</Citation></Reference><Reference><Citation>Agnew S. K., Morris R. G.
1998. 
The heterogeneity of anosognosia for memory impairment in Alzheimer's disease: a review of the literature and a proposed model. Aging Mental Health
2, 7&#x2013;1910.1080/13607869856876 (doi:10.1080/13607869856876)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13607869856876</ArticleId><ArticleId IdType="doi">10.1080/13607869856876</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson C., Alcantar O., Rothlind J., Cahn-Weiner D., Miller B. L., Rosen H. J.
2010. 
Standardised measurement of self-awareness deficits in FTD and AD. J. Neurol. Neurosurg. Psychiat.
81, 140&#x2013;14510.1136/jnnp.2008.166041 (doi:10.1136/jnnp.2008.166041)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.166041</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2008.166041</ArticleId><ArticleId IdType="pmc">PMC2820148</ArticleId><ArticleId IdType="pubmed">19204020</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks S. J., Weintraub S.
2009. 
Generalized and symptom-specific insight in behavioral variant frontotemporal dementia and primary progressive aphasia. J. Neuropsychiatr. Clin. Neurosci.
21, 299&#x2013;30610.1176/appi.neuropsych.21.3.299 (doi:10.1176/appi.neuropsych.21.3.299)</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.neuropsych.21.3.299</ArticleId><ArticleId IdType="doi">10.1176/appi.neuropsych.21.3.299</ArticleId><ArticleId IdType="pmc">PMC2957481</ArticleId><ArticleId IdType="pubmed">19776310</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keeffe F. M., Murray B., Coen R. F., Dockree P. M., Bellgrove M. A., Garavan H., Lynch T., Robertson I. H.
2007. 
Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy. Brain
130, 753&#x2013;76410.1093/brain/awl367 (doi:10.1093/brain/awl367)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl367</ArticleId><ArticleId IdType="doi">10.1093/brain/awl367</ArticleId><ArticleId IdType="pubmed">17347257</ArticleId></ArticleIdList></Reference><Reference><Citation>Osatuke K., Ciesla J., Kasckow J. W., Zisook S., Mohamed S.
2008. 
Insight in schizophrenia: a review of etiological models and supporting research. Compr. Psychiat.
49, 70&#x2013;7710.1016/j.comppsych.2007.08.001 (doi:10.1016/j.comppsych.2007.08.001)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.comppsych.2007.08.001</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2007.08.001</ArticleId><ArticleId IdType="pubmed">18063044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintz A. R., Dobson K. S., Romney D. M.
2003. 
Insight in schizophrenia: a meta-analysis. Schizophr. Res.
61, 75&#x2013;8810.1016/S0920-9964(02)00316-X (doi:10.1016/S0920-9964(02)00316-X)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0920-9964(02)00316-X</ArticleId><ArticleId IdType="doi">10.1016/S0920-9964(02)00316-X</ArticleId><ArticleId IdType="pubmed">12648738</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalakeas A., Skoutas C., Charalambous A., Peristeris A., Marinos V., Keramari E., Theologou A.
1994. 
Insight in schizophrenia and mood disorders and its relation to psychopathology. Acta. Psychiat. Scand.
90, 46&#x2013;4910.1111/j.1600-0447.1994.tb01554.x (doi:10.1111/j.1600-0447.1994.tb01554.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1994.tb01554.x</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1994.tb01554.x</ArticleId><ArticleId IdType="pubmed">7976449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaemi S. N., Rosenquist K. J.
2004. 
Is insight in mania state-dependent?: a meta-analysis. J. Nerv. Ment. Dis.
192, 771&#x2013;77510.1097/01.nmd.0000145036.76435.c3 (doi:10.1097/01.nmd.0000145036.76435.c3)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.nmd.0000145036.76435.c3</ArticleId><ArticleId IdType="doi">10.1097/01.nmd.0000145036.76435.c3</ArticleId><ArticleId IdType="pubmed">15505521</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador X. F., Flaum M., Andreasen N. C., Strauss D. H., Yale S. A., Clark S. C., Gorman J. M.
1994. 
Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch. Gen. Psychiat.
51, 826&#x2013;83610.1001/archpsyc.1994.03950100074007 (doi:10.1001/archpsyc.1994.03950100074007)</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.1994.03950100074007</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1994.03950100074007</ArticleId><ArticleId IdType="pubmed">7944872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pini S., Cassano G. B., Dell'Osso L., Amador X. F.
2001. 
Insight into illness in schizophrenia, schizoaffective disorder, and mood disorders with psychotic features. Am. J. Psychiat.
158, 122&#x2013;12510.1176/appi.ajp.158.1.122 (doi:10.1176/appi.ajp.158.1.122)</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.158.1.122</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.158.1.122</ArticleId><ArticleId IdType="pubmed">11136644</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga M., Magnusson A., Flekkoy K., David A. S., Opjordsmoen S. 2007. Clinical and neuropsychological correlates of insight in schizophrenia and bipolar I disorder: does diagnosis matter? Compr. Psychiat. 28, 583&#x2013;591</Citation><ArticleIdList><ArticleId IdType="pubmed">17954145</ArticleId></ArticleIdList></Reference><Reference><Citation>David A., van Os J., Jones P., Harvey I., Foerster A., Fahy T.
1995. 
Insight and psychotic illness. Cross-sectional and longitudinal associations. Brit. J. Psychiat.
167, 621&#x2013;62810.1192/bjp.167.5.621 (doi:10.1192/bjp.167.5.621)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.167.5.621</ArticleId><ArticleId IdType="doi">10.1192/bjp.167.5.621</ArticleId><ArticleId IdType="pubmed">8564318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuesta M. J., Peralta V., Zarzuela A.
2000. 
Reappraising insight in psychosis. Multi-scale longitudinal study. Brit. J. Psychiat.
177, 233&#x2013;24010.1192/bjp.177.3.233 (doi:10.1192/bjp.177.3.233)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.177.3.233</ArticleId><ArticleId IdType="doi">10.1192/bjp.177.3.233</ArticleId><ArticleId IdType="pubmed">11040884</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll A., Fattah S., Clyde Z.
1999. 
Correlations of insight and insight change in schizophrenia. Schizophr. Res.
35, 247&#x2013;25310.1016/S0920-9964(98)00142-X (doi:10.1016/S0920-9964(98)00142-X)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0920-9964(98)00142-X</ArticleId><ArticleId IdType="doi">10.1016/S0920-9964(98)00142-X</ArticleId><ArticleId IdType="pubmed">10093870</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T. E., Hull J. W., Israel L. M., Willson D. F. 2000. Insight, symptoms, and neurocognition in schizophrenia and schizoaffective disorder. Schizophr. Bull. 26, 193&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pubmed">10755681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyne J. M., Bean D., Sullivan G.
2001. 
Characteristics of patients with schizophrenia who do not believe they are mentally ill. J. Nerv. Ment. Dis.
189, 146&#x2013;15310.1097/00005053-200103000-00002 (doi:10.1097/00005053-200103000-00002)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005053-200103000-00002</ArticleId><ArticleId IdType="doi">10.1097/00005053-200103000-00002</ArticleId><ArticleId IdType="pubmed">11277350</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore O., Cassidy E., Carr A., O'Callaghan E.
1999. 
Unawareness of illness and its relationship with depression and self-deception in schizophrenia. Eur. Psychiat.
14, 264&#x2013;26910.1016/S0924-9338(99)00172-8 (doi:10.1016/S0924-9338(99)00172-8)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-9338(99)00172-8</ArticleId><ArticleId IdType="doi">10.1016/S0924-9338(99)00172-8</ArticleId><ArticleId IdType="pubmed">10572356</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal Z., Birchwood M., Chadwick P., Trower P.
2000. 
Cognitive approach to depression and suicidal thinking in psychosis. 2. Testing the validity of a social ranking model. Brit. J. Psychiat.
177, 522&#x2013;52810.1192/bjp.177.6.522 (doi:10.1192/bjp.177.6.522)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.177.6.522</ArticleId><ArticleId IdType="doi">10.1192/bjp.177.6.522</ArticleId><ArticleId IdType="pubmed">11102327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz R. C.
2001. 
Self-awareness in schizophrenia: its relationship to depressive symptomatology and broad psychiatric impairments. J. Nerv. Ment. Dis.
189, 401&#x2013;40310.1097/00005053-200106000-00010 (doi:10.1097/00005053-200106000-00010)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005053-200106000-00010</ArticleId><ArticleId IdType="doi">10.1097/00005053-200106000-00010</ArticleId><ArticleId IdType="pubmed">11434643</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen G. S., Richardson G., David A. S., Szmukler G., Hayward P., Hotopf M.
2009. 
Mental capacity, diagnosis, and insight in psychiatric inpatients: a cross-sectional study. Psychol. Med.
39, 1389&#x2013;139810.1017/S0033291708004637 (doi:10.1017/S0033291708004637)</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291708004637</ArticleId><ArticleId IdType="doi">10.1017/S0033291708004637</ArticleId><ArticleId IdType="pmc">PMC7611628</ArticleId><ArticleId IdType="pubmed">18940026</ArticleId></ArticleIdList></Reference><Reference><Citation>David A. S.
1999. 
&#x2018;To see ourselves as others see us.&#x2019; Aubrey Lewis's Insight. Brit. J. Psychiat.
174, 210&#x2013;21610.1192/bjp.175.3.210 (doi:10.1192/bjp.175.3.210)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.175.3.210</ArticleId><ArticleId IdType="doi">10.1192/bjp.175.3.210</ArticleId><ArticleId IdType="pubmed">10645320</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan M. S., Rabinowitz J., DeSmedt G., Harvey P. D., Schooler N.
2004. 
Correlates of insight in first episode psychosis. Schizophr. Res.
70, 187&#x2013;19410.1016/j.schres.2003.11.007 (doi:10.1016/j.schres.2003.11.007)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2003.11.007</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2003.11.007</ArticleId><ArticleId IdType="pubmed">15329295</ArticleId></ArticleIdList></Reference><Reference><Citation>Young D. A., Zakzanis K. K., Bailey C., Davila R., Griese J., Sartory G., Thom A.
1998. 
Further parameters of insight and neuropsychological deficit in schizophrenia and other chronic mental disease. J. Nerv. Ment. Dis.
186, 44&#x2013;5010.1097/00005053-199801000-00007 (doi:10.1097/00005053-199801000-00007)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005053-199801000-00007</ArticleId><ArticleId IdType="doi">10.1097/00005053-199801000-00007</ArticleId><ArticleId IdType="pubmed">9457146</ArticleId></ArticleIdList></Reference><Reference><Citation>Young D. A., Campbell Z., Zakzanis K. K., Weinstein E.
2003. 
A comparison between an interview and a self-report method of insight assessment in chronic schizophrenia. Schizophr. Res.
63, 103&#x2013;10910.1016/S0920-9964(02)00378-X (doi:10.1016/S0920-9964(02)00378-X)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0920-9964(02)00378-X</ArticleId><ArticleId IdType="doi">10.1016/S0920-9964(02)00378-X</ArticleId><ArticleId IdType="pubmed">12892864</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke M. A., Peters E. R., Kuipers E., Kumari V.
2005. 
Disease, deficit or denial? Models of poor insight in psychosis. Acta. Psychiat. Scand.
112, 4&#x2013;1710.1111/j.1600-0447.2005.00537.x (doi:10.1111/j.1600-0447.2005.00537.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2005.00537.x</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2005.00537.x</ArticleId><ArticleId IdType="pubmed">15952940</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleman A., Agrawal N., Morgan K. D., David A. S.
2006. 
Insight in psychosis and neuropsychological function: meta-analysis. Brit. J. Psychiat.
189, 204&#x2013;21210.1192/bjp.189.3.204 (doi:10.1192/bjp.189.3.204)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.189.3.204</ArticleId><ArticleId IdType="doi">10.1192/bjp.189.3.204</ArticleId><ArticleId IdType="pubmed">16946354</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy J. P., Johnson J., Perkins D., Lieberman J. A., Hamer R. M., Keefe R. S., Tohen M., Glick I. D., Sharma T.
2006. 
Insight in first-episode psychosis. Psychol. Med.
36, 1385&#x2013;139310.1017/S0033291706007793 (doi:10.1017/S0033291706007793)</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291706007793</ArticleId><ArticleId IdType="doi">10.1017/S0033291706007793</ArticleId><ArticleId IdType="pubmed">16740175</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan K. D., David A. S. 2004. Neuropsychological studies of insight in patients with psychotic disorders. In Insight and psychosis: awareness of illness in schizophrenia and related disorders (eds Amador X. F., David A. S.), pp. 177&#x2013;193, 2nd edn New York, NY: Oxford University Press</Citation></Reference><Reference><Citation>Parellada M., et al. 
2011. 
Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: a 2-year longitudinal study. Schizophr. Bull.
37, 38&#x2013;5110.1093/schbul/sbq109 (doi:10.1093/schbul/sbq109)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbq109</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbq109</ArticleId><ArticleId IdType="pmc">PMC3004178</ArticleId><ArticleId IdType="pubmed">20884756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsatsa S. H., Joyce E. M., Hutton S. B., Barnes T. R.
2006. 
Relationship between insight, cognitive function, social function and symptomatology in schizophrenia: the West London first episode study. Eur. Arch. Psychiat. Clin. Neuros.
256, 356&#x2013;36310.1007/s00406-006-0645-7 (doi:10.1007/s00406-006-0645-7)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-006-0645-7</ArticleId><ArticleId IdType="doi">10.1007/s00406-006-0645-7</ArticleId><ArticleId IdType="pubmed">16902732</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren D., Seidman L. J., Poyurovsky M., Goldsmith M., Viksman P., Zichel S., Klein E.
2004. 
The neuropsychological basis of insight in first-episode schizophrenia: a pilot metacognitive study. Schizophr. Res.
70, 195&#x2013;20210.1016/j.schres.2004.02.004 (doi:10.1016/j.schres.2004.02.004)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2004.02.004</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2004.02.004</ArticleId><ArticleId IdType="pubmed">15329296</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck A. T., Warman D. M. 2004. Cognitive insight: theory and assessment. In Insight and psychosis: awareness of illness in schizophrenia and related disorders (eds Amador X. F., David A. S.), pp. 79&#x2013;87, 2nd edn. New York, NY: Oxford University Press</Citation></Reference><Reference><Citation>Beck A. T., Baruch E., Balter J. M., Steer R. A., Warman D. M.
2004. 
A new instrument for measuring insight: the Beck cognitive insight scale. Schizophr. Res.
68, 319&#x2013;32910.1016/S0920-9964(03)00189-0 (doi:10.1016/S0920-9964(03)00189-0)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0920-9964(03)00189-0</ArticleId><ArticleId IdType="doi">10.1016/S0920-9964(03)00189-0</ArticleId><ArticleId IdType="pubmed">15099613</ArticleId></ArticleIdList></Reference><Reference><Citation>Riggs S. E., Grant P. M., Perivoliotis D., Beck A. T.
2012. 
Assessment of cognitive insight: a qualitative review. Schizophr. Bull.
38, 338&#x2013;35010.1093/schbul/sbq085 (doi:10.1093/schbul/sbq085)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbq085</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbq085</ArticleId><ArticleId IdType="pmc">PMC3283158</ArticleId><ArticleId IdType="pubmed">20693342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bora E., Erkan A., Kayahan B., Veznedaroglu B.
2007. 
Cognitive insight and acute psychosis in schizophrenia. Psychiat. Clin. Neurosci.
61, 634&#x2013;63910.1111/j.1440-1819.2007.01731.x (doi:10.1111/j.1440-1819.2007.01731.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1819.2007.01731.x</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2007.01731.x</ArticleId><ArticleId IdType="pubmed">18081624</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchy L., Malla A., Joober R., Lepage M.
2009. 
Delusions are associated with low self-reflectiveness in first-episode psychosis. Schizophr. Res.
112, 187&#x2013;19110.1016/j.schres.2009.03.019 (doi:10.1016/j.schres.2009.03.019)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2009.03.019</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2009.03.019</ArticleId><ArticleId IdType="pubmed">19372032</ArticleId></ArticleIdList></Reference><Reference><Citation>Engh J. A., et al. 
2009. 
Delusions are associated with poor cognitive insight in schizophrenia. Schizophr. Bull.
36, 830&#x2013;83510.1093/schbul/sbn193 (doi:10.1093/schbul/sbn193)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbn193</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbn193</ArticleId><ArticleId IdType="pmc">PMC2894586</ArticleId><ArticleId IdType="pubmed">19176474</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrelli P., McQuaid J. R., Granholm E., Patterson T. L., McClure F., Beck A. T., Jeste D.V.
2004. 
Measuring cognitive insight in middle-aged and older patients with psychotic disorders. Schizophr. Res.
71, 297&#x2013;30510.1016/j.schres.2004.02.019 (doi:10.1016/j.schres.2004.02.019)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2004.02.019</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2004.02.019</ArticleId><ArticleId IdType="pubmed">15474900</ArticleId></ArticleIdList></Reference><Reference><Citation>Favrod J., Zimmermann G., Raffard S., Pomini V., Khazaal Y. 2008. The Beck Cognitive Insight Scale in outpatients with psychotic disorders: further evidence from a French-speaking sample. Can. J. Psychiat. 53, 783&#x2013;787</Citation><ArticleIdList><ArticleId IdType="pubmed">19087473</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranulis C., Lepage M., Malla A.
2008. 
Insight in first episode psychosis: who is measuring what?
Early Interv. Psychiat.
2, 34&#x2013;4110.1111/j.1751-7893.2007.00054.x (doi:10.1111/j.1751-7893.2007.00054.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-7893.2007.00054.x</ArticleId><ArticleId IdType="doi">10.1111/j.1751-7893.2007.00054.x</ArticleId><ArticleId IdType="pubmed">21352129</ArticleId></ArticleIdList></Reference><Reference><Citation>Warman D. M., Lysaker P. H., Martin J. M.
2007. 
Cognitive insight and psychotic disorder: the impact of active delusions. Schizophr. Res.
90, 325&#x2013;33310.1016/j.schres.2006.09.011 (doi:10.1016/j.schres.2006.09.011)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2006.09.011</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2006.09.011</ArticleId><ArticleId IdType="pubmed">17092694</ArticleId></ArticleIdList></Reference><Reference><Citation>Warman D. M., Martin J. M.
2006. 
Cognitive insight and delusion proneness: an investigation using the Beck cognitive insight scale. Schizophr. Res.
84, 297&#x2013;30410.1016/j.schres.2006.02.004 (doi:10.1016/j.schres.2006.02.004)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2006.02.004</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2006.02.004</ArticleId><ArticleId IdType="pubmed">16545944</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin J. M., Warman D. M., Lysaker P. H.
2010. 
Cognitive insight in non-psychiatric individuals and individuals with psychosis: an examination using the Beck cognitive insight scale. Schizophr. Res.
121, 39&#x2013;4510.1016/j.schres.2010.03.028 (doi:10.1016/j.schres.2010.03.028)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2010.03.028</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2010.03.028</ArticleId><ArticleId IdType="pubmed">20399611</ArticleId></ArticleIdList></Reference><Reference><Citation>Engh J. A., Friis S., Birkenaes A., Jonsdottir H., Ringen P., Ruud T., Sundet K. S., Opjordsmoen S., Andreassen O. A.
2007. 
Measuring cognitive insight in schizophrenia and bipolar disorder: a comparative study. BMC Psychiat.
7, 71.10.1186/1471-244X-7-71 (doi:10.1186/1471-244X-7-71)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-244X-7-71</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-7-71</ArticleId><ArticleId IdType="pmc">PMC2222246</ArticleId><ArticleId IdType="pubmed">18072961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke M. A., Peters E. R., Fannon D., Aasen I., Kuipers E., Kumari V.
2010. 
Cognitive insight in psychosis: the relationship between self-certainty and self-reflection dimensions and neuropsychological measures. Psychiat. Res.
178, 284&#x2013;28910.1016/j.psychres.2009.05.009 (doi:10.1016/j.psychres.2009.05.009)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2009.05.009</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2009.05.009</ArticleId><ArticleId IdType="pmc">PMC3184477</ArticleId><ArticleId IdType="pubmed">20483170</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberger C., Serper M. R.
2010. 
Examination of clinical and cognitive insight in acute schizophrenia patients. J. Nerv. Ment. Dis.
198, 465&#x2013;46910.1097/NMD.0b013e3181e4f35d (doi:10.1097/NMD.0b013e3181e4f35d)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NMD.0b013e3181e4f35d</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e3181e4f35d</ArticleId><ArticleId IdType="pubmed">20611048</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepage M., Buchy L., Bodnar M., Bertrand M.-C., Joober R., Malla A.
2008. 
Cognitive insight and verbal memory in first episode of psychosis. Eur. Psychiat.
23, 368&#x2013;37410.1016/j.eurpsy.2008.02.003 (doi:10.1016/j.eurpsy.2008.02.003)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eurpsy.2008.02.003</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2008.02.003</ArticleId><ArticleId IdType="pubmed">18374546</ArticleId></ArticleIdList></Reference><Reference><Citation>Orfei M. D., Caltagirone C., Cacciari C., Assogna F., Spalletta G.
2011. 
The neuropsychological correlates of cognitive insight in healthy participants. App. Cogn. Psychol. 25, 927&#x2013;93210.1002/acp.1771 (doi:10.1002/acp.1771)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acp.1771</ArticleId><ArticleId IdType="doi">10.1002/acp.1771</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysaker P. H., Warman D. M., Dimaggio G., Procacci M., LaRocco V. A., Clark L. K., Dike C. A., Nicolo G.
2008. 
Metacognition in schizophrenia: associations with multiple assessments of executive function. J. Nerv. Ment. Dis.
196, 384&#x2013;38910.1097/NMD.0b013e3181710916 (doi:10.1097/NMD.0b013e3181710916)</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NMD.0b013e3181710916</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e3181710916</ArticleId><ArticleId IdType="pubmed">18477880</ArticleId></ArticleIdList></Reference><Reference><Citation>Orfei M. D., Spoletini I., Banfi G., Caltagirone C., Spalletta G.
2010. 
Neuropsychological correlates of cognitive insight in schizophrenia. Psychiat. Res.
178, 51&#x2013;5610.1016/j.psychres.2009.05.013 (doi:10.1016/j.psychres.2009.05.013)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2009.05.013</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2009.05.013</ArticleId><ArticleId IdType="pubmed">20452049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiffen B. D. R., O'Connor J. A., Russo M., Falcone A., Sood P., Taylor H., Aas M., Murray R. M., David A. S. In preparation The neuropsychological basis of cognitive insight in first episode psychosis and healthy controls.</Citation></Reference><Reference><Citation>Colis M., Steer R., Beck A. T.
2006. 
Cognitive insight in inpatients with psychotic, bipolar, and major depressive disorders. J. Psychopathol. Behav. Assess.
28, 242&#x2013;24910.1007/s10862-005-9012-7 (doi:10.1007/s10862-005-9012-7)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10862-005-9012-7</ArticleId><ArticleId IdType="doi">10.1007/s10862-005-9012-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford N. J.
2009. 
Denial of illness in schizophrenia as a disturbance of insight and self-awareness. Schizophrenia&#x2014;academic dissertations [MESH]. Institute of Psychiatry Theses PhD,
University of London; 
System No 001296598. pp. 361. See http://library.kcl.ac.uk/</Citation></Reference><Reference><Citation>Bedford N., David A.
2008. 
Impression management of deficiencies and denial of illness in schizophrenia: reluctance to expose mental illness unmoderated by its level of advantageousness. Schizophr. Res.
102(suppl 2), 117.10.1016/S0920-9964(08)70353-0 (doi:10.1016/S0920-9964(08)70353-0)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0920-9964(08)70353-0</ArticleId><ArticleId IdType="doi">10.1016/S0920-9964(08)70353-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford N., David A. 2009. Poor insight in psychosis: cognitive deficit or bias? Schizophr. Bull. 35(suppl 1), 281</Citation></Reference><Reference><Citation>Pronin E.
2008. 
How we see ourselves and how we see others. Science
320, 1177&#x2013;118010.1126/science.1154199 (doi:10.1126/science.1154199)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154199</ArticleId><ArticleId IdType="doi">10.1126/science.1154199</ArticleId><ArticleId IdType="pubmed">18511681</ArticleId></ArticleIdList></Reference><Reference><Citation>Flashman L. A., McAllister T. W., Andreasen N. C., Saykin A. J.
2000. 
Smaller brain size associated with unawareness of illness in patients with schizophrenia. Am. J. Psychiat.
157, 1167&#x2013;116910.1176/appi.ajp.157.7.1167 (doi:10.1176/appi.ajp.157.7.1167)</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.157.7.1167</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.157.7.1167</ArticleId><ArticleId IdType="pubmed">10873930</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy J. P., Johnson J., Perkins D., Lieberman J. A., Hamer R. M., Keefe R. S., Tohen M., Glick I. D., Sharma T.
2006. 
Insight in first-episode psychosis. Psychol. Med.
36, 1385&#x2013;139310.1017/S0033291706007793 (doi:10.1017/S0033291706007793)</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291706007793</ArticleId><ArticleId IdType="doi">10.1017/S0033291706007793</ArticleId><ArticleId IdType="pubmed">16740175</ArticleId></ArticleIdList></Reference><Reference><Citation>Takai A., Uematsu M., Ueki H., Sone H., Kaiya H. 1992. Insight and its related factors in chronic schizophrenic patients: a preliminary study. Eur. J. Psychiat. 6, 159&#x2013;170</Citation></Reference><Reference><Citation>Laroi F., Fannemel M., Ronneberg U., Flekkoy K., Opjordsmoen S., Dullerud R., Haakonsen M.
2000. 
Unawareness of illness in chronic schizophrenia and its relationship to structural brain measures and neuropsychological tests. Psychiat. Res.
100, 49&#x2013;5810.1016/S0925-4927(00)00063-9 (doi:10.1016/S0925-4927(00)00063-9)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4927(00)00063-9</ArticleId><ArticleId IdType="doi">10.1016/S0925-4927(00)00063-9</ArticleId><ArticleId IdType="pubmed">11090725</ArticleId></ArticleIdList></Reference><Reference><Citation>Flashman L. A., McAllister T. W., Johnson S. C., Rick J. H., Green R. L., Saykin A. J.
2001. 
Specific frontal lobe subregions correlated with unawareness of illness in schizophrenia: a preliminary study. J. Neuropsychiatr. Clin. Neurosci.
13, 255&#x2013;25710.1176/appi.neuropsych.13.2.255 (doi:10.1176/appi.neuropsych.13.2.255)</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.neuropsych.13.2.255</ArticleId><ArticleId IdType="doi">10.1176/appi.neuropsych.13.2.255</ArticleId><ArticleId IdType="pubmed">11449033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapara A., et al. 
2007. 
Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr. Res.
89, 22&#x2013;3410.1016/j.schres.2006.09.016 (doi:10.1016/j.schres.2006.09.016)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2006.09.016</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2006.09.016</ArticleId><ArticleId IdType="pubmed">17097853</ArticleId></ArticleIdList></Reference><Reference><Citation>Shad M. U., Muddasani S., Keshavan M. S.
2006. 
Prefrontal subregions and dimensions of insight in first-episode schizophrenia&#x2014;a pilot study. Psychiat. Res.
146, 35&#x2013;4210.1016/j.pscychresns.2005.11.001 (doi:10.1016/j.pscychresns.2005.11.001)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2005.11.001</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2005.11.001</ArticleId><ArticleId IdType="pubmed">16361089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha T., Youn T., Ha K., Rho K., Lee J., Kim I., Kim S., Kwon J.
2004. 
Grey matter abnormalities in paranoid schizophrenia and their clinical correlations. Psychiat. Res. Neuroimag.
132, 251&#x2013;26010.1016/j.pscychresns.2004.05.001 (doi:10.1016/j.pscychresns.2004.05.001)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2004.05.001</ArticleId><ArticleId IdType="doi">10.1016/j.pscychresns.2004.05.001</ArticleId><ArticleId IdType="pubmed">15664796</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke M.A., Fannon D., Kuipers E., Peters E., Williams S.C., Kumari V.
2008. 
Neurological basis of poor insight in psychosis: a voxel-based MRI study. Schizophr. Res.
103, 40&#x2013;5110.1016/j.schres.2008.04.022 (doi:10.1016/j.schres.2008.04.022)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2008.04.022</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2008.04.022</ArticleId><ArticleId IdType="pmc">PMC2845803</ArticleId><ArticleId IdType="pubmed">18539438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassitt D. P., Neto M. R. L., de Castro C. C., Busatto G. F.
2007. 
Insight and regional brain volumes in schizophrenia. Eur. Arch. Psychiat. Clin. Neurosci.
257, 58&#x2013;6210.1007/s00406-006-0685-z (doi:10.1007/s00406-006-0685-z)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-006-0685-z</ArticleId><ArticleId IdType="doi">10.1007/s00406-006-0685-z</ArticleId><ArticleId IdType="pubmed">16960651</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonius D., Prudent V., Rebani Y., D'Angelo D., Ardekani B.A., Malaspina D., Hoptman M.J.
2011. 
White matter integrity and lack of insight in schizophrenia and schizoaffective disorder. Schizophr. Res.
128, 76&#x2013;8210.1016/j.schres.2011.02.020 (doi:10.1016/j.schres.2011.02.020)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2011.02.020</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2011.02.020</ArticleId><ArticleId IdType="pmc">PMC3085627</ArticleId><ArticleId IdType="pubmed">21429714</ArticleId></ArticleIdList></Reference><Reference><Citation>Berge D., Carmona S., Rovira M., Bulbena A., Salgado P., Vilarroya O.
2010. 
Gray matter volume deficits and correlation with insight and negative symptoms in first-psychotic-episode subjects. Acta. Psychiatr. Scand.
123, 1&#x2013;910.1111/j.1600-0447.2010.01635.x (doi:10.1111/j.1600-0447.2010.01635.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.2010.01635.x</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2010.01635.x</ArticleId><ArticleId IdType="pubmed">21054282</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchy L., Ad-Dab'bagh Y., Malla A., Lepage C., Bodnar M., Joober R., Sergerie K., Evans A., Lepage M.
2010. 
Cortical thickness is associated with poor insight in first-episode psychosis. J. Psychiat. Res.
45, 781&#x2013;78710.1016/j.jpsychires.2010.10.016 (doi:10.1016/j.jpsychires.2010.10.016)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2010.10.016</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2010.10.016</ArticleId><ArticleId IdType="pubmed">21092987</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan K. D., et al. 
2010. 
Insight, grey matter and cognitive function in first-onset psychosis. Brit. J. Psychiat.
197, 141&#x2013;14810.1192/bjp.bp.109.070888 (doi:10.1192/bjp.bp.109.070888)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.109.070888</ArticleId><ArticleId IdType="doi">10.1192/bjp.bp.109.070888</ArticleId><ArticleId IdType="pubmed">20679268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz T. W., Johnson S. C.
2007. 
Relevance to self: a brief review and framework of neural systems underlying appraisal. Neurosci. Biobehav. Rev.
31, 585&#x2013;59610.1016/j.neubiorev.2006.12.003 (doi:10.1016/j.neubiorev.2006.12.003)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2006.12.003</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2006.12.003</ArticleId><ArticleId IdType="pmc">PMC1973156</ArticleId><ArticleId IdType="pubmed">17418416</ArticleId></ArticleIdList></Reference><Reference><Citation>Northoff G., Heinzel A., de Greck M., Bermpohl F., Dobrowolny H., Panksepp J.
2006. 
Self-referential processing in our brain&#x2013;a meta-analysis of imaging studies on the self. Neuroimage
31, 440&#x2013;45710.1016/j.neuroimage.2005.12.002 (doi:10.1016/j.neuroimage.2005.12.002)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2005.12.002</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2005.12.002</ArticleId><ArticleId IdType="pubmed">16466680</ArticleId></ArticleIdList></Reference><Reference><Citation>Berti A., Bottini G., Gandola M., Pia L., Smania N., Stracciari A., Castiglioni I., Vallar G., Paulesu E.
2005. 
Shared cortical anatomy for motor awareness and motor control. Science
309, 488&#x2013;49110.1126/science.1110625 (doi:10.1126/science.1110625)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110625</ArticleId><ArticleId IdType="doi">10.1126/science.1110625</ArticleId><ArticleId IdType="pubmed">16020740</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming S. M., Weil R. S., Nagy Z., Dolan R. J., Rees G.
2010. 
Relating introspective accuracy to individual differences in brain structure. Science
329, 1541&#x2013;154310.1126/science.1191883 (doi:10.1126/science.1191883)</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1191883</ArticleId><ArticleId IdType="doi">10.1126/science.1191883</ArticleId><ArticleId IdType="pmc">PMC3173849</ArticleId><ArticleId IdType="pubmed">20847276</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meer L., Costafreda S. C., Aleman A., David A. S.
2010. 
Self-reflection and the brain: a theoretical review and meta-analysis of neuroimaging studies with implications for schizophrenia. Neurosci. Biobehav. Rev.
34, 935&#x2013;4610.1016/j.neubiorev.2009.12.004 (doi:10.1016/j.neubiorev.2009.12.004)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2009.12.004</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2009.12.004</ArticleId><ArticleId IdType="pubmed">20015455</ArticleId></ArticleIdList></Reference><Reference><Citation>David A. S., Bedford N., Gilleen J., Greenwood K., Morgan K., Wiffen B. 2001. The etiology of lack of insight in schizophrenia. Schizophr. Bull. 37(suppl 1), 14</Citation></Reference><Reference><Citation>Holt D. J., Cassidy B. S., Andrews-Hanna J. R., Lee S. M., Coombs G., Goff D. C., Gabrieli J. D., Moran J. M.
2011. 
An anterior-to-posterior shift in midline cortical activity in schizophrenia during self-reflection. Biol. Psychiat.
69, 415&#x2013;42310.1016/j.biopsych.2010.10.003 (doi:10.1016/j.biopsych.2010.10.003)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2010.10.003</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2010.10.003</ArticleId><ArticleId IdType="pmc">PMC3740539</ArticleId><ArticleId IdType="pubmed">21144498</ArticleId></ArticleIdList></Reference><Reference><Citation>Modinos G., Renken R., Ormel J., Aleman A.
2011. 
Self-reflection and the psychosis-prone brain: an fMRI study. Neuropsychology
25, 295&#x2013;30510.1037/a0021747 (doi:10.1037/a0021747)</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0021747</ArticleId><ArticleId IdType="doi">10.1037/a0021747</ArticleId><ArticleId IdType="pubmed">21443341</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson T. O., Narens L. 1990. Metamemory: a theoretical framework and some new findings. In The psychology of learning and motivation, vol. 26 (ed. Bower G. H.), pp. 125&#x2013;173 San Diego, CA: Academic Press</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22483294</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1996-3181</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>CNS &amp; neurological disorders drug targets</Title><ISOAbbreviation>CNS Neurol Disord Drug Targets</ISOAbbreviation></Journal><ArticleTitle>Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings.</ArticleTitle><Pagination><StartPage>299</StartPage><EndPage>305</EndPage><MedlinePgn>299-305</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is the leading cause of dementia worldwide and is associated with a marked individual, familial and social burden. Catechol-O-mehyltransferase (COMT) is surfacing with a prominent role in AD pathophysiology by affecting the metabolism of catecholamine neurotransmitters and estrogen. COMT gene regulates dopamine levels in the prefrontal cortex which are involved in working memory and executive functioning. Impaired executive functioning is reported in a subgroup of AD patients and is associated with a more severe disorder, a more rapid disease progression and a shorter survival. The COMT rs4680 gene polymorphism has been investigated as a susceptibility factor for AD. No statistically significant results were found in meta-analysis but one study reported that the rs4680 Val allele was associated with AD-related psychosis. The COMT rs4680 polymorphism was also found to modulate declarative episodic memory in normal people and schizophrenic subjects. COMT inhibitors, that are adjunctive drugs in Parkinson's disease treatment, lower homocysteine levels and improve executive memory processes in normal subjects. A preliminary study, which needs replication, demonstrates that COMT inhibitors block beta-amyloid fibrils in vitro. Taken together, these findings suggest that research should focus on the role of COMT in AD pathogenesis and on the feasibility of targeting COMT activity in AD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, University of Bologna, Italy. alessandro.serretti@unibo.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olgiati</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>CNS Neurol Disord Drug Targets</MedlineTA><NlmUniqueID>101269155</NlmUniqueID><ISSNLinking>1871-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22483294</ArticleId><ArticleId IdType="doi">10.2174/187152712800672472</ArticleId><ArticleId IdType="pii">CDTCNSND-EPUB-20120404-003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22453181</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1933-690X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Prion</Title><ISOAbbreviation>Prion</ISOAbbreviation></Journal><ArticleTitle>PRND 3'UTR polymorphism may be associated with behavioral disturbances in Alzheimer disease.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>80</EndPage><MedlinePgn>73-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4161/pri.6.1.18428</ELocationID><Abstract><AbstractText>The etiology of behavioral and psychological symptoms of dementia (BPSD) is complex, including putative biological, psychological, social and environmental factors. Recent years have witnessed accumulation of data on the association between genetic factors and behavioral abnormalities in Alzheimer disease (AD). In this research paper, our aim is to evaluate the association between the APOE, CYP46, PRNP and PRND genes and the profile of neuropsychiatric symptoms in Polish subjects with AD and mild cognitive impairment (MCI). We studied 99 patients with AD and 48 subjects with MCI. The presence and profile of BPSD were evaluated at baseline and prospectively with the Neuropsychiatric Inventory (NPI). Patients were dichotomized into those having ever experienced a particular symptom and those who did not over the whole disease period. Genotyping was performed using previously described standard protocols. The prevalence of comorbid behavioral symptoms and the overall level of behavioral burden were significantly greater in AD compared with the MCI group. In AD patients, carrier status of the T allele of the 3'UTR (untranslated region) PRND polymorphism was associated with an increased cumulative behavioral load and an elevated risk for delusions, anxiety, agitation/aggression, apathy and irritability/emotional ability. Among MCI subjects, APOE &#x3b5;4 carriers demonstrated a reduced risk for nighttime behavior change. No other statistically significant genotype-phenotype correlations were observed, including the APOE, CYP46 and PRNP genes. A precise estimation of the exact significance of particular polymorphisms in BPSD etiology requires future studies on large populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Lodz, Poland. marcin.flirski@umed.lodz.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sieruta</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gola&#x144;ska</LastName><ForeName>Ewa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawe&#x142; P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prion</MedlineTA><NlmUniqueID>101472305</NlmUniqueID><ISSNLinking>1933-6896</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501125">PRND protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020413" MajorTopicYN="N">3' Untranslated Regions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22453181</ArticleId><ArticleId IdType="pmc">PMC3338968</ArticleId><ArticleId IdType="doi">10.4161/pri.6.1.18428</ArticleId><ArticleId IdType="pii">18428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics and memory study. Neuroepidemiology. 2007;29:125&#x2013;132. doi: 10.1159/000109998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109998</ArticleId><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez M, Gobartt AL, Bala&#xf1;&#xe1; M COOPERA Study Group, author. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol. 2010;10:87. doi: 10.1186/1471-2377-10-87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-10-87</ArticleId><ArticleId IdType="pmc">PMC2955564</ArticleId><ArticleId IdType="pubmed">20920205</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62:1199&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15079026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry. 2008;20:396&#x2013;404. doi: 10.1080/09540260802099968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540260802099968</ArticleId><ArticleId IdType="pubmed">18925489</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res. 2010;7:158&#x2013;164. doi: 10.2174/156720510790691173.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510790691173</ArticleId><ArticleId IdType="pubmed">19715553</ArticleId></ArticleIdList></Reference><Reference><Citation>Flirski M, Sobow T, Kloszewska I. Behavioural genetics of Alzheimer's disease: a comprehensive review. Arch Med Sci. 2011;2:195&#x2013;210. doi: 10.5114/aoms.2011.22068.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2011.22068</ArticleId><ArticleId IdType="pmc">PMC3258720</ArticleId><ArticleId IdType="pubmed">22291757</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303. doi: 10.1016/j.neuron.2009.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.06.026</ArticleId><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, L&#xfc;tjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27&#x2013;32. doi: 10.1016/S0022-3956(01)00050-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3956(01)00050-4</ArticleId><ArticleId IdType="pubmed">11755458</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia AN, Muniz MT, Souza e Silva HR, da Silva HA, Athayde-Junior L. Cyp46 polymorphisms in Alzheimer's disease: a review. J Mol Neurosci. 2009;39:342&#x2013;345. doi: 10.1007/s12031-009-9227-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-009-9227-2</ArticleId><ArticleId IdType="pubmed">19705089</ArticleId></ArticleIdList></Reference><Reference><Citation>Golanska E, Hulas-Bigoszewska K, Wojcik I, Rieske P, Styczynska M, Peplonska B, et al. CYP46: a risk factor for Alzheimer's disease or a coincidence? Neurosci Lett. 2005;383:105&#x2013;108. doi: 10.1016/j.neulet.2005.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.03.049</ArticleId><ArticleId IdType="pubmed">15936520</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352:340&#x2013;342. doi: 10.1038/352340a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352340a0</ArticleId><ArticleId IdType="pubmed">1677164</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Wollmer MA, Aguzzi A, Hock C, Nitsch RM, de Quervain DJ. The prion gene is associated with human long-term memory. Hum Mol Genet. 2005;14:2241&#x2013;2246. doi: 10.1093/hmg/ddi228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi228</ArticleId><ArticleId IdType="pubmed">15987701</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorell L, Valero J, Mulet B, Guti&#xe9;rrez-Zotes A, Cort&#xe9;s MJ, Jariod M, et al. M129V variation in the prion protein gene and psychotic disorders: relationship to neuropsychological and psychopathological measures. J Psychiatr Res. 2007;41:885&#x2013;892. doi: 10.1016/j.jpsychires.2006.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2006.07.003</ArticleId><ArticleId IdType="pubmed">16949098</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging. 2006;27:7701&#x2013;7705.</Citation><ArticleIdList><ArticleId IdType="pubmed">16099550</ArticleId></ArticleIdList></Reference><Reference><Citation>Peoc'h K, Gu&#xe9;rin C, Brandel JP, Launay JM, Laplanche JL. First report of polymorphisms in the prion-like protein gene (PRND): implications for human prion diseases. Neurosci Lett. 2000;286:144&#x2013;148. doi: 10.1016/S0304-3940(00)01100-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01100-9</ArticleId><ArticleId IdType="pubmed">10825657</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead S, Beck J, Dickinson A, Fisher EM, Collinge J. Examination of the human prion protein-like gene doppel for genetic susceptibility to sporadic and variant Creutzfeldt-Jakob disease. Neurosci Lett. 2000;290:117&#x2013;120. doi: 10.1016/S0304-3940(00)01319-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01319-7</ArticleId><ArticleId IdType="pubmed">10936691</ArticleId></ArticleIdList></Reference><Reference><Citation>Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, Styczynska M, Peplonska B, Barcikowska M, et al. Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD. Neurology. 2004;62:313&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745079</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Agosti C, Costanzi C, Archetti S, Franzoni S, et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging. 2006;27:1595&#x2013;603. doi: 10.1016/j.neurobiolaging.2005.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.029</ArticleId><ArticleId IdType="pubmed">16257094</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78:123&#x2013;126. doi: 10.1136/jnnp.2006.092122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.092122</ArticleId><ArticleId IdType="pmc">PMC2077651</ArticleId><ArticleId IdType="pubmed">16980336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, et al. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology. 2007;32:171&#x2013;179. doi: 10.1038/sj.npp.1301148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1301148</ArticleId><ArticleId IdType="pubmed">16841077</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Russ C, Kirov G, Aitchison KJ, Powell JF, Collier DA, et al. Apolipoprotein E: depressive illness, depressive symptoms and Alzheimer's disease. Biol Psychiatry. 1998;43:159&#x2013;164. doi: 10.1016/S0006-3223(97)00326-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3223(97)00326-0</ArticleId><ArticleId IdType="pubmed">9494696</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, Passmore AP. Genetically increased risk of sleep disruption in Alzheimer's disease. Sleep. 2006;29:1003&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">16944667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Friedman L, Kraemer H, Tinklenberg JR, Salehi A, Noda A, et al. Sleep/wake disruption in Alzheimer's disease: APOE status and longitudinal course. J Geriatr Psychiatry Neurol. 2004;17:20&#x2013;24. doi: 10.1177/0891988703261994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988703261994</ArticleId><ArticleId IdType="pubmed">15018693</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopa EG, Volicer L, Kuo-Leblanc V, Harper D, Lathi D, Tate B, et al. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol. 1999;58:29&#x2013;39. doi: 10.1097/00005072-199901000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199901000-00004</ArticleId><ArticleId IdType="pubmed">10068311</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;der B, Franz B, Hempfling P, Selbert M, J&#xfc;rgens T, Kretzschmar HA, et al. Polymorphisms within the prion-like protein gene (Prnd) and their implications in human prion diseases, Alzheimer's disease and other neurological disorders. Hum Genet. 2001;109:319&#x2013;325. doi: 10.1007/s004390100591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004390100591</ArticleId><ArticleId IdType="pubmed">11702213</ArticleId></ArticleIdList></Reference><Reference><Citation>Infante J, Llorca J, Rodero L, Palacio E, Berciano J, Combarros O. Polymorphism at codon 174 of the prion-like protein gene is not associated with sporadic Alzheimer's disease. Neurosci Lett. 2002;332:213&#x2013;215. doi: 10.1016/S0304-3940(02)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(02)00941-2</ArticleId><ArticleId IdType="pubmed">12399017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Freixas M, Blanco R, Carmona M, Puig B. Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer's disease. Neuropathol Appl Neurobiol. 2004;30:329&#x2013;337. doi: 10.1111/j.1365-2990.2003.00534.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2003.00534.x</ArticleId><ArticleId IdType="pubmed">15305978</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore RC, Lee IY, Silverman GL, Harrison PM, Strome R, Heinrich C, et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol. 1999;292:797&#x2013;817. doi: 10.1006/jmbi.1999.3108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1999.3108</ArticleId><ArticleId IdType="pubmed">10525406</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;308. doi: 10.1001/archneur.56.3.303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.56.3.303</ArticleId><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9:173&#x2013;176. doi: 10.1017/S1041610297004870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610297004870</ArticleId><ArticleId IdType="pubmed">9447441</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman J, Estupi&#xf1;an J, Asherov A, Goldfarb LG. A simple and efficient method for apolipoprotein E genotype determination. Neurology. 1996;46:1484&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">8628509</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, et al. Increased brain beta-amyloid load, phosphorylated tau and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol. 2003;60:29&#x2013;35. doi: 10.1001/archneur.60.1.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.60.1.29</ArticleId><ArticleId IdType="pubmed">12533085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22452126</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2012</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0342-9601</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Medizinische Monatsschrift fur Pharmazeuten</Title><ISOAbbreviation>Med Monatsschr Pharm</ISOAbbreviation></Journal><ArticleTitle>[Medication review for dementia patients].</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>103</EndPage><MedlinePgn>95-103</MedlinePgn></Pagination><Abstract><AbstractText>Due to demographic changes we are faced with several challenges as an increasing prevalence of dementia patients. We report on a medication review of a patient with Alzheimer's disease as well as Lewy body dementia. The intake of risperidone was interrupted instead of a dose reduction which was recommended by the psychiatrist to improve mobility. As an adverse event the patient developed serious psychiatric symptoms which were treated in an acute care facility. We discussed several alternative treatment options (pipamperon, melperon, haloperidol, risperidone, clozapine, olanzapine, aripiprazol, and quetiapin) in a case conference. Due to a short half life period and insignificant anticholinergic effects we decided to choose quetiapin. Despite a small number of taken drugs we identified several potential drug related problems which were solved in a multipartite health care professional team.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jahns</LastName><ForeName>Karl-Peter</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Ernst-Moritz-Arndt-Universit&#xe4;t Greifswald, Institut f&#xfc;r Pharmazie, Friedrich-Ludwig-Jahn-Strasse 17, 17487 Greifswald.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilimann</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ritter</LastName><ForeName>Christoph A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Teipel</LastName><ForeName>Stefan J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Fiss</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Medikationsreview in der psychiatrischen Institutsambulanz.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Med Monatsschr Pharm</MedlineTA><NlmUniqueID>7802665</NlmUniqueID><ISSNLinking>0342-9601</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22452126</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22429885</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>12</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>&#x3b2;-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis.</ArticleTitle><Pagination><StartPage>2807</StartPage><EndPage>2816</EndPage><MedlinePgn>2807-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2012.02.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(12)00160-1</ELocationID><Abstract><AbstractText>Psychosis in Alzheimer disease differentiates a subgroup with more rapid decline, is heritable, and aggregates within families, suggesting a distinct neurobiology. Evidence indicates that greater impairments of cerebral cortical synapses, particularly in dorsolateral prefrontal cortex, may contribute to the pathogenesis of psychosis in Alzheimer disease (AD) phenotype. Soluble &#x3b2;-amyloid induces loss of dendritic spine synapses through impairment of long-term potentiation. In contrast, the Rho guanine nucleotide exchange factor (GEF) kalirin is an essential mediator of spine maintenance and growth in cerebral cortex. We therefore hypothesized that psychosis in AD would be associated with increased soluble &#x3b2;-amyloid and reduced expression of kalirin in the cortex. We tested this hypothesis in postmortem cortical gray matter extracts from 52 AD subjects with and without psychosis. In subjects with psychosis, the &#x3b2;-amyloid(1-42)/&#x3b2;-amyloid(1-40) ratio was increased, due primarily to reduced soluble &#x3b2;-amyloid(1-40), and kalirin-7, -9, and -12 were reduced. These findings suggest that increased cortical &#x3b2;-amyloid(1-42)/&#x3b2;-amyloid(1-40) ratio and decreased kalirin expression may both contribute to the pathogenesis of psychosis in AD.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Patrick S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkwood</LastName><ForeName>Caitlin M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Megan C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Paljug</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Abrahamson</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Henteleff</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Kofler</LastName><ForeName>Julia K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Penzes</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027224-05</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019986</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449-14</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX000452</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019986-13</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH071316</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P50AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32MH019986</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5P01AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-29</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020662">Guanine Nucleotide Exchange Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C503866">KALRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020662" MajorTopicYN="N">Guanine Nucleotide Exchange Factors</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22429885</ArticleId><ArticleId IdType="mid">NIHMS360867</ArticleId><ArticleId IdType="pmc">PMC3381843</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.02.015</ArticleId><ArticleId IdType="pii">S0197-4580(12)00160-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alam MR, Johnson RC, Darlington DN, Hand TA, Mains RE, Eipper BA. Kalirin, a cytosolic protein with spectrin-like and GDP/GTP exchange factor-like domains that interacts with peptidylglycine -amidating monooxygenase, an integral membrane peptide-processing enzyme. J Biol Chem. 1997;272(19):12667&#x2013;12675.</Citation><ArticleIdList><ArticleId IdType="pubmed">9139723</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20(2):187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(7):624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Brain. 2008;131(9):2455&#x2013;2463.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill ME, Xie Z, Day M, Photowala H, Barbolina MV, Miller CA, Weiss C, Radulovic J, Sweatt JD, Disterhoft JF. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. Proc Natl Acad Sci U S A. 2009;106(31):13058&#x2013;13063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722269</ArticleId><ArticleId IdType="pubmed">19625617</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerione RA, Zheng Y. The Dbl family of oncogenes. Curr Opin Cell Biol. 1996;8(2):216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8791419</ArticleId></ArticleIdList></Reference><Reference><Citation>Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol. 2006;65(6):592&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by amyloid precursor protein fragments. Neuroreport. 1997;8(15):3213&#x2013;3217.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351645</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Deo AJ, Cahill ME, Li S, Goldszer I, Henteleff R, VanLeeuwen JE, Rafalovich I, Gao R, Stachowski EK, Sampson AR. Increased Expression of Kalirin-9 in the Auditory Cortex of Schizophrenia Subjects: Its Role in Dendritic Pathology. Neurobiol Dis. 2011 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259283</ArticleId><ArticleId IdType="pubmed">22120753</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, DeMichele-Sweet MAA, Kuller L, Sweet RA. Trajectory of Cognitive Decline as a Predictor of Psychosis in Early Alzheimer Disease in the Cardiovascular Health Study. Am J Geriatr Psychiatry. 2011;19(2):160&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000865</ArticleId><ArticleId IdType="pubmed">20808116</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB, Rubin EH, Newcomer JW, Kinscherf DA, Miller JP, Morris JC, Olney JW, McKeel DW., Jr Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57(12):1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">11115331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, Suzuki N, Younkin SG. Amyloid beta protein (A beta) in Alzheimer&#x2019;s disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43) J Biol Chem. 1995;270(13):7013&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706234</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J, Helmin K, Tsai J, Gan WB. Various Dendritic Abnormalities Are Associated with Fibrillar Amyloid Deposits in Alzheimer&#x2019;s Disease. Ann N Y Acad Sci. 2007;1097(1):30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci U S A. 1999;96(6):3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(6):1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2006;103(13):5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Duffy LK, Morris JH, Selkoe DJ. Protein chemical and immunocytochemical studies of meningovascular [beta]-amyloid protein in Alzheimer&#x2019;s disease and normal aging. Brain Res. 1988;474(1):100&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">3214703</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RC, Penzes P, Eipper BA, Mains RE. Isoforms of kalirin, a neuronal Dbl family member, generated through use of different 5 -and 3 -ends along with an internal translational initiation site. J Biol Chem. 2000;275(25):19324&#x2013;19333.</Citation><ArticleIdList><ArticleId IdType="pubmed">10777487</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashani A, Lepicard, Poirel O, Videau C, David J, Fallet-Bianco C, Simon A, Delacourte A, Giros B, Epelbaum J. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging. 2008;29(11):1619&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27(3):627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM. Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106(10):4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R. SPECT findings on psychosis in Alzheimer&#x2019;s disease. Am J Psychiatry. 1995;152(10):1470&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pubmed">7573586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V. Neurotoxicity of Alzheimer&#x2019;s disease A peptides is induced by small changes in the A 42 to A 40 ratio. The EMBO journal. 2010;29(19):3408&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56(10):1266&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M. Factors critical for the plasticity of dendritic spines and memory storage. Neurosci Res. 2007;57(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17070951</ArticleId></ArticleIdList></Reference><Reference><Citation>May V, Schiller MR, Eipper BA, Mains RE. Kalirin Dbl-homology guanine nucleotide exchange factor 1 domain initiates new axon outgrowths via RhoG-mediated mechanisms. J Neurosci. 2002;22(16):6980&#x2013;6990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757900</ArticleId><ArticleId IdType="pubmed">12177196</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H. Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">14693108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2000;69(2):167&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737034</ArticleId><ArticleId IdType="pubmed">10896687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L. The consortium to establish a registry for Alzheimer&#x2019;s disease (CERAD) Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray MM, Bernstein SL, Nyugen V, Condron MM, Teplow DB, Bowers MT. Amyloid protein: A&#x3b2;40 inhibits A&#x3b2;42 oligomerization. J Am Chem Soc. 2009;131(18):6316&#x2013;6317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697393</ArticleId><ArticleId IdType="pubmed">19385598</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid -peptide in the brain and cognitive decline. JAMA: The Journal of the American Medical Association. 2000;283(12):1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon D, Thal L, Romero R, Weisstein&#x2013;Jenkins C, Galasko D, Hofstetter C, Thomas R, Grant I, Jeste D. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Beeser A, Chernoff J, Schiller MR, Eipper BA, Mains RE, Huganir RL. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron. 2003;37(2):263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12546821</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14(3):285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530413</ArticleId><ArticleId IdType="pubmed">21346746</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Johnson RC, Alam MR, Kambampati V, Mains RE, Eipper BA. An isoform of kalirin, a brain-specific GDP/GTP exchange factor, is enriched in the postsynaptic density fraction. J Biol Chem. 2000;275(9):6395&#x2013;6403.</Citation><ArticleIdList><ArticleId IdType="pubmed">10692441</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, VanLeeuwen JE. Impaired regulation of synaptic actin cytoskeleton in Alzheimer&#x2019;s disease. Brain Res Rev. 2011;67(1&#x2013;2):184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109125</ArticleId><ArticleId IdType="pubmed">21276817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakic P, Bourgeois JP, Eckenhoff MF, Zecevic N, Goldman-Rakic PS. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science. 1986;232(4747):232&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">3952506</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, Jr, Kaye JWW, Manczak M. Differential loss of synaptic proteins in Alzheimer&#x2019;s disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005;7(2):103&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11):2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida O. Soluble -amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25(48):11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62(10):1601&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Alzheimer&#x2019;s disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis. 2006;9:101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914849</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298(5594):789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid- protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27(11):2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA. Amyloid- protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff RT, Shanks MF, Macintosh L, Pestell SJ, Gemmell HG, Venneri A. Delusions in Alzheimer&#x2019;s disease: spet evidence of right hemispheric dysfunction. Cortex. 1999;35(4):549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">10574080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 1995;7(4):476&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">8555751</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am J Pathol. 1994;145(2):452&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887395</ArticleId><ArticleId IdType="pubmed">8053502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer&#x2019;s disease from the National Institute on Aging Late Onset Alzheimer&#x2019;s Disease Family Study. Brain. 2010;133(4):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Butters MA, Mulsant BH, Pollock BG, Lewis DA, Lopez OL, DeKosky ST, Reynolds CF. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology. 2004;29(12):2242&#x2013;2250.</Citation><ArticleIdList><ArticleId IdType="pubmed">15354182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, Lewis DA, DeKosky ST. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58(3):466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255451</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Lopez OL, Klunk WE, Wisniewski SR, Kaufer DI, Healy MT, DeKosky ST. Psychotic symptoms in Alzheimer&#x2019;s disease are not associated with more severe neuropathologic features. Int Psychogeriatr. 2000;12(4):547&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">11263720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002a;58(6):907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Panchalingam K, Pettegrew JW, McClure RJ, Hamilton RL, Lopez OL, Kaufer DI, DeKosky ST, Klunk WE. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002b;23(4):547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer&#x2019;s disease. The behavioral pathology committee of the consortium to establish a registry for Alzheimer&#x2019;s disease. Am J Psychiatry. 1995;152(9):1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer&#x2019;s disease. Neuron. 2004;44(1):181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA. Soluble oligomers of [beta] amyloid (1&#x2013;42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002;924(2):133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CC, Chawla F, Games D, Rydel RE, Freedman S, Schenk D, Young WG, Morrison JH, Bloom FE. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci U S A. 2004;101(18):7141&#x2013;7146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC406479</ArticleId><ArticleId IdType="pubmed">15118092</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Srivastava DP, Photowala H, Kai L, Cahill ME, Woolfrey KM, Shum CY, Surmeier DJ, Penzes P. Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines. Neuron. 2007;56(4):640&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118058</ArticleId><ArticleId IdType="pubmed">18031682</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn HS, Jeoung MK, Koo YB, Ji H, Markesbery WR, Ji I, Ji TH. Kalirin is under-expressed in Alzheimer&#x2019;s disease hippocampus. J Alzheimers Dis. 2007a;11(3):385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">17851188</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn HS, Ji I, Ji HP, Markesbery WR, Ji TH. Under-expression of kalirin-7 increases iNOS activity in cultured cells and correlates to elevated iNOS activity in Alzheimer&#x2019;s disease hippocampus. J Alzheimers Dis. 2007b;12(3):271&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nature. 2006;9:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415866</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22422615</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms.</ArticleTitle><Pagination><StartPage>135</StartPage><EndPage>141</EndPage><MedlinePgn>135-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.3799</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Caring for people with dementia incurs significant stress for carers. Stress has been related to the duration of caring role, the number of weekly hours provided and severity of cognitive impairment. What remains less clear is the impact of neuropsychiatric symptoms and subtype of dementia on carer stress and this study aimed to examine these.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Dementia carers were recruited for people with a range of dementia subtypes. Carers were interviewed using the Neuropsychiatric Inventory with the Carer Distress Scale. Cognitive fluctuations were assessed using the Dementia Cognitive Fluctuations Scale. All patients were also examined with The Cambridge Assessment for mental disorders in the elderly.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dementia diagnostic subtype, the presence of cognitive fluctuations and some neuropsychiatric symptoms (psychosis and mood disturbance) did predict carer stress (all at p&#x2009;&lt;&#x2009;0.01) but age, gender and severity of cognitive impairment did not (all p&#x2009;&gt;&#x2009;0.33). Carers of people with dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) experienced more stress than those caring for patients with Alzheimer's disease and vascular dementia. Carer stress was associated with higher levels of psychosis, mood disturbances, daytime sleep and cognitive fluctuations in the person with dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study identified the significant impact on carers of providing care for people with DLB and PDD dementia subtypes and also highlighted the significant impact of providing care for patients with high levels of psychosis, mood disturbances and cognitive fluctuations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Institute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK. D.R.Lee@newcastle.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeith</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Mosimann</LastName><ForeName>Urs</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Ghosh-Nodyal</LastName><ForeName>Arunima</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22422615</ArticleId><ArticleId IdType="doi">10.1002/gps.3799</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22413500</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2012</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0047-1852</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nihon rinsho. Japanese journal of clinical medicine</Title><ISOAbbreviation>Nihon Rinsho</ISOAbbreviation></Journal><ArticleTitle>[Neurodegenerative diseases].</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>98</EndPage><MedlinePgn>94-8</MedlinePgn></Pagination><Abstract><AbstractText>Neurodegenerative diseases are characterized by pathological changes, neuronal loss and gliosis. These disease involved changes of neurotransmitter in central nervous system. In Alzheimer's disease, cholinergic neurons were depleted. In Parkinson's disease(PD), while several kinds of mediator were affected, dopaminergic neurons were mainly associated with motor and non-motor symptoms. Antipsychotic drugs may induce worsening of parkinsonism and neuroleptic malignant syndrome in PD and dementia Lewy bodies(DLB). Therefore, it is recommended to use atypical antipsychotic drugs, especially quetiapine, for treatment of psychosis in PD and DLB.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takanashi</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Juntendo University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Nobutaka</ForeName><Initials>N</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Rinsho</MedlineTA><NlmUniqueID>0420546</NlmUniqueID><ISSNLinking>0047-1852</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22413500</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22375104</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1662-5099</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2012</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>Frontiers in molecular neuroscience</Title><ISOAbbreviation>Front Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease-old wine in new bottles.</ArticleTitle><Pagination><StartPage>20</StartPage><MedlinePgn>20</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnmol.2012.00020</ELocationID><Abstract><AbstractText>The neuronal Ca(2+)-sensor (NCS) proteins VILIP-1 and VILIP-3 have been implicated in the etiology of Alzheimer's disease (AD). Genome-wide association studies (GWAS) show association of genetic variants of VILIP-1 (VSNL1) and VILIP-3 (HPCAL1) with AD+P (+psychosis) and late onset AD (LOAD), respectively. In AD brains the expression of VILIP-1 and VILIP-3 protein and mRNA is down-regulated in cortical and limbic areas. In the hippocampus, for instance, reduced VILIP-1 mRNA levels correlate with the content of neurofibrillary tangles (NFT) and amyloid plaques, the pathological characteristics of AD, and with the mini mental state exam (MMSE), a test for cognitive impairment. More recently, VILIP-1 was evaluated as a cerebrospinal fluid (CSF) biomarker and a prognostic marker for cognitive decline in AD. In CSF increased VILIP-1 levels correlate with levels of A&#x3b2;, tau, ApoE4, and reduced MMSE scores. These findings tie in with previous results showing that VILIP-1 is involved in pathological mechanisms of altered Ca(2+)-homeostasis leading to neuronal loss. In PC12 cells, depending on co-expression with the neuroprotective Ca(2+)-buffer calbindin D28K, VILIP-1 enhanced tau phosphorylation and cell death. On the other hand, VILIP-1 affects processes, such as cyclic nucleotide signaling and dendritic growth, as well as nicotinergic modulation of neuronal network activity, both of which regulate synaptic plasticity and cognition. Similar to VILIP-1, its interaction partner &#x3b1;4&#x3b2;2 nicotinic acetylcholine receptor (nAChR) is severely reduced in AD, causing severe cognitive deficits. Comparatively little is known about VILIP-3, but its interaction with cytochrome b5, which is part of an antioxidative system impaired in AD, hint toward a role in neuroprotection. A current hypothesis is that the reduced expression of visinin-like protein (VSNLs) in AD is caused by selective vulnerability of subpopulations of neurons, leading to the death of these VILIP-1-expressing neurons, explaining its increased CSF levels. While the Ca(2+)-sensor appears to be a good biomarker for the detrimental effects of A&#x3b2; in AD, its early, possibly A&#x3b2;-induced, down-regulation of expression may additionally attenuate neuronal signal pathways regulating the functions of dendrites and neuroplasticity, and as a consequence, this may contribute to cognitive decline in early AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braunewell</LastName><ForeName>Karl H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Molecular and Cellular Neuroscience Laboratory, Department Biochemistry and Molecular Biology, Southern Research Institute, Birmingham AL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Neurosci</MedlineTA><NlmUniqueID>101477914</NlmUniqueID><ISSNLinking>1662-5099</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MAPK pathways</Keyword><Keyword MajorTopicYN="N">cAMP/cGMP signaling</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">neurite outgrowth</Keyword><Keyword MajorTopicYN="N">neuronal Ca2+-sensors</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">nicotinic acetylcholine receptors</Keyword><Keyword MajorTopicYN="N">plasma membrane redox system</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22375104</ArticleId><ArticleId IdType="pmc">PMC3284765</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2012.00020</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ames J. B., Ishima R., Tanaka T., Gordon J. I., Stryer L., Ikura M. (1997). Molecular mechanics of calcium-myristoyl switches. Nature 389, 198&#x2013;202 10.1038/38310</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/38310</ArticleId><ArticleId IdType="pubmed">9296500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ames J. B., Tanaka T., Stryer L., Ikura M. (1996). Portrait of a myristoyl switch protein. Curr. Opin. Struct. Biol. 6, 432&#x2013;438 10.1016/S0959-440X(96)80106-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-440X(96)80106-0</ArticleId><ArticleId IdType="pubmed">8794166</ArticleId></ArticleIdList></Reference><Reference><Citation>An W. F., Bowlby M. R., Betty M., Cao J., Ling H. P., Mendoza G., Hinson J. W., Mattsson K. I., Strassle B. W., Trimmer J. S., Rhodes K. J. (2000). Modulation of A-type potassium channels by a family of calcium sensors. Nature 403, 553&#x2013;556 10.1038/35000592</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35000592</ArticleId><ArticleId IdType="pubmed">10676964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacher I., Wu B., Shytle D. R., George T. P. (2009). Mecamylamine-a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opin. Pharmacother. 10, 2709&#x2013;2721 10.1517/14656560903329102</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656560903329102</ArticleId><ArticleId IdType="pubmed">19874251</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglietto-Vargas D., Moreno-Gonzalez I., Sanchez-Varo R., Jimenez S., Trujillo-Estrada L., Sanchez-Mejias E., Torres M., Romero-Acebal M., Ruano D., Vizuete M., Vitorica J., Gutierrez A. (2010). Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus. J. Alzheimers Dis. 21, 119&#x2013;132 10.3233/JAD-2010-100066</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100066</ArticleId><ArticleId IdType="pubmed">20413859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein H-G., Baumann B., Danos P., Diekmann S., Bogerts B., Gundelfinger E. D., Braunewell K-H. (1999). Regional and cellular distribution of neural visinin-like protein immunoreactivities (VILIP-1 and VILIP-3) in human brain. J. Neurocytol. 28, 655&#x2013;662 10.1023/A:1007056731551</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1007056731551</ArticleId><ArticleId IdType="pubmed">10851344</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge M. J. (2010). Calcium hypothesis of Alzheimer's disease. Pflugers Arch. 459, 441&#x2013;449 10.1007/s00424-009-0736-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-009-0736-1</ArticleId><ArticleId IdType="pubmed">19795132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I., Mattson M. P. (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 31, 454&#x2013;463 10.1016/j.tins.2008.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2008.06.005</ArticleId><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E. M., Geddes J. W., Chen K. C., Porter N. M., Markesbery W. R., Landfield P. W. (2004). Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U.S.A. 101, 2173&#x2013;2178 10.1073/pnas.0308512100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308512100</ArticleId><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Blandini F., Braunewell K-H., Manahan-Vaughan D., Orzi F., Sarti P. (2004). Neurodegeneration and energy metabolism: from chemistry and clinics. Cell Death Differ. 11, 479&#x2013;484 10.1038/sj.cdd.4401323</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401323</ArticleId><ArticleId IdType="pubmed">14713955</ArticleId></ArticleIdList></Reference><Reference><Citation>Brackmann M., Schuchmann S., Anand R., Braunewell K-H. (2005). Neuronal Ca2+ sensor protein VILIP-1 affects cGMP signalling of guanylyl cyclase B by regulating clathrin-dependent receptor recycling in hippocampal neurons. J. Cell. Sci. 118, 2495&#x2013;2505 10.1242/jcs.02376</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.02376</ArticleId><ArticleId IdType="pubmed">15923662</ArticleId></ArticleIdList></Reference><Reference><Citation>Brackmann M., Zhao C., Kuhl D., Manahan-Vaughan D., Braunewell K. H. (2004). MGluRs regulate the expression of neuronal calcium sensor proteins NCS-1 and VILIP-1 and the immediate early gene arg3.1/arc in the hippocampus in vivo. Biochem. Biophys. Res. Commun. 322, 1073&#x2013;1079</Citation><ArticleIdList><ArticleId IdType="pubmed">15336574</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H. (2005). The dark side of Ca2+ signalling by neuronal Ca2+- sensor proteins: from Alzheimer's disease to cancer. Trends Pharmacol. Sci. 26, 345&#x2013;351 10.1016/j.tips.2005.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2005.04.008</ArticleId><ArticleId IdType="pubmed">15982480</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H. (2009). VSNL-1. UCSD-nature molecule pages. 10.1038/mp.a004095.01</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.a004095.01</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Bernstein H. G. (2009). Notes on visinin-like proteins and Alzheimer's disease. Clin. Chem. 55, 1041&#x2013;1043 10.1373/clinchem.2008.116970</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.116970</ArticleId><ArticleId IdType="pubmed">19264852</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Brackmann M., Manahan-Vaughan D. (2003). Group I mGluRs regulate the expression of the intracellular neuronal calcium sensor protein VILIP-1 in vitro and in vivo: possible implications for mGluR-dependent hippocampal plasticity? Neuropharmacology 44, 707&#x2013;715 10.1016/S0028-3908(03)00051-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(03)00051-0</ArticleId><ArticleId IdType="pubmed">12681369</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Gundelfinger E. D. (1997). Low level expression of calcium-sensor protein VILIP induces cAMP- dependent differentiation in rat C6 glioma cells. Neurosci. Lett. 234, 139&#x2013;142</Citation><ArticleIdList><ArticleId IdType="pubmed">9364517</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Gundelfinger E. D. (1999). Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Cell Tissue Res. 299, 1&#x2013;12 10.1007/s004410051207</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004410051207</ArticleId><ArticleId IdType="pubmed">9931348</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Dwary A. D., Richter F., Trappe K., Zhao C., Giegling I., Sch&#xf6;nrath K., Rujescu D. (2011). Association of VSNL1 with schizophrenia, frontal cortical function, and biological significance for its gene product as a modulator of cAMP levels and neuronal morphology. Transl Psychol 1, e22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309514</ArticleId><ArticleId IdType="pubmed">22832524</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Klein-Szanto A. J. P. (2009). Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+-sensor proteins. Cell Tissue Res. 335, 301&#x2013;316 10.1007/s00441-008-0716-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-008-0716-3</ArticleId><ArticleId IdType="pmc">PMC2742949</ArticleId><ArticleId IdType="pubmed">18989702</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Paul B., Altarche-Xifro W., Noack C., Lange K., Hofmann A. (2010). Interactions of visinin-like proteins with phospho-inositides. Aust. J. Chem. 63, 350</Citation></Reference><Reference><Citation>Braunewell K. H., Riederer P., Spilker C., Gundelfinger E. D., Bogerts B., Bernstein H. G. (2001a). Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (VILIPs)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement. Geriatr. Cogn. Disord. 2, 110&#x2013;115 10.1159/000051244</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000051244</ArticleId><ArticleId IdType="pubmed">11173883</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Brackmann M., Schaupp M., Spilker C., Anand R., Gundelfinger E. D. (2001b). Intracellular neuronal calcium sensor (NCS) protein VILIP-1 modulates cGMP signalling pathways in transfected neural cells and cerebellar granule neurones. J. Neurochem. 78, 1277&#x2013;1286 10.1046/j.1471-4159.2001.00506.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00506.x</ArticleId><ArticleId IdType="pubmed">11579136</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell K. H., Spilker C., Behnisch T., Gundelfinger E. D. (1997). The neuronal calcium-sensor protein VILIP modulates cyclic AMP accumulation in stably transfected C6 glioma cells: amino-terminal myristoylation determines functional activity. J. Neurochem. 68, 2129&#x2013;2139 10.1046/j.1471-4159.1997.68052129.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.68052129.x</ArticleId><ArticleId IdType="pubmed">9109541</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckingham S. D., Jones A. K., Brown L. A., Sattelle D. B. (2009). Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol. Rev. 61, 39&#x2013;61 10.1124/pr.108.000562</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.108.000562</ArticleId><ArticleId IdType="pmc">PMC2830120</ArticleId><ArticleId IdType="pubmed">19293145</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgoyne R. D. (2007). Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling. Nat. Rev. Neurosci. 8, 182&#x2013;193 10.1038/nrn2093</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2093</ArticleId><ArticleId IdType="pmc">PMC1887812</ArticleId><ArticleId IdType="pubmed">17311005</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgoyne R. D., O'Callaghan D. W., Hasdemir B., Haynes L. P., Tepikin A. V. (2004). Neuronal Ca2+-sensor proteins: multitalented regulators of neuronal function. Trends Neurosci. 27, 203&#x2013;209 10.1016/j.tins.2004.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2004.01.010</ArticleId><ArticleId IdType="pubmed">15046879</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgoyne R. D., Weiss J. L. (2001). The neuronal calcium sensor family of Ca2+-binding proteins. Biochem. J. 353, 1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1221537</ArticleId><ArticleId IdType="pubmed">11115393</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J. D. (2004). A role for calsenilin and related proteins in multiple aspects of neuronal function. Biochem. Biophys. Res. Commun. 322, 1140&#x2013;1144 10.1016/j.bbrc.2004.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.08.001</ArticleId><ArticleId IdType="pubmed">15336961</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum J. D., Choi E. K., Luo Y., Lilliehook C., Crowley A. C., Merriam D. E., Wasco W. (1998). Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat. Med. 4, 1177&#x2013;1181 10.1038/2673</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/2673</ArticleId><ArticleId IdType="pubmed">9771752</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri&#xf3;n A. M., Link W. A., Ledo F., Mellstr&#xf6;m B., Naranjo J. R. (1999). DREAM is a Ca2+-regulated transcriptional repressor. Nature 398, 80&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">10078534</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaumont S., Compan V., Toulme E., Richler E., Housley G. D., Rassendren F., Khakh B. S. (2008). Regulation of P2X2 receptors by the neuronal calcium sensor VILIP1. Sci. Signal. 1, ra8 10.1126/scisignal.1162329</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.1162329</ArticleId><ArticleId IdType="pmc">PMC3523710</ArticleId><ArticleId IdType="pubmed">18922787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S., Stutzmann G. E. (2011). Early calcium dysregulation in Alzheimer's disease: setting the stage for synaptic dysfunction. Sci. China Life Sci. 54, 752&#x2013;762 10.1007/s11427-011-4205-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-011-4205-7</ArticleId><ArticleId IdType="pubmed">21786198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Yoo S. E., Na R., Liu Y., Ran Q. (2012). Cognitive impairment and increased A&#x3b2; levels induced by paraquat exposure are attenuated by enhanced removal of mitochondrial H(2)O(2). Neurobiol. Aging 33, 432.e15&#x2013;26 10.1016/j.neurobiolaging.2011.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.01.008</ArticleId><ArticleId IdType="pubmed">21429624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K. C., Wang L. K., Chang L. S. (2009). Regulatory elements and functional implication for the formation of dimeric visinin-like protein-1. J. Pept. Sci. 15, 89&#x2013;94 10.1002/psc.1097</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psc.1097</ArticleId><ArticleId IdType="pubmed">19065602</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi W. S., Chun S. Y., Markelonis G. J., Oh T. H., Oh Y. J. (2001). Overexpression of calbindin-D28K induces neurite outgrowth in dopaminergic neuronal cells via activation of p38 MAPK. Biochem. Biophys. Res. Commun. 287, 656&#x2013;661 10.1006/bbrc.2001.5649</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2001.5649</ArticleId><ArticleId IdType="pubmed">11563845</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussen F., Perrais D., Jaskolski F., Sachidhanandam S., Normand E., Bockaert J., Marin P., Mulle C. (2005). Co-assembly of two GluR6 kainate receptor splice variants within a functional protein complex. Neuron 47, 555&#x2013;566 10.1016/j.neuron.2005.06.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.06.033</ArticleId><ArticleId IdType="pubmed">16102538</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R., Fagan A. M., Holtzman D. M. (2009). Biomarkers of Alzheimer's disease. Neurobiol. Dis. 35, 128&#x2013;140 10.1016/j.nbd.2008.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.10.003</ArticleId><ArticleId IdType="pmc">PMC2747727</ArticleId><ArticleId IdType="pubmed">19010417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai F. F., Zhang Y., Kang Y., Wang Q., Gaisano H. Y., Braunewell K. H., Chan C. B., Wheeler M. B. (2006). The neuronal Ca2+ sensor protein visinin-like protein-1 is expressed in pancreatic islets and regulates insulin secretion. J. Biol. Chem. 281, 21942&#x2013;22153 10.1074/jbc.M512924200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M512924200</ArticleId><ArticleId IdType="pubmed">16731532</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorov N. B., Benson L. C., Graef J., Lippiello P. M., Bencherif M. (2009). Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition. J. Pharmacol. Exp. Ther. 328, 525&#x2013;532 10.1124/jpet.108.146910</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.108.146910</ArticleId><ArticleId IdType="pubmed">18957576</ArticleId></ArticleIdList></Reference><Reference><Citation>Few A. P., Lautermilch N. J., Westenbroek R. E., Scheuer T., Catterall W. A. (2005). Differential regulation of CaV2.1 channels by calcium-binding protein 1 and visinin-like protein-2 requires N-terminal myristoylation. J. Neurosci. 25, 7071&#x2013;7080 10.1523/JNEUROSCI.0452-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0452-05.2005</ArticleId><ArticleId IdType="pmc">PMC6724826</ArticleId><ArticleId IdType="pubmed">16049184</ArticleId></ArticleIdList></Reference><Reference><Citation>Font&#xe1;n-Lozano A., Romero-Granados R., del-Pozo-Mart&#xed;n Y., Su&#xe1;rez-Pereira I., Delgado-Garc&#xed;a J. M., Penninger J. M., Carri&#xf3;n A. M. (2009). Lack of DREAM protein enhances learning and memory and slows brain aging. Curr. Biol. 19, 54&#x2013;60 10.1016/j.cub.2008.11.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2008.11.056</ArticleId><ArticleId IdType="pubmed">19110430</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster T. C. (2007). Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell 6, 319&#x2013;325 10.1111/j.1474-9726.2007.00283.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2007.00283.x</ArticleId><ArticleId IdType="pubmed">17517041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierke P., Zhao C., Bernstein H. G., Noack C., Anand R., Heinemann U., Braunewell K. H. (2008). Implication of neuronal Ca(2+)-sensor protein VILIP-1 in the glutamate hypothesis of schizophrenia. Neurobiol. Dis. 32, 162&#x2013;175 10.1016/j.nbd.2008.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.07.008</ArticleId><ArticleId IdType="pubmed">18691652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierke P., Zhao C., Brackmann M., Linke B., Heinemann U., Braunewell K. H. (2004). Expression analysis of members of the neuronal calcium sensor protein family: combining bioinformatics and Western blot analysis. Biochem. Biophys. Res. Commun. 323, 38&#x2013;43 10.1016/j.bbrc.2004.08.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.08.055</ArticleId><ArticleId IdType="pubmed">15351697</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez Ravetti M., Rosso O. A., Berretta R., Moscato P. (2010). Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease. PLoS One 5:e10153 10.1371/journal.pone.0010153</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010153</ArticleId><ArticleId IdType="pmc">PMC2854141</ArticleId><ArticleId IdType="pubmed">20405009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamashima H., Tamaru T., Noguchi H., Kobayashi M., Takamatsu K. (2001). Immunochemical assessment of neural visinin-like calcium-binding protein 3 expression in rat brain. Neurosci. Res. 39, 133&#x2013;143 10.1016/S0168-0102(00)00208-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-0102(00)00208-X</ArticleId><ArticleId IdType="pubmed">11164261</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 10.1126/science.1072994</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P., Sweet R., Sims R., Harold D., Russo G., Abraham R., Stretton A., Jones N., Gerrish A., Chapman J., Ivanov D., Moskvina V., Lovestone S., Priotsi P., Lupton M., Brayne C., Gill M., Lawlor B., Lynch A., Craig D., McGuinness B., Johnston J., Holmes C., Livingston G., Bass N. J., Gurling H., McQuillin A., the GERAD Consortium; the National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group, Holmans P., Jones L., Devlin B., Klei L., Barmada M. M., Demirci F. Y., Dekosky S. T., Lopez O. L., Passmore P., Owen M. J., O'Donovan M. C., Mayeux R., Kamboh M. I., Williams J. (2011). Genome-wide association study of Alzheimer's disease with psychotic symptoms. Mol. Psychiatry [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3272435</ArticleId><ArticleId IdType="pubmed">22005930</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D. M., Morris J. C., Goate A. M. (2011). Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3, 77sr1 10.1126/scitranslmed.3002369</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun D. H., Emerson S. S., Jo D. G., Mattson M. P., de Cabo R. (2006). Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc. Natl. Acad. Sci. U.S.A. 103, 19908&#x2013;19912 10.1073/pnas.0608008103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0608008103</ArticleId><ArticleId IdType="pmc">PMC1750890</ArticleId><ArticleId IdType="pubmed">17167053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun D. H., Mughal M. R., Yang H., Lee J. H., Ko E. J., Hunt N. D., de Cabo R., Mattson M. P. (2010). The plasma membrane redox system is impaired by amyloid &#x3b2;-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp. Neurol. 225, 423&#x2013;429 10.1016/j.expneurol.2010.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.07.020</ArticleId><ArticleId IdType="pmc">PMC2946538</ArticleId><ArticleId IdType="pubmed">20673763</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacopino A. M., Christakos S. (1992). Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 87, 4078&#x2013;4082</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54050</ArticleId><ArticleId IdType="pubmed">2140897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivings L., Pennington S. R., Jenkins R., Weiss J. L., Burgoyne R. D. (2002). Identification of Ca2+-dependent binding partners for the neuronal calcium sensor protein neurocalcin delta: interaction with actin, clathrin and tubulin. Biochem. J. 363, 599&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1222513</ArticleId><ArticleId IdType="pubmed">11964161</ArticleId></ArticleIdList></Reference><Reference><Citation>Jheng F. F., Wang L., Lee L., Chang L. S. (2006). Functional contribution of Ca2+ and Mg2+ to the intermolecular interaction of visinin-like proteins. Protein J. 25, 250&#x2013;256 10.1007/s10930-006-9008-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10930-006-9008-5</ArticleId><ArticleId IdType="pubmed">16703469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo D. G., Lee J. Y., Hong Y. M., Song S., Mook-Jung I., Koh J. Y., Jung Y. K. (2004). Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in Alzheimer's disease and cultured neurons after amyloid-beta exposure. J. Neurochem. 88, 604&#x2013;611 10.1111/j.1471-4159.2004.02159.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02159.x</ArticleId><ArticleId IdType="pubmed">14720210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajimoto Y., Shirai Y., Mukai H., Kuno T., Tanaka C. (1993). Molecular cloning of two additional members of the neural visinin-like Ca(2+)-binding protein gene family. J. Neurochem. 61, 1091&#x2013;1096</Citation><ArticleIdList><ArticleId IdType="pubmed">8360675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M., Watanabe Y., Iino S., Takaoka Y., Kobayashi S., Haga T., Hidaka H. (1998). Cloning and expression of a cDNA encoding a new neurocalcin isoform (neurocalcin alpha) from bovine brain. Biochem. J. 331, 871&#x2013;876</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1219429</ArticleId><ArticleId IdType="pubmed">9560316</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann W. A., Barnas U., Humpel C., Nowakowski K., DeCol C., Gurka P., Ransmayr G., Hinterhuber H., Winkler H., Marksteiner J. (1998). Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimer's disease. Eur. J. Neurosci. 10, 1084&#x2013;1094 10.1046/j.1460-9568.1998.00121.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.1998.00121.x</ArticleId><ArticleId IdType="pubmed">9753176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. H., Lee J. A., Song Y. M., Park C. H., Hwang S. J., Kim Y. S., Kaang B. K., Son H. (2006). Overexpression of calbindin-D28K in hippocampal progenitor cells increases neuronal differentiation and neurite outgrowth. FASEB J. 20, 109&#x2013;111 10.1096/fj.05-4826fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4826fje</ArticleId><ArticleId IdType="pubmed">16278289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. H., Fountoulakis M., Cairns N., Lubec G. (2001). Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl. 61, 223&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">11771746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M., Masaki T., Hori K., Masuo Y., Miyamoto M., Tsubokawa H., Noguchi H., Nomura M., Takamatsu K. (2005). Hippocalcin-deficient mice display a defect in cAMP response element-binding protein activation associated with impaired spatial and associative memory. Neuroscience 133, 471&#x2013;484 10.1016/j.neuroscience.2005.02.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2005.02.034</ArticleId><ArticleId IdType="pubmed">15878804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M., Takamatsu K., Fujishiro M., Saitoh S., Noguchi T. (1994). Molecular cloning of a novel calcium-binding protein structurally related to hippocalcin from human brain and chromosomal mapping of its gene. Biochim. Biophys. Acta 1222, 515&#x2013;518</Citation><ArticleIdList><ArticleId IdType="pubmed">8038222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M., Takamatsu K., Saitoh S., Nogushi T. (1993). Myristoylation of hippocalcin is linked to its membrane association properties. J. Biol. Chem. 268, 18898&#x2013;18904</Citation><ArticleIdList><ArticleId IdType="pubmed">8360179</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen L., Hansson I., Kukkonen J. P., Br&#xe4;nnvall K., Kobayashi M., Takamatsu K., Lindholm D. (2005). Hippocalcin protects against caspase-12-induced and age-dependent neuronal degeneration. Mol. Cell. Neurosci. 28, 85&#x2013;95 10.1016/j.mcn.2004.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2004.08.015</ArticleId><ArticleId IdType="pubmed">15607944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraut N., Frampton J., Graf T. (1995). Rem-1, a putative direct target gene of the Myb-Ets fusion oncoprotein in haematopoietic progenitors, is a member of the recoverin family. Oncogene 10, 1027&#x2013;1036</Citation><ArticleIdList><ArticleId IdType="pubmed">7700627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno T., Kajimoto Y., Hashimoto T., Mukai H., Shirai Y., Saheki S., Tanaka C. (1992). cDNA cloning of a neural visinin-like Ca(2+)-binding protein. Biochem. Biophys. Res. Commun. 184, 1219&#x2013;1225 10.1016/S0006-291X(05)80012-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(05)80012-9</ArticleId><ArticleId IdType="pubmed">1375457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladant D. (1995). Calcium and membrane binding properties of bovine neurocalcin delta expressed in Escherichia coli. J. Biol. Chem. 270, 3179&#x2013;3185</Citation><ArticleIdList><ArticleId IdType="pubmed">7852401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. M., Blennow K., Andreasen N., Laterza O., Modur V., Olander J., Gao F., Ohlendorf M., Ladenson J. H. (2008). The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin. Chem. 54, 1617&#x2013;1623 10.1373/clinchem.2008.104497</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.104497</ArticleId><ArticleId IdType="pmc">PMC2672199</ArticleId><ArticleId IdType="pubmed">18703769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. H., Cheng R., Barral S., Reitz C., Medrano M., Lantigua R., Jim&#xe9;nez-Velazquez I. Z., Rogaeva E., StGeorge-Hyslop P. H., Mayeux R. (2011). Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch. Neurol. 68, 320&#x2013;328 10.1001/archneurol.2010.292</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.292</ArticleId><ArticleId IdType="pmc">PMC3268783</ArticleId><ArticleId IdType="pubmed">21059989</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring M. A., Yamasaki T. R., Wasco W., Buxbaum J. D., Parker I., LaFerla F. M. (2000). Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proc. Natl. Acad. Sci. U.S.A. 97, 8590&#x2013;8593 10.1073/pnas.97.15.8590</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.15.8590</ArticleId><ArticleId IdType="pmc">PMC26992</ArticleId><ArticleId IdType="pubmed">10900016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz S. E., Braunewell K. H., Weise C., Nedlina-Chittka A., Gundelfinger E. D. (1996). The neuronal EF-hand Ca(2+)-binding protein VILIP: interaction with cell membrane and actin-based cytoskeleton. Biochem. Biophys. Res. Commun. 225, 1078&#x2013;1083 10.1006/bbrc.1996.1298</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1996.1298</ArticleId><ArticleId IdType="pubmed">8780737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz S. E., Henschel Y., Zopf D., Voss B., Gundelfinger E. D. (1992). VILIP, a cognate protein of the retinal calcium binding proteins visinin and recoverin, is expressed in the developing chicken brain. Brain Res. Mol. Brain Res. 15, 133&#x2013;140</Citation><ArticleIdList><ArticleId IdType="pubmed">1359372</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E. D., McClernon F. J., Rezvani A. H. (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.) 184, 523&#x2013;539 10.1007/s00213-005-0164-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-005-0164-7</ArticleId><ArticleId IdType="pubmed">16220335</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Pan W., Braunewell K. H., Ames J. B. (2011). Structural analysis of Mg2+ and Ca2+ binding, myristoylation, and dimerization of the neuronal calcium sensor and visinin-like protein 1 (VILIP-1). J. Biol. Chem. 286, 6354&#x2013;6366 10.1074/jbc.M110.173724</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.173724</ArticleId><ArticleId IdType="pmc">PMC3057812</ArticleId><ArticleId IdType="pubmed">21169352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian L. Y., Pandalaneni S. R., Patel P., McCue H. V., Haynes L. P., Burgoyne R. D. (2011). Characterisation of the interaction of the C-terminus of the dopamine D2 receptor with neuronal calcium sensor-1. PLoS One 6:e27779 10.1371/journal.pone.0027779</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027779</ArticleId><ArticleId IdType="pmc">PMC3218054</ArticleId><ArticleId IdType="pubmed">22114693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Jeanclos E. M., Treuil M., Braunewell K. H., Gundelfinger E. D., Anand R. (2002a). The calcium sensor protein visinin-like protein-1 modulates the surface expression and agonist-sensitivity of the a4&#x3b2;2 nicotinic acetylcholine receptor. J. Biol. Chem. 277, 41872&#x2013;41878 10.1074/jbc.M206857200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M206857200</ArticleId><ArticleId IdType="pubmed">12202488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Braunewell K. H., Gundelfinger E. D., Anand R. (2002b). Functional analysis of calcium-binding EF-hand motifs of visinin-like protein-1. Biochem. Biophys. Res. Commun. 296, 827&#x2013;832 10.1016/S0006-291X(02)00943-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)00943-9</ArticleId><ArticleId IdType="pubmed">12200122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm D., Mercer E. A., Yu L. Y., Chen Y., Kukkonen J., Korhonen L., Arum&#xe4;e U. (2002). Neuronal apoptosis inhibitory protein: structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. Biochim. Biophys. Acta 1600, 138&#x2013;147</Citation><ArticleIdList><ArticleId IdType="pubmed">12445469</ArticleId></ArticleIdList></Reference><Reference><Citation>Loring J. F., Porter J. G., Seilhammer J., Kaser M. R., Wesselschmidt R. (2001). A gene expression profile of Alzheimer's disease. DNA Cell Biol. 20, 683&#x2013;695 10.1089/10445490152717541</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/10445490152717541</ArticleId><ArticleId IdType="pubmed">11788046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahloogi H., Gonzalez-Guerrico A. M., De Cicco R. L., Bassi D. E., Goodrow T., Braunewell K. H., Klein-Szanto A. J. P. (2003). Graduate decrease of VILIP-1 Expression during mouse skin tumor progression and its role in regulating tumor cell invasive behavior. Cancer Res. 63, 4997&#x2013;5004</Citation><ArticleIdList><ArticleId IdType="pubmed">12941826</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuo Y., Ogura A., Kobayashi M., Masaki T., Furuta Y., Ono T., Takamatsu K. (2007). Hippocalcin protects hippocampal neurons against excitotoxin damage by enhancing calcium extrusion. Neuroscience 145, 495&#x2013;504 10.1016/j.neuroscience.2006.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.12.011</ArticleId><ArticleId IdType="pubmed">17257765</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon A., Wong B. S., Iacopino A. M., Ng M. C., Chi S., German D. C. (1998). Calbindin-D28k buffers intracellular calcium and promotes resistance to degeneration in PC12 cells. Brain Res. Mol. Brain Res. 54, 56&#x2013;63 10.1016/S0169-328X(97)00305-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(97)00305-7</ArticleId><ArticleId IdType="pubmed">9526044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer E. A., Korhonen L., Skogl&#xf6;sa Y., Olsson P. A., Kukkonen J. P., Lindholm D. (2000). NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways. EMBO J. 19, 3597&#x2013;3607 10.1093/emboj/19.14.3597</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/19.14.3597</ArticleId><ArticleId IdType="pmc">PMC313967</ArticleId><ArticleId IdType="pubmed">10899114</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J. A., Oldham M. C., Geschwind D. H. (2008). A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J. Neurosci. 28, 1410&#x2013;1420 10.1523/JNEUROSCI.4098-07.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4098-07.2008</ArticleId><ArticleId IdType="pmc">PMC2902235</ArticleId><ArticleId IdType="pubmed">18256261</ArticleId></ArticleIdList></Reference><Reference><Citation>Monfort P., Munoz M. D., Kosenko E., Felipo V. (2002). Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. J. Neurosci. 22, 10116&#x2013;10124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758733</ArticleId><ArticleId IdType="pubmed">12451112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanou E., Martinez G. Q., Scheuer T., Catterall W. A. (2012). Molecular determinants of modulation of CaV2.1 channels by visinin-like protein 2. J. Biol. Chem. 287, 504&#x2013;513 10.1074/jbc.M111.292581</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.292581</ArticleId><ArticleId IdType="pmc">PMC3249104</ArticleId><ArticleId IdType="pubmed">22074920</ArticleId></ArticleIdList></Reference><Reference><Citation>Nef P. (1996). &#x201c;Neuron-specific calcium sensors (the NCS subfamily),&#x201d; in: Guidebook to the Calcium-Binding Proteins, ed M. R. Celio (New York: Oxford University Press; ), 94&#x2013;98</Citation></Reference><Reference><Citation>O'Callaghan D. W., Haynes L. P., Burgoyne R. D. (2005). High-affinity interaction of the N-terminal myristoylation motif of the neuronal calcium sensor protein hippocalcin with phosphatidylinositol 4,5-bisphosphate. Biochem. J. 391, 231&#x2013;238 10.1042/BJ20051001</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20051001</ArticleId><ArticleId IdType="pmc">PMC1276920</ArticleId><ArticleId IdType="pubmed">16053445</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Callaghan D. W., Ivings L., Weiss J. L., Ashby M. C., Tepikin A. V., Burgoyne R. D. (2002). Differential use of myristoyl groups on neuronal calcium sensor proteins as a determinant of spatio-temporal aspects of Ca2+ signal transduction. J. Biol. Chem. 277, 14227&#x2013;14237 10.1074/jbc.M111750200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111750200</ArticleId><ArticleId IdType="pubmed">11836243</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Callaghan D. W., Tepikin A. V., Burgoyne R. D. (2003). Dynamics and calcium sensitivity of the Ca2+-myristoyl switch protein hippocalcin in living cells. J. Cell Biol. 163, 715&#x2013;721 10.1083/jcb.200306042</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200306042</ArticleId><ArticleId IdType="pmc">PMC2173692</ArticleId><ArticleId IdType="pubmed">14638856</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh D. Y., Cho J. H., Park S. Y., Kim Y. S., Yoon Y. J., Yoon S. H., Chung K. C., Lee K. S., Han J. S. (2008). A novel role of hippocalcin in bFGF-induced neurite outgrowth of H19&#x2013;7 cells. J. Neurosci. Res. 86, 1557&#x2013;1565 10.1002/jnr.21602</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21602</ArticleId><ArticleId IdType="pubmed">18183620</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa K., Kimura S., Aoki N., Atsuta Y., Takiyama Y., Nagato T., Yanai M., Kobayashi H., Sato K., Sasajima T., Tateno M. (2004). Neuronal calcium sensor protein visinin-like protein-3 interacts with microsomal cytochrome b5 in a Ca2+-dependent manner. J. Biol. Chem. 279, 15142&#x2013;11552 10.1074/jbc.M312766200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M312766200</ArticleId><ArticleId IdType="pubmed">14739275</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer C. L., Lim W., Hastie P. G., Toward M., Korolchuk V. I., Burbidge S. A., Banting G., Collingridge G. L., Isaac J. T., Henley J. M. (2005). Hippocalcin functions as a calcium sensor in hippocampal LTD. Neuron 47, 487&#x2013;494 10.1016/j.neuron.2005.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.06.014</ArticleId><ArticleId IdType="pmc">PMC1563146</ArticleId><ArticleId IdType="pubmed">16102532</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J., Chin J., Roberson E. D., Wang J., Thwin M. T., Bien-Ly N., Yoo J., Ho K. O., Yu G. Q., Kreitzer A., Finkbeiner S., Noebels J. L., Mucke L. (2007). Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697&#x2013;711 10.1016/j.neuron.2007.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.07.025</ArticleId><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J., Jones B., Kekonius L., Chin J., Yu G. Q., Raber J., Masliah E., Mucke L. (2003). Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U.S.A. 100, 9572&#x2013;9577 10.1073/pnas.1133381100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1133381100</ArticleId><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J., Mucke L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812&#x2013;818 10.1038/nn.2583</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2583</ArticleId><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterlini M., Revilla V., Grant A. L., Wisden W. (2000). Expression of the neuronal calcium sensor protein family in the rat brain. Neuroscience 99, 205&#x2013;216 10.1016/S0306-4522(00)00201-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(00)00201-3</ArticleId><ArticleId IdType="pubmed">10938426</ArticleId></ArticleIdList></Reference><Reference><Citation>Petratos S., Li Q. X., George A. J., Hou X., Kerr M. L., Unabia S. E., Hatzinisiriou I., Maksel D., Aguilar M. I., Small D. H. (2008). The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain 131, 90&#x2013;108 10.1093/brain/awm260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm260</ArticleId><ArticleId IdType="pubmed">18000012</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M. H., Ide S., Soares M. B., Lennon G. G. (1995). Sequence characterization and genetic mapping of the human VSNL1 gene, a homolo gue of the rat visinin-like peptide RNVP1. Genomics 29, 273&#x2013;275 10.1006/geno.1995.1244</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1995.1244</ArticleId><ArticleId IdType="pubmed">8530085</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovi&#xe6; M., Caballero-Bleda M., Kadish I., Van Groen T. (2008). Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice. Neuroscience 155, 182&#x2013;191 10.1016/j.neuroscience.2008.05.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.05.023</ArticleId><ArticleId IdType="pmc">PMC2596990</ArticleId><ArticleId IdType="pubmed">18583063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezvani A. H., Levin E. D. (2001). Cognitive effects of nicotine. Biol. Psychiatry 49, 258&#x2013;267</Citation><ArticleIdList><ArticleId IdType="pubmed">11230877</ArticleId></ArticleIdList></Reference><Reference><Citation>Richler E., Shigetomi E., Khakh B. S. (2011). Neuronal P2X2 receptors are mobile ATP sensors that explore the plasma membrane when activated. J. Neurosci. 31, 16716&#x2013;16730 10.1523/JNEUROSCI.3362-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3362-11.2011</ArticleId><ArticleId IdType="pmc">PMC3282184</ArticleId><ArticleId IdType="pubmed">22090499</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas M., Aurrekoetxea K., Mellstr&#xf6;m B., Naranjo J. R. (2011). Redox signaling regulates transcriptional activity of the Ca2+-dependent repressor DREAM. Antioxid. Redox Signal. 14, 1237&#x2013;1243 10.1089/ars.2010.3385</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2010.3385</ArticleId><ArticleId IdType="pubmed">20618065</ArticleId></ArticleIdList></Reference><Reference><Citation>Saab B. J., Georgiou J., Nath A., Lee F. J., Wang M., Michalon A., Liu F., Mansuy I. M., Roder J. C. (2009). NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory. Neuron 63, 643&#x2013;656 10.1016/j.neuron.2009.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.08.014</ArticleId><ArticleId IdType="pubmed">19755107</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnurra I., Riederer P., Bernstein H. G., Braunewell K. H. (2001). The neuronal calcium sensor (NCS) protein VILIP-1 is associated with amyloid plaques and extracellular tangles and promotes cell death and tau-phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Neurobiol. Dis. 8, 900&#x2013;909</Citation><ArticleIdList><ArticleId IdType="pubmed">11592857</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nrath K., Pan W., Klein-Szanto A. J., Braunewell K. H. (2011). Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signalling in in vitro cell migration of murine skin squamous cell carcinoma. Mol. Carcinog. 50, 319&#x2013;333 10.1002/mc.20707</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.20707</ArticleId><ArticleId IdType="pmc">PMC3202085</ArticleId><ArticleId IdType="pubmed">21480386</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuman E. M., Madison D. V. (1991). A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science 254, 1503&#x2013;1506 10.1126/science.1720572</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1720572</ArticleId><ArticleId IdType="pubmed">1720572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sippy T., Cruz-Mart&#xed;n A., Jeromin A., Schweizer F. E. (2003). Acute changes in short-term plasticity at synapses with elevated levels of neuronal calcium sensor-1. Nat. Neurosci. 6, 1031&#x2013;1038 10.1038/nn1117</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1117</ArticleId><ArticleId IdType="pmc">PMC3132582</ArticleId><ArticleId IdType="pubmed">12947410</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D. L., Pozueta J., Gong B., Arancio O., Shelanski M. (2009). Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U.S.A. 106, 16877&#x2013;16882 10.1073/pnas.0908706106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908706106</ArticleId><ArticleId IdType="pmc">PMC2743726</ArticleId><ArticleId IdType="pubmed">19805389</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilker C., Braunewell K-H. (2003). The calcium-myristoyl switch of neuronal calcium sensor (NCS) proteins: same biochemical principle but different calcium-dependent localization of VILIP-3 and -1 in hippocampal neurons. Mol. Cell. Neurosci. 24, 766&#x2013;778 10.1016/S1044-7431(03)00242-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1044-7431(03)00242-2</ArticleId><ArticleId IdType="pubmed">14664824</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilker C., Gundelfinger E. D., Braunewell K-H. (2002a). Different properties of the intracellular neuronal Calcium sensor proteins VILIP-1 and VILIP-3: from subcellular localization to cellular function. Biochim. Biophys. Acta proteins and proteomics 1600, 118&#x2013;127 10.1016/S1570-9639(02)00452-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1570-9639(02)00452-1</ArticleId><ArticleId IdType="pubmed">12445467</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilker C., Dresbach T., Braunewell K-H. (2002b). Reversible translocation and activity-dependent localization of the calcium-myristoyl switch protein VILIP-1 to different membrane compartments in living hippocampal neurons. J. Neurosci. 22, 7331&#x2013;7339</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757958</ArticleId><ArticleId IdType="pubmed">12196554</ArticleId></ArticleIdList></Reference><Reference><Citation>Spilker C., Richter K., Smalla K-H., Manahan-Vaughan D., Gundelfinger E. D., Braunewell K-H. (2000). The neuronal EF-hand calcium-binding protein VILIP-3 is expressed in cerebellar Purkinje cells and shows a calcium-dependent membrane association. Neuroscience 96, 121&#x2013;129 10.1016/S0306-4522(99)00536-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(99)00536-9</ArticleId><ArticleId IdType="pubmed">10683417</ArticleId></ArticleIdList></Reference><Reference><Citation>Supnet C., Bezprozvanny I. (2010). The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 47, 183&#x2013;189 10.1016/j.ceca.2009.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2009.12.014</ArticleId><ArticleId IdType="pmc">PMC2834825</ArticleId><ArticleId IdType="pubmed">20080301</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H., Brasnjevic I., Rutten B. P., Van Der Kolk N., Perl D. P., Bouras C., Steinbusch H. W., Schmitz C., Hof P. R., Dickstein D. L. (2010). Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct. Funct. 214, 145&#x2013;160 10.1007/s00429-010-0242-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-010-0242-4</ArticleId><ArticleId IdType="pmc">PMC3038332</ArticleId><ArticleId IdType="pubmed">20213270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Ames J. B., Harvey T. S., Stryer L., Ikura M. (1995). Sequestration of the membrane-targeting myristoyl group of recoverin in the calcium-free state. Nature 376, 444&#x2013;447 10.1038/376444a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/376444a0</ArticleId><ArticleId IdType="pubmed">7630423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W. Y., Morey L. M., Cheung Y. Y., Birch L., Prins G. S., Ho S. M. (2012). Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life. Endocrinology 153, 42&#x2013;55 10.1210/en.2011-1308</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2011-1308</ArticleId><ArticleId IdType="pmc">PMC3249669</ArticleId><ArticleId IdType="pubmed">22109888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R., D'Angelo G., Macy E., Xiong C., Carter D., Cairns N. J., Fagan A. M., Head D., Mintun M. A., Ladenson J. H., Lee J. M., Morris J. C., Holtzman D. M. (2011). Visinin-like protein-1:diagnostic and prognostic biomarker in Alzheimer disease. Ann. Neurol. 70, 274&#x2013;285 10.1002/ana.22448</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22448</ArticleId><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Telegdy G. (1994). The action of ANP, BNP and related peptides on motivated behavior in rats. Rev. Neurosci. 5, 309&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pubmed">7697199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzingounis A. V., Kobayashi M., Takamatsu K., Nicoll R. A. (2007). Hippocalcin gates the calcium activation of the slow afterhyperpolarization in hippocampal pyramidal cells. Neuron 53, 487&#x2013;493 10.1016/j.neuron.2007.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.011</ArticleId><ArticleId IdType="pmc">PMC1832111</ArticleId><ArticleId IdType="pubmed">17296551</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek M. M., Olde Rikkert M. G. (2008). Cerebrospinal fluid biomarkers in the evaluation of Alzheimer disease. Clin. Chem. 54, 1589&#x2013;1591 10.1373/clinchem.2008.113027</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.113027</ArticleId><ArticleId IdType="pubmed">18824570</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalobos C., Andrade R. (2010). Visinin-like neuronal calcium sensor proteins regulate the slow calcium-activated afterhyperpolarizing current in the rat cerebral cortex. J. Neurosci. 30, 14361&#x2013;14365 10.1523/JNEUROSCI.3440-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3440-10.2010</ArticleId><ArticleId IdType="pmc">PMC2980356</ArticleId><ArticleId IdType="pubmed">20980592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C. K., Simon A., Jessen C. M., Oliveira C. L., Mack L., Braunewell K. H., Ames J. B., Pedersen J. S., Hofmann A. (2011). Divalent cations and redox conditions regulate the molecular structure and function of Visinin-like Protein-1. PLoS One 6:e26793 10.1371/journal.pone.0026793</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026793</ArticleId><ArticleId IdType="pmc">PMC3206844</ArticleId><ArticleId IdType="pubmed">22073194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Nguyen L. N., Kessels H. W., Hagiwara H., Sisodia S., Malinow R. (2010). Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 13, 190&#x2013;196 10.1038/nn.2476</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2476</ArticleId><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmot B., McWeeney S. K., Nixon R. R., Montine T. J., Laut J., Harrington C. A., Kaye J. A., Kramer P. L. (2008). Translational gene mapping of cognitive decline. Neurobiol. Aging 29, 524&#x2013;541 10.1016/j.neurobiolaging.2006.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.11.008</ArticleId><ArticleId IdType="pmc">PMC2684335</ArticleId><ArticleId IdType="pubmed">17174450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L. J., Mellstr&#xf6;m B., Wang H., Ren M., Domingo S., Kim S. S., Li X. Y., Chen T., Naranjo J. R., Zhuo M. (2010). DREAM (downstream regulatory element antagonist modulator) contributes to synaptic depression and contextual fear memory. Mol. Brain 3, 3 10.1186/1756-6606-3-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-3-3</ArticleId><ArticleId IdType="pmc">PMC2822766</ArticleId><ArticleId IdType="pubmed">20205763</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamatani H., Kawasaki T., Mita S., Inagaki N., Hirata T. (2010). Proteomics analysis of the temporal changes in axonal proteins during maturation. Dev. Neurobiol. 70, 523&#x2013;537 10.1002/dneu.20794</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.20794</ArticleId><ArticleId IdType="pubmed">20225247</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn H., Jeoung M., Koo Y., Ji H., Markesbery W. R., Ji I., Ji T. H. (2007). Kalirin is under-expressed in Alzheimer's disease hippocampus. J. Alzheimers Dis. 11, 385&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">17851188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Braunewell K-H. (2008). Expression of the neuronal calcium sensor VILIP-1 in the rat hippocampus. Neuroscience 153, 1202&#x2013;1212 10.1016/j.neuroscience.2007.10.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2007.10.067</ArticleId><ArticleId IdType="pubmed">18440708</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C. J., Noack C., Brackmann M., Gloveli T., Maelicke A., Heinemann U., Anand R., Braunewell K. H. (2009a). Neuronal Ca2+ sensor VILIP-1 leads to the upregulation of functional alpha4beta2 nicotinic acetylcholine receptors in hippocampal neurons. Mol. Cell. Neurosci. 40, 280&#x2013;292 10.1016/j.mcn.2008.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2008.11.001</ArticleId><ArticleId IdType="pmc">PMC2683982</ArticleId><ArticleId IdType="pubmed">19063970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Anand R., Braunewell K. H. (2009b). Nicotine-induced Ca2+-myristoyl switch of neuronal Ca2+ sensor VILIP-1 in hippocampal neurons: a possible crosstalk mechanism for nicotinic receptors. Cell. Mol. Neurobiol. 29, 273&#x2013;286 10.1007/s10571-008-9320-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-008-9320-z</ArticleId><ArticleId IdType="pubmed">18925431</ArticleId></ArticleIdList></Reference><Reference><Citation>Zozulya S., Stryer L. (1992). Calcium-myristoyl protein switch. Proc. Natl. Acad. Sci. U.S.A. 89, 11569&#x2013;11573</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50594</ArticleId><ArticleId IdType="pubmed">1454850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22367129</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Aggressive and impulsive behavior in Alzheimer's disease and progression of dementia.</ArticleTitle><Pagination><StartPage>CR182</StartPage><EndPage>CR189</EndPage><MedlinePgn>CR182-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The symptoms of Alzheimer's disease (AD) are numerous, including worsening of mood, psychotic symptoms, aggressive and impulsive behaviours, and many others. It is generally assumed that there exists a relationship between the severity of dementia and aggressive symptoms. The aim of this study was to assess the relationship between aggressive and impulsive behaviours and cognitive function disorders in AD patients.</AbstractText><AbstractText Label="MATERIAL/METHODS" NlmCategory="METHODS">Forty-eight AD patients living in a nursing home were included in the research group on the basis of NINCDS/ADRDA criteria. The subjects underwent two years of naturalistic observation. The intensity of agitation and aggressive behaviours was assessed on the basis of the Cohen-Mansfield Agitation Inventory (CMAI). The Alzheimer's Disease Assessment Scale Cog (ADAS-cog) was used to assess cognitive function. Pharmacotherapy administered during the observation period was also taken into account.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-one patients completed the two year long observation. Individuals with more severe cognitive deficiencies demonstrated a greater intensity of aggressive and impulsive behaviours, as assessed using the CMAI scale. Aggression escalated together with the development of dementia disorders. The intensity of dementia disorders was most significantly connected with physical agitation and verbal aggression. The use of neuroleptics and mood stabilisers decreased the progression of aggressive and impulsive behaviours.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is a relationship between cognitive functioning disorders and the intensification of aggressive and impulsive behaviours. More severe forms of dementia are connected with greater intensification of aggressive and impulsive behaviours as the disease progresses. Periodical administration of pharmacotherapy may reduce the development of aggressive behaviours.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Leszek</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department for Developmental Psychiatry, Psychotic Disorders and Old Age Psychiatry, Medical University of Gdansk, Gdansk, Poland. leszekbidzan@gumed.edu.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Mariola</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>P&#x105;chalska</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="Y">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="Y">Impulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22367129</ArticleId><ArticleId IdType="pmc">PMC3560760</ArticleId><ArticleId IdType="doi">10.12659/msm.882523</ArticleId><ArticleId IdType="pii">882523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings JL. The neuropsychiatry of Alzheimer&#x2019;s disease and related dementias. London: Martin Dunitz Ltd; 2003.</Citation></Reference><Reference><Citation>Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. I: a conceptual review. J Am Geriatr Soc. 1998;36:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Werner P. Agitation in elderly persons: an integrative report of findings in a nursing home. Int Psychogeriatr. 1992;4(Suppl 2):221&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1288664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Rosenthal AS. Dementia and agitation in nursing home residents: how are they related? Psychol Aging. 1990;5:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2317299</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck C, Frank L, Chumbler NR, et al. Correlates of disruptive behavior in severely cognitively impaired nursing home residents. Gerontologist. 1998;38:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9573663</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">2386336</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236577</ArticleId></ArticleIdList></Reference><Reference><Citation>Swearer JM, Drachmann DA, O&#x2019;Donnel BF, Mitchell AL. Troublesome and disruptive behaviours in dementia &#x2013; relationship to diagnosis and disease severity. J Am Geriatric Soc. 1988;76:784&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">3411060</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry S, Cummings JL, Hill MA, Shapira J. Personality alterations in dementia of the Alzheimer&#x2019;s type. Arch Neurol. 1988;45:1187&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">3190498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidzan L, P&#x105;chalska M, Grochmal-Bach B, et al. Behavioral and psychological symptoms and the progression of dementia of the Alzheimer type in nursing home residents. Med Sci Monit. 2008;14(11):CR559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18971872</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler M. The efficacy of cholinesterase inhibitors In treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 2002;127:20&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache Country Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhan G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the suspicies of Department of Health Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachinski VC. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet. 1974;2:207&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">4135618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44:M77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">2715584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidzan L, Bidzan M. Ocena rzetelno&#x15b;ci i trafno&#x15b;ci polskiej wersji j&#x119;zykowej skali pobudzenia Cohena-Mansfielda (The Cohen-Mansfield Agitation Inventory) Psychogeriatr Pol. 2005;2:89&#x2013;98. [in Polish]</Citation><ArticleIdList><ArticleId IdType="pubmed">18540422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141:1356&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Eefsting JA, Boersma F, van Tilburg W, van den Brink W. Usefulness of the &#x2018;Mini-Mental State Test&#x2019; for the diagnosis of dementia; study of criterion validity in a Dutch rural population. Ned Tijdschr Geneeskd. 1997;141:2066&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9550765</ArticleId></ArticleIdList></Reference><Reference><Citation>Crum RM, Anthony JC, Bassett SS. Population-based norms for the mini-mental state examination by age and educational level. JAMA. 1993;269:2386&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479064</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Marshall SC, Weldon W, et al. Age and education correction of Mini Mental State Examination for English and Spanish &#x2013; speaking elderly. Neurology. 1996;46:700&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618670</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer&#x2019;s disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">8109647</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh SW, Corrigan FM, Scott M. Language impairment and aggression in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1996;11:257&#x2013;61.</Citation></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer&#x2019;s disease. Cochrane Database Syst Rev. 2006;25:CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Grochmal-Bach B, Bidzan L, Pachalska M, et al. Aggressive and impulsive behaviors in Frontotemporal dementia and Alzheimer&#x2019;s disease. Med Sci Monit. 2009;15(15):CR248&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">19396041</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachalska M, Bidzan L, Lukowicz M, et al. Differential diagnosis of behavioral variant of Fronto-Temporal Dementia (bvFTD) Med Sci Monit. 2011;17(6):CS311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3539546</ArticleId><ArticleId IdType="pubmed">21629185</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22349686</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Anosognosia and neuropsychiatric symptoms and disorders in mild Alzheimer disease and mild cognitive impairment.</ArticleTitle><Pagination><StartPage>761</StartPage><EndPage>772</EndPage><MedlinePgn>761-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2012-111886</ELocationID><Abstract><AbstractText>Anosognosia is a multidimensional phenomenon that negatively affects course of illness. This study aimed to explore the association between anosognosia and neuropsychiatric phenomena in mild Alzheimer's disease (AD) and in mild cognitive impairment (MCI). The Anosognosia Questionnaire for Dementia to assess anosognosia, and the Neuropsychiatric Inventory to assess neuropsychiatric symptoms were administered to 209 patients (103 mild AD, 52 amnestic-MCI, and 54 amnestic multidomain-MCI). Categorical diagnoses of apathy, depression, and psychosis were made using specific criteria for dementia. With regard to continuous scores, in mild AD, we found positive correlation between symptoms of anosognosia and apathy, agitation and aberrant motor behaviors, while in MCI, we did not find significant association. At a categorical level, the diagnosis of anosognosia in mild AD was associated with the diagnosis of apathy. In mild AD, the frequent co-occurrence of frontally mediated behavioral disorders and anosognosia, particularly apathy, supports the hypothesis of a shared neuropsychogenic process due to the disruption of frontal brain networks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IRCCS Santa Lucia Foundation, Department of Clinical and Behavioural Neurology, Neuropsychiatry Laboratory, Rome, Italy. g.spalletta@hsantalucia.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Orfei</LastName><ForeName>Maria Donata</ForeName><Initials>MD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000377" MajorTopicYN="N">Agnosia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22349686</ArticleId><ArticleId IdType="doi">10.3233/JAD-2012-111886</ArticleId><ArticleId IdType="pii">W1V837138GN1Q105</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22305994</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7528</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuroscience and biobehavioral reviews</Title><ISOAbbreviation>Neurosci Biobehav Rev</ISOAbbreviation></Journal><ArticleTitle>Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review.</ArticleTitle><Pagination><StartPage>1140</StartPage><EndPage>1152</EndPage><MedlinePgn>1140-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neubiorev.2012.01.004</ELocationID><Abstract><AbstractText>Standard univariate analysis of neuroimaging data has revealed a host of neuroanatomical and functional differences between healthy individuals and patients suffering a wide range of neurological and psychiatric disorders. Significant only at group level however these findings have had limited clinical translation, and recent attention has turned toward alternative forms of analysis, including Support-Vector-Machine (SVM). A type of machine learning, SVM allows categorisation of an individual's previously unseen data into a predefined group using a classification algorithm, developed on a training data set. In recent years, SVM has been successfully applied in the context of disease diagnosis, transition prediction and treatment prognosis, using both structural and functional neuroimaging data. Here we provide a brief overview of the method and review those studies that applied it to the investigation of Alzheimer's disease, schizophrenia, major depression, bipolar disorder, presymptomatic Huntington's disease, Parkinson's disease and autistic spectrum disorder. We conclude by discussing the main theoretical and practical challenges associated with the implementation of this method into the clinic and possible future directions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orr&#xf9;</LastName><ForeName>Graziella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, PO Box 67, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettersson-Yeo</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Marquand</LastName><ForeName>Andre F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Sartori</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mechelli</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosci Biobehav Rev</MedlineTA><NlmUniqueID>7806090</NlmUniqueID><ISSNLinking>0149-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001321" MajorTopicYN="N">Autistic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002965" MajorTopicYN="N">Classification</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060388" MajorTopicYN="Y">Support Vector Machine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22305994</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2012.01.004</ArticleId><ArticleId IdType="pii">S0149-7634(12)00013-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22304604</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>196</Volume><PubDate><Year>2012</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>Memory loss.</ArticleTitle><Pagination><StartPage>114</StartPage><EndPage>117</EndPage><MedlinePgn>114-7</MedlinePgn></Pagination><Abstract><AbstractText>Most older people with memory loss do not have dementia. Those with mild cognitive impairment are at increased risk of progressing to dementia, but no tests have been shown to enhance the accuracy of assessing this risk. Although no intervention has been convincingly shown to prevent dementia, data from cohort studies and randomised controlled trials are compelling in indicating that physical activity and treatment of hypertension decrease the risk of dementia. There is no evidence that pharmaceutical treatment will benefit people with mild cognitive impairment. In people with Alzheimer's disease, treatment with a cholinesterase inhibitor or memantine (an N-methyl- D-aspartate receptor antagonist) may provide symptomatic relief and enhance quality of life, but does not appear to alter progression of the illness. Non-pharmacological strategies are recommended as first-line treatments for behavioural and psychological symptoms of dementia, which are common in Alzheimer's disease. Atypical antipsychotics have modest benefit in reducing agitation and psychotic symptoms but increase the risk of cardiovascular events. The role of antidepressants in managing depressive symptoms in patients with mild cognitive impairment is uncertain and may increase the risk of delirium and falls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flicker</LastName><ForeName>Leon A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Ageing, University of Western Australia and Royal Perth Hospital, Perth, WA. leonflic@cyllene.uwa.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Andrew H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Beer</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Osvaldo P</ForeName><Initials>OP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22304604</ArticleId><ArticleId IdType="doi">10.5694/mja11.11399</ArticleId><ArticleId IdType="pii">fli11399_fm</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22291757</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1896-9151</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of medical science : AMS</Title><ISOAbbreviation>Arch Med Sci</ISOAbbreviation></Journal><ArticleTitle>Behavioural genetics of Alzheimer's disease: a comprehensive review.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>210</EndPage><MedlinePgn>195-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5114/aoms.2011.22068</ELocationID><Abstract><AbstractText>Behavioural and psychological symptoms of dementia (BPSD) are present in the course of the illness in up to 90% of patients with Alzheimer's disease (AD). They are the main source of caregiver burden and one of the major factors contributing to early institutionalization. The involvement of a genetic component in BPSD aetiology seems beyond controversy, though the exact significance of particular polymorphisms is uncertain in the majority of cases. Multiple genes have been assessed for their putative influence on BPSD risk. In this paper we review the behavioural genetics of AD, particularly the importance, with respect to BPSD risk, of genes coding for apolipoprotein E and proteins involved in the process of neurotransmission: serotonin receptors, serotonin transporter, COMT, MAO-A, tryptophan hydroxylase and dopamine receptors. A general conclusion is the striking inconsistency of the findings, unsurprising in the field of psychiatric genetics. The potential reasons for such discrepancy are exhaustively discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobow</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kloszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Arch Med Sci</MedlineTA><NlmUniqueID>101258257</NlmUniqueID><ISSNLinking>1734-1922</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">behavioural and psychological symptoms of dementia</Keyword><Keyword MajorTopicYN="N">behavioural disturbances</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">polymorphisms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22291757</ArticleId><ArticleId IdType="pmc">PMC3258720</ArticleId><ArticleId IdType="doi">10.5114/aoms.2011.22068</ArticleId><ArticleId IdType="pii">AMS-7-2-195</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hartm DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2003;18:1037&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">14618556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris SH, Steinberg G, Shulman E, Kahn R, Reisberg B. Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. Home Health Care Serv Q. 1987;8:23&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">10317902</ArticleId></ArticleIdList></Reference><Reference><Citation>Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer&#x2019;s disease. J Gerontol B Psychol Sci Soc Sci. 2000;55:S2&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Mintzer JE. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005;19:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15764870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanct&#xf4;t KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207325</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis and aggression in Alzheimer disease. Arch Neurol. 1998;55:1335&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Lanct&#xf4;t KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2004;16:261&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15377733</ArticleId></ArticleIdList></Reference><Reference><Citation>Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology. 2000;55:1460&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11094098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanct&#xf4;t KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49:439&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15362248</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Lanct&#xf4;t KL. Pharmacologic management of neuropsychiatric symptoms of Alzheimer&#x2019;s disease. Can J Psychiatry. 2007;52:630&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">18020111</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;21:144&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16391476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DY, Choo IH, Kim KW, et al. White matter changes associated with psychotic symptoms in Alzheimer's disease patients. J Neuropsychiatry Clin Neurosci. 2006;18:191&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720796</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards-Lee T, Cook I, Fairbanks L, Leuchter A, Cummings JL. Quantitative electroencephalographic correlates of psychosis in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13:163&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910086</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J Clin Invest. 1999;104:1175&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC409831</ArticleId><ArticleId IdType="pubmed">10545516</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer&#x2019;s disease Relation to apolipoprotein E polymorphism. Neurology. 1996;46:413&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran G, Marder K, Tang M, et al. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer&#x2019;s disease. Neurology. 1996;47:256&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710089</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Levy R, McLoughlin DM, Powell JF, Lovestone S. Apolipoprotein E non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;61:580&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486650</ArticleId><ArticleId IdType="pubmed">8971103</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, McLoughlin DM, Powell J, Lovestone S. Reply. J Neurol Neurosurg Psychiatry. 1997;63:273&#x2013;4.</Citation></Reference><Reference><Citation>Holmes C, Russ C, Kirov G, et al. Apolipoprotein E depressive illness depressive symptoms and Alzheimer's disease. Biol Psychiatry. 1998;43:159&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">9494696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Massey H, Lamb H, Morris C. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late-onset Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatr. 1997;63:273&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R, Rodriguez B, Carrera C, Beyer K, Lao JI, Sellers MA. Behavioral changes associated with different apolipoprotein E genotypes in dementia. Alzheimer Dis Assoc Disord. 1997;11:S27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339270</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantillon M, Harwood D, Barker W, et al. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease. Biol Psychiatry. 1997;41:246&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9018400</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsell Y, Corder EH, Basun H, Lannfelt L, Viitanen M, Winblad B. Depression and dementia in relation to apolipoprotein E polymorphism in a population sample age 75+ Biol Psychiatry. 1997;42:898&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">9359975</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsell Y, Basun H, Corder EH, Lannfelt L, Winblad B. Psychotic symptoms and apolipoprotein E genotypes in an elderly population. Biol Psychiatry. 1998;44:139&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E e4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer&#x2019;s disease. Neurology. 1997;49:794&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Baker L, Warren A, et al. Depression, delusions and hallucinations in Alzheimer&#x2019;s Disease No relationship to apolipoprotein E genotype. J Neuropsychiatr Clin Neurosci. 1997;9:64&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9017530</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy GM Jr, Taylor J, Tinklenberg JR, Yesavage JA, et al. The apolipoprotein E epsilon 4 allele is associated with increased behavioral disturbance in Alzheimer's disease. Am J Geriatr Psychiatry. 1997;5:88&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, et al. Factors associated with psychotic symptoms in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatr. 1998:648&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170086</ArticleId><ArticleId IdType="pubmed">9598682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, et al. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 1999;11:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9990558</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Barker WW, Ownby RL St. George-Hyslop PH, Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease. Am J Geriatr Psychiatr . 1999;7:119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322238</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer&#x2019;s disease. Biol Psychiatr. 1999;45:422&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071711</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Vega G, Risser RC, et al. Apolipoprotein E epsilon 4 other risk factors and course of Alzheimer's disease. Biol Psychiatry. 1999;45:633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088051</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabryelewicz T, Religa D, Styczynska M, et al. Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype. Dement Geriatr Cogn Disord. 2002;14:208&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411763</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer&#x2019;s disease. Neurology. 2002;58:1182&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3029097</ArticleId><ArticleId IdType="pubmed">11971084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet R, Kamboh MI, Wisniewski SR, et al. Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer&#x2019;s disease. J Geriatr Psychiatr Neurol. 2002;15:24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11936240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JB, Wang PN, Chen WT, et al. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology. 2004;63:1105&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452311</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart D, McCool K, McIlroy S, Passmore A. Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:1327&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739225</ArticleId><ArticleId IdType="pubmed">15314125</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, McIlroy SP, Passmore AP. Association analysis of apolipoprotein E genotype and risk of depressive symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19:154&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15627763</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J, Curley J, Kaye J, Quinn J, Pfankuch T, Raber J. APOE isoforms and measures of anxiety in probable AD patients and apoe -/- mice. Neurobiol Aging. 2005;26:637&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15708438</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Agosti C, et al. Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2006;14:343&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582043</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Agosti C, et al. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT 5-HTTLPR and APOE polymorphisms. Neurobiol Aging. 2006;27:1595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257094</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, Passmore AP. Genetically increased risk of sleep disruption in Alzheimer's disease. Sleep. 2006;29:1003&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16944667</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Deraut B, Mari&#xeb;n P. Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol Aging. 2006;27:285&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399213</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer's disease with late onset. Eur J Neurol. 2006;13:176&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, et al. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78:123&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077651</ArticleId><ArticleId IdType="pubmed">16980336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobow T, Kloszewska I, Flirski M, Golanska E, Liberski PP. Apoliprotein E genotype and its relation to behavioral and psychological symptoms in Alzheimer&#x2019;s disease [Polish] Post Psych Neurol. 2007;16:215&#x2013;220.</Citation></Reference><Reference><Citation>Zdanys KF, Kleiman TG, MacAvoy MG, et al. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease. Neuropsychopharmacology. 2007;32:171&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16841077</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Archetti S, Costanzi C, et al. ITINAD Working Group. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging. 2009;30:1406&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18179845</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;nblatt E, Zehetmayer S, Bartl J, et al. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res. 2009;43:298&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">18603262</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaranta D, Bizzarro A, Marra C, et al. Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene evidence for an association. J Alzheimers Dis. 2009;16:173&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19158433</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. Int Psychogeriatr. 2009;21:722&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470200</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001;49:355&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherbuin N, Leach LS, Christensen H, Anstey KJ. Neuroimaging and APOE genotype a systematic qualitative review. Dement Geriatr Cogn Disord. 2007;24:348&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911980</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain. 2005;128:2612&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820861</ArticleId><ArticleId IdType="pubmed">16195246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanct&#xf4;t KL, Herrmann N, Nadkarni NK, Leibovitch FS, Caldwell CB, Black SE. Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch Neurol. 2004;61:1731&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534184</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes N, Sharp T. A review of central 5HT receptors and their functions. Neuropharmacology. 1999;38:1083&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10462127</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton N, Owen M. HTR2A association and expression studies in neuropsychiatric genetics. Ann Med. 2005;37:121&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16026119</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Arranz M, Powell J, Collier D, Lovestone S. 5HT2A and 5HT2C receptor polymorphisms and psychopathology in late onset Alzheimer&#x2019;s disease. Hum Mol Genet. 1998;7:1507&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacmias B, Tedde A, Forleo P, et al. Association between 5HT2A receptor polymorphism and psychotic symptoms in Alzheimer&#x2019;s disease. Biol Psychiatry. 2001;50:472&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566166</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer&#x2019;s disease the effect of serotonin receptor gene variation. Am J Med Genet (Neuropsychiatric Genet) 2003;119B:40&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12707936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Micheli R, Ceravolvo M, et al. Serotonergic polymorphisms (5-HTTLPR and 5-HT2A) association studies with psychosis in Alzheimer&#x2019;s disease. Genet Test. 2003;7:309&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15000807</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, Alarcon M, Soloman E, Masterman D, Geshwind D, Cummings J. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Arch Neurol. 2004;61:1249&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wa Lam L, Tang N, Ma S, Zhang W, Chiu K. 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Int J Geriatric Psychiatry. 2004;19:523&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211529</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheli D, Bonvicini C, Rocchi A, et al. No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis. 2006;10:371&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183148</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Donnelly C, Hart D, Carson R, Passmore P. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:126&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16967466</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Kodavali C, Weamer EA, et al. Prediction of psychosis onset in Alzheimer disease the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1054&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818007</ArticleId><ArticleId IdType="pubmed">17525976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, et al. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol Aging. 2008;29:341&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17098333</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelucci F, Bernardini S, Gravina P, et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease a 3-year follow-up longitudinal study. J Alzheimers Dis. 2009;17:203&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">19494443</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HC, Hong CJ, Liu CY, et al. Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer's disease. Psychiatry Clin Neurosci. 2001;55:427&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442897</ArticleId></ArticleIdList></Reference><Reference><Citation>Polesskaya OO, Sokolov BP. Differential expression of the C and T alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res. 2002;67:812&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891796</ArticleId></ArticleIdList></Reference><Reference><Citation>Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem. 2007;14:2053&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17691947</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago A, Serretti A. Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet Part B. 2009;150B:601&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802918</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg KA, Clarke WP, Cunningham KA, Spampinato U. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology. 2008;55:969&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124806</ArticleId><ArticleId IdType="pubmed">18602407</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddley K, Vasiliou AS, Ali FR, Paredes UM, Bubb VJ, Quinn JP. Molecular genetics of monoamine transporters: relevance to brain disorders. Neurochem Res. 2008;33:652&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">17960477</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Holmes C, Sham PC, et al. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer&#x2019;s disease. Neuroreport. 1997;8:683&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106747</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukonick DL, Pollock BG, Sweet RA. The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol. 2001;58:1425&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Pollock BG, Sukonick DL, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. 2001;13:401&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12003247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha TM, Cho DM, Park SW, et al. Evaluating associations between 5-HTTLPR polymorphism and Alzheimer's disease for Korean patients. Dement Geriatr Cogn Disord. 2005;20:31&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15832033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24:201&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease. J Alzheimers Dis. 2007;12:245&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057558</ArticleId></ArticleIdList></Reference><Reference><Citation>Albani D, Prato F, Tettamanti M, et al. The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimer's disease related behavioral disturbances. J Alzheimers Dis. 2009;18:125&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">19625753</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized demented patients. Am J Psychiatry. 2002;159:460&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11870012</ArticleId></ArticleIdList></Reference><Reference><Citation>Munafo` MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry. 2008;63:852&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755289</ArticleId><ArticleId IdType="pubmed">17949693</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Souza UM, Craig IW. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog Brain Res. 2008;172:73&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">18772028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78:815&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1474042</ArticleId><ArticleId IdType="pubmed">16642437</ArticleId></ArticleIdList></Reference><Reference><Citation>Luddington NS, Mandadapu A, Husk M, El-Mallakh RS. Clinical implications of genetic variation in the serotonin transporter promoter region: a review. Prim Care Companion J Clin Psychiatry. 2009;11:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708005</ArticleId><ArticleId IdType="pubmed">19617941</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsey RV, Hastings RS Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry. 2006;163:48&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16390888</ArticleId></ArticleIdList></Reference><Reference><Citation>Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JA. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 2003;23:2008&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742018</ArticleId><ArticleId IdType="pubmed">12657658</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatt S, Faraone SV, Tsuang MT. Association between a functional catechol-O-methyltransferasegene polymorphism and schizoprenia meta-analysis of case&#x2013;control and family-based studies. Am J Psychiatry. 2003;160:469&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12611827</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems genes and the pathogenesis of schizophrenia. Cereb Cortex. 2007;Suppl 1:i171&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17726000</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Agosti C, Archetti S, et al. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci Lett. 2004;370:127&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488308</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Devlin B, Pollock BG, et al. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry. 2005;10:1026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Costanzi C, et al. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging. 2007;28:1231&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837108</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett JH, Scoriels L, Munafo` MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008;64:137&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18339359</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;nsson EG, Kaiser R, Brockm&#xf6;ller J, Nimgaonkar VL, Crocq MA. Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia. Psychiatr Genet. 2004;14:9&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15091310</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves S, Brown R, Howard R, Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology. 2009;72:528&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818181</ArticleId><ArticleId IdType="pubmed">19204262</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Smith H, Ganderton R, et al. Psychosis and aggression in Alzheimer's disease the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737623</ArticleId><ArticleId IdType="pubmed">11723200</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett. 2004;368:33&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Ratcliffe L, Sorour E, et al. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. Int J Geriatr Psychiatry. 2009;24:1020&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19235789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato N, Ueki A, Ueno H, Shinjo H, Morita Y. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type. J Alzheimers Dis. 2009;17:441&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19363270</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;26:257&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18841010</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia. Ann Neurol. 2004;56:121&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15236409</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulley MC, Day IN, Holmes C. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2004;124B:50&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681913</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarim&#xf3;n J, Bertranpetit J, Boada M, Ta`rraga L, Comas D. HSP70-2 (HSPA1B) is associated with noncognitive symptoms in late-onset Alzheimer's disease. J Geriatr Psychiatry Neurol. 2003;16:146&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12967056</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Bernardini S, Bellincampi L, et al. Glutathione S-transferase P1 and T1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am J Geriatr Psychiatry. 2007;15:879&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">17911365</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Allelic variation at the A218C tryptophan hydroxylase polymorphism influences agitation and aggression in Alzheimer's disease. Neurosci Lett. 2004;363:199&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182943</ArticleId></ArticleIdList></Reference><Reference><Citation>Go RC, Perry RT, Wiener H, et al. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato N, Ueki A, Ueno H, Shinjo H, Morita Y. IDE Gene Polymorphism influences on BPSD in mild dementia of Alzheimer's type. Curr Gerontol Geriatr Res. 2008;00:858759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671997</ArticleId><ArticleId IdType="pubmed">19415148</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int J Neuropsychopharm. 2007;10:281&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16817981</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22265590</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Addressing the Alzheimer's disease crisis through better understanding, treatment, and eventual prevention of associated neuropsychiatric syndromes.</ArticleTitle><Pagination><StartPage>60</StartPage><EndPage>64</EndPage><MedlinePgn>60-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2011.11.001</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins Bayview, Baltimore, MD, USA. kostas@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><CollectiveName>Neuropsychiatric Syndromes Professional Interest Area of the International Society to Advance Alzheimer&#x2019;s Research and Treatment</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22265590</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2011.11.001</ArticleId><ArticleId IdType="pii">S1552-5260(11)03003-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22250004</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2012</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Investigating the stability of neuropsychiatric sub-syndromes with progression of dementia: a 2-year prospective study.</ArticleTitle><Pagination><StartPage>1118</StartPage><EndPage>1123</EndPage><MedlinePgn>1118-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2829</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Previous studies have identified sub-syndromes of behavioral and psychological symptoms of dementia. But because of their cross-sectional design, the stability of these sub-syndromes over time remains unknown.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Behavioral and psychological symptoms of dementia of 84 participants (out of an original sample of 144 patients) with Alzheimer's disease and vascular dementia were assessed by using the Neuropsychiatric Inventory every six months for two years. Principal component factor analysis with Varimax rotation was used to detect neuropsychiatric sub-syndromes at each time point.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 12 symptoms were reduced to four factors at baseline, 12, 18, and 24 months and three factors at six months. None of the factor structures matched the four sub-syndromes previously identified by studies. The most stable group of symptoms were a combination of "psychosis" and "hyperactivity" symptoms (delusions, hallucinations, irritability, agitation), which became stable at 18 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The pattern of behavioral and psychological symptoms of dementia sub-syndromes over time has not been studied before, and this research suggests that some stability is evident particularly during the later stages of the disease process. These findings have implications for patients and their caregiver.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bettney</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Manchester Mental Health and Social Care Trust, Park House, North Manchester General Hospital, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Shameem</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Connolly</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>McCollum</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Purandare</LastName><ForeName>Nitin</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22250004</ArticleId><ArticleId IdType="doi">10.1002/gps.2829</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">22234438</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0876</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatrische Praxis</Title><ISOAbbreviation>Psychiatr Prax</ISOAbbreviation></Journal><ArticleTitle>[The most cited work in the 36th year of "Psychiatrischen Praxis." Congratulations!].</ArticleTitle><Pagination><StartPage>3</StartPage><MedlinePgn>3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0031-1298836</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riedel-Heller</LastName><ForeName>Steffi G</ForeName><Initials>SG</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><VernacularTitle>Die meistzitierten Arbeiten im 36. Jahrgang der Psychiatrischen Praxis - Herzlichen Gl&#xfc;ckwunsch!</VernacularTitle><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Prax</MedlineTA><NlmUniqueID>0423204</NlmUniqueID><ISSNLinking>0303-4259</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Psychiatr Prax. 2009 Jan;36(1):7-15. doi: 10.1055/s-2008-1067498</RefSource><PMID Version="1">18777464</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Psychiatr Prax. 2009 Apr;36(3):119-24. doi: 10.1055/s-2008-1067572</RefSource><PMID Version="1">18988143</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Psychiatr Prax. 2009 Jan;36(1):16-22. doi: 10.1055/s-2008-1067566</RefSource><PMID Version="1">18988144</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Psychiatr Prax. 2009 Mar;36(2):53-4. doi: 10.1055/s-0028-1090202</RefSource><PMID Version="1">19263330</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Psychiatr Prax. 2009 Sep;36(6):273-8. doi: 10.1055/s-0028-1090216</RefSource><PMID Version="1">19358086</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Psychiatr Prax. 2009 May;36(4):169-74. doi: 10.1055/s-0028-1090150</RefSource><PMID Version="1">19424939</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016223" MajorTopicYN="Y">Advance Directives</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003134" MajorTopicYN="Y">Commitment of Mentally Ill</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="Y">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054242" MajorTopicYN="N">Emigrants and Immigrants</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="Y">Exercise Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007207" MajorTopicYN="Y">Individuation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="Y">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010358" MajorTopicYN="Y">Patient Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011287" MajorTopicYN="Y">Prejudice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055070" MajorTopicYN="Y">Resistance Training</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012149" MajorTopicYN="N">Restraint, Physical</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013001" MajorTopicYN="N">Somatoform Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22234438</ArticleId><ArticleId IdType="doi">10.1055/s-0031-1298836</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25205955</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0972-7531</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Annals of neurosciences</Title><ISOAbbreviation>Ann Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rapid neurobehavioural analysis based on the effects of an acetylcholinesterase inhibitor from Tephrosia purpurea in Zebrafish.</ArticleTitle><Pagination><StartPage>8</StartPage><EndPage>13</EndPage><MedlinePgn>8-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5214/ans.0972.7531.180403</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Zebrafish is an important model organism for human neurobehavioural studies and compound screening for neurodegenerative disorders like Alzheimer's disease and dementia.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We wanted to analyse the rapid neurobehavioural effects based on acetylcholinesterase inhibitors from Tephrosia purpurea in zebrafish.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Tephrosia purpurea (a herbal neuroactive molecule) extract was analyzed for its rapid neurobehavioural effects and the corresponding psychotic twitches were quantified. The inhibitory activity of acetylcholinesterase was analysed in Zebrafish. The activity of the molecule was confirmed after column chromatography and RP-HPLC purifications. The toxicity of the molecule was also studied in developing zebrafish embryos.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The psychotic body twitches were calculated as crude 484.67 &#xb1; 18.01 at 10 &#x3bc;g/mL, column purified 616 &#xb1; 9.64 at 8 &#x3bc;g/mL, Sep-Pak C18 712.67 &#xb1; 19.5 at 6 &#x3bc;g/mL, and HPLC elution showed 815 &#xb1; 14.93. The minimum inhibitory concentration of acetylcholinesterase in crude and column purified was 100 ng/mL and 5 ng/mL. The IC50 value of acetylcholinesterase inhibitor was calculated as 626ng/mL for crude (P&lt;0.0001), 28.92 ng/mL for Sep-Pak column elution and 64 ng/mL for Donepezil. The HPLC fifth elution showed inhibition percentage as 96.97 &#xb1; 0.12. The organogenesis effects were seen in the drug concentration of 10 &#x3bc;g/mL. Pericardial bulging, trunk and tail flexure with heart edema and head edema were observed in the embryos at higher dose of 30- 40 &#x3bc;g. The LC50 value was 34.87 &#x3bc;g/mL. The studies showed that the inhibitory concentration of acetylcholinesterase is comparatively higher than Donepezil.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Rapid behaviour based screening is an inexpesive assay to identify neuroactive small molecules. This herbal can be further used for the development of drugs for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajaretinam</LastName><ForeName>Rajesh Kannan</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>International Centre for Nanobiotechnology (ICN), Centre for Marine Science and Technology (CMST), Manonmaniam Sundaranar University, Rajakkamangalam, Kanyakumari Dist-629502, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samuel Gnana</LastName><ForeName>Prakash Vincent</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>International Centre for Nanobiotechnology (ICN), Centre for Marine Science and Technology (CMST), Manonmaniam Sundaranar University, Rajakkamangalam, Kanyakumari Dist-629502, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurosci</MedlineTA><NlmUniqueID>101523367</NlmUniqueID><ISSNLinking>0972-7531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acetylcholinesterase</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Tephrosia purpurea</Keyword></KeywordList><CoiStatement>Competing interests: None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25205955</ArticleId><ArticleId IdType="pmc">PMC4117067</ArticleId><ArticleId IdType="doi">10.5214/ans.0972.7531.180403</ArticleId><ArticleId IdType="pii">180403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lanctot KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer&#x2019;s disease: a meta-analysis. Canadian Medical Association Journal. 2003;169:557&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191283</ArticleId><ArticleId IdType="pubmed">12975222</ArticleId></ArticleIdList></Reference><Reference><Citation>Massouli&#xe9; J, Pezzementi L, Bon S et al. Molecular and cellular biology of cholinesterases. Prog Neurobiol. 1993;41:31&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8321908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand C, Chatonnet A, Takke C et al. Zebra fish acetylcholinesterase is encoded by a single gene localized on linkage group 7 gene structure and polymorphism: Molecular forms and expression pattern during development. J Biol Chem. 2001;276(1):464&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">11016933</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq H, Seidman S. Acetylcholinesterase&#x2014;new roles for an old actor. Nat Rev Neurosci. 2001;2:294&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloszewska I. Acetylcholinesterase inhibitors&#x2014;beyond Alzheimer&#x2019;s disease. Psychiatri Pols. 2002;36(6 Suppl):133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12647432</ArticleId></ArticleIdList></Reference><Reference><Citation>Auriacombe S, Pere JJ, Loria-Kanza Y et al. Efficacy and safety of rivastigmine in patients with Alzheimer&#x2019;s disease who failed to benefit from treatment with Donepezil. Curr Med Res Opin. 2002;18:129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer&#x2019;s disease &#x2013; donepezil to rivastigmine, is it worth it? Int J Geriat Psychiat. 2002;17(3):288&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11921158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanneman E, Trevarrow B, Metcalfe WK et al. Segmental pattern of development of the hindbrain and spinal cord of the zebrafish embryo. Development. 1988;103:49&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">3197633</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley K, Kelly RB. Identification of transmembrane glyco- protein specific for secretory vesicles fo neural and endocrine cells. J Cell Biol. 1985;100:1284&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113776</ArticleId><ArticleId IdType="pubmed">2579958</ArticleId></ArticleIdList></Reference><Reference><Citation>Scranton TW, Iwata M, Carlson SS. The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan. J Neurochem. 1993;61:29&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">7685814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresbach T, Qualmann B, Kessels MM et al. The presynaptic cytomatrix of brain synapses. Cell Mol Lif Sci. 2001;58:94&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11146498</ArticleId><ArticleId IdType="pubmed">11229820</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajaretinam RK, Vincent SGV. Isolation of a novel bioactive compound from Rhizophora mucronata for methicillin resistant Staphylococcus aureus (MRSA) and Compound toxicity assessment in Zebrafish embryos. J Pharm Res. 2010;3(8):2000&#x2013;2003.</Citation></Reference><Reference><Citation>Ellman GL, Courtney KD, Andres V et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">13726518</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosasa T, Kuriya Y, Matsui K et al. Inhibitory effect of orally administered donepezil hydrochloride, a novel treatment for AD, on cholinesterase activity in rats. Europ J Pharmocol. 2000;389:173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10688981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannan RR, Jerley AJA, Ranjani M et al. Antimicrobial silver nanoparticle induces organ deformities in the developing Zebrafish (Danio rerio) embryos. J Biomed Sci Engg. 2011b;4:246&#x2013;252.</Citation></Reference><Reference><Citation>OECD. Test Guideline 203 OECD Guideline for Testing of Chemicals Fish, Acute Toxicity Test 1992.</Citation></Reference><Reference><Citation>Fero K, Yokogawa T, Burgees HA. The behavioural repertoire of larval Zebrafish, Zebrafish models in Neurobehavioural Research. In: Kalueff AV, Cachat JM, editors. Neurometh. Vol. 52. 2011. pp. 249&#x2013;290.</Citation></Reference><Reference><Citation>Li J, Mack JA, Souren M et al. Early development of functional spatial maps in the zebrafish olfactory bulb. J Neurosci. 2005;25:5784&#x2013;5795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724871</ArticleId><ArticleId IdType="pubmed">15958745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarotsky V, Sramek JJ, Cutler NR. Galanthamine hydro-bromide: an agent for AD. Am J Healt Sys Pharm. 2003;60:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12635450</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CH, Kim SH, Choi W et al. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodiarutaecarpa. Plant Medic. 1996;62:405&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">8923803</ArticleId></ArticleIdList></Reference><Reference><Citation>Suganthy N, Pandian SK, Devi KP. Neuroprotective effect of seaweeds inhabiting South Indian coastal area (Hare Island, Gulf of Mannar Marine Biosphere Reserve): Cholinesterase inhibitory effect of Hypnea valentiae and Ulva reticulate. Neurosci Lett. 2010;468:216&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">19897016</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer disease, Neurochem Res. 2004;28:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">12675140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR. Alzheimer&#x2019;s centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain. 2006;129:2811&#x2013;2822.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann M, Gardoni F, Marcello E et al. Acetylcholinesterase inhibitors increase ADAM 10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem. 2004;90:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">15341532</ArticleId></ArticleIdList></Reference><Reference><Citation>Greig NH, Utsuki T, Yu Q et al. A new therapeutic target in Alzheimer&#x2019;s treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17:159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11900310</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhomida AS, Al-rajhi AA, Kamal MA et al. Kinetic analysis of the toxicological effect of tacrine (Cognex) on human retinal acetylcholinesterase activity. Toxicol. 2000;147:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837930</ArticleId></ArticleIdList></Reference><Reference><Citation>Perola E, Celai L, Lamba D et al. Long chain analogs of physostigmine as potential drugs for AD: new insight into the mechanism of action in the inhibition of acetylcholinesterase. Biochim Biophys Acta. 1997;1343:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9428657</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23762764</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Print">2090-7966</ISSN><JournalIssue CitedMedium="Print"><Volume>2012</Volume><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>ISRN psychiatry</Title><ISOAbbreviation>ISRN Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Religion, spirituality, and health: the research and clinical implications.</ArticleTitle><Pagination><StartPage>278730</StartPage><MedlinePgn>278730</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">278730</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5402/2012/278730</ELocationID><Abstract><AbstractText>This paper provides a concise but comprehensive review of research on religion/spirituality (R/S) and both mental health and physical health. It is based on a systematic review of original data-based quantitative research published in peer-reviewed journals between 1872 and 2010, including a few seminal articles published since 2010. First, I provide a brief historical background to set the stage. Then I review research on R/S and mental health, examining relationships with both positive and negative mental health outcomes, where positive outcomes include well-being, happiness, hope, optimism, and gratefulness, and negative outcomes involve depression, suicide, anxiety, psychosis, substance abuse, delinquency/crime, marital instability, and personality traits (positive and negative). I then explain how and why R/S might influence mental health. Next, I review research on R/S and health behaviors such as physical activity, cigarette smoking, diet, and sexual practices, followed by a review of relationships between R/S and heart disease, hypertension, cerebrovascular disease, Alzheimer's disease and dementia, immune functions, endocrine functions, cancer, overall mortality, physical disability, pain, and somatic symptoms. I then present a theoretical model explaining how R/S might influence physical health. Finally, I discuss what health professionals should do in light of these research findings and make recommendations in this regard.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koenig</LastName><ForeName>Harold G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Psychiatry, Duke University Medical Center, P.O. Box 3400, Durham, NC 27705, USA ; Department of Medicine, King Abdulaziz University, Jeddah 21413, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>ISRN Psychiatry</MedlineTA><NlmUniqueID>101606355</NlmUniqueID><ISSNLinking>2090-7966</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23762764</ArticleId><ArticleId IdType="pmc">PMC3671693</ArticleId><ArticleId IdType="doi">10.5402/2012/278730</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012. A history of religion, medicine, and healthcare; pp. 15&#x2013;34.</Citation></Reference><Reference><Citation>Koenig HG. Faith and Mental Health: Religious Resources For Healing. Conshohocken, Pa, USA: Templeton Press; 2005.</Citation></Reference><Reference><Citation> See website:  http://www.d.umn.edu/cla/faculty/tbacig/studproj/is3099/pplfrst/Untitled1.html, 2012.</Citation></Reference><Reference><Citation> Restoration and 18th Century Studies in English,  http://instruct.uwo.ca/english/234e/site/bckgrnds/maps/lndnmpbedlam.html, 2012.</Citation></Reference><Reference><Citation>Gamwell L, Tomes N. Madness in America: Cultural and Medical Perceptions of Mental Illness Before 1914. New York, NY, USA: Cornell University Press; 1995.</Citation></Reference><Reference><Citation>Taubes T. &#x2019;Healthy avenues of the mind&#x2019;: psychological theory building and the influence of religion during the era of moral treatment. American Journal of Psychiatry. 1998;155(8):1001&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">9699685</ArticleId></ArticleIdList></Reference><Reference><Citation> See website:  http://friendshospital.com/about/timeline/, 2012.</Citation></Reference><Reference><Citation>Freud S. Obsessive acts and religious practices. In: Strachey J, editor. Sigmund Freud: Collected Papers. Vol. 8. New York, NY, USA: Basic Books; 1907. pp. 25&#x2013;35.</Citation></Reference><Reference><Citation>Freud S. Psycho-analysis and religious origins. In: Strachey J, editor. Sigmund Freud: Collected Papers. Vol. 2. New York: Basic Books; 1919. pp. 92&#x2013;97.</Citation></Reference><Reference><Citation>Freud S. Future of an Illusion. In: Strachey J, editor. The Standard Edition of the Complete Psychological Works of Sigmund Freud. London, UK: Hogarth Press and the Institute of Psycho-Analysis; 1927. pp. 1953&#x2013;1973.</Citation></Reference><Reference><Citation>Freud S. Moses and monotheism. In: Strachey J, editor. The Standard Edition of the Complete Psychological Works of Sigmund Freud. London, UK: Hogarth Press and the Institute of Psycho-Analysis; 1939. pp. 1953&#x2013;1973.</Citation></Reference><Reference><Citation>Larson DB, Thielman SB, Greenwold MA, et al. Religious content in the DSM-III-R glossary of technical terms. American Journal of Psychiatry. 1993;150(12):1884&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pubmed">8238649</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Religion and mental health: what are psychiatrists doing and should do? Psychiatric Bulletin. 2008;32(6):201&#x2013;203.</Citation></Reference><Reference><Citation>Dein S, Cook CCH, Powell A, Eagger S. Religion, spirituality and mental health. The Psychiatrist. 2010;34:63&#x2013;64.</Citation></Reference><Reference><Citation>Poole R, Cook CCH. Praying with a patient constitutes a breach of professional boundaries in psychiatric practice. British Journal of Psychiatry. 2011;199(2):94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804145</ArticleId></ArticleIdList></Reference><Reference><Citation>Curlin FA, Lawrence RE, Odell S, et al. Religion, spirituality, and medicine: psychiatrists&#x2019; and other physicians&#x2019; differing observations, interpretations, and clinical approaches. American Journal of Psychiatry. 2007;164(12):1825&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2861911</ArticleId><ArticleId IdType="pubmed">18056237</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Koenig HG. Concerns about measuring &#x201c;spirituality&#x201d; in research. Journal of Nervous and Mental Disease. 2008;196(5):349&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">18477877</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang MT, Simpson JC. Commentary on Koenig (2008): &#x2018;Concerns about measuring &#x201c;Spirituality&#x201d; in research&#x2019;. Journal of Nervous and Mental Disease. 2008;196(8):647&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">18974679</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Spirituality and Health Research: Methods, Measurement, Statistics, and Resources. Philadelphia, Pa, USA: Templeton Foundation Press; 2011. Definitions; pp. 193&#x2013;206.</Citation></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Koenig HG, McCullough ME, Larson DB. Handbook of Religion and Health. 1st edition. New York, NY, USA: Oxford University Press; 2001.</Citation></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Cooper HM. The IntegrAted ReseArch Review: A SystemAtic ApproAch. Vol. 2. Beverly Hills, Calif, USA: Sage Publications; 1984.</Citation></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, McCullough ME, Larson DB. Handbook of Religion and Health. 1st edition. New York, NY, USA: Oxford University Press; 2001.</Citation></Reference><Reference><Citation>Koenig HG. Religious beliefs and practices of hospitalized medically ill older adults. International Journal of Geriatric Psychiatry. 1998;13:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646148</ArticleId></ArticleIdList></Reference><Reference><Citation>Pargament KI, Koenig HG, Tarakeshwar N, Hahn J. Religious coping methods as predictors of psychological, physical and spiritual outcomes among medically ill elderly patients: a two-year longitudinal study. Journal of Health Psychology. 2004;9(6):713&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367751</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;ssing A, Michalsen A, Balzat HJ, et al. Are spirituality and religiosity resources for patients with chronic pain conditions? Pain Medicine. 2009;10(2):327&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">19284487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tix AP, Frazier PA. The use of religious coping during stressful life events: main effects, moderation, and mediation. Journal of Consulting and Clinical Psychology. 1998;66(2):411&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pubmed">9583344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zald&#xed;var A, Smolowitz J. Perceptions of the importance placed on religion and folk medicine by non-Mexican-American Hispanic adults with diabetes. The Diabetes educator. 1994;20(4):303&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">7851245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitchett G, Murphy PE, Kim J, Gibbons JL, Cameron JR, Davis JA. Religious struggle: prevalence, correlates and mental health risks in diabetic, congestive heart failure, and oncology patients. International Journal of Psychiatry in Medicine. 2004;34(2):179&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15387401</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodergren SC, Hyland ME, Crawford A, Partridge MR. Positivity in illness: self-delusion or existential. British Journal of Health Psychology. 2004;9(2):163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15125802</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimoto SM, Ghorbani S, Baer JM, et al. Religious coping and problem-solving by couples faced with prostate cancer. European Journal of Cancer Care. 2006;15(5):481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">17177907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw B, Han JY, Kim E, et al. Effects of prayer and religious expression within computer support groups on women with breast cancer. Psycho-Oncology. 2007;16(7):676&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">17131348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Effa M, Blount W, Kaslow N, Rothenberg R, Eckman J. Role of spirituality in patients with sickle cell disease. Journal of the American Board of Family Practice. 2001;14(2):116&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">11314918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes JW, Tomlinson A, Blumenthal JA, Davidson J, Sketch MH, Watkins LL. Social support and religiosity as coping strategies for anxiety in hospitalized cardiac patients. Annals of Behavioral Medicine. 2004;28(3):179&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai AL, Park CL, Bu Huang, Rodgers W, Tice TN. Psychosocial mediation of religious coping styles: a study of short-term psychological distress following cardiac surgery. Personality and Social Psychology Bulletin. 2007;33(6):867&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">17483394</ArticleId></ArticleIdList></Reference><Reference><Citation>Heydecke G, Tedesco LA, Kowalski C, Inglehart MR. Complete dentures and oral health-related quality of life&#x2014;do coping styles matter? Community Dentistry and Oral Epidemiology. 2004;32(4):297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">15239781</ArticleId></ArticleIdList></Reference><Reference><Citation>Magyar-Russell G, Fosarelli P, Taylor H, Finkelstein D. Ophthalmology patients&#x2019; religious and spiritual beliefs: an opportunity to build trust in the patient-physician relationship. Archives of Ophthalmology. 2008;126(9):1262&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">18779488</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaquinto S, Spiridigliozzi C, Caracciolo B. Can faith protect from emotional distress after stroke? Stroke. 2007;38(3):993&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303768</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton S, Puchalski CM, Sherman SN, et al. Spirituality and religion in patients with HIV/AIDS. Journal of General Internal Medicine. 2006;21(5):S5&#x2013;S13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924778</ArticleId><ArticleId IdType="pubmed">17083501</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi S, Ghisi M, Iaccarino L, et al. Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care and Research. 2006;55(3):427&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">16739209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuttner L, Chambers CT, Hardial J, Israel DM, Jacobson K, Evans K. A randomized trial of yoga for adolescents with irritable bowel syndrome. Pain Research and Management. 2006;11(4):217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673138</ArticleId><ArticleId IdType="pubmed">17149454</ArticleId></ArticleIdList></Reference><Reference><Citation>Abra&#xed;do-Lanza AF, V&#xe1;squez E, Echeverr&#xed;a SE. En las Manos de Dios [in God&#x2019;s Hands]: religious and other forms of coping among Latinos with arthritis. Journal of Consulting and Clinical Psychology. 2004;72(1):91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657202</ArticleId><ArticleId IdType="pubmed">14756618</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Fitting MD, Eastham J, Zabora J. Emotional adaptation over time in care-givers for chronically ill elderly people. Age and Ageing. 1990;19(3):185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">2363379</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkman S, Chesney MA, Cooke M, Boccellari A, Collette L. Caregiver burden in HIV-positive and HIV-negative partners of men with AIDS. Journal of Consulting and Clinical Psychology. 1994;62(4):746&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">7962878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert RS, Dang Q, Schulz R. Religious beliefs and practices are associated with better mental health in family caregivers of patients with dementia: findings from the reach study. American Journal of Geriatric Psychiatry. 2007;15(4):292&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17158632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepper L, Rogers SA, Coleman EM, Malony HN. The prevalence of religious coping among persons with persistent mental illness. Psychiatric Services. 2001;52(5):660&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">11331802</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosworth HB, Park KS, McQuoid DR, Hays JC, Steffens DC. The impact of religious practice and religious coping on geriatric depression. International Journal of Geriatric Psychiatry. 2003;18(10):905&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">14533123</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SA, Johnson LC, Lohan J. Finding meaning in a child&#x2019;s violent death: a five-year prospective analysis of parents&#x2019; personal narratives and empirical data. Death Studies. 2003;27(5):381&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12793448</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown SL, Nesse RM, House JS, Utz RL. Religion and emotional compensation: results from a prospective study of widowhood. Personality and Social Psychology Bulletin. 2004;30(9):1165&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15359019</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL, Kasl SV, Hays JC. Patterns of religious practice and belief in the last year of life. Journals of Gerontology B. 2001;56(6):S326&#x2013;S334.</Citation><ArticleIdList><ArticleId IdType="pubmed">11682593</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel EJ, Fairclough DL, Wolfe P, Emanuel LL. Talking with terminally ill patients and their caregivers about death, dying, and bereavement: is it stressful? Is it helpful? Archives of Internal Medicine. 2004;164(18):1999&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477434</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Cohen HJ, Blazer DG, et al. Religious coping and depression among elderly, hospitalized medically ill men. American Journal of Psychiatry. 1992;149(12):1693&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">1443246</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson RW, Hansen DM, Moneta G. Differing profiles of developmental experiences across types of organized youth activities. Developmental Psychology. 2006;42(5):849&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">16953691</ArticleId></ArticleIdList></Reference><Reference><Citation>Pienaar J, Rothmann S, Van Devijver FJR. Occupational stress, personality traits, coping strategies, and suicide ideation in the South African police service. Criminal Justice and Behavior. 2007;34(2):246&#x2013;258.</Citation></Reference><Reference><Citation>Smith BW. Coping as a predictor of outcomes following the 1993 midwest flood. Journal of Social Behavior and Personality. 1996;11(2):225&#x2013;239.</Citation></Reference><Reference><Citation>Hollifield M, Hewage C, Gunawardena CN, Kodituwakku P, Bopagoda K, Weerarathnege K. Symptoms and coping in Sri Lanka 20-21 months after the 2004 tsunami. British Journal of Psychiatry. 2008;192(1):39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18174508</ArticleId></ArticleIdList></Reference><Reference><Citation>Pargament KI, Ishler K, Dubow E, et al. Methods of religious coping with the Gulf War: cross-sectional and longitudinal analyses. Journal For the Scientific Study of Religion. 1994;33(4):347&#x2013;361.</Citation></Reference><Reference><Citation>Scholte WF, Olff M, Ventevogel P, et al. Mental health symptoms following war and repression in Eastern Afghanistan. Journal of the American Medical Association. 2004;292(5):585&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292084</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster MA, Stein BD, Jaycox LH, et al. A national survey of stress reactions after the September 11, 2001, terrorist attacks. New England Journal of Medicine. 2001;345(20):1507&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison CG, Taylor RJ. Turning to prayer: social and situational antecedents of religious coping among African Americans. Review of Religious Research. 1996;38(2):111&#x2013;131.</Citation></Reference><Reference><Citation>Pargament KI, Koenig HG, Perez LM. A comprehensive measure of religious coping: development and initial validation of the RCOPE. Journal of Clinical Psychology. 1999;56(4):519&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">10775045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooney J, Woodrum E. Religious coping and church-based social support as predictors of mental health outcomes: testing a conceptual model. Journal For the Scientific Study of Religion. 2002;41(2):359&#x2013;368.</Citation></Reference><Reference><Citation>Koenig HG, Kvale JN, Ferrel C. Religion and well-being in later life. Gerontologist. 1988;28(1):18&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">3342990</ArticleId></ArticleIdList></Reference><Reference><Citation>Willits FK, Crider DM. Religion and well-being: men and women in the middle years. Review of Religious Research. 1988;29(3):281&#x2013;294.</Citation></Reference><Reference><Citation>Levin JS, Chatters LM, Taylor RJ. Religious effects on health status and life satisfaction among Black Americans. Journals of Gerontology B. 1995;50(3):S154&#x2013;S163.</Citation><ArticleIdList><ArticleId IdType="pubmed">7767699</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin JS, Markides KS, Ray LA. Religious attendance and psychological well-being in Mexican Americans: a panel analysis of three-generations data. Gerontologist. 1996;36(4):454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">8771973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison CG, Boardman JD, Williams DR, Jackson JS. Religious involvement, stress, and mental health: findings from the 1995 Detroit area study. Social Forces. 2001;80(1):215&#x2013;249.</Citation></Reference><Reference><Citation>Krause N. Religious meaning and subjective well-being in late life. Journals of Gerontology B. 2003;58(3):S160&#x2013;S170.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730317</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Common facets of religion, unique facets of religion, and life satisfaction among older African Americans. Journals of Gerontology B. 2004;59(2):S109&#x2013;S117.</Citation><ArticleIdList><ArticleId IdType="pubmed">15014098</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene KV, Yoon BJ. Religiosity, economics and life satisfaction. Review of Social Economy. 2004;62(2):245&#x2013;273.</Citation></Reference><Reference><Citation>Lelkes O. Tasting freedom: happiness, religion and economic transition. Journal of Economic Behavior and Organization. 2006;59(2):173&#x2013;194.</Citation></Reference><Reference><Citation>Uppal S. Impact of the timing, type and severity of disability on the subjective well-being of individuals with disabilities. Social Science and Medicine. 2006;63(2):525&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530905</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree S, Pelham B, World Gallup Poll. 2009. Religion Provides Emotional Boost to World&#x2019;s Poor, Gallup.</Citation></Reference><Reference><Citation>Dalgalarrondo P, Mar&#xed;n-Le&#xf3;n L, Botega JN, De Azevedo Barros MB, Bosco de Oliveira H. Religious affiliation and psychiatric morbidity in Brazil: higher rates among evangelicals and spiritists. International Journal of Social Psychiatry. 2008;54(6):562&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18974194</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S, Seligman MEP. The hope of fundamentalists. Psychological Science. 1994;5:58&#x2013;59.</Citation></Reference><Reference><Citation>Murphy PE, Ciarrocchi JW, Piedmont RL, Cheston S, Peyrot M, Fitchett G. The relation of religious belief and practices, depression, and hopelessness in persons with clinical depression. Journal of Consulting and Clinical Psychology. 2000;68(6):1102&#x2013;1106.</Citation><ArticleIdList><ArticleId IdType="pubmed">11142544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai AL, Park CL, Bu Huang, Rodgers W, Tice TN. Psychosocial mediation of religious coping styles: a study of short-term psychological distress following cardiac surgery. Personality and Social Psychology Bulletin. 2007;33(6):867&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">17483394</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL, Kasl SV. Religion among disabled and nondisabled persons I: cross-sectional patterns in health practices, social activities, and well-being. Journals of Gerontology B. 1997;52(6):S294&#x2013;S305.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403523</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Church-based social support and health in old age: exploring variations by race. Journals of Gerontology B. 2002;57(6):S332&#x2013;S347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai AL, Peterson C, Bolling SF, Koenig H. Private prayer and optimism in middle-aged and older patients awaiting cardiac surgery. Gerontologist. 2002;42(1):70&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11815701</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Religious doubt and psychological well-being: a longitudinal investigation. Review of Religious Research. 2006;47(3):287&#x2013;302.</Citation></Reference><Reference><Citation>Francis LJ. The relationship between bible reading and purpose in life among 13-15-year-olds. Mental Health, Religion and Culture. 2000;3(1):33&#x2013;36.</Citation></Reference><Reference><Citation>Skrabski A, Kopp M, R&#xf3;zsa S, R&#xe9;thelyi J, Rahe RH. Life meaning: an important correlate of health in the Hungarian population. International Journal of Behavioral Medicine. 2005;12(2):78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15901216</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Meaning in life and mortality. Journal of Gerontology B. 2009;(supplement 64)(4):S517&#x2013;S527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905132</ArticleId><ArticleId IdType="pubmed">19515991</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. God-mediated control and change in self-rated health. International Journal for the Psychology of Religion. 2010;20(4):267&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2971554</ArticleId><ArticleId IdType="pubmed">21057586</ArticleId></ArticleIdList></Reference><Reference><Citation>Watters W. Deadly Doctrine: Health, Illness, and Christian God-Talk. Buffalo, NY, USA: Prometheus Books; 1992.</Citation></Reference><Reference><Citation>Ellison CG. Religious involvement and self-perception among Black Americans. Social Forces. 1993;71:1027&#x2013;1055.</Citation></Reference><Reference><Citation>Krause N, Van Tran T. Stress and religious involvement among older Blacks. Journals of Gerontology. 1989;44(1):S4&#x2013;S13.</Citation><ArticleIdList><ArticleId IdType="pubmed">2911002</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Stress, religiosity, and psychological well-being among older blacks. Journal of Aging and Health. 1992;4(3):412&#x2013;439.</Citation></Reference><Reference><Citation>Krause N. Religiosity and self-esteem among older adults. Journals of Gerontology B. 1995;50(5):P236&#x2013;P246.</Citation><ArticleIdList><ArticleId IdType="pubmed">7656073</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Religious meaning and subjective well-being in late life. Journals of Gerontology B. 2003;58(3):S160&#x2013;S170.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730317</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TN, Tov W, Taylor J. Religiousness and depressive symptoms in five ethnic adolescent groups. International Journal for the Psychology of Religion. 2007;17(3):209&#x2013;232.</Citation></Reference><Reference><Citation>Hill TD, Burdette AM, Regnerus M, Angel RJ. Religious involvement and attitudes toward parenting among low-income Urban women. Journal of Family Issues. 2008;29(7):882&#x2013;900.</Citation></Reference><Reference><Citation>Trevino KM, Pargament KI, Cotton S, et al. Religious coping and physiological, psychological, social, and spiritual outcomes in patients with HIV/AIDS: cross-sectional and longitudinal findings. AIDS and Behavior. 2010;14(2):379&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison CG, Taylor RJ. Turning to prayer: social and situational antecedents of religious coping among African Americans. Review of Religious Research. 1996;38(2):111&#x2013;131.</Citation></Reference><Reference><Citation>Miller K, Yost B, Flaherty S, et al. Health status, health conditions, and health behaviors among Amish women. Results from the Central Pennsylvania Women&#x2019;s Health Study (CePAWHS) Women&#x2019;s Health Issues. 2007;17(3):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17459726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivett VR. Religious motivation in middle age: correlates and implications. Journals of Gerontology. 1979;34(1):106&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">759486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky FD, Stump TE. Age and the sense of control among older adults. Journals of Gerontology B. 1996;51(4):S217&#x2013;S220.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieman S, Van Gundy K, Taylor J. The relationship between age and depressive symptoms: a test of competing explanatory and suppression influences. Journal of Aging and Health. 2002;14(2):260&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">11995743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiori KL, Brown EE, Cortina KS, Antonucci TC. Locus of control as a mediator of the relationship between religiosity and life satisfaction: Age, race, and gender differences. Mental Health, Religion and Culture. 2006;9(3):239&#x2013;263.</Citation></Reference><Reference><Citation>Shaw BA, Krause N. Exploring race variations in aging and personal control. Journals of Gerontology B. 2001;56(supplement 2):S119&#x2013;S124.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky FD, Wyrwich KW, Kroenke K, Babu AN, Tierney WM. 9&#x2013;11, Personal stress, mental health, and sense of control among older adults. Journals of Gerontology B. 2003;58(supplement 3):S146&#x2013;S150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce MA, Thornton MC. It&#x2019;s my world? Exploring black and white perceptions of personal control. Sociological Quarterly. 2004;45(3):597&#x2013;612.</Citation></Reference><Reference><Citation>Nelson LD, Dynes RR. The impact of devotionalism and attendance on ordinary and emergency helping behavior. Journal For the Scientific Study of Religion. 1976;15(1):47&#x2013;59.</Citation></Reference><Reference><Citation>Okun MA. Predictors of volunteer status in a retirement community. International Journal of Aging and Human Development. 1993;36(1):57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425747</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris AHS, Thoresen CE. Volunteering is associated with delayed mortality in older people: analysis of the longitudinal study of aging. Journal of Health Psychology. 2005;10(6):739&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">16176953</ArticleId></ArticleIdList></Reference><Reference><Citation>Saroglou V, Pichon I, Trompette L, Verschueren M, Dernelle R. Prosocial behavior and religion: new evidence based on projective measures and peer ratings. Journal for the Scientific Study of Religion. 2005;44(3):323&#x2013;348.</Citation></Reference><Reference><Citation>Warburton J, Stirling C. Factors affecting volunteering among older Rural and city dwelling adults in Australia. Educational Gerontology. 2007;33(1):23&#x2013;43.</Citation></Reference><Reference><Citation>Ecklund EH, Park JZ. Religious diversity and community volunteerism among Asian Americans. Journal for the Scientific Study of Religion. 2007;46(2):233&#x2013;244.</Citation></Reference><Reference><Citation>Yew YW, Saw SM, Pan JCH, et al. Knowledge and beliefs on corneal donation in Singapore adults. British Journal of Ophthalmology. 2005;89(7):835&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1772726</ArticleId><ArticleId IdType="pubmed">15965162</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan SE. Many facets of reluctance: African Americans and the decision (not) to donate organs. Journal of the National Medical Association. 2006;98(5):695&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569263</ArticleId><ArticleId IdType="pubmed">16749644</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorsuch RL, Hao JY. Forgiveness: an exploratory factor analysis and its relationship to religious variables. Review of Religious Research. 1993;34(4):333&#x2013;347.</Citation></Reference><Reference><Citation>Krause N, Ellison CG. Forgiveness by God, forgiveness of others, and psychological well-being in late life. Journal For the Scientific Study of Religion. 2003;42(1):77&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046863</ArticleId><ArticleId IdType="pubmed">21373377</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussaint LL, Williams DR. National survey results for Protestant, Catholic, and nonreligious experiences of seeking forgiveness and of forgiveness of self, of others, and by God. Journal of Psychology and Christianity. 2008;27(2):120&#x2013;130.</Citation></Reference><Reference><Citation>Krause N. Church-based emotional support and self-forgiveness in late life. Review of Religious Research. 2010;52(1):72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3113535</ArticleId><ArticleId IdType="pubmed">21686035</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussaint LL, Marschall JC, Williams DR. Prospective associations between religiousness/spirituality and depression and mediating effeccts of forgiveness in a nationally representative sample of United States adults. Depression Research and Treatment. 2012;2012:10 pages.267820</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364534</ArticleId><ArticleId IdType="pubmed">22675623</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmons RA, Kneezel TT. Giving thanks: spiritual and religious correlates of gratitude. Journal of Psychology and Christianity. 2005;24(2):140&#x2013;148.</Citation></Reference><Reference><Citation>Krause N. Religious involvement, gratitude, and change in depressive symptoms over time. International Journal for the Psychology of Religion. 2009;19(3):155&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843928</ArticleId><ArticleId IdType="pubmed">20333271</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen PR, Masters KS. Does compassion mediate the intrinsic religion-health relationship? Annals of Behavioral Medicine. 2005;30(3):217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16336073</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL, Kasl SV. Religion, disability, depression, and the timing of death. American Journal of Sociology. 1992;97(4):1052&#x2013;1079.</Citation></Reference><Reference><Citation>Kennedy GJ, Kelman HR, Thomas C, Chen J. The relation of religious preference and practice to depressive symptoms among 1,855 older adults. Journals of Gerontology. 1996;51(6):P301&#x2013;P308.</Citation><ArticleIdList><ArticleId IdType="pubmed">8931617</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Cohen HJ, Blazer DG, et al. Religious coping and depression among elderly, hospitalized medically ill men. American Journal of Psychiatry. 1992;149(12):1693&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">1443246</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, George LK, Peterson BL. Religiosity and remission of depression in medically ill oder patients. American Journal of Psychiatry. 1998;155(4):536&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546001</ArticleId></ArticleIdList></Reference><Reference><Citation>Musick MA, Koenig HG, Hays JC, Cohen HJ. Religious activity and depression among community-dwelling elderly persons with cancer: The moderating effect of race. Journals of Gerontology. 1998;53(4):S218&#x2013;S227.</Citation><ArticleIdList><ArticleId IdType="pubmed">9679523</ArticleId></ArticleIdList></Reference><Reference><Citation>Propst LR, Ostrom R, Watkins P, Dean T, Mashburn D. Comparative efficacy of religious and nonreligious cognitive-behavioral therapy for the treatment of clinical depression in religious individuals. Journal of Consulting and Clinical Psychology. 1992;60(1):94&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">1556292</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge WJ, Shema SJ, Cohen RD, Kaplan GA. Religious attendance increases survival by improving and maintaining Good health behaviors, mental health, and social relationships. Annals of Behavioral Medicine. 2001;23(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11302358</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Religion and remission of depression in medical inpatients with heart failure/pulmonary disease. Journal of Nervous and Mental Disease. 2007;195(5):389&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502804</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Voorhees BW, Paunesku D, Kuwabara SA, et al. Protective and vulnerability factors predicting new-onset depressive episode in a representative of U.S. adolescents. Journal of Adolescent Health. 2008;42(6):605&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">18486870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison CG, Flannelly KJ. Religious involvement and risk of major depression in a prospective nationwide study of African American adults. Journal of Nervous and Mental Disease. 2009;197(8):568&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">19684492</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Religious involvement, gratitude, and change in depressive symptoms over time. International Journal for the Psychology of Religion. 2009;19(3):155&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843928</ArticleId><ArticleId IdType="pubmed">20333271</ArticleId></ArticleIdList></Reference><Reference><Citation>Payman V, George K, Ryburn B. Religiosity of depressed elderly inpatients. International Journal of Geriatric Psychiatry. 2008;23(1):16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17503542</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel D, Bloom JR, Gottheil E. Family environment as a predictor of adjustment to metastatic breast carcinoma. Journal of Psychosocial Oncology. 1983;1(1):33&#x2013;44.</Citation></Reference><Reference><Citation>Pargament KI, Koenig HG, Tarakeshwar N, Hahn J. Religious coping methods as predictors of psychological, physical and spiritual outcomes among medically ill elderly patients: a two-year longitudinal study. Journal of Health Psychology. 2004;9(6):713&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367751</ArticleId></ArticleIdList></Reference><Reference><Citation>Braam AW, Delespaul P, Beekman AT, et al. National context of healthcare, economy and religion, and the association between disability and depressive symptoms in older Europeans: results from the EURODEP concerted action. European Journal of Ageing. 2004;1(1):26&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547688</ArticleId><ArticleId IdType="pubmed">28794699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijngaards-De Meij L, Stroebe M, Schut H, et al. Couples at risk following the death of their child: Predictors of grief versus depression. Journal of Consulting and Clinical Psychology. 2005;73(4):617&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">16173849</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon Z, Gelkopf M, Bleich A. Is terror gender-blind? Gender differences in reaction to terror events. Social Psychiatry and Psychiatric Epidemiology. 2005;40(12):947&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341617</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliassen AH, Taylor J, Lloyd DA. Subjective religiosity and depression in the transition to adulthood. Journal for the Scientific Study of Religion. 2005;44(2):187&#x2013;199.</Citation></Reference><Reference><Citation>Bormann JE, Gifford AL, Shively M, et al. Effects of spiritual mantram repetition on HIV outcomes: a randomized controlled trial. Journal of Behavioral Medicine. 2006;29(4):359&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847590</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamins MR. Predictors of preventive health care use among middle-aged and older adults in Mexico: the role of religion. Journal of Cross-Cultural Gerontology. 2007;22(2):221&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17340204</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco KJ. Religious activities, strength from faith, and social functioning among African American and white nursing home residents. Journal of Religion, Spirituality and Aging. 2007;19(4):3&#x2013;20.</Citation></Reference><Reference><Citation>Braam AW, Deeg DJH, Poppelaars JL, Beekman ATF, Van Tilburg W. Prayer and depressive symptoms in a period of secularization: patterns among older adults in the Netherlands. American Journal of Geriatric Psychiatry. 2007;15(4):273&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">17384312</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson G. Chronic pain and praying to a higher power: useful or useless? Journal of Religion and Health. 2008;47(2):176&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">19105010</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WR, Forcehimes A, O&#x2019;Leary MJ, LaNoue MD. Spiritual direction in addiction treatment: two clinical trials. Journal of Substance Abuse Treatment. 2008;35(4):434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600849</ArticleId><ArticleId IdType="pubmed">18657945</ArticleId></ArticleIdList></Reference><Reference><Citation>Maselko J, Buka S. Religious activity and lifetime prevalence of psychiatric disorder. Social Psychiatry and Psychiatric Epidemiology. 2008;43(1):18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17960316</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann JE, Gifford AL, Shively M, et al. Effects of spiritual mantram repetition on HIV outcomes: a randomized controlled trial. Journal of Behavioral Medicine. 2006;29(4):359&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847590</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WR, Forcehimes A, O&#x2019;Leary MJ, LaNoue MD. Spiritual direction in addiction treatment: two clinical trials. Journal of Substance Abuse Treatment. 2008;35(4):434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600849</ArticleId><ArticleId IdType="pubmed">18657945</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TB, McCullough ME, Poll J. Religiousness and depression: evidence for a main effect and the moderating influence of stressful life events. Psychological Bulletin. 2003;129(4):614&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">12848223</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L, Wickramaratne P, Gameroff MJ, Sage M, Tenke CE, Weissman MM. Religiosity and major depression in adults at high risk: a ten-year prospective study. American Journal of Psychiatry. 2012;169(1):89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3547523</ArticleId><ArticleId IdType="pubmed">21865527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasen S, Wickramaratne P, Gameroff MJ. Religiosity and resilience in persons at high risk for major depression. Psychological Medicine. 2012;42(3):509&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552391</ArticleId><ArticleId IdType="pubmed">21849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L, Bansai R, Wickramaratne P, Hao X, Tenke CE, Weissman MM. &#x2018;Neuroanatomical correlates of religiosity and spirituality in adults at high and low familial risk for depression&#x2019; (forthcoming)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3921896</ArticleId><ArticleId IdType="pubmed">24369341</ArticleId></ArticleIdList></Reference><Reference><Citation>Paykel ES, Myers JK, Lindenthal JJ, Tanner J. Suicidal feelings in the general population: a prevalence study. British Journal of Psychiatry. 1974;124(5):460&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">4836376</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh BK, Williams JS, Ryther BJ. Public approval of suicide: a situational analysis. Suicide and Life-Threatening Behavior. 1986;16(4):409&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">3798519</ArticleId></ArticleIdList></Reference><Reference><Citation>Truett KR, Eaves LJ, Meyer JM, Heath AC, Martin NG. Religion and education as mediators of attitudes: a multivariate analysis. Behavior Genetics. 1992;22(1):43&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590730</ArticleId></ArticleIdList></Reference><Reference><Citation>Stack S, Wasserman I. The effect of marriage, family, and religious ties on African American suicide ideology. Journal of Marriage and the Family. 1995;57(1):215&#x2013;222.</Citation></Reference><Reference><Citation>Krull C, Trovato F. The quiet revolution and the sex differential in Quebec&#x2019;s suicide rates: 1931&#x2013;1986. Social Forces. 1994;72(4):1121&#x2013;1147.</Citation></Reference><Reference><Citation>Siegrist M. Church attendance, denomination, and suicide ideology. Journal of Social Psychology. 1996;136(5):559&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">8942315</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeleman J, Halpern D, Leon D, Lewis G. Tolerance of suicide, religion and suicide rates: an ecological and individual study in 19 Western countries. Psychological Medicine. 1997;27(5):1165&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">9300520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison CG, Burr JA, Mccall PL. Religious homogeneity and metropolitan suicide rates. Social Forces. 1997;76(1):273&#x2013;299.</Citation></Reference><Reference><Citation>Neeleman J, Wessely S, Lewis G. Suicide acceptability in African- and white Americans: the role of religion. Journal of Nervous and Mental Disease. 1998;186(1):12&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9457142</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeleman J. Regional suicide rates in the Netherlands: does religion still play a role? International Journal of Epidemiology. 1998;27(3):466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">9698137</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeleman J, Lewis G. Suicide, religion, and socioeconomic conditions. An ecological study in 26 countries, 1990. Journal of Epidemiology and Community Health. 1999;53(4):204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1756856</ArticleId><ArticleId IdType="pubmed">10396545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet PA, Duberstein PR, Conwell Y, Seidlitz L. The effect of participation in religious activities on suicide versus natural death in adults 50 and older. Journal of Nervous and Mental Disease. 2000;188(8):543&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">10972575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonnemaker JM, McNeely CA, Blum RW. Public and private domains of religiosity and adolescent health risk behaviors: evidence from the National Longitudinal Study of Adolescent Health. Social Science and Medicine. 2003;57(11):2049&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearman PS, Moody J. Suicide and friendships among American adolescents. American Journal of Public Health. 2004;94(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449832</ArticleId><ArticleId IdType="pubmed">14713704</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MP, Ho CH, Kingree JB. Prospective associations between delinquency and suicidal behaviors in a nationally representative sample. Journal of Adolescent Health. 2007;40(3):232&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">17321423</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasic DT, Belik SL, Elias B, Katz LY, Enns M, Sareen J. Spirituality, religion and suicidal behavior in a nationally representative sample. Journal of Affective Disorders. 2009;114(1-3):32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18799219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhartha T, Jena S. Suicidal behaviors in adolescents. Indian Journal of Pediatrics. 2006;73(9):783&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">17006035</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson CV, Hayes JA. Troubled spirits: prevalence of predictors of religious and spiritual concerns among university students and counseling center clients. Journal of Counseling Psychology. 2003;50(4):409&#x2013;419.</Citation></Reference><Reference><Citation>Williams DR, Larson DB, Buckler RE, Heckmann RC, Pyle CM. Religion and psychological distress in a community sample. Social Science and Medicine. 1991;32(11):1257&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">2068608</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Fpord SM, George LK, Blazer DG, Meador KG. Religion and anxiety disorder: an examination and comparison of associations in young, middle-aged, and elderly adults. Journal of Anxiety Disorders. 1993;7(4):321&#x2013;342.</Citation></Reference><Reference><Citation>Azhar MZ, Varma SL, Dharap AS. Religious psychotherapy in anxiety disorder patients. Acta Psychiatrica Scandinavica. 1994;90(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">7976440</ArticleId></ArticleIdList></Reference><Reference><Citation>Razali SM, Hasanah CI, Aminah K, Subramaniam M. Religious-sociocultural psychotherapy in patients with anxiety and depression. Australian and New Zealand Journal of Psychiatry. 1998;32(6):867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardozo LB, Bilukha OO, Gotway Crawford CA, et al. Mental health, social functioning, and disability in postwar Afghanistan. Journal of the American Medical Association. 2004;292(5):575&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292083</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YY. Written emotional expression and religion: effects on PTSD symptoms. International Journal of Psychiatry in Medicine. 2005;35(3):273&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">16480242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehnder D, Prchal A, Vollrath M, Landolt MA. Prospective study of the effectiveness of coping in pediatric patients. Child Psychiatry and Human Development. 2006;36(3):351&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16362238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pargament KI. Migraines and meditation: does spirituality matter? Journal of Behavioral Medicine. 2008;31(4):351&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">18551362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill TD, Burdette AM, Ellison CG, Musick MA. Religious attendance and the health behaviors of Texas adults. Preventive Medicine. 2006;42(4):309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">16445971</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley E, Baillie A, Huxter M, Price M, Sinclair E. Mindfulness-based cognitive therapy for individuals whose lives have been affected by cancer: a randomized controlled trial. Journal of Consulting and Clinical Psychology. 2010;78(1):72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">20099952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidner M, Hammer AL. Coping with missile attack: resources, strategies, and outcomes. Journal of Personality. 1992;60(4):709&#x2013;746.</Citation></Reference><Reference><Citation>Martz E. Death anxiety as a predictor of posttraumatic stress levels among individuals with spinal cord injuries. Death Studies. 2004;28(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">14969275</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon Z, Gelkopf M, Bleich A. Is terror gender-blind? Gender differences in reaction to terror events. Social Psychiatry and Psychiatric Epidemiology. 2005;40(12):947&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341617</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WR, Forcehimes A, O&#x2019;Leary MJ, LaNoue MD. Spiritual direction in addiction treatment: two clinical trials. Journal of Substance Abuse Treatment. 2008;35(4):434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600849</ArticleId><ArticleId IdType="pubmed">18657945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollifield M, Hewage C, Gunawardena CN, Kodituwakku P, Bopagoda K, Weerarathnege K. Symptoms and coping in Sri Lanka 20-21 months after the 2004 tsunami. British Journal of Psychiatry. 2008;192(1):39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18174508</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisenhelder JB, Marcum JP. Terrorism, post-traumatic stress, coping strategies, and spiritual outcomes. Journal of Religion and Health. 2009;48(1):46&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19229625</ArticleId></ArticleIdList></Reference><Reference><Citation>Korenromp MJ, Page-Christiaens GCML, van den Bout J, Mulder EJH, Visser GHA. Adjustment to termination of pregnancy for fetal anomaly: a longitudinal study in women at 4, 8, and 16 months. American Journal of Obstetrics and Gynecology. 2009;201(2):160-e1&#x2013;160-e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19560116</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller WR, Forcehimes A, O&#x2019;Leary MJ, LaNoue MD. Spiritual direction in addiction treatment: two clinical trials. Journal of Substance Abuse Treatment. 2008;35(4):434&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600849</ArticleId><ArticleId IdType="pubmed">18657945</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese A, John JK, Rajkumar S, Richard J, Sethi BB, Trivedi JK. Factors associated with the course and outcome of schizophrenia in India. Results of a two-year multicentre follow-up study. British Journal of Psychiatry. 1989;154:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">2686796</ArticleId></ArticleIdList></Reference><Reference><Citation>Benda BB. Factors associated with rehospitalization among veterans in a substance abuse treatment program. Psychiatric Services. 2002;53(9):1176&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221320</ArticleId></ArticleIdList></Reference><Reference><Citation>Benda BB. A survival analysis of dimensions of religion among homeless substance abusers: going into the remotest regions. Marriage &amp; Family. 2002;5(1):99&#x2013;114.</Citation></Reference><Reference><Citation>Siddle R, Haddock G, Tarrier N, Faragher EB. Religious delusions in patients admitted to hospital with schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 2002;37(3):130&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">11990010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis-Fern&#xe1;ndez R, Horvitz-Lennon M, Blanco C, Guarnaccia PJ, Cao Z, Alegr&#xed;a M. Significance of endorsement of psychotic symptoms by US latinos. Journal of Nervous and Mental Disease. 2009;197(5):337&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782526</ArticleId><ArticleId IdType="pubmed">19440107</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Schizophrenia and other psychotic disorders. In: Peteet J, Lu FG, Narrow WE, editors. Religious and Spiritual Issues in Psychiatric Diagnosis: A Research Agenda For DSM-V. chapter 2. Arlington, Va, USA: American Psychiatric Association Press; 2011. pp. 31&#x2013;52.</Citation></Reference><Reference><Citation>Cruz M, Pincus HA, Welsh DE, Greenwald D, Lasky E, Kilbourne AM. The relationship between religious involvement and clinical status of patients with bipolar disorder. Bipolar Disorders. 2010;12(1):68&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853940</ArticleId><ArticleId IdType="pubmed">20148868</ArticleId></ArticleIdList></Reference><Reference><Citation>Baetz M, Bowen R, Jones G, Koru-Sengul T. How spiritual values and worship attendance relate to psychiatric disorders in the Canadian population. Canadian Journal of Psychiatry. 2006;51(10):654&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17052033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorston GA. Mania precipitated by meditation: a case report and literature review. Mental Health, Religion and Culture. 2001;4(2):209&#x2013;213.</Citation></Reference><Reference><Citation>Costa PT, McCrae RR. Normal personality assessment in clinical practice: the NEO personality inventory. Psychological Assessment. 1992;4(1):5&#x2013;13.</Citation></Reference><Reference><Citation>Liu XH. Eysenck personality questionnaire and Eysenck personality theory. Chinese Journal of Neurology and Psychiatry. 1984;17(1):53&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">6468114</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. chapter 14. New York, NY, USA: Oxford University Press; 2012. Personality and personality disorder; pp. 281&#x2013;288.</Citation></Reference><Reference><Citation>Jensen-Campbell LA, Adams R, Perry DG, Workman KA, Furdella JQ, Egan SK. Agreeableness, extraversion, and peer relations in early adolescence: Winning friends and deflecting aggression. Journal of Research in Personality. 2002;36(3):224&#x2013;251.</Citation></Reference><Reference><Citation>O&#x2019;Cleirigh C, Ironson G, Weiss A, Costa PT. Conscientiousness predicts disease progression (CD4 Number and Viral Load) in people living with HIV. Health Psychology. 2007;26(4):473&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">17605567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Archives of General Psychiatry. 2007;64(10):1204&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisin IH, Cahalan D. Comparison of abstainers and heavy drinkers in a national survey. Psychiatric Research Reports. 1968;24:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">5720441</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoateng AY, Bahr SJ. Religion, family, and adolescent drug use. Sociological Perspectives. 1986;29(1):53&#x2013;76.</Citation></Reference><Reference><Citation>Cochran JK, Beeghley L, Bock EW. Religiosity and alcohol behavior: an exploration of reference group theory. Sociological Forum. 1988;3(2):256&#x2013;276.</Citation></Reference><Reference><Citation>Bock EW, Cochran JK, Beehgley L. Moral messages: the relative influence of denomination on the religiosity-alcohol relationship. Sociological Quarterly. 1987;28(1):89&#x2013;103.</Citation></Reference><Reference><Citation>Beeghley L, Bock EW, Cochran JK. Religious change and alcohol use: An application of reference group and socialization theory. Sociological Forum. 1990;5(2):261&#x2013;278.</Citation></Reference><Reference><Citation>Koenig HG, George LK, Meador KG, Blazer DG, Ford SM. Religious practices and alcoholism in a southern adult population. Hospital and Community Psychiatry. 1994;45(3):225&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">8188192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler KS, Gardner CO, Prescott CA. Religion, psychopathology, and substance use and abuse: A multimeasure, genetic-epidemiologic study. American Journal of Psychiatry. 1997;154(3):322&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">9054778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace JM, Forman TA. Religion&#x2019;s role in promoting health and reducing risk among American youth. Health Education and Behavior. 1998;25(6):721&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">9813744</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TN, Schulenberg J, Bachman JG, O&#x2019;Malley PM, Johnston LD. Are risk and protective factors for substance use consistent across historical time?: national data from the high school classes of 1976 through 1997. Prevention Science. 2001;2(1):29&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11519373</ArticleId></ArticleIdList></Reference><Reference><Citation>Regnerus MD, Elder GH. Religion and vulnerability among low-risk adolescents. Social Science Research. 2003;32(4):633&#x2013;658.</Citation></Reference><Reference><Citation>Gotham HJ, Sher KJ, Wood PK. Alcohol involvement and developmental task completion during young adulthood. Journal of Studies on Alcohol. 2003;64(1):32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12608481</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth BM, Curran GM, Han X. Predictors of short-term course of drinking in untreated rural and urban at-risk drinkers: effects of gender, illegal drug use and psychiatric comorbidity. Journal of Studies on Alcohol. 2004;65(1):63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">15000505</ArticleId></ArticleIdList></Reference><Reference><Citation>Windle M, Mun EY, Windle RC. Adolescent-to-young adulthood heavy drinking trajectories and their prospective predictors. Journal of Studies on Alcohol. 2005;66(3):313&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">16047520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliewer W, Murrelle L. Risk and protective factors for adolescent substance use: findings from a study in selected central American countries. Journal of Adolescent Health. 2007;40(5):448&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448403</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KM, Sher KJ, Schulenberg JE. Conjoint developmental trajectories of young adult substance use. Alcoholism: Clinical and Experimental Research. 2008;32(5):723&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705997</ArticleId><ArticleId IdType="pubmed">18331376</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano ME, Zemore SE, Onder CC, Stout RL. Predictors of initial AA-related helping: findings from project MATCH. Journal of Studies on Alcohol and Drugs. 2009;70(1):117&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629624</ArticleId><ArticleId IdType="pubmed">19118400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallot RD, Heckman JP. Religious/spiritual coping among women trauma survivors with mental health and substance use disorders. Journal of Behavioral Health Services and Research. 2005;32(2):215&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin D, Endicott J, Lewis C. Alcohol and drug abuse in patients with affective syndromes. Comprehensive Psychiatry. 1985;26(3):283&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">3995939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays RD, Stacy AW, Widaman DMR, Downey R. Multistage path models of adolescent alcohol and drug use: a reanalysis. Journal of Drug Issues. 1986;16:357&#x2013;369.</Citation></Reference><Reference><Citation>Amey CH, Albrecht SL, Miller MK. Racial differences in adolescent drug use: The impact of religion. Substance Use and Misuse. 1996;31(10):1311&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pubmed">8879076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R, Wechsler H, Johnston LD. Correlates of college student marijuana use: results of a US National Survey. Addiction. 1997;92(5):571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">9219379</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinkoff AM, Zhou Q, Storr CL, Soeken KL. Workplace access, negative proscriptions, job strain, and substance use in registered nurses. Nursing Research. 2000;49(2):83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10768584</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller L, Davies M, Greenwald S. Religiosity and substance use and abuse among adolescents in the national comorbidity survey. Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39(9):1190&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10986817</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland I, Shepherd JP. Social dimensions of adolescent substance use. Addiction. 2001;96(3):445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255584</ArticleId></ArticleIdList></Reference><Reference><Citation>Strote J, Lee JE, Wechsler H. Increasing MDMA use among college students: results of a national survey. Journal of Adolescent Health. 2002;30(1):64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills TA, Yaeger AM, Sandy JM. Buffering effect of religiosity for adolescent substance use. Psychology of Addictive Behaviors. 2003;17(1):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12665078</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyers JM, Toumbourou JW, Catalano RF, Arthur MW, Hawkins JD. A cross-national comparison of risk and protective factors for adolescent substance use: The United States and Australia. Journal of Adolescent Health. 2004;35(1):3&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193569</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputo RK. Parent religiosity, family processes, and adolescent outcomes. Families in Society. 2004;85(4):495&#x2013;510.</Citation></Reference><Reference><Citation>Steinman KJ. Drug selling among high school students: related risk behaviors and psychosocial characteristics. Journal of Adolescent Health. 2005;36(1):71&#x2013;e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">15661603</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC. Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents. Journal of Adolescent Health. 2006;39(3):374&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919799</ArticleId></ArticleIdList></Reference><Reference><Citation>Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC. Epidemiological patterns of extra-medical drug use in the United States: evidence from the National Comorbidity Survey Replication, 2001&#x2013;2003. Drug and Alcohol Dependence. 2007;90(2-3):210&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739901</ArticleId><ArticleId IdType="pubmed">17481828</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman KJ, Ferketich AK, Sahr T. The dose-response relationship of adolescent religious activity and substance use: variation across demographic groups. Health Education and Behavior. 2008;35(1):22&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861596</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell ZAT, Broman CL. Racial/ethnic differences in correlates of prescription drug misuse among young adults. Drug and Alcohol Dependence. 2009;104(3):268&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19616903</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC. Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25. Addictive Behaviors. 2007;32(5):1003&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes AL, Reiss AJ. The, &#x201c;religious factor&#x201d; and delinquent behavior. Journal of Research in Crime &amp; Delinquency. 1970;7:83&#x2013;98.</Citation></Reference><Reference><Citation>Freeman RB. Who escapes? The relation of churchgoing and other background factors to the socioeconomic performance of black male youths from inner-city tracts. In: Richard Freeman B, Harry Holzer J, editors. The Black Youth Employment Crisis. Chicago, Ill, USA: University of Chicago Press; 1986.</Citation></Reference><Reference><Citation>Sloane DM, Potvin RH. Religion and delinquency: cutting through the maze. Social Forces. 1986;65:87&#x2013;105.</Citation></Reference><Reference><Citation>Benson PL, Donahue MJ. Ten-year trends in at-risk behaviors: a national study of black adolescents. Journal of Adolescent Research. 1989;4(4):125&#x2013;139.</Citation></Reference><Reference><Citation>Stark R. Religion as context: hellfire and delinquency one more time. Sociology of Religion. 1996;57(2):163&#x2013;173.</Citation></Reference><Reference><Citation>Barber BK. Political violence, social integration, and youth functioning: Palestinian youth from the Intifada. Journal of Community Psychology. 2001;29(3):259&#x2013;280.</Citation></Reference><Reference><Citation>Regnerus MD. Moral communities and adolescent delinquency: religious contexts and community social control. Sociological Quarterly. 2003;44(4):523&#x2013;554.</Citation></Reference><Reference><Citation>Benda BB, Toombs NJ, Peacock M. Discriminators of types of recidivism among boot camp graduates in a five-year follow-up study. Journal of Criminal Justice. 2003;31(6):539&#x2013;551.</Citation></Reference><Reference><Citation>Pearce LD, Haynie DL. Intergenerational religious dynamics and adolescent delinquency. Social Forces. 2004;82(4):1553&#x2013;1572.</Citation></Reference><Reference><Citation>Johnson BR. Religious programs and recidivism among former inmates in Prison Fellowship programs: a long-term follow-up study. Justice Quarterly. 2004;21(2):329&#x2013;354.</Citation></Reference><Reference><Citation>Torgler B. The importance of faith: tax morale and religiosity. Journal of Economic Behavior and Organization. 2006;61(1):81&#x2013;109.</Citation></Reference><Reference><Citation>Stack S, Kposowa A. The effect of religiosity on tax fraud acceptability: a cross-national analysis. Journal for the Scientific Study of Religion. 2006;45(3):325&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">21969937</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanville JL, Sikkink D, Hern&#xe1;ndez EI. Religious involvement and educational outcomes: the role of social capital and extracurricular participation. Sociological Quarterly. 2008;49(1):105&#x2013;137.</Citation></Reference><Reference><Citation>Ozbay O. Does social capital deter youth from cheating, alcohol use, and violence in Turkey?: bringing torpil in. Journal of Criminal Justice. 2008;36(5):403&#x2013;415.</Citation></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012. Appendix; p. p. 786.</Citation></Reference><Reference><Citation>Shrum W. Religion and marital instability: change in the 1970&#x2019;s? Review of Religious Research. 1980;21(2):135&#x2013;147.</Citation></Reference><Reference><Citation>Truett KR, Eaves LJ, Meyer JM, Heath AC, Martin NG. Religion and education as mediators of attitudes: a multivariate analysis. Behavior Genetics. 1992;22(1):43&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">1590730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wineberg H. Marital reconciliation in the United States: which couples are successful? Journal of Marriage and the Family. 1994;56(1):80&#x2013;88.</Citation></Reference><Reference><Citation>Wilson J, Musick M. Religion and marital dependency. Journal for the Scientific Study of Religion. 1996;35(1):30&#x2013;40.</Citation></Reference><Reference><Citation>Call VRA, Heaton TB. Religious influence on marital stability. Journal For the Scientific Study of Religion. 1997;36(3):382&#x2013;392.</Citation></Reference><Reference><Citation>Strawbridge WJ, Shema SJ, Cohen RD, Kaplan GA. Religious attendance increases survival by improving and maintaining Good health behaviors, mental health, and social relationships. Annals of Behavioral Medicine. 2001;23(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11302358</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurenceau JP, Stanley SM, Olmos-Gallo A, Baucom B, Markman HJ. Community-based prevention of marital dysfunction: multilevel modeling of a randomized effectiveness study. Journal of Consulting and Clinical Psychology. 2004;72(6):933&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">15612841</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox WB, Wolfinger NH. Then comes marriage? Religion, race, and marriage in urban America. Social Science Research. 2007;36(2):569&#x2013;589.</Citation></Reference><Reference><Citation>Burdette AM, Ellison CG, Sherkat DE, Gore KA. Are there religious variations in marital infidelity? Journal of Family Issues. 2007;28(12):1553&#x2013;1581.</Citation></Reference><Reference><Citation>Brown E, Orbuch TL, Bauermeister JA. Religiosity and marital stability among Black American and White American couples. Family Relations. 2008;57(2):186&#x2013;197.</Citation></Reference><Reference><Citation>Uecker JE. Religion, pledging, and the premarital sexual behavior of married Young adults. Journal of Marriage and Family. 2008;70(3):728&#x2013;744.</Citation></Reference><Reference><Citation>Mahoney A, Pargament KI, Tarakeshwar N, Swank AB. Religion in the home in the 1980s and 1990s: a meta-analytic review and conceptual analysis of links between religion, marriage, and parenting. Journal of Family Psychology. 2001;15(4):559&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch LR. Informal support patterns of older African-American and white women: examining effects of family, paid work, and religious participation. Research on Aging. 1991;13(2):144&#x2013;170.</Citation></Reference><Reference><Citation>Koenig HG, Hays JC, George LK, Blazer DG, Larson D, Landerman LR. Modeling the cross-sectional relationships between religion, physical health, social support, and depressive symptoms. American Journal of Geriatric Psychiatry. 1997;5(2):131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106377</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge WJ, Shema SJ, Cohen RD, Kaplan GA. Religious attendance increases survival by improving and maintaining Good health behaviors, mental health, and social relationships. Annals of Behavioral Medicine. 2001;23(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11302358</ArticleId></ArticleIdList></Reference><Reference><Citation>Szaflarski M. Gender, self-reported health, and health-related lifestyles in Poland. Health Care for Woman International. 2001;22(3):207&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814069</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill TD, Burdette AM, Regnerus M, Angel RJ. Religious involvement and attitudes toward parenting among low-income Urban women. Journal of Family Issues. 2008;29(7):882&#x2013;900.</Citation></Reference><Reference><Citation>Contrada RJ, Boulifard DA, Hekler EB, et al. Psychosocial factors in heart surgery: presurgical vulnerability and postsurgical recovery. Health Psychology. 2008;27(3):309&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">18624595</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N, Bastida E. Core religious beliefs and providing support to others in late life. Mental Health, Religion and Culture. 2009;12(1):75&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947450</ArticleId><ArticleId IdType="pubmed">20890390</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevino KM, Pargament KI, Cotton S, et al. Religious coping and physiological, psychological, social, and spiritual outcomes in patients with HIV/AIDS: cross-sectional and longitudinal findings. AIDS and Behavior. 2010;14(2):379&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064557</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler SJ. Membership in different types of voluntary associations and psychological well being. Gerontologist. 1976;16(4):335&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">1026576</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Moberg DO, Kvale JN. Religious activities and attitudes of older adults in a geriatric assessment clinic. Journal of the American Geriatrics Society. 1988;36(4):362&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">3351176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuthnow R. Religious involvement and status-bridging social capital. Journal For the Scientific Study of Religion. 2002;41(4):669&#x2013;684.</Citation></Reference><Reference><Citation>Kim D, Kawachi I. A multilevel analysis of key forms of community- and individual-level social capital as predictors of self-rated health in the United States. Journal of Urban Health. 2006;83(5):813&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438597</ArticleId><ArticleId IdType="pubmed">16810567</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson RW, Hansen DM, Moneta G. Differing profiles of developmental experiences across types of organized youth activities. Developmental Psychology. 2006;42(5):849&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pubmed">16953691</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanville JL, Sikkink D, Hern&#xe1;ndez EI. Religious involvement and educational outcomes: the role of social capital and extracurricular participation. Sociological Quarterly. 2008;49(1):105&#x2013;137.</Citation></Reference><Reference><Citation>The Holy Bible. New Kings James Version. Nashville, Tenn, USA: Thomas Nelson Publishers; 1982.</Citation></Reference><Reference><Citation>Jewish Virtual Library. Asceticism. 2008.   http://www.jewishvirtuallibrary.org/jsource/judaica/ejud_0002_0002_0_01417.html.</Citation></Reference><Reference><Citation>Conrad L. Islam and the body. 2010.   http://www.answers.com/topic/islam-and-the-body.</Citation></Reference><Reference><Citation>Wilso. Body, perspectives on the: an entry from macmillan reference USA&#x2019;s encyclopedia of Buddhism. In: Buswell RE, editor. Macmillan Encyclopedia of Buddhism, USA. New York, NY, USA: Macmillan; 2004. pp. 63&#x2013;66.</Citation></Reference><Reference><Citation>Koenig HG, George LK, Cohen HJ, Hays JC, Larson DB, Blazer DG. The relationship between religious activities and cigarette smoking in older adults. Journals of Gerontology. 1998;53(6):M426&#x2013;M434.</Citation><ArticleIdList><ArticleId IdType="pubmed">9823746</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TN, Schulenberg J, Bachman JG, O&#x2019;Malley PM, Johnston LD. Are risk and protective factors for substance use consistent across historical time?: national data from the high school classes of 1976 through 1997. Prevention Science. 2001;2(1):29&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11519373</ArticleId></ArticleIdList></Reference><Reference><Citation>Whooley MA, Boyd AL, Gardin JM, Williams DR. Religious involvement and cigarette smoking in young adults: the CARDIA study. Archives of Internal Medicine. 2002;162(14):1604&#x2013;1610.</Citation><ArticleIdList><ArticleId IdType="pubmed">12123404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonnemaker JM, McNeely CA, Blum RW. Public and private domains of religiosity and adolescent health risk behaviors: evidence from the National Longitudinal Study of Adolescent Health. Social Science and Medicine. 2003;57(11):2049&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512236</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyers JM, Toumbourou JW, Catalano RF, Arthur MW, Hawkins JD. A cross-national comparison of risk and protective factors for adolescent substance use: the United States and Australia. Journal of Adolescent Health. 2004;35(1):3&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193569</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonnemaker J, McNeely CA, Blum RW. Public and private domains of religiosity and adolescent smoking transitions. Social Science and Medicine. 2006;62(12):3084&#x2013;3095.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson KM, Sher KJ, Schulenberg JE. Conjoint developmental trajectories of young adult substance use. Alcoholism. 2008;32(5):723&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705997</ArticleId><ArticleId IdType="pubmed">18331376</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamins MR, Buck AC. Religion: a sociocultural predictor of health behaviors in Mexico. Journal of Aging and Health. 2008;20(3):290&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">18263855</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong HH, Hamann SL, Borland R, Fong GT, Omar M. Adult smokers&#x2019; perception of the role of religion and religious leadership on smoking and association with quitting: a comparison between Thai Buddhists and Malaysian Muslims. Social Science and Medicine. 2009;69(7):1025&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775092</ArticleId><ArticleId IdType="pubmed">19695758</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein M, Liu K, Ning H, Fitchett G, Lloyd-Jones DM. Burden of cardiovascular risk factors, subclinical atherosclerosis, and incident cardiovascular events across dimensions of religiosity: the multi-ethnic study of atherosclerosis. Circulation. 2010;121(5):659&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871276</ArticleId><ArticleId IdType="pubmed">20100975</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge WJ, Cohen RD, Shema SJ, Kaplan GA. Frequent attendance at religious services and mortality over 28 years. American Journal of Public Health. 1997;87(6):957&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380930</ArticleId><ArticleId IdType="pubmed">9224176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraut A, Melamed S, Gofer D, Froom P. Effect of school age sports on leisure time physical activity in adults: the CORDIS study. Medicine and Science in Sports and Exercise. 2003;35(12):2038&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">14652499</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillum RF. Frequency of attendance at religious services and leisure-time physical activity in American women and men: the Third National Health and Nutrition Examination Survey. Annals of Behavioral Medicine. 2006;31(1):30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill TD, Burdette AM, Ellison CG, Musick MA. Religious attendance and the health behaviors of Texas adults. Preventive Medicine. 2006;42(4):309&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">16445971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillum RF, King DE, Obisesan TO, Koenig HG. Frequency of attendance at religious services and mortality in a U.S. national cohort. Annals of Epidemiology. 2008;18(2):124&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659561</ArticleId><ArticleId IdType="pubmed">18083539</ArticleId></ArticleIdList></Reference><Reference><Citation>Baetz M, Bowen R. Chronic pain and fatigue: associations with religion and spirituality. Pain Research and Management. 2008;13(5):383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799261</ArticleId><ArticleId IdType="pubmed">18958309</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron-Epel O, Haviv A, Garty N, Tamir D, Green MS. Who are the sedentary people in Israel? A public health indicator. Israel Medical Association Journal. 2005;7(11):694&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">16308990</ArticleId></ArticleIdList></Reference><Reference><Citation>McHenry JH. Prayer Walk. Colorado Springs, Colo, USA: WaterBrook Press; 2001.</Citation></Reference><Reference><Citation>Crawford DR, Miller C. Prayer Walking. Chattanooga, Tenn, USA: AMG Publishers; 2002.</Citation></Reference><Reference><Citation>Hanh TN, Nquyen AH. Walking Meditation. Louisville, Colo, USA: Sounds True; 2006.</Citation></Reference><Reference><Citation>Underwood SM, Powell RL. Religion and spirituality: influence on health/risk behavior and cancer screening behavior of African Americans. The ABNF Journal. 2006;17(1):20&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16596897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lytle LA, Varnell S, Murray DM, et al. Predicting adolescents&#x2019; intake of fruits and vegetables. Journal of Nutrition Education and Behavior. 2003;35(4):170&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859881</ArticleId></ArticleIdList></Reference><Reference><Citation>Locher JL, Ritchie CS, Roth DL, Baker PS, Bodner EV, Allman RM. Social isolation, support, and capital and nutritional risk in an older sample: Ethnic and gender differences. Social Science and Medicine. 2005;60(4):747&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763304</ArticleId><ArticleId IdType="pubmed">15571893</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt CL, Haire-Joshu DL, Lukwago SN, Lewellyn LA, Kreuter MW. The role of religiosity in dietary beliefs and behaviors among urban African American women. Cancer Control. 2005;12(supplement 2):84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16327755</ArticleId></ArticleIdList></Reference><Reference><Citation>Obisesan T, Livingston I, Trulear HD, Gillum F. Frequency of attendance at religious services, cardiovascular disease, metabolic risk factors and dietary intake in Americans: An age-stratified exploratory analysis. International Journal of Psychiatry in Medicine. 2006;36(4):435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160830</ArticleId><ArticleId IdType="pubmed">17407997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart A, Jr, Bowen DJ, Kuniyuki A, Hannon P, Campbell MK. The relationship between the social environment within religious organizations and intake of fat versus fruits and vegetables. Health Education and Behavior. 2007;34(3):503&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">17456858</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlander Y, Kark JD, Stein Y. Religious observance and plasma lipids and lipoproteins among 17-year-old Jewish residents of Jerusalem. Preventive Medicine. 1987;16(1):70&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">3823011</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, Davidson M, Silverman JM, et al. Religious education and midlife observance are associated with dementia three decades later in Israeli men. Journal of Clinical Epidemiology. 2008;61(11):1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911134</ArticleId><ArticleId IdType="pubmed">18538995</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein M, Liu K, Ning H, Fitchett G, Lloyd-Jones DM. Burden of cardiovascular risk factors, subclinical atherosclerosis, and incident cardiovascular events across dimensions of religiosity: The multi-ethnic study of atherosclerosis. Circulation. 2010;121(5):659&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871276</ArticleId><ArticleId IdType="pubmed">20100975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarri KO, Tzanakis NE, Linardakis MK, Mamalakis GD, Kafatos AG. Effects of Greek orthodox christian church fasting on serum lipids and obesity. BMC Public Health. 2003;3:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156653</ArticleId><ArticleId IdType="pubmed">12753698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijlani RL, Vempati RP, Yadav RK, et al. A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus. Journal of Alternative and Complementary Medicine. 2005;11(2):267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15865492</ArticleId></ArticleIdList></Reference><Reference><Citation>Obisesan T, Livingston I, Trulear HD, Gillum F. Frequency of attendance at religious services, cardiovascular disease, metabolic risk factors and dietary intake in Americans: An age-stratified exploratory analysis. International Journal of Psychiatry in Medicine. 2006;36(4):435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160830</ArticleId><ArticleId IdType="pubmed">17407997</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge WJ, Cohen RD, Shema SJ, Kaplan GA. Frequent attendance at religious services and mortality over 28 years. American Journal of Public Health. 1997;87(6):957&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380930</ArticleId><ArticleId IdType="pubmed">9224176</ArticleId></ArticleIdList></Reference><Reference><Citation>Oman D, Reed D. Religion and mortality among the community-dwelling elderly. American Journal of Public Health. 1998;88(10):1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1508463</ArticleId><ArticleId IdType="pubmed">9772846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro KF. Firm believers? Religion, body weight, and well-being. Review of Religious Research. 1998;39(3):224&#x2013;244.</Citation></Reference><Reference><Citation>Kim KH, Sobal J, Wethington E. Religion and body weight. International Journal of Obesity. 2003;27(4):469&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">12664080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce MA, Sims M, Miller S, Elliott V, Ladipo M. One size fits all? Race, gender and body mass index among U.S. adults. Journal of the National Medical Association. 2007;99(10):1152&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574391</ArticleId><ArticleId IdType="pubmed">17987919</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein M, Liu K, Ning H, Fitchett G, Lloyd-Jones DM. Burden of cardiovascular risk factors, subclinical atherosclerosis, and incident cardiovascular events across dimensions of religiosity: The multi-ethnic study of atherosclerosis. Circulation. 2010;121(5):659&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871276</ArticleId><ArticleId IdType="pubmed">20100975</ArticleId></ArticleIdList></Reference><Reference><Citation>Musick MA, House JS, Williams DR. Attendance at religious services and mortality in a national sample. Journal of Health and Social Behavior. 2004;45(2):198&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">15305760</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller K, Yost B, Flaherty S, et al. Health status, health conditions, and health behaviors among Amish women. Results from the Central Pennsylvania Women&#x2019;s Health Study (CePAWHS) Women&#x2019;s Health Issues. 2007;17(3):162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17459726</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, Davidson M, Silverman JM, et al. Religious education and midlife observance are associated with dementia three decades later in Israeli men. Journal of Clinical Epidemiology. 2008;61(11):1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911134</ArticleId><ArticleId IdType="pubmed">18538995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arambepola C, Allender S, Ekanayake R, Fernando D. Urban living and obesity: Is it independent of its population and lifestyle characteristics? Tropical Medicine and International Health. 2008;13(4):448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">18331534</ArticleId></ArticleIdList></Reference><Reference><Citation>Maselko J, Kubzansky L, Kawachi I, Seeman T, Berkman L. Religious service attendance and allostatic load among high-functioning elderly. Psychosomatic Medicine. 2007;69(5):464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumanyika SK, Charleston JB. Lose weight and win: a church-based weight loss program for blood pressure control among black women. Patient Education and Counseling. 1992;19(1):19&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">1298945</ArticleId></ArticleIdList></Reference><Reference><Citation>Perk G, Ghanem J, Aamar S, Ben-Ishay D, Bursztyn M. The effect of the fast of Ramadan on ambulatory blood pressure in treated hypertensives. Journal of Human Hypertension. 2001;15(10):723&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">11607803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy BM, Paeratakul S, Champagne CM, et al. A pilot church-based weight loss program for African-American adults using church members as health educators: A comparison of individual and group intervention. Ethnicity and Disease. 2005;15(3):373&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">16108295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KHC, Linnan L, Campbell MK, Brooks C, Koenig HG, Wiesen C. The WORD (wholeness, oneness, righteousness, deliverance): a Faith-based weight-loss program utilizing a community-based participatory research approach. Health Education and Behavior. 2008;35(5):634&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">17200103</ArticleId></ArticleIdList></Reference><Reference><Citation>Anson O, Antonovsky A, Sagy S. Religiosity and well-being among retirees: a question of causality. Behavior, Health, and Aging. 1990;1:85&#x2013;97.</Citation></Reference><Reference><Citation>Cochran JK, Chamlin MB, Beeghley L, Fenwick M. Religion, religiosity, and nonmarital sexual conduct: an application of reference group theory. Sociological Inquiry. 2004;74(1):102&#x2013;158.</Citation></Reference><Reference><Citation>Seidman SN, Mosher WD, Aral SO. Women with multiple sexual partners: United States, 1988. American Journal of Public Health. 1992;82(10):1388&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1695854</ArticleId><ArticleId IdType="pubmed">1415868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammers C, Ireland M, Resnick M, Blum R. Influences on adolescents&#x2019; decision to postpone onset of sexual intercourse: a survival analysis of virginity among youths aged 13 to 18 years. Journal of Adolescent Health. 2000;26(1):42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">10638717</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins DC, Baucom DH, Jacobson NS. Understanding infidelity: correlates in a national random sample. Journal of Family Psychology. 2001;15(4):735&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770478</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonnemaker JM, McNeely CA, Blum RW. Public and private domains of religiosity and adolescent health risk behaviors: evidence from the National Longitudinal Study of Adolescent Health. Social Science and Medicine. 2003;57(11):2049&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512236</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostosky SS, Regnerus MD, Wright MLC. Coital debut: the role of religiosity and sex attitudes in the add health survey. Journal of Sex Research. 2003;40(4):358&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735410</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern CT, Young ML, Waller MW, Martin SL, Kupper LL. Prevalence of partner violence in same-sex romantic and sexual relationships in a national sample of adolescents. Journal of Adolescent Health. 2004;35(2):124&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261641</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser ROD, Smith AMA, Richters J, Rissel CE. Associations between religiosity and sexuality in a representative sample of Australian adults. Archives of Sexual Behavior. 2007;36(1):33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17136592</ArticleId></ArticleIdList></Reference><Reference><Citation>Whisman MA, Gordon KC, Chatav Y. Predicting sexual infidelity in a population-based sample of married individuals. Journal of Family Psychology. 2007;21(2):320&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">17605555</ArticleId></ArticleIdList></Reference><Reference><Citation>Uecker JE. Religion, pledging, and the premarital sexual behavior of married Young adults. Journal of Marriage and Family. 2008;70(3):728&#x2013;744.</Citation></Reference><Reference><Citation>Burdette AM, Ellison CG, Hill TD, Glenn ND. &#x2018;Hooking up&#x2019; at college: does religion make a difference? Journal for the Scientific Study of Religion. 2009;48(3):535&#x2013;551.</Citation></Reference><Reference><Citation>McEwen BS. Seminars in medicine of the Beth Israel Deaconess Medical Center: protective and damaging effects of stress mediators. New England Journal of Medicine. 1998;338(3):171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">9428819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(15):9090&#x2013;9095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC166443</ArticleId><ArticleId IdType="pubmed">12840146</ArticleId></ArticleIdList></Reference><Reference><Citation>Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin. 2004;130(4):601&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1361287</ArticleId><ArticleId IdType="pubmed">15250815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S, Tyrrell DAJ, Smith AP. Psychological stress and susceptibility to the common cold. New England Journal of Medicine. 1991;325(9):606&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">1713648</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. The Lancet. 2003;362(9384):604&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">12944059</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosomatic Medicine. 2003;65(4):636&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">12883115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubzansky LD, Thurston RC. Emotional vitality and incident coronary heart disease: benefits of healthy psychological functioning. Archives of General Psychiatry. 2007;64(12):1393&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056547</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews KA, Gump BB, Harris KF, Haney TL, Barefoot JC. Hostile behaviors predict cardiovascular mortality among men enrolled in the multiple risk factor intervention trial. Circulation. 2004;109(1):66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">14662707</ArticleId></ArticleIdList></Reference><Reference><Citation>Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(49):17312&#x2013;17315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534658</ArticleId><ArticleId IdType="pubmed">15574496</ArticleId></ArticleIdList></Reference><Reference><Citation>Russ TC, Stamatakis E, Hamer M, Starr JM, Kivim&#xe4;ki M, Batty GD. Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. British Medical Journal. 2012;345e4933</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409083</ArticleId><ArticleId IdType="pubmed">22849956</ArticleId></ArticleIdList></Reference><Reference><Citation>House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988;241(4865):540&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">3399889</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea S, Tracy M, Hoggatt KJ, DiMaggio C, Karpati A. Estimated deaths attributable to social factors in the united states. American Journal of Public Health. 2011;101(8):1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134519</ArticleId><ArticleId IdType="pubmed">21680937</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt-Lunstad J, Smith TB. Social relationships and mortality. Social and Personality Psychology Compass. 2012;6(1):41&#x2013;53.</Citation></Reference><Reference><Citation>Comstock GW. Fatal arteriosclerotic heart disease, water hardness at home, and socioeconomic characteristics. American Journal of Epidemiology. 1971;94(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">5556219</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlander Y, Kark JD, Stein Y. Religious orthodoxy and myocardial infarction in Jerusalem. A case control study. International Journal of Cardiology. 1986;10(1):33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">3943927</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees: A 23-year mortality follow-up in the Israeli ischemic heart disease study. Cardiology. 1993;82(2-3):100&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">8324774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamarra JW, Schneider RH, Besseghini I, Robinson DK, Salerno JW. Usefulness of the transcendental meditation program in the treatment of patients with coronary artery disease. American Journal of Cardiology. 1996;77(10):867&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8623742</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, Prakash H, Gupta VP, Gupta KD. Prevalence and determinants of coronary heart disease in a rural population of India. Journal of Clinical Epidemiology. 1997;50(2):203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">9120514</ArticleId></ArticleIdList></Reference><Reference><Citation>Obisesan T, Livingston I, Trulear HD, Gillum F. Frequency of attendance at religious services, cardiovascular disease, metabolic risk factors and dietary intake in Americans: an age-stratified exploratory analysis. International Journal of Psychiatry in Medicine. 2006;36(4):435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160830</ArticleId><ArticleId IdType="pubmed">17407997</ArticleId></ArticleIdList></Reference><Reference><Citation>Berntson GG, Norman GJ, Hawkley LC, Cacioppo JT. Spirituality and autonomic cardiac control. Annals of Behavioral Medicine. 2008;35(2):198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689369</ArticleId><ArticleId IdType="pubmed">18357497</ArticleId></ArticleIdList></Reference><Reference><Citation>Burazeri G, Goda A, Kark JD. Religious observance and acute coronary syndrome in predominantly Muslim Albania: a population-based case-control study in Tirana. Annals of Epidemiology. 2008;18(12):937&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041593</ArticleId></ArticleIdList></Reference><Reference><Citation>Horne BD, May HT, Anderson JL, et al. Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. American Journal of Cardiology. 2008;102(7):814&#x2013;e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572991</ArticleId><ArticleId IdType="pubmed">18805103</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnall E, Wassertheil-Smoller S, Swencionis C, et al. The relationship between religion and cardiovascular outcomes and all-cause mortality in the women&#x2019;s health initiative observational study. Psychology and Health. 2010;25(2):249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20391218</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxman TE, Freeman DH, Manheimer ED. Lack of social participation or religious strength and comfort as risk factors for death after cardiac surgery in the elderly. Psychosomatic Medicine. 1995;57(1):5&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">7732159</ArticleId></ArticleIdList></Reference><Reference><Citation>Contrada RJ, Goyal TM, Cather C, Rafalson L, Idler EL, Krause TJ. Psychosocial factors in outcomes of heart surgery: the impact of religious involvement and depressive symptoms. Health Psychology. 2004;23(3):227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">15099162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai AL, Wink P, Tice TN, Bolling SF, Shearer M. Prayer and reverence in naturalistic, aesthetic, and socio-moral contexts predicted fewer complications following coronary artery bypass. Journal of Behavioral Medicine. 2009;32(6):570&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">19856203</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmondson KA, Lawler KA, Jobe RL, Younger JW, Piferi RL, Jones WH. Spirituality predicts health and cardiovascular responses to stress in young adult women. Journal of Religion and Health. 2005;44(2):161&#x2013;171.</Citation></Reference><Reference><Citation>Chen YY, Contrada RJ. Religious involvement and perceived social support: interactive effects on cardiovascular reactivity to laboratory stressors. Journal of Applied Biobehavioral Research. 2007;12(1):1&#x2013;12.</Citation></Reference><Reference><Citation>Hefti R. Religion as a moderator of cardiovascular reactivity in patients with mild to severe depression. Proceedings of the 2009 Congress of the International Association for the Psychology of Religion; August 2009; Vienna, Austria.</Citation></Reference><Reference><Citation>Berntson GG, Norman GJ, Hawkley LC, Cacioppo JT. Spirituality and autonomic cardiac control. Annals of Behavioral Medicine. 2008;35(2):198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689369</ArticleId><ArticleId IdType="pubmed">18357497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Sleight P, Bandinelli G, et al. Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: Comparative study. British Medical Journal. 2001;323(7327):1446&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61046</ArticleId><ArticleId IdType="pubmed">11751348</ArticleId></ArticleIdList></Reference><Reference><Citation>King DE, Mainous AG, Steyer TE, Pearson W. The relationship between attendance at religious services and cardiovascular inflammatory markers. International Journal of Psychiatry in Medicine. 2001;31(4):415&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">11949739</ArticleId></ArticleIdList></Reference><Reference><Citation>King DE, Mainous AG, Pearson WS. C-reactive protein, diabetes, and attendance at religious services. Diabetes Care. 2002;25(7):1172&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12087015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Loucks EB, Berkman LF. Social integration and concentrations of C-reactive protein among US adults. Annals of Epidemiology. 2006;16(2):78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271297</ArticleId></ArticleIdList></Reference><Reference><Citation>Loucks EB, Berkman LF, Gruenewald TL, Seeman TE. Social integration is associated with fibrinogen concentration in elderly men. Psychosomatic Medicine. 2005;67(3):353&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911896</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrist PA. Cardiovascular Psychophysiology. New York, NY, USA: Plenum Press; 1981.</Citation></Reference><Reference><Citation>Markovitz JH, Jonas BS, Davidson K. Psychologic factors as precursors to hypertension. Current hypertension reports. 2001;3(1):25&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11177704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrenberger F, Cichelero FT, Ascoli AM, et al. Does psychosocial stress cause hypertension? A systematic review of observational studies. Journal of Human Hypertension. 2009;23(1):12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">18615099</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotch NA. Sociocultural factors in the epidemiology of Zulu hypertension. American Journal of Public Health and the Nation&#x2019;s Health. 1963;53:1205&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1254243</ArticleId><ArticleId IdType="pubmed">14051256</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham TW, Kaplan BH, Cornoni-Huntley JC. Frequency of church attendance and blood pressure elevation. Journal of Behavioral Medicine. 1978;1(1):37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">556112</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavig GR, Igra A, Leonard AR. Hypertension among Asians and Pacific islanders in California. American Journal of Epidemiology. 1984;119(5):677&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">6720667</ArticleId></ArticleIdList></Reference><Reference><Citation>Timio M, Verdecchia P, Venanzi S, et al. Age and blood pressure changes. A 20-year follow-up study in nuns in a secluded order. Hypertension. 1988;12(4):457&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">3169953</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson DB, Koenig HG, Kaplan BH, Greenberg RS, Logue E, Tyroler HA. The impact of religion on men&#x2019;s blood pressure. Journal of Religion &amp; Health. 1989;28(4):265&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">24276962</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston IL, Levine DM, Moore RD. Social integration and black intraracial variation in blood pressure. Ethnicity &amp; Disease. 1991;1(2):135&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">1842530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapane KL, Lasater TM, Allan C, Carleton RA. Religion and cardiovascular disease risk. Journal of Religion and Health. 1997;36(2):155&#x2013;163.</Citation></Reference><Reference><Citation>Walsh A. Religion and hypertension: testing alternative explanations among immigrants. Behavioral Medicine. 1998;24(3):122&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850806</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen PR, Hinderliter AL, Blumenthal JA, Sherwood A. Religious coping, ethnicity, and ambulatory blood pressure. Psychosomatic Medicine. 2001;63(4):523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11485105</ArticleId></ArticleIdList></Reference><Reference><Citation>Imio M, Saronio P, Verdura C, Schiaroli M, Timio F, Monarca C. A link between psychosocial factors and blood pressure trend in women. Physiology and Behavior. 2001;73(3):359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">11438362</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kandari YY. Religiosity and its relation to blood pressure among selected Kuwaitis. Journal of Biosocial Science. 2003;35(3):463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillum RF, Ingram DD. Frequency of attendance at religious services, hypertension, and blood pressure: the third national health and nutrition examination survey. Psychosomatic Medicine. 2006;68(3):382&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">16738068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeager DM, Glei DA, Au M, Lin HS, Sloan RP, Weinstein M. Religious involvement and health outcomes among older persons in Taiwan. Social Science and Medicine. 2006;63(8):2228&#x2013;2241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel C, North WRS. Randomised controlled trial of yoga and bio feedback in management of hypertension. The Lancet. 1975;2(7925):93&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">49737</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel C, Datey KK. Relaxation and biofeedback techniques in the management of hypertension. Angiology. 1976;27(2):106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">802884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudsuang R, Chentanez V, Veluvan K. Effect of Buddhist meditation on serum cortisol and total protein levels, blood pressure, pulse rate, lung volume and reaction time. Physiology and Behavior. 1991;50(3):543&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">1801007</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider RH, Staggers F, Alexander CN, et al. A randomized controlled trial of stress reduction for hypertension in older African Americans. Hypertension. 1995;26(5):820&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">7591024</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander CN, Schneider RH, Staggers F, et al. Trial of stress reduction for hypertension in older African Americans: II. Sex and risk subgroup analysis. Hypertension. 1996;28(2):228&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">8707387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenneberg SR, Schneider RH, Walton KG, et al. A controlled study of the effects of the transcendental meditation&#xae; program on cardiovascular reactivity and ambulatory blood pressure. International Journal of Neuroscience. 1997;89(1-2):15&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">9134445</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes VA, Treiber FA, Davis H. Impact of transcendental meditation&#xae; on cardiovascular function at rest and during acute stress in adolescents with high normal blood pressure. Journal of Psychosomatic Research. 2001;51(4):597&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216051</ArticleId><ArticleId IdType="pubmed">11595248</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes VA, Treiber FA, Johnson MH. Impact of transcendental meditation on ambulatory blood pressure in African-American adolescents. American Journal of Hypertension. 2004;17(4):366&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293501</ArticleId><ArticleId IdType="pubmed">15062892</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider RH, Alexander CN, Staggers F, et al. A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year. American Journal of Hypertension. 2005;18(1):88&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224896</ArticleId><ArticleId IdType="pubmed">15691622</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul-Labrador M, Polk D, Dwyer JH, et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Archives of Internal Medicine. 2006;166(11):1218&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772250</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin JS, Markides KS. Religion and health in Mexican Americans. Journal of Religion &amp; Health. 1985;24(1):60&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24307194</ArticleId></ArticleIdList></Reference><Reference><Citation>Topacoglu H, Karcioglu O, Yuruktumen A, et al. Impact of Ramadan on demographics and frequencies of disease-related visits in the emergency department. International Journal of Clinical Practice. 2005;59(8):900&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033610</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Olphen J, Schulz A, Israel B, et al. Religious involvement, social support, and health among African-American women on the east side of Detroit. Journal of General Internal Medicine. 2003;18(7):549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1494889</ArticleId><ArticleId IdType="pubmed">12848838</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard TM, Carlin LE, Bhopal R, Unwin N, White M, Fischbacher C. Social networks and coronary heart disease risk factors in South Asians and Europeans in the UK. Ethnicity and Health. 2003;8(3):263&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">14577999</ArticleId></ArticleIdList></Reference><Reference><Citation>Maselko J, Kubzansky L, Kawachi I, Seeman T, Berkman L. Religious service attendance and allostatic load among high-functioning elderly. Psychosomatic Medicine. 2007;69(5):464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567709</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck AC, Williams DR, Musick MA, Sternthal MJ. An examination of the relationship between multiple dimensions of religiosity, blood pressure, and hypertension. Social Science and Medicine. 2009;68(2):314&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654362</ArticleId><ArticleId IdType="pubmed">19019516</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitchett G, Powell LH. Daily spiritual experiences, systolic blood pressure, and hypertension among midlife women in swan. Annals of Behavioral Medicine. 2009;37(3):257&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867660</ArticleId><ArticleId IdType="pubmed">19662465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999&#x2013;2004. Hypertension. 2007;49(1):69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159087</ArticleId></ArticleIdList></Reference><Reference><Citation>Newport F. Religion and party ID strongly linked among whites, not blacks.  The Gallup Poll,  http://www.gallup.com/poll/148361/Religion-Party-Strongly-Linked-Among-Whites-Not-Blacks.aspx, 2012.</Citation></Reference><Reference><Citation>Colantonio A, Kasl SV, Ostfeld AM. Depressive symptoms and other psychosocial factors as predictors of stroke in the elderly. American Journal of Epidemiology. 1992;136(7):884&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">1442754</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody MM, Mandel JS, Linet MS, Ron E, Lubin JH, Boice JD., Jr Mortality among Catholic nuns certified as radiologic technologists. American Journal of Industrial Medicine. 2000;37(4):339&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">10706745</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Richmond A, Schneider RH, Alexander CN, et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke. 2000;31(3):568&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9341385</ArticleId><ArticleId IdType="pubmed">10700487</ArticleId></ArticleIdList></Reference><Reference><Citation>Obisesan T, Livingston I, Trulear HD, Gillum F. Frequency of attendance at religious services, cardiovascular disease, metabolic risk factors and dietary intake in Americans: an age-stratified exploratory analysis. International Journal of Psychiatry in Medicine. 2006;36(4):435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160830</ArticleId><ArticleId IdType="pubmed">17407997</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein M, Liu K, Ning H, Fitchett G, Lloyd-Jones DM. Burden of cardiovascular risk factors, subclinical atherosclerosis, and incident cardiovascular events across dimensions of religiosity: the multi-ethnic study of atherosclerosis. Circulation. 2010;121(5):659&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871276</ArticleId><ArticleId IdType="pubmed">20100975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Archives of General Psychiatry. 2000;57(10):925&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015810</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad CD. Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability hypothesis. Reviews in the Neurosciences. 2008;19(6):395&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746750</ArticleId><ArticleId IdType="pubmed">19317179</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. American Journal of Psychiatry. 2006;163(12):2164&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780275</ArticleId><ArticleId IdType="pubmed">17151169</ArticleId></ArticleIdList></Reference><Reference><Citation>Tata DA, Anderson BJ. The effects of chronic glucocorticoid exposure on dendritic length, synapse numbers and glial volume in animal models: implications for hippocampal volume reductions in depression. Physiology and Behavior. 2010;99(2):186&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154795</ArticleId><ArticleId IdType="pubmed">19786041</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Cohen HJ, Blazer DG, et al. Religious coping and depression among elderly, hospitalized medically ill men. American Journal of Psychiatry. 1992;149(12):1693&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">1443246</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Ness PH, Kasl SV. Religion and cognitive dysfunction in an elderly cohort. Journals of Gerontology. 2003;58(1):S21&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353608</ArticleId><ArticleId IdType="pubmed">12496305</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco KJ. Religious activities, strength from faith, and social functioning among African American and white nursing home residents. Journal of Religion, Spirituality and Aging. 2007;19(4):3&#x2013;20.</Citation></Reference><Reference><Citation>Hill TD, Burdette AM, Angel JL, Angel RJ. Religious attendance and cognitive functioning among older Mexican Americans. Journals of Gerontology. 2006;61(1):P3&#x2013;P9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399939</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman Y, Anaki D, Binns M, Freedman M. Cognitive decline in Alzheimer disease: impact of spirituality, religiosity, and QOL. Neurology. 2007;68(18):1509&#x2013;1514.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470754</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray-Swank A, Goldberg R, Dickerson F, Medoff D, Wohlheiter K, Dixon L. Correlates of religious service attendance and contact with religious leaders among persons with co-occurring serious mental illness and type 2 diabetes. Journal of Nervous and Mental Disease. 2007;195(5):382&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502803</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Ortiz CA, Berges IM, Raji MA, Koenig HG, Kuo YF, Markides KS. Church attendance mediates the association between depressive symptoms and cognitive functioning among older Mexican Americans. Journals of Gerontology. 2008;63(5):480&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851403</ArticleId><ArticleId IdType="pubmed">18511751</ArticleId></ArticleIdList></Reference><Reference><Citation>Corsentino EA, Collins N, Sachs-Ericsson N, Blazer DG. Religious attendance reduces cognitive decline among older women with high levels of depressive symptoms. Journals of Gerontology. 2009;64(12):1283&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773810</ArticleId><ArticleId IdType="pubmed">19675176</ArticleId></ArticleIdList></Reference><Reference><Citation>Park RM, Schulte PA, Bowman JD, et al. Potential occupational risks for neurodegenerative diseases. American Journal of Industrial Medicine. 2005;48(1):63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15940722</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamins MR. Predictors of preventive health care use among middle-aged and older adults in Mexico: the role of religion. Journal of Cross-Cultural Gerontology. 2007;22(2):221&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17340204</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, Davidson M, Silverman JM, et al. Religious education and midlife observance are associated with dementia three decades later in Israeli men. Journal of Clinical Epidemiology. 2008;61(11):1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911134</ArticleId><ArticleId IdType="pubmed">18538995</ArticleId></ArticleIdList></Reference><Reference><Citation>Coin A, Perissinotto E, Najjar M, et al. Does religiosity protect against cognitive and behavioral decline in alzheimer&#x2019;s dementia? Current Alzheimer Research. 2010;7(5):445&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">20088813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W. Religious participation, gender differences, and cognitive impairment among the oldest-old in China. Journal of Aging Research. 2010;2010:10 pages.160294</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2990098</ArticleId><ArticleId IdType="pubmed">21152194</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BM. Changes in cytokine production in healthy subjects practicing Guolin Qigong: a pilot study. BMC Complementary and Alternative Medicine. 2001;1:p. 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC59661</ArticleId><ArticleId IdType="pubmed">11696251</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Cohen HJ, George LK, Hays JC, Larson DB, Blazer DG. Attendance at religious services, interleukin-6, and other biological parameters of immune function in older adults. International Journal of Psychiatry in Medicine. 1997;27(3):233&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">9565726</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods TE, Antoni MH, Ironson GH, Kling DW. Religiosity is associated with affective and immune status in symptomatic HIV-infected gay men. Journal of Psychosomatic Research. 1999;46(2):165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">10098825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ironson G, Stuetzle R, Fletcher MA. An increase in religiousness/spirituality occurs after HIV diagnosis and predicts slower disease progression over 4 years in people with HIV. Journal of General Internal Medicine. 2006;21(supplement 5):S62&#x2013;S68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924782</ArticleId><ArticleId IdType="pubmed">17083503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ironson G, Stuezle R, Fletcher MA, Ironson D. View of God is associated with disease progression in HIV. Annals of Behavioral Medicine. 2006;(supplement 31):p. S074.</Citation></Reference><Reference><Citation>Ironson G, Stuetzle R, Ironson D, et al. View of God as benevolent and forgiving or punishing and judgmental predicts HIV disease progression. Journal of Behavioral Medicine. 2011;34(6):414&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">21340531</ArticleId></ArticleIdList></Reference><Reference><Citation>Safiya GD, Marcia MH, Colleen D, Laderman G. Spiritual well-being, depressive symptoms, and immune status among women living with HIV/AIDS. Women and Health. 2009;49(2-3):119&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699019</ArticleId><ArticleId IdType="pubmed">19533506</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutgendorf SK, Ullrich P, Wallace R, Russell D, Harris TB. Religious participation, interleukin-6, and mortality in older adults. Health Psychology. 2004;23(5):465&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367066</ArticleId></ArticleIdList></Reference><Reference><Citation>McClelland DC. The effect of motivational arousal through films on salivary immunoglobulin A. Psychology and Health. 1988;2(1):31&#x2013;52.</Citation></Reference><Reference><Citation>McCain NL, Gray DP, Elswick RK, et al. A randomized clinical trial of alternative stress management interventions in persons with HIV infection. Journal of Consulting and Clinical Psychology. 2008;76(3):431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629773</ArticleId><ArticleId IdType="pubmed">18540736</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. Psychosomatic Medicine. 2003;65(4):564&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12883106</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace TWW, Negi LT, Adame DD, et al. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009;34(1):87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695992</ArticleId><ArticleId IdType="pubmed">18835662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton SE, Koopman C, Schaal M, Thoresen C, Spiegel D. Spiritual expression and immune status in women with metastatic breast cancer: An exploratory study. Breast Journal. 2001;7(5):345&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906445</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchant AT, Pitiphat W, Ahmed B, Kawachi I, Joshipura K. A prospective study of social support, anger expression and risk of periodontitis in men. Journal of the American Dental Association. 2003;134(12):1591&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">14719755</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinitapoli J, Regnerus MD. Religion and HIV risk behaviors among married men: initial results from a study in rural sub-Saharan Africa. Journal for the Scientific Study of Religion. 2006;45(4):505&#x2013;528.</Citation></Reference><Reference><Citation>Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. British Medical Journal. 2006;332(7539):445&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382533</ArticleId><ArticleId IdType="pubmed">16473859</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira DB, Christian LM, Patidar S, et al. Spiritual absence and 1-year mortality after hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation. 2010;16(8):1171&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">20227510</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillum RF, Holt CL. Religious involvement and seroprevalence of six infectious diseases in US adults. Southern Medical Journal. 2010;103(5):403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">20375957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ironson G, Stuetzle R, Fletcher MA. An increase in religiousness/spirituality occurs after HIV diagnosis and predicts slower disease progression over 4 years in people with HIV. Journal of General Internal Medicine. 2006;21(5):S62&#x2013;S68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924782</ArticleId><ArticleId IdType="pubmed">17083503</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Cohen HJ. The Link Between Religion and Health: Psychoneuroimmunology and the Faith Factor. New York, NY, USA: Oxford University Press; 2002.</Citation></Reference><Reference><Citation>Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain, Behavior, and Immunity. 2007;21(4):374&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">17360153</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaal MD, Sephton SE, Thoreson C, Koopman C, Spiegel D. Religious expression and immune competence in women with advanced cancer. Proceedings of the Meeting of the American Psychological Association; August 1998; San Francisco, Calif, USA.</Citation></Reference><Reference><Citation>Ironson G, Solomon GF, Balbin EG, et al. The ironson-woods spirituality/religiousness index is associated with long survival, health behaviors, less distress, and low cortisol in people with HIV/AIDS. Annals of Behavioral Medicine. 2002;24(1):34&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12008793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaro J, Luecken LJ, Gunn HE. Exploring heart and soul: effects of religiosity/spirituality and gender on blood pressure and cortisol stress responses. Journal of Health Psychology. 2005;10(6):753&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">16176954</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrico AW, Ironson G, Antoni MH, et al. A path model of the effects of spirituality on depressive symptoms and 24-hurinary-free cortisol in HIV-positive persons. Journal of Psychosomatic Research. 2006;61(1):51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">16813845</ArticleId></ArticleIdList></Reference><Reference><Citation>Maselko J, Kubzansky L, Kawachi I, Seeman T, Berkman L. Religious service attendance and allostatic load among high-functioning elderly. Psychosomatic Medicine. 2007;69(5):464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17567709</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P. Efficacy of Tai Chi, brisk walking, meditation, and reading in reducing mental and emotional stress. Journal of Psychosomatic Research. 1992;36(4):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">1593511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudsuang R, Chentanez V, Veluvan K. Effect of Buddhist meditation on serum cortisol and total protein levels, blood pressure, pulse rate, lung volume and reaction time. Physiology and Behavior. 1991;50(3):543&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">1801007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann JE, Aschbacher K, Wetherell JL, Roesch S, Redwine L. Effects of faith/assurance on cortisol levels are enhanced by a spiritual mantram intervention in adults with HIV: a randomized trial. Journal of Psychosomatic Research. 2009;66(2):161&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760973</ArticleId><ArticleId IdType="pubmed">19154859</ArticleId></ArticleIdList></Reference><Reference><Citation>Granath J, Ingvarsson S, von Thiele U, Lundberg U. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cognitive Behaviour Therapy. 2006;35(1):3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16500773</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Religious vs. conventional psychotherapy for major depression in patients with chronic medical illness: rationale, methods, and preliminary results. Depression Research and Treatment. 2012;2012:11 pages.460419</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384942</ArticleId><ArticleId IdType="pubmed">22778932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrensch M, Chew T, Farren G, et al. Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Research. 2003;5(4):R88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165017</ArticleId><ArticleId IdType="pubmed">12817999</ArticleId></ArticleIdList></Reference><Reference><Citation>MacArthur AC, Le ND, Abanto ZU, Gallagher RP. Occupational female breast and reproductive cancer mortality in British Columbia, Canada, 1950&#x2013;94. Occupational Medicine. 2007;57(4):246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">17317704</ArticleId></ArticleIdList></Reference><Reference><Citation>Naguib SM, Lundin FE, Davis HJ. Relation of various epidemiologic factors to cervical cancer as determined by a screening program. Obstetrics and Gynecology. 1966;28(4):451&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">5925030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner JW, Lyon JL. Cancer in Utah Mormon men by lay priesthood level. American Journal of Epidemiology. 1982;116(2):243&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114035</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner JW, Lyon JL. Cancer in Utah Mormon women by Church activity level. American Journal of Epidemiology. 1982;116(2):258&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringdal GI. Religiosity, quality of life, and survival in cancer patients. Social Indicators Research. 1996;38(2):193&#x2013;211.</Citation></Reference><Reference><Citation>Enstrom JE. Health practices and cancer mortality among active California Mormons. Journal of the National Cancer Institute. 1989;81(23):1807&#x2013;1814.</Citation><ArticleIdList><ArticleId IdType="pubmed">2585528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwyer JW, Clarke LL, Miller MK. The effect of religious concentration and affiliation on county cancer mortality rates. Journal of Health and Social Behavior. 1990;31(2):185&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">2102497</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Ness PH, Kasl SV, Jones BA. Religion, race, and breast cancer survival. International Journal of Psychiatry in Medicine. 2003;33(4):357&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15152786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney AY, Bloor LE, Dudley WN, et al. Roles of religious involvement and social support in the risk of colon cancer among blacks and whites. American Journal of Epidemiology. 2003;158(11):1097&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630606</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels M, Merrill RM, Lyon JL, Stanford JB, White GL., Jr Associations between breast cancer risk factors and religious practices in Utah. Preventive Medicine. 2004;38(1):28&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">14672639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong YK, Tsai WC, Lin JC, et al. Socio-demographic factors in the prognosis of oral cancer patients. Oral Oncology. 2006;42(9):893&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">16730220</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucino C, Sonnenberg A. Occupational mortality from squamous cell carcinoma of the esophagus in the United States during 1991&#x2013;1996. Digestive Diseases and Sciences. 2002;47(3):568&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11911344</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnall E, Wassertheil-Smoller S, Swencionis C, et al. The relationship between religion and cardiovascular outcomes and all-cause mortality in the women&#x2019;s health initiative observational study. Psychology and Health. 2010;25(2):249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20391218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. Journal of the American Medical Association. 2007;298(14):1685&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">17925521</ArticleId></ArticleIdList></Reference><Reference><Citation>Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nature Clinical Practice Oncology. 2008;5(8):466&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">18493231</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL. Religious involvement and the health of the elderly: some hypotheses and an initial test. Social Forces. 1987;66:226&#x2013;238.</Citation></Reference><Reference><Citation>Idler EL, Kasl SV. Religion among disabled and nondisabled persons II: attendance at religious services as a predictor of the course of disability. Journals of Gerontology. 1997;52(6):S306&#x2013;S316.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403524</ArticleId></ArticleIdList></Reference><Reference><Citation>Pressman P, Lyons JS, Larson DB, Strain JJ. Religious belief, depression, and ambulation status in elderly women with broken hips. American Journal of Psychiatry. 1990;147(6):758&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">2343920</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamins MR, Musick MA, Gold DT, George LK. Age-related declines in activity level: the relationship between chronic illness and religious activities. Journals of Gerontology. 2003;58(6):S377&#x2013;S385.</Citation><ArticleIdList><ArticleId IdType="pubmed">14614127</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow-Howell N, Hinterlong J, Rozario PA, Tang F. Effects of volunteering on the well-being of older adults. Journals of Gerontology. 2003;58(3):S137&#x2013;S145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes Cardozo B, Bilukha OO, Gotway Crawford CA, et al. Mental health, social functioning, and disability in postwar Afghanistan. Journal of the American Medical Association. 2004;292(5):575&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292083</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Ortiz CA, Ayele H, Mulligan T, Espino DV, Berges IM, Markides KS. Higher church attendance predicts lower fear of falling in older Mexican-Americans. Aging and Mental Health. 2006;10(1):13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai AL, Peterson C, Bolling SF, Rodgers W. Depression, faith-based coping, and short-term postoperative global functioning in adult and older patients undergoing cardiac surgery. Journal of Psychosomatic Research. 2006;60(1):21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380306</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco KJ. Religious activities, strength from faith, and social functioning among African American and white nursing home residents. Journal of Religion, Spirituality and Aging. 2007;19(4):3&#x2013;20.</Citation></Reference><Reference><Citation>Arcury TA, Stafford JM, Bell RA, Golden SL, Snively BM, Quandt SA. The association of health and functional status with private and public religious practice among rural, ethnically diverse, older adults with diabetes. Journal of Rural Health. 2007;23(3):246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653177</ArticleId><ArticleId IdType="pubmed">17565525</ArticleId></ArticleIdList></Reference><Reference><Citation>Berges IM, Kuo YF, Markides KS, Ottenbacher K. Attendance at religious services and physical functioning after stroke among older Mexican Americans. Experimental Aging Research. 2007;33(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132561</ArticleId></ArticleIdList></Reference><Reference><Citation>Park NS, Klemmack DL, Roff LL, et al. Religiousness and longitudinal trajectories in elders&#x2019; functional status. Research on Aging. 2008;30(3):279&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871343</ArticleId><ArticleId IdType="pubmed">20485460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekur P, Singphow C, Nagendra HR, Raghuram N. Effect of short-term intensive yoga program on pain, functional disability and spinal flexibility in chronic low back pain: a randomized control study. Journal of Alternative and Complementary Medicine. 2008;14(6):637&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">18673078</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL. Religion, health, and nonphysical senses of self. Social Forces. 1995;74:683&#x2013;704.</Citation></Reference><Reference><Citation>Hendershot GE. Mobility limitations and complementary and alternative medicine: are people with disabilities more likely to pray? American Journal of Public Health. 2003;93(7):1079&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1447910</ArticleId><ArticleId IdType="pubmed">12835186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pargament KI, Koenig HG, Tarakeshwar N, Hahn J. Religious coping methods as predictors of psychological, physical and spiritual outcomes among medically ill elderly patients: a two-year longitudinal study. Journal of Health Psychology. 2004;9(6):713&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilgil E, Ka&#xe7;ar C, B&#xfc;t&#xfc;n B, et al. Prevalence of low back pain in a developing urban setting. Spine. 2005;30(9):1093&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">15864165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai AL, Peterson C, Bolling SF, Rodgers W. Depression, faith-based coping, and short-term postoperative global functioning in adult and older patients undergoing cardiac surgery. Journal of Psychosomatic Research. 2006;60(1):21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380306</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmueli A. Health and religiosity among Israeli Jews. European Journal of Public Health. 2007;17(1):104&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877450</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamins MR. Religion and functional health among the elderly: is there a relationship and is it constant? Journal of Aging and Health. 2004;16(3):355&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">15155067</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, George LK, Titus P. Religion, spirituality, and health in medically Ill hospitalized older patients. Journal of the American Geriatrics Society. 2004;52(4):554&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066070</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin KR, Levy BR. Opposing trends of religious attendance and religiosity in predicting elders&#x2019; functional recovery after an acute myocardial infarction. Journal of Religion and Health. 2006;45(3):440&#x2013;451.</Citation></Reference><Reference><Citation>Bath PA. Self-rated health as a risk factor for prescribed drug use and future health and social service use in older people. Journals of Gerontology. 1999;54(11):M565&#x2013;M570.</Citation><ArticleIdList><ArticleId IdType="pubmed">10619319</ArticleId></ArticleIdList></Reference><Reference><Citation>Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. Journal of Health and Social Behavior. 1997;38(1):21&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">9097506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jylh&#xe4; M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Social Science and Medicine. 2009;69(3):307&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">19520474</ArticleId></ArticleIdList></Reference><Reference><Citation>Musick MA. Religion and subjective health among black and white elders. Journal of Health and Social Behavior. 1996;37(3):221&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">8898494</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Neighborhood deterioration, religious coping, and changes in health during late life. Gerontologist. 1998;38(6):653&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">9868846</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin J. God, love, and health: findings from a clinical study. Review of Religious Research. 2001;42(3):277&#x2013;293.</Citation></Reference><Reference><Citation>Hyypp&#xe4; MT, M&#xe4;ki J. Individual-level relationships between social capital and self-rated health in a bilingual community. Preventive Medicine. 2001;32(2):148&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">11162340</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Church-based social support and health in old age: exploring variations by race. Journals of Gerontology. 2002;57(6):S332&#x2013;S347.</Citation><ArticleIdList><ArticleId IdType="pubmed">12426442</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch BK, Vega WA. Acculturation stress, social support, and self-rated health among Latinos in California. Journal of immigrant health. 2003;5(3):109&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14512765</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Olphen J, Schulz A, Israel B, et al. Religious involvement, social support, and health among African-American women on the east side of Detroit. Journal of General Internal Medicine. 2003;18(7):549&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1494889</ArticleId><ArticleId IdType="pubmed">12848838</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough ME, Laurenceau JP. Religiousness and the trajectory of self-rated health across adulthood. Personality and Social Psychology Bulletin. 2005;31(4):560&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">15743989</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Exploring the stress-buffering effects of church-based and secular social support on self-rated health in late life. Journals of Gerontology. 2006;61(1):S35&#x2013;S43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16399948</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Gratitude toward God, stress, and health in late life. Research on Aging. 2006;28(2):163&#x2013;183.</Citation></Reference><Reference><Citation>Kim D, Kawachi I. A multilevel analysis of key forms of community- and individual-level social capital as predictors of self-rated health in the United States. Journal of Urban Health. 2006;83(5):813&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438597</ArticleId><ArticleId IdType="pubmed">16810567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sujold&#x17e;i&#x107; A, Peternel L, Kulenovi&#x107; T, Terzi&#x107; R. Social determinants of health-a comparative study of Bosnian adolescents in different cultural contexts. Collegium Antropologicum. 2006;30(4):703&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243537</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes-Ortiz CA, Pelaez M, Koenig HG, Mulligan T. Religiosity and self-rated health among Latin American and Caribbean elders. International Journal of Psychiatry in Medicine. 2007;37(4):425&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">18441630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillum RF, King DE, Obisesan TO, Koenig HG. Frequency of attendance at religious services and mortality in a U.S. National cohort. Annals of Epidemiology. 2008;18(2):124&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659561</ArticleId><ArticleId IdType="pubmed">18083539</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig LB, Vaillant GE. A prospective study of church attendance and health over the lifespan. Health Psychology. 2009;28(1):117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">19210025</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Church-based volunteering, providing informal support at church, and self-rated health in late life. Journal of Aging and Health. 2009;21(1):63&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844660</ArticleId><ArticleId IdType="pubmed">19144969</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Religious involvement, humility, and self-rated health. Social Indicators Research. 2010;98(1):23&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918920</ArticleId><ArticleId IdType="pubmed">20703366</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. Close companions at church, health, and health care use in late life. Journal of Aging and Health. 2010;22(4):434&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866809</ArticleId><ArticleId IdType="pubmed">20194685</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause N. God-mediated control and change in self-rated health. International Journal for the Psychology of Religion. 2010;20(4):267&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2971554</ArticleId><ArticleId IdType="pubmed">21057586</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputo RK. Parent religiosity, family processes, and adolescent outcomes. Families in Society. 2004;85(4):495&#x2013;510.</Citation></Reference><Reference><Citation>Benjamins MR. Predictors of preventive health care use among middle-aged and older adults in Mexico: the role of religion. Journal of Cross-Cultural Gerontology. 2007;22(2):221&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17340204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross LE, Hall IJ, Fairley TL, Taylor YJ, Howard DL. Prayer and self-reported health among cancer survivors in the United States, National Health Interview Survey, 2002. Journal of Alternative and Complementary Medicine. 2008;14(8):931&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3152800</ArticleId><ArticleId IdType="pubmed">18925865</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronan TA, Kaplan RM, Posner L, Blumberg E, Kozin F. Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. Arthritis and Rheumatism. 1989;32(12):1604&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">2597213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pearce MJ. Does spirituality as a coping mechanism help or hinder coping with chronic pain? Current Pain and Headache Reports. 2009;13(2):127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19272278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pearce MJ. Does spirituality as a coping mechanism help or hinder coping with chronic pain? Current Pain and Headache Reports. 2009;13(2):127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19272278</ArticleId></ArticleIdList></Reference><Reference><Citation>Charcot JM. Lemon d&#x2019;ouverture. Progr&#xe8;s M&#xe9;dical. 1882;10:p. 336.</Citation></Reference><Reference><Citation>Turner JA, Clancy S. Strategies for coping with chronic low back pain: relationship to pain and disability. Pain. 1986;24(3):355&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">2938059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. Journal of Behavioral Medicine. 1985;8(2):163&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">3897551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pargament KI. Is spirituality a critical ingredient of meditation? Comparing the effects of spiritual meditation, secular meditation, and relaxation on spiritual, psychological, cardiac, and pain outcomes. Journal of Behavioral Medicine. 2005;28(4):369&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16049627</ArticleId></ArticleIdList></Reference><Reference><Citation>John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache. 2007;47(5):654&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17501846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech K, Kalisch R, Weiskopf N, Pleger B, Stephan KE, Dolan RJ. Anterolateral prefrontal cortex mediates the analgesic effect of expected and perceived control over pain. Journal of Neuroscience. 2006;26(44):11501&#x2013;11509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635565</ArticleId><ArticleId IdType="pubmed">17079679</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekur P, Singphow C, Nagendra HR, Raghuram N. Effect of short-term intensive yoga program on pain, functional disability and spinal flexibility in chronic low back pain: a randomized control study. Journal of Alternative and Complementary Medicine. 2008;14(6):637&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">18673078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pargament KI. Migraines and meditation: does spirituality matter? Journal of Behavioral Medicine. 2008;31(4):351&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">18551362</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant JA, Rainville P. Pain sensitivity and analgesic effects of mindful states in zen meditators: a cross-sectional study. Psychosomatic Medicine. 2009;71(1):106&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">19073756</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant JA, Courtemanche J, Duerden EG, Duncan GH, Rainville P. Cortical thickness and pain sensitivity in Zen meditators. Emotion. 2010;10(1):43&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">20141301</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco KJ. Religiosity and depression among nursing home residents: results of a survey of ten states. Journal of Religious Gerontology. 2000;12(1):43&#x2013;61.</Citation></Reference><Reference><Citation>Cohen L, Fouladi RT, Katz J. Preoperative coping strategies and distress predict postoperative pain and morphine consumption in women undergoing abdominal gynecologic surgery. Journal of Psychosomatic Research. 2005;58(2):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820849</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson G. Chronic pain and praying to a higher power: useful or useless? Journal of Religion and Health. 2008;47(2):176&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">19105010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pargament KI. Is spirituality a critical ingredient of meditation? Comparing the effects of spiritual meditation, secular meditation, and relaxation on spiritual, psychological, cardiac, and pain outcomes. Journal of Behavioral Medicine. 2005;28(4):369&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">16049627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wachholtz AB, Pargament KI. Migraines and meditation: does spirituality matter? Journal of Behavioral Medicine. 2008;31(4):351&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">18551362</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenbach VJ, Kaplan BH, Fredman L, Kleinbaum DG. Social ties and mortality in Evans county, Georgia. American Journal of Epidemiology. 1986;123(4):577&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">3953538</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant S, Rakowski W. Predictors of mortality among elderly African-Americans. Research on Aging. 1992;14(1):50&#x2013;67.</Citation></Reference><Reference><Citation>Kark JD, Shemi G, Friedlander Y, Martin O, Manor O, Blondheim SH. Does religious observance promote health? Mortality in secular vs religious Kibbutzim in Israel. American Journal of Public Health. 1996;86(3):341&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380514</ArticleId><ArticleId IdType="pubmed">8604758</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge WJ, Cohen RD, Shema SJ, Kaplan GA. Frequent attendance at religious services and mortality over 28 years. American Journal of Public Health. 1997;87(6):957&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1380930</ArticleId><ArticleId IdType="pubmed">9224176</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Does religious attendance prolong survival? a six-year follow-up study of 3,968 older adults. Journals of Gerontology. 1999;54(7):M370&#x2013;M376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10462170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummer RA, Rogers RG, Nam CB, Ellison CG. Religious involvement and U.S. adult mortality. Demography. 1999;36(2):273&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">10332617</ArticleId></ArticleIdList></Reference><Reference><Citation>Helm HM, Hays JC, Flint EP, Koenig HG, Blazer DG. Does private religious activity prolong survival? A six-year follow-up study of 3,851 older adults. Journals of Gerontology. 2000;55(7):M400&#x2013;M405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10898257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison CG, Hummer RA, Cormier S, Rogers RG. Religious involvement and mortality risk among African American adults. Research on Aging. 2000;22(6):630&#x2013;667.</Citation></Reference><Reference><Citation>Eng PM, Rimm EB, Fitzmaurice G, Kawachi I. Social ties and change in social ties in relation to subsequent total and cause-specific mortality and coronary heart disease incidence in men. American Journal of Epidemiology. 2002;155(8):700&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutgendorf SK, Ullrich P, Wallace R, Russell D, Harris TB. Religious participation, interleukin-6, and mortality in older adults. Health Psychology. 2004;23(5):465&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367066</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris AHS, Thoresen CE. Volunteering is associated with delayed mortality in older people: analysis of the longitudinal study of aging. Journal of Health Psychology. 2005;10(6):739&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">16176953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill TD, Angel JL, Ellison CG, Angel RJ. Religious attendance and mortality: an 8-year follow-up of older Mexican Americans. The Journals of Gerontology. 2005;60(2):S102&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">15746025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupre ME, Franzese AT, Parrado EA. Religious attendance and mortality: implications for the black-white mortality crossover. Demography. 2006;43(1):141&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">16579212</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W. Religious participation and mortality risk among the oldest old in China. Journals of Gerontology. 2008;63(5):S293&#x2013;S297.</Citation><ArticleIdList><ArticleId IdType="pubmed">18818449</ArticleId></ArticleIdList></Reference><Reference><Citation>Enstrom JE, Breslow L. Lifestyle and reduced mortality among active California Mormons, 1980-2004. Preventive Medicine. 2008;46(2):133&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">17920112</ArticleId></ArticleIdList></Reference><Reference><Citation>Ironson G, Kremer H. Spiritual transformation, psychological well-being, health, and survival in people with HIV. International Journal of Psychiatry in Medicine. 2009;39(3):263&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">19967899</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough ME, Friedman HS, Enders CK, Martin LR. Does devoutness delay death? Psychological investment in religion and its association with longevity in the terman sample. Journal of Personality and Social Psychology. 2009;97(5):866&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">19857007</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnall E, Wassertheil-Smoller S, Swencionis C, et al. The relationship between religion and cardiovascular outcomes and all-cause mortality in the women&#x2019;s health initiative observational study. Psychology and Health. 2010;25(2):249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20391218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummer RA, Benjamins MR, Ellison CG, Rogers RG. Religious involvement and mortality risk among pre-retirement aged U.S. adults. In: Ellison CG, Hummer RA, editors. Religion, Families, and Health: Population-Based Research in the United States. Piscataway, NJ, USA: Rutgers Press; 2010. pp. 273&#x2013;291.</Citation></Reference><Reference><Citation>Parkerson GR, Jr, Gutman RA. Health-related quality of life predictors of survival and hospital utilization. Health Care Financing Review. 2000;21(3):171&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194681</ArticleId><ArticleId IdType="pubmed">11481754</ArticleId></ArticleIdList></Reference><Reference><Citation>Park RM, Schulte PA, Bowman JD, et al. Potential occupational risks for neurodegenerative diseases. American Journal of Industrial Medicine. 2005;48(1):63&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">15940722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnall E, Wassertheil-Smoller S, Swencionis C, et al. The relationship between religion and cardiovascular outcomes and all-cause mortality in the women&#x2019;s health initiative observational study. Psychology and Health. 2010;25(2):249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20391218</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell LH, Shahabi L, Thoresen CE. Religion and spirituality: linkages to physical health. American Psychologist. 2003;58(1):36&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12674817</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough ME, Hoyt WT, Larson DB, Koenig HG, Thoresen C. Religious involvement and mortality: a meta-analytic review. Health Psychology. 2000;19(3):211&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10868765</ArticleId></ArticleIdList></Reference><Reference><Citation>Chida Y, Steptoe A, Powell LH. Religiosity/spirituality and mortality: a systematic quantitative review. Psychotherapy and Psychosomatics. 2009;78(2):81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19142047</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough M. Religious involvement and mortality. In: Plane TG, Sherman AC, editors. Faith and Health: Psychological Perspectives. New York, NY, USA: Guilford Press; 2001. pp. 53&#x2013;74.</Citation></Reference><Reference><Citation>House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988;241(4865):540&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">3399889</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S, Underwood LG, Gottlieb BH. Social Support, Measurement, and Intervention: A Guide For Health and Social Scientists. New York, NY, USA: Oxford University Press; 2000.</Citation></Reference><Reference><Citation>Uchino BN. Understanding the links between social support and physical health. Perspectives on Psychological Science. 2009;4(3):236&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">26158961</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Koenig HG. Spirituality in Patient Care. 3rd edition. Conshohocken, Pa, USA: Templeton Press; 2013.</Citation></Reference><Reference><Citation>Fitchett G, Burton LA, Sivan AB. The religious needs and resources of psychiatric inpatients. Journal of Nervous and Mental Disease. 1997;185(5):320&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9171809</ArticleId></ArticleIdList></Reference><Reference><Citation>Balboni TA, Vanderwerker LC, Block SD, et al. Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. Journal of Clinical Oncology. 2007;25(5):555&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515558</ArticleId><ArticleId IdType="pubmed">17290065</ArticleId></ArticleIdList></Reference><Reference><Citation>Pargament KI, Koenig HG, Tarakeshwar N, Hahn J. Religious struggle as a predictor of mortality among medically ill elderly patients: a 2-Year longitudinal study. Archives of Internal Medicine. 2001;161(15):1881&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pubmed">11493130</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Religious beliefs and practices of hospitalized medically Ill older adults. International Journal of Geriatric Psychiatry. 1998;13:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646148</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Shelp F, Goli V, Cohen HJ, Blazer DG. Survival and health care utilization in elderly medical inpatients with major depression. Journal of the American Geriatrics Society. 1989;37(7):599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">2738278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehman JW, Ott BB, Short TH, Ciampa RC, Hansen-Flaschen J. Do patients want physicians to inquire about their spiritual or religious beliefs if they become gravely ill? Archives of Internal Medicine. 1999;159(15):1803&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448785</ArticleId></ArticleIdList></Reference><Reference><Citation>McCord G, Gilchrist VJ, Grossman SD, et al. Discussing spirituality with patients: a rational and ethical approach. Annals of Family Medicine. 2004;2(4):356&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1466687</ArticleId><ArticleId IdType="pubmed">15335136</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri GA, Knittig S, Zoller JS, Nietert PJ. Importance of faith on medical decisions regarding cancer care. Journal of Clinical Oncology. 2003;21(7):1379&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaldjian LC, Jekel JF, Friedland G. End-of-life decisions in HIV-positive patientsthe role of spiritual beliefs. AIDS. 1998;12(1):103&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">9456260</ArticleId></ArticleIdList></Reference><Reference><Citation>Curlin FA, Lawrence RE, Chin MH, Lantos JD. Religion, conscience, and controversial clinical practices. New England Journal of Medicine. 2007;356(6):593&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867473</ArticleId><ArticleId IdType="pubmed">17287479</ArticleId></ArticleIdList></Reference><Reference><Citation>Stulberg DB, Dude AM, Dahlquist I. Abortion provision among practicing obstetrician-gynecologists. Curlin FAObstetrics &amp; Gynecology. 2011;118(3):609&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170127</ArticleId><ArticleId IdType="pubmed">21860290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi KL, Koopmans J, Curlin FA, Alexander KA, Ross LF. Paediatricians&#x2019; attitudes and practices towards HPV vaccination. Acta Paediatrica, International Journal of Paediatrics. 2008;97(11):1550&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2607063</ArticleId><ArticleId IdType="pubmed">18671696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence RE, Rasinski KA, Yoon JD, Curlin FA. Obstetrician-gynecologist physicians&#x2019; beliefs about emergency contraception: a national survey. Contraception. 2010;82(4):324&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943429</ArticleId><ArticleId IdType="pubmed">20851225</ArticleId></ArticleIdList></Reference><Reference><Citation>Balboni T, Balboni M, Paulk ME, et al. Support of cancer patients&#x2019; spiritual needs and associations with medical care costs at the end of life. Cancer. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177963</ArticleId><ArticleId IdType="pubmed">21563177</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare and Medicaid Services (CMS)  State Operations Manual, Appendix M-Guidance to Surveyors: Hospice,  https://www.cms.gov/manuals/downloads/som107ap_m_hospice.pdf.</Citation></Reference><Reference><Citation>Koenig HG. An 83-year-old woman with chronic illness and strong religious beliefs. Journal of the American Medical Association. 2002;288(4):487&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12132980</ArticleId></ArticleIdList></Reference><Reference><Citation>Curlin FA, Chin MH, Sellergren SA, Roach CJ, Lantos JD. The association of physicians&#x2019; religious characteristics with their attitudes and self-reported behaviors regarding religion and spirituality in the clinical encounter. Medical Care. 2006;44(5):446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">16641663</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG, Hooten EG, Lindsay-Calkins E, Meador KG. Spirituality in medical school curricula: findings from a national survey. International Journal of Psychiatry in Medicine. 2010;40(4):391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">21391410</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely D, Minford EJ. Current status of teaching on spirituality in UK medical schools. Medical Education. 2008;42(2):176&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">18230090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchetti G, Espinha DCM, de Oliveira LR, Leite JR, Lucchetti ALG, Koenig HG. Spirituality and health in the curricula of medical schools in Brazil. BMC Medical Education. 2012;12:p. 78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3502099</ArticleId><ArticleId IdType="pubmed">22900476</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig HG. Spirituality in Patient Care. 2nd edition. ch 13. Conshohocken, PA: Templeton Press; 2007. Information on specific religions; pp. 188&#x2013;227.</Citation></Reference><Reference><Citation>Koenig HG, King DE, Carson VB. Handbook of Religion and Health. 2nd edition. New York, NY, USA: Oxford University Press; 2012.</Citation></Reference><Reference><Citation>Koenig HG. Spirituality in Patient Care. 3rd edition. Conshohocken, Pa, USA: Templeton Press; 2013.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22196307</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6844</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>2-3</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Epilepsy research</Title><ISOAbbreviation>Epilepsy Res</ISOAbbreviation></Journal><ArticleTitle>Olanzapine-associated myoclonus.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>250</EndPage><MedlinePgn>247-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eplepsyres.2011.07.020</ELocationID><Abstract><AbstractText>Olanzapine is an atypical antipsychotic drug that infrequently has been reported to cause seizures and myoclonus despite a small proconvulsant risk. This is the first report of generalized myoclonus induced in a patient who had been maintained on low dose olanzapine for over seven years without any change in her dose. Olanzapine was discontinued, and the myoclonic jerks completely resolved within 48 h.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Jennifer Block</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milstein</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Haut</LastName><ForeName>Sheryl R</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Epilepsy Res</MedlineTA><NlmUniqueID>8703089</NlmUniqueID><ISSNLinking>0920-1211</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009207" MajorTopicYN="N">Myoclonus</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22196307</ArticleId><ArticleId IdType="doi">10.1016/j.eplepsyres.2011.07.020</ArticleId><ArticleId IdType="pii">S0920-1211(11)00223-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22177623</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Parkinsonism &amp; related disorders</Title><ISOAbbreviation>Parkinsonism Relat Disord</ISOAbbreviation></Journal><ArticleTitle>Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>326</EndPage><MedlinePgn>321-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.parkreldis.2011.11.015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">No recent analysis details Parkinson's Disease (PD) costs or survival for Medicare beneficiaries. This study assesses excess direct costs and survival in Medicare beneficiaries with early and advanced PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with &#x2265; 2 PD diagnoses (ICD-9-CM: 332.0), &#x2265; age 65, continuously enrolled in Parts A&amp;B during one-year baseline and study periods were selected from the Medicare 5% sample (N = 3.2 million, 1999-2008). Newly diagnosed patients were defined as having no baseline claims for movement disorder, dementia, Alzheimer's, bipolar disorder, psychosis, falls or related injuries, ambulatory assistance device (walker or wheelchair), or skilled nursing facility. Controls without PD were demographically matched 1:1. Costs to Medicare were compared via Wilcoxon rank-sum tests and inverse probability weighted multivariate regression. Survival was assessed via Cox proportional hazards analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Costs in the year post-diagnosis were higher for newly diagnosed patients (N = 9,201, $7423) than controls ($5024), resulting in excess PD-associated costs of $2399 (p &lt; 0.001). Cumulative excess costs were $28,422 from the year prior to index quarter to five years following (p &lt; 0.01). PD patients receiving their first claim for an ambulatory assistance device (N = 11,294) had excess cumulative costs of $50,923 (p &lt; 0.001) over the same period; those receiving their first claim for a skilled nursing facility (N = 10,152) had excess costs of $102,750 (p &lt; 0.001). Hazard rates of mortality were higher among newly diagnosed PD (1.43, p &lt; 0.001), ambulatory assistance device (2.37, p &lt; 0.001) and skilled nursing facility (3.34, p &lt; 0.001) cohorts than in corresponding non-PD groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Medicare beneficiaries with PD have substantially and progressively higher costs and mortality compared with controls.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaltenboeck</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Analysis Group, Inc, NY 10020, USA. akaltenboeck@analysisgroup.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Birnbaum</LastName><ForeName>H G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Tarrants</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Siderowf</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parkinsonism Relat Disord</MedlineTA><NlmUniqueID>9513583</NlmUniqueID><ISSNLinking>1353-8020</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013534" MajorTopicYN="Y">Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22177623</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2011.11.015</ArticleId><ArticleId IdType="pii">S1353-8020(11)00397-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22151240</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1479-8301</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society</Title><ISOAbbreviation>Psychogeriatrics</ISOAbbreviation></Journal><ArticleTitle>Reliability and validity of the Japanese version of the Agitated Behaviour in Dementia Scale in Alzheimer's disease: three dimensions of agitated behaviour in dementia.</ArticleTitle><Pagination><StartPage>212</StartPage><EndPage>220</EndPage><MedlinePgn>212-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1479-8301.2011.00371.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Agitation in dementia seriously affects not only patients' quality of life (QOL), but also caregivers' QOL. Thus, an appropriate assessment of agitated behaviour in dementia is needed for clinical management. We developed the Japanese version of the Agitated Behaviour in Dementia scale (ABID), examined its reliability and validity, and carried out its factor analysis to elucidate its factor structure.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Japanese version of the ABID was given caregivers of 149 Japanese patients with Alzheimer's disease (AD). The internal-consistency, test-retest reliability and concurrent validity of the Japanese version of the ABID were then examined. A factor analysis was used to examine the agitated behavioural dimensions underlying ABID.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Japanese version of the ABID showed an excellent internal reliability for both frequency ratings (Cronbach's &#x3b1;= 0.89) and reaction ratings (Cronbach's &#x3b1;= 0.92), and an excellent test-retest reliability for both frequency ratings and reaction ratings. The total score for the frequency ratings of the ABID was significantly associated with the Cohen-Mansfield Agitation Inventory (CMAI), and the total score for the reaction ratings of the ABID was significantly associated with the Zarit Burden Interview. The factor analysis showed three subtypes: physically agitated behaviour, verbally agitated behaviour and psychosis symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Japanese version of the ABID promises to be useful for assessing agitated behaviour in patients with AD. Importantly, understanding these subtypes of agitated behaviour might have implications for individualized treatment plans.</AbstractText><CopyrightInformation>&#xa9; 2011 The Authors. Psychogeriatrics &#xa9; 2011 Japanese Psychogeriatric Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Katsuyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Cognitive-Behavioural Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaaki</LastName><ForeName>Shutaro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Banno</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Junko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tatsumi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yamanaka</LastName><ForeName>Katsuo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Narumoto</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mimura</LastName><ForeName>Masaru</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Akechi</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Toshi A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychogeriatrics</MedlineTA><NlmUniqueID>101230058</NlmUniqueID><ISSNLinking>1346-3500</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22151240</ArticleId><ArticleId IdType="doi">10.1111/j.1479-8301.2011.00371.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22141191</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0260-1060</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>3-4</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Nutrition and health</Title><ISOAbbreviation>Nutr Health</ISOAbbreviation></Journal><ArticleTitle>Infantile autism: a chronic psychosis since infancy due to synaptic pruning of the supplementary motor area.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>182</EndPage><MedlinePgn>171-82</MedlinePgn></Pagination><Abstract><AbstractText>The rise in infantile autism, learning problems, cognitive decline with age, Alzheimer's, Parkinson's diseases and the SIDS epidemic, has a common cause in the rising dietary deficit in Omega-3 brain-food. This paper suggests that aside from the wider concept of autism spectrum disorders (ASD) and pervasive developmental disorders (PDD), the rise in infantile autism (IA) in the last decade is the effect of deficient brain-food (Omega-3). The consequent delay of development, prolongs the 2nd regressive event in infancy to pruning of the centre in the Medial Frontal Lobe System that connects hippocampus and singulum. With a consequently defective supplementary motor area (SMA), the Delayed Response Function is affected leading to persistent psychosis. Post-pubertal episodic psychoses are associated with acute reduction of excitation, a risk of breakdown of circuitry, insufficient fill-in mechanisms, and silent spots. An acute psychosis occurs if the silent spots compromise SMA. Only two brain areas have continuous neurogenesis, indicating their important functions: the Hippocampus and Olfactory Bulb that belongs to the lateral frontal lobe system essential to survival. Concerned with necessity of action in response to the environment, it relies upon short-term memory and acute feedback mechanisms influenced by emotion and motivation from the external world. In contrast, the medial frontal lobe network is controlled by feed-forward predictive mechanisms related to storage of information The Delayed Response Function is mastered at 7 months, when 2nd event occurs with pruning of axons and dendrites. An abolished or defective delayed response function seriously incapacitates an individual: a defective "social brain" with an inability for conscious action and to communicate, predominates in IA. There is a near lack of speech, despite normal vision and hearing in the minority without marked adversity in pregnancy, at delivery or in infancy. The recent rise in IA despite no rise in adversity signifies a rising deficiency in brain-food. This is suggested by a changing clinical picture: no Mental Retardation in an IA majority. Deficit in olfaction is pathognomonic in schizophrenia since 30 yrs and distinguishes the Asperger syndrome. If brain-food deficiency alone sufficiently prolongs pruning to cause absent activity in SMA in infancy, less mentally retarded IA from other causes might be observed. Deficit in brain-food was evident in the Sudden Infant Death Syndrome: birthweight averaged 200-300g lower than sibs, Omega-3 levels in brainstem were lower than controls. Only 20% SIDS died in first hypoxic episode, suggesting such episodes are more frequent than we imagined. Children with learning-behaviour problems have similarly depressed birthweight. A general deficiency in omega-3 contributes to the lacking reduction in Schizophrenia, despite early puberty predominates. Olfactory bulb is first affected in the Alzheimer's and Parkinson's disease. Cognitive decline with age, hippocampal dysfunctions rises markedly irrespective of disease, but the major mental illnesses and Infantile Autism in particular, benefit from "brainfood" that might also prevent a development of these disorders. To secure optimal brain function in the coming generations, there is a need to change the diet now from its emphasis on protein for body growth to food for the brain. This means there is a need to increase fish and sea food consumption.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saugstad</LastName><ForeName>Letten F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, University of Oslo.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nutr Health</MedlineTA><NlmUniqueID>8306569</NlmUniqueID><ISSNLinking>0260-1060</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001321" MajorTopicYN="N">Autistic Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22141191</ArticleId><ArticleId IdType="doi">10.1177/026010601102000402</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22137220</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Psychiatric, psychological comorbidities of typical and atypical Charles-Bonnet syndrome].</ArticleTitle><Pagination><StartPage>473</StartPage><EndPage>480</EndPage><MedlinePgn>473-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2011.05.006</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Charles-Bonnet syndrome (CBS) is conventionally defined by the presence of visual hallucinations in patients suffering from lowered visual acuity without having psychosis or dementia. Actually, it is a syndrome that interests many specialties, especially ophthalmology, geriatrics, neurology and psychiatry. "Atypical CBS" or "CBS plus" was introduced to designate any kind of visual hallucinations that could be considered as a CBS but accompanied by a low level of insight, a possible cognitive decline, other hallucinatory modalities etc. Since all patients suffering from CBS have to be psychiatrically evaluated, psychological and psychiatric implications of their syndrome have to be well understood in order to better manage them. These psychiatric and psychological implications are: the relationship between the CBS and dementia, the psychological reaction of the patients towards their hallucinations and psychiatric comorbidities that could be developed during the course of the syndrome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A research via MEDLINE for all the articles published in French or in English between January 1999 and December 2009 was done using the following keywords Charles-Bonnet, psychiatric comorbidities and Charles-Bonnet syndrome, Charles-Bonnet syndrome and dementia, psychological reaction and Charles-Bonnet syndrome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although some studies report an association between the CBS and dementia, the majority of these studies do not confirm this association and point towards an atypical initial presentation of the syndrome. The psychological reaction accompanying the visual hallucinations of the typical CBS is variable (mild distress, indifference, pleasure). Patients suffering from a typical CBS conserve a full insight during the course of the syndrome. A positive personal psychiatric history or a concomitant psychiatric disorder changes the clinical presentation of the syndrome.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our research allowed us to define the following diagnostic criteria for the atypical CBS: 1) diminished level or absence of insight towards the visual hallucinations; 2) presence of a mild cognitive decline; 3) presence of an atypical psychological reaction towards the visual hallucinations as in the case of a severe and prolonged stressful reaction; 4) presence of other hallucinatory modalities; 5) presence of a positive personal psychiatric history or a concomitant psychiatric disorder. Each patient suffering from CBS should be initially evaluated psychiatrically and neurologically in order to confirm or to eliminate the presence of the most common causes of visual hallucinations. In the presence of a lowered visual acuity and a conserved cognitive functioning, the typical CBS is diagnosed after eliminating more common disorders. Once this diagnosis is established, patients should be evaluated in order to rule out the presence of an atypical clinical presentation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Atypical CBS is a syndrome that could be eventually associated with dementia, accompanied with a major depressive disorder or another psychiatric disorder, or with vulnerability towards psychiatric disorders. Patients suffering from atypical CBS should be closely followed psychiatrically and neurologically. Patients suffering from the typical CBS should also benefit from a psychiatric follow-up, due to their multiple psychiatric vulnerability factors and their possible management with psychotropic drugs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 L&#x2019;Enc&#xe9;phale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bou Khalil</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de psychiatrie, facult&#xe9; de m&#xe9;decine de l'universit&#xe9; Saint-Joseph de Beyrouth, Liban.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richa</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Comorbidit&#xe9;s psychiatriques et pychologiques du syndrome de Charles-Bonnet typique et atypique.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="N">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22137220</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2011.05.006</ArticleId><ArticleId IdType="pii">S0013-7006(11)00107-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22120173</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2012</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5118</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Progress in neurobiology</Title><ISOAbbreviation>Prog Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Cognitive and behavioural effects of physical exercise in psychiatric patients.</ArticleTitle><Pagination><StartPage>46</StartPage><EndPage>68</EndPage><MedlinePgn>46-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pneurobio.2011.11.007</ELocationID><Abstract><AbstractText>The current review outlines the under-appreciated effects of physical exercise on the course of psychiatric disorders, focussing on recent findings from animal and human research. Several studies have shown that regular physical exercise is significantly beneficial for psychiatric patients both on a biological and a psychological level. Positive effects of controlled exercise include improved metabolic responses, neuro-protection, increased quality of life, and reduced psychopathological symptoms. Studies investigating the effectiveness of various physical training interventions in alleviating severe mental diseases, such as Alzheimer's dementia (AD), schizophrenia (SZ) or major depressive disorder (MDD) indicate that physical exercise can relieve symptoms of depression, psychosis and dementia and more importantly can curtail further progression of these diseases. This review assesses the most effective methods of physical training for specific psychiatric symptoms. Introducing physical exercise in therapeutic regimes would be an innovative approach that could significantly reduce the severity of psychopathological and cognitive symptoms in patients. The positive biological and molecular outcomes associated with physical exercise render it a concrete therapeutic strategy for improving the quality of live and reducing physical illness in psychiatric patients. Therefore, integrating physical activity into a patient's social life may be an effective treatment strategy. Furthermore, exercise might have the potential to be a preventative treatment within the context of multi-modal therapeutic programs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kn&#xf6;chel</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University of Frankfurt/Main, Heinrich Hoffmann Str. 12, 60528 Frankfurt, Germany. christian.knoechel@kgu.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oertel-Kn&#xf6;chel</LastName><ForeName>Viola</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>O'Dwyer</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Prvulovic</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Gilberto</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kollmann</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neurobiol</MedlineTA><NlmUniqueID>0370121</NlmUniqueID><ISSNLinking>0301-0082</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="Y">Exercise Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013177" MajorTopicYN="N">Sports</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22120173</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2011.11.007</ArticleId><ArticleId IdType="pii">S0301-0082(11)00213-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22089639</PMID><DateCompleted><Year>2013</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Historical changes in the severity of dementia and accompanying neuropsychiatric symptoms in persons presenting for evaluation in a multiracial urban dementia center.</ArticleTitle><Pagination><StartPage>352</StartPage><EndPage>357</EndPage><MedlinePgn>352-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0b013e31823cfbdd</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We examine historical changes from 1992 to 2008 in the severity of dementia and accompanying neuropsychiatric symptoms among persons presenting for evaluation and treatment at a multiracial urban dementia center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed intakes of white (n=197) and black (n=568) patients seen at a dementia center in New York City. Intakes were divided into 3 time categories: period 1 (1992 to 1996), period 2 (1997 to 2002), and period 3 (2003 to 2008). Diagnoses included the following: Alzheimer disease (73%), vascular dementia (13%), mixed dementia (9%), mild cognitive impairment (2%), and other dementias (4%).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over the 3 assessment periods, persons increasingly presented at an earlier stage of illness with significantly higher levels of cognition and functioning, and a declining prevalence of psychotic symptoms and agitation. Blacks had a more advanced stage of illness, lower cognitive scores, and a greater prevalence of psychotic symptoms than whites in period 1, but not during the other time periods. There were no racial differences in functioning, agitation, or depression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Over the period 1992 to 2008, patients were increasingly more likely to present with early stages of dementia and fewer symptoms of psychoses and agitation, and racial differences in illness severity and neuropsychiatric symptoms disappeared. If our sample reflects trends in the United States, then it suggests that more persons will be in care for longer periods of time, previous research findings derived from dementia centers must be considered historically specific, and clinicians must be prepared to work with persons with milder forms of neurocognitive disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Carl I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Medicine, SUNY Downstate Medical Center, Brooklyn 11203NY, USA. carl.cohen@downstate.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Sharon E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Rahmani</LastName><ForeName>Morteza</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jasvir</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Prospere</LastName><ForeName>Everton</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D01HP08799</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009462" MajorTopicYN="N">Neurology</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22089639</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e31823cfbdd</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22048323</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and psychosis.</ArticleTitle><Pagination><StartPage>994</StartPage><EndPage>1000</EndPage><MedlinePgn>994-1000</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3182358921</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Behavioral disturbances occur in nearly all Alzheimer disease (AD) patients together with an array of cognitive impairments. Prior investigations have failed to demonstrate specific associations between them, suggesting an independent, rather than shared, pathophysiology. The objective of this study was to reexamine this issue using an extensive cognitive battery together with a sensitive neurobehavioral and functional rating scale to correlate behavioral syndromes and cognitive domains across the spectrum of impairment in dementia.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study of comprehensive cognitive and behavioral ratings in subjects with AD and mild cognitive impairment.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Memory disorders research center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Fifty subjects with AD and 26 subjects with mild cognitive impairment; and their caregivers.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Cognitive rating scales administered included the Mini-Mental State Examination; the Modified Mini-Mental State Examination; the Boston Naming Test; the Benton Visual Retention Test; the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychology Assessment; the Controlled Oral Word Test; the Wechsler Memory Scale logical memory I and logical memory II task; the Wechsler Memory Scale-Revised digit span; the Wechsler Adult Intelligence Scale-Revised digit symbol task; and the Clock Drawing Task together with the Clinical Dementia Rating Scale and the Neuropsychiatric Inventory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Stepwise regression of cognitive domains with symptom domains revealed significant associations of mood with impaired executive function/speed of processing (&#x394;r = 0.22); impaired working memory (&#x394;r = 0.05); impaired visual memory (&#x394;r = 0.07); and worsened Clinical Dementia Rating Scale (&#x394;r = 0.08). Psychosis was significantly associated with impaired working memory (&#x394;r = 0.13).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mood symptoms appear to impact diverse cognitive realms and to compromise functional performance. Among neuropsychological indices, the unique relationship between working memory and psychosis suggests a possible common underlying neurobiology.</AbstractText><CopyrightInformation>2012 American Association for Geriatric Psychiatry</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koppel</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Litwin-Zucker Research Center for the Study of Alzheimer's Disease and Memory Disorders, The Feinstein Institute for Medical Research, The North Shore-Long Island Jewish Health System, Manhasset, NY, USA. jkoppel@lij.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Terry E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Marc L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Keehlisen</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Huet</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Christen</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Greenwald</LastName><ForeName>Blaine S</ForeName><Initials>BS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22048323</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3182358921</ArticleId><ArticleId IdType="pii">S1064-7481(12)62031-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22039732</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-2640</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[Treatment of behavioral disorders in Alzheimer's disease].</ArticleTitle><Pagination><StartPage>939</StartPage><EndPage>944</EndPage><MedlinePgn>939-44</MedlinePgn></Pagination><Abstract><AbstractText>Behavioural and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer's disease and related disorders. Recommendations for the management of BPSD have been proposed. Non-pharmacological interventions should be the first-line treatment. Anti-dementia agents (cholinesterase inhibitors, memantine) and psychotropic drugs (antipsychotics, antidepressants and anticonvulsivants) could be associated to non-pharmacological interventions only in case of limited response with non pharmacologic approaches. Low-dose antipsychotics should only be prescribed for limited periods of time, in case of psychotic and/or aggressive refractory symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>David</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre m&#xe9;moire de ressources et de recherche - EA CoBTeK, CHU de Nice, universit&#xe9; de Nice Sophia Antipolis, 06000 Nice. david.r@chu-nice.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piano</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prise en charge des troubles du comportement dans les maladies d'Alzheimer.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22039732</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22035233</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-960X</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of chemical information and modeling</Title><ISOAbbreviation>J Chem Inf Model</ISOAbbreviation></Journal><ArticleTitle>Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials.</ArticleTitle><Pagination><StartPage>3262</StartPage><EndPage>3274</EndPage><MedlinePgn>3262-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/ci200435b</ELocationID><Abstract><AbstractText>Histamine receptors (HRs) are excellent drug targets for the treatment of diseases, such as schizophrenia, psychosis, depression, migraine, allergies, asthma, ulcers, and hypertension. Among them, the human H(3) histamine receptor (hH(3)HR) antagonists have been proposed for specific therapeutic applications, including treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), epilepsy, and obesity. However, many of these drug candidates cause undesired side effects through the cross-reactivity with other histamine receptor subtypes. In order to develop improved selectivity and activity for such treatments, it would be useful to have the three-dimensional structures for all four HRs. We report here the predicted structures of four HR subtypes (H(1), H(2), H(3), and H(4)) using the GEnSeMBLE (GPCR ensemble of structures in membrane bilayer environment) Monte Carlo protocol, sampling &#x223c;35 million combinations of helix packings to predict the 10 most stable packings for each of the four subtypes. Then we used these 10 best protein structures with the DarwinDock Monte Carlo protocol to sample &#x223c;50&#x2009;000 &#xd7; 10(20) poses to predict the optimum ligand-protein structures for various agonists and antagonists. We find that E206(5.46) contributes most in binding H(3) selective agonists (5, 6, 7) in agreement with experimental mutation studies. We also find that conserved E5.46/S5.43 in both of hH(3)HR and hH(4)HR are involved in H(3)/ H(4) subtype selectivity. In addition, we find that M378(6.55) in hH(3)HR provides additional hydrophobic interactions different from hH(4)HR (the corresponding amino acid of T323(6.55) in hH(4)HR) to provide additional subtype bias. From these studies, we developed a pharmacophore model based on our predictions for known hH(3)HR selective antagonists in clinical study [ABT-239 1, GSK-189,254 2, PF-3654746 3, and BF2.649 (tiprolisant) 4] that suggests critical selectivity directing elements are: the basic proton interacting with D114(3.32), the spacer, the aromatic ring substituted with the hydrophilic or lipophilic groups interacting with lipophilic pockets in transmembranes (TMs) 3-5-6 and the aliphatic ring located in TMs 2-3-7. These 3D structures for all four HRs should help guide the rational design of novel drugs for the subtype selective antagonists and agonists with reduced side effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Soo-Kyung</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Materials and Process Simulation Center (MC139-74), California Institute of Technology, 1200 E. California Blvd., Pasadena, California 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fristrup</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Abrol</LastName><ForeName>Ravinder</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Suffix>3rd</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS073115</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS071112</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS073115</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 HD036385-02</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS071112</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Chem Inf Model</MedlineTA><NlmUniqueID>101230060</NlmUniqueID><ISSNLinking>1549-9596</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017442">Histamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054828">Histamine H3 Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011968">Receptors, Histamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018100">Receptors, Histamine H3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017442" MajorTopicYN="N">Histamine Agonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054828" MajorTopicYN="N">Histamine H3 Antagonists</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011968" MajorTopicYN="N">Receptors, Histamine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018100" MajorTopicYN="N">Receptors, Histamine H3</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22035233</ArticleId><ArticleId IdType="mid">NIHMS338929</ArticleId><ArticleId IdType="pmc">PMC3246544</ArticleId><ArticleId IdType="doi">10.1021/ci200435b</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lorenzi S, Mor M, Bordi F, Rivara S, Rivara M, Morini G, Bertoni S, Ballabeni V, Barocelli E, Plazzi PV. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists. Bioorg. Med. Chem. 2005;13:5647&#x2013;5657.</Citation><ArticleIdList><ArticleId IdType="pubmed">16085419</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrol R, Bray JK, Goddard WA., III BiHelix: Towards de novo Structure Prediction of an Ensemble of G-Protein Coupled Receptor Conformations. Proteins. 2011 DOI: 10.1002/prot.23216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310341</ArticleId><ArticleId IdType="pubmed">22173949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissinen MJ, Karlstedt K, Castren E, Panula P. Expression of histidine decarboxylase and cellular histamine-like immunoreactivity in rat embryogenesis. J. Histochem. Cytochem. 1995;43:1241&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hough LB. Genomics meets histamine receptors: New subtypes, new receptors. Mol. Pharmacol. 2001;59:415&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">11179433</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin M, Boyce CW, de Lera Ruiz M. Histamine H3 Receptor as a Drug Discovery Target. J. Med. Chem. 2010;54:26&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss R, Kiss B, Konczol A, Szalai F, Jelinek I, Laszlo V, Noszal B, Falus A, Keseru GM. Discoovery of Novel Human Histamine H4 Receptor Ligands by Large-Scale Structure-Based Virtual Screening. J. Med. Chem. 2008;51:3145&#x2013;3153.</Citation><ArticleIdList><ArticleId IdType="pubmed">18459760</ArticleId></ArticleIdList></Reference><Reference><Citation>Carballo F. Efficiency of potent gastric acid inhibition. Drugs. 2005;65:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16335864</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettit M. Treatment of gastroesophageal reflux disease. Pharm. World Sci. 2005;27:432&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341949</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider EH, Strasser A, Thurmond RL, Seifert R. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands. J. Pharmacol. Exp. Ther. 2010;334:513&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">20484153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligneau X, Morisset S, Tardivel-Lacombe J, Gbahou F, Ganellin CR, Stark H, Schunack W, Schwartz J-C, Arrang J-M. Distinct Pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain. British J. Pharma. 2000;131:1247&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572469</ArticleId><ArticleId IdType="pubmed">11090094</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW, Kobayashi T, Stevens RC, Iwata S. Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011;475:65&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131495</ArticleId><ArticleId IdType="pubmed">21697825</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh K, Kuma K, Toh H, Miyata T. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acid Res. 2005;33:511&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548345</ArticleId><ArticleId IdType="pubmed">15661851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimley WC, Creamer TP, White SH. Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides. Biochem. 1996;35:5109&#x2013;5124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8611495</ArticleId></ArticleIdList></Reference><Reference><Citation>Hessa TM-B, Bernsel A, Kim H, Sato Y, Lerch-Bader M, Nilsson I, White SH, von Heijne G. Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature. 2007;450:1026&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">18075582</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi H-J, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Sci. 2007;318:1258&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583103</ArticleId><ArticleId IdType="pubmed">17962520</ArticleId></ArticleIdList></Reference><Reference><Citation>Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AGW, Tate CG, Schertler GFX. Structure of a &#x3b2;1-adrenergic G-protein coupled receptor. Nature. 2008;454:486&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923055</ArticleId><ArticleId IdType="pubmed">18594507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam VWT, Goddard WA., III Flat-Bottom Strategy for Improved Accuracy in Protein Side-Chain Placements. J. Chem. Theo. &amp; Comp. 2008;4:2160&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692055</ArticleId><ArticleId IdType="pubmed">26620487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray JK, Goddard WA., III The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. J. Mol. Graph. Model. 2008;27:66&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">18499489</ArticleId></ArticleIdList></Reference><Reference><Citation>Venable JD, Thurmond RL. Development and chemistry of histamine H4 receptor ligands as potential modulators of inflamationary and allergic diseases. Anti-Inflamm. Anti-Allergy Agents in Med. Chem. 2006;5:307&#x2013;322.</Citation></Reference><Reference><Citation>Stark H, Kathmann M, Schlicker E, Schunack W, Schlegel B, Sippl W. Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists. Mini Rev. Med. Chem. 2004;4:965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">15544557</ArticleId></ArticleIdList></Reference><Reference><Citation>Letavic MA. Recent medicinal chemistry of the histmine H3 receptor. Prog. Med. Chem. 2006;44:181&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">16697898</ArticleId></ArticleIdList></Reference><Reference><Citation>Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Discorders and Alzheimer's Disease. J. Pharmacol. Exp. Ther. 2011;336:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864505</ArticleId></ArticleIdList></Reference><Reference><Citation>Esbenshade TA, Fox GBK,KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J. Pharmacol. Exp. Ther. 2005;313:165&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608078</ArticleId></ArticleIdList></Reference><Reference><Citation>Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 2007;321:1032&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, I. B-B, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology. J. Pharmacol. Exp. Ther. 2007;320:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">17005916</ArticleId></ArticleIdList></Reference><Reference><Citation>Uveges AJ, Kowal D, Zhang Y, Spangler TB, Dunlop J, Semus S, Jones PG. The role of transmembnane Helix 5 in agonist binding to the human H3 receptor. J. Pharmacol. Exp. Ther. 2002;301:451&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">11961043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin N, Coates E, Murgolo NJ, Morse KL, Bayne M, Strader CD, Monsma FJ., Jr. Moledular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mol. Pharmacol. 2002;62:38&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12065753</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongejan A, Lim HD, Smits RA, de Esch IJP, Haaksma E, Leurs R. Delineation of agonist binding to the human histamine H4 receptor using mutational analysis, homology modeling, and ab initio calculations. J. Chem. Inf. Model. 2008;48:1455&#x2013;1463.</Citation><ArticleIdList><ArticleId IdType="pubmed">18553960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. Evaluation of Histamine H1-,H2-, and H3-Receptor Ligands at the Human Histamine H4 Receptor: Identification of 4-Methylhistamine as the First Potent and Selective H4 Receptor Agonist. J. Pharmacol. Exp. Ther. 2005;314:1310&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15947036</ArticleId></ArticleIdList></Reference><Reference><Citation>Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 2003;305:887&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">12606603</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Goddard WA., III Structure and Function of GPCRs. Proc. Natl. Acad. Sci. USA. 2002;99:12622&#x2013;12627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130510</ArticleId><ArticleId IdType="pubmed">12351677</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho AE, Wendel JA, Vaidehi N, Kekenes-Huskey PM, Floriano WB, Maiti PK, Goddard WA., III The MPSim-Dock Hierarchical Docking Algorithm: Application to the eight trypsin Inhibitor co-crystals. J. Comp. Chem. 2005;26:48&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15529328</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalani Y, Vaidehi N, Hall SE, Floriano WB, Trabanino RJ, Freddolino PL, Kam V, Goddard WA., III Three-dimensional structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. USA. 2004;101:3815&#x2013;3820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC374327</ArticleId><ArticleId IdType="pubmed">14999101</ArticleId></ArticleIdList></Reference><Reference><Citation>Freddolino PL, Kalani MY, Vaidehi N, Floriano WB, Trabanino RJ, Freddolino PL, Kam V, Goddard WA., III Structure and function prediction for human b2- adrenergic receptor. Proc. Natl. Acad. Sci. USA. 2004;101:2736&#x2013;2741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365690</ArticleId><ArticleId IdType="pubmed">14981238</ArticleId></ArticleIdList></Reference><Reference><Citation>Spijker P, Vaidehi N, Freddolino PL, Hilbers PA, Goddard WA., III Dynamic behavior of fully solvated b2-adrenergic receptor, embedded in the membrane with bound agonist or antagonist. Proc. Natl. Acad. Sci., USA. 2006;103:4882&#x2013;4887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458764</ArticleId><ArticleId IdType="pubmed">16551744</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng JY, Vaidehi N, Hall SE, Goddard WA., III The Predicted 3D Structures of the Human M1 Muscarinic Acetylcholine Receptor with Agonist or Antagonist Bound. Chem. Med. Chem. 2006;1:878&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902941</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, R. A, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M, Fox JM, de Mendonca FL, Pease JE, Goddard WA, III, Horuk R. Predictions of CCR1 Chemokine Receptor Structure and BX 471 Antagonist Binding Followed by Experimental Validation. J. Biol. Chem. 2006;281:27613&#x2013;27620.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837468</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo J, Han S-K, Vaidehi N, Wendel J, Kekenes-Huskey P, Goddard WA., III Prediction of the 3D Structure of FMRF-amide Neutopeptides Bound to the Mouse MrgC11 GPCR and Experimental Validation. Chem. Bio. Chem. 2007;8:1527&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">17647204</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo J, Vaidehi N, Wendel J, Goddard WA., III Prediction of the 3-D structure of rat MrgA G protein-coupled receptor and identification of its binding site. J. Mol. Graph. Model. 2007;26:800&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2151207</ArticleId><ArticleId IdType="pubmed">17728165</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhu F, Vaidehi N, Goddard WA, III, Sheinerman F, Reiling S, Morize I, Mu L, Harris K, Ardati A, Laoui A. Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist. J. Am. Chem. Soc. 2007;129:10720&#x2013;10731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2535578</ArticleId><ArticleId IdType="pubmed">17691773</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard WA, III, Kim S-K, Li Y, Trzaskowski B, Griffith AR, Abrol R. Predicted 3D structures for adenosine receptors bound to ligands: Comparison to the crystal structure. J. Struct. Biol. 2010;170:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20079848</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo SL, Olafson BD, Goddard WA., III DREIDING - a generic force field for molecular simulations. J. Phys. Chem. 1990;94:8897&#x2013;8909.</Citation></Reference><Reference><Citation>Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Sci. 2008;322:1211&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586971</ArticleId><ArticleId IdType="pubmed">18832607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22005930</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2012</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association study of Alzheimer's disease with psychotic symptoms.</ArticleTitle><Pagination><StartPage>1316</StartPage><EndPage>1327</EndPage><MedlinePgn>1316-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2011.125</ELocationID><Abstract><AbstractText>Psychotic symptoms occur in ~40% of subjects with Alzheimer's disease (AD) and are associated with more rapid cognitive decline and increased functional deficits. They show heritability up to 61% and have been proposed as a marker for a disease subtype suitable for gene mapping efforts. We undertook a combined analysis of three genome-wide association studies (GWASs) to identify loci that (1) increase susceptibility to an AD and subsequent psychotic symptoms; or (2) modify risk of psychotic symptoms in the presence of neurodegeneration caused by AD. In all, 1299 AD cases with psychosis (AD+P), 735 AD cases without psychosis (AD-P) and 5659 controls were drawn from Genetic and Environmental Risk in AD Consortium 1 (GERAD1), the National Institute on Aging Late-Onset Alzheimer's Disease (NIA-LOAD) family study and the University of Pittsburgh Alzheimer Disease Research Center (ADRC) GWASs. Unobserved genotypes were imputed to provide data on &gt;1.8 million single-nucleotide polymorphisms (SNPs). Analyses in each data set were completed comparing (1) AD+P to AD-P cases, and (2) AD+P cases with controls (GERAD1, ADRC only). Aside from the apolipoprotein E (APOE) locus, the strongest evidence for association was observed in an intergenic region on chromosome 4 (rs753129; 'AD+PvAD-P' P=2.85 &#xd7; 10(-7); 'AD+PvControls' P=1.11 &#xd7; 10(-4)). SNPs upstream of SLC2A9 (rs6834555, P=3.0 &#xd7; 10(-7)) and within VSNL1 (rs4038131, P=5.9 &#xd7; 10(-7)) showed strongest evidence for association with AD+P when compared with controls. These findings warrant further investigation in larger, appropriately powered samples in which the presence of psychotic symptoms in AD has been well characterized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Neurosciences and Mental Health Research Institute, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Harold</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stretton</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gerrish</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ivanov</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Moskvina</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Priotsi</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>N J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Gurling</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McQuillin</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><CollectiveName>GERAD Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Holmans</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Klei</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Demirci</LastName><ForeName>F Y</ForeName><Initials>FY</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>O L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M I</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG027224-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-23</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U123160651</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG165574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016579</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>082604</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG13854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH057881</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0800509</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268200782096C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>095317</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U123160657</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021901">DNA, Intergenic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051246">Glucose Transport Proteins, Facilitative</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051596">Neurocalcin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C411811">SLC2A9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496688">VSNL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002894" MajorTopicYN="N">Chromosomes, Human, Pair 4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021901" MajorTopicYN="N">DNA, Intergenic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051246" MajorTopicYN="N">Glucose Transport Proteins, Facilitative</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051596" MajorTopicYN="N">Neurocalcin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Harold</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abraham</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sims</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerrish</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamshere</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Jaspreet Singh</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moskvina</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dowzell</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stretton</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>Angharad</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynch</LastName><ForeName>Aoibhinn</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Kristelle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Passmore</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuinness</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmes</LastName><ForeName>Clive</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>A David</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Love</LastName><ForeName>Seth</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kehoe</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mead</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collinge</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maier</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jessen</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heun</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xf6;lsch</LastName><ForeName>Heike</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sch&#xfc;rmann</LastName><ForeName>Britta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Bussche</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heuser</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornhuber</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dichgans</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fr&#xf6;lich</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xfc;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rujescu</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bass</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurling</LastName><ForeName>Hugh</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gwilliam</LastName><ForeName>Rhian</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xfc;hleisen</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Investigator><Investigator ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moebus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xf6;ckel</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klopp</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wichmann</LastName><ForeName>H-Erich</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasquillo</LastName><ForeName>Minerva M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pankratz</LastName><ForeName>V Shane</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmans</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santana</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmechel</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaskel</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horner</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuntz</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norgaard</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kistler</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Fracine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haddow</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schnaider Beeri</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Joy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lally</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulum</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne-Murphy</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Holli</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Jeen-Soo</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arends</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toland</LastName><ForeName>Usha</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brickhouse</LastName><ForeName>Alise</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarty Wood</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>I Helena</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varpetian</LastName><ForeName>Arousiak</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rumbaugh</LastName><ForeName>Malia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levitch</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Betsy</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coats</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22005930</ArticleId><ArticleId IdType="mid">NIHMS330566</ArticleId><ArticleId IdType="pmc">PMC3272435</ArticleId><ArticleId IdType="doi">10.1038/mp.2011.125</ArticleId><ArticleId IdType="pii">mp2011125</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hollingworth P, Harold D, Jones L, Owen MJ, Williams J. Alzheimer's disease genetics: current knowledge and future challenges. Int J Geriatr Psychiatry. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20957767</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19(16):3295&#x2013;3301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908469</ArticleId><ArticleId IdType="pubmed">20534741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, et al. Complement receptor 1 polymorphisms and risk of late onset Alzheimer's disease. Brain Res. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20558149</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol. 2010;67(8):961&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919638</ArticleId><ArticleId IdType="pubmed">20554627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch Neurol. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67(6):677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC. Common variants in MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831613</ArticleId><ArticleId IdType="pubmed">19812666</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome. Hum Genet. 2009;126(1):3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19521722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8(4):383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162(11):2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric Symptoms and Quality of Life in Alzheimer Disease. Am J Geriatr Psychiatry. 2005;13(6):469&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956266</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, Dekosky ST, et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr. 2009:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834298</ArticleId><ArticleId IdType="pubmed">19781112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56(10):1266&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, O'Donovan MC, Sims R, Powell J, et al. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(7):841&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58(6):907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13(7):624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain. 2010;133(Pt 4):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis. 2010;19(3):761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, et al. Genome Wide Association of Familial Late Onset Alzheimer's Disease Replicates BIN1 and CLU, and Nominates CUGBP2 in Interaction With APOE. PLoS Genet. 2011 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Klei L, Devlin B, Ferrell RE, Weamer EA, Emanuel JE, et al. No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol Aging. 2011 In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065549</ArticleId><ArticleId IdType="pubmed">21093110</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R. Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci. Arch Neurol. 2008;65(11):1518&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694670</ArticleId><ArticleId IdType="pubmed">19001172</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009;21(1):78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, DeKosky ST. Neuropathology of Alzheimer's disease and mild cognitive impairment. Rev Neurol. 2003;37(2):155&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12938076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology. 2000;54(5):1109&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995;152(9):1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Kodavali C, Weamer EA, Miyahara S, Lopez OL, Nimgaonkar VL, et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818007</ArticleId><ArticleId IdType="pubmed">17525976</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Moskvina V, Dowzell K, Moore PJ, Foy C, et al. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc. 2006;54(9):1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970641</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">7114305</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L. Clinical Dementia Rating (CDR) Psychopharmacol Bull. 1988;24(4):637&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AB, Luca D, Klei L, Devlin B, Roeder K. Discovering genetic ancestry using spectral graph theory. Genet Epidemiol. 2010;34(1):51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610359</ArticleId><ArticleId IdType="pubmed">19455578</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55(4):997&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">11315092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077530</ArticleId><ArticleId IdType="pubmed">19571808</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18677311</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460(7256):753&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775422</ArticleId><ArticleId IdType="pubmed">19571809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40(9):1056&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703780</ArticleId><ArticleId IdType="pubmed">18711365</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera-Wadleigh SD, et al. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet. 2010;42(2):128&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854040</ArticleId><ArticleId IdType="pubmed">20081856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cichon S, Muhleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J, et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet. 2011;88(3):372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059436</ArticleId><ArticleId IdType="pubmed">21353194</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol. 2005;18(5):1368&#x2013;1373.</Citation><ArticleIdList><ArticleId IdType="pubmed">16135132</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunewell KH, Klein-Szanto AJ. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+ -sensor proteins. Cell Tissue Res. 2009;335(2):301&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742949</ArticleId><ArticleId IdType="pubmed">18989702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54(10):1617&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672199</ArticleId><ArticleId IdType="pubmed">18703769</ArticleId></ArticleIdList></Reference><Reference><Citation>Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008;17(8):1156&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">18184693</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. Journal of neural transmission. 2009;116(3):275&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">19034380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rule AD, de Andrade M, Matsumoto M, Mosley TH, Kardia S, Turner ST. Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families. Rheumatology (Oxford) 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077913</ArticleId><ArticleId IdType="pubmed">21186168</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40(4):437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">18327257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19(4):1331&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859185</ArticleId><ArticleId IdType="pubmed">20061611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80(1):29&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9727961</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam M, Massare J, Gallinger S, Kinzie J, Weaver D, Dingell JD, et al. Peutz-Jeghers syndrome diagnosed in a schizophrenic patient with a large deletion in the STK11 gene. Dig Dis Sci. 2006;51(9):1567&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">16927138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Liu CM, Wen CC, Chang SM, Hwu HG. Genetic copy number variants in sib pairs both affected with schizophrenia. J Biomed Sci. 2010;17:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843606</ArticleId><ArticleId IdType="pubmed">20064257</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichele-Sweet MA, Lopez OL, Sweet RA. Psychosis in Alzheimer's disease in the national Alzheimer's disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e. Int J Alzheimers Dis. 2011;2011:926597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065057</ArticleId><ArticleId IdType="pubmed">21461363</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu SH, Roeder K, Ferrell RE, Devlin B, DeMichele-Sweet MA, Kamboh MI, et al. TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease. Neurobiology of Aging. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192304</ArticleId><ArticleId IdType="pubmed">21820212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879718</ArticleId><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17(R2):R116&#x2013;R121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782355</ArticleId><ArticleId IdType="pubmed">18852199</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock N, O'Donovan MC, Owen MJ. Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull. 2009;35(3):482&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669589</ArticleId><ArticleId IdType="pubmed">19329560</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskvina V, Holmans P, Schmidt KM, Craddock N. Design of case-controls studies with unscreened controls. Ann Hum Genet. 2005;69(Pt 5):566&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">16138915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Minster RL, Demirci FY, Ganguli M, Dekosky ST, Lopez OL, et al. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging. 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010357</ArticleId><ArticleId IdType="pubmed">20570404</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry. 2011;68(2):207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">21300948</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21956773</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2012</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive and behavioural predictors of survival in Alzheimer disease: results from a sample of treated patients in a tertiary-referral memory clinic.</ArticleTitle><Pagination><StartPage>844</StartPage><EndPage>853</EndPage><MedlinePgn>844-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2795</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study examined the influence of cognitive and non-cognitive factors at the time of diagnosis on the survival of patients with treated probable Alzheimer Disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Consecutive patients seen at a regional, tertiary-referral clinic completed a battery of cognitive tests and assessments of activities of daily living and neuropsychiatric symptoms. These clinic data were linked with death certificate data for all individuals and survival from diagnosis was calculated. Cox regression models were constructed using the baseline covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The sample comprised 653 patients (459 women), mean age 77.1 years (SD 7.6, range 48-94 years), diagnosed with probable AD and treated with a cholinesterase inhibitor. In the survival analysis, age was a consistently significant predictor of survival with a gender-adjusted hazard ratio of 1.35 (95% CI 1.23, 1.48) for one standard deviation increase in age. Men were at greater risk of death than women (age-adjusted HR 1.44, 95% CI 1.19, 1.73). In a model adjusted for all study variables, Paired-Associate Learning (Cambridge Automated Neuropsychological Test Assessment Battery) and the psychotic factor of the Neuropsychiatric Inventory were significant predictors of survival.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">At diagnosis, in addition to the anticipated impact of age and gender, the presence of psychotic symptoms and poor performance on paired-associate learning are also indicators of poor prognosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russ</LastName><ForeName>Tom C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Scottish Dementia Clinical Research Network, NHS, Scotland, UK. tom.russ@nhs.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batty</LastName><ForeName>G David</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003644" MajorTopicYN="N">Death Certificates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21956773</ArticleId><ArticleId IdType="doi">10.1002/gps.2795</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21939611</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>121</StartPage><EndPage>128</EndPage><MedlinePgn>121-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.10m06574</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) imposes a severe burden upon patients and their caregivers. Severity of psychiatric symptoms and behavioral disturbances is an important determinant of caregivers' experience of burden. These symptoms may be improved with atypical antipsychotic treatment.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Data from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial were used to evaluate the effect of atypical antipsychotics versus placebo on the experiences of caregivers of outpatients with AD.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We compared the effect of atypical antipsychotic drugs (olanzapine, risperidone, or quetiapine-considered together as a group) versus placebo on the experiences of caregivers of AD outpatients (diagnosed according to DSM-IV-TR). We also evaluated whether improvement in patients' psychiatric and behavioral symptoms mediated the relationship between drug treatment and caregiver burden. The CATIE-AD trial, conducted from April 2001 through November 2004, included outpatients (mean age = 77.9 years [SD = 7.5 years]) in usual care settings and assessed treatment effectiveness over a 9-month period at 42 US sites. In a set of secondary analyses, data from CATIE-AD participants who had at least 1 postbaseline outcome assessment and data from their caregivers were examined in an intention-to-treat (ITT) analysis (N = 361). A phase 1-only analysis was conducted including only observations while patients were receiving the initially randomized drug (N = 153). The Burden Interview, the Beck Depression Inventory, and the Neuropsychiatric Inventory (NPI) Caregiver Distress Scale were used to evaluate caregiver burden.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In both ITT and phase 1-only analyses, caregivers of patients treated with second-generation antipsychotics scored significantly lower than caregivers of patients receiving placebo on both the Burden Interview (P = .0090) and the NPI Caregiver Distress Scale (P = .0209). These differences appeared to have been mediated by lower levels of agitation, hostility, and psychotic distortions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden.</AbstractText><CopyrightInformation>&#xa9; Copyright 2012 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Somaia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven, CT, USA. Somaia.Mohamed@yale.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Kaczynski</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH9001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21939611</ArticleId><ArticleId IdType="mid">NIHMS445643</ArticleId><ArticleId IdType="pmc">PMC4040971</ArticleId><ArticleId IdType="doi">10.4088/JCP.10m06574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manca A, Davies L, Burns A. Cost-effectiveness of therapeutics for Alzheimer&#x2019;s Disease. In: Davis K, Charney D, Coyle J, editors. Neuropsychopharmacology: The Fifth Generation of Progress. New York, NY: Lippincott Williams &amp; Wilkins; 2002. pp. 1267&#x2013;1280.</Citation></Reference><Reference><Citation>Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005 Dec 17;:2112&#x2013;2117. Sect.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson C, Tarrier N, Burns A. The impact of the symptoms of dementia on caregivers. Br J Psychiatry. 1997 Jan;170:62&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9068778</ArticleId></ArticleIdList></Reference><Reference><Citation>Haley WE. The family caregiver&#x2019;s role in Alzheimer&#x2019;s disease. Neurology. 1997 May;48(5 Suppl 6):S25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153157</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1998 Apr;13(4):248&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646153</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguglia E, Onor ML, Trevisiol M, Negro C, Saina M, Maso E. Stress in the caregivers of Alzheimer&#x2019;s patients: an experimental investigation in Italy. Am J Alzheimers Dis Other Demen. 2004 Jul-Aug;19(4):248&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833810</ArticleId><ArticleId IdType="pubmed">15359564</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirkhanyan AA, Wolf DA. Caregiver stress and noncaregiver stress: exploring the pathways of psychiatric morbidity. Gerontologist. 2003 Dec;43(6):817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">14704381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattanach L, Tebes JK. The nature of elder impairment and its impact on family caregivers&#x2019; health and psychosocial functioning. Gerontologist. 1991 Apr;31(2):246&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">1828449</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Williamson GM. A 2-year longitudinal study of depression among Alzheimer&#x2019;s caregivers. Psychol Aging. 1991 Dec;6(4):569&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">1777145</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson GM, Schulz R. Coping with specific stressors in Alzheimer&#x2019;s disease caregiving. Gerontologist. 1993 Dec;33(6):747&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">8314101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallant MP, Connell CM. Predictors of decreased self-care among spouse caregivers of older adults with dementing illnesses. J Aging Health. 1997 Aug;9(3):373&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">10182399</ArticleId></ArticleIdList></Reference><Reference><Citation>Song LY, Biegel DE, Milligan SE. Predictors of depressive symptomatology among lower social class caregivers of persons with chronic mental illness. Community Ment Health J. 1997 Aug;33(4):269&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">9250425</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Boerner K, Shear K, Zhang S, Gitlin LN. Predictors of complicated grief among dementia caregivers: a prospective study of bereavement. Am J Geriatr Psychiatry. 2006 Aug;14(8):650&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiecolt-Glaser JK, Dura JR, Speicher CE, Trask OJ, Glaser R. Spousal caregivers of dementia victims: longitudinal changes in immunity and health. Psychosom Med. 1991 Jul-Aug;53(4):345&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">1656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Draper BM, Poulos CJ, Cole AM, Poulos RG, Ehrlich F. A comparison of caregivers for elderly stroke and dementia victims. J Am Geriatr Soc. 1992 Sep;40(9):896&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512385</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgarten M, Battista RN, Infante-Rivard C, Hanley JA, Becker R, Gauthier S. The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol. 1992 Jan;45(1):61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738013</ArticleId></ArticleIdList></Reference><Reference><Citation>Grafstrom M, Fratiglioni L, Sandman PO, Winblad B. Health and social consequences for relatives of demented and non-demented elderly. A population-based study. J Clin Epidemiol. 1992 Aug;45(8):861&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">1624968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ory MG, Hoffman RR, 3rd, Yee JL, Tennstedt S, Schulz R. Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers. Gerontologist. 1999 Apr;39(2):177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10224714</ArticleId></ArticleIdList></Reference><Reference><Citation>Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. N Engl J Med. 2006 Feb 16;354(7):719&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000 May;157(5):708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005 Nov;162(11):2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen RF, Swanwick GR, O&#x2019;Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1997 Mar;12(3):331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152717</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 2004 Mar;161(3):532&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">14992980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed S, Rosenheck R, Sneider L. Caregiver Burden in Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry under review</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972419</ArticleId><ArticleId IdType="pubmed">20808108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Ismail MS, Dagerman K, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer&#x2019;s disease trial. Schizophr Bull. 2003;29(1):57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer&#x2019;s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008 Jul;165(7):844&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. N Engl J Med. 2006 Oct 12;355(15):1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980 Dec;20(6):649&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">13688369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns. J Gerontol. 1984 Mar;39(2):194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">6699375</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. Introduction-the Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3387516</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">3337862</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984 Nov;141(11):1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease. The Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins P, Kasper J, Kleinman L. Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimer&#x2019;s Disease. Journal of Mental Health Aging. 1999;5:33&#x2013;48.</Citation></Reference><Reference><Citation>Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer&#x2019;s disease. J Gerontol. 1994 Sep;49(5):M216&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056940</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Marin DB, Kane R, et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 1997 Oct;12(10):978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395929</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness &#x2013; Alzheimer&#x2019;s Disease (CATIE-AD): baseline characteristics. Curr Alzheimer Res. 2007 Jul;4(3):325&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17627490</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenheck RA, Leslie DL, Sindelar JL, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007 Nov;64(11):1259&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984395</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JH, Klocinski JL, Merz J, Clark CM, Asch DA. Caregivers&#x2019; preferences for the treatment of patients with Alzheimer&#x2019;s disease. Neurology. 2000 Oct 10;55(7):1008&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">11061260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher-Thompson D, Coon DW. Evidence-based psychological treatments for distress in family caregivers of older adults. Psychol Aging. 2007 Mar;22(1):37&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17385981</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003 Oct 15;290(15):2015&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559955</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinquart M, Sorensen S. Helping caregivers of persons with dementia: which interventions work and how large are their effects? Int Psychogeriatr. 2006 Dec;18(4):577&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686964</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21905989</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>12 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Gene therapy for psychiatric disorders.</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>18</EndPage><MedlinePgn>16-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/15622975.2011.601927</ELocationID><Abstract><AbstractText>There is no indication that gene therapy can be applied in psychiatric patients any time soon. However, there are several promising developments on the level of experimental neuroscience indicating that gene therapy approaches have an effect in animal models of several psychiatric disorders including drug addiction, affective disorders, psychoses and dementia, modifying behavioural parameters via interventions on the molecular and cellular level. However, before gene therapy in psychiatric disorders can be considered on the human level, not only neurobiological and technical problems need to be overcome, but also important ethical questions answered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thome</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinic and Policlinic for Psychiatry and Psychotherapy, University of Rostock, Rostock, Germany. johannes.thome@med.uni-rostock.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;ssler</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zachariou</LastName><ForeName>Vanna</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 DA008227</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Statement of Interest</b>. JT has received financial support which was also partially used for this paper, from the following pharmaceutical companies: AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Lundbeck, MEDICE, Merz, Novartis, Pfizer, Servier, Shire.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21905989</ArticleId><ArticleId IdType="mid">NIHMS385941</ArticleId><ArticleId IdType="pmc">PMC3394098</ArticleId><ArticleId IdType="doi">10.3109/15622975.2011.601927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med. 2010;2:54&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026098</ArticleId><ArticleId IdType="pubmed">20962330</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzon L, Zanusso M, Colombo F, Pal&#xf9; G. Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther. 2006;13:539&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410822</ArticleId></ArticleIdList></Reference><Reference><Citation>Burmeister M, McInnis MG, Z&#xf6;llner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet. 2008;9:527&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">18560438</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2010;107:22687&#x2013;22692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012497</ArticleId><ArticleId IdType="pubmed">21149712</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlezon WA, Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, et al. Regulation of cocaine reward by CREB. Science. 1998;282:2272&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856954</ArticleId></ArticleIdList></Reference><Reference><Citation>Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C, et al. Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther. 2008;16:1580&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706523</ArticleId><ArticleId IdType="pubmed">18665160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Twyman R, Manji HK. p11 and gene therapy for severe psychiatric disorders: a practical goal? Sci Transl Med. 2010;2:54ps51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20962329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplitt MG. Gene therapy clinical trials in the human brain. Protocol development and review of current applications. Front Neurol Neurosci. 2009;25:180&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">19478520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch KP. Gene transfer to the brain: emerging therapeutic strategy in psychiatry? Biol Psychiatry. 1999;45:247&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023497</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Serrano A, Rubio FJ, Navarro B, Bueno C, Villa A. Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS. Curr Gene Ther. 2001;1:279&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">12109143</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumaier JF. Gene therapy in psychiatric disorders: too early, too complex? Curr Opin Pharmacol. 2003;3:68&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12550744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocaranza P, Quintanilla ME, Tampier L, Karahanian E, Sapag A, Israel Y. Gene therapy reduces ethanol intake in an animal model of alcohol dependence. Alcohol Clin Exp Res. 2008;32:52&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18070247</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo SJ. The potential for viral gene therapy in psychiatry. Am J Psychiatry. 2008;165:675.</Citation><ArticleIdList><ArticleId IdType="pubmed">18519532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM. Gene therapy for psychiatric disorders. Am J Psychiatry. 2003;160:208&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562564</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri AJ, Hayashi-Takagi A. Gene manipulation with stereotaxic viral infection for psychiatric research: spatiotemporal components for schizophrenia. Prog Brain Res. 2009;179:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20302814</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, et al. Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioural improvement in APP transgenic mice. BMC Neursci. 2008;9:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596170</ArticleId><ArticleId IdType="pubmed">19014502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21912367</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1940-087X</ISSN><JournalIssue CitedMedium="Internet"><Issue>55</Issue><PubDate><Year>2011</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of visualized experiments : JoVE</Title><ISOAbbreviation>J Vis Exp</ISOAbbreviation></Journal><ArticleTitle>Habituation and prepulse inhibition of acoustic startle in rodents.</ArticleTitle><Pagination><StartPage>e3446</StartPage><MedlinePgn>e3446</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3446</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3791/3446</ELocationID><Abstract><AbstractText>The acoustic startle response is a protective response, elicited by a sudden and intense acoustic stimulus. Facial and skeletal muscles are activated within a few milliseconds, leading to a whole body flinch in rodents(1). Although startle responses are reflexive responses that can be reliably elicited, they are not stereotypic. They can be modulated by emotions such as fear (fear potentiated startle) and joy (joy attenuated startle), by non-associative learning processes such as habituation and sensitization, and by other sensory stimuli through sensory gating processes (prepulse inhibition), turning startle responses into an excellent tool for assessing emotions, learning, and sensory gating, for review see( 2, 3). The primary pathway mediating startle responses is very short and well described, qualifying startle also as an excellent model for studying the underlying mechanisms for behavioural plasticity on a cellular/molecular level(3). We here describe a method for assessing short-term habituation, long-term habituation and prepulse inhibition of acoustic startle responses in rodents. Habituation describes the decrease of the startle response magnitude upon repeated presentation of the same stimulus. Habituation within a testing session is called short-term habituation (STH) and is reversible upon a period of several minutes without stimulation. Habituation between testing sessions is called long-term habituation (LTH)(4). Habituation is stimulus specific(5). Prepulse inhibition is the attenuation of a startle response by a preceding non-startling sensory stimulus(6). The interval between prepulse and startle stimulus can vary from 6 to up to 2000 ms. The prepulse can be any modality, however, acoustic prepulses are the most commonly used. Habituation is a form of non-associative learning. It can also be viewed as a form of sensory filtering, since it reduces the organisms' response to a non-threatening stimulus. Prepulse inhibition (PPI) was originally developed in human neuropsychiatric research as an operational measure for sensory gating(7). PPI deficits may represent the interface of "psychosis and cognition" as they seem to predict cognitive impairment(8-10). Both habituation and PPI are disrupted in patients suffering from schizophrenia(11), and PPI disruptions have shown to be, at least in some cases, amenable to treatment with mostly atypical antipsychotics(12, 13). However, other mental and neurodegenerative diseases are also accompanied by disruption in habituation and/or PPI, such as autism spectrum disorders (slower habituation), obsessive compulsive disorder, Tourette's syndrome, Huntington's disease, Parkinson's disease, and Alzheimer's Disease (PPI)(11, 14, 15) Dopamine induced PPI deficits are a commonly used animal model for the screening of antipsychotic drugs(16), but PPI deficits can also be induced by many other psychomimetic drugs, environmental modifications and surgical procedures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valsamis</LastName><ForeName>Bridget</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmid</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vis Exp</MedlineTA><NlmUniqueID>101313252</NlmUniqueID><ISSNLinking>1940-087X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006185" MajorTopicYN="Y">Habituation, Psychophysiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013216" MajorTopicYN="Y">Reflex, Startle</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21912367</ArticleId><ArticleId IdType="pmc">PMC3217252</ArticleId><ArticleId IdType="doi">10.3791/3446</ArticleId><ArticleId IdType="pii">3446</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis M. The mammalian startle response. In: Eaton RC, editor. Neural Mechanisms of startle. New York: Plenum Press; 1984.</Citation></Reference><Reference><Citation>Koch M. The neurobiology of startle. Prog Neurobiol. 1999;59:107&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">10463792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fendt M, Li L, Yeomans JS. Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology (Berl) 2001;156:216&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11549224</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis M, Wagner AR. Habituation of startle response under incremental sequence of stimulus intensities. J Comp Physiol Psychol. 1969;67:486&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">5787400</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz PK, Carl TD, Plappert CF. Habituation of the acoustic and the tactile startle responses in mice: two independent sensory processes. Behav Neurosci. 2004;118:975&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">15506880</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001;156:194&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11549223</ArticleId></ArticleIdList></Reference><Reference><Citation>Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 1992;49:206&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">1567275</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull. 2010;36:246&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2833124</ArticleId><ArticleId IdType="pubmed">19900963</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer MA. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci. 2006;8:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181759</ArticleId><ArticleId IdType="pubmed">16640109</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton WS, Stover EL, Insel TR. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology (Berl) 2003;169:365&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">12955292</ArticleId></ArticleIdList></Reference><Reference><Citation>Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001;156:234&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">11549226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari V, Soni W, Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry. 1999;156:1046&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401450</ArticleId></ArticleIdList></Reference><Reference><Citation>Weike AI, Bauer U, Hamm AO. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiatry. 2000;47:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650450</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow NR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry. 1995;58:192&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1073317</ArticleId><ArticleId IdType="pubmed">7876851</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos FX. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry. 1996;39:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8719124</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow NR. Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett. 2006;402:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16644125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannizzaro C. Prenatal exposure to diazepam and alprazolam, but not to zolpidem, affects behavioural stress reactivity in handling-naive and handling-habituated adult male rat progeny. Brain Res. 2002;953:170&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gururajan A, Taylor DA, Malone DT. Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia. Behav Brain Res. 2011;222:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">21458498</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosda J. Pharmacological and parametrical investigation of prepulse inhibition of startle and prepulse elicited reactions in Wistar rats. Pharmacol Biochem Behav. 2011;99:22&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">21447356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballmaier M. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology. 2007;32:2098&#x2013;2107.</Citation><ArticleIdList><ArticleId IdType="pubmed">17299506</ArticleId></ArticleIdList></Reference><Reference><Citation>Glowa JR, Hansen CT. Differences in response to an acoustic startle stimulus among forty-six rat strains. Behav Genet. 1994;24:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8192623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock AE. Inbred mouse strains differ in the regulation of startle and prepulse inhibition of the startle response. Behav Neurosci. 1997;111:1353&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">9438803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bast T. Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav. 2000;67:647&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164097</ArticleId></ArticleIdList></Reference><Reference><Citation>Buuse Mvanden. Deficient prepulse inhibition of acoustic startle in Hooded-Wistar rats compared with Sprague-Dawley rats. Clin Exp Pharmacol Physiol. 2003;30:254&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">12680843</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis M. Sensitization of the rat startle response by noise. J Comp Physiol Psychol. 1974;87:571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">4415724</ArticleId></ArticleIdList></Reference><Reference><Citation>Groves PM, Thompson RF. Habituation: a dual-process theory. Psychol Rev. 1970;77:419&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">4319167</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillon C, Baas J. A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol. 2003;114:1557&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pubmed">12948786</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis M, Walker DL, Myers KM. Role of the amygdala in fear extinction measured with potentiated startle. Ann N Y Acad Sci. 2003;985:218&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">12724161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pare WP, Glavin GB. Restraint stress in biomedical research: a review. Neurosci Biobehav Rev. 1986;10:339&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">3095718</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L. Top-down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci Biobehav Rev. 2009;33:1157&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">19747594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee BK, Russig H, Feldon J. Apomorphine-induced prepulse inhibition disruption is associated with a paradoxical enhancement of prepulse stimulus reactivity. Neuropsychopharmacology. 2004;29:240&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">14666120</ArticleId></ArticleIdList></Reference><Reference><Citation>Csomor PA. Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophr Bull. 2009;35:244&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643951</ArticleId><ArticleId IdType="pubmed">18245063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeomans JS. GABA receptors and prepulse inhibition of acoustic startle in mice and rats. Eur J Neurosci. 2010;31:2053&#x2013;2061.</Citation><ArticleIdList><ArticleId IdType="pubmed">20497471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Shannon HE. Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. Eur J Pharmacol. 2000;391:105&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720641</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark MG. Impaired processing of complex auditory stimuli in rats with induced cerebrocortical microgyria: An animal model of developmental language disabilities. J Cogn Neurosci. 2000;12:828&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">11054924</ArticleId></ArticleIdList></Reference><Reference><Citation>McClure MM. Rapid auditory processing and learning deficits in rats with P1 versus P7 neonatal hypoxic-ischemic injury. Behav Brain Res. 2006;172:114&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960850</ArticleId><ArticleId IdType="pubmed">16765458</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitch RH. Use of a modified prepulse inhibition paradigm to assess complex auditory discrimination in rodents. Brain Res Bull. 2008;76:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888703</ArticleId><ArticleId IdType="pubmed">18395604</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21905100</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2012</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1070</EndPage><MedlinePgn>1062-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2644</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neuropsychiatric symptoms (NPS) are a common feature of Alzheimer's disease (AD), resulting in particular AD endophenotypes. The common AD genetic risk factor apolipoprotein E (APOE) has been suggested underlying these AD endophenotypes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">APOE genotyping, a comprehensive geriatric assessment (CGA), and Neuropsychiatric Inventory were performed on 322 consecutive older patients. Patients were divided into three groups: AD with NPS (N&#x2009;=&#x2009;93), AD without NPS (N&#x2009;=&#x2009;108), and, as a control group, patients with no cognitive impairment (NoCI: N&#x2009;=&#x2009;121). Patients with NPS were further sub-divided in four groups according to the European Alzheimer's Disease Consortium (EADC) classification of neuropsychiatric syndromes in AD: hyperactive, psychotic, affective, and apathetic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AD patients with NPS showed a significantly higher grade of cognitive impairment, more severity stage of dementia, more disability in the activities of daily living (ADL), and the instrumental ADL than AD patients without NPS. As expected, an higher frequency of APOE &#x3b5;3/&#x3b5;4 genotype was observed in patients with AD, both with and without NPS, than patients with NoCI. No difference in the distribution of APOE genotypes was found between AD patients with vs. without NPS. However, in AD patients APOE &#x3b5;4-carriers, there was an increased risk of affective [odds ratio (OR): 2.34, 95% confidence interval (CI): 1.19-4.58) and apathetic (OR: 2.24,95%CI: 1.19-4.22) syndromes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings did not suggest a significant association between APOE polymorphism and presence of NPS in AD patients. In AD patients with NPS, however, APOE &#x3b5;4-carrier status was associated with an increased risk of affective and apathetic syndromes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Onofrio</LastName><ForeName>Grazia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Geriatrics Unit and Gerontology-Geriatric Research Laboratory, Department of Medical Sciences, IRCCS 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, FG, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sancarlo</LastName><ForeName>Daniele</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Paris</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cascavilla</LastName><ForeName>Leandro</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Urbano</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gravina</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fontana</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Pellegrini</LastName><ForeName>Fabio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21905100</ArticleId><ArticleId IdType="doi">10.1002/gps.2644</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">21860845</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2158-8341</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Innovations in clinical neuroscience</Title><ISOAbbreviation>Innov Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Four cases of takotsubo cardiomyopathy linked with exacerbations of psychiatric illness.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>53</EndPage><MedlinePgn>50-3</MedlinePgn></Pagination><Abstract><AbstractText>Objective. Takotsubo cardiomyopathy is a rare cardiac syndrome most often occurring in post-menopausal women after an acute episode of severe emotional or physical stress. Prior literature suggests a higher prevalence of anxiety and depression among patients with Takotsubo cardiomyopathy. We observed four cases of Takotsubo cardiomyopathy at one tertiary care center preceded by and concurrent with exacerbations of psychiatric illness rather than after acute episodes of stress. We examined each to further understand Takotsubo cardiomyopathy's pathogenesis and relationship to psychiatric illness.Methods. We retrospectively reviewed four consecutive cases of Takotsubo cardiomyopathy at one tertiary center from August 2009 to October 2009. The Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision criteria were used to diagnose psychiatric illness. Each patient was diagnosed with Takotsubo cardiomyopathy via cardiac catheterization.Results. Each woman (age range 53-67 years) was previously diagnosed with psychiatric illness. Psychiatric illnesses were as follows: Alzheimer's dementia with psychotic features, adjustment disorder, major depressive disorder, and bipolar affective disorder type 1. All four cases demonstrated exacerbations of their psychiatric illness just prior to and concurrent with their diagnosis of Takotsubo cardiomyopathy. They showed improved left ventricular ejection fraction within 1 to 3 weeks after diagnosis with supportive care.Conclusions. Differing from the traditional cases of Takotsubo cardiomyopathy, which follow acute events of stress, our four cases indicate exacerbations of underlying psychiatric illness can lead to Takotsubo cardiomyopathy. In addition to anxiety and depression, psychosis and mania may predispose an individual to Takotsubo cardiomyopathy. We suggest that cardiologists and psychiatrists be aware of this association and screen patients. We suggest further studies that may help better understand the connection between the heart and mind.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corrigan</LastName><ForeName>Frank E</ForeName><Initials>FE</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Dr. Corrigan is from the Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmel</LastName><ForeName>Mary C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Jayaram</LastName><ForeName>Geetha</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Innov Clin Neurosci</MedlineTA><NlmUniqueID>101549695</NlmUniqueID><ISSNLinking>2158-8333</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">patient safety</Keyword><Keyword MajorTopicYN="N">psychiatric illness</Keyword><Keyword MajorTopicYN="N">psychosomatic</Keyword><Keyword MajorTopicYN="N">takotsubo cardiomyopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21860845</ArticleId><ArticleId IdType="pmc">PMC3159544</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA. 2001;286(13):1621&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pubmed">11585486</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PK, Carney RM, Freedland KE, et al. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J Psychosom Res. 2000;48(4&#x2013;5):493&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">10880671</ArticleId></ArticleIdList></Reference><Reference><Citation>Dote K, Sato H, Tateishi H, et al. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. J diol.Car. 1991;21:203&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">1841907</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni M, Dentali F, Grandi AM, et al. Apical ballooning syndrome or Takotsubo cardiomyopathy: a systematic review. Eur Heart J. 2006;27(13):1523&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352(6):539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111(4):472&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687136</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidi V, Rajesh V, Singh PP, et al. Clinical characteristics of takotsubo cardiomyopathy. Am J Cardiol. 2009;104:578&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">19660615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd JO, Navin KK, Hunter CC, et al. Patients with stress-induced (Takotsubo) cardiomyopathy have an increased prevalence of mood disorders and antidepressant use compared to patients with acute myocardial infarction. J Cardiac Failure. 2007;13(Suppl 6):S176.</Citation></Reference><Reference><Citation>The Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press Inc.; 2000. American Psychiatric Association.</Citation></Reference><Reference><Citation>Lyon AR, Rees PS, Prasad S, et al. Stress (Takotsubo) cardiomyopathy&#x2014;a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med. 2008;5:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094670</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen SB, Cevik C, Otahbachi M, et al. Do comorbid psychiatric disorders contribute to the pathogenesis of tako-tsubo syndrome? A review of pathogenesis. Congest Heart Fail. 2009;15(1):31&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19187405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegelstein RC. Depression and tako-tsubo cardiomyopathy. Am J Cardiol. 2010;105(2):281&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiecolt-Glaser JK, Newton T, Cacioppo JT, et al. Marital stress: immunologic, neuroendocrine, and autonomic correlates. Ann N Y Acad Sci. 1998;840:656&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629292</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabi H, Hall M, Koskenvuo M, et al. Psychological and somatic symptoms of anxiety and risk of coronary heart disease: the health and social support prospective cohort study. Biol Psychiatry. 2010;67(4):378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963017</ArticleId><ArticleId IdType="pubmed">19819425</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton DA, Dawood T, Lambert EA, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25:2117&#x2013;2124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17885556</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21850285</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1699-3993</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Drugs of today (Barcelona, Spain : 1998)</Title><ISOAbbreviation>Drugs Today (Barc)</ISOAbbreviation></Journal><ArticleTitle>A report from the 164th American Psychiatric Association (May 14-18, 2011 - Honolulu, Hawai'i, U.S.A.).</ArticleTitle><Pagination><StartPage>625</StartPage><EndPage>644</EndPage><MedlinePgn>625-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1358/dot.2011.47.8.1667109</ELocationID><Abstract><AbstractText>Although tradition mandates that men should be dressed up in colorless attires, why do men visiting Hawai'i run to the first Aloha shop right after landing to get a multicolored flowery shirt, with a lei flower or kukui tree nut necklace to go with it? The answer to this question could be very complex, but psychiatrists attending this year's American Psychiatric Association meeting in the Honolulu Convention Center acted in a not dissimilar way by running to the new research poster and educational oral sessions of the meeting to learn new colors to paint the life of their patients with. And many colors, or at least an ample variety of treatment modalities, were discussed throughout the 5-day convention, including, notably, a number of innovative drugs with the capability of improving the functioning and quality of life of individuals suffering from psychosis, depression and a broad range of psychiatric diseases. The following report summarizes the main findings from clinical and experimental studies related to new psychiatric pharmacotherapies as reported and discussed during the meeting.</AbstractText><CopyrightInformation>Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabasseda</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Department, Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Drugs Today (Barc)</MedlineTA><NlmUniqueID>101160518</NlmUniqueID><ISSNLinking>1699-3993</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006254" MajorTopicYN="N">Hawaii</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21850285</ArticleId><ArticleId IdType="doi">10.1358/dot.2011.47.8.1667109</ArticleId><ArticleId IdType="pii">1667109</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21845596</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>937</StartPage><EndPage>943</EndPage><MedlinePgn>937-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2630</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5-5&#x2009;mg daily) were randomized to a 24-week, double-blind pilot trial of discontinuation on placebo versus continuation haloperidol. Phase A response criteria were minimum 50% reduction in three target symptoms, and improvement on the Clinical Global Impression-Change (CGI-C) score for psychosis/agitation. Phase B relapse criteria required 50% worsening in target symptoms and on the CGI-C. &#x3b1;&#x2009;=&#x2009;0.1 was the significance criterion in this pilot study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 44 patients, 22 patients responded in Phase A. The sum score of target symptoms, and Brief Psychiatric Rating Scale (BPRS) psychosis and hostile suspiciousness factor scores, decreased in Phase A (p's&#x2009;&lt;&#x2009;0.001). Extrapyramidal signs increased in Phase A (p&#x2009;&lt;&#x2009;0.01). Of 22 responders, 21 patients entered Phase B, and 20 had at least one follow-up visit. Four of 10 patients (40%) on continuation haloperidol relapsed compared to eight of 10 patients on placebo (80%, &#x3c7;(2) &#x2009;=&#x2009;3.3, p&#x2009;=&#x2009;0.07). In survival analyses, time to relapse was shorter on placebo than haloperidol (&#x3c7;(2) &#x2009;=&#x2009;4.1, p&#x2009;=&#x2009;0.04).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation. In patients with AD who have psychosis or agitation and respond to antipsychotic medication, the increased risk of relapse after discontinuation needs to be weighed against the side effects associated with continuing the medication.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA. dpd3@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Cunqueiro</LastName><ForeName>Karine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sackeim</LastName><ForeName>Harold A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH055735</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH55735</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21845596</ArticleId><ArticleId IdType="mid">NIHMS475451</ArticleId><ArticleId IdType="pmc">PMC3685500</ArticleId><ArticleId IdType="doi">10.1002/gps.2630</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psych. 2004;65:114&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Margallo Lana M, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or discontinued from treatment with neuroleptics (the DARTAD trial) PLoS Med. 2008;5:e76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276521</ArticleId><ArticleId IdType="pubmed">18384230</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Brown R, Fossey J, Douglas S, Bradley P, Hancock J, James IA, Juszczak E, Bentham P, Burns A, Lindesay J, Jacoby R, O&#x2019;Brien J, Bullock R, Johnson T, Holmes C, Howard R. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD trial) Am J Geriatr Psychiatry. 2009a;17(9):726&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009b;8(2):151&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138567</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">5662937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalised dementia patients, results of a doubleblind baseline-treatment-controlled pilot study. J Geriatric Psych Neurol. 1997;10:119&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9322135</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer&#x2019;s disease. Arch Neurol. 1994;51(7):676&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999;159(15):1733&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448776</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDeyn, Rabheru, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand D, Miller L, Richards, et al. The Columbia University Scale for Psychopathology in Alzheimer&#x2019;s Disease. Arch Neurol. 1992;49:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1558517</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Miller L, Richards M, Marder K, Bell K, Mayeux R, Stern Y. The Columbia University Scale for Psychopathology in Alzheimer&#x2019;s disease. Arch Neurol. 1992b;49:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1558517</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Jacobs DM, Tang M-X, Castillo-Castaneda CD, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y. The course of psychopathologic symptoms in mild to moderate Alzheimer&#x2019;s disease. Arch Gen Psychiatry. 1997;54:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH, Mayeux R. A randomized, placebo-controlled, dose-comparison trial of haloperidol treatment for psychosis and disruptive behaviors in Alzheimer&#x2019;s disease. Am J Psychiatry. 1998;155:1512&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Marsden CD, Calne D. Recent developments in Parkinson&#x2019;s disease. Macmillan Healthcare Information; Florham Park, NJ: 1987.</Citation></Reference><Reference><Citation>Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement of current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz D, Mallya A. Discontinuation of a psychogeriatric program for nursing home residents: psychotropic medication changes and behavioral reactions. J Appl Gerontol. 1992;11(1):50&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10116945</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm A, Michel M, Stern GA, Hung TM, Klein T, Flaherty L, Michel S, Maletta G. The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist. 1999;39(6):668&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650676</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz GJ, Tariot PN, Mead K, Cox C. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry. 1995;3:290&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">28531062</ArticleId></ArticleIdList></Reference><Reference><Citation>Raivio MM, Laurie JV, Strandberg TE, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15:416&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463191</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17:417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773714</ArticleId><ArticleId IdType="pubmed">19390299</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh GH, Shah A. Effects of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr. 2005;17:429&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">16252375</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer&#x2019;s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13:512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">19629775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovner BW, Steele CD, Shmuely Y, Folstein MF. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc. 1996;44(1):7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537594</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B, Devanand D, Honig L, Stern Y. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007;64(12):1755&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690610</ArticleId><ArticleId IdType="pubmed">18071039</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006a;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, et al. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. New Engl J Med. 2006b;355:1525&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64:171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">115037</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Mayeux R, Hesdorfer D, Sano M. Measurement and prediction of functional change in Alzheimer&#x2019;s disease. Neurology. 1990;40:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">2296387</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JW, Clark WS, Gannon KS, et al. Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients with Alzheimer Disease in Nursing Care Facilities. Arch Gen Psychiatry. 2000;57:2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer&#x2019;s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y. The Behavior Rating Scale for Dementia (BRSD) of the Consortium to establish a registry for Alzheimer&#x2019;s disease (CERAD) Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa PB, Meador KG, Gideon P, Fought RL, Ray WA. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc. 1994;42(3):280&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907098</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21837855</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2078-9947</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan</Title><ISOAbbreviation>East Asian Arch Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Presenile dementia: a case of Hashimoto's encephalopathy.</ArticleTitle><Pagination><StartPage>32</StartPage><EndPage>36</EndPage><MedlinePgn>32-6</MedlinePgn></Pagination><Abstract><AbstractText>Hashimoto's encephalopathy may present with a variety of neurological symptoms and signs, including myoclonus, epileptic seizures, disturbance of consciousness, psychosis, ataxia, and presenile dementia. This report is of a 57-year-old woman with a history of thyroid disease who was investigated for generalised seizures, rapid decline in cognitive function, increasing dependency, and gradual change in personality. High thyroid autoantibody titres confirmed the diagnosis of Hashimoto's encephalopathy and her symptoms improved with treatment with prednisolone. The differential diagnosis of presenile dementia, aetiology and pathogenesis of Hashimoto's encephalomyelitis, and treatment options are discussed. Hashimoto's encephalomyelitis should be considered in the differential diagnosis of presenile dementia, particularly in patients with a history of thyroid disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>C S Y</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, United Christian Hospital, Kwun Tong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>J L M</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>I H H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>P W</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>M Y K</ForeName><Initials>MY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>East Asian Arch Psychiatry</MedlineTA><NlmUniqueID>101536416</NlmUniqueID><ISSNLinking>2078-9947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C535841">Hashimoto's encephalitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050031" MajorTopicYN="N">Hashimoto Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21837855</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21820212</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.</ArticleTitle><Pagination><StartPage>2328.e1</StartPage><EndPage>2328.e23289</EndPage><MedlinePgn>2328.e1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2011.06.016</ELocationID><Abstract><AbstractText>Apolipoprotein E (APOE) &#x3b5;4 alleles increase the risk for late-onset Alzheimer disease (LOAD) and decrease the age of onset. Recently, sequencing the APOE region in a small sample of LOAD subjects identified a variable length poly-T repeat sequence in the nearby gene, TOMM40, which may affect age of onset. We genotyped the TOMM40 poly-T repeat using a novel statistical approach to refine the identification of allele length in 892 LOAD subjects and evaluated its effects on age of onset. Because psychosis in LOAD is a heritable phenotype which has shown conflicting associations with APOE genotype, we also evaluated the association of poly-T repeat length with psychosis. Poly-T repeat lengths had a trimodal distribution which differed between APOE genotype groups. After accounting for APOE &#x3b5;4 there was no association of poly-T repeat length with age of onset. Neither APOE &#x3b5;4 nor poly-T repeat length was associated with psychosis. Our findings do not support the association of poly-T repeat length with age of onset in LOAD. The clinical implications of this repeat length polymorphism remain to be elucidated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Su Hee</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Statistics, Carnegie Mellon University, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roeder</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ferrell</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Bernie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>DeMichele-Sweet</LastName><ForeName>Mary Ann A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Kamboh</LastName><ForeName>M Ilyas</ForeName><Initials>MI</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005133-20</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000005</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-05</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090622">Mitochondrial Precursor Protein Import Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C400783">TOMM40 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>25086-81-1</RegistryNumber><NameOfSubstance UI="D011071">Poly T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090622" MajorTopicYN="N">Mitochondrial Precursor Protein Import Complex Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011071" MajorTopicYN="N">Poly T</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosure Statement</b>. The authors have no conflict of interest to report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21820212</ArticleId><ArticleId IdType="mid">NIHMS307887</ArticleId><ArticleId IdType="pmc">PMC3192304</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.06.016</ArticleId><ArticleId IdType="pii">S0197-4580(11)00233-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829359</ArticleId><ArticleId IdType="pubmed">19554612</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Klei L, Devlin B, Ferrell RE, Weamer EA, Emanuel JE, Lopez OL, Sweet RA. No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol Aging. 2011;32:555.e9-11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065549</ArticleId><ArticleId IdType="pubmed">21093110</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Lopez OL, Sweet RA. Psychosis in Alzheimer disease in the National Alzheimer Disease Coordinating Center Uniform Data Set: Clinical correlates and association with apoliprotien E. International Journal of Alzheimer&#x2019;s Disease. 2011 in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065057</ArticleId><ArticleId IdType="pubmed">21461363</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer&#x2019;s disease: a review. J Alzheimers Dis. 2010;19:761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, Michele-Sweet MA, Kuller L, Sweet RA. Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry. 2011;19:160&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000865</ArticleId><ArticleId IdType="pubmed">20808116</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, Posner SF, Viitanen M, Winblad B, Ahlbom A. Heritability for Alzheimer&#x2019;s disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci. 1997;52:M117&#x2013;M125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9060980</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen NL, Posner SF, Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet. 2001;105:724&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803520</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Mayeux R. Endophenotypes in normal brain morphology and Alzheimer&#x2019;s disease: a review. Neuroscience. 2009;164:174&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812814</ArticleId><ArticleId IdType="pubmed">19362127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Lutz MW, mrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer&#x2019;s disease. Pharmacogenomics J. 2010;10:375&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946560</ArticleId><ArticleId IdType="pubmed">20029386</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer&#x2019;s disease from the National Institute on Aging Late Onset Alzheimer&#x2019;s Disease Family Study. Brain. 2010;133:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, Wijsman EM, Tsuang DW, Devlin B, Schellenberg GD. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer&#x2019;s disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89:655&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978251</ArticleId><ArticleId IdType="pubmed">17434289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21813491</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Consequences of antipsychotic medications for the dementia patient.</ArticleTitle><Pagination><StartPage>767</StartPage><EndPage>769</EndPage><MedlinePgn>767-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2011.11040629</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2011 Aug;168(8):831-9. doi: 10.1176/appi.ajp.2011.08121844</RefSource><PMID Version="1">21572163</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003221" MajorTopicYN="N">Confusion</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21813491</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2011.11040629</ArticleId><ArticleId IdType="pii">168/8/767</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21810649</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.</ArticleTitle><Pagination><StartPage>853</StartPage><EndPage>861</EndPage><MedlinePgn>853-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2011.72</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Agitation and psychosis are common in Alzheimer disease and cause considerable morbidity. We attempted to delay or to prevent agitation and psychosis with the use of divalproex sodium (valproate).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether treatment with valproate could delay or prevent emergence of agitation or psychosis.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PATIENTS" NlmCategory="METHODS">A multicenter, randomized, double-blind, placebo-controlled trial of flexible-dose valproate in 313 (of 513 screened) individuals with moderate Alzheimer disease who had not yet experienced agitation or psychosis. The study was conducted from November 1, 2005, through March 31, 2009, at 46 sites in the United States.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Participants were randomly assigned to valproate treatment at a target dose of 10 to 12 mg per kilogram of body weight per day or identical-appearing placebo for 24 months followed by a 2-month period of single-blind placebo treatment.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Time to emergence of clinically significant agitation or psychosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 122 participants (59 receiving valproate and 63 receiving placebo) completed 24 months of treatment while taking study medication; 42 (27 receiving valproate and 15 receiving placebo) reached 24 months having discontinued study medication; 150 reached month 26. There was no difference between groups in time to emergence of agitation or psychosis (Cox proportional hazard ratio, 0.96; P = .88). There was no difference between groups in change on any secondary outcome. The valproate group had higher rates of somnolence, gait disturbance, tremor, diarrhea, and weakness. Eighty-eight participants underwent magnetic resonance imaging scans at baseline and 12 months; the valproate group showed greater loss in hippocampal and whole-brain volume, accompanied by greater ventricular expansion (P &lt; .001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Valproate treatment did not delay emergence of agitation or psychosis or slow cognitive or functional decline in patients with moderate Alzheimer disease and was associated with significant toxic effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, 901 E Willetta St., Phoenix, AZ 85006, USA. pierre.tariot@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jakimovich</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Loy</LastName><ForeName>Rebekah</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bartocci</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Cooperative Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00071721</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG 10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030048</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Vicari</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corey-Bloom</LastName><ForeName>Jody</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbas</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tune</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahern</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>John Chuang-Kuo</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charleston</LastName><ForeName>North</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossberg</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebedeva</LastName><ForeName>Zinaida</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thein</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diego</LastName><ForeName>San</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baskys</LastName><ForeName>Andrius</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beach</LastName><ForeName>Long</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zabar</LastName><ForeName>Yuval</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foley</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Care</LastName><ForeName>Health</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alto</LastName><ForeName>Palo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Health</LastName><ForeName>Brain</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21810649</ArticleId><ArticleId IdType="mid">NIHMS1002590</ArticleId><ArticleId IdType="pmc">PMC7003728</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.72</ArticleId><ArticleId IdType="pii">68/8/853</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer&#x2019;s disease. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Werner P. Longitudinal changes in behavioral problems in old age: a study in an adult day care population. J Gerontol A Biol Sci Med Sci. 1998;53(1):M65&#x2013;M71.</Citation><ArticleIdList><ArticleId IdType="pubmed">9467436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, Blass DM, McIntyre JS, Charles SC, Anzia DJ, Cook IA, Finnerty MT, Johnson BR, Nininger JE, Schneidman B, Summergrad P, Woods SM, Berger J, Cross CD, Brandt HA, Margolis PM, Shemo JP, Blinder BJ, Duncan DL, Barnovitz MA, Carino AJ, Freyberg ZZ, Gray SH, Tonnu T, Kunkle R, Albert AB, Craig TJ, Regier DA, Fochtmann LJ; American Psychiatric Association Practice Guidelines Work Group on Alzheimer&#x2019;s Disease and Other Dementias. Practice guidelines for the treatment of patients with dementia and other dementias, 2nd ed. Am J Psychiatry. 2007;164(12)(suppl):5&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">18340692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y; the CERAD Behavioral Pathology Committee. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly, I: a conceptual review. J Am Geriatr Soc. 1986;34(10):711&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">3531296</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 1996;153(11):1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer&#x2019;s disease. Neurology. 1998;50(5):1222&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">9595967</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI; Metrifonate Study Group. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer&#x2019;s disease patients. J Clin Psychiatry. 1999;60(5):318&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hope T, Keene J, Fairburn CG, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer&#x2019;s disease: a longitudinal study. Br J Psychiatry. 1999;174:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211149</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, Keene J, Fairburn C, Jacoby R, Hope T. Psychiatric symptoms in patients with dementia predict the later development of behavioural abnormalities. Psychol Med. 1998;28(5):1119&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794019</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, Bell K, Bylsma FW, Brandt J, Albert M, Stern Y. The course of psychopatho-logic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997; 54(3):257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty HJ, Roth DL, Goode KT, Owen JE, Harrell L, Donovan K, Haley WE. Longitudinal course of behavioral problems during Alzheimer&#x2019;s disease: linear versus curvilinear patterns of decline. J Gerontol A Biol Sci Med Sci. 2000; 55(4):M200&#x2013;M206.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811149</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Cummings JL, Yenner G, Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 1996;153(2):243&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">8561206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Wilson RS, Beckett LA, Evans DA. Psychotic symptoms and physically aggressive behavior in Alzheimer&#x2019;s disease. J Am Geriatr Soc. 1997;45 (9):1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot PN, Yaffe K. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553721</ArticleId><ArticleId IdType="pubmed">17637610</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9(1):58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Schneider L, Mintzer J, Cutler A, Cunningham M, Thomas J, Somerville K. Safety and tolerability of divalproex sodium for the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp. 2001;62(1):51&#x2013;67.</Citation></Reference><Reference><Citation>Mark RJ, Ashford JW, Goodman Y, Mattson MP. Anticonvulsants attenuate amyloid [H9252]-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging. 1995;16(2):187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">7777136</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999;72(2):879&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">9930766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999;72(3): 1327&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037507</ArticleId></ArticleIdList></Reference><Reference><Citation>Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer&#x2019;s disease. J Biochem. 1997;121(2):179&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">9089387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett GD, Wlodarczyk B, Calvin JA, Craig JC, Finnell RH. Valproic acid&#x2013;induced alterations in growth and neurotrophic factor gene expression in murine embryos [published correction appears in Reprod Toxicol. 2000;14(2)181]. Reprod Toxicol. 2000;14(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10689198</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734&#x2013;36741.</Citation><ArticleIdList><ArticleId IdType="pubmed">11473107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S. Mood stabilizers in Alzheimer&#x2019;s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev. 2002;54(12):1567&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453674</ArticleId></ArticleIdList></Reference><Reference><Citation>Profenno LA, Jakimovich L, Holt C, Porsteinsson A, Tariot PN. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2005;2(5):553&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">16375658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripich DN. Functional communication with AD patients: a caregiver training program. Alzheimer Dis Assoc Disord. 1994;8(suppl 3):95&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">7999352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripich D, Ziol E, Fritsch T, Durand EJ. Training Alzheimer&#x2019;s disease caregivers for successful communication. Clin Gerontol. 1999;21:37&#x2013;53.</Citation></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope: The Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24(4):637&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer&#x2019;s Disease Cooperative Study&#x2013;Clinical Global Impression of Change: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer&#x2019;s disease: patient and caregiver reports. J Ment Health Aging. 1999;5:21&#x2013;32.</Citation></Reference><Reference><Citation>Gunter JL, Shiung MM, Manduca A, Jack CR Jr. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imaging. 2003;18(1): 16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740859</ArticleId><ArticleId IdType="pubmed">12815635</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grndman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ; for the Alzheimer&#x2019;s Disease Cooperative Study. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer&#x2019;s disease: the Alzheimer&#x2019;s Disease Cooperative Study. N Engl J Med. 1997;336(17):1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">3567285</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou Y, Liu F, Ni B. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-&#x3b2; precursor protein processing. Biochemistry. 2004;43(22):6899&#x2013;6908.</Citation><ArticleIdList><ArticleId IdType="pubmed">15170327</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W, Wang K, Song W. Valproic acid inhibits A&#x3b2; production, neuritic plaque formation, and behavioral deficits in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2008;205(12):2781&#x2013;2789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585842</ArticleId><ArticleId IdType="pubmed">18955571</ArticleId></ArticleIdList></Reference><Reference><Citation>McLachlan RS. Pseudoatrophy of the brain with valproic acid monotherapy. Can J Neurol Sci. 1987;14(3):294&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">3117347</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrini R, Belmonte A, Canapicchi R, Casalini C, Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia. 1998;39(1):27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9578009</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanouchi H, Ota T, Imataka G, Nakagawa E, Eguchi M. Reversible altered consciousness with brain atrophy caused by valproic acid. Pediatr Neurol. 2003; 28(5):382&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878301</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti CA, Diegoli M, Sartori I, Uggetti C, Brega A, Tartara A, Arbustini E. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology. 2006;67(9):1715&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101920</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia M, Huppertz J, Ziyeh S, Buechert M, Schumacher M, Mader I. Valproate-induced changes in brain volume in patients with epilepsy: assessment with H-MRS. Epilepsia. 2009;50(3):486&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">19183221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mint-zer J, Brenner R, Schafer K, Thal L; Alzheimer&#x2019;s Disease Cooperative Study; Valproate Nursing Home Study Group. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005;13(11):942&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21763789</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9649</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Ageing research reviews</Title><ISOAbbreviation>Ageing Res Rev</ISOAbbreviation></Journal><ArticleTitle>Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>103</EndPage><MedlinePgn>87-103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arr.2011.06.005</ELocationID><Abstract><AbstractText>Neuropsychiatric symptoms (NPS) in dementia, previously denominated as behavioural and psychological symptoms of dementia, are often more distressing, impairing, and costly than cognitive symptoms, representing a major health burden for older adults. These symptoms are common features of Alzheimer's disease (AD), and are one of the major risk factors for institutionalization. There is a high prevalence of neuropsychiatric disturbances in patients with AD, including depression, anxiety, apathy, psychosis, aggression, and agitation. At present, the role of the apolipoprotein E (APOE) genotypes in the development of NPS or neuropsychiatric syndromes/endophenotypes in AD patients is unclear. In this article, we summarized the findings of the studies of NPS and neuropsychiatric syndromes in AD in relation to APOE genotypes, with special attention to the possible underlying mechanisms. While some studies failed to find a significant association between the APOE polymorphism and NPS in late-onset AD, other studies reported a significant association between the APOE &#x25b;4 allele and an increase in agitation/aggression, hallucinations, delusions, and late-life depression or anxiety. However, current cumulative evidence coming from the few existing longitudinal studies shows no association of APOE genotypes with NPS as a whole in AD. Some negative studies that focused on the distribution of APOE genotypes between AD patients with or without NPS further emphasized the importance of sub-grouping NPS in distinct neuropsychiatric syndromes. Explanations for the variable findings in the existing studies included differences in patient populations, differences in the assessment of neuropsychiatric symptomatology, possible lack of statistical power to detect associations in the negative studies, and small sample sizes generating false positives that cannot be consistently replicated. Finally, many reviewed studies were cross-sectional, whereas it would be of paramount importance to evaluate the risk for incident NPS in relation to the APOE genotype in prospectively followed cohorts of AD patients. In fact, identifying predisposing genetic risk factors may allow us to understand the pathophysiological features of neuropsychiatric syndromes or symptoms in AD, so optimizing possible therapeutic options.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panza</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Geriatric Unit &amp; Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. f.panza@operapadrepio.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisardi</LastName><ForeName>Vincenza</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>D'Onofrio</LastName><ForeName>Grazia</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Santamato</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Masullo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Logroscino</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Solfrizzi</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ageing Res Rev</MedlineTA><NlmUniqueID>101128963</NlmUniqueID><ISSNLinking>1568-1637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21763789</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2011.06.005</ArticleId><ArticleId IdType="pii">S1568-1637(11)00052-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21714473</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0032-6518</ISSN><JournalIssue CitedMedium="Print"><Volume>255</Volume><Issue>1740</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>The Practitioner</Title><ISOAbbreviation>Practitioner</ISOAbbreviation></Journal><ArticleTitle>Diagnosing and managing psychosis in primary care.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>3</EndPage><MedlinePgn>17-20, 2-3</MedlinePgn></Pagination><Abstract><AbstractText>Psychosis is broadly defined as the presence of delusions and hallucinations. It can be organic or functional. The former is secondary to an underlying medical condition, such as delirium or dementia, the latter to a psychiatric disorder, such as schizophrenia or bipolar disorder. The identification and treatment of psychosis is vital as it is associated with a 10% lifetime risk of suicide and significant social exclusion. Psychosis can be recognised by taking a thorough history, examining the patient's mental state and obtaining a collateral history. The history usually enables a distinction to be made between bipolar disorder, schizophrenia and other causes. Early symptoms often include low mood, declining educational or occupational functioning, poor motivation, changes in sleep, perceptual changes, suspiciousness and mistrust. The patient's appearance, e.g. unkempt or inappropriately attired, may reflect their predominant mental state. There may be signs of agitation, hostility or distractibility. Speech may be disorganised and difficult to follow or there may be evidence of decreased speech. Mood may be depressed or elated or change rapidly. Patients may describe abnormal thoughts and enquiry into thoughts of suicide should be routine. Disturbances of thought such as insertion or withdrawal may be present along with perceptual abnormalities i.e. illusions, hallucinations. Insight varies during the course of a psychotic illness but should be explored as it has implications for management. All patients presenting with first episode psychosis for which no organic cause can be found should be referred to the local early intervention service. In patients with a known diagnosis consider referral if there is: poor response or nonadherence to treatment; intolerable side effects; comorbid substance misuse; risk to self or others.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Oxford University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brain</LastName><ForeName>Susannah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ebmeier</LastName><ForeName>Klaus P</ForeName><Initials>KP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Practitioner</MedlineTA><NlmUniqueID>0404245</NlmUniqueID><ISSNLinking>0032-6518</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="Y">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21714473</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21707862</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1479-8301</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society</Title><ISOAbbreviation>Psychogeriatrics</ISOAbbreviation></Journal><ArticleTitle>Pet therapy in elderly patients with mental illness.</ArticleTitle><Pagination><StartPage>125</StartPage><EndPage>129</EndPage><MedlinePgn>125-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1479-8301.2010.00329.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To evaluate the effects of pet therapy on cognitive function, mood and perceived quality of life on elderly inpatients (mean age 84.7 years; 95.2% women) affected by dementia, depression and psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Mini-Mental State Examination (MMSE) and 15-items Geriatric Depression Scale (GDS) were administered to 10 patients (pet group) and 11 controls (control group) together with a self-perceived quality-of-life questionnaire, before and after a pet therapy intervention that lasted 6 weeks. MMSE and GDS mean scores were compared between and within groups by Student's t-test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both the pet group and control group improved on GDS and MMSE. Within the pet group, GDS symptoms decreased by 50% (from 5.9 to 2.7, P= 0.013), whereas mean MMSE score increased by 4.5 (P= 0.060). The between group comparison showed a positive effect of pet therapy intervention on GDS (P= 0.070). Most of the participants reported an improvement of their perceived quality of life.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pet therapy is efficient in improving depressive symptoms and cognitive function in residents of long-term care facilities with mental illness.</AbstractText><CopyrightInformation>&#xa9; 2011 The Authors; Psychogeriatrics &#xa9; 2011 Japanese Psychogeriatric Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moretti</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, University of Bologna, Local Health Authority of Imola, Bologna, Italy. fra-moretti@libero.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Ronchi</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bernabei</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Forlani</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Negretti</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sacchetti</LastName><ForeName>Cleta</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Atti</LastName><ForeName>Anna Rita</ForeName><Initials>AR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychogeriatrics</MedlineTA><NlmUniqueID>101230058</NlmUniqueID><ISSNLinking>1346-3500</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056447" MajorTopicYN="Y">Animal Assisted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="N">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21707862</ArticleId><ArticleId IdType="doi">10.1111/j.1479-8301.2010.00329.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21688522</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1105-2333</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Psychiatrike = Psychiatriki</Title><ISOAbbreviation>Psychiatriki</ISOAbbreviation></Journal><ArticleTitle>[Behavioral and psychological symptoms of dementia and their management].</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>33</EndPage><MedlinePgn>24-33</MedlinePgn></Pagination><Abstract><AbstractText>The decline in cognitive function is a core feature of dementias. However, other symptoms of the disease are also crucial. These symptoms are the behavioral and psychological manifestations of dementia and include symptoms such as delusions, hallucinations, delusional misindentification syndromes (DMS), illusions, anxiety, aggression, depression, personality changes, disinhibition-impulsivity, violation of social and moral norms, changes in dietary or eating behavior and repetitive behaviors. Delusions, hallucinations, anxiety, depression and aggression are highly prevalent in Alzheimer's disease, vascular dementia and dementia with Lewy bodies, whereas symptoms that include severe disturbance of behavior are highly prevalent in frontotemporal dementias. Psychotic symptoms are associated with subcortical disturbances mainly of the limbic system. Patients with depression present greater loss of noradrenergic cells in the locus coeruleus and loss of serotonergic nuclei of dorsal raphe. Furthermore, disturbances of behavior are associated with frontal lobe dysfunction. Atypical antipsychotics is the first treatment option for delusions, hallucinations, misidentifications, anxiety and aggression. Furthermore, antidepressants may be useful for moderate or severe depression as well as for disinhibition-impulsivity, aggression, changes in dietary or eating behavior and repetitive behaviors. Cholinesterase inhibitors may also improve apathy, anxiety, disinhibition, aberrant behavior, mood disorders and hallucinations. Moreover, non-pharmacological methods alone or in combination with psychotropic drugs may also improve patient's symptomatology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lykouras</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>2nd Department of Psychiatry, Attikon General Hospital of Athens, University of Athens, Athens, Greece. elykoura@med.uoa.gr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gournellis</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>gre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Psychiatriki</MedlineTA><NlmUniqueID>101534363</NlmUniqueID><ISSNLinking>1105-2333</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21688522</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21684792</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Parkinsonism &amp; related disorders</Title><ISOAbbreviation>Parkinsonism Relat Disord</ISOAbbreviation></Journal><ArticleTitle>Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria.</ArticleTitle><Pagination><StartPage>621</StartPage><EndPage>624</EndPage><MedlinePgn>621-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.parkreldis.2011.05.017</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diagnostic criteria and procedures for dementia in Parkinson's disease (PDD) have been proposed by a Movement Disorders Society Task Force (MDS-TF). The objective of this study was to explore the utility of the new MDS-TF criteria and procedures in clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred ninety nine PD patients (36.5% with PDD as per MDFS-TF criteria; 33.1% according the DSM-IV) were included in the study. A variety of standardized motor, cognitive, psychiatric, and global severity measures were administered. A multivariate logistic regression model was built to determine the variables producing discrepancy between the MDS-TF and DSM-IV criteria for PDD and the clinical features that distinguished false negative cases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Agreement between MDS-TF and DSM-IV criteria was substantial (87.3%; kappa&#xa0;=&#xa0;0.72), but the DSM-IV criteria failed to identify 22% of patients fulfilling MDS-TF criteria. False negative cases were older and had more severe motor symptoms but less psychosis than those true non-demented PD. False positives had less severe motor symptoms than true PDD, although the difference did not reach statistical significance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that the MDS-TF criteria are more sensitive than the DSM-IV for a diagnosis of PDD. Old age, absence of psychiatric symptoms, and severe motor impairment can hinder the diagnosis of PDD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez-Martin</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Alzheimer Center Reina Sofia Foundation, Madrid, Spain. pmartinez@isciii.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falup-Pecurariu</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rodriguez-Blazquez</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Serrano-Due&#xf1;as</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Carod Artal</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Rojo Abuin</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parkinsonism Relat Disord</MedlineTA><NlmUniqueID>9513583</NlmUniqueID><ISSNLinking>1353-8020</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21684792</ArticleId><ArticleId IdType="doi">10.1016/j.parkreldis.2011.05.017</ArticleId><ArticleId IdType="pii">S1353-8020(11)00149-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21629185</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Differential diagnosis of behavioral variant of fronto-temporal dementia (bvFTD).</ArticleTitle><Pagination><StartPage>CR311</StartPage><EndPage>CR321</EndPage><MedlinePgn>CR311-21</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of the paper is the differential diagnosis of various types of Fronto-Temporal Dementia (FTD), with the focus on its behavioural variant (bvFTD).</AbstractText><AbstractText Label="MATERIAL/METHOD" NlmCategory="METHODS">Screening was done in order to assess the depth of dementia with the short version of MMSE, while evaluation of various variants of FTD was performed with the use of such neuropsychological tests as Newcomb and Chicago Fluency Tests, Wechsler Memory Scale-III (WMS-III), Western Aphasia Battery (WAB-R), and the Boston Naming Test (BNT). Behaviour was evaluated with a Polish version of the Frontal Behavioral Inventory (FBInv). The inventory consists of 24 questions which enable an evaluation of social behaviour disorders. The study included 112 patients--68 men and 46 women treated in the Reintegrative-Training Centre of the Foundation for Persons with Brain Dysfunctions in Krak&#xf3;w and in the Clinic for Developmental Psychiatry, Psychotic Disorders and Old Age Psychiatry, of the Medical University at Gda&#x144;sk, who were suffering from various types of dementia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">It was found that FTD patients scored the highest, while the VAD patients scored somewhat lower in the FBInv. At the same time the scores obtained by PPA patients were higher in comparison to the control groups, but not as high as in the case of patients with FTD. In the process of the neurotherapy of FTD patients we found a reduction of the behavioral disturbances, despite the progression of the illness.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results obtained in the present study confirmed the diagnostic value of FBInv in the differential diagnosis of various types of FTD and in the evaluation of neurotherapy efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>P&#x105;chalska</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Andrzej Frycz-Modrzewski Cracow University, Cracow, Poland. neuropsychologia23@o2.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Leszek</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>&#x141;ukowicz</LastName><ForeName>Ma&#x142;gorzata</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bidzan</LastName><ForeName>Mariola</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Markiewicz</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jastrz&#x119;bowska</LastName><ForeName>Gra&#x17c;yna</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Talar</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="N">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21629185</ArticleId><ArticleId IdType="pmc">PMC3539546</ArticleId><ArticleId IdType="doi">10.12659/msm.881803</ArticleId><ArticleId IdType="pii">881803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaczmarek BLJ. Regulatory function of the frontal lobes. A neurolinguistic perspective. In: Perecman WE, editor. The frontal lobes revisited. Nowy Jork: IRBN Press; 1987. pp. 225&#x2013;40.</Citation></Reference><Reference><Citation>Kaczmarek BLJ. P&#x142;aty czo&#x142;owe a j&#x119;zyk i zachowanie cz&#x142;owieka. Lublin: Wydawnictwo Popularnonaukowe &#x201e; Linea&#x201d;; 1993. [in Polish]</Citation></Reference><Reference><Citation>Gustafson L, Nielson L. Differential diagnosis of presenile dementia on clinical grounds. Acta Psychiatr Scand. 1982;65:194&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">7072512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A, Gustafson L . The Lund longitudinal dementia study. A 25-year perspective on neuropathology, differential diagnosis and treatment. In: Corain B, Nicolini M, Winblad B, et al., editors. Alzheimer&#x2019;s disease advances in clinical and basic research. Chichester, New York, Bristone, Toronto, Singapore: Wiley; 1993. pp. 4&#x2013;18.</Citation></Reference><Reference><Citation>Brun A, Englund E, Gustafson L, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994;57(4):416&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072868</ArticleId><ArticleId IdType="pubmed">8163988</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer&#x2019;s disease: Retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry. 1995;59:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1073603</ArticleId><ArticleId IdType="pubmed">7608712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Gonzalez MP, Becker JT, et al. Symptoms of depression and psychosis in Alzheimer&#x2019;s disease and frontotemporal dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:154&#x2013;61.</Citation></Reference><Reference><Citation>Gregory CA, Hodges JR. Frontotemporal dementia: Use of consensus criteria and prevalence of psychiatric features. Neuropsychiatr Neuropsychol Behav Neurol. 1996;9:145&#x2013;53.</Citation></Reference><Reference><Citation>P&#x105;chalska M. Behawioralny wariant ot&#x119;pienia czo&#x142;owo-skroniowego. In: P&#x105;chalska M, Bidzan L, editors. Ot&#x119;pienie czo&#x142;owo-skroniowe: uj&#x119;cie interdyscyplinarne. Krak&#xf3;w: Wydawnictwo Akademii Krakowskiej; 2011. [in Polish]</Citation></Reference><Reference><Citation>Lebert F. Behavioral changes, non-cognitive assessment and management in frontotemporal dementia. In: Pasquier F, Lebert F, Scheltens Ph, editors. Frontotemporal Dementia. The Netherlands: ICG Publications; 1996. pp. 71&#x2013;82.</Citation></Reference><Reference><Citation>Miller BL, Ikonte C, Ponton M, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: Clinical and single-photon emission CT correlations. Neurology. 1997;48:937&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Davidson W, Fox H. Frontal Behavioral Inventory: Diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. 1997;24:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc. 2000;6:460&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10902415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A. Pick complex and Pick&#x2019;s disease. Eur J Neurol. 1996;3:280&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21284785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersch EL, Kral VA, Palmer RB. Clinical value of the London Psychogeriatric Rating Scale. J Am Geriatr Soc. 1978;26:348&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">670622</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz GE. Development and validation of the Geriatric Evaluation by Relatives Rating Instrument (GERRI) Psychol Rep. 1983;53:479&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">6647694</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer&#x2019;s disease: Phenomenology and treatment. J Clin Psychiatry. 1987;48(Suppl):9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Niederehe G. Trims Behavioral Problem Checklist (BPC) Psychopharmacol Bull. 1988;24:771&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Weiler P, Franzi C, Henry R. Assessment of disruptive behavior associated with dementia: The Disruptive Behavior Rating Scales. J Geriatr Psychiatry Neurol. 1989;2:196&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">2635016</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgarten M, Becker R, Gauthier S. Validity and reliability of the Dementia Behavior Disturbance Scale. J Am Geriatr Soc. 1990;38:221&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2313003</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA, Swearer JM, O&#x2019;Donnell BF, et al. The Caretaker Obstreperous-Behavior Rating Assessment (COBRA) Scale. J Am Geriatr Soe. 1992;40:463&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1634698</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Miller B, Hill MA, Neshkes R. Neuropsychiatric aspects of multi-infarct dementia and dementia of the alzheimer type. Arch Neurol. 1987;44:389&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">3827694</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall DR, Mahurin RK, Cornell J. Bedside assessment of executive cognitive impairment: The Executive Interview (EXIT) J Am Geriatr Soc. 1992;40:1221&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">1447438</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Primary progressive aphasia-differentiation from Alzheimer&#x2019;s disease. Ann Neurol. 1987;22:533&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">3324947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Hudson L, Mackenzie IRA, Munoz DG. The pathology and nosology of primary progressive aphasia. Neurology. 1994;44:2065&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969961</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzezi&#x144;ski J, Gaul M, Hornowska E, et al. Pracownia Test&#xf3;w Psychologicznych PTP. 1996. Skala Inteligencji D. Wechslera dla Doros&#x142;ych. Wersja Zrewidowana. WAIS-R (PL). Podr&#x119;cznik. Warszawa. [in Polish]</Citation></Reference><Reference><Citation>Pachalska M, MacQueen BD. Autoryzowana Wersja Polska. Krak&#xf3;w: Fundacja na Rzecz Os&#xf3;b z Dysfunkcjami M&#xf3;zgu; 2000. Skala Pami&#x119;ci Wechslera (WMS-R) [in Polish]</Citation></Reference><Reference><Citation>Kertesz A. Western Aphasia Battery &#x2013; Test Booklet. New York: Grune and Stratton; 1982.</Citation></Reference><Reference><Citation>Benton AL, Hamsher K, Varney NR, Spreen O. Contribution in neuropsychological assessment: A clinical manual. New York: Oxford University Press; 1983.</Citation></Reference><Reference><Citation>Dekosky ST, Heilman KM, Bowers D, Valenstein E. Recognition and discrimination of emotional facecs and pictures. Brain &amp; Language. 1980;9:206&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7363065</ArticleId></ArticleIdList></Reference><Reference><Citation>Keane J, Calder AJ, Hodges JR, Young AW. Face and emotion processing in frontal variant frontotemporal dementia. Neuropsychologia. 2002:655&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11792405</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#x105;chalska M, MacQueen BD. Bosto&#x144;ski Test Nazywania [Boston Naming Test, BNT] &#x2013; Autoryzowana Wersja Polska. Krak&#xf3;w: Fundacja na Rzecz Os&#xf3;b z Dysfunkcjami M&#xf3;zgu; 1988. [in Polish]</Citation></Reference><Reference><Citation>Kertesz A, Munoz D. Clinical and pathological overlap between frontal dementia, progressive aphasia and corticobasal degeneration-the Pick complex. Neurology. 1997;48:A293.</Citation><ArticleIdList><ArticleId IdType="pubmed">10436340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornberger M, Savage S, Hsieh S, et al. Orbitofrontal dysfunction discriminates behavioral variant frontotemporal dementia from Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2010;30(6):547&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21252550</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#x105;chalska M. Rehabilitacja Neuropsychologiczna. Lublin: Wydawnictwo UMCS; 2008. [in Polish]</Citation></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer&#x2019;s disease. N Engl J Med. 2000;343:450&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Harciarek M, Jodzio K. Neuropsychological differences between frontotemporal dementia and Alzheimer&#x2019;s disease: A review. Neuropsychology Review. 2005;15(3):131&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16328732</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe FM, Murray B, Coen RF, et al. Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy. Brain. 2007;130(Pt 3):753&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347257</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcikowska M. Pacjent z zaburzeniami pami&#x119;ci u lekarza podstawowej opieki zdrowotnej. Psychogeriatria Polska. 2007;4(4):223. [in Polish]</Citation></Reference><Reference><Citation>Bidzan L, P&#x105;chalska M, Grochmal-Bach B, et al. Behavioral and psychological symptoms and the progression of dementia of the Alzheimer type in nursing home residents. Medical Science Monitor. 2008;14(11):CR559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18971872</ArticleId></ArticleIdList></Reference><Reference><Citation>Grochmal-Bach B, Bidzan L, Pachalska M, et al. Aggressive and impulsive behaviors in Frontotemporal dementia and Alzheimer&#x2019;s disease. Med Sci Monit. 2009;15(5):CR248&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">19396041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A. Clinical features and diagnosis of frontotemporal dementia. Front Neurol Neurosci. 2009;24:140&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">19182472</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Marx MS, Rosenthal AS. Dementia and agitation in nursing home residents: how are they related? Psychol Aging. 1990;5:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2317299</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck C, Frank L, Chumbler NR, et al. Correlates of disruptive behavior in severely cognitively impaired nursing home residents. Gerontologist. 1998;38:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9573663</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#x105;chalska M. Rehabilitacja Neuropsychologiczna. Lublin: Wydawnictwo UMCS; 2008. [in Polish]</Citation></Reference><Reference><Citation>Cummings JL, Bathgate D. Behaviour in frontotemporal dementia, Alzheimer&#x2019;s disease and vascular dementia. Acta Neurol Scand. 2001;103(6):367&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11421849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihori N. A case of frontotemporal lobar degeneration with progressive dysarthria. Behav Neurol. 2006;17(2):97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5471526</ArticleId><ArticleId IdType="pubmed">16873920</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet. 2003;2:89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849265</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K, Ebly E, Hackinski V, et al. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol. 1997;54:33&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9006411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmusson DX, Brandt J, Steele C, et al. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis Assoc Disord. 1996;10:180&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8939276</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman G. Perspectives in the treatment of vascular dementia. Drugs of Today. 2000;36:641&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidzan L. Zaburzenia niekognitywne w zespo&#x142;ach ot&#x119;piennych typu Alzheimera i naczyniopochodnych. Rocznik Psychogeriatryczny. 1998;1:67&#x2013;79. [in Polish]</Citation></Reference><Reference><Citation>Kendell RE. The stability of psychiatric diagnoses. Brit J Psychiat. 1974;124:352&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">4836157</ArticleId></ArticleIdList></Reference><Reference><Citation>Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic: a threee-year prospective study. Arch Neurol. 1985;42:894&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">4026634</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings MI, Schoevers RA, Beekman AT, et al. Depression and risk of cognitive decline and Alzheimer&#x2019;s disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry. 2000;176:568&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10974964</ArticleId></ArticleIdList></Reference><Reference><Citation>Speck CE, Kukull WA, Brenner DE. History of depression as a risk factor for Alzheimer&#x2019;s disease. Epidemiol. 1995;6:366&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">7548342</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Neuropathologica. 1991;82:259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 1982;32:164&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">7198741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilikiewicz A, Bidzan L. Zale&#x17c;no&#x15b;&#x107; mi&#x119;dzy poziomem kortyzolu w osoczu a stopniem upo&#x15b;ledzenia intelektualnego w zespo&#x142;ach ot&#x119;piennych pierwotnie zwyrodnieniowych. Psychiatr Pol. 1990;24:2&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2284355</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald BS, Mathe AA, Mohs RC, et al. Cortisol and alzheimer&#x2019;s disease: dexamethasone suppression, dementia severity and affective symptoms. Am J Psychiatry. 1986;143(4):442&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">3953887</ArticleId></ArticleIdList></Reference><Reference><Citation>Spar JE, Gerner R. Does the dexamethasone suppression test distinquish dementia from depression? Am. J Psychiatry. 1982;139(2):238&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7055301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinow DR, Post RM, Savard R. Cortisol hypersecretion and cognitive impairment in depression. Arch. Gen Psychiatry. 1984;41:279&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">6703846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kropotov JD. Quantitative EEG, event related potentials and neurotherapy. San Diego: Academic Press, Elsevier; 2009.</Citation></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;5:404&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Moosy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol. 1988;45:1182&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">3190497</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweig RM, Ross CA, Hedreen JC. The neuropathology of aminergic nuclei in Alzheimer&#x2019;s disease. Ann Neurol. 1988;24:233&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">3178178</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstl H, Burns A, Luthert P, et al. Clinical and neuropathological correlates of depression in Alzheimer&#x2019;s disease. Psychol Med. 1992;22:877&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">1488485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolanowski AM, Garr M. The relation of premorbid factors to aggressive physical behavior in dementia. J Neurosci Nurs. 1999;31:278&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10633304</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">2386336</ArticleId></ArticleIdList></Reference><Reference><Citation>Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997;54:878&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236577</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl J. Frontotemporal dementia: patient characteristics, cognition, and behaviour. Int J Geriatr Psychiatry. 2002;17(10):914&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325050</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JW, P&#x105;chalska M. The nature of the symptom and its relevance for neuropsychology. Acta Neuropsychologica. 2003;1(1):1&#x2013;11.</Citation></Reference><Reference><Citation>Pachalska M, MacQueen BD. The Microgenetic Revolution in Contemporary Neuropsychology and Neurolinguistics. In: Weber M, Weekes A, editors. Whiteheadian Approaches to Consciousness in Psychology, Neuropsychiatry and Philosophy of Mind. New York: SUNY Press; 2008. pp. 164&#x2013;85.</Citation></Reference><Reference><Citation>Cohen L, Benoit N, Van Eeckhout P, et al. Pure progressive aphemia. J Neurol Neurosurg Psychiatry. 1993;56:923&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1015154</ArticleId><ArticleId IdType="pubmed">8350114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Munoz DG. Pick&#x2019;s disease and Pick complex. Introductory nosology. In: Kertesz A, Munoz DG, editors. Pick&#x2019;s disease and Pick complex. Nowy Jork: Willey-Liss, Inc; 1998. pp. 1&#x2013;11.</Citation></Reference><Reference><Citation>Fukui T, Kertesz A. A quantitative study of brain atrophy in primary progressive aphasia and frontotemporal dementia. J Int Neuropsychol Soc. 1998;4:216.</Citation></Reference><Reference><Citation>Cardarelli R, Kertesz A, Knebl JA. Frontotemporal dementia: a review for primary care physicians. Am Fam Physician. 2010;82(11):1372&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">21121521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21601587</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0333</ISSN><JournalIssue CitedMedium="Internet"><Volume>256</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Toxicology and applied pharmacology</Title><ISOAbbreviation>Toxicol Appl Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Association between environmental exposure to pesticides and neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>379</StartPage><EndPage>385</EndPage><MedlinePgn>379-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2011.05.006</ELocationID><Abstract><AbstractText>Preliminary studies have shown associations between chronic pesticide exposure in occupational settings and neurological disorders. However, data on the effects of long-term non-occupational exposures are too sparse to allow any conclusions. This study examines the influence of environmental pesticide exposure on a number of neuropsychiatric conditions and discusses their underlying pathologic mechanisms. An ecological study was conducted using averaged prevalence rates of Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebral degeneration, polyneuropathies, affective psychosis and suicide attempts in selected Andalusian health districts categorized into areas of high and low environmental pesticide exposure based on the number of hectares devoted to intensive agriculture and pesticide sales per capita. A total of 17,429 cases were collected from computerized hospital records (minimum dataset) between 1998 and 2005. Prevalence rates and the risk of having Alzheimer's disease, Parkinson's disease, multiple sclerosis and suicide were significantly higher in districts with greater pesticide use as compared to those with lower pesticide use. The multivariate analyses showed that the population living in areas with high pesticide use had an increased risk for Alzheimer's disease and suicide attempts and that males living in these areas had increased risks for polyneuropathies, affective disorders and suicide attempts. In conclusion, this study supports and extends previous findings and provides an indication that environmental exposure to pesticides may affect the human health by increasing the incidence of certain neurological disorders at the level of the general population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parr&#xf3;n</LastName><ForeName>Tesif&#xf3;n</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Almer&#xed;a, Department of Neurosciences and Health Sciences, Almer&#xed;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requena</LastName><ForeName>Mar</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Antonio F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Alarc&#xf3;n</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Toxicol Appl Pharmacol</MedlineTA><NlmUniqueID>0416575</NlmUniqueID><ISSNLinking>0041-008X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010575">Pesticides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000383" MajorTopicYN="N">Agriculture</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="N">Environmental Exposure</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010575" MajorTopicYN="N">Pesticides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011115" MajorTopicYN="N">Polyneuropathies</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21601587</ArticleId><ArticleId IdType="doi">10.1016/j.taap.2011.05.006</ArticleId><ArticleId IdType="pii">S0041-008X(11)00175-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21584738</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study.</ArticleTitle><Pagination><StartPage>23</StartPage><EndPage>31</EndPage><MedlinePgn>23-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-011-0618-0</ELocationID><Abstract><AbstractText>The aim of this study is to evaluate memantine effectiveness on behavioural and psychological symptoms of dementia (BPSD) in clinical practice and to identify variables that may predict the therapy effects. The effects of memantine on behaviour were analysed in the database of a post-marketing surveillance study promoted by the Lombardy Region Health Office and involving 43 Alzheimer's disease (AD) Units. From July to December 2005, 399 moderately severe-to-severe AD patients free of cholinergic medications were enrolled, treated with memantine and followed-up for 6 months. BPSD were assessed in a subgroup of 297 patients [mean age 77 &#xb1; 8 years; 73% females; mean neuropsychiatric inventory (NPI) score 28 &#xb1; 24] for whom the 12-item NPI subscores at baseline, and at 3 and 6 months were available. The 12 BPSD were clustered as follows: affect, physical behaviour, psychosis and hypomania. The main outcome measure was the proportion of individual cluster responders at 6 months of therapy. The proportion of individual cluster responders was 30% affect, 24% physical behaviour, 29% psychosis, 27% hypomania. Patients taking 20 mg memantine daily during the study period had a statistically significant higher probability to experience behavioural improvement than those who discontinued treatment or did not complete memantine titration (affect OR 9.0; 95% CI 3.8-21.6; physical behaviour OR 17.8; 95% CI 5.9-53.6; psychosis OR 23.6; 95% CI 5.1-110.8). The logistic regression analysis was not applicable to the hypomania subsyndrome because of the low cluster prevalence. The standard 20 mg daily memantine treatment regimen was found to be associated with a modest 6-month behavioural improvement in the affect, physical behaviour and psychosis domains in 24-30% of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clerici</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre for Research and Treatment on Cognitive Dysfunctions, Chair of Neurology, University of Milan, Luigi Sacco Hospital, Via G.B. Grassi, 74, 20157 Milan, Italy. francesca.clerici1@unimi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanacore</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Elia</LastName><ForeName>Antonietta</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Spila-Alegiani</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pomati</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Da Cas</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Raschetti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><CollectiveName>Memantine Lombardy Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="N">Apathy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005247" MajorTopicYN="N">Feeding Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Altavilla</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Appollonio</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isella</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avanzi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bargnani</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bascelli</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellelli</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerini</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belotti</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bottini</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerini</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheldi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellotti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chia</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cislaghi</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cusi</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesina</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuzzoni</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farina</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alberoni</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franceschi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zucchi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerini</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iori</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lanza</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finotti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucchelli</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maggiore</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratti</LastName><ForeName>P L</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magnani</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiatti</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcone</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giusti</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margarito</LastName><ForeName>F P</ForeName><Initials>FP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martina</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauri</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merlo</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazza</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moleri</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riva</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montecalvo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinaglia</LastName><ForeName>C Negri</ForeName><Initials>CN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engaddi</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perini</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carnicelli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petr&#xf2;</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pettenati</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perotta</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranzenigo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertozzi</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redaelli</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reverberi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvi</LastName><ForeName>G P</ForeName><Initials>GP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manzoni</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saviotti</LastName><ForeName>F M</ForeName><Initials>FM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpini</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinforiani</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zucchella</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcon</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turla</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viti</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zanetti</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alberici</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21584738</ArticleId><ArticleId IdType="doi">10.1007/s10072-011-0618-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurology. 2006 Jul 11;67(1):57-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16832078</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2008 May;23(5):537-45</Citation><ArticleIdList><ArticleId IdType="pubmed">18058838</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Apr 3;348(14):1333-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1963 Sep 21;185:914-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14044222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1997 Aug;45(8):923-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9256842</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2005 May;20(5):459-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15852444</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2004;17(1-2):100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14564129</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1990 Nov;89(5):630-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1978566</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1987 Oct;37(10):1649-53</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Apr 24;287(16):2090-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11966383</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Mar;69(3):341-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18294023</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2007;24(1):20-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17496417</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Dec;44(12):2308-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):136-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17545739</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2008 Mar 4;148(5):379-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18316756</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1998 Apr;55(4):539-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9561983</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2005 Sep 8;353(10):969-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16148281</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Jul;14(7):605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16816014</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs Aging. 2009;26(4):321-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19476399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2008 Jan;42(1):32-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18056833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476</Citation><ArticleIdList><ArticleId IdType="pubmed">16437455</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154</Citation><ArticleIdList><ArticleId IdType="pubmed">15846650</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1995 Feb;43(2):130-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7836636</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 May;157(5):708-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2002;(2):CD002852</Citation><ArticleIdList><ArticleId IdType="pubmed">12076456</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1996 Jan;46(1):130-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 1996 May;3(3):198-202</Citation><ArticleIdList><ArticleId IdType="pubmed">21284770</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Nov;19(11):1035-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15481075</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2006 Feb;5(2):160-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16424917</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21574121</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3843</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Neurologia i neurochirurgia polska</Title><ISOAbbreviation>Neurol Neurochir Pol</ISOAbbreviation></Journal><ArticleTitle>[Psychopathological syndromes of neurological diseases in the elderly].</ArticleTitle><Pagination><StartPage>161</StartPage><EndPage>168</EndPage><MedlinePgn>161-8</MedlinePgn></Pagination><Abstract><AbstractText>Vascular and degenerative diseases of the central nervous system are one of the most common health problems in the elderly. Cognitive dysfunction, mood disorders and behavioural changes as well as psychotic symptoms constitute an invariable part of the clinical manifestation of these diseases. Psychopathological syndromes influence management decisions, commonly being a reason for patients' institutionalization; they are also a cause of suffering of patients and their caregivers and relatives. Relevant diagnosis of psychological symptoms is crucial in establishing adequate therapy, which improves quality of life of patients and their caregivers. The paper provides an overview of the psychopathological presentation of the most common central nervous system diseases in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Owecki</LastName><ForeName>Micha&#x142; K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Klinika Neurologii UM w Poznaniu, ul. Przybyszewskiego 49, 60-355 Pozna&#x144;. michal.owecki@wp.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalak</LastName><ForeName>S&#x142;awomir</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kozubski</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Psychopatologia chor&#xf3;b uk&#x142;adu nerwowego w wieku podesz&#x142;ym.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Neurol Neurochir Pol</MedlineTA><NlmUniqueID>0101265</NlmUniqueID><ISSNLinking>0028-3843</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21574121</ArticleId><ArticleId IdType="doi">10.1016/s0028-3843(14)60028-1</ArticleId><ArticleId IdType="pii">S0028-3843(14)60028-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21572163</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.</ArticleTitle><Pagination><StartPage>831</StartPage><EndPage>839</EndPage><MedlinePgn>831-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2011.08121844</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer's disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease study (CATIE-AD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">CATIE-AD included 421 outpatients with Alzheimer's disease and psychosis or agitated/aggressive behavior who were randomly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo. Based on their clinicians' judgment, patients could discontinue the originally assigned medication and receive another randomly assigned medication. Patients were followed for 36 weeks, and cognitive assessments were obtained at baseline and at 12, 24, and 36 weeks. Outcomes were compared for 357 patients for whom data were available for at least one cognitive measure at baseline and one follow-up assessment that took place after they had been on their prescribed medication or placebo for at least 2 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, patients showed steady, significant declines over time in most cognitive areas, including in scores on the Mini-Mental State Examination (MMSE; -2.4 points over 36 weeks) and the cognitive subscale of the Alzheimer's Disease Assessment Scale (-4.4 points). Cognitive function declined more in patients receiving antipsychotics than in those given placebo on multiple cognitive measures, including the MMSE, the cognitive subscale of the Brief Psychiatric Rating Scale, and a cognitive summary score summarizing change on 18 cognitive tests.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In CATIE-AD, atypical antipsychotics were associated with worsening cognitive function at a magnitude consistent with 1 year's deterioration compared with placebo. Further cognitive impairment is an additional risk of treatment with atypical antipsychotics that should be considered when treating patients with Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vigen</LastName><ForeName>Cheryl L P</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Keck School of Medicine, Universityof Southern California, Los Angeles, CA 90033, USA</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mack</LastName><ForeName>Wendy J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Keefe</LastName><ForeName>Richard S E</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>T Scott</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>Barry D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH-9001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2011 Aug;168(8):767-9. doi: 10.1176/appi.ajp.2011.11040629</RefSource><PMID Version="1">21813491</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21572163</ArticleId><ArticleId IdType="mid">NIHMS348870</ArticleId><ArticleId IdType="pmc">PMC3310182</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2011.08121844</ArticleId><ArticleId IdType="pii">appi.ajp.2011.08121844</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry. 2000;157(5):708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's Disease: a review of 55 studies published from 1990&#x2013;2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP. A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2005;13:460&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, O'Brien AT, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates and causes. The Gerontologist. 1995;35:771&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557205</ArticleId></ArticleIdList></Reference><Reference><Citation>Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol. 1996;9:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang M-X, Albert MS, Brandt J, Jacobs DM, Bell K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;227(10):806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry. 2006;14(3):191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin. 1999;25(2):201&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10416727</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology. 2005 Sep;8(3):457&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">15784157</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry. 2001 Feb;158(2):176&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156796</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Archives of General Psychiatry. 2007 Oct;64(10):1115&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">17909123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Bmj. 2005;330(7496):874. [see comment].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556156</ArticleId><ArticleId IdType="pubmed">15722369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. International Journal of Geriatric Psychiatry. 2005;20(11):1020&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">16250069</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, et al. Clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial. Schizophrenia Bulletin. 2003;29(1):57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail S, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C: American Psychiatric Association Press; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHugh P. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3387516</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry. 1984;141(11):1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale (ADAS) that broaden its scope. Alzheimer's Disease and Associated Disorders. 1997;11 Supplement 2:S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL. Development of a multilingual aphasia battery. Progress and problems. 1969 Jul&#x2013;Aug;:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">5820858</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Vacca JL, Massman PJ, Liao TY. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. Archives of Neurology. 1999 Sep;56(9):1133&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pubmed">10488815</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Lafont S, Auriacombe S, Rainville C, Orgogozo JM, Dartigues JF, et al. Analysis of error types in the trial making test evidences an inhibitory deficit in dementia of the Alzheimer type. Official Journal of the International Neuropsychological Society. 1998 Apr;20(2):280&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777482</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, et al. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research. 1995 Sep;17(1):25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8541247</ArticleId></ArticleIdList></Reference><Reference><Citation>Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research. II. Representative profile patterns. Journal of Gerontology. 1984;39:194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">6699375</ArticleId></ArticleIdList></Reference><Reference><Citation>Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2006:CD005593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006343</ArticleId><ArticleId IdType="pubmed">16437532</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas RG, Berg JD, Sano M, Thal L. Analysis of longitudinal data in an Alzheimer's disease clinical trial. Stat Med. 2000;19(11&#x2013;12):1433&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">10844708</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 2007 Jun;64(6):633&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca P, Marino F, Montemagni C, Perrone D, Bogetto F. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study. Psychiatry &amp; Clinical Neurosciences. 2007;61(6):622&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">18081622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. American Journal of Psychiatry. 2008;165(7):844&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21558436</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0103</ISSN><JournalIssue CitedMedium="Internet"><Volume>338</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of pharmacology and experimental therapeutics</Title><ISOAbbreviation>J Pharmacol Exp Ther</ISOAbbreviation></Journal><ArticleTitle>Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.</ArticleTitle><Pagination><StartPage>622</StartPage><EndPage>632</EndPage><MedlinePgn>622-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1124/jpet.111.182063</ELocationID><Abstract><AbstractText>Alzheimer's disease and schizophrenia are characterized by expression of psychotic, affective, and cognitive symptoms. Currently, there is a lack of adequate treatment for the cognitive symptoms associated with these diseases. Cholinergic signaling and, in particular, M1 muscarinic acetylcholine receptor (m1AChR) signaling have been implicated in the regulation of multiple cognitive domains. Thus, the M1AChR has been identified as a therapeutic drug target for diseases, such as schizophrenia and Alzheimer's disease, that exhibit marked cognitive dysfunction as part of their clinical manifestation. Unfortunately, the development of selective M1 agonist medications has not been successful, mostly because of the highly conserved orthosteric acetylcholine binding site among the five muscarinic receptor subtypes. More recent efforts have focused on the development of allosteric M1AChR modulators that target regions of the receptor distinct from the orthosteric site that are less conserved between family members. However, orthosteric and allosteric ligands may differentially modulate receptor function and ultimately downstream signaling pathways. Thus, the need for highly selective M1AChR orthosteric agonists still exists, not only as a potential therapeutic but also as a pharmacological tool to better understand the physiologic consequences of M1AChR orthosteric activation. Here, we describe the novel, potent and selective M1AChR orthosteric partial agonist LY593093 [N-[(1R,2R)-6-({(1E)-1-[(4-fluorobenzyl)(methyl)amino]ethylidene})amino)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]biphenyl-4-carboxamide]. This compound demonstrates modest to no activity at the other muscarinic receptor subtypes, stimulates G&#x3b1;(q)-coupled signaling events as well as &#x3b2;-arrestin recruitment, and displays significant efficacy in in vivo models of cognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watt</LastName><ForeName>Marla L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Lilly Research Laboratories, Eli Lilly &amp; Co., Lilly Corporate Center, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schober</LastName><ForeName>Douglas A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Hitchcock</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Chesterfield</LastName><ForeName>Amy K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>McKinzie</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Felder</LastName><ForeName>Christian C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharmacol Exp Ther</MedlineTA><NlmUniqueID>0376362</NlmUniqueID><ISSNLinking>0022-3565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007192">Indenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561313">N-(6-((1-((4-fluorobenzyl)(methyl)amino)ethylidene))amino)-2-hydroxy-2,3-dihydro-1H-inden-1-ylbiphenyl-4-carboxamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054333" MajorTopicYN="Y">Drug Partial Agonism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007192" MajorTopicYN="N">Indenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="N">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21558436</ArticleId><ArticleId IdType="doi">10.1124/jpet.111.182063</ArticleId><ArticleId IdType="pii">jpet.111.182063</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21538537</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.</ArticleTitle><Pagination><StartPage>296</StartPage><EndPage>304</EndPage><MedlinePgn>296-304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2720</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to assess the safety and tolerability of extended-release quetiapine fumarate (quetiapine XR) compared with quetiapine immediate-release (quetiapine IR) in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a 6-week, double-blind, double-dummy, randomised study. Of the 109 patients screened, 100 were randomised to receive quetiapine XR (n = 68) or quetiapine IR (n = 32), at doses of 50 and 25 mg/day, respectively. Treatment was escalated to 100 mg/day by Day 4. At Day 8, a flexible-dose (50-300 mg/day) period began when dose adjustment was made at the investigator's discretion. The primary variable was incidence and type of adverse events (AEs). Secondary variables included efficacy and other safety assessments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean daily doses were 143.6 and 142.0 mg in the quetiapine XR and quetiapine IR groups, respectively. Ninety patients completed the study; only one withdrew (in the quetiapine XR group) because of an AE. Laboratory evaluations identified severe neutropaenia (one patient), mild neutropaenia (three patients) and eosinophilia (five patients); however, these were not reported, as AEs and confounding factors, such as patient age, concomitant illness and medication, made it difficult to determine any relationship to quetiapine treatment. Numerical improvements from baseline were seen across both treatment groups in Neuropsychiatric Inventory frequency &#xd7; severity total, Neuropsychiatric Inventory-Nursing Home version, Cohen-Mansfield Agitation Inventory, Clinical Global Impression-Severity of Illness and Clinical Global Impression-Improvement scores.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Quetiapine XR dosed up to 300 mg/day was generally well tolerated, with a similar profile to that of quetiapine IR.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Middelheim Hospital and Laboratory of Neurochemistry and Behaviour, Department of Biomedical Sciences, Institute Born Bunge, University of Antwerp, Antwerp, Belgium. dedeyn@skynet.be</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Svensson</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><CollectiveName>Study 115 investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Brodaty</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hustig</LastName><ForeName>Harry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinburg</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Souza</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouckaert</LastName><ForeName>Filip</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roger</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabheru</LastName><ForeName>Kian</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nashed</LastName><ForeName>Yousery</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Reekum</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moksnnes</LastName><ForeName>Kjell Martin</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindvig</LastName><ForeName>Torgeir</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorentzen</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selemani</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potoctik</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mkize</LastName><ForeName>Dan L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gagiano</LastName><ForeName>Carllo Andrias</ForeName><Initials>CA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21538537</ArticleId><ArticleId IdType="doi">10.1002/gps.2720</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21536160</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3147</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Psychiatric clinics of North America</Title><ISOAbbreviation>Psychiatr Clin North Am</ISOAbbreviation></Journal><ArticleTitle>New wine in old bottle: late-life psychosis.</ArticleTitle><Pagination><StartPage>295</StartPage><EndPage>vii</EndPage><MedlinePgn>295-318, vii</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psc.2011.02.008</ELocationID><Abstract><AbstractText>Psychosis is common in late-life and exacts enormous costs to society, affected individuals, and their caregivers. A multitude of etiologies for late-life psychosis exist, the two most prototypical being schizophrenia and psychosis of Alzheimer disease (AD). As such, this article focuses on the nonaffective, neuropsychiatric causes of chronic psychosis in the elderly, specifically schizophrenia, delusional disorder, and the psychosis of AD and other dementias.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iglewicz</LastName><ForeName>Alana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, Mail Code 0664, La Jolla, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meeks</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 MH019934</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 MH001993</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH080002</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH080002</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01993</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH080002-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Clin North Am</MedlineTA><NlmUniqueID>7708110</NlmUniqueID><ISSNLinking>0193-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21536160</ArticleId><ArticleId IdType="mid">NIHMS289382</ArticleId><ArticleId IdType="pmc">PMC3093110</ArticleId><ArticleId IdType="doi">10.1016/j.psc.2011.02.008</ArticleId><ArticleId IdType="pii">S0193-953X(11)00026-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palmer BW, McClure F, Jeste DV. Schizophrenia in late-life: Findings challenge traditional concepts. Harvard Rev Psychiatry. 2001;9:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11266402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wender PH. Dementia praecox: The development of the concept. Am J Psychiatry. 1963;119:1143&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">13999926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Symonds LL, Harris MJ, et al. Non-dementia non-praecox dementia praecox? Late-onset schizophrenia. Am J Geriatr Psychiatry. 1997;5:302&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraeplin E. Dementia Praecox and Paraphrenia [Translated in 1919 from the eighth German edition of the &#x2018;Test-book of Psychiatry,&#x2019; vol. iii, part ii, section on Endogenous Dementias published in 1913] Huntington, NY: Krieger; 1971.</Citation></Reference><Reference><Citation>Seeman M, Jeste DV. Historical perspective. In: Hassett A, Ames D, Chiu E, editors. Psychosis in the Elderly. New York, NY: Taylor &amp; Francis Group; 2005. pp. 1&#x2013;9.</Citation></Reference><Reference><Citation>Bleuler E. In: Dementia Praecox or the Group of Schizophrenias. Zinkin J, translator. New York: International Universities Press; 1950.</Citation></Reference><Reference><Citation>Bleuler M. Late schizophrenic clinical pictures. Fortschr Neurol Psychiatr. 1943;15:259&#x2013;290.</Citation></Reference><Reference><Citation>Palmer BW, Heaton SC, Jeste DV. Older patients with schizophrenia: Challenges in the coming decades. Psychiatr Serv. 1999;50:1178&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">10478904</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next two decades. Arch Gen Psychiatry. 1999;56:848&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">12884891</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle DJ. Epidemiology of late onset schizophrenia. In: Howard R, Rabins PV, Castle DJ, editors. Late Onset Schizophrenia. Philadelphia: Wrightson Biomedical Publishing Ltd; 1999. pp. 139&#x2013;146.</Citation></Reference><Reference><Citation>Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York: The Free Press; 1991.</Citation></Reference><Reference><Citation>Regier DA, Kaelber CT, Rae DS, et al. Limitations of diagnostic criteria and assessment instruments for mental disorders. Implications for research and policy. Arch Gen Psychiatry. 1998;55:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9477922</ArticleId></ArticleIdList></Reference><Reference><Citation>Auquier P, Lan&#xe7;on C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2007;16:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17944000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuffel BJ, Jeste DV, Halpain M, et al. Treatment costs and use of community mental health services for schizophrenia by age cohorts. Am J Psychiatry. 1996;153:870&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">8659608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasylenki DA. The cost of schizophrenia. Can J Psychiatry. 1994;39:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">7874667</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels SJ, Clark RE, Peacock WJ, et al. Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medical ill patients. Am J Geriatr Psychiatry. 2003;11:648&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609805</ArticleId></ArticleIdList></Reference><Reference><Citation>Folsom DP, Lebowitz BD, Lindamer LA, et al. Schizophrenia in late life: Emerging issues. Dialogues Clin Neurosci. 2006;8:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181756</ArticleId><ArticleId IdType="pubmed">16640113</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TL, Semple SJ, Shaw WS, et al. Researching the caregiver: Family members who care for older psychotic patients. Psychiatric Annals. 1996;26:772&#x2013;784.</Citation></Reference><Reference><Citation>Cohen CI, Cohen GD, Blank K, et al. Schizophrenia and older adults: An overview: Directions for research and policy. Am J Geriatr Psychiatry. 2000;8:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648291</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson M, Harvey PD, Powchik P, et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995;152:197&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">7840352</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD, Silverman JM, Mohs RC, et al. Cognitive decline in late-life schizophrenia: A longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999;45:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9894573</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding C, Brooks G, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144:727&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">3591992</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding CM. Changes in schizophrenia across time: Paradoxes, patterns and predictors. In: Carl I, Cohen M, editors. Schizophrenia into Later Live. Washington, DC: American Psychiatric Publishing Inc; 2003. pp. 19&#x2013;42.</Citation></Reference><Reference><Citation>Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: A 15- and 25-year international follow-up study. Br J Psychiatry. 2001;178:506&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">11388966</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Twamley EW, Eyler Zorrilla LT, et al. Aging and outcome in schizophrenia. Acta Psychiatr Scand. 2003;107:336&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752029</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen CI, Vahia I, Reyes P, et al. Focus on geriatric psychiatry: Schizophrenia in later life: Clinical symptoms and social well-being. Psychiatr Serv. 2008;59:232&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">18308900</ArticleId></ArticleIdList></Reference><Reference><Citation>Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients. Am J Psychiatry. 2004;161:1490&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">15285980</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton RK, Gladsjo JA, Palmer BW, et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">11146755</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton R, Paulsen J, McAdams LA, et al. Neuropsychological deficits in schizophrenia. Relationship to age, chronicity and dementia. Arch Gen Psychiatry. 1994;51:469&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">8192549</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyler-Zorrilla LT, Heaton RK, McAdams LA, et al. Cross-sectional study of older outpatients with schizophrenia and healthy comparison subjects: No difference in age-related cognitive decline. Am J Psychiatry. 2000;157:1324&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">10910798</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer BW, Bondi MW, Twamley EW, et al. Are late-onset schizophrenia-spectrum disorders a neurodegenerative condition? Annual rates of change on two dementia measures. J Neuropsychiat Clin Neurosci. 2003;15:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12556570</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer BW, Dawes SE, Heaton RK. What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev. 2009;19:365&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745531</ArticleId><ArticleId IdType="pubmed">19639412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology. 1998;12:426&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9673998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting C, Rajji TK, Ismail Z, et al. Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late life. PLoS ONE. 2010;5:e10151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853579</ArticleId><ArticleId IdType="pubmed">20405043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Harris MJ, Krull A, et al. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am J Psychiatry. 1995;152:722&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">7726312</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Heaton RK, Sadek JR, et al. The nature of learning and memory impairments in schizophrenia. Journal of the International Neuropsychological Society. 1995;1:88&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375213</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer BW, Dawes SE. Cognitive aging: From basic skills to scripts and schemata. In: Jeste DV, Depp CD, editors. Handbook of Successful Cognitive and Emotional Aging. Arlington, VA: American Psychiatric Publishing, Inc; 2010. pp. 37&#x2013;54.</Citation></Reference><Reference><Citation>Patterson TL, Klapow JC, Eastham J, et al. Correlates of functional status in older patients with schizophrenia. Psychiatry Res. 1998;80:41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9727962</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer BW, Heaton RK, Gladsjo JA, et al. Heterogeneity in functional status among older outpatients with schizophrenia: Employment history, living situation, and driving. Schizophr Res. 2002;55:205&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">12048144</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd S, Depp CA, Harris G, et al. Perspectives on schizophrenia over the lifespan: A qualitative study. Schizophr Bull. 2010 Jul 5; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3283145</ArticleId><ArticleId IdType="pubmed">20603443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen CI, Talavera N, Hartung R. Predictors of subjective well-being among older, community-dwelling persons with schizophrenia. The American Journal of Geriatric Psychiatry. 1997;5:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106378</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TL, Kaplan RM, Grant I, et al. Quality of well-being in late life psychosis. Psychiatry Res. 1996;63:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciolla A, Patterson TL, Wetherell J, et al. Functioning and well-being of middle-aged and older patients with schizophrenia; Measurement with the 36-item short-form (SF-36) health survey. Am J Geriatr Psychiatry. 2003;11:629&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609803</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TL, Shaw W, Semple SJ, et al. Health-related quality of life in older patients with schizophrenia and other psychoses: Relationships among psychosocial and psychiatric factors. Int J Geriatr Psychiatry. 1997;12:452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">9178049</ArticleId></ArticleIdList></Reference><Reference><Citation>Priebe S, Reininghaus U, McCabe R, et al. Factors influencing subjective quality of life in patients with schizophrenia and other mental disorders: A pooled analysis. Schizophr Res. 2010;121:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">20483566</ArticleId></ArticleIdList></Reference><Reference><Citation>Folsom DP, Depp C, Palmer BW, et al. Physical and mental health-related quality of life among older people with schizophrenia. Schizophr Res. 2009;108:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643118</ArticleId><ArticleId IdType="pubmed">19168328</ArticleId></ArticleIdList></Reference><Reference><Citation>Semple SJ, Patterson TL, Shaw WS, et al. The social networks of older schizophrenia patients. Int Psychogeriatr. 1997;9:84&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9195282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram R, Bromet EJ, Eaton WW, et al. The natural course of schizophrenia: A review of first-admission studies. Schizophr Bull. 1992;18:185&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">1621068</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, Rabins PV, Seeman MV, et al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. Am J Psychiatry. 2000;157:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleuler M. In: The Schizophrenic Disorders: Long-term Patient and Family Studies. Clemens SM, translator. New Haven and London: Yale University Press; 1978.</Citation></Reference><Reference><Citation>van Os J, Howard R, Takei N, et al. Increasing age is a risk factor for psychosis in the elderly. Soc Psychiatry Psychiatr Epidemiol. 1995;30:161&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">7491511</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler S, van Os J, de Graaf R, et al. Psychosis risk as a function of age at onset: a comparison between early- and late-onset psychosis in a general population sample. Soc Psychiatry Psychiatr Epidemiol. 2007;42:288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913178</ArticleId><ArticleId IdType="pubmed">17370045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr JB, Alder M, Flynn K, et al. Minor physical anomalies in older patients with late-onset schizophrenia, early-onset schizophrenia, depression, and Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 1997;5:318&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlson GD, Kreger L, Rabins RV, et al. A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry. 1989;146:1568&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">2574011</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, Castle D, Wessely S, et al. A comparative study of 470 cases of early and late-onset schizophrenia. Brit J Psychiat. 1993;163:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett A. Defining psychotic disorders in an aging population. In: Hassett A, Ames D, Chiu E, editors. Psychosis in the Elderly. Oxford: Taylor and Francis; 2005.</Citation></Reference><Reference><Citation>Vahia IV, Palmer BW, Depp C, et al. Late-onset schizophrenia: A subtype of schizophrenia? Acta Psychiatr Scand. 2010 March 20; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939834</ArticleId><ArticleId IdType="pubmed">20199491</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, Mellers J, Petty R, et al. Magnetic resonance imaging volumetric measurements of the superior temporal gyrus, hippocampus, parahippocampal gyrus, frontal and temporal lobes in late paraphrenia. Psychol Med. 1995;25:495&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">7480430</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J, Jernigan T, Archibald S, et al. Quantitative magnetic resonance imaging of the brain in late-life schizophrenia. Am J Psychiatry. 1995;152:447&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">7864275</ArticleId></ArticleIdList></Reference><Reference><Citation>Symonds LL, Olichney JM, Jernigan TL, et al. Lack of clinically significant structural abnormalities in MRIs of older patients with schizophrenia and related psychoses. J Neuropsychiat Clin Neurosci. 1997;9:251&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">9144105</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R, Cox T, Almeida O, et al. White matter signal hyperintensities in the brains of patients with late paraphrenia and the normal community-living elderly. Biol Psychiatry. 1995;38:86&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">7578654</ArticleId></ArticleIdList></Reference><Reference><Citation>Barak Y, Aizenberg D, Mirecki I, et al. Very late-onset schizophrenia-like psychosis: Clinical and imaging characteristics in comparison with elderly patients with schizophrenia. J Nerv Ment Dis. 2002;190:733&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">12436012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes AN, Rabins PV, Slavney PR. Onset of schizophrenia at age 100. Psychosomatics. 2006;47:356&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">16844897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler KS. Demography of paranoid psychosis (Delusional Disorder): A review and comparison with schizophrenia and affective illness. Arch Gen Psychiatry. 1982;39:890&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">7103678</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Association; 2000. Text Revision.</Citation></Reference><Reference><Citation>de Portugal E, Gonz&#xe1;lez N, Miriam V, et al. Gender differences in delusional disorder: Evidence from an outpatient sample. Psychiatry Res. 2010;177:235&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">20334930</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland JRM, Dewey ME, Scott A, et al. Schizophrenia and delusional disorder in older age: Community prevalence, incidence, comorbidity and outcome. Schizophr Bull. 1998;19:153&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">9502553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwell E, Krull AJ, Dimsdale J, et al. Late-onset psychosis with somatic delusions. Psychosomatics. 1994;35:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8134531</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JD, Paulsen JS, Harris MJ, et al. A clinical and neuropsychological comparison of delusional disorder and schizophrenia. J Neuropsychiat Clin Neurosci. 1996;8:281&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">8854299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler S, Davis KL. The genetics and biochemistry of paranoid schizophrenia and other paranoid psychoses. Schizophr Bull. 1981;7:689&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">7034192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostling S, Gustafson D, Blennow K, et al. Psychotic symptoms in a population-based sample of 85-year-old individuals with dementia. JGeriatr Psychiatry Neurol. 2010 Jul 2; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">20601646</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer&#x2019;s disease. Am J Psychiatry. 1996;153:1438&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">8890677</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Caligiuri MP, Peavy G, Salmon DP, et al. Neuromotor abnormalities and risk for psychosis in Alzheimer&#x2019;s disease. Neurology. 2003;61:954&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">14557567</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Finkel SI. Psychosis of Alzheimer&#x2019;s Disease and related dementias: Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bennett DA, Graff-Radford NR, et al. Assessment and familial aggregation of psychosis in Alzheimer&#x2019;s disease from the National Institute on Aging Late Onset Alzheimer&#x2019;s Disease Family Study. Brain. 2010;133:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Wragg RE, Salmon DP, et al. Cognitive deficits of patients with Alzheimer&#x2019;s disease with and without delusions. Am J Psychiatry. 1992;149:184&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS. Psychosis of Alzheimer&#x2019;s disease: Clinical characteristics and history. J Psychiatr Res. 2004;38:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer&#x2019;s disease: Prevalence and clinical correlates. Int J Geriatr Psychiatry. 2000;15:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, et al. Psychotic symptoms in Alzheimer Disease: Evidence for a distinct phenotype. Molecular Psychiatry. 2003;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer&#x2019;s disease: A review. J Alzheimers Dis. 2010;19:761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DY, Choo IH, Kim KW, et al. White matter changes associated with psychotic symptoms in Alzheimer&#x2019;s disease patients. J Neuropsychiatry Clin Neurosci. 2006;18:191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, et al. Prediction of psychosis onset in Alzheimer disease: The role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry. 2006;14:352&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer&#x2019;s disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009;21:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer&#x2019;s disease: The Neuropsychiatry Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto N, Ikeda M, Fukuhara R, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord. 2007;23:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">17299264</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Diaz C, Levy ML, et al. Neuropsychiatric syndromes in neurodegenerative diseases: Frequency and significance. Seminars in Clinical Neuropsychiatry. 1996;1:241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320427</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer&#x2019;s disease: Prospective analyses from the predictors study. Neurology. 1994;44:2300&#x2013;2307.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991116</ArticleId></ArticleIdList></Reference><Reference><Citation>Magni E, Binetti G, Bianchetti A, et al. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol. 1996;9:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Krueger KR, Kamenetsky JM, et al. Hallucinations and mortality in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:984&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Katz IR, Park S, et al. Psychosis of Alzheimer Disease: Validity of the construct and response to risperidone. Am J Geriatr Psychiatry. 2003;11:414&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">12837670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotrla KJ, Chacko RC, Harper RG, et al. Clinical variables associated with psychosis in Alzheimer&#x2019;s disease. Am J Psychiatry. 1995;152:1377&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer&#x2019;s disease. J Neuropsychiat Clin Neurosci. 1991;3:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Wilson RS, Beckett LA, et al. Psychotic symptoms and physically aggressive behavior in Alzheimer&#x2019;s disease. JAGS. 1997;45:1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288014</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology. 2005;65:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson&#x2019;s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164:1491&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137166</ArticleId><ArticleId IdType="pubmed">17898337</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67:996&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">20697051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson&#x2019;s disease: Report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">17266092</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti MJ, Tolosa E, de la Cerda A. Dementia in Parkinson&#x2019;s disease. J Neurol. 2007;254:41&#x2013;48.</Citation></Reference><Reference><Citation>Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson&#x2019;s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11376470</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Cummins JL, et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study. Arch Neurol. 1999;56:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">10328255</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277623</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson&#x2019;s disease: A population-based, prospective study. J AmGeriatr Soc. 2000;48:938&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10968298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahama Y, Okina T, Suzuki N, et al. Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry. 2007;15:961&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">17974867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Holmes C, McKeith IG, et al. Psychiatric morbidity in dementia with lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer&#x2019;s disease. Am J Psychiatry. 1999;156:1039&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Cummings JL. Neuropsychiatric aspects of dementia with Lewy bodies. Curr Psychiatry Rep. 1999;1:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11122909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci M, Guidoni SV, Sepe-Monti M, et al. Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer&#x2019;s disease (AD) Arch Gerontol Geriatr. 2009;49:e101&#x2013;e104.</Citation><ArticleIdList><ArticleId IdType="pubmed">19084284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahama Y, Okina T, Suzuki N, et al. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain. 2010;133:557&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">19920063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sable JA, Jeste DV. Antipsychotic treatment for late-life schizophrenia. Current Psychiatry Reports. 2002;4:299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">12126599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohen I, Lester PE, Lam S. Antipsychotic treatments for the elderly: Efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat. 2010;24:47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846120</ArticleId><ArticleId IdType="pubmed">20361061</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry. 1996;57:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626369</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry. 1999;7:132&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322240</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000;15:506&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11:638&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609804</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Streim JE, Carpenter D. Expert consensus guidelines for using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65:5&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">14994733</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunpongpaisal S, Ahmed I, Aqeel N, et al. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev. 2009;2</Citation><ArticleIdList><ArticleId IdType="pubmed">12804499</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell AJ. Drug treatment as a cause of falls in old age: A review of the offending agents. Drugs &amp; Aging. 1991;1:289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">1794021</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61:27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10739328</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Journal of the American Geriatric Society. 1999;47:716&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">10366172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12046641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Meyer J, Mudaliar S, et al. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. J Clin Psychiatry. 2010 in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">21062616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Meyer JM, Mudaliar S, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008;100:70&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699769</ArticleId><ArticleId IdType="pubmed">18206351</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TL, McKibbin CL, Taylor MJ, et al. Functional Adaptation Skills Training (FAST): A pilot psychosocial intervention study in middle-aged and older patients with chronic psychotic disorders. Am J Geriatr Psychiatry. 2003;11:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12527536</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TL, McKibbin C, Mausbach BT, et al. Functional Adaptation Skills Training (FAST): A randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophr Res. 2006;86:291&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16814526</ArticleId></ArticleIdList></Reference><Reference><Citation>Mausbach BT, Cardenas V, McKibbin CL, et al. Reducing emergency medical service use in patients with chronic psychotic disorders: Results from the FAST intervention study. Behav Res Ther. 2008;46:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2249612</ArticleId><ArticleId IdType="pubmed">17997395</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson TL, Bucardo J, McKibbin CL, et al. Development and pilot testing of a new psychosocial intervention for older Latinos with chronic psychosis. Schizophr Bull. 2005;31:922&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">16037481</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuaid JR, Granholm E, McClure FS, et al. Development of an integrated cognitive-behavioral, social skills training intervention for older patients with schizophrenia. Journal of Psychotherapy Practice and Research. 2000;9:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330598</ArticleId><ArticleId IdType="pubmed">10896740</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm E, McQuaid JR, McClure FS, et al. A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. Am J Psychiatry. 2005;162:520&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">15741469</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm E, McQuaid JR, McClure FS, et al. Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. J Clin Psychiatry. 2007;68:730&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">17503982</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm E, McQuaid JR, Link PC, et al. Neuropsychological predictors of functional outcome in Cognitive Behavioral Social Skills Training for older people with schizophrenia. Schizophr Res. 2008;100:133&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2352154</ArticleId><ArticleId IdType="pubmed">18222648</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmerson LC, Granholm E, Link PC, et al. Insight and treatment outcome with cognitive-behavioral social skills training for older people with schizophrenia. J Rehabil Res Dev. 2009;46:1053&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157862</ArticleId></ArticleIdList></Reference><Reference><Citation>Twamley EW, Jeste DV, Bellack AS. A review of cognitive training in schizophrenia. Schizophr Bull. 2003;29:359&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">14552510</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk SR, Twamley EW, Sitzer DI, et al. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007;164:1791&#x2013;1802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3634703</ArticleId><ArticleId IdType="pubmed">18056233</ArticleId></ArticleIdList></Reference><Reference><Citation>Twamley EW, Padin DS, Bayne KS, et al. Work rehabilitation for middle-aged and older people with schizophrenia: A comparison of three approaches. J Nerv Ment Dis. 2005;193:596&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">16131942</ArticleId></ArticleIdList></Reference><Reference><Citation>Twamley EW, Narvaez JM, Becker DR, et al. Supported employment for middle-aged and older people with schizophrenia. Am J Psychiatr Rehabil. 2008;11:76&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638571</ArticleId><ArticleId IdType="pubmed">19212460</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman C, Jeste DV, Meyer RE, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674239</ArticleId><ArticleId IdType="pubmed">18494535</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Blazer D, Casey DE, et al. ACNP White Paper: Update on the use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553721</ArticleId><ArticleId IdType="pubmed">17637610</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Ismail MS, Dagerman K, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer&#x2019;s disease trial. Schizophr Bull. 2003;29:57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry. 1999;60:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDeyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeh N, Gyulai L, Weintraub D, et al. Pharmacologic management of psychosis in the elderly: A critical review. J Geriatr Psychiatry Neurol. 2003;16:213&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">14653429</ArticleId></ArticleIdList></Reference><Reference><Citation>Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13:722&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">16085789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">1970586</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeks TW, Jeste DV. Beyond the Black Box: What is the role for antipsychotics in dementia? Curr Psychiatr. 2008;7:50&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2641030</ArticleId><ArticleId IdType="pubmed">19221607</ArticleId></ArticleIdList></Reference><Reference><Citation>The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson&#x2019;s disease. Lancet. 1999;353:2041&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pubmed">10376627</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson&#x2019;s disease. N Engl J Med. 1999;340:757&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072410</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson&#x2019;s disease patients: A double-blind labeled study of 3 months&#x2019; duration. Mov Disord. 2007;22:313&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">17034006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson&#x2019;s disease. Mov Disord. 2005;20:958&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pubmed">15800937</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319699</ArticleId></ArticleIdList></Reference><Reference><Citation>Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson&#x2019;s disease patients. The Lancet. 1994;343:1370&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">7514254</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieling H, Hillemacher T, Ziegenbein M, et al. Treating dopamimetic psychosis in Parkinson&#x2019;s disease: Structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17070675</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Fairbaim A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305:673&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1882909</ArticleId><ArticleId IdType="pubmed">1356550</ArticleId></ArticleIdList></Reference><Reference><Citation>Culo S, Mulsant BH, Rosen J, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: A randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010 Jul 9; [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">20625270</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162:1996&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Nonpharmacologic interventions for psychotic symptoms in dementia. J Geriatr Psychiatry Neurol. 2003;16:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">14653430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalon L, Gum AM, Feliciano L, et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: A systematic review. Arch Intern Med. 2006;166:2182&#x2013;2188.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101935</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21492498</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.</ArticleTitle><Pagination><StartPage>1515</StartPage><EndPage>1519</EndPage><MedlinePgn>1515-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610211000743</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer's disease (AD), but safety warnings abound. Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD. We compared escitalopram and risperidone for psychotic symptoms and agitation associated with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Inpatients with AD, who had been hospitalized because of behavioral symptoms, were recruited to a six-week randomized, double-blind, controlled trial. Participants (n = 40) were randomized to once daily risperidone 1 mg or escitalopram 10 mg.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The NPI total score improved in both groups. Onset was earlier in the risperidone-treated group, but improvement did not significantly differ between groups by study end. Completion rates differed for escitalopram (75%) and risperidone (55%), mainly due to adverse events. There were no adverse events in the escitalopram group, while in the risperidone group two patients suffered severe extrapyramidal symptoms and four patients suffered acute physical illness necessitating transfer to general hospital.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Escitalopram and risperidone did not differ in efficacy in reducing psychotic symptoms and agitation in patients with AD. Completion rates were higher for escitalopram-treated patients. Replication in larger trials with ambulatory patients is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barak</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Abarbanel Mental Health Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. mdybarak@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plopski</LastName><ForeName>Igor</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Tadger</LastName><ForeName>Shelly</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Paleacu</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21492498</ArticleId><ArticleId IdType="doi">10.1017/S1041610211000743</ArticleId><ArticleId IdType="pii">S1041610211000743</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">21461363</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2090-0252</ISSN><JournalIssue CitedMedium="Internet"><Volume>2011</Volume><PubDate><Year>2011</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>International journal of Alzheimer's disease</Title><ISOAbbreviation>Int J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Psychosis in Alzheimer's disease in the national Alzheimer's disease coordinating center uniform data set: clinical correlates and association with apolipoprotein e.</ArticleTitle><Pagination><StartPage>926597</StartPage><MedlinePgn>926597</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">926597</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4061/2011/926597</ELocationID><Abstract><AbstractText>Approximately 50% of late-onset Alzheimer's disease (AD) patients develop psychosis (AD+P), a heritable phenotype associated with more rapid cognitive decline. Prior studies conflict regarding whether apolipoprotein E (APOE) &#x3f5;4 alleles are associated with AD+P, possibly due to small sample sizes, inconsistent diagnostic criteria, and different methodologies to assess psychosis. We used the National Alzheimer's Coordinating Center Uniform Data Set to evaluate the largest uniformly characterized sample of AD+P subjects studied to date for the association of APOE &#x3f5;4 genotype, along with other demographic and clinical variables. Greater cognitive impairment and depressive symptoms were associated with AD+P, while the Caucasian race was protective. Neither APOE &#x3f5;4 carrier status nor allele number was associated with psychosis. The AD+P phenotype is not associated with the APOE &#x3f5;4 genotype. AD+P may represent a useful phenotype for the discovery of non-APOE &#x3f5;4 genetic variation contributing to the risk of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demichele-Sweet</LastName><ForeName>Mary Ann A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213-2593, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Alzheimers Dis</MedlineTA><NlmUniqueID>101525141</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21461363</ArticleId><ArticleId IdType="pmc">PMC3065057</ArticleId><ArticleId IdType="doi">10.4061/2011/926597</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. American Journal of Psychiatry. 2005;162(11):2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the neuropsychiatric inventory caregiver distress scale. Journal of the American Geriatrics Society. 1998;46(2):210&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Archives of Neurology. 2005;62(10):1601&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, et al. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. American Journal of Medical Genetics Part B. 2007;144(7):841&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58(6):907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National institute on aging late onset Alzheimer's disease family study. Brain. 2010;133(4):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. American Journal of Geriatric Psychiatry. 2005;13(7):624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Molecular Psychiatry. 2003;8(4):383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. International Psychogeriatrics. 2009;21(1):78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, DeKosky ST, Sweet RA. Prediction of psychosis onset in Alzheimer disease: the role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. American Journal of Geriatric Psychiatry. 2006;14(4):352&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer's disease: a review. Journal of Alzheimer's Disease. 2010;19(3):761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. Alzheimer Disease and Associated Disorders. 2007;21(3):249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Disease and Associated Disorders. 2006;20(4):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. Journal of Neuropsychiatry and Clinical Neurosciences. 2000;12(2):233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. British Journal of Psychiatry. 1982;140(6):566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Annals of Neurology. 1980;7(5):486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7396427</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA. Geriatric depression scale. Psychopharmacology Bulletin. 1988;24(4):709&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">3249773</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biological Psychiatry. 1989;25(1):39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Kamboh MI, Wisniewski SR, et al. Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology. 2002;15(1):24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11936240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Warren A, Rosenblatt A, et al. The relationship between delusions and depression in Alzheimer's disease. International Journal of Geriatric Psychiatry. 2002;17(6):549&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JME, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County Study. International Journal of Geriatric Psychiatry. 2001;16(11):1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Kodavali C, Weamer EA, et al. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. American Journal of Medical Genetics Part B. 2007;144(8):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818007</ArticleId><ArticleId IdType="pubmed">17525976</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Seltman HJ, Devlin B, et al. Trajectories of cognitive decline in Alzheimer's disease. International Psychogeriatrics. 2010;22(2):281&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834298</ArticleId><ArticleId IdType="pubmed">19781112</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. Journal of the American Medical Association. 1997;277(10):813&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Devlin B, Pollock BG, et al. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Molecular Psychiatry. 2005;10(11):1026&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21418522</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1582-4934</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of cellular and molecular medicine</Title><ISOAbbreviation>J Cell Mol Med</ISOAbbreviation></Journal><ArticleTitle>Cerebral correlates of psychotic syndromes in neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>995</StartPage><EndPage>1012</EndPage><MedlinePgn>995-1012</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1582-4934.2011.01311.x</ELocationID><Abstract><AbstractText>Psychosis has been recognized as a common feature in neurodegenerative diseases and a core feature of dementia that worsens most clinical courses. It includes hallucinations, delusions including paranoia, aggressive behaviour, apathy and other psychotic phenomena that occur in a wide range of degenerative disorders including Alzheimer's disease, synucleinopathies (Parkinson's disease, dementia with Lewy bodies), Huntington's disease, frontotemporal degenerations, motoneuron and prion diseases. Many of these psychiatric manifestations may be early expressions of cognitive impairment, but often there is a dissociation between psychotic/behavioural symptoms and the rather linear decline in cognitive function, suggesting independent pathophysiological mechanisms. Strictly neuropathological explanations are likely to be insufficient to explain them, and a large group of heterogeneous factors (environmental, neurochemical changes, genetic factors, etc.) may influence their pathogenesis. Clinico-pathological evaluation of behavioural and psychotic symptoms (PS) in the setting of neurodegenerative and dementing disorders presents a significant challenge for modern neurosciences. Recognition and understanding of these manifestations may lead to the development of more effective preventive and therapeutic options that can serve to delay long-term progression of these devastating disorders and improve the patients' quality of life. A better understanding of the pathophysiology and distinctive pathological features underlying the development of PS in neurodegenerative diseases may provide important insights into psychotic processes in general.</AbstractText><CopyrightInformation>&#xa9; 2011 The Author Journal of Cellular and Molecular Medicine &#xa9; 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jellinger</LastName><ForeName>Kurt A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, Vienna, Austria. kurt.jellinger@univie.ac.at</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cell Mol Med</MedlineTA><NlmUniqueID>101083777</NlmUniqueID><ISSNLinking>1582-1838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054022" MajorTopicYN="N">Cerebrum</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21418522</ArticleId><ArticleId IdType="pmc">PMC4365880</ArticleId><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01311.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation> Wikipedia. Dementia.  http://enwikipediaorg/wiki/Dementia 2010; accessed January 17, 2011.</Citation></Reference><Reference><Citation>Piccininni M, Di Carlo A, Baldereschi M, et al. Behavioral and psychological symptoms in Alzheimer&#x2019;s disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord. 2005;19:276&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">15775717</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2003;15:346&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692822</ArticleId><ArticleId IdType="pubmed">19104448</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstl H, Besthorn C, Geiger-Kabisch C, et al. Psychotic features and the course of Alzheimer&#x2019;s disease: relationship to cognitive, electroencephalographic and computerized tomography findings. Acta Psychiatr Scand. 1993;87:395&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8356890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer&#x2019;s disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8:301&#x2013;8. discussion 51&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154579</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez M, Gobartt AL, Balana M. Behavioural symptoms in patients with Alzheimer&#x2019;s disease and their association with cognitive impairment. BMC Neurol. 2010;10:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955564</ArticleId><ArticleId IdType="pubmed">20920205</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry. 2004;161:843&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15121649</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Massimo L, Powers C, Moore P, et al. Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2009;27:96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820577</ArticleId><ArticleId IdType="pubmed">19158440</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Finkel SI. Psychosis of Alzheimer&#x2019;s disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu MJ, Chen TF, Yip PK, et al. Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc. 2006;105:556&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877235</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward M, Brodaty H, Boundy K, et al. Does executive impairment define a frontal variant of Alzheimer&#x2019;s disease? Int Psychogeriatr. 2010;22:1280&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20719041</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson&#x2019;s disease: a retrospective autopsy study. Lancet Neurol. 2005;4:605&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16168928</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozeat S, Gregory CA, Ralph MA, et al. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer&#x2019;s disease? J Neurol Neurosurg Psychiatry. 2000;69:178&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737062</ArticleId><ArticleId IdType="pubmed">10896690</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8:497&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert PH, Verhey FR, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005;20:490&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310680</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeks TW, Ropacki SA, Jeste DV. The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiatry. 2006;19:581&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012935</ArticleId></ArticleIdList></Reference><Reference><Citation>Garre-Olmo J, Lopez-Pousa S, Vilalta-Franch J, et al. Grouping and trajectories of the neuropsychiatric symptoms in patients with Alzheimer&#x2019;s disease, part I: symptom clusters. J Alzheimers Dis. 2010;22:1157&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">20930289</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, de Vugt ME, Lousberg R, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord. 2003;15:99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566599</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24:457&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Diaz C, Levy M, et al. Neuropsychiatric syndromes in neurodegenerative disease: frequency and significance. Semin Clin Neuropsychiatry. 1996;1:241&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Krueger KR, Kamenetsky JM, et al. Hallucinations and mortality in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:984&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286442</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011 ; doi: 10.1007/s00401-011-0821-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21455688</ArticleId></ArticleIdList></Reference><Reference><Citation>International Psychogeriatric Association. BPSD: introduction to behavioral and psychological symptoms of dementia. http://ipa-onlineorg/ipaonlinev3/ipaprograms/taskforces/bpsd/introasp. 2010; accessed February 24, 2011.</Citation></Reference><Reference><Citation>Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Draper B, Saab D, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry. 2001;16:504&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11376467</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer&#x2019;s disease. Neurology. 1996;46:130&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord. 2006;21:2140&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17029272</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res. 2010;7:158&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19715553</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS. Psychosis of Alzheimer&#x2019;s disease: clinical characteristics and history. J Psychiatr Res. 2004;38:105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson&#x2019;s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17266092</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G, Alves G. Epidemiology of psychosis in Parkinson&#x2019;s disease. J Neurol Sci. 2010;289:12&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19740486</ArticleId></ArticleIdList></Reference><Reference><Citation>Molho ES, Factor SA. Psychosis. In: Pfeiffer RF, Bodis-Wollner I, editors. Current clinical neurology: Parkinson&#x2019;s disease and nonmotor dysfunction. Totowa, NJ: Humana Press; 2005: 49&#x2013;74.</Citation></Reference><Reference><Citation>Williams DR, Poewe W. Lesions associated with visual hallucinations and psychoses. In: Halliday G, Barker RA, Rowe DB, editors. Non-dopamine lesions in Parkinson&#x2019;s disease. Oxford, New York: Oxford University Press; 2011: 242&#x2013;60.</Citation></Reference><Reference><Citation>Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson&#x2019;s disease. Mov Disord. 2009;24:2175&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787875</ArticleId><ArticleId IdType="pubmed">19768724</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson&#x2019;s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16:528&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11376470</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub D, Mamikonyan E. Neuropsychiatric symptoms in Parkinson&#x2019;s disease dementia. In: Emre M, editor. Cognitive impairment and dementia in Parkinson&#x2019;s disease. Oxford, UK: Oxford University Press; 2010: 45&#x2013;64.</Citation></Reference><Reference><Citation>Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson&#x2019;s disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand. 2005;112:201&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16095475</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Cummings JL. Neuropsychiatric features of dementia with Lewy bodies. In: O&#x2019;Brien J, McKeith I, Ames D, Chiu E, editors. Dementia with Lewy bodies. London: Taylor &amp; Francis; 2006: 73&#x2013;94.</Citation></Reference><Reference><Citation>Byrne EJ, Lennox G, Lowe J, et al. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry. 1989;52:709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1032020</ArticleId><ArticleId IdType="pubmed">2545827</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahama Y, Okina T, Suzuki N, et al. Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry. 2007;15:961&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17974867</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneczky R, Drzezga A, Boecker H, et al. Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord. 2008;25:531&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18477846</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard M, van Reekum R, Cohen T. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 2000;12:425&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11083160</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc. 2010;58:330&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875937</ArticleId><ArticleId IdType="pubmed">20374406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde (About a peculiar disease of the cerebral cortex) Allgem Z Psychiatr. 1907;64:146&#x2013;8.</Citation></Reference><Reference><Citation>Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer&#x2019;s disease: a natural history study. J Am Geriatr Soc. 1996;44:1078&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">8790235</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel BF, Luciani V, Geda YE, et al. [In Alzheimer&#x2019;s disease, the clinical expression of behavioral and psychological signs and symptoms is early and specific of neuropathological stages] Encephale. 2010;36:314&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">20850603</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;lden W. &#xdc;ber anatomische Befunde und klinische Verlaufsformen bei senilen Psychosen (About anatomical findings and clinical types of senile psychoses). Univ. Hamburg Medical School: Thesis, 1946.</Citation></Reference><Reference><Citation>Schreinzer D, Ballaban T, Brannath W, et al. Components of behavioral pathology in dementia. Int J Geriatr Psychiatry. 2005;20:137&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">15660411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer&#x2019;s disease. Biol Psychiatry. 1991;29:224&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2015329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer&#x2019;s disease. Am J Psychiatry. 1999;156:1039&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10401449</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Maertens K, Marien P, et al. Behavioural and neuropsychological correlates of frontal lobe features in dementia. Psychol Med. 2006;36:1173&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16700962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer&#x2019;s disease: review of the brain decade. Psychosomatics. 2003;44:388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">12954913</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">11844739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol. 2000;48:868&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117543</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostling S, Gustafson D, Blennow K, et al. Psychotic symptoms in a population-based sample of 85-year-old individuals with dementia. J Geriatr Psychiatry Neurol. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20601646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostling S, Borjesson-Hanson A, Skoog I. Psychotic symptoms and paranoid ideation in a population-based sample of 95-year-olds. Am J Geriatr Psychiatry. 2007;15:999&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056818</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstl H, Burns A, Levy R, et al. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer&#x2019;s disease. Br J Psychiatry. 1994;165:53&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7953058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, et al. Prediction of psychosis onset in Alzheimer disease: the role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry. 2006;14:352&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer&#x2019;s disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009;21:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002;15:445&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151841</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer&#x2019;s disease. IV: disorders of behaviour. Br J Psychiatry. 1990;157:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397368</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer&#x2019;s disease. III: disorders of mood. Br J Psychiatry. 1990;157:81&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397367</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EH, Drevets WC, Burke WJ. The nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol. 1988;1:16&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">3266997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Bannister CL, Patel A, et al. Classification of psychotic symptoms in dementia sufferers. Acta Psychiatr Scand. 1995;92:63&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7572250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang JP, Tsai SJ, Yang CH, et al. Persecutory delusions in dementia. J Clin Psychiatry. 1999;60:550&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485638</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Madrinan G, Cook SE, Saxton JA, et al. Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. Am J Geriatr Psychiatry. 2004;12:449&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353383</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitani E, Francescani A, Spinnler H. Are hallucinations and extrapyramidal signs associated with a steeper cognitive decline in degenerative dementia patients? Neurol Sci. 2007;28:245&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">17972038</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Mayeux R, Sano M, et al. Predictors of disease course in patients with probable Alzheimer&#x2019;s disease. Neurology. 1987;37:1649&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">3658173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, et al. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8:383&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer&#x2019;s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Chithiramohan RN, Bannister C, et al. Paranoid features in the elderly with dementia. Int J Geriatr Psychiatry. 1991;6:155&#x2013;7.</Citation></Reference><Reference><Citation>Chen JY, Stern Y, Sano M, et al. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer&#x2019;s disease. Arch Neurol. 1991;48:1141&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">1953398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 1991;3:371&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821255</ArticleId></ArticleIdList></Reference><Reference><Citation>Deutsch LH, Bylsma FW, Rovner BW, et al. Psychosis and physical aggression in probable Alzheimer&#x2019;s disease. Am J Psychiatry. 1991;148:1159&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">1882992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Brenner RP, et al. Alzheimer&#x2019;s disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology. 1991;41:906&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">2046938</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Wilson RS, Beckett LA, et al. Psychotic symptoms and physically aggressive behavior in Alzheimer&#x2019;s disease. J Am Geriatr Soc. 1997;45:1074&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, et al. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58:907&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, et al. Increased familial risk and genomewide significant linkage for Alzheimer&#x2019;s disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:841&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, et al. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete M, Spaccavento S, Craca A, et al. Neuropsychiatric symptoms and the APOE genotype in Alzheimer&#x2019;s disease. Neurol Sci. 2009;30:367&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19590821</ArticleId></ArticleIdList></Reference><Reference><Citation>Go RC, Perry RT, Wiener H, et al. Neuregulin-1 polymorphism in late onset Alzheimer&#x2019;s disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082692</ArticleId></ArticleIdList></Reference><Reference><Citation>Middle F, Pritchard AL, Handoko H, et al. No association between neuregulin 1 and psychotic symptoms in Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2010;20:561&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182055</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramopoulos D, Fallin MD, Bassett SS. Linkage to chromosome 14q in Alzheimer&#x2019;s disease (AD) patients without psychotic symptoms. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389761</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Pritchard CW, Bentham P, et al. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24:201&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690552</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, Alarcon M, Solomon EC, et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61:1249&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313842</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Donnelly C, Hart D, et al. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer&#x2019;s disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:126&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16967466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009;17:839&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">19910872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Ratcliffe L, Sorour E, et al. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2009;24:1020&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19235789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55:1335&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006;60:141&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476412</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichele-Sweet MA, Klei L, Devlin B, et al. No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol Aging. 2010 ; online 2010&#x2013;11-17: doi:10.1016/j.neurobiolaging.2010.10.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065549</ArticleId><ArticleId IdType="pubmed">21093110</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer&#x2019;s disease: a review. J Alzheimers Dis. 2010;19:761&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotrla KJ, Chacko RC, Harper RG, et al. SPECT findings on psychosis in Alzheimer&#x2019;s disease. Am J Psychiatry. 1995;152:1470&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7573586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 1995;7:476&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8555751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrini P, Furey ML, Graff-Radford N, et al. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer&#x2019;s disease: clinical implications. Am J Psychiatry. 1996;153:1261&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8831432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Lee L, Dinov ID, et al. Cerebral correlates of psychotic symptoms in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2000;69:167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737034</ArticleId><ArticleId IdType="pubmed">10896687</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran EK, Becker JA, Satlin A, et al. Psychosis of Alzheimer&#x2019;s disease: gender differences in regional perfusion. Neurobiol Aging. 2008;29:1218&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17408808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanctot KL, Herrmann N, Nadkarni NK, et al. Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch Neurol. 2004;61:1731&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano S, Yamashita F, Matsuda H, et al. Relationship between delusions and regional cerebral blood flow in Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2006;21:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16254426</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff RT, Venneri A, Gemmell HG, et al. HMPAO SPECT imaging of Alzheimer&#x2019;s disease patients with similar content-specific autobiographic delusion: comparison using statistical parametric mapping. J Nucl Med. 2000;41:1451&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10994722</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Brown CV, Mandelkern MA, et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer&#x2019;s disease. Am J Psychiatry. 2003;160:341&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12562582</ArticleId></ArticleIdList></Reference><Reference><Citation>Geroldi C, Bresciani L, Zanetti O, et al. Regional brain atrophy in patients with mild Alzheimer&#x2019;s disease and delusions. Int Psychogeriatr. 2002;14:365&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670058</ArticleId></ArticleIdList></Reference><Reference><Citation>Holroyd S, Shepherd ML, Downs JH., 3rd Occipital atrophy is associated with visual hallucinations in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2000;12:25&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10678508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruen PD, McGeown WJ, Shanks MF, et al. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Brain. 2008;131:2455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669506</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra L, Perri R, Cercignani M, et al. Are the behavioral symptoms of Alzheimer&#x2019;s disease directly associated with neurodegeneration. J Alzheimers Dis. 2010;21:627&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">20555138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DY, Choo IH, Kim KW, et al. White matter changes associated with psychotic symptoms in Alzheimer&#x2019;s disease patients. J Neuropsychiatry Clin Neurosci. 2006;18:191&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SH, Yu CY, Pai MC. The occipital white matter lesions in Alzheimer&#x2019;s disease patients with visual hallucinations. Clin Imaging. 2006;30:388&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101407</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Panchalingam K, Pettegrew JW, et al. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002;23:547&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer&#x2019;s disease. Mech Ageing Dev. 2006;127:158&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16297434</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer&#x2019;s disease. Curr Alzheimer Res. 2008;5:342&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Kerwin J, Perry RH, et al. Visual hallucinations and the cholinergic system in dementia (letter) J Neurol Neurosurg Psychiatry . 1990; 53: 88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014109</ArticleId><ArticleId IdType="pubmed">2154559</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55:1454&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1697897</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, Gedling K, Reading M, et al. Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1995;59:185&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC485998</ArticleId><ArticleId IdType="pubmed">7629537</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Organic delusions: phenomenology, anatomical correlations, and review. Br J Psychiatry. 1985;146:184&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">3156653</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, Marie RM, Chabot B, et al. Neuropsychological and 18FDG-PET studies in a family with idiopathic basal ganglia calcifications. J Neurol Sci. 2007;258:115&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481663</ArticleId></ArticleIdList></Reference><Reference><Citation>Staton RD, Brumback RA, Wilson H. Reduplicative paramnesia: a disconnection syndrome of memory. Cortex. 1982;18:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">7187632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MK, Chen CP, Hope T, et al. Hippocampal neurofibrillary tangle changes and aggressive behaviour in dementia. Neuroreport. 2010;21:1111&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20890229</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63:161&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461859</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes HC, Levy R, Teixeira AL, et al. Neurobiology of apathy in Alzheimer&#x2019;s disease. Arq Neuropsiquiatr. 2008;66:436&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">18641892</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G. Psychosis in Parkinson&#x2019;s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 2008;13:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">18323763</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother. 2010;8:316&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">20869621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66:93&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401853</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson&#x2019;s disease: critique and recommendations. Mov Disord. 2008;23:484&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">18175343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson&#x2019;s disease without dementia. Mov Disord. 2008;23:1889&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">18709682</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G, Soulas T, Zenasni F, et al. The changing face of Parkinson&#x2019;s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:755&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891710</ArticleId><ArticleId IdType="pubmed">20437542</ArticleId></ArticleIdList></Reference><Reference><Citation>Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2001;70:734&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737419</ArticleId><ArticleId IdType="pubmed">11385005</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G, Thobois S, Bonnet AM, et al. Tactile hallucinations in Parkinson&#x2019;s disease. J Neurol. 2002;249:1699&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">12529792</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Wuu J, Curgian L, et al. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson&#x2019;s disease patients. Mov Disord. 2006;21:267&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16161144</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1998;64:533&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170055</ArticleId><ArticleId IdType="pubmed">9576549</ArticleId></ArticleIdList></Reference><Reference><Citation>Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2004;10:253&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120101</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson&#x2019;s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10734005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14:153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16473980</ArticleId></ArticleIdList></Reference><Reference><Citation>Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson&#x2019;s disease: phenomenology and possible origins. Expert Rev Neurother. 2007;7:1731&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18052766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010;25:167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20063433</ArticleId></ArticleIdList></Reference><Reference><Citation>Meppelink AM, de Jong BM, Renken R, et al. Impaired visual processing preceding image recognition in Parkinson&#x2019;s disease patients with visual hallucinations. Brain. 2009;132:2980&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19755518</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP. Mental and behavioral dysfunctions in movement disorders. Totowa, NJ: Humana Press Inc.; 2003. Diagnosis and treatment of hallucinations and delusions in Parkinson&#x2019;s disease. In: B&#xe9;dard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lesp&#xe9;rance P, editors. pp. 369&#x2013;82.</Citation></Reference><Reference><Citation>Verbaan D, van Rooden SM, Visser M, et al. Psychotic and compulsive symptoms in Parkinson&#x2019;s disease. Mov Disord. 2009;24:738&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19133665</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters E. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl. 2006;71:31&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17447413</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauterbach EC. The neuropsychiatry of Parkinson&#x2019;s disease and related disorders. Psychiatr Clin North Am. 2004;27:801&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550293</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1999;67:492&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736593</ArticleId><ArticleId IdType="pubmed">10486397</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Gray CH, Foltynie T, Lewis SJ, et al. Cognitive deficits and psychosis in Parkinson&#x2019;s disease: a review of pathophysiology and therapeutic options. CNS Drugs. 2006;20:477&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">16734499</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Ouyang B, Negron A, et al. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010;75:1773&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995381</ArticleId><ArticleId IdType="pubmed">20962287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramos JR, Ortoll R, et al. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53:1265&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970453</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Wada-Isoe K, Kitayama M, et al. Executive dysfunction in non-demented Parkinson&#x2019;s disease patients with hallucinations. Acta Neurol Scand. 2008;117:255&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17922890</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67:996&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">20697051</ArticleId></ArticleIdList></Reference><Reference><Citation>Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson&#x2019;s disease patients with psychosis. Neurology. 2003;60:1756&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796526</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75:1270&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20921512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Aarsland D. Spectrum of Lewy body dementias: relationship of Parkinson&#x2019;s disease dementia to dementia with Lewy bodies. In: Emre M, editor. Cognitive impairment and dementia in Parkinson&#x2019;s disease. Oxford, UK: Oxford University Press; 2010: 199&#x2013;214.</Citation></Reference><Reference><Citation>Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46:101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17467082</ArticleId></ArticleIdList></Reference><Reference><Citation>Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease comparison groups. Neurology. 1996;47:1148&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909420</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Ser T, Hachinski V, Merskey H, et al. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001;15:31&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ala TA, Yang KH, Sung JH, et al. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer&#x2019;s disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1997;62:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC486689</ArticleId><ArticleId IdType="pubmed">9010394</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Salmon DP, Hansen LA, et al. What best differentiates Lewy body from Alzheimer&#x2019;s disease in early-stage dementia? Brain. 2006;129:729&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, O&#x2019;Brien JT, Swann AG, et al. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer&#x2019;s disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry. 2001;62:46&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11235928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Lowery K, Harrison R, et al. Noncognitive symptoms in Lewy body dementia. In: Perry EK, McKeith IG, Perry EK, editors. Dementia with Lewy bodies. 1st ed. Cambridge, UK: Cambridge Univ. Press; 1996: 67&#x2013;84.</Citation></Reference><Reference><Citation>Stavitsky K, Brickman AM, Scarmeas N, et al. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2006;63:1450&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030662</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori E, Shimomura T, Fujimori M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol. 2000;57:489&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">10768622</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63:2091&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15596755</ArticleId></ArticleIdList></Reference><Reference><Citation>Oinas M, Polvikoski T, Sulkava R, et al. Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study. J Alzheimers Dis. 2009;18:677&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">19625740</ArticleId></ArticleIdList></Reference><Reference><Citation>Boecker H, Ceballos-Baumann AO, Volk D, et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64:984&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620488</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada K, Suyama N, Oguro H, et al. Medication-induced hallucination and cerebral blood flow in Parkinson&#x2019;s disease. J Neurol. 1999;246:365&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10399867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson&#x2019;s disease with FDG PET. Mov Disord. 2004;19:801&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254938</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344511</ArticleId></ArticleIdList></Reference><Reference><Citation>Colloby S, O&#x2019;Brien J. Functional imaging in Parkinson&#x2019;s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17:158&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312279</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien JT, Firbank MJ, Mosimann UP, et al. Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res. 2005;139:79&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">15964748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56:643&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245717</ArticleId></ArticleIdList></Reference><Reference><Citation>Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer&#x2019;s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11976799</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. 1997;24:320&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143472</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T, Ishii K, Hirono N, et al. Occipital glucose metabolism in dementia with Lewy bodies with and without Parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord. 2001;12:194&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244212</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier J, Michel BF, Brenot-Rossi I, et al. Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2002;29:1342&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12271417</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T, Ishii K, Hirono N, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB) Neuroreport. 1999;10:1903&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501530</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63:1409&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505157</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahama Y, Okina T, Suzuki N, et al. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain. 2010;133:557&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">19920063</ArticleId></ArticleIdList></Reference><Reference><Citation>Middelkoop HA, van der Flier WM, Burton EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology. 2001;57:2117&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11739838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson&#x2019;s disease with dementia. Mov Disord. 2010;25:615&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20175186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson&#x2019;s disease with hallucinations and with dementia. J Neurol. 2008;255:1324&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson&#x2019;s disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010;81:650&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965847</ArticleId></ArticleIdList></Reference><Reference><Citation>Teaktong T, Piggott MA, McKeith IG, et al. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res. 2005;161:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15922057</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, et al. Diffuse Lewy body disease and progressive dementia. Neurology. 1988;38:1520&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2843793</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E, Ingraham AO, Irizarry MC, et al. Dementia with Lewy bodies. J Am Geriatr Soc. 1998;46:1449&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaitzakis ME, Christian LM, Moran LB, et al. Dementia and visual hallucinations associated with limbic pathology in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2009;15:196&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">18602855</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102:355&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603811</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapetropoulos S, Lieberman A, Gonzalez J, et al. Can Alzheimer&#x2019;s type pathology influence the clinical phenotype of Parkinson&#x2019;s disease? Acta Neurol Scand. 2005;111:353&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15876335</ArticleId></ArticleIdList></Reference><Reference><Citation>Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson&#x2019;s disease: relationship to dementia and hallucinations. Mov Disord. 2005;20:989&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852364</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane R, Keene J, Gedling K, et al. Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptics use in dementia. In: Perry EK, McKeith IG, Perry EK, editors. Dementia with Lewy bodies. 1st ed. Cambridge, UK: Cambridge Univ. Press; 1996: p. 85&#x2013;98.</Citation></Reference><Reference><Citation>Gomez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology. 1999;53:1284&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">10522886</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempster PA, O&#x2019;Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson&#x2019;s disease: a clinico-pathological study. Brain. 2010;133:1755&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20371510</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks D, Halliday GM. Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull. 2009;78:97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">18804518</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM. Thalamic changes in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2009;15:S152&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20082979</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang DW, Riekse RG, Purganan KM, et al. Lewy body pathology in late-onset familial Alzheimer&#x2019;s disease: a clinicopathological case series. J Alzheimers Dis. 2006;9:235&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer&#x2019;s disease: a clinical and pathologic entity. Neurology. 1990;40:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2153271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen LA. The Lewy body variant of Alzheimer disease. J Neural Transm Suppl. 1997;51:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9470130</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol. 2001;58:186&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176955</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Larson EB, Bolen E, et al. Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry. 2009;17:317&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2742470</ArticleId><ArticleId IdType="pubmed">19307860</ArticleId></ArticleIdList></Reference><Reference><Citation>Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60:1586&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12771246</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine ED, Shoulson I. Psychiatric syndromes in Huntington&#x2019;s disease. Am J Psychiatry. 1983;140:728&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">6221669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF. Huntington&#x2019;s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med. 1994;24:189&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">7890478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Almqvist EW, Lipe H, et al. Familial aggregation of psychotic symptoms in Huntington&#x2019;s disease. Am J Psychiatry. 2000;157:1955&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11097960</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2001;71:310&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737562</ArticleId><ArticleId IdType="pubmed">11511702</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttman M, Alpay M, Chouinard S, et al. Clinical management of psychosis and mood disorders in Huntington&#x2019;s disease. In: B&#xc8;dard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, editors. Mental and behavioral dysfunction in movement disorders. Totowa, NJ: Humana Press; 2003: 409&#x2013;26.</Citation></Reference><Reference><Citation>Julien CL, Thompson JC, Wild S, et al. Psychiatric disorders in preclinical Huntington&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2007;78:939&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117854</ArticleId><ArticleId IdType="pubmed">17178819</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall J, White K, Weaver M, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol. 2007;64:116&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210818</ArticleId></ArticleIdList></Reference><Reference><Citation>van Duijn E, Kingma EM, Timman R, et al. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington&#x2019;s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry. 2008;69:1804&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">19026253</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Paulsen JS, Beglinger LJ, et al. Psychiatric symptoms in Huntington&#x2019;s disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62:1341&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17481592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington&#x2019;s disease. Arch Neurol. 1996;53:493&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblatt A. Neuropsychiatry of Huntington&#x2019;s disease. Dialogues Clin Neurosci. 2007;9:191&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181855</ArticleId><ArticleId IdType="pubmed">17726917</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch EE. The midline and intralaminar thalamic nuclei: anatomic and functional specificity and implications in neurologic disease. Neurology. 2008;71:944&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18794498</ArticleId></ArticleIdList></Reference><Reference><Citation>Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington&#x2019;s disease. Mov Disord. 2001;16:407&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Shapira JS, Woods RJ, et al. Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord. 2008;25:206&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204254</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ. Delusion of pregnancy in frontotemporal lobar degeneration with motor neurone disease (FTLD/MND) Behav Neurol. 2008;19:199&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452457</ArticleId><ArticleId IdType="pubmed">19096144</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Kogoj A. Social behaviour versus psychiatric features of frontotemporal dementia &#x2013; Clinical report of two cases. Psychiatr Danub. 2010;22:179&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">20562743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Lauterbach EC, Sampson SM. An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci. 2008;20:130&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18451185</ArticleId></ArticleIdList></Reference><Reference><Citation>Reischle E, Sturm K, Schuierer G, et al. A case of schizophreniform disorder in frontotemporal dementia (FTD). Psychiatr Prax. 2003;30:S78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">14509045</ArticleId></ArticleIdList></Reference><Reference><Citation>Reischle E, Sturm K, Schuierer G, et al. Frontotemporal dementia presenting as acute late onset schizophrenia. Psychiatr Prax. 2003;30:78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">13130343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerssens CJ, Pijnenburg YA, Schouws S, et al. The development of psychotic symptoms in later life: late-onset schizophrenia or frontotemporal dementia? A case study. Tijdschr Psychiatr. 2006;48:739&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17007480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillo P, Garcin B, Hornberger M, et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010;67:826&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">20625088</ArticleId></ArticleIdList></Reference><Reference><Citation>Velakoulis D, Walterfang M, Mocellin R, et al. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry. 2009;194:298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">19336778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia MC, Kertesz A, Ang LC. Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. Cogn Behav Neurol. 2008;21:107&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541988</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy CT, Kril JJ, Trollor JN, et al. The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol. 2010;6:175&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20212429</ArticleId></ArticleIdList></Reference><Reference><Citation>Claassen DO, Parisi JE, Giannini C, et al. Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol. 2008;21:157&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">18797258</ArticleId></ArticleIdList></Reference><Reference><Citation>Roeber S, Mackenzie IR, Kretzschmar HA, et al. TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol. 2008;116:147&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536926</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Munoz DG, Kusaka H, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 2011;121:207&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052700</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland RH. Schizophrenia and amyotrophic lateral sclerosis. Compr Psychiatry. 1990;31:327&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2201483</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel A, Pilichowska ME, Hemmerlein B, et al. Dementia and psychotic symptoms in amyotrophic lateral sclerosis. Nervenarzt. 1993;64:618&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8413765</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervaux A, Laine H. [The psychiatric forms of Creutzfeldt-Jakob disease] Presse Med. 2003;32:1466&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14534481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall CA, Rummans TA, Aksamit AJ, et al. Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25-year analysis. J Neuropsychiatry Clin Neurosci. 2005;17:489&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16387988</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn NR, Alfonso CA, Young RA, et al. Creutzfeldt-Jakob disease appearing as paranoid psychosis (Letter to the Editor) Am J Psychiatry. 1999;156:2016&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588426</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens EM, Lament R. Psychiatric presentation of Jakob-Creutzfeldt disease. J Clin Psychiatry. 1979;40:445&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">385584</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardri R, DiPaola C, Lajugie C, et al. Depressive disorder with psychotic symptoms as psychiatric presentation of sporadic Creutzfeldt-Jakob disease: a case report. Gen Hosp Psychiatry. 2006;28:452&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidler M, Johnstone EC, Bamber RW, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997;350:908&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9314868</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervaux A, Vicart S, Lopes F, et al. Psychiatric manifestations of a new variant of Creutzfeldt-Jakob disease. Apropos of a case. Encephale. 2001;27:194&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11407273</ArticleId></ArticleIdList></Reference><Reference><Citation>Martindale JL, Geschwind MD, Miller BL. Psychiatric and neuroimaging findings in Creutzfeldt-Jakob disease. Curr Psychiatry Rep. 2003;5:43&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12686001</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Baldinetti F, Buccione I, et al. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer&#x2019;s disease. J Neurol. 2004;251:688&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311344</ArticleId></ArticleIdList></Reference><Reference><Citation>Senanarong V, Cummings JL, Fairbanks L, et al. Agitation in Alzheimer&#x2019;s disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14560060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamboni G, Huey ED, Krueger F, et al. Apathy and disinhibition in frontotemporal dementia: insights into their neural correlates. Neurology. 2008;71:736&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676948</ArticleId><ArticleId IdType="pubmed">18765649</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies &#x2013; response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007;23:307&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356274</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee AK, Falkai PG, Savidge M. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J. 1989;65:358&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2429337</ArticleId><ArticleId IdType="pubmed">2692012</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson&#x2019;s disease, Parkinson&#x2019;s disease dementia, and dementia with Lewy bodies. Mov Disord. 2007;22:S351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18175396</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson&#x2019;s disease. Vol. 25. Mov Disord; 2010. pp. S104&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20187250</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson&#x2019;s disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998;50:515&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484386</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabey JM. Hallucinations and psychosis in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2009;15:S105&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20123547</ArticleId></ArticleIdList></Reference><Reference><Citation>Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav. 2001;70:571&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng AV, Ferrier IN, Morris CM, et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J Neurol Sci. 1991;106:50&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1779239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010;25:167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20063433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori T, Ikeda M, Fukuhara R, et al. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology. 2006;66:935&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567718</ArticleId></ArticleIdList></Reference><Reference><Citation>Diederich NJ, Fenelon G, Stebbins G, et al. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5:331&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19498436</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001;58:209&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176958</ArticleId></ArticleIdList></Reference><Reference><Citation>Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: rostrocaudal distribution. Brain. 1999;122:1449&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Healy MT, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001;58:466&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255451</ArticleId></ArticleIdList></Reference><Reference><Citation>Langlais PJ, Thal L, Hansen L, et al. Neurotransmitters in basal ganglia and cortex of Alzheimer&#x2019;s disease with and without Lewy bodies. Neurology. 1993;43:1927&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">8105420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson&#x2019;s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007;422:228&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17614196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67:416&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20385906</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci. 2004;226:13&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Alafuzoff I, Al-Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008;26:343&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18849605</ArticleId></ArticleIdList></Reference><Reference><Citation>Klugman A, Marshall J, Tabet N. Impact of cerebrovascular pathology on behavioural and neuropsychiatric symptoms in patients with Alzheimer&#x2019;s dementia: findings from a retrospective, naturalistic study. Int J Clin Pract. 2009;63:1024&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">19570120</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002;50:1431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis. 2010;7:112&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20173339</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodward M, Mackenzie IR, Feldman H. High prevalence of multiple brain pathologies in demenmtia (abs.). Alzheimer&#x2019;s &amp; Dem. 2006;2:S426.</Citation></Reference><Reference><Citation>Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007;3:40&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007;257:80&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17324442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010;119:421&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">20204386</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Zaccai J, Matthews FE, et al. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194:212&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19252147</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Musicco M, Padovani A, et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:1026&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">20808086</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow RE, Arnold SE. Psychosis in neurodegenerative disease. Semin Clin Neuropsychiatry. 1996;1:282&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320431</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21407047</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.</ArticleTitle><Pagination><StartPage>362</StartPage><EndPage>373</EndPage><MedlinePgn>362-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3182110563</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">: Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients with psychosis or agitation receive open treatment with risperidone for 16 weeks. Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">: Several design features provide unique strengths to this trial: identification of target symptoms and systematic open antipsychotic treatment with only responders randomized in the discontinuation trial, use of a single antipsychotic medication, two clinically relevant time-points for discontinuation to evaluate the impact of duration of treatment on relapse, exclusion of patients at increased risk of stroke, assessment of several affected symptom domains, and state-of-the-art approaches to assess relapse and handle dropout.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">: This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment. Given the warnings about antipsychotic use in patients with dementia, studies of this type are essential to determine the optimal duration of treatment that confers the greatest benefit to risk ratio and to improve evidence-based treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, NY, USA. dpd3@columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sultzer</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>de la Pena</LastName><ForeName>Danilo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Colon</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schimming</LastName><ForeName>Corbett</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021488-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488-05</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488-05S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG17761</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488-03</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021488-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028761" MajorTopicYN="Y">Withholding Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21407047</ArticleId><ArticleId IdType="mid">NIHMS274784</ArticleId><ArticleId IdType="pmc">PMC3146556</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3182110563</ArticleId><ArticleId IdType="pii">S1064-7481(12)60020-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Devanand DP, Jacobs DM, Tang M-X, et al. The course of psychopathologic symptoms in mild to moderate Alzheimer&#x2019;s disease. Arch Gen Psychiatry. 1997;54:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007;64(12):1755&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690610</ArticleId><ArticleId IdType="pubmed">18071039</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm A, Michel M, Stern GA, et al. The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist. 1999;39(6):668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650676</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovner BW, Steele CD, Shmuely Y, et al. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc. 1996;44(1):7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health. 2009;13:512&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">19629775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Brown R, Fossey J, et al. Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (The CALM-AD trial) Am J Geriatr Psychiatry. 2009;17(9):726&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">19700946</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz I, de Deyn PP, Mintzer J, et al. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer&#x2019;s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471598</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled, dose-comparison trial of haloperidol treatment for psychosis and disruptive behaviors in Alzheimer&#x2019;s disease. Am J Psychiatry. 1998;155:1512&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>DeDeyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084637</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JW, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with alzheimer disease in nursing care facilities. Arch Gen Psychiaty. 2000;57:2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">17974864</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846102</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157(7):1150&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pubmed">10873925</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. New Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Raivio MM, Laurie JV, Strandberg TE, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15:416&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463191</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoni-Wastila L, Ryder PT, Qian J, et al. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17:417&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773714</ArticleId><ArticleId IdType="pubmed">19390299</ArticleId></ArticleIdList></Reference><Reference><Citation>Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. New Engl J Med. 1992;327:168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">1608408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz D, Mallya A. Discontinuation of a psychogeriatric program for nursing home residents: psychotropic medication changes and behavioral reactions. J Appl Gerontol. 1992;11(1):50&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10116945</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapa PB, Meador KG, Gideon P, et al. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc. 1994;42(3):280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalised dementia patients, results of a doubleblind baseline-treatment-controlled pilot study. J Geriatric Psych Neurol. 1997;10:119&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9322135</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz GJ, Tariot PN, Mead K, et al. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry. 1995;3:290&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">28531062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruths S, Straand J, Nygaard HA, et al. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. J Am Geriatr Soc. 2004;52(10):1737&#x2013;1743.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J, Lipson S, Werner P, et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999;159(15):1733&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">10448776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psych. 2004;65:114&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Margallo LM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing to take or discontinued from treatment with neuroleptics (the DARTAD trial) PLoS Med. 2008;5:e76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276521</ArticleId><ArticleId IdType="pubmed">18384230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, et al. CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer&#x2019;s disease: phase A outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844&#x2013;54. Epub Jun 2, 2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633121</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863&#x2013;1872. Epub Oct 19, 2005. Review. Erratum in: Neurology 2005; 65(12):1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton JM, Salmon DP, Galasko D, et al. Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. Neuropsychology. 2008;22(6):729&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587484</ArticleId><ArticleId IdType="pubmed">18999346</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3. Hoboken, NJ: John Wiley &amp; Sons; 2003.</Citation></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22(9):1068&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">11048905</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT. Clinical global impressions in Alzheimer&#x2019;s clinical trials. Int Psychogeriatr. 1996;8(2):277&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994897</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology. 1979;64:171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">115037</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Peto R, Peto J. Asymptotically efficient rank invariant procedures (with discussion) J R Statist Soc. 1972;135:185&#x2013;207.</Citation></Reference><Reference><Citation>Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984.</Citation></Reference><Reference><Citation>Rosenberg PB, Drye LT, Martin BK, et al. DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842121</ArticleId><ArticleId IdType="pubmed">20087081</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr JP, Thompson JL, Lazar RM, et al. Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">11794192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Algozzine TW, Pitner J, Mintzer J. The use of very-low-dose lorazepam for agitation in elderly persons with dementia. Consult Pharm. 1999;14:868&#x2013;872.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21404128</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Neurobiology of delusions in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>211</StartPage><EndPage>218</EndPage><MedlinePgn>211-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11920-011-0195-1</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is associated with cognitive and functional impairment as well as neuropsychiatric sequelae, including psychotic symptoms such as delusions and hallucinations. Strong evidence supports the need to study delusions separate from hallucinations. Integrating the epidemiology, clinical correlates, and neuropathological and genetic literature for delusions in AD allows us to speculate on etiology and mechanisms. Plaque and tangle deposition in individuals with susceptible alleles of serotonergic, muscarinic, nicotinic, or Apo&#x3b5;4 genes appears to result in disruption of cortical circuitry, culminating in delusions. While delusions in AD correspond to a phenotype distinct from AD without delusions, subtypes of delusions may also define further distinct clinical entities. Persecutory delusions may occur earlier in the illness and have a more significant genetic component than misidentification delusions, which are associated with increased cognitive impairment and advanced dementia. Clearly distinguishing between these two syndromes is essential to making progress in the area of delusions in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Zahinoor</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Centre for Addiction and Mental Health, Geriatric Mental Health Program, University of Toronto, 1001 Queen Street W., Toronto, Ontario, Canada. zahinoor@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Minh-Quan</ForeName><Initials>MQ</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Corinne E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Schweizer</LastName><ForeName>Tom A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Mamo</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21404128</ArticleId><ArticleId IdType="doi">10.1007/s11920-011-0195-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):777-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11723200</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Jul;14(7):573-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16816010</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Jul;165(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7953058</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2001 Sep 11;57(5):805-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11552008</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2009 Feb;21(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):960-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19293172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1998 Sep;7(9):1507-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9700207</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2001 Sep;16(9):866-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11571766</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Sep 28;63(6):1105-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15452311</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Mar 1;45(5):633-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10088051</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):163-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18525289</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2000 Winter;8(1):29-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2004 Nov;11(11):728-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15525293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):123-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16980336</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Feb;149(2):184-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1734737</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2009 Aug;63(4):449-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19460120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2010;19(3):761-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Mar;194(3):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19252147</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2009;17(1):203-11</Citation><ArticleIdList><ArticleId IdType="pubmed">19494443</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2006 Nov;27(11):1595-603</Citation><ArticleIdList><ArticleId IdType="pubmed">16257094</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2002 Jul-Aug;23(4):547-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2011 Mar;24(1):3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20601646</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2006 Jun;2(2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19412462</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2007 Sep 15;260(1-2):132-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17540407</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Alzheimers Dis Other Demen. 2004 Jan-Feb;19(1):19-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15002340</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Dec;57(12):1165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11115331</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1994;27(3-5):194-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7846237</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2004 Aug;61(8):1249-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15313842</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Ment Health. 2009 Jul;13(4):563-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19629781</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2007 Nov;15(11):942-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17846102</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1991 Jun;48(6):619-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1710105</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Feb;176:156-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10755053</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Apr 23;58(8):1182-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11971084</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Jun;19(6):523-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15211529</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2001 Nov;16(11):1037-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11746649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2007;23(1):42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17077632</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2004 Sep-Oct;12(5):449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15353383</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2010 Apr;133(Pt 4):1155-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2004 Jul;56(1):121-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15236409</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2006 Feb;13(2):176-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16490049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dement Geriatr Cogn Disord. 2009;27(2):105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19169029</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2010 May;22(3):346-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20096151</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2022-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2003 Jul-Aug;11(4):414-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12837670</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2003 Jul-Aug;11(4):406-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12837669</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2005 Jan 5;132B(1):9-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15389761</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromolecular Med. 2008;10(4):377-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18696274</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21378378</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5843</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists</Title><ISOAbbreviation>Arch Clin Neuropsychol</ISOAbbreviation></Journal><ArticleTitle>Olfactory deficits in normal aging and Alzheimer's disease in the polish elderly population.</ArticleTitle><Pagination><StartPage>270</StartPage><EndPage>279</EndPage><MedlinePgn>270-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/arclin/acr011</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most frequent cause of dementia. For this reason, a simple, reliable, and inexpensive method of early AD detection is urgently required. The location of neuropathological changes in AD patients indicates the potential diagnostic utility of olfactory tests. The purpose of this study was to compare odor identification performance among Polish subjects and to define the correlation between olfactory deficits and cognitive impairment. Olfactory identification performance was established in AD patients, and young and elderly healthy subjects using the Pocket Smell Test. AD Assessment Scale, the cognitive subscale, was used to evaluate cognitive functioning in the elderly participants. Compared with young subjects, the elderly individuals exhibited a diminished capacity to identify odors. AD patients also identified significantly fewer odors than healthy participants of the same age. In both the AD patients and the elderly control group, odor identification ability correlated with performance in cognitive tests. It may be concluded that deficits in olfactory identification occur in AD and may be valuable as an indicator of this condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Makowska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Grabowska</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Szatkowska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rymarczyk</LastName><ForeName>Krystyna</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Clin Neuropsychol</MedlineTA><NlmUniqueID>9004255</NlmUniqueID><ISSNLinking>0887-6177</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="Y">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21378378</ArticleId><ArticleId IdType="doi">10.1093/arclin/acr011</ArticleId><ArticleId IdType="pii">acr011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21328305</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Antidepressants for agitation and psychosis in dementia.</ArticleTitle><Pagination><StartPage>CD008191</StartPage><MedlinePgn>CD008191</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD008191.pub2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Agitation and psychosis are common among older adults with dementia and are challenging to manage. At the present time, little is known about the efficacy and safety of antidepressant medications when used to treat these symptoms.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the safety and efficacy of antidepressants in treating psychosis and agitation in older adults with Alzheimer's disease, vascular, or mixed dementia.</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">We searched the Cochrane Dementia and Cognitive Improvement Group's Specialized Register which included Cochrane Central Register of Controlled Trials (The Cochrane Library 2009, Issue 3), MEDLINE (January 1950 to October 2009), EMBASE (1980 - October 2009), CINAHL (all dates - October 2009) and PsycINFO (1806 to October 2009).</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two authors independently assessed trial quality and extracted trial data. We collected information on efficacy as measured by dementia neuropsychiatric symptom rating scales and adverse effects. Study authors were contacted for additional information.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Nine trials including a total of 692 individuals were included in the review. Five studies compared SSRIs to placebo and two studies were combined in a meta-analysis for the outcome of change in Cohen-Mansfield Agitation Inventory (CMAI) scores. There was a significant difference between antidepressants and placebo on measures of agitation as reported on the change in CMAI total score (mean difference (MD), -0.89, 95% CI, -1.22 to -0.57) although the results were heavily weighted by one large study. There were no significant differences in change in behavioral symptoms of dementia for SSRIs compared to placebo in the one study that reported on changes in the Neuropsychiatric Inventory and Behavioral Pathology in Dementia scales. One study comparing citalopram to placebo found a significant difference in NPS as measured on the Neurobehavioral Rating Scale (NBRS) after controlling for baseline severity NBRS score although the unadjusted mean difference was not statistically significant (MD - 7.70, 95% CI: -16.57 to 1.17). There was no difference in the rates of trial withdrawals due to adverse events for SSRIs compared to placebo for four studies reporting this outcome (relative risk (RR), 1.07, 95% CI: 0.55 to 2.11) or in the number of trial withdrawals due to any cause in the three studies reporting this outcome (RR, 0.91, 95% CI, 0.65 to 1.26). One study compared the SSRI citalopram to the atypical antipsychotic risperidone and found no difference in NBRS scores, trial withdrawals due to any cause or trial withdrawals due to adverse events although the rates of adverse events as measured on the UKU side effect scale total score were lower for citalopram (MD -2.82, 95% CI: -4.94 to -0.70). Three studies compared SSRIs to typical antipsychotics. In meta-analysis of two studies there was no statistically significant differences in changes in CMAI total scores (MD, 4.66, 95% CI: -3.58 to 12.90). There was also no difference in trial withdrawals due to any cause or due to adverse events for SSRIs compared to typical antipsychotics. One study of trazodone compared to placebo did not find any significant difference in change in CMAI total scores (MD, 5.18, 95% CI, -2.86 to 13.22) or trial withdrawals due to any cause (RR, 1.06, 95% CI, 0.54 to 2.09). Two studies comparing trazodone to haloperidol also failed to detect any difference in change in CMAI total scores (MD, 3.28, 95% CI, -3.28 to 9.85) or trial withdrawals due to any cause (RR, 0.79, 95% CI, 0.43 to 1.46).</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia. The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies. Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics. Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seitz</LastName><ForeName>Dallas P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Queen's University, 752 King Street West, Kingston, Ontario, Canada, K7L 4X3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adunuri</LastName><ForeName>Nikesh</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Sudeep S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Gruneir</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rochon</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>YBK48BXK30</RegistryNumber><NameOfSubstance UI="D014196">Trazodone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014196" MajorTopicYN="N">Trazodone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21328305</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD008191.pub2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21322823</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>110</Volume><Issue>5 Pt 1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>38</EndPage><MedlinePgn>33-8</MedlinePgn></Pagination><Abstract><AbstractText>To assess efficacy and safety of 4-month therapy with rivastigmine in Alzheimer's disease (AD) and to evaluate the burden of caregivers to these patients, 25 AD patients have been studied. Rivastigmine was prescribed internally and 22 patients were assigned to additional antipsychotic therapy at the admission to the hospital. The treatment duration was 16 weeks (12 weeks in the hospital and 4 weeks after the discharge). The study revealed that rivastigmine improved cognitive functions and led to the reduction of psychotic and behavioral disorders in AD patients at the moderate stage of the disease. The inclusion of rivastigmine in the complex treatment of AD patients resulted in the significant reduction in doses of necessary psychotropic drugs and in the complete withdrawal of all antipsychotic drugs in some patients. It should be specifically emphasized that the treatment with rivastigmine of patients with moderate AD and behavioral disorders led to the significant (up to 30%) reduction of the time spent for caregiving, the decrease of burden and the health improvement of caregivers that increase quality of life of both the patient and the family.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kolykhalov</LastName><ForeName>I V</ForeName><Initials>IV</Initials></Author><Author ValidYN="Y"><LastName>Rassadina</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Gavrilova</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Gerasimov</LastName><ForeName>N P</ForeName><Initials>NP</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21322823</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21301322</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5849</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Behavioural pharmacology</Title><ISOAbbreviation>Behav Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.</ArticleTitle><Pagination><StartPage>122</StartPage><EndPage>135</EndPage><MedlinePgn>122-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/FBP.0b013e328343d804</ELocationID><Abstract><AbstractText>5-Hydroxytryptamine 6 (5-HT6) receptors are involved in learning and memory processes and are discussed as promising targets for the treatment of cognitive impairment in central nervous system disorders. A number of 5-HT6 antagonists are currently in the clinical development for schizophrenia and Alzheimer's disease (AD). There is some discrepancy regarding cognitive efficacy in subjects, and only limited data are available on the role of the 5-HT6 receptor in animal models of psychosis. The aim of this study was to investigate the efficacy of the selective 5-HT6 antagonists, Ro-4368554 (1-10 mg/kg, intraperitoneally) and SB-258585 (3-30 mg/kg, intraperitoneally), in animal models for schizophrenia and AD. Both compounds showed cognition-enhancing effects in object recognition, whereas only SB-258585 was able to prevent the scopolamine-induced deficit in the Morris water-maze test. Neither Ro-4368554 nor SB-258585 prevented scopolamine-induced impairment in contextual fear conditioning. Similarly, both compounds were ineffective on MK-801-induced deficits in contextual fear conditioning and spatial working memory. Ro-4368554, but not SB-258585 reversed the apomorphine-induced deficit in prepulse inhibition. Amphetamine-induced hyperlocomotion was not affected by either compound. Taken together, the overall efficacy of Ro-4368554 and SB-258585 in animal models for AD and schizophrenia is rather limited. These data show moderate efficacy in some models for AD but do not support the therapeutic potential of 5-HT6 antagonists for schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gravius</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of In vivo Pharmacology bIn vitro Pharmacology, Merz Pharmaceuticals GmbH, Frankfurt, Germany. andreas.gravius@merz.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laszy</LastName><ForeName>Judit</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pietraszek</LastName><ForeName>Malgorzata</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>S&#xe1;ghy</LastName><ForeName>Katalin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nagel</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chambon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wegener</LastName><ForeName>Nico</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Valastro</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Danysz</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Gyerty&#xe1;n</LastName><ForeName>Istv&#xe1;n</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Behav Pharmacol</MedlineTA><NlmUniqueID>9013016</NlmUniqueID><ISSNLinking>0955-8810</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507242">Ro4368554</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C418570">SB 258585</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097216">serotonin 6 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>CK833KGX7E</RegistryNumber><NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006948" MajorTopicYN="N">Hyperkinesis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21301322</ArticleId><ArticleId IdType="doi">10.1097/FBP.0b013e328343d804</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21057419</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>22 Suppl 1</Volume><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Old age depression and its treatment.</ArticleTitle><Pagination><StartPage>S124</StartPage><EndPage>S125</EndPage><MedlinePgn>S124-5</MedlinePgn></Pagination><Abstract><AbstractText>The Numbers of elderly people are gradually increasing in our society, and mood disorders are progressively increasing among older people. Old age depression may also occur after life events: the death of the significant other, economical reasons, health problems (neurological and/or cardiovascular diseases, arthritis, cancer, nutritional deficiency) and can develop into a depressive state. Old age depression is often mistreated, or undertreated, and also underdiagnosed, and this for several reasons: older people reduce their social relations, depression very often presents as a comorbidity with organic diseases (that cover and mask depressive symptoms); finally,the patient may believe that a depressive state is a normal course of life in older people. Recovering from depression is really feasible both in young/adults and in old people, but in older people we can find a higher frequency of admission to hospital, or mortality or suicidality. The depressive symptoms in old age depression is similar to those in adults, however the following aspects require special care, in order to ensure a correct diagnosis despite the presence of comorbidities: - the mood: in contrast with the young and adult, old people often do not complain about their low mood; - the psychotic simptoms: hypocondriacal and psychotic, including hallucinatory symptoms are often present; - the anxiety symptoms: these are often present together with neuro-sensory symptoms; - the somatic symptoms: the comorbidity with organic diseases can mask and overlap the depressive state; - reduction of congnitive functioning: in these cases, which are quite frequent, it is essential to make a differential diagnosis from "pseudodementia" and "dementia". In conclusion, several factors contribute to the onset of depression in old age, so that we can assert that it is a really a multifactorial disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maier&#xe0;</LastName><ForeName>Enza</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Consultant Mental Health, Dept. Cosenza, Italy. maieraenza@libero.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21057419</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21292041</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9649</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Ageing research reviews</Title><ISOAbbreviation>Ageing Res Rev</ISOAbbreviation></Journal><ArticleTitle>Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type.</ArticleTitle><Pagination><StartPage>404</StartPage><EndPage>412</EndPage><MedlinePgn>404-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arr.2011.01.003</ELocationID><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD) include agitation, aberrant motor behavior, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite impairment. These symptoms have adverse consequences for patients and caregivers, such as greater impairment in activities of daily living, worsening quality of life and earlier institutionalization. While the etiology of BPSD has not been clearly delineated, studies assessing the benefits of acetylcholinesterase inhibitors on BPSD suggest that some of the neuropsychiatric symptoms of dementia such as agitation, apathy and psychosis may represent a specific central cholinergic deficiency syndrome. Biochemical and neuroimaging studies of BPSD in Alzheimer's patients support these pharmacological data. This review discusses the literature describing the association between cholinergic deficiency and manifestations of BPSD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanct&#xf4;t</LastName><ForeName>Krista L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ageing Res Rev</MedlineTA><NlmUniqueID>101128963</NlmUniqueID><ISSNLinking>1568-1637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018678" MajorTopicYN="N">Cholinergic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002799" MajorTopicYN="N">Cholinergic Fibers</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21292041</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2011.01.003</ArticleId><ArticleId IdType="pii">S1568-1637(11)00004-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21266484</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1362-4962</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nucleic acids research</Title><ISOAbbreviation>Nucleic Acids Res</ISOAbbreviation></Journal><ArticleTitle>A high-throughput DNA methylation analysis of a single cell.</ArticleTitle><Pagination><StartPage>e44</StartPage><MedlinePgn>e44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/nar/gkq1357</ELocationID><Abstract><AbstractText>In recent years, the field of epigenetics has grown dramatically and has become one of the most dynamic and fast-growing branches of molecular biology. The amount of diseases suspected of being influenced by DNA methylation is rising steadily and includes common diseases such as schizophrenia, bipolar disorder, Alzheimer's disease, diabetes, atherosclerosis, cancer, major psychosis, lupus and Parkinson's disease. Due to cellular heterogeneity of methylation patterns, epigenetic analyses of single cells become a necessity. One rationale is that DNA methylation profiles are highly variable across individual cells, even in the same organ, dependent on the function of the gene, disease state, exposure to environmental factors (e.g. radiation, drugs or nutrition), stochastic fluctuations and various other causes. Using a polymerase chain reaction (PCR)-slide microreaction system, we present here a methylation-sensitive PCR analysis, the restriction enzyme-based single-cell methylation assay (RSMA), in the analysis of DNA methylation patterns in single cells. This method addresses the problems of cell heterogeneity in epigenetics research; it is comparably affordable, avoids complicated microfluidic systems and offers the opportunity for high-throughput screening, as many single cells can be screened in parallel. In addition to this study, critical principles and caveats of single cell methylation analyses are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kantlehner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Beckman Coulter Biomedical GmbH, Advalytix Products, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchner</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ellwart</LastName><ForeName>Joachim W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Alunni-Fabbroni</LastName><ForeName>Marianna</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nucleic Acids Res</MedlineTA><NlmUniqueID>0411011</NlmUniqueID><ISSNLinking>0305-1048</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.21.-</RegistryNumber><NameOfSubstance UI="D004262">DNA Restriction Enzymes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018899" MajorTopicYN="N">CpG Islands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004262" MajorTopicYN="N">DNA Restriction Enzymes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="Y">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21266484</ArticleId><ArticleId IdType="pmc">PMC3074158</ArticleId><ArticleId IdType="doi">10.1093/nar/gkq1357</ArticleId><ArticleId IdType="pii">gkq1357</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schumacher A, Petronis A. Epigenetics of complex diseases: from general theory to laboratory experiments. Curr. Top. Microbiol. Immunol. 2006;310:81&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909908</ArticleId></ArticleIdList></Reference><Reference><Citation>Le TT, Harlepp S, Guet CC, Dittmar K, Emonet T, Pan T, Cluzel P. Real-time RNA profiling within a single bacterium. Proc. Natl Acad. Sci. USA. 2005;102:9160&#x2013;9164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166617</ArticleId><ArticleId IdType="pubmed">15967986</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims CE, Allbritton NL. Analysis of single mammalian cells on-chip. Lab Chip. 2007;7:423&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">17389958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cluzel P, Surette M, Leibler S. An ultrasensitive bacterial motor revealed by monitoring signaling proteins in single cells. Science. 2000;287:1652&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">10698740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 2005;352:2211&#x2013;2221.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Chen SY, Wiesner RJ, Huang YF. Simple flow cytometric method used to assess lipid accumulation in fat cells. J. Lipid Res. 2004;45:1162&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerjean A, Vieillefond A, Thiounn N, Sibony M, Jeanpierre M, Jouannet P. Bisulfite genomic sequencing of microdissected cells. Nucleic Acids Res. 2001;29:E106&#x2013;E106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60205</ArticleId><ArticleId IdType="pubmed">11691943</ArticleId></ArticleIdList></Reference><Reference><Citation>Easley CJ, Karlinsey JM, Bienvenue JM, Legendre LA, Roper MG, Feldman SH, Hughes MA, Hewlett EL, Merkel TJ, Ferrance JP, et al. A fully integrated microfluidic genetic analysis system with sample-in-answer-out capability. Proc. Natl Acad. Sci. USA. 2006;103:19272&#x2013;19277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748216</ArticleId><ArticleId IdType="pubmed">17159153</ArticleId></ArticleIdList></Reference><Reference><Citation>Toriello NM, Douglas ES, Thaitrong N, Hsiao SC, Francis MB, Bertozzi CR, Mathies RA. Integrated microfluidic bioprocessor for single-cell gene expression analysis. Proc. Natl Acad. Sci. USA. 2008;105:20173&#x2013;20178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629289</ArticleId><ArticleId IdType="pubmed">19075237</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A, Yau P, Virtanen C, Winegarden N, Cheng J, Gingeras T, et al. Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res. 2006;34:528&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345696</ArticleId><ArticleId IdType="pubmed">16428248</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibovitz A, Stinson JC, McCombs WB, III, McCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976;36:4562&#x2013;4569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1000501</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994;22:2990&#x2013;2997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC310266</ArticleId><ArticleId IdType="pubmed">8065911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am. J. Hum. Genet. 2008;82:696&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427301</ArticleId><ArticleId IdType="pubmed">18319075</ArticleId></ArticleIdList></Reference><Reference><Citation>May A, Kirchner R, Muller H, Hartmann P, El Hajj N, Tresch A, Zechner U, Mann W, Haaf T. Multiplex rt-PCR expression analysis of developmentally important genes in individual mouse preimplantation embryos and blastomeres. Biol. Reprod. 2009;80:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18784354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31:3406&#x2013;3415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC169194</ArticleId><ArticleId IdType="pubmed">12824337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister R, Ecker JR. Finding the fifth base: genome-wide sequencing of cytosine methylation. Genome Res. 2009;19:959&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807530</ArticleId><ArticleId IdType="pubmed">19273618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, et al. Identification and investigation of methylated genes in hepatoma. Eur. J. Cancer. 2005;41:1185&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15911243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Enokida H, Kagara I, Kawakami K, Chiyomaru T, Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa M. CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. Int. J. Oncol. 2009;34:1593&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">19424577</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5&#x2032; CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1995;1:686&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585152</ArticleId></ArticleIdList></Reference><Reference><Citation>Mund C, Beier V, Bewerunge P, Dahms M, Lyko F, Hoheisel JD. Array-based analysis of genomic DNA methylation patterns of the tumour suppressor gene p16INK4A promoter in colon carcinoma cell lines. Nucleic Acids Res. 2005;33:e73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087791</ArticleId><ArticleId IdType="pubmed">15860770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A, Trias M, Wiencke JK. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis. 2000;21:2057&#x2013;2064.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta PK, Smith EM, Kim K, Murnane MJ, Smith BD. DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res. 2003;63:1789&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702564</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525&#x2013;4530.</Citation><ArticleIdList><ArticleId IdType="pubmed">7553621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J. Clin. Pathol. 2006;59:921&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1860467</ArticleId><ArticleId IdType="pubmed">16565223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy E, Veress G, Szarka K, Csoma E, Beck Z. Frequent methylation of p16INK4A/p14ARF promoters in tumorigenesis of Epstein&#x2013;Barr virus transformed lymphoblastoid cell lines. Anticancer Res. 2005;25:2153&#x2013;2160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16158958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovatsi L, Georgiou E, Ioannou A, Haitoglou C, Tzimagiorgis G, Tsoukali H, Kouidou S. p16 promoter methylation in Pb2+-exposed individuals. Clin. Toxicol. (Phila) 2010;48:124&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">20199129</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat. Med. 2009;15:1010&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324:1670&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873047</ArticleId><ArticleId IdType="pubmed">19556499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst C, McGowan PO, Deleva V, Meaney MJ, Szyf M, Turecki G. The effects of pH on DNA methylation state: in vitro and post-mortem brain studies. J. Neurosci. Methods. 2008;174:123&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">18656499</ArticleId></ArticleIdList></Reference><Reference><Citation>Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout WM, III, Biniszkiewicz D, Yanagimachi R, Jaenisch R. Epigenetic instability in ES cells and cloned mice. Science. 2001;293:95&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">11441181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann MR, Chung YG, Nolen LD, Verona RI, Latham KE, Bartolomei MS. Disruption of imprinted gene methylation and expression in cloned preimplantation stage mouse embryos. Biol. Reprod. 2003;69:902&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748125</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher A, Doerfler W. Influence of in vitro manipulation on the stability of methylation patterns in the Snurf/Snrpn-imprinting region in mouse embryonic stem cells. Nucleic Acids Res. 2004;32:1566&#x2013;1576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390307</ArticleId><ArticleId IdType="pubmed">15004243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kangaspeska S, Stride B, Metivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, Benes V, Gannon F, Reid G. Transient cyclical methylation of promoter DNA. Nature. 2008;452:112&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322535</ArticleId></ArticleIdList></Reference><Reference><Citation>Subkhankulova T, Gilchrist MJ, Livesey FJ. Modelling and measuring single cell RNA expression levels find considerable transcriptional differences among phenotypically identical cells. BMC Genomics. 2008;9:268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2429916</ArticleId><ArticleId IdType="pubmed">18522723</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suner D, Cigudosa JC, Urioste M, Benitez J, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA. 2005;102:10604&#x2013;10609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1174919</ArticleId><ArticleId IdType="pubmed">16009939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-C, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS ONE. 2008;3:e2698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2444024</ArticleId><ArticleId IdType="pubmed">18628954</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21223356</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>916</EndPage><MedlinePgn>907-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2125.2011.03902.x</ELocationID><Abstract><AbstractText Label="WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT" NlmCategory="BACKGROUND">&#x2022; Several lines of evidence suggest a possible role of 5-HT(6) receptor antagonists in dementia or cognitive dysfunction of schizophrenia. SB-742457 is a potent 5-HT(6) antagonist and has shown efficacy in different animal models of cognitive impairment. It is currently in development as a cognitive enhancer. Risperidone, commonly used to control agitation and psychotic features in both schizophrenia and Alzheimer's disease, is a D(2)/5-HT(2A ) antagonist with low affinity for 5-HT(6) receptors and limited effects on cognitive parameters.</AbstractText><AbstractText Label="WHAT THIS STUDY ADDS" NlmCategory="CONCLUSIONS">&#x2022; As the combination of risperidone and SB-742457 may constitute a reasonable combination in cognitively impaired patients, pharmacodynamic interaction effects were investigated in this study. The only significant drug-drug interaction was a small increase of electroencephalogram (EEG) alpha and beta bands, which might suggest mild arousing activity of SB-742457 on the central nervous system-depressant effects of risperidone. The clinical relevance of these findings in patients remains to be established. Additionally, this study provided an extensive multidimensional pharmacodynamic profile of risperidone in healthy volunteers, showing that this antipsychotic suppresses motor performance (eye-hand coordination, finger tapping and postural stability), alertness, memory and neurophysiological functions (saccadic eye movements and EEG power spectrum).</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Several lines of evidence suggest a possible role of 5-HT(6 ) receptor antagonists in cognitive dysfunction of schizophrenia. Atypical antipsychotics, such as risperidone, are currently used in these disorders. Therefore, the pharmacological interactions between the 5-HT(6) antagonist SB-742457 and risperidone were investigated in the light of possible co-medication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, double-blind, two-way crossover design was used to study the interaction between multiple doses SB-742457 50 mg and a single dose risperidone 2 mg in 18 healthy subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment was well tolerated. The most common adverse event was somnolence in 83% during the combination vs. 50% of subjects after risperidone, 32% after placebo and 11% after SB-742457. Combination treatment produced a statistically significant increase in the maximum plasma concentration of risperidone and had no effect on SB-742457 pharmacokinetics. Risperidone decreased saccadic peak velocity, finger tapping, adaptive tracking, subjective alertness, delayed word recognition and body sway and increased electroencephalogram (EEG) theta power and prolactin. The only pharmacodynamic interaction of risperidone and SB-742457 was an increase of absolute EEG alpha (ratio = 1.25, 95% CI = 1.11, 1.40, P= 0.0004) and beta power (ratio = 1.14, 95% CI = 1.03, 1.27, P= 0.016). No significant effects of SB-742457 alone were found.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The pharmacokinetic interactions between SB-742457 and risperidone detected in this study were not clinically relevant. The increase in EEG alpha and beta power is incompatible with enhanced risperidone activity, but could point to mild arousing effects of the combination. Most pharmacodynamic changes of risperidone are consistent with previously reported data. The potential cognitive effects of SB-742457 remain to be established.</AbstractText><CopyrightInformation>&#xa9; 2011 Centre for Human Drug Research. British Journal of Clinical Pharmacology &#xa9; 2011 The British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liem-Moolenaar</LastName><ForeName>Marieke</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, the Netherlands. mmoolenaar@chdr.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rad</LastName><ForeName>Mandana</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zamuner</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Adam F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Lemme</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Franson</LastName><ForeName>Kari L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>van Gerven</LastName><ForeName>Joop M A</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Pich</LastName><ForeName>Emilio Merlo</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097216">serotonin 6 receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21223356</ArticleId><ArticleId IdType="pmc">PMC3099377</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2125.2011.03902.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7) J Med Chem. 2003;46:2795&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">12825922</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA, Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">17069795</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Huang M, Prus AJ, Dai J, Meltzer HY. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 2007;1134:70&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17207474</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouzet B, Didriksen M, Arnt J. Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav. 2002;71:635&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11888555</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RH, Bos M. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003;46:1273&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646038</ArticleId></ArticleIdList></Reference><Reference><Citation>Routledge C, Bromidge SM, Moss SF, Newman H, Riley G, Hagan JJ. Characterisation of SB-271046: a potent and selective 5-HT6 receptor antagonist. Br J Pharmacol. 2000;130:1606&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1572216</ArticleId><ArticleId IdType="pubmed">10928964</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley ML, Marsden CA, Sleight AJ, Fone KC. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl) 2003;170:358&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">13680084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, Medhurst AD. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol. 2003;64:1295&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourson A, Borroni E, Austin RH, Monsma FJ, Jr, Sleight AJ. Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther. 1995;274:173&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol. 1998;125:1562&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565738</ArticleId><ArticleId IdType="pubmed">9884085</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerard C, Martres MP, Lefevre K, Miquel MC, Verge D, Lanfumey L, Doucet E, Hamon M, el Mestikawy S. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 1997;746:207&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther. 2005;108:320&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16005519</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell MG, Dias R. Memories are made of this (perhaps): a review of serotonin 5-HT(6) receptor ligands and their biological functions. Curr Top Med Chem. 2002;2:643&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052198</ArticleId></ArticleIdList></Reference><Reference><Citation>Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 2008;5:458&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084247</ArticleId><ArticleId IdType="pubmed">18625457</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldenhuys WJ, Van der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother. 2009;9:1073&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">19589055</ArticleId></ArticleIdList></Reference><Reference><Citation>East SZ, Burnet PW, Leslie RA, Roberts JC, Harrison PJ. 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002;45:191&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112397</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick JA, Meador-Woodruff JH. Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain. Schizophr Res. 1999;38:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10427606</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2010 Sep 24. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">20872778</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang ATT, Foley A, Pugh PL, Sunter D, Tong X, Regan C, Dawson LA, Medhurst AD, Upton N. 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer's disease. Alzheimers Dement. 2006;2:S631&#x2013;2.</Citation></Reference><Reference><Citation>Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004;174:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">15205874</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548746</ArticleId></ArticleIdList></Reference><Reference><Citation>de Visser SJ, van der Post JP, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001;51:119&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014436</ArticleId><ArticleId IdType="pubmed">11259983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">10048600</ArticleId></ArticleIdList></Reference><Reference><Citation>Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl):13&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7520903</ArticleId></ArticleIdList></Reference><Reference><Citation>Causon R, Allanson J. Validation of an analytical method for the determination of risperidone and 9-hydroxyrisperidone in human plasma using protein precipitation and liquid chromatography with tandem mass spectrometric detection. 2008. York Bioanalytical Solutions Study Number YAY/047. DNG number: WD2005/00549/00.</Citation></Reference><Reference><Citation>Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol. 1985;20:619&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1400839</ArticleId><ArticleId IdType="pubmed">4091994</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobczak S, Honig A, Schmitt JA, Riedel WJ. Pronounced cognitive deficits following an intravenous L-tryptophan challenge in first-degree relatives of bipolar patients compared to healthy controls. Neuropsychopharmacology. 2003;28:711&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12655316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright BM. A simple mechanical ataxia-meter. J Physiol. 1971;218:27P&#x2013;28P.</Citation><ArticleIdList><ArticleId IdType="pubmed">5130616</ArticleId></ArticleIdList></Reference><Reference><Citation>Liem-Moolenaar M, Gray F, de Visser S, Franson K, Schoemaker R, Schmitt J, Cohen A, van Gerven J. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol. 2010;24:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18755817</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther. 1991;50:172&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1868679</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol. 1999;13:10&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221355</ArticleId></ArticleIdList></Reference><Reference><Citation>de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol. 2007;21:374&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">17092968</ArticleId></ArticleIdList></Reference><Reference><Citation>de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol. 2003;55:39&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884188</ArticleId><ArticleId IdType="pubmed">12534639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijsman HJ, van Gerven JM, Verkes RJ, Schoemaker RC, Pieters MS, Pennings EJ, Hessing TJ, Cohen AF. Saccadic peak velocity and EEG as end-points for a serotonergic challenge test. Hum Psychopharmacol. 2002;17:83&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12404696</ArticleId></ArticleIdList></Reference><Reference><Citation>de Visser SJ, van Gerven JM, Schoemaker RC, Cohen AF. Concentration. effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. Br J Clin Pharmacol. 2001;51:423&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014466</ArticleId><ArticleId IdType="pubmed">11421999</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemme MJ, vd Post JP, Schoemaker RC, Straub M, Cohen AF, van Gerven JM. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension. Br J Clin Pharmacol. 2003;55:518&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884251</ArticleId><ArticleId IdType="pubmed">12814444</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF, van Gerven JM. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. J Psychopharmacol. 2004;18:221&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260911</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steveninck AL. Methods of assessment of central nervous system effects of drugs in man. 1993. Thesis. Leiden University, the Netherlands.</Citation></Reference><Reference><Citation>Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol. 1984;18(Suppl)(1):69S&#x2013;72S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1463351</ArticleId><ArticleId IdType="pubmed">6525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuurman L, Roy C, Schoemaker RC, Hazekamp A, Den Hartigh J, Bender JCME, Verpoorte R, Pinquier J-P, Cohen AF, Van Gerven JMA. Effect of intrapulmonary THC administration in humans. J Psychopharmacol. 2008;22:707&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18515447</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971;10:181&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">5093959</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;47:211&#x2013;8.</Citation></Reference><Reference><Citation>de Haas SL, Schoemaker RC, Van Gerven JMA, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics, and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol. 2010;24:1619&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">19648220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998;88:82&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447860</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew JM. Delinquents and the tapping test. J Clin Psychol. 1977;33:786&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">893714</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt JAJ, Jorissen BL, Sobczak S, van Boxtel MPJ, Hogervorst E, Deutz NEP, Riedel WJ. Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J Psychopharmacol. 2000;14:21&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10757249</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L'examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.</Citation></Reference><Reference><Citation>Liem-Moolenaar M, Zoethout R, de Boer P, Schmidt M, de Kam ML, Cohen A, Franson K, van Gerven JM. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J Psychopharmacol. 2010;24:1681&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19648218</ArticleId></ArticleIdList></Reference><Reference><Citation>Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol. 1999;39:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">10073330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol. 1999;48:323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014341</ArticleId><ArticleId IdType="pubmed">10510142</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">16003291</ArticleId></ArticleIdList></Reference><Reference><Citation>Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, Prieto D, Palomo T. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry. 2006;163:488&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513871</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol. 2004;18:156&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15260903</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper NR, Croft RJ, Dominey SJ, Burgess AP, Gruzelier JH. Paradox lost? Exploring the role of alpha oscillations during externally vs. internally directed attention and the implications for idling and inhibition hypotheses. Int J Psychophysiol. 2003;47:65&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12543447</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Post JP, Schram MT, Schoemaker RC, Pieters MS, Fuseau E, Pereira A, Baggen S, Cohen AF, van Gerven JM. CNS effects of sumatriptan and rizatriptan in healthy female volunteers. Cephalalgia. 2002;22:271&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">12100089</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol. 2005;59:495&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884839</ArticleId><ArticleId IdType="pubmed">15842547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21159998</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0111</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Molecular pharmacology</Title><ISOAbbreviation>Mol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.</ArticleTitle><Pagination><StartPage>618</StartPage><EndPage>626</EndPage><MedlinePgn>618-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1124/mol.110.067488</ELocationID><Abstract><AbstractText>Dual orthosteric agonists of metabotropic glutamate 2 (mGlu2) and mGlu3 receptors are being developed as novel antipsychotic agents devoid of the adverse effects of conventional antipsychotics. Therefore, these drugs could be helpful for the treatment of psychotic symptoms associated with Alzheimer's disease (AD). In experimental animals, the antipsychotic activity of mGlu2/3 receptor agonists is largely mediated by the activation of mGlu2 receptors and is mimicked by selective positive allosteric modulators (PAMs) of mGlu2 receptors. We investigated the distinct influence of mGlu2 and mGlu3 receptors in mixed and pure neuronal cultures exposed to synthetic &#x3b2;-amyloid protein (A&#x3b2;) to model neurodegeneration occurring in AD. The mGlu2 receptor PAM, N-4'-cyano-biphenyl-3-yl)-N-(3-pyridinylmethyl)-ethanesulfonamide hydrochloride (LY566332), devoid of toxicity per se, amplified A&#x3b2;-induced neurodegeneration, and this effect was prevented by the mGlu2/3 receptor antagonist (2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl)glycine (LY341495). LY566332 potentiated A&#x3b2; toxicity regardless of the presence of glial mGlu3 receptors, but it was inactive when neurons lacked mGlu2 receptors. The dual mGlu2/3 receptor agonist, (-)-2-oxa-4-aminobicyclo[3.1.0]exhane-4,6-dicarboxylic acid (LY379268), was neuroprotective in mixed cultures via a paracrine mechanism mediated by transforming growth factor-&#x3b2;1. LY379268 lost its protective activity in neurons grown with astrocytes lacking mGlu3 receptors, indicating that protection against A&#x3b2; neurotoxicity was mediated entirely by glial mGlu3 receptors. The selective noncompetitive mGlu3 receptor antagonist, (3S)-1-(5-bromopyrimidin-2-yl)-N-(2,4-dichlorobenzyl)pyrrolidin-3-amine methanesulfonate hydrate (LY2389575), amplified A&#x3b2; toxicity on its own, and, interestingly, unmasked a neurotoxic activity of LY379268, which probably was mediated by the activation of mGlu2 receptors. These data indicate that selective potentiation of mGlu2 receptors enhances neuronal vulnerability to A&#x3b2;, whereas dual activation of mGlu2 and mGlu3 receptors is protective against A&#x3b2;-induced toxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caraci</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, University of Catania, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinaro</LastName><ForeName>Gemma</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Battaglia</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Giuffrida</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Riozzi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Traficante</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Cannella</LastName><ForeName>Milena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Merlo</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xushan</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Beverly A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Nisenbaum</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Britton</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Drago</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sortino</LastName><ForeName>Maria Angela</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Copani</LastName><ForeName>Agata</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharmacol</MedlineTA><NlmUniqueID>0035623</NlmUniqueID><ISSNLinking>0026-895X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114624">LY 341495</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118218">LY 379268</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C542802">N-(4'-cyanobiphenyl-3-yl)-N-(3-pyridinylmethyl)ethanesulfonamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018094">Receptors, Metabotropic Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014966">Xanthenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108822">metabotropic glutamate receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102718">metabotropic glutamate receptor 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018094" MajorTopicYN="N">Receptors, Metabotropic Glutamate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014966" MajorTopicYN="N">Xanthenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21159998</ArticleId><ArticleId IdType="doi">10.1124/mol.110.067488</ArticleId><ArticleId IdType="pii">mol.110.067488</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21157019</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2011</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Predicting disease progression in Alzheimer's disease: the role of neuropsychiatric syndromes on functional and cognitive decline.</ArticleTitle><Pagination><StartPage>35</StartPage><EndPage>45</EndPage><MedlinePgn>35-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-101836</ELocationID><Abstract><AbstractText>Patients with Alzheimer's disease (AD) have heterogeneous rates of disease progression. The aim of the current study is to investigate whether neuropsychiatric disturbances predict cognitive and functional disease progression in AD, according to failure theory. We longitudinally examined 177 memory-clinic AD outpatients (mean age = 73.1, SD = 8.1; 70.6% women). Neuropsychiatric disturbances at baseline were categorized into five syndromes. Patients were followed for up to two years to detect rapid disease progression defined as a loss of &#x2265; 1 abilities in Activities of Daily living (ADL) or a drop of &#x2265; 5 points on Mini-Mental State Examination (MMSE). Hazard ratios (HR) were calculated with Gompertz regression, adjusting for sociodemographics, baseline cognitive and functional status, and somatic comorbidities. Most patients (74.6%) exhibited one or more neuropsychiatric syndromes at baseline. The most common neuropsychiatric syndrome was Apathy (63.8%), followed by Affective (37.3%), Psychomotor (8.5%), Manic (7.9%), and Psychotic (5.6%) syndromes. The variance between the observed (Kaplen Meier) and predicted (Gompertz) decline for disease progression in cognition (0.30, CI = 0.26-0.35), was higher than the variance seen for functional decline (0.22, CI = 0.18-0.26). After multiple adjustment, patients with the Affective syndrome had an increased risk of functional decline (HR = 2.0; CI = 1.1-3.6), whereas the risk of cognitive decline was associated with the Manic (HR = 3.2, CI = 1.3-7.5) syndrome. In conclusion, specific neuropsychiatric syndromes are associated with functional and cognitive decline during the progression of AD, which may help with the long-term planning of care and treatment. These results highlight the importance of incorporating a thorough psychiatric examination in the evaluation of AD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carettere Scientifico, Rome, Italy. k.palmer@hsantalucia.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupo</LastName><ForeName>Federica</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Perri</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Salamone</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Musicco</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cravello</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="N">Apathy</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21157019</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-101836</ArticleId><ArticleId IdType="pii">057840J64744454G</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21093110</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>No association of psychosis in Alzheimer disease with neurodegenerative pathway genes.</ArticleTitle><Pagination><StartPage>555.e9</StartPage><EndPage>555.e11</EndPage><MedlinePgn>555.e9-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2010.10.003</ELocationID><Abstract><AbstractText>Psychotic symptoms occur in approximately 40% of subjects with Alzheimer disease (AD with psychosis; AD + P) and identify a subgroup with more rapid cognitive decline. We evaluated in 867 AD subjects the association of AD + P with genes which may modify the pathological process via effects on the accumulation of amyloid beta (A&#x3b2;) protein and/or hyperphosphorylated microtubule-associated protein tau (MAPT): amyloid precursor protein (APP), beta-site amyloid precursor protein cleaving enzyme (BACE1), sortilin-related receptor (SORL1), and MAPT. Each gene was thoroughly interrogated with tag single-nucleotide polymorphisms (SNPs), and gene-based tests were used to enhance power. We found no association of these genes with AD + P.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeMichele-Sweet</LastName><ForeName>Mary Ann A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klei</LastName><ForeName>Lambertus</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Bernie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Ferrell</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Emanuel</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027224-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-210020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21093110</ArticleId><ArticleId IdType="mid">NIHMS243698</ArticleId><ArticleId IdType="pmc">PMC3065549</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.10.003</ArticleId><ArticleId IdType="pii">S0197-4580(10)00426-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Health Disorders. Fourth. APA; Washington, D.C.: 1994.</Citation></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van BC, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008;29:769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Wijsman EM, NOchlin D, Leehey M, Sumi SM, Payami H, Poorkaj P, Nemens E, Rafkind M, Schellenberg GD. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology. 1997;48:950&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109883</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean FB, Hosono S, Fang L, Wu X, Faruqi AF, Bray-Ward P, Sun Z, Zong Q, Du Y, Du J, Driscoll M, Song W, Kingsmore SF, Egholm M, Lasken RS. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A. 2002;99:5261&#x2013;5266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122757</ArticleId><ArticleId IdType="pubmed">11959976</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis. 2010;19:761&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, Schonig K, Bujard H, Haemisch A, Mandelkow E, Zhou L, Rune G, Mandelkow EM. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem. 2007;282:31755&#x2013;31765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel JE, Sweet RA, Lopez OL, Becker JT, Weamer EA, Wilkosz PA, DeMichele-Sweet MA, Kuller L. Predictors of psychosis in mild cognitive impairment and Alzheimer disease in the cardiovascular health study cognition study. Am J Psychiatry. 2010 In Press.</Citation></Reference><Reference><Citation>Farber NB, Rubin EH, Newhouse PA, Kinscherf DA, Miller JP, Morris JC, Olney JW, McKeel DW. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer's disease. Arch Gen Psychiatry. 2000;57:1165&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">11115331</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, Kuhn KA, Krawczak M, Schreiber S, Nikolaus S, Forstl H, Kurz A, Riemenschneider M. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2010;15:756&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Forstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry. 1994;165:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">7953058</ArticleId></ArticleIdList></Reference><Reference><Citation>Grear KE, Ling IF, Simpson JF, Furman JL, Simmons CR, Peterson SL, Schmitt FA, Markesbery WR, Liu Q, Crook JE, Younkin SG, Bu G, Estus S. Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Mol Neurodegener. 2009;4:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776013</ArticleId><ArticleId IdType="pubmed">19889229</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, O'Donovan MC, Sims R, Powell J, Lovestone S, Myers A, Devrieze FW, Hardy J, Goate A, Owen M, Williams J. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:841&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky ST. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Yamamoto M, Morihara T, Akatsu H, Kudo T, Kamino K, Takeda M. SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett. 2009;461:177&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19539718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, Kornhuber J, Frolich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den BH, Hull M, Kurz A, Ruther E, Henn FA, Maier W. Association of SORL1 gene variants with Alzheimer's disease. Brain Res. 2009;1264:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19368828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasken RS. Genomic DNA amplification by the multiple displacement amplification (MDA) method. Biochem Soc Trans. 2009;37:450&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">19290880</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AB, Luca D, Klei L, Devlin B, Roeder K. Discovering genetic ancestry using spectral graph theory. Genet Epidemiol. 2010;34:51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610359</ArticleId><ArticleId IdType="pubmed">19455578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 2009;119:706&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662560</ArticleId><ArticleId IdType="pubmed">19339762</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rowland C, Catanese J, Morris J, Lovestone S, O'Donovan MC, Goate A, Owen M, Williams J, Grupe A. SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis. 2008;29:293&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323581</ArticleId><ArticleId IdType="pubmed">17949987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E &#x3b5;4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology. 1997;49:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566948</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca D, Ringquist S, Klei L, Lee AB, Gieger C, Wichmann HE, Schreiber S, Krawczak M, Lu Y, Styche A, Devlin B, Roeder K, Trucco M. On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet. 2008;82:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427172</ArticleId><ArticleId IdType="pubmed">18252225</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, George-Hyslop P. Brain traffic: subcellular transport of the amyloid precursor protein. Arch Neurol. 2009;66:433&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811871</ArticleId><ArticleId IdType="pubmed">19364927</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaetova-Ladinska EB, Harrington CR, Xuereb J, Roth M, Wischik CM. Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease. In: Bergener M, Finkel SI, editors. Treating Alzheimer's and other dementias. New York: Springer; 1995. pp. 57&#x2013;80.</Citation></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldo A, Bacanu SA, Devlin B, Sonpar V, Wasserman L, Roeder K. Characterization of multilocus linkage disequilibrium. Genet Epidemiol. 2005;28:193&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">15637716</ArticleId></ArticleIdList></Reference><Reference><Citation>Roeder K, Bacanu SA, Sonpar V, Zhang X, Devlin B. Analysis of single-locus tests to detect gene/disease associations. Genet Epidemiol. 2005;28:207&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15637715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A. 2008;105:5585&#x2013;5590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291091</ArticleId><ArticleId IdType="pubmed">18385378</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging. 2003;24:1029&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643375</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain. 2010;133:1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="pubmed">20147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Lopez OL, Klunk WE, Wisniewski SR, Kaufer DI, Healy MT, DeKosky ST. Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features. Int Psychogeriatr. 2000;12:547&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">11263720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002a;58:907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer's disease. Arch Neurol. 1998;55:1335&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Panchalingam K, Pettegrew JW, McClure RJ, Hamilton RL, Lopez OL, Kaufer DI, DeKosky ST, Klunk WE. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002b;23:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL. SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging. 2009;30:1048&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y, Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL, DeKosky ST, Sweet RA. The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009;21:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Kodavali C, Weamer EA, Miyahara S, Lopez OL, Nimgaonkar VL, DeKosky ST, Sweet RA. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818007</ArticleId><ArticleId IdType="pubmed">17525976</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21054329</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Quality of life in nursing home residents with advanced dementia.</ArticleTitle><Pagination><StartPage>2394</StartPage><EndPage>2400</EndPage><MedlinePgn>2394-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1532-5415.2010.03170.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine quality of life (QOL) in nursing home (NH) residents with advanced dementia and identify correlates of QOL near the end of life.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional data derived from NH records, interviews with residents' surrogate decision-makers, QOL ratings by NH caregivers, and assessment of residents' cognitive function.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Three NHs in Maryland.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A cohort of NH residents with dementia (n=119) who were receiving hospice or palliative care or met hospice criteria for dementia and their surrogates.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">QOL based on the proxy-rated Alzheimer' Disease-Related Quality of Life (ADRQL) scale administered to NH staff and validated against a single-item surrogate-rated measure of QOL, the Severe Impairment Rating Scale, to measure cognitive function and dichotomous indicators of neuropsychiatric symptoms (behavior problems, mood disorders, psychosis, delusions).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Total ADRQL scores, ranging from 12.4 to 95.1 out of 100, were normally distributed and positively correlated (P&lt;.001) with surrogate-rated QOL. Multiple regression analysis of ADRQL scores showed that residents with higher cognitive function (P&lt;.001, 95% confidence interval (CI)=0.97-1.65) and those receiving pain medication (P=.006, 95% CI=3.30-19.59) had higher QOL, whereas residents with behavior problems (P=.01, 95% CI=-11.60 to -1.30) had lower QOL.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ADRQL is a valid indicator of QOL in NH residents with advanced dementia. QOL in this population may be improved near the end of life using appropriate assessment and treatment of pain and effective management of behavior problems.</AbstractText><CopyrightInformation>&#xa9; 2010, Copyright the Authors. Journal compilation &#xa9; 2010, The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cordner</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blass</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Rabins</LastName><ForeName>Peter V</ForeName><Initials>PV</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Betty S</ForeName><Initials>BS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS039810</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039810-05</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39810</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006707" MajorTopicYN="Y">Homes for the Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017051" MajorTopicYN="N">Hospice Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008396" MajorTopicYN="N" Type="Geographic">Maryland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="Y">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010166" MajorTopicYN="N">Palliative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019727" MajorTopicYN="N">Proxy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest:</b> The following is a disclosure statement for Peter Rabins that is required by the Johns Hopkins University: &#x201c;Under an agreement between DEMeasure and Dr. Rabins, Dr. Rabins is entitled to a share of income received by DEMeasure from sales of the ADRQL questionnaire and scale used in the study described in this article. Dr. Rabins has an ownership interest in DEMeasure. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.&#x201d; In addition, Dr. Rabins has provided expert testimony for Janssen Pharmaceutica and received grant support from the Jewish Community Federation of Baltimore. The following is a disclosure statement for Betty Black that is required by the Johns Hopkins University: &#x201c;Under an agreement between DEMeasure and Dr. Black, Dr. Black is entitled to a share of income received by DEMeasure from sales of the ADRQL questionnaire and scale used in the study described in this article. Dr. Black has an ownership interest in DEMeasure. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.&#x201d; In addition, Dr. Black has received grant support from the Jewish Community Federation of Baltimore.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21054329</ArticleId><ArticleId IdType="mid">NIHMS236456</ArticleId><ArticleId IdType="pmc">PMC3057956</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.2010.03170.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Patrick DL, Erickson P. Concepts of health-related quality of life. In: Patrick DL, Erickson P, editors. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press; 1993. pp. 76&#x2013;112.</Citation></Reference><Reference><Citation>Whitehouse PJ, Rabins PV. Quality of life and dementia. Alzheimer Dis Assoc Disord. 1992;6:135&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">1485928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs GA, Shega JW, Cox-Hayley D. Barriers to excellent end-of-life care for patients with dementia. J Gen Intern Med. 2004;19:1057&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1492583</ArticleId><ArticleId IdType="pubmed">15482560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane RA. Definition, measurement, and correlates of quality of life in nursing homes: Toward a reasonable practice, research, and policy agenda. Gerontologist. 2003;43(Special Issue):28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12711722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Kasper JD, Kleinman L, et al. Concepts and methods in the development of the ADRQL: An instrument for assessing health-related quality of life in persons with Alzheimer disease. J Ment Health Aging. 1999;5:33&#x2013;48.</Citation></Reference><Reference><Citation>Black BS, Finucane T, Baker A, et al. Health problems and correlates of pain in nursing home residents with advanced dementia. Alzheimer Dis Assoc Disord. 2006;20:283&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132974</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart B, Alexander C. Medical guidelines for determining prognosis in selected non-cancer diseases. 2nd Ed. Washington DC: National Hospice Organization; 1996.</Citation><ArticleIdList><ArticleId IdType="pubmed">8949013</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Steele CD. A scale to measure impairment in severe dementia and similar conditions. Am J Geriatr Psychiatry. 1996;4:247&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">28531083</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JHT, Casarett D, Klocinski J, et al. The relationship between caregivers&#x2019; global rating of Alzheimer&#x2019;s disease patients&#x2019; quality of life, disease severity, and the caregiving experience. J Am Geriatr Soc. 2001;49:1066&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">11555068</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Salvador T, Lyketsos CG, Baker A, et al. Quality of life in dementia patients in long term care. Int J Geriatr Psychiatry. 2000;15:181&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Gonzales-Salvador T, Chin JJ, et al. A follow-up study of change in quality of life among persons with dementia residing in a long-term care facility. Int J Geriatr Psychiatry. 2003;18:275&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">12673600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper JD, Black BS, Shore A, et al. Evaluation of the validity and reliability of the Alzheimer Disease-related Quality of Life Assessment instrument. Alzheimer Dis Assoc Disord. 2009;23:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086660</ArticleId><ArticleId IdType="pubmed">19812471</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopmans RTCM, van der Molen M, Raats M, et al. Neuropsychiatric symptoms and quality of life in patients in the final phase of dementia. Int J Geriatr Psychiatry. 2009;24:25&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">18512257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawes C, Morris J, Phillips C, et al. Report of the Field Test of the Resident Assessment Instrument (RAI) Research Triangle Park, NC: Research Triangle Institute; 1991. Development of Resident Assessment System and Data Base for Nursing Home Residents.</Citation></Reference><Reference><Citation>Saliba D, Buchanan J. Development and Evaluation of a Revised Nursing Home Assessment Tool: MDS 3.0. RAND Corporation. 2008</Citation></Reference><Reference><Citation>Edelman P, Fulton BR, Kuhn D, et al. A comparison of three methods of measuring dementia-specific quality of life: Perspectives of residents, staff, and observers. Gerontologist. 2005;45:27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230747</ArticleId></ArticleIdList></Reference><Reference><Citation>Samus QM, Rosenblatt A, Onyike C, et al. Correlates of caregiver-rated quality of life in assisted living: The Maryland Assisted Living Study. J Gerontol B Psychol Sci Soc Sci. 2006;61:311&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960235</ArticleId></ArticleIdList></Reference><Reference><Citation>Winzelberg G, Williams C, Preisser J, et al. Factors associated with nursing assistant quality-of-life ratings for residents with dementia in long-term care facilities. Gerontologist. 2005;45:106&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16230757</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Samsi K, Petrie CD, et al. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry. 2009;24:15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">18727132</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JH, Zbrozek A, Kinosian B, et al. Preference-based quality of life in patients with Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631968</ArticleId></ArticleIdList></Reference><Reference><Citation>Missotten P, Squelard G, Ylieff M, et al. Relationship between quality of life and cognitive decline in dementia. Dement Geriatr Cogn Disord. 2008;25:564&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">18544978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalieri TA. Management of pain in older adults. J Am Osteopath Assoc. 2007;105:S12&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">18154193</ArticleId></ArticleIdList></Reference><Reference><Citation>Caltagirone C, Spoletini I, Gianni W, et al. Inadequate pain relief and consequences in oncological elderly patients. J Surg Oncol. 2009 doi:10.1016/j.suronc.2009.11.009.</Citation><ArticleIdList><ArticleId IdType="pubmed">20015635</ArticleId></ArticleIdList></Reference><Reference><Citation>American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57:1331&#x2013;1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573219</ArticleId></ArticleIdList></Reference><Reference><Citation>Horgas AL, Elliott AF, Marsiske M. Pain assessment in persons with dementia: Relationship between self-report and behavioral observation. J Am Geriatr Soc. 2009;57:126&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712941</ArticleId><ArticleId IdType="pubmed">19054191</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott AF, Horgas AL. Effects of an analgesic trial in reducing pain behaviors in community-dwelling older adults with dementia. Nurs Res. 2009;58:140&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19289936</ArticleId></ArticleIdList></Reference><Reference><Citation>Black BS, Rabins PV. In: Quality of life in dementia: Conceptual and practical issues. 3rd Ed. Burns A, Ames D, O&#x2019;Brien J, Dementia, editors. London, England: Edward Arnold Publishers; 2005. pp. 215&#x2013;228.</Citation></Reference><Reference><Citation>Kverno KS, Rabins PV, Blass DM. Prevalence and treatment of neuropsychiatric symptoms in hospice-eligible nursing home residents with advanced dementia. J Gerontol Nurs. 2008;34:8&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828146</ArticleId><ArticleId IdType="pubmed">19112999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell SL, Teno JM, Miller SC, et al. A national study of the location of death for older persons with dementia. J Am Geriatr Soc. 2005;53:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">15673356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21044653</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>356</StartPage><EndPage>362</EndPage><MedlinePgn>356-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2010.10.020</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder with a high prevalence. Since behavioral disturbances, such as psychotic symptoms, represent a key feature of AD, genes related to dopamine, serotonin and brain derived neurotrophic factor (BDNF), are considered as candidate genes for AD. BDNF is a neurotrophin that regulates neurodevelopment, neuroplasticity, and neuronal functions. BDNF is involved in the etiopathogenesis of psychiatric and neurodegenerative disorders. A single base pair polymorphism (BDNF Val66Met) was reported to be associated with AD and/or schizophrenia, as well as other psychoses, although some studies failed to replicate these findings. The aim of the study was to evaluate the association between BDNF Val66Met variants and AD, as well as onset of AD or presence of psychotic symptoms in AD.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">BDNF Val66Met was analyzed in 211 patients with AD and in 402 aged healthy control subjects. All subjects were ethnically homogenous Caucasians from Croatia, and were subdivided according to the gender, onset of AD, and presence of psychotic symptoms. A &#x3c7;(2) test, with Bonferroni correction and standardized residuals were used to evaluate the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Distribution of the BDNF Val66Met genotypes differed significantly between male and female AD patients with or without psychotic symptoms. This difference was due to the significant contribution of the Met/Val genotype and the combined Met/Met and Met/Val genotypes between psychotic and non-psychotic symptoms in male, but not in female patients with AD. The frequency of the gene variants of the BDNF Val66Met did not differ significantly among male and female patients with AD and control subjects, or between male and female patients with early or late onset AD. There were significant sex related differences in age, duration of illness and scores of dementia between patients with AD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our male patients were younger, had shorter duration of illness, and had less severe dementia and higher cognitive performance than female AD patients. The gene variants of the BDNF Val66Met polymorphism were significantly associated with the presence of psychotic symptoms in male, but not in female patients with AD. The results had adequate statistical power to suggest that BDNF Val66Met was not related to susceptibility to AD or the onset of AD, but that presence of one or two Met alleles of BDNF Val66Met polymorphism might present a risk factor for psychosis in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pivac</LastName><ForeName>Nela</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Molecular Medicine, Rudjer Boskovic Institute, Croatia. npivac@irb.hr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolac</LastName><ForeName>Matea</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nedic</LastName><ForeName>Gordana</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mustapic</LastName><ForeName>Maja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Borovecki</LastName><ForeName>Fran</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hajnsek</LastName><ForeName>Sanja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Presecki</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pavlovic</LastName><ForeName>Mladen</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mimica</LastName><ForeName>Ninoslav</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Muck Seler</LastName><ForeName>Dorotea</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017523" MajorTopicYN="N" Type="Geographic">Croatia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21044653</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2010.10.020</ArticleId><ArticleId IdType="pii">S0278-5846(10)00406-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21037137</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Schizophrenia-like psychosis and dysfunction of the right-dominant temporoparietal lobe in early-onset Alzheimer's disease.</ArticleTitle><Pagination><StartPage>451</StartPage><EndPage>451.e9</EndPage><MedlinePgn>451-e.e8-451.e9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Teruyuki</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kitabayashi</LastName><ForeName>Yurinosuke</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Aiko</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Narumoto</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fukui</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21037137</ArticleId><ArticleId IdType="doi">10.1176/jnp.2010.22.4.451.e8</ArticleId><ArticleId IdType="pii">22/4/451-e.e8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">21433394</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK50704</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Center for Biotechnology Information (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="mlprobe">Probe Reports from the NIH Molecular Libraries Program</BookTitle><PubDate><Year>2010</Year></PubDate><BeginningDate><Year>2010</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="mlprobe" part="ml169">Discovery and development of a second highly selective M<sub>1</sub> Positive Allosteric Modulator (PAM)</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Bridges</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>L Michelle</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>C David</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Lindsley</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>The specific aim of this project is to identify, via a functional high-throughput screening (HTS) approach, small molecule positive allosteric modulators (PAMs) and/or allosteric agonists of the M1 muscarinic acetylcholine receptor (mAChR) that are cell permeable, possess submicromolar potency, and show greater than 10-fold selectivity over the other mAChRs (M2-M5). The currently identified probe ML169 (CID-44475955) can be used for in vitro molecular pharmacology and electrophysiology experiments to study the receptor trafficking profile, and the role of selective M1 receptor activation by this unique M1 PAM chemotype. Use of this probe alongside the authors' initially identified M1 PAM probe, ML137 (CID-44251556) could improve understanding of the M1 signaling pathway and elucidate the difference, if any, between high and low ACh fold-shift compounds due to their different pharmacological characteristics. This probe possesses high selectivity versus M2-M5, as well as a large panel of GPCRs, ion channels and transporters. While in vivo studies are possible, it has not been investigated for such uses. Probes developed from these efforts will greatly advance the current state of the art by aiding in the understanding of M1's role in cell-based physiology, and may extend the clinical understanding of psychotic and cognitive symptoms associated with neurodegenerative disorders like Alzheimer's Disease and schizophrenia.</AbstractText></Abstract><Sections><Section><SectionTitle book="mlprobe" part="ml169" sec="ml169.s2">Probe Structure &amp; Characteristics</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml169" sec="ml169.s3">Recommendations for the scientific use of this probe</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml169" sec="ml169.s7">Assay Implementation and Screening</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml169" sec="ml169.rl1">Bibliography</SectionTitle></Section><Section><LocationLabel Type="section">Appendix I</LocationLabel><SectionTitle book="mlprobe" part="ml169" sec="ml169.app1">Solubility, Stability and Reactivity data as determined by Absorption Systems</SectionTitle></Section><Section><LocationLabel Type="section">Appendix II</LocationLabel><SectionTitle book="mlprobe" part="ml169" sec="ml169.app2">Liquid Chromatography-Mass Spectrometry (LCMS) and Nuclear Magnetic Resonance (NMR) as prepared by Vanderbilt Specialized Chemistry Center</SectionTitle></Section></Sections><ContributionDate><Year>2010</Year><Month>3</Month><Day>31</Day></ContributionDate><DateRevised><Year>2010</Year><Month>10</Month><Day>29</Day></DateRevised><ReferenceList><Reference><Citation>Bonner TI, Buckley NJ, Young AC, Brann MR. Science. 1987;237:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">3037705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner TI, Young AC, Brann MR, Buckley NJ. Neuron. 1988;1:403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wess J. Annu. Rev. Pharmacol. Toxicol. 2004;44:423&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744253</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead CJ, Watson J, Reavill C. Pharmacol. Ther. 2008;117:232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082893</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglen RM, Choppin A, Dillon MP, Hedge S. Curr. Opin. Chem. Biol. 1999;3:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">10419852</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder CC, Bymaster FP, Ward J, DeLapp N. J.Med. Chem. 2000;43:4333&#x2013;4353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, Ofen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymster FP, Hurley DJ, Potter WZ, Paul SM. Arch. Neurol. 1997;54:465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A. Neurodegener. Dis. 2008;5:237&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Am. J. Psychiatry. 2008;165:1033&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593778</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn PJ, Christopoulos A, Lindsley CW. Nat. Rev. Durg Disc. 2009;8:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907734</ArticleId><ArticleId IdType="pubmed">19116626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Lindsley CW. ACS Chem. Biol. 2008;3:530&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18652471</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ. Mol. Pharmacol. 2009;75:577&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684909</ArticleId><ArticleId IdType="pubmed">19047481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Seager M, Wittman M, Bickel N, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danzinger A, Regan C, Garson S, Doran S, Kreatsoulas C, Veng L, Lindsley CW, Shipe W, Kuduk S, Jacobson M, Sur C, Kinney G, Seabrook GR, Ray WJ. Proc. Natl. Acad Sci. USA. 2009;106:15950&#x2013;15955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732705</ArticleId><ArticleId IdType="pubmed">19717450</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Jadhav SB, Menon U, Christain EP, Doherty JJ, Quirk MC, Snyder DH, Levey AI, Watson ML, Nicolle MM, Lindsley CW, Conn PJ. J. Neurosci. 2009;29:14271&#x2013;14286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811323</ArticleId><ArticleId IdType="pubmed">19906975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang FV, Shipe WD, Bunda JL, Nolt MB, Wisnoski DD, Zhao Z, Barrow JC, Ray WJ, Ma L, Wittman M, Seager M, Koeplinger K, Hartman GD, Lindsley CW. Bioorg. Med. Chem. Lett. 2010;20:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">20004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebois EP, Bridges TM, Dawson ES, Kennedy Jp, Xiang Z, Jadhav SB, Yin H, Meiler J, Jones CK, Conn PJ, Weaver CD, Lindsley CW. ACS Chemical Neurosci. 2010;1:104&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180826</ArticleId><ArticleId IdType="pubmed">21961051</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding TA, Trotter C, Skajaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Mol. Pharm. 2002;61:1297&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021390</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MW, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ. J. Neurosci. 2008;28:10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady A, Jones CK, Bridges TM, Kennedy PJ, Thompson AD, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey J, Conn PJ, Lindsley CW. J. Pharm. &amp; Exp. Ther. 2008;327:941&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745822</ArticleId><ArticleId IdType="pubmed">18772318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Marlo JE, Niswender CM, Jones JK, Jadhav SB, Gentry PR, Weaver CD, Conn PJ, Lindsley CW. J. Med. Chem. 2009;52:3445&#x2013;3448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875304</ArticleId><ArticleId IdType="pubmed">19438238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Kennedy JP, Cho HP, Conn PJ, Lindsley CW. Bioorg. Med. Chem. Lett. 2010;20:558&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177601</ArticleId><ArticleId IdType="pubmed">20004578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Kennedy JP, Cho HP, Conn PJ, Lindsley CW. Bioorg Med Chem Lett. in press.</Citation></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21433394</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20963199</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1866-0452</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>39</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Deutsches Arzteblatt international</Title><ISOAbbreviation>Dtsch Arztebl Int</ISOAbbreviation></Journal><ArticleTitle>Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.</ArticleTitle><Pagination><StartPage>684</StartPage><EndPage>691</EndPage><MedlinePgn>684-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3238/arztebl.2010.0684</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are the two most common types of dementing neurodegenerative disease after Alzheimer's disease (AD). Both of these conditions are often diagnosed late or not at all.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Selective literature review.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The severe cholinergic and dopaminergic deficits that are present in both DLB and PDD produce not only motor manifestations, but also cognitive deficits, mainly in the executive and visual-constructive areas, as well as psychotic manifestations such as visual hallucinations, delusions, and agitation. The intensity of these manifestations can fluctuate markedly over the course of the day, particularly in DLB. Useful tests for differential diagnosis include magnetic resonance imaging and electroencephalography; in case of clinical uncertainty, nuclear medical procedures and cerebrospinal fluid analysis can be helpful as well. Neuropathological studies have revealed progressive alpha-synuclein aggregation in affected areas of the brain. In DLB, beta-amyloid abnormalities are often seen as well.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DLB should be included in the differential diagnosis of early dementia. If motor manifestations arise within one year (DLB), dopaminergic treatment should be initiated. On the other hand, patients with Parkinson's disease should undergo early screening for signs of dementia so that further diagnostic and therapeutic steps can be taken in timely fashion, as indicated. Cholinesterase inhibitors are useful for the treatment of cognitive deficits and experiential/behavioral disturbances in both DLB (off-label indication) and PDD (approved indication).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Paracelsus-Elena-Klinik, Kassel, Germany. brit.mollenhauer@pk-mx.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;rstl</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Deuschl</LastName><ForeName>G&#xfc;nther</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Storch</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Oertel</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Trenkwalder</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Arztebl Int</MedlineTA><NlmUniqueID>101475967</NlmUniqueID><ISSNLinking>1866-0452</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2010 Oct;107(39):675-6. doi: 10.3238/arztebl.2010.0675</RefSource><PMID Version="1">20963197</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2011 Feb;108(8):131; author reply 132. doi: 10.3238/arztebl.2011.0131b</RefSource><PMID Version="1">21403806</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2011 Feb;108(8):131; author reply 132. doi: 10.3238/arztebl.2011.0131a</RefSource><PMID Version="1">21403807</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20963199</ArticleId><ArticleId IdType="pmc">PMC2957617</ArticleId><ArticleId IdType="doi">10.3238/arztebl.2010.0684</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bickel H. Dementia in advanced age: estimating incidence and health care costs. Z Gerontol Geriatr. 2001;34(2):108&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">11393002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostrom F, Jonsson L, Minthon L, Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2007;22(8):713&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">17195278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34:561&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267179</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson&#x2019;s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">15889951</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000;54(2):407&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">10668703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Kryscio RJ, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839040</ArticleId><ArticleId IdType="pubmed">19795154</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16(4):622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481685</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson&#x2019;s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">11376470</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, O&#x2019;Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pubmed">17362834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Cepek L, Bibl M, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005;19(2-3):164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">15637452</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert KM, Deuschl G, Gasser T. Leitlinien in der Neurologie Therapie-Parkinson-Syndrome. In: Diener HC, Putzki N, et al., editors. &#x201e;Leitlinien f&#xfc;r die Diagnostik und Therapie in der Neurologie&#x201c;. 4th edition . Stuttgart: Georg Thieme Verlag; 2008.</Citation></Reference><Reference><Citation>Emre M, Aarsland D, Albanese A, et al. Rivastigmine for Dementia Associated with Parkinson&#x2019;s Disease. N Engl J Med. 2004;351(24):2509&#x2013;2518.</Citation><ArticleIdList><ArticleId IdType="pubmed">15590953</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study Lancet. 2000;356(9247):2031&#x2013;2036.</Citation><ArticleIdList><ArticleId IdType="pubmed">11145488</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuschl G MW, et al.  S3-Leitlinie Demenz; 2009.  www.dgn.org/statement.html. </Citation></Reference><Reference><Citation>Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson&#x2019;s disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pubmed">14618549</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1882909</ArticleId><ArticleId IdType="pubmed">1356550</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulloch JA, Ashwood TJ, Bateman DN, Woodhouse KW. A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients. Age Ageing. 1991;20(6):424&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">1776591</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W. When a Parkinson&#x2019;s disease patient starts to hallucinate. Pract Neurol. 2008;8(4):238&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">18644910</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology. 2005;65(12):1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 1999;53(5):902&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496243</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson Disease. Mov Disord. 2007;12:1689&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Knecht S, Berger K. Vascular factors contributing to the development of dementia .Einfluss vaskul&#xe4;rer Faktoren auf die Entwicklung einer Demenz] [Dtsch Arztebl. 2004;101(31-32):A 2185&#x2013;A 2189.</Citation></Reference><Reference><Citation>Mok W, Chow TW, Zheng L, Mack WJ, Miller C. Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians. Am J Alzheimers Dis Other Demen. 2004;19(3):161&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626585</ArticleId><ArticleId IdType="pubmed">15214202</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson&#x2019;s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14(10):866&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">10521886</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M. Dementia associated with Parkinson&#x2019;s disease. Lancet Neurol. 2003;2(4):229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849211</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson&#x2019;s disease. Mov Disord. 2005;20(10):1255&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041803</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Intellectual impairment in Parkinson&#x2019;s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988;1(1):24&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2908099</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Pillon B. Cognitive deficits in Parkinson&#x2019;s disease. J Neurol. 1997;244(1):2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007738</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of &#x2019;idiopathic&#x2019; REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128(Pt 1):126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548552</ArticleId></ArticleIdList></Reference><Reference><Citation>Werhahn KJ. Epilepsy in the elderly [Altersepilepsie] Dtsch Arztebl Int. 2009;106(9):135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696249</ArticleId><ArticleId IdType="pubmed">19568380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer&#x2019;s disease, dementia with Lewy bodies and Parkinson&#x2019;s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">18202105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66(12):1850&#x2013;1854.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E, Gonzalo I, Fanjul S, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol. 2003;60(9):1218&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12975286</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson&#x2019;s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737925</ArticleId><ArticleId IdType="pubmed">12023410</ArticleId></ArticleIdList></Reference><Reference><Citation>Putt ME, Ravina B. Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson&#x2019;s disease. Control Clin Trials. 2002;23(2):111&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson&#x2019;s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739697</ArticleId><ArticleId IdType="pubmed">15965198</ArticleId></ArticleIdList></Reference><Reference><Citation>Beversdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW. Donepezil in the treatment of dementia with lewy bodies. Am J Geriatr Psychiatry. 2004;12(5):542&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">15353396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;(3) CD003672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7389676</ArticleId><ArticleId IdType="pubmed">12917981</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhasin M, Rowan E, Edwards K, McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22(9):890&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">17265415</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27(4):153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15319699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27(6):1405&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson&#x2019;s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014720</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20962362</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1419-8711</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacol Hung</ISOAbbreviation></Journal><ArticleTitle>[9-hydroxy-risperidone (9OHRIS) prevents stress-induced &#x3b2;-actin overexpression in rat hippocampus].</ArticleTitle><Pagination><StartPage>425</StartPage><EndPage>431</EndPage><MedlinePgn>425-31</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is the most frequent form of neurodegenerative dementias. The aetiology and the exact pathomechanism of AD is not known, but stress has been considered recently in the aetiology. Beside the abnormal metabolism of the amyloid protein precursor (APP), the hyperactivity of the mitogen-activated protein kinase 1 (MAPK1) involved in the hyperphosphorylation of the tau proteins, which are considered the major component of neurofibrillary tangles, in addition to &#x3b2;-actin, being involved in synaptogenesis and neuronal plasticity, are all considered important contributors to the development of AD specific neuropathological changes. The chief aim of our present investigation was to examine the effect of stress on the expression of APP, MAPK1 and &#x3b2;-actin mRNAs in the rat hippocampus and cortex. The effect of 9-hydroxy-risperidone (9OHRIS) on the transcription of these genes was also examined. Adult, male Wistar rats were exposed to chronic immobilization stress for 3 weeks. The 9OHRIS (4 mg/bwkg) was administred by gastric tube. Four groups were formed depending on the treatment: (1) control, (2) stress, (3) 9OHRIS, (4) stress and parallel 9OHRIS treatment (n=5-6). The expression of APP, MAPK1, &#x3b2;-actin mRNAs from the perfused brain samples was measured with real-time PCR technique. The &#x3b2;-actin mRNA was significantly overexpressed in the hippocampus after 3 weeks of stress treatment. On the other hand, the stress induced hippocampal &#x3b2;-actin mRNA overexpression was repressed by the 9OHRIS treatment. There were no changes in the cortical or hippocampal expression of APP and MAPK1 mRNAs after neither the stress nor the 9OHRIS treatments. These results emphasize the importance of the stress induced &#x3b2;-actin expression in rat hippocampus. The stress induced alterations in the &#x3b2;-actin RNA expression could be associated with neuronal plasticity and adaptional processes, which could be modified by the 9OHRIS treatment. Our findings indicate that a second generation antipsychotic drug could have a beneficial effect in the pathomechanism of stress and this may have relevance in the treatment of such devastating conditions like AD and psychotic disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalman</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Szegedi Tudom&#xe1;nyegyetem, Pszichi&#xe1;triai Klinika, Alzheimer-k&#xf3;r Kutat&#xf3;csoport, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pakaski</LastName><ForeName>Magdolna</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Szucs</LastName><ForeName>Szabina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kalman</LastName><ForeName>Janos</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Fazekas</LastName><ForeName>Orsike</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Santha</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Gyula</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Janka</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kalman</LastName><ForeName>Janos</ForeName><Initials>J</Initials></Author></AuthorList><Language>hun</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>A 9-hidroxi-risperidon kiv&#xe9;di a stressz induk&#xe1;lta &#x3b2;-aktin v&#xe1;laszt patk&#xe1;ny hippokampuszban.</VernacularTitle></Article><MedlineJournalInfo><Country>Hungary</Country><MedlineTA>Neuropsychopharmacol Hung</MedlineTA><NlmUniqueID>100961631</NlmUniqueID><ISSNLinking>1419-8711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="C535149">Mapk1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>R8P8USM8FR</RegistryNumber><NameOfSubstance UI="D000068882">Paliperidone Palmitate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068882" MajorTopicYN="N">Paliperidone Palmitate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20962362</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">21433387</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK50695</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Center for Biotechnology Information (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="mlprobe">Probe Reports from the NIH Molecular Libraries Program</BookTitle><PubDate><Year>2010</Year></PubDate><BeginningDate><Year>2010</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="mlprobe" part="ml137">Discovery and development of the a highly selective M<sub>1</sub> Positive Allosteric Modulator (PAM)</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Bridges</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>L Michelle</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Eric S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>C David</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Lindsley</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>The specific aim of this project is to identify, via a functional high-throughput screening (HTS) approach, small molecule positive allosteric modulators (PAMs) and/or allosteric agonists of the M1 muscarinic acetylcholine receptor (mAChR) that are cell permeable, possess submicromolar potency, and show greater than 10-fold selectivity over the other mAChRs (M2-M5). The identified small molecular probe ML137 (CID-44251556) can be used for in vitro molecular pharmacology and electrophysiology experiments to study the receptor trafficking profile and role of selective M1 receptor activation by this unique M1 PAM chemotype. Probes developed from these efforts will greatly advance the current state of the art by aiding in the understanding of M1's role in cell-based physiology, and may extend the clinical understanding of psychotic and cognitive symptoms associated with neurodegenerative disorders, such as Alzheimer's Disease and schizophrenia.</AbstractText></Abstract><Sections><Section><SectionTitle book="mlprobe" part="ml137" sec="ml137.s2">Probe Structure &amp; Characteristics</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml137" sec="ml137.s3">Recommendations for the scientific use of this probe</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml137" sec="ml137.s7">Assay Implementation and Screening</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml137" sec="ml137.rl1">Bibliography</SectionTitle></Section><Section><LocationLabel Type="section">APPENDIX I</LocationLabel><SectionTitle book="mlprobe" part="ml137" sec="ml137.app1">Solubility, Stability and Reactivity data as determined by Absorption Systems</SectionTitle></Section><Section><LocationLabel Type="section">APPENDIX II</LocationLabel><SectionTitle book="mlprobe" part="ml137" sec="ml137.app2">Liquid Chromatography-Mass Spectrometry (LCMS) and Nuclear Magnetic Resonance (NMR) as prepared by Vanderbilt Specialized Chemistry Center</SectionTitle></Section></Sections><ContributionDate><Year>2010</Year><Month>2</Month><Day>26</Day></ContributionDate><DateRevised><Year>2010</Year><Month>10</Month><Day>20</Day></DateRevised><ReferenceList><Reference><Citation>Bonner TI, Buckley NJ, Young AC, Brann MR. Science. 1987;237:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">3037705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner TI, Young AC, Brann MR, Buckley NJ. Neuron. 1988;1:403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wess J. Annu. Rev. Pharmacol. Toxicol. 2004;44:423&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744253</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead CJ, Watson J, Reavill C. Pharmacol. Ther. 2008;117:232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082893</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglen RM, Choppin A, Dillon MP, Hedge S. Curr. Opin. Chem. Biol. 1999;3:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">10419852</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder CC, Bymaster FP, Ward J, DeLapp N. J.Med. Chem. 2000;43:4333&#x2013;4353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, Ofen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymster FP, Hurley DJ, Potter WZ, Paul SM. Arch. Neurol. 1997;54:465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A. Neurodegener. Dis. 2008;5:237&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Am. J. Psychiatry. 2008;165:1033&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593778</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn PJ, Christopoulos A, Lindsley CW. Nat. Rev. Durg Disc. 2009;8:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907734</ArticleId><ArticleId IdType="pubmed">19116626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Lindsley CW. ACS Chem. Biol. 2008;3:530&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18652471</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, Luo Q, Austin CA, Williams MB, Kim K, Williams R, Orton D, Brown HA, Lindsley CW, Weaver CD, Conn PJ. Mol. Pharmacol. 2009;75:577&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684909</ArticleId><ArticleId IdType="pubmed">19047481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Seager M, Wittman M, Bickel N, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danzinger A, Regan C, Garson S, Doran S, Kreatsoulas C, Veng L, Lindsley CW, Shipe W, Kuduk S, Jacobson M, Sur C, Kinney G, Seabrook GR, Ray WJ. Proc. Natl. Acad Sci. USA. 2009;106:15950&#x2013;15955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732705</ArticleId><ArticleId IdType="pubmed">19717450</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Jadhav SB, Menon U, Christain EP, Doherty JJ, Quirk MC, Snyder DH, Levey AI, Watson ML, Nicolle MM, Lindsley CW, Conn PJ. J. Neurosci. 2009;29:14271&#x2013;14286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811323</ArticleId><ArticleId IdType="pubmed">19906975</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang FV, Shipe WD, Bunda JL, Nolt MB, Wisnoski DD, Zhao Z, Barrow JC, Ray WJ, Ma L, Wittman M, Seager M, Koeplinger K, Hartman GD, Lindsley CW. Bioorg. Med. Chem. Lett. 2010;20:531&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">20004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebois EP, Bridges TM, Dawson ES, Kennedy Jp, Xiang Z, Jadhav SB, Yin H, Meiler J, Jones CK, Conn PJ, Weaver CD, Lindsley CW. ACS Chemical Neurosci. 2010;1:104&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3180826</ArticleId><ArticleId IdType="pubmed">21961051</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding TA, Trotter C, Skajaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Mol. Pharm. 2002;61:1297&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021390</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MW, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ. J. Neurosci. 2008;28:10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady A, Jones CK, Bridges TM, Kennedy PJ, Thompson AD, Breininger ML, Gentry PR, Yin H, Jadhav SB, Shirey J, Conn PJ, Lindsley CW. J. Pharm. &amp; Exp. Ther. 2008;327:941&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745822</ArticleId><ArticleId IdType="pubmed">18772318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Marlo JE, Niswender CM, Jones JK, Jadhav SB, Gentry PR, Weaver CD, Conn PJ, Lindsley CW. J. Med. Chem. 2009;52:3445&#x2013;3448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875304</ArticleId><ArticleId IdType="pubmed">19438238</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Kennedy JP, Cho HP, Conn PJ, Lindsley CW. Bioorg. Med. Chem. Lett. 2010;20:558&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177601</ArticleId><ArticleId IdType="pubmed">20004578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, Kennedy JP, Cho HP, Conn PJ, Lindsley CW. Bioorg Med Chem Lett, in press</Citation></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21433387</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20926739</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1945-1997</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>9 Suppl 8</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of the American Osteopathic Association</Title><ISOAbbreviation>J Am Osteopath Assoc</ISOAbbreviation></Journal><ArticleTitle>Current treatments for patients with Alzheimer disease.</ArticleTitle><Pagination><StartPage>S16</StartPage><EndPage>S26</EndPage><MedlinePgn>S16-26</MedlinePgn></Pagination><Abstract><AbstractText>There is neither proven effective prevention for Alzheimer disease nor a cure for patients with this disorder. Nevertheless, a spectrum of biopsychosocial therapeutic measures is available for slowing progression of the illness and enhancing quality of life for patients. These measures include a range of educational, psychological, social, and behavioral interventions that remain fundamental to effective care. Also available are a number of pharmacologic treatments, including prescription medications approved by the US Food and Drug Administration for Alzheimer disease, "off-label" uses of medications to manage target symptoms, and controversial complementary therapies. Physicians must make the earliest possible diagnosis to use these treatments most effectively. Physicians' goals should be to educate patients and their caregivers, to plan long-term care options, to maximally manage concurrent illnesses, to slow and ameliorate the most disabling symptoms, and to preserve effective functioning for as long as possible. The authors review the various current treatments for patients with Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osborn</LastName><ForeName>Gerald G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Medicine, Lincoln Memorial University-DeBusk College of Osteopathic Medicine, Harrogate, Tennessee 37752-8245, USA. Gerald.Osborn@lmunet.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Amanda Vaughn</ForeName><Initials>AV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Osteopath Assoc</MedlineTA><NlmUniqueID>7503065</NlmUniqueID><ISSNLinking>0098-6151</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010277">Parasympathomimetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010277" MajorTopicYN="N">Parasympathomimetics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20926739</ArticleId><ArticleId IdType="pii">110/9_suppl_8/S16</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20930289</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Grouping and trajectories of the neuropsychiatric symptoms in patients with Alzheimer's disease, part I: symptom clusters.</ArticleTitle><Pagination><StartPage>1157</StartPage><EndPage>1167</EndPage><MedlinePgn>1157-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-101212</ELocationID><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD) are frequently observed in Alzheimer's disease (AD) and affect more than 80% of patients over the course of AD. The goal of this study was to establish a model for grouping the symptoms of BPSD into clinical syndromes. Over a 24-month period, an observational study was conducted using a population of ambulatory patients with AD of mild to moderate severity. The Neuropsychiatric Inventory (NPI) was administered to the patients' caregivers every 6 months. BPSD were grouped using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) of the NPI scores of each assessment. The sample population consisted of 491 patients (70.9% women) with an average age of 75.2 years (SD=6.6). The five EFA suggested that there was a stable three-factor structure. According to the results of the EFA, three models of symptom grouping were adjusted using CFA methodology. The CFA model that satisfactorily grouped the NPI scores into three factors included a psychotic syndrome (hallucinations, delusions), an affective syndrome (depression, anxiety, irritability, agitation) and a behavior syndrome (euphoria, disinhibition, apathy, aberrant motor behavior). Based on our findings, we propose a model for grouping the BDSD in which there are core nuclear syndromes (psychotic and affective) as well as an unspecified behavior syndrome comprising satellite symptoms that may be related to the presence of the nuclear syndromes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garre-Olmo</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit, Institut d'Assist&#xe8;ncia Sanit&#xe0;ria, Salt, Spain. josep.garre@ias.scs.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Pousa</LastName><ForeName>Secundino</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vilalta-Franch</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>de Gracia Blanco</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vilarrasa</LastName><ForeName>Antoni Bulbena</ForeName><Initials>AB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20930289</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-101212</ArticleId><ArticleId IdType="pii">2M5556782078HT27</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20930287</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2011</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Grouping and trajectories of neuropsychiatric symptoms in patients with Alzheimer's disease. Part II: two-year patient trajectories.</ArticleTitle><Pagination><StartPage>1169</StartPage><EndPage>1180</EndPage><MedlinePgn>1169-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-101215</ELocationID><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD) are characterized by fluctuations in their frequency and severity as well as by differences in the concurrent presentation of different symptoms. The goal of the current study was to identify groups of patients with Alzheimer's disease (AD) that had similar trajectories in the expression of BPSD. Over a 24-month period, an observational study was conducted using a population of ambulatory patients with AD of mild or moderate severity. The Neuropsychiatric Inventory (NPI) was administered every 6 months to the patient's caregiver. To classify patients according to changes in the frequency and severity of BPSD, growth mixture models were fitted to the applied to the grouping of NPI subscales in the following three categories: psychotic syndrome (hallucinations and delusions), affective syndrome (depression, anxiety, irritability, and agitation), and behavioral syndrome (disinhibition, euphoria, apathy, and aberrant motor behavior). The sample population consisted of 491 patients (70.9% women) that had an average age of 75.2 years (SD=6.6). Different trajectory patterns were identified based on differences in changes over the time in the frequency (stable, increasing, decreasing, or fluctuating in course) and severity (low, moderate, or elevated severity) for psychotic syndrome, emotional syndrome, and behavior syndrome. Patients with AD display a high degree of variability in the evolutionary course of BPSD. It is possible to identify groups of patients with similar evolutionary trajectories in terms of changes in the frequency and severity of BPSD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garre-Olmo</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit, Institut d'Assist&#xe8;ncia Sanit&#xe0;ria, Salt, Spain. josep.garre@ias.scs.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Pousa</LastName><ForeName>Secundino</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vilalta-Franch</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>de Gracia Blanco</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vilarrasa</LastName><ForeName>Antoni Bulbena</ForeName><Initials>AB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20930287</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-101215</ArticleId><ArticleId IdType="pii">TJ677237717GG79V</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20930269</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN).</ArticleTitle><Pagination><StartPage>1123</StartPage><EndPage>1133</EndPage><MedlinePgn>1123-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-101413</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) is one of the commonest forms of early-onset dementia, accounting for up to 20% of all dementia patients. Recently, it has been shown that mutations in progranulin gene (PGRN) cause many familial cases of FTD. Members of a family affected by FTD spectrum disorders were ascertained in Poland and Canada. Clinical, radiological, molecular, genetic, and pathological studies were performed. A sequencing analysis of PGRN exons 1-13 was performed in the proband. Genotyping of the identified PGRN mutation and pathological analysis was carried out in the proband's brother. The onset of symptoms of FTD in the proband included bradykinesia, apathy, and somnolence followed by changes in personality, cognitive deficits, and psychotic features. The proband's clinical diagnosis was FTD and parkinsonism (FTDP). DNA sequence analysis of PGRN revealed a novel, heterozygous mutation in exon 11 (g.2988_2989delCA, P439_R440fsX6). The mutation introduced a premature stop codon at position 444. The proband's brother with the same mutation had a different course first presenting as progressive non-fluent aphasia, and later evolving symptoms of behavioral variant of FTD. He also developed parkinsonism late in the disease course evolving into corticobasal syndrome. Pathological analysis in the brother revealed Frontotemporal Lobar Degeneration-Ubiquitin (FTLD-U)/TDP-43 positive pathology. The novel PGRN mutation is a disease-causing mutation and is associated with substantial intra-familial clinical heterogeneity. Although presenting features were different, rapid and substantial deterioration in the disease course was observed in both family members.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gabryelewicz</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Berdynski</LastName><ForeName>Mariusz</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bilbao</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rogaeva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Barczak</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Czyzewski</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Barcikowska</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Zekanowski</LastName><ForeName>Cezary</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>13129</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>MT417763</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 NS070276</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1P50NS07218701</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS05756701A2</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RC2NS07027601</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>081864</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MT13129</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>R01 NS057567</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="N">Sequence Deletion</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20930269</ArticleId><ArticleId IdType="mid">CAMS2686</ArticleId><ArticleId IdType="pmc">PMC5045304</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-101413</ArticleId><ArticleId IdType="pii">4Q33G2V27653QT07</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Tolnay M, Mackenzie IR. The molecular basis of frontotemporal dementia. Expert Rev Mol Med. 2009;11:e23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19638255</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick&#x2019;s Disease. Arch Neurol. 2001;58:1803&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072868</ArticleId><ArticleId IdType="pubmed">8163988</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, III, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der ZJ, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, van DC, Peeters K, Sciot R, Santens P, De PT, Mattheijssens M, Van den BM, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van BC. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R, Melquist S, Kuntz K, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Wszolek Z, Gonzalez J, Beach TG, Bigio E, Johnson N, Weintraub S, Mesulam M, White CL, III, Woodruff B, Caselli R, Hsiung GY, Feldman H, Knopman D, Hutton M, Rademakers R. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15:2988&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950801</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation. 2007;4:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1805428</ArticleId><ArticleId IdType="pubmed">17291356</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi L, Binetti G, Sina E, Gigola L, Bettecken T, Meitinger T, Ghidoni R. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neurobiol Aging. 2008;29:427&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">17157414</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley BJ, Haidar W, Boeve BF, Baker M, Graff-Radford NR, Krefft T, Frank AR, Jack CR, Jr, Shiung M, Knopman DS, Josephs KA, Parashos SA, Rademakers R, Hutton M, Pickering-Brown S, Adamson J, Kuntz KM, Dickson DW, Parisi JE, Smith GE, Ivnik RJ, Petersen RC. Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging. 2009;30:739&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3164546</ArticleId><ArticleId IdType="pubmed">17949857</ArticleId></ArticleIdList></Reference><Reference><Citation>Masellis M, Momeni P, Meschino W, Heffner R, Jr, Elder J, Sato C, Liang Y, St George-Hyslop P, Hardy J, Bilbao J, Black S, Rogaeva E. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain. 2006;129:3115&#x2013;3123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030534</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, Spina S, Coppola G, Karydas AM, Stewart H, Johnson N, Hsiung GY, Kelley B, Kuntz K, Steinbart E, Wood EM, Yu CE, Josephs K, Sorenson E, Womack KB, Weintraub S, Pickering-Brown SM, Schofield PR, Brooks WS, Van DV, Snowden J, Clark CM, Kertesz A, Boylan K, Ghetti B, Neary D, Schellenberg GD, Beach TG, Mesulam M, Mann D, Grafman J, Mackenzie IR, Feldman H, Bird T, Petersen R, Knopman D, Boeve B, Geschwind DH, Miller B, Wszolek Z, Lippa C, Bigio EH, Dickson D, Graff-Radford N, Hutton M. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C&#x2013;&gt;T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007;6:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">17826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Beck J, Warren JD, King A, Al SS, Holton J, Revesz T, Collinge J, Mead S. Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation. J Neurol Neurosurg Psychiatry. 2009;80:1297&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">19864668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E, Galloway NM, Feldman H, Woltjer R, Miller CA, Wood EM, Grossman M, McCluskey L, Clark CM, Neumann M, Danek A, Galasko DR, Arnold SE, Chen-Plotkin A, Karydas A, Miller BL, Trojanowski JQ, Lee VM, Schellenberg GD, Van Deerlin V. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol. 2010;67:161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901991</ArticleId><ArticleId IdType="pubmed">20142524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekanowski C, Styczynska M, Peplonska B, Gabryelewicz T, Religa D, Ilkowski J, Kijanowska-Haladyna B, Kotapka-Minc S, Mikkelsen S, Pfeffer A, Barczak A, Luczywek E, Wasiak B, Chodakowska-Zebrowska M, Gustaw K, Laczkowski J, Sobow T, Kuznicki J, Barcikowska M. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer&#x2019;s disease in Poland. Exp Neurol. 2003;184:991&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">14769392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekanowski C, Peplonska B, Styczynska M, Gustaw K, Kuznicki J, Barcikowska M. Mutation screening of the MAPT and STH genes in Polish patients with clinically diagnosed frontotemporal dementia. Dement Geriatr Cogn Disord. 2003;16:126&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">12826737</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker KE, Parker R. Nonsense-mediated mRNA decay: terminating erroneous gene expression. Curr Opin Cell Biol. 2004;16:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">15145354</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der ZJ, Pickut BA, Van den BM, Mattheijssens M, Peeters K, Schymkowitz J, Rousseau F, Martin JJ, Cruts M, De Deyn PP, Van BC. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71:656&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF, Warrington EK, Stevens J, Revesz T, Holton J, Al-Sarraj S, King A, Scahill R, Warren JD, Fox NC, Rossor MN, Collinge J, Mead S. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain. 2008;131:706&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577762</ArticleId><ArticleId IdType="pubmed">18234697</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D, Mann DM. Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain. 2006;129:3091&#x2013;3102.</Citation><ArticleIdList><ArticleId IdType="pubmed">17003069</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno F, Indakoetxea B, Barandiaran M, Alzualde A, Gabilondo A, Estanga A, Ruiz J, Ruibal M, Bergareche A, Marti-Masso JF, Lopez de MA. &#x201c;Frontotemporoparietal&#x201d; dementia: clinical phenotype associated with the c.709-1G&gt;A PGRN mutation. Neurology. 2009;73:1367&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pubmed">19858458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering-Brown SM, Rollinson S, Du PD, Morrison KE, Varma A, Richardson AM, Neary D, Snowden JS, Mann DM. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain. 2008;131:721&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">18192287</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoglund L, Brundin R, Olofsson T, Kalimo H, Ingvast S, Blom ES, Giedraitis V, Ingelsson M, Lannfelt L, Basun H, Glaser A. Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. Neurogenetics. 2009;10:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">18855025</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 2007;114:31&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569065</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR, Parisi JE, Dickson DW. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401843</ArticleId></ArticleIdList></Reference><Reference><Citation>Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59:156&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16374817</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, Petersen RC, Davies P, Duara R, Graff-Radford NR, Uitti RJ, Rademakers R, Adamson J, Baker M, Hutton ML, Dickson DW. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol. 2007;66:142&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SH, Lecky BR, Steiger MJ. Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. Mov Disord. 2009;24:618&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">19133655</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN) Arch Neurol. 2008;65:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746630</ArticleId><ArticleId IdType="pubmed">18413467</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Archetti S, Alberici A, Agosti C, Gennarelli M, Bigni B, Bonvicini C, Ferrari M, Bellelli G, Galimberti D, Scarpini E, Di LD, Caimi L, Caltagirone C, Di LM, Padovani A. Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics. 2008;9:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">18392865</ArticleId></ArticleIdList></Reference><Reference><Citation>Llado A, Sanchez-Valle R, Rene R, Ezquerra M, Rey MJ, Tolosa E, Ferrer I, Molinuevo JL. Late-onset frontotemporal dementia associated with a novel PGRN mutation. J Neural Transm. 2007;114:1051&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417739</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Caselli RJ, Wszolek ZK, Uitti RJ, Feldman H, Hutton ML, Mackenzie IR, Graff-Radford NR, Dickson DW. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008;17:3631&#x2013;3642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581433</ArticleId><ArticleId IdType="pubmed">18723524</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20921878</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>The measurement of psychosis in dementia: a comparison of assessment tools.</ArticleTitle><Pagination><StartPage>101</StartPage><EndPage>108</EndPage><MedlinePgn>101-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0b013e3181f811f4</ELocationID><Abstract><AbstractText>The precise operational definition of psychosis in dementia lacks consensus, partially owing to incongruence in the various assessment tools used. This study compares assessments of psychotic symptoms in persons with dementia, specifically of hallucinations and delusions, through the 4 most frequently used assessments. Participants were 74 nursing home residents from 9 nursing homes in Israel, diagnosed with dementia. Assessment tools used included the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD), the Neuropsychiatric Inventory-Nursing Homes (NPI-NH), the Consortium to Establish a Registry for Alzheimer's Disease Behavior Rating Scale for Dementia (CERAD-BRSD), and the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD). The highest prevalence rates of delusions were found through the CUSPAD, and the lowest through the CERAD-BRSD. Rates identified by the BEHAVE-AD were intermediate and similar to those of the NPI-NH. As for hallucinations, rates indicated by the BEHAVE-AD, the NPI-NH, and the CUSPAD were similar, with small sample-based differences, and higher than those found through the CERAD-BRSD. The CERAD-BRSD, soliciting reports of the fewest specific symptoms, detected the fewest psychotic symptoms. The CUSPAD, soliciting the most items, presented the highest prevalence rates. The BEHAVE-AD and the NPI-NH had similar rates and showed a high convergent validity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen-Mansfield</LastName><ForeName>Jiska</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Herczeg Institute on Aging, Department of Health Promotion, Sackler Faculty of Medicine, School of Public Health, Tel-Aviv University, Tel-Aviv, Israel. Jiska@post.tau.ac.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golander</LastName><ForeName>Hava</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20921878</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e3181f811f4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20920205</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2010</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment.</ArticleTitle><Pagination><StartPage>87</StartPage><MedlinePgn>87</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2377-10-87</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Behavioural and psychological symptoms of dementia (BPSD) are non-cognitive symptoms commonly associated to Alzheimer's disease (AD). The characterization of the clinical profile of AD patients might help to better understand disease evolution and to improve diagnosis and treatment. Thus, the aim of the present study is to describe the clinical profile of AD patients, and to correlate the presence of BPSD with the severity of the disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional, observational and multicenter study was conducted at 115 centres in Spain. Patients suffering from AD with higher and lower BPSD scores (ADAS-Noncog score 26-50 and &#x2264;25, respectively) were included. Demographic and clinical data were collected, and dementia severity was assessed by the Mini Mental State Examination (MMSE) [mild 27-21, moderate 20-11, severe &#x2264;10]. The use of ADAS-Noncog in clinical practice was also explored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1014 patients (463 with higher and 551 with lower BPSD scores) were included (mean age 77 &#xb1; 7 years, 65% women). Almost all patients (90%) had BPSD at inclusion, 17% of which reported psychotic outbreaks. The most prevalent symptoms were lack of concentration (56%), tremors (56%), depression (44%), lack of cooperation (36%), and delusions (32%). Patients with higher BPSD scores showed a significantly higher prevalence of psychotic symptoms (delusions, hallucinations, and delirium) and tremors, while emotional symptoms (tearfulness and apathy) predominated in patients with lower BPSD scores. MMSE and ADAS-Noncog scores were negatively associated (p = 0.0284), suggesting a correlation between cognitive impairment and BPSD. Lack of concentration and appetite change significantly correlated with MMSE (p = 0.0472 and p = 0.0346, respectively). Rivastigmine and donepezil were the first choice therapies in mild to moderate dementia. ADAS-Noncog was generally considered better or similar to other scales (82%), and 68% of the investigators were willing to use it in the future.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study shows that patients with AD have a high prevalence of noncognitive symptoms, and that cognitive impairment and BPSD are correlated. Therefore, ADAS-Noncog is a useful evaluation tool.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Hospital de Cruces, Plaza de Cruces s/n, Barakaldo, Spain. mfernandezm@meditex.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobartt</LastName><ForeName>Ana L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Bala&#xf1;&#xe1;</LastName><ForeName>Montse</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>COOPERA Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Abell&#xe1;n</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abell&#xe1;n</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguado</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alastuey</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alay&#xf3;n</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alfonso</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almajano</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xc1;lvarez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andr&#xe9;s</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andr&#xe9;s</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aranceta</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asencio</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanco</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergareche</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burriel</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabello</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calatayud</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campayo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campos</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carballo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardozo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carnero</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerd&#xe1;</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobato</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dom&#xed;guez</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Due&#xf1;as</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escudero</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreres</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franquet</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frutos</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gahete</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galiano</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xe1;mez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>V J</ForeName><Initials>VJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a de Casasola</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gast&#xf3;n</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gir&#xf3;n</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giron&#xe8;s</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomis</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Go&#xf1;i</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandes</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jim&#xe9;nez</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacruz</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lajo</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landete</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>M D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez-Zuazo</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lozano</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lozano</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llanero</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Llanero</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallada</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marey</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsal</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;n</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massons</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mata</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>M&#xe9;ndez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montes</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monferrer</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mu&#xf1;oz-Torrero</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olcoz</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortega</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orts</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padilla</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pampliega</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pascual</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pascual</LastName><ForeName>Ll F</ForeName><Initials>LF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prat</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;rez</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;rez de las Heras</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perino</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pil&#xf3;s</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pujadas</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salamero</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xe1;nchez</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xe1;nchez</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanz</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sistiaga</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Toledo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tort</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valeru</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villegas</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20920205</ArticleId><ArticleId IdType="pmc">PMC2955564</ArticleId><ArticleId IdType="doi">10.1186/1471-2377-10-87</ArticleId><ArticleId IdType="pii">1471-2377-10-87</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease. Stat Med. 2000;19(11-12):1481&#x2013;1493. doi: 10.1002/(SICI)1097-0258(20000615/30)19:11/12&lt;1481::AID-SIM440&gt;3.0.CO;2-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(20000615/30)19:11/12&lt;1481::AID-SIM440&gt;3.0.CO;2-U</ArticleId><ArticleId IdType="pubmed">10844713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EH, Kinscherf DA. Psychopathology of very mild dementia of the Alzheimer type. Am J Psychiatry. 1989;146(8):1017&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">2750973</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry S, Cummings JL, Hill MA, Shapira J. Personality alterations in dementia of the Alzheimer type. Arch Neurol. 1988;45(11):1187&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">3190498</ArticleId></ArticleIdList></Reference><Reference><Citation>Artaso Irigoyen B, Goni Sarries A, Gomez Martinez AR. Neuropsychiatric symptoms in dementia syndrome. Rev Neurol. 2004;38(6):506&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054711</ArticleId></ArticleIdList></Reference><Reference><Citation>Swearer JM, Drachman DA, O'Donnell BF, Mitchell AL. Troublesome and disruptive behaviours in dementia. Relationships to diagnosis and disease severity. J Am Geriatr Soc. 1988;36(9):784&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">3411060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steele C, Baker L, Galik E, Kopunek S, Steinberg M, Warren A. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci. 1997;9(4):556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok WY, Chu LW, Chung CP, Chan NY, Hui SL. The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19(11):1040&#x2013;1046. doi: 10.1002/gps.1207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1207</ArticleId><ArticleId IdType="pubmed">15481076</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM. et al.Predicting time to nursing home care and death in individuals with Alzheimer disease. Jama. 1997;277(10):806&#x2013;812. doi: 10.1001/jama.277.10.806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.277.10.806</ArticleId><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Salvador T, Lyketsos CG, Baker A, Hovanec L, Roques C, Brandt J, Steele C. Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry. 2000;15(2):181&#x2013;189. doi: 10.1002/(SICI)1099-1166(200002)15:2&lt;181::AID-GPS96&gt;3.0.CO;2-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1099-1166(200002)15:2&lt;181::AID-GPS96&gt;3.0.CO;2-I</ArticleId><ArticleId IdType="pubmed">10679850</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147(8):1049&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci. 2001;56(11):M693&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">11682577</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H, Cummings J. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council. Manag Care Interface. 2000;13(1):51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Pousa S, Garre-Olmo J, Vilalta-Franch J, Turon-Estrada A, Pericot-Nierga I. Trazodone for Alzheimer's disease: a naturalistic follow-up study. Archives of gerontology and geriatrics. 2008;47(2):207&#x2013;215. doi: 10.1016/j.archger.2007.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2007.07.010</ArticleId><ArticleId IdType="pubmed">17897735</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mackell J, Kaufer D. Behavioural effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Dement. 2008;4(1):49&#x2013;60. doi: 10.1016/j.jalz.2007.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2007.10.011</ArticleId><ArticleId IdType="pubmed">18631950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Jama. 2002;288(12):1475&#x2013;1483. doi: 10.1001/jama.288.12.1475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.288.12.1475</ArticleId><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Fukuhara R, Shigenobu K, Hokoishi K, Maki N, Nebu A, Komori K, Tanabe H. Dementia associated mental and behavioural disturbances in elderly people in the community: findings from the first Nakayama study. J Neurol Neurosurg Psychiatry. 2004;75(1):146&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1757456</ArticleId><ArticleId IdType="pubmed">14707327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16(11):1043&#x2013;1053. doi: 10.1002/gps.448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.448</ArticleId><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioural changes in Alzheimer's disease. Neurology. 1996;46(1):130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559361</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioural symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(Suppl):9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19(3):448&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">6635122</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano JM, Llorca G, Ledesma A, Lopez-Ibor JJ. Spanish adaptation of the Alzheimer's disease assessment scale (ADAS) Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994;22(2):64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8079673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena-Casanova J, Aguilar M, Santacruz P, Bertran-Serra I, Hernandez G, Sol JM, Pujol A, Blesa R. Adaptation and normalization of the Alzheimer's disease Assessment Scale for Spain (NORMACODEM) (II) Neurologia. 1997;12(2):69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9147454</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel SI, Costae Silva J, Cohen G, Miller S, Sartorius N. Behavioural and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry. 2005;162(11):2086&#x2013;2093. doi: 10.1176/appi.ajp.162.11.2086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.162.11.2086</ArticleId><ArticleId IdType="pubmed">16263848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC. et al.A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry. 2003;160(5):857&#x2013;866. doi: 10.1176/appi.ajp.160.5.857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.160.5.857</ArticleId><ArticleId IdType="pubmed">12727688</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin DB, Green CR, Schmeidler J, Harvey PD, Lawlor BA, Ryan TM, Aryan M, Davis KL, Mohs RC. Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc. 1997;45(11):1331&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA. et al.The Behaviour Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioural Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995;152(9):1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen D, Eisdorfer C, Gorelick P, Paveza G, Luchins DJ, Freels S, Ashford JW, Semla T, Levy P, Hirschman R. Psychopathology associated with Alzheimer's disease and related disorders. J Gerontol. 1993;48(6):M255&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">8227995</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez-Gonzalez A, Garcia-Sanchez C, Boltes A, Garcia-Nonell C, Rigau-Ratera E, Otermin P, Gironell A, Kulisevsky J. Sustained attention in the preclinical phase of Alzheimer's disease. Rev Neurol. 2003;36(9):829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Lee BH, Seo SW, Moon SY, Jung DS, Park KH, Heilman KM, Na DL. Attentional distractibility by optokinetic stimulation in Alzheimer disease. Neurology. 2007;69(11):1105&#x2013;1112. doi: 10.1212/01.wnl.0000276956.65528.d4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000276956.65528.d4</ArticleId><ArticleId IdType="pubmed">17846410</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998;13(1):5&#x2013;10. doi: 10.1002/mds.870130105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.870130105</ArticleId><ArticleId IdType="pubmed">9452318</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis ED, Ford B, Pullman S, Baron K. How normal is 'normal'? Mild tremor in a multiethnic cohort of normal subjects. Arch Neurol. 1998;55(2):222&#x2013;227. doi: 10.1001/archneur.55.2.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.55.2.222</ArticleId><ArticleId IdType="pubmed">9482364</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis ED, Wendt KJ, Ford B. Senile tremor. What is the prevalence and severity of tremor in older adults? Gerontology. 1998;46(1):12&#x2013;16. doi: 10.1159/000022127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000022127</ArticleId><ArticleId IdType="pubmed">11111223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez Martinez M, Castro Flores J, Perez de las Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Imirizaldu JJ. Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain) Dement Geriatr Cogn Disord. 2008;25(2):103&#x2013;108. doi: 10.1159/000112215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000112215</ArticleId><ArticleId IdType="pubmed">18063866</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord. 2004;18(1):17&#x2013;21. doi: 10.1097/00002093-200401000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200401000-00004</ArticleId><ArticleId IdType="pubmed">15195459</ArticleId></ArticleIdList></Reference><Reference><Citation>Troisi A, Pasini A, Gori G, Sorbi T, Biagini C, Aulisi A, Baroni A, Ciani N. Assessment of depression in Alzheimer's disease: symptoms, syndrome, and computed tomography findings. Dementia. 1993;4(2):87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8358517</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie TB, Robiner WN, Knopman DS. Differences between patient and family assessments of depression in Alzheimer's disease. Am J Psychiatry. 1989;146(9):1174&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">2764175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabryelewicz T, Styczynska M, Luczywek E, Barczak A, Pfeffer A, Androsiuk W, Chodakowska-Zebrowska M, Wasiak B, Peplonska B, Barcikowska M. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry. 2007;22(6):563&#x2013;567. doi: 10.1002/gps.1716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1716</ArticleId><ArticleId IdType="pubmed">17136705</ArticleId></ArticleIdList></Reference><Reference><Citation>Purandare N, Burns A, Craig S, Faragher B, Scott K. Depressive symptoms in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16(10):960&#x2013;964. doi: 10.1002/gps.449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.449</ArticleId><ArticleId IdType="pubmed">11607939</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkaik R, Nuyen J, Schellevis F, Francke A. The relationship between severity of Alzheimer's disease and prevalence of comorbid depressive symptoms and depression: a systematic review. Int J Geriatr Psychiatry. 2007;22(11):1063&#x2013;1086. doi: 10.1002/gps.1809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1809</ArticleId><ArticleId IdType="pubmed">17457960</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour. Br J Psychiatry. 1990;157:86&#x2013;94. doi: 10.1192/bjp.157.1.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.157.1.86</ArticleId><ArticleId IdType="pubmed">2397368</ArticleId></ArticleIdList></Reference><Reference><Citation>Treiber KA, Lyketsos CG, Corcoran C, Steinberg M, Norton M, Green RC, Rabins P, Stein DM, Welsh-Bohmer KA, Breitner JC. et al.Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. Int Psychogeriatr. 2008;20(3):538&#x2013;553. doi: 10.1017/S1041610208006704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610208006704</ArticleId><ArticleId IdType="pmc">PMC2692675</ArticleId><ArticleId IdType="pubmed">18289451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper JK, Mungas D, Weiler PG. Relation of cognitive status and abnormal behaviours in Alzheimer's disease. J Am Geriatr Soc. 1990;38(8):867&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">2201714</ArticleId></ArticleIdList></Reference><Reference><Citation>Merriam AE, Aronson MK, Gaston P, Wey SL, Katz I. The psychiatric symptoms of Alzheimer's disease. J Am Geriatr Soc. 1988;36(1):7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">3335733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003;15(3):346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Tang Y, Aggarwal NT, Gilley DW, McCann JJ, Bienias JL, Evans DA. Hallucinations, cognitive decline, and death in Alzheimer's disease. Neuroepidemiology. 2006;26(2):68&#x2013;75. doi: 10.1159/000090251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000090251</ArticleId><ArticleId IdType="pubmed">16352909</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K. et al.Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62(10):1601&#x2013;1608. doi: 10.1001/archneur.62.10.1601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.10.1601</ArticleId><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport MJ, van Reekum R, Freedman M, Streiner D, Simard M, Clarke D, Cohen T, Conn D. Relationship of psychosis to aggression, apathy and function in dementia. Int J Geriatr Psychiatry. 2001;16(2):123&#x2013;130. doi: 10.1002/1099-1166(200102)16:2&lt;123::AID-GPS260&gt;3.0.CO;2-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1099-1166(200102)16:2&lt;123::AID-GPS260&gt;3.0.CO;2-1</ArticleId><ArticleId IdType="pubmed">11241716</ArticleId></ArticleIdList></Reference><Reference><Citation>White HK, McConnell ES, Bales CW, Kuchibhatla M. A 6-month observational study of the relationship between weight loss and behavioural symptoms in institutionalized Alzheimer's disease subjects. J Am Med Dir Assoc. 2004;5(2):89&#x2013;97. doi: 10.1016/S1525-8610(04)70061-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1525-8610(04)70061-4</ArticleId><ArticleId IdType="pubmed">14984619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset PJ, Riviere D, Albarede JL, Vellas B. Weight loss in Alzheimer disease. Am J Clin Nutr. 2000;71(2):637S&#x2013;642S.</Citation><ArticleIdList><ArticleId IdType="pubmed">10681272</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunther J, Albert M. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord. 2003;17(1):1&#x2013;8. doi: 10.1097/00002093-200301000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200301000-00001</ArticleId><ArticleId IdType="pubmed">12621314</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman C. Treatment of agitation, anxiety, and depression in dementia. Psychopharmacol Bull. 1988;24(1):39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">3290946</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Auer SR, Monteiro IM. Behavioural pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(Suppl 3):301&#x2013;308. discussion 351-304.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti L, McCurry SM, Logsdon R, Gibbons L, Teri L. Anxiety and Alzheimer's disease. J Geriatr Psychiatry Neurol. 2001;14(1):52&#x2013;58. doi: 10.1177/089198870101400111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/089198870101400111</ArticleId><ArticleId IdType="pubmed">11281317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Koss E, Metzler D, Moore A, Friedland RP. Behavioural symptomatology in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1988;2(4):363&#x2013;365. doi: 10.1097/00002093-198802040-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-198802040-00005</ArticleId><ArticleId IdType="pubmed">3196470</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TP, Tinklenberg JR, Brooks JO, Fenn HH, Yesavage JA. Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 1993;6(4):235&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">8251053</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider I, Shah A. A pilot study of behavioural and psychological signs and symptoms of dementia in patients of Indian sub-continent origin admitted to a dementia day hospital in the United Kingdom. Int J Geriatr Psychiatry. 2004;19(12):1195&#x2013;1204. doi: 10.1002/gps.1245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.1245</ArticleId><ArticleId IdType="pubmed">15526310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sicras-Mainar A, Vergara J, Leon-Colombo T, Febrer L, Rejas-Gutierrez J. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol. 2006;43(8):449&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17033976</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K. et al.Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24(6):457&#x2013;463. doi: 10.1159/000110738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000110738</ArticleId><ArticleId IdType="pubmed">17986816</ArticleId></ArticleIdList></Reference><Reference><Citation>Green CR, Marin DB, Mohs RC, Schmeidler J, Aryan M, Fine E, Davis KL. The impact of behavioural impairment of functional ability in Alzheimer's disease. Int J Geriatr Psychiatry. 1999;14(4):307&#x2013;316. doi: 10.1002/(SICI)1099-1166(199904)14:4&lt;307::AID-GPS908&gt;3.0.CO;2-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1099-1166(199904)14:4&lt;307::AID-GPS908&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="pubmed">10340193</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">21433356</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK47340</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Center for Biotechnology Information (US)</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="mlprobe">Probe Reports from the NIH Molecular Libraries Program</BookTitle><PubDate><Year>2010</Year></PubDate><BeginningDate><Year>2010</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="mlprobe" part="ml071">Discovery of a Highly Selective <i>in vitro</i> and <i>in vivo</i> M1 Allosteric Agonist Probe</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindsley</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>Dave</ForeName><Initials>D</Initials></Author></AuthorList><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>Previous attempts to develop compounds that are highly selective for M1 or other specific muscarinic acetylcholine receptor (mAChR) subtypes have failed because of the high conservation of the ACh binding site and difficulty in developing truly specific compounds. Basic and clinical studies suggest that mAChR activation has the potential to be disease modifying, as well as to provide palliative cognitive therapy. Probes developed from these efforts will greatly advance the current state of the art by aiding in the understanding of M1's role in cell-based physiology and may extend the clinical understanding of psychotic and cognitive symptoms associated with neurodegenerative disorders such as Alzheimer's Disease and schizophrenia. This probe report describes ML071 (CID-25010775), a highly selective, potent M1 agonist that activates M1 by virtue of binding at an allosteric site in the third extracellular loop of the M1 receptor. The compound represents a "best in class" probe that provides unprecedented mAChR selectivity, clean ancillary pharmacology, saline solubility, and central penetrance. Furthermore, it can be employed for in vitro and in vivo studies to examine the role of selective M1 receptor activation.</AbstractText></Abstract><Sections><Section><SectionTitle book="mlprobe" part="ml071" sec="ml071.s2">Probe Structure &amp; Characteristics</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml071" sec="ml071.s3">Recommendations for the scientific use of this probe</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml071" sec="ml071.s11">PubChem Primary Assay Description</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml071" sec="ml071.s13">Probe Chemical Lead Optimization Strategy</SectionTitle></Section><Section><SectionTitle book="mlprobe" part="ml071" sec="ml071.rl1">Bibliography</SectionTitle></Section></Sections><ContributionDate><Year>2008</Year><Month>12</Month><Day>3</Day></ContributionDate><DateRevised><Year>2010</Year><Month>10</Month><Day>4</Day></DateRevised><ReferenceList><Reference><Citation>Bodick NC, Ofen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymster FP, Hurley DJ, Potter WZ, Paul SM. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer&#x2019;s disease. Arch. Neurol. 1997;54:465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor gene. Science. 1987237:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">3037705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner TI, Young AC, Buckley NJ, Brann MR. Cloning and expression of the human and rat m5 muscarinic receptor gene. Neuron. 1988;1:403&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of M1&#x2013;M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res. 2003;28:437&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">12675128</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a cnetral role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglen RM, Choppin A, Dillon MP, Hedge S. Muscarinic receptor ligands and their therapeutic potential. Curr. Opin. Chem. Biol. 1999;3:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">10419852</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 2000;43:4333&#x2013;4353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane A, Bridges TM, Kennedy JP, Bradley SR, Peterson T, Baldwin RM, Kessler R, Deutch A, Lah JL, Levey AI, Lindsley CW, Conn PJ. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008;28(41):10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>May LT, Christopoulos A. Allosteric modulators of G-protein&#x2013;coupled receptors. Curr Opin Pharmacol. 2003;3(5):551&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry. 2008;165:1033&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593778</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding TA, Trotter C, Skajaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Discovery of an ectopic site activation site on the M1 muscarinic receptor. Mol. Pharm. 2002;61:1297&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021390</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21433356</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20850798</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>299</Volume><Issue>1-2</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Particular aspects in patients with coronary heart disease and vascular cognitive impairment.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>50</EndPage><MedlinePgn>49-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2010.08.049</ELocationID><Abstract><AbstractText>Among the patients with cognitive vascular impairment, a particular group is represented by those who have concomitant cerebrovascular and coronary heart disease (CHD). The clinical evolution of some of these patients is dominated apparently by the progressive cognitive impairment and sometimes psychotic episodes and not by evident clinical stroke and/or symptoms of their heart disease, so that they receive the diagnosis of Alzheimer's disease or of a psychiatric disease. Most of these patients have a severe evolution, particularly if their cardiovascular disease is not recognized and die unexpectedly. In the author's clinical experience, the systematic cardiovascular examination in all patients hospitalized with the diagnosis of dementia or cognitive impairment, even if they did not have previously been diagnosed with cerebrovascular and/or coronary heart disease, disclosed in many instances the presence of severe but apparently silent cardiovascular disorders characterized always by concomitant severe CHD and significant large vessel disease of the brain. It is important to emphasize the particular situation in which the progressive cognitive impairment associated or not with psychiatric manifestations could mask severe cardio- and cerebrovascular disorders, which could further be worsened by symptomatic psychiatric treatment, and which evolution is to "unexpected" cardiovascular death.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bajenaru</LastName><ForeName>Ovidiu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>University of Medicine and Pharmacy Carol Davila Bucharest, Romania. ovalbajenaru@xnet.ro</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antochi</LastName><ForeName>Florina</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tiu</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20850798</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2010.08.049</ArticleId><ArticleId IdType="pii">S0022-510X(10)00416-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20850604</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Source monitoring: general presentation and review of literature in schizophrenia].</ArticleTitle><Pagination><StartPage>326</StartPage><EndPage>333</EndPage><MedlinePgn>326-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2009.12.010</ELocationID><Abstract><AbstractText Label="UNLABELLED">SOURCE MONITORING FRAMEWORK: Source monitoring refers to the ability to remember the origin of information. Three source monitoring processes can be distinguished: external source monitoring, internal or self-monitoring and reality monitoring (i.e. discrimination between internal and external sources of information). Source monitoring decisions are based on memory characteristics recorded such as perceptions, contextual information or emotional reactions and heuristic or more controlled judgement processes.</AbstractText><AbstractText Label="BRAIN STRUCTURES" NlmCategory="UNASSIGNED">Several studies suggested that specific structures in the prefrontal and the mediotemporal lobes are the main areas implicated in source monitoring.</AbstractText><AbstractText Label="ASSESSMENT" NlmCategory="RESULTS">A typical source monitoring paradigm includes an items generation stage and a second stage of recognition of items (old versus new) and identification of their sources: external (usually the examiner) or internal (the subject). Several indices can be calculated based on the raw data such as the number of false alarms, attribution biases or discrimination indexes. To date, there is no standardized source monitoring task and differences in the type of items used (words, pictures), in the cognitive or emotional effort involved or in the delay between the two test stages, contribute to the heterogeneity of results.</AbstractText><AbstractText Label="FACTORS INFLUENCING SOURCE MONITORING" NlmCategory="UNASSIGNED">Factors such as age (either very young or very old) and emotions influence source monitoring performances. Influence of gender was not properly explored, whereas the role of IQ and selective attention is still debated.</AbstractText><AbstractText Label="SOURCE MONITORING DEFICITS IN NEUROLOGICAL DISORDERS" NlmCategory="UNASSIGNED">Source monitoring deficits are observed mainly in disorders affecting frontotemporal areas, such as frontal trauma, Alzheimer's disease or frontotemporal dementia.</AbstractText><AbstractText Label="SOURCE MONITORING AND SCHIZOPHRENIA" NlmCategory="UNASSIGNED">Source monitoring errors (e.g. external misattribution of self-generated information) are observed in schizophrenia and seem to correlate with positive symptomatology, in particular auditory hallucinations, thought intrusion and alien control symptoms. These results are of particular interest in clinical research because source monitoring is one of the rare cognitive tests showing a correlation with the positive dimension. Source monitoring deficits have been proposed as a potential explanation for the positive symptoms and some, but not all studies lent support to this hypothesis. Heterogeneity of studied samples, in particular different criteria to define hallucinating subjects (e.g. currently versus anytime during their lives), could explain the discordant results.</AbstractText><AbstractText Label="SOURCE MONITORING IN PSYCHIATRIC DISORDERS WITHIN THE SCHIZOPHRENIC SPECTRUM" NlmCategory="UNASSIGNED">Source monitoring impairments were observed in pharmacological models of psychosis, in first degree relatives of schizophrenic patients, and also in the general population associated with schizotypal dimensions. These results support a relationship between source monitoring deficits and some of the symptomatic dimensions of the schizophrenic spectrum but still await replication.</AbstractText><AbstractText Label="SOURCE MONITORING AND OTHER PSYCHIATRIC DISORDERS" NlmCategory="UNASSIGNED">Some studies found source monitoring deficits in other psychiatric conditions such as mania or obsessive-compulsive disorder. Thus, those studies suggest that source monitoring deficits may be not specific to schizophrenia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Source monitoring competencies are critical for good (i.e. adapted) everyday functioning. Source monitoring deficits have been suggested as a potential explanation for some (or all) positive psychotic symptoms. However, to date, methodological inconsistencies (especially with regard to test design and choice of subjects' samples) have precluded firm, definite conclusions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 L&#x2019;Enc&#xe9;phale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferchiou</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm U 955, Equipe de Psychiatrie G&#xe9;n&#xe9;tique, D&#xe9;partement de G&#xe9;nomique M&#xe9;dicale, Institut Mondor de Recherches Biom&#xe9;dicales, 94000 Cr&#xe9;teil, France. aziz.ferchiou@inserm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;rhoff</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bulzacka</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mahbouli</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sz&#xf6;ke</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>M&#xe9;moire de source--pr&#xe9;sentation g&#xe9;n&#xe9;rale et revue des &#xe9;tudes dans la schizophr&#xe9;nie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004192" MajorTopicYN="N">Discrimination, Psychological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007092" MajorTopicYN="N">Imagination</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="Y">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007600" MajorTopicYN="Y">Judgment</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="Y">Mental Recall</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011936" MajorTopicYN="Y">Reality Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012938" MajorTopicYN="N">Social Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20850604</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2009.12.010</ArticleId><ArticleId IdType="pii">S0013-7006(09)00259-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20843397</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>A late form of neurosyphilis manifesting with psychotic symptoms in old age and good response to ceftriaxone therapy.</ArticleTitle><Pagination><StartPage>666</StartPage><EndPage>669</EndPage><MedlinePgn>666-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S104161021000181X</ELocationID><Abstract><AbstractText>Neurosyphilis can present with psychiatric symptoms. The late form can occur in old age with psychosis, paranoid delusions, affective disorders or cognitive impairment. Here we present a case of neurosyphilis in an elderly woman who, over six months, progressively manifested personality changes and paranoid delusions which were initially suspected as Alzheimer's disease. Psychotic symptoms showed a good response to antibiotic treatment. We conclude that neurosyphilis is a relevant differential diagnosis in patients developing severe psychiatric symptoms in old age. As a causal antibiotic treatment is possible this infectious disease should be considered seriously in gerontopsychiatric patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xfc;ler</LastName><ForeName>Erdem</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyhe</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>75J73V1629</RegistryNumber><NameOfSubstance UI="D002443">Ceftriaxone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002443" MajorTopicYN="N">Ceftriaxone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009494" MajorTopicYN="N">Neurosyphilis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010258" MajorTopicYN="N">Paranoid Behavior</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20843397</ArticleId><ArticleId IdType="doi">10.1017/S104161021000181X</ArticleId><ArticleId IdType="pii">S104161021000181X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20808116</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study.</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>168</EndPage><MedlinePgn>160-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181e446c8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare the trajectories of cognitive decline between groups with, and without, the later development of psychotic symptoms during Alzheimer disease (AD) or mild cognitive impairment (MCI).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">: The authors examined cognitive function in a new analysis of an existing data set, the Cardiovascular Health Study, an epidemiologic, longitudinal follow-up study. Our analyses examined 9 years of follow-up data.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Community.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The authors examined subjects who were without dementia at study entry, received a diagnosis of AD or MCI during follow-up, and had been rated on the Neuropsychiatric Inventory for the presence of psychosis; 362 participants for the modified Mini-Mental State Examination (3MS) analysis and 350 participants for the digit symbol substitution test (DSST) analysis had sufficient follow-up data and apolipoprotein-&#x220a; (APOE) genotyping.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">The 3MS and DSST were administered annually and analyzed using mixed-effects models including APOE4 status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">: Mean 3MS and DSST scores did not differ between AD with psychosis (AD + P) and without psychosis groups at baseline. The 3MS and DSST scores decreased more rapidly in subjects who ultimately developed psychosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Individuals who ultimately develop psychosis have more rapid cognitive deterioration during the earliest phases of AD than individuals with AD not developing psychosis. The genetic and other neurobiologic factors leading to the expression of AD + P may exert their effects by acceleration of the neurodegenerative process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emanuel</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>James T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Demichele-Sweet</LastName><ForeName>Mary Ann A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lewis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 HC085086</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015928-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC075150</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085085</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC55222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085082</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC055222</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85079</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC045133</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC035129</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085081</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295-04</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL080295</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC015103</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085083</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-85086</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85086</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085080</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC-55222</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-HC-75150</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085084</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC75150</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-210020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01HC85079</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 HC085079</GrantID><Acronym>HC</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20808116</ArticleId><ArticleId IdType="mid">NIHMS199880</ArticleId><ArticleId IdType="pmc">PMC3000865</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181e446c8</ArticleId><ArticleId IdType="pii">S1064-7481(12)60161-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer&#x2019;s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, et al. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, et al. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58:907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, et al. Increased familial risk and genomewide significant linkage for Alzheimer&#x2019;s disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:841&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, et al. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer&#x2019;s disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2008:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal L, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer&#x2019;s disease. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, et al. Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes. Am J Geriatr Psychiatry. 2006;14:352&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Beiser A, Wolf PA, et al. The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57:808&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Fitzpatrick A, et al. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566948</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669507</ArticleId></ArticleIdList></Reference><Reference><Citation>Tell GS, Fried LP, Hermanson B, et al. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275211</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48:314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler Adult Intelligence Scale Manual. New York: Psychological Corporation; 1955.</Citation></Reference><Reference><Citation>Lopez OL, Becker JT, Jagust WJ, et al. Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry. 2006;77:159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077558</ArticleId><ArticleId IdType="pubmed">16103044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kuller LH, Becker JT, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol. 2007;64:416&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353386</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J, Helmin K, Tsai J, et al. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer&#x2019;s disease. Ann N Y Acad Sci. 2007;1097:30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413007</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Panchalingam K, Pettegrew JW, et al. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002;23:547&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J Clin Invest. 2009;119:706&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662560</ArticleId><ArticleId IdType="pubmed">19339762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Hamilton RL, Lopez OL, et al. Psychotic symptoms in Alzheimer&#x2019;s disease are not associated with more severe neuropathologic features. Int Psychogeriatr. 2000;12:547&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">11263720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20808108</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates.</ArticleTitle><Pagination><StartPage>917</StartPage><EndPage>927</EndPage><MedlinePgn>917-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181d5745d</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Alzheimer disease (AD) imposes a severe burden on patients and their caregivers. Although there is substantial evidence of the adverse impact of burden, considerably less is known about its specific correlates and potential causes.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">The authors use data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)-AD study to examine the relationship of burden and depression among AD caregivers to patient and caregiver sociodemographic characteristics, patients' cognitive status, psychiatric and behavioral symptoms, functional abilities, quality of life, and intensity of care provided by caregivers.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">CATIE-AD included outpatients in usual care settings and assessed treatment outcomes during 9 months.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Data were examined from 421 ambulatory outpatients with a diagnosis of dementia of the Alzheimer type or probable AD with agitation or psychosis.</AbstractText><AbstractText Label="MEASURES" NlmCategory="METHODS">The Burden Interview, the Beck Depression Inventory, and the Caregiver Distress Scale were used to evaluate caregiver burden.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">More severe psychiatric and behavioral problems and decreased patient quality of life, as well as lower functional capability were significantly associated with higher levels of burden and depression among caregivers at baseline. Six-month changes showed that decreased symptoms and improved quality of life were associated with decreased burden and accounted for most of the explained variance in change in burden measures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Severity of psychiatric symptoms, behavioral disturbances, and patients' quality of life are the main correlates of caregivers' experience burden. Psychosocial and pharmacologic interventions targeting these two aspects of the disorder are likely to not only alleviate patient suffering but also promote caregiver well-being.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Somaia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New England Mental Illness, Research, Education and Clinical Center, West Haven, CT, USA. Somaia.Mohamed@yale.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH90001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142-26A16897</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH9001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20808108</ArticleId><ArticleId IdType="mid">NIHMS198712</ArticleId><ArticleId IdType="pmc">PMC3972419</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181d5745d</ArticleId><ArticleId IdType="pii">S1064-7481(12)60220-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manca A, Davies L, Burns A. Cost-effectiveness of therapeutics for Alzheimer&#x2019;s Disease. In: Davis K, Charney D, Coyle J, editors. Neuropsychopharmacology: The Fifth Generation of Progress. New York NY: Lippincott Williams &amp; Wilkins; 2002. pp. 1267&#x2013;1280.</Citation></Reference><Reference><Citation>Donaldson C, Tarrier N, Burns A. The impact of the symptoms of dementia on caregivers. Br J Psychiatry. 1997;170:62&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9068778</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry. 1998;13:248&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9646153</ArticleId></ArticleIdList></Reference><Reference><Citation>Haley WE. The family caregiver's role in Alzheimer's disease. Neurology. 1997;48:S25&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattanach L, Tebes JK. The nature of elder impairment and its impact on family caregivers' health and psychosocial functioning. Gerontologist. 1991;31:246&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">1828449</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallant MP, Connell CM. Predictors of decreased self-care among spouse caregivers of older adults with dementing illnesses. J. Aging Health. 1997;9:373&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">10182399</ArticleId></ArticleIdList></Reference><Reference><Citation>Song LY, Biegel DE, Milligan SE. Predictors of depressive symptomatology among lower social class caregivers of persons with chronic mental illness. Community Ment. Health J. 1997;33:269&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">9250425</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Williamson GM. A 2-year longitudinal study of depression among Alzheimer's caregivers. Psychol. Aging. 1991;6:569&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">1777145</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson GM, Schulz R. Coping with specific stressors in Alzheimer's disease caregiving. Gerontologist. 1993;33:747&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">8314101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen D, Eisdorfer C. Depression in family members caring for a relative with Alzheimer's disease. J. Am. Geriatr. Soc. 1988;36:885&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">3171027</ArticleId></ArticleIdList></Reference><Reference><Citation>Drinka TJ, Smith JC, Drinka PJ. Correlates of depression and burden for informal caregivers of patients in a geriatrics referral clinic. J. Am. Geriatr. Soc. 1987;35:522&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher D, Rose J, Rivera P, et al. Prevalence of depression in family caregivers. Gerontologist. 1989;29:449&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">2521102</ArticleId></ArticleIdList></Reference><Reference><Citation>Draper BM, Poulos CJ, Cole AM, et al. A comparison of caregivers for elderly stroke and dementia victims. J. Am. Geriatr. Soc. 1992;40:896&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiecolt-Glaser JK, Dura JR, Speicher CE, et al. Spousal caregivers of dementia victims: longitudinal changes in immunity and health. Psychosom. Med. 1991;53:345&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">1656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgarten M, Battista RN, Infante-Rivard C, et al. The psychological and physical health of family members caring for an elderly person with dementia. J. Clin. Epidemiol. 1992;45:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">1738013</ArticleId></ArticleIdList></Reference><Reference><Citation>Grafstrom M, Fratiglioni L, Sandman PO, et al. Health and social consequences for relatives of demented and non-demented elderly. A population-based study. J. Clin. Epidemiol. 1992;45:861&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">1624968</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA. 1999;282:2215&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pubmed">10605972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ory MG, Hoffman RR, 3rd, Yee JL, et al. Prevalence and impact of caregiving: a detailed comparison between dementia and nondementia caregivers. Gerontologist. 1999;39:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10224714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilleard CJ, Belford H, Gilleard E, et al. Emotional distress amongst the supporters of the elderly mentally infirm. Br J Psychiatry. 1984;145:172&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">6466915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangone CA, Sanguinetti RM, Baumann PD, et al. Influence of feelings of burden on the caregiver's perception of the patient's functional status. Dementia. 1993;4:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8261026</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R, O'Brien AT, Bookwala J, et al. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist. 1995;35:771&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557205</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery R, Gonyea J, Hooyman N. Caregiving and the Experience of Subjective and Objective Burden. Family Relations. 1985;34:19&#x2013;26.</Citation></Reference><Reference><Citation>Robinson BC. Validation of a Caregiver Strain Index. J. Gerontol. 1983;38:344&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">6841931</ArticleId></ArticleIdList></Reference><Reference><Citation>George LK, Gwyther LP. Caregiver well-being: a multidimensional examination of family caregivers of demented adults. Gerontologist. 1986;26:253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">3721232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund D, Pett M, Caserta M. Institutionalizing Dementia Victims: Some Caregiver Considerations. Journal of Gerontological Social Work. 1987;11:119&#x2013;135.</Citation></Reference><Reference><Citation>Cantor MH. Strain among caregivers: a study of experience in the United States. Gerontologist. 1983;23:597&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">6662373</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitting M, Rabins P, Lucas MJ, et al. Caregivers for dementia patients: a comparison of husbands and wives. Gerontologist. 1986;26:248&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">3721231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooyman N. Taking Care: Supporting Older People and Their Families. 1986</Citation></Reference><Reference><Citation>Coen RF, Swanwick GR, O'Boyle CA, et al. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int. J. Geriatr. Psychiatry. 1997;12:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152717</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am. J. Psychiatry. 2004;161:532&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">14992980</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Ismail MS, Dagerman K, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr. Bull. 2003;29:57&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908661</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">7203086</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961;4:561&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">13688369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns. J. Gerontol. 1984;39:194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">6699375</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">3387516</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos GS, Lieberman KW, Young RC, et al. Platelet MAO activity and age at onset of depression in elderly depressed women. Am. J. Psychiatry. 1984;141:1276&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">6486267</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Kasper JD, Kleinman L, et al. Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimer disease. J Ment Health Aging. 1999;5:33&#x2013;48.</Citation></Reference><Reference><Citation>Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer's disease. J. Gerontol. 1994;49:M216&#x2013;M222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056940</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Marin DB, Kane R, et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395929</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV) Washington DC: American Psychiatric Press Inc.; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner AS, Morimoto T, Arai Y, et al. Assessing family caregiver's mental health using a statistically derived cut-off score for the Zarit Burden Interview. Aging Ment Health. 2006;10:107&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16517485</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry. 1990;147:1049&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch. Gen. Psychiatry. 1997;54:257&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">9075466</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am. J. Psychiatry. 1989;146:577&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">2653053</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54:1965&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">10822438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am. J. Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry. 2000;157:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 2003;15:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steele C, Baker L, et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J. Neuropsychiatry Clin. Neurosci. 1997;9:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am. J. Psychiatry. 2008;165:844&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714365</ArticleId><ArticleId IdType="pubmed">18519523</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am. J. Psychiatry. 1998;155:1512&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9812111</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">10496251</ArticleId></ArticleIdList></Reference><Reference><Citation>Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry. 2000;57:968&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas S, James I, Ballard C. Non-pharmacological interventions in dementia. Advan. Psychiatr. Treat. 2004;10:171&#x2013;177.</Citation></Reference><Reference><Citation>Devanand DP, Lawlor BA. Treatment of Behavioral and Psychological Symptoms of Dementia. London: Martin Dunitz; 2000.</Citation></Reference><Reference><Citation>Ostwald SK, Hepburn KW, Caron W, et al. Reducing caregiver burden: a randomized psychoeducational intervention for caregivers of persons with dementia. Gerontologist. 1999;39:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">10396888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepburn KW, Tornatore J, Center B, et al. Dementia family caregiver training: affecting beliefs about caregiving and caregiver outcomes. J. Am. Geriatr. Soc. 2001;49:450&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Teri L, Rabins P, Whitehouse P, et al. Management of behavior disturbance in Alzheimer disease: current knowledge and future directions. Alzheimer Dis. Assoc. Disord. 1992;6:77&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1389083</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlawish JH, Klocinski JL, Merz J, et al. Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology. 2000;55:1008&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">11061260</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vugt ME, Stevens F, Aalten P, et al. Do caregiver management strategies influence patient behaviour in dementia? Int. J. Geriatr. Psychiatry. 2004;19:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716704</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20808086</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease.</ArticleTitle><Pagination><StartPage>1026</StartPage><EndPage>1035</EndPage><MedlinePgn>1026-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181d6b68d</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Neuropsychiatric symptoms are common in patients with Alzheimer disease (AD). Treatment for both AD and psychiatric disturbances may affect the clinical observed pattern and comorbidity. The authors aimed to identify whether particular neuropsychiatric syndromes occur in untreated patients with AD, establish the severity of syndromes, and investigate the relationship between specific neuropsychiatric syndromes and AD disease severity.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional, multicenter, clinical study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 1,015 newly diagnosed, untreated outpatients with AD from five Italian memory clinics were consecutively enrolled in the study from January 2003 to December 2005.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">All patients underwent thorough examination by clinical neurologists/geriatricians, including neuropsychiatric symptom evaluation with the Neuropsychiatric Inventory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Factor analysis revealed five distinct neuropsychiatric syndromes: the apathetic syndrome (as unique syndrome) was the most frequent, followed by affective syndrome (anxiety and depression), psychomotor (agitation, irritability, and aberrant motor behavior), psychotic (delusions and hallucinations), and manic (disinhibition and euphoria) syndromes. More than three quarters of patients with AD presented with one or more of the syndromes (N = 790, 77.8%), and more than half exhibited clinically significant severity of symptoms (N = 603, 59.4%). With the exception of the affective one, all syndromes showed an increased occurrence with increasing severity of dementia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The authors' study supports the use of a syndrome approach for neuropsychiatric evaluation in patients with AD. Individual neuropsychiatric symptoms can be reclassified into five distinct psychiatric syndromes. Clinicians should incorporate a thorough psychiatric and neurologic examination of patients with AD and consider therapeutic strategies that focus on psychiatric syndromes, rather than specific individual symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spalletta</LastName><ForeName>Gianfranco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia, Instituto di Ricovero e Cura a Carettere Scientifico, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musicco</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alesandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rozzini</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Perri</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Canonico</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Trequattrini</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pettenati</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20808086</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181d6b68d</ArticleId><ArticleId IdType="pii">S1064-7481(12)60315-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20736422</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1542-6270</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Annals of pharmacotherapy</Title><ISOAbbreviation>Ann Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Use of psychostimulants in patients with dementia.</ArticleTitle><Pagination><StartPage>1624</StartPage><EndPage>1632</EndPage><MedlinePgn>1624-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1345/aph.1P341</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the efficacy and safety of psychostimulants for negative behavioral symptoms (ie, apathy, excessive daytime sedation) and cognition in patients with dementia.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Literature was accessed through PubMed and MEDLINE (1966-June 2010), using the terms stimulant, psychostimulant, methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, lisdexamfetamine, atomoxetine, modafinil, armodafinil, dementia, Alzheimer disease, vascular dementia, Lewy body dementia, mixed dementia, frontotemporal dementia, therapy, treatment, and therapeutic. Additional references identified from the initial search were reviewed.</AbstractText><AbstractText Label="STUDY SELECTION AND DATA EXTRACTION" NlmCategory="METHODS">All relevant clinical trials published in English and involving primarily older adults with dementia were included. Case reports, review articles, and other preclinical literature were included as appropriate.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Psychostimulants have been employed as a treatment for cognitive and behavioral symptoms in dementia for decades, but the literature has lagged behind this practice. Eight reports on use of psychostimulants as a treatment of apathy in dementia were reviewed. Methylphenidate was the most frequently studied medication and improvements in apathy were consistently noted; however, the magnitude and duration of effect remain unclear. Six studies examining the cognitive effects of a variety of psychostimulants in patients with dementia were reviewed; psychostimulants had little to no effect on cognition. A lack of studies exists to draw conclusions about the use of psychostimulants for the treatment of excessive daytime sedation in dementia. The possibility of psychostimulants to increase blood pressure; elevate heart rate; and lead to irritability, agitation, and psychosis makes careful patient selection critical, especially in older adults with severe cardiovascular disease or other underlying cardiac abnormalities.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Based on limited studies, methylphenidate is a possible treatment for apathy in patients with dementia. Psychostimulants, as a group, do not appear to be broadly effective treatments for behavioral or cognitive symptoms of dementia. The potential utility of psychostimulants must be balanced with careful patient selection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dolder</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Wingate University, NC, USA. cdolder@wingate.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Lauren Nicole</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>McKinsey</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Pharmacother</MedlineTA><NlmUniqueID>9203131</NlmUniqueID><ISSNLinking>1060-0280</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="N">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006970" MajorTopicYN="N">Disorders of Excessive Somnolence</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20736422</ArticleId><ArticleId IdType="doi">10.1345/aph.1P341</ArticleId><ArticleId IdType="pii">aph.1P341</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20689284</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms underlying caregiver stress and insight in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>63</EndPage><MedlinePgn>57-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000315513</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cluster analysis based on Alzheimer's disease (AD) neuropsychiatric profile demonstrated validity on caregiver burden, nursing-home placement and survival. The aims of our study were to explore the validity of this approach on caregiver burden, lack of insight and cognitive impairment and to examine the impact of neuropsychiatric profiles on these variables.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A data-driven approach (two-step cluster analysis) identified groups of patients based on similarities of their neuropsychiatric symptom profile, as assessed by the Neuropsychiatric Inventory (NPI). ANOVAs and chi(2) tests were used to compare groups with regard to continuous and categorical variables. Linear regressions tested the relationships between NPI and clinical variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Psychotic/behavioral, depressive and minimally symptomatic clusters differed for caregiver burden and lack of insight. Patients in the minimally symptomatic cluster showed better insight than those in the depressive cluster. Caregivers of the psychotic/behavioral cluster experienced the highest burden. We found positive relationships between NPI and lack of insight in the depressive and minimally symptomatic clusters and between NPI and caregiver burden in all three clusters. Caregiver burden was influenced by the type of symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The cluster analysis was valid for lack of insight and caregiver burden. Symptoms predominant on caregiver burden could become targets for therapy.</AbstractText><CopyrightInformation>Copyright 2010 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Turin, Turin, Italy. paola.rocca@unito.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leotta</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Liffredo</LastName><ForeName>Cesare</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mingrone</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sigaudo</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Capellero</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rocca</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Simoncini</LastName><ForeName>Mara</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pirfo</LastName><ForeName>Elvezio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bogetto</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20689284</ArticleId><ArticleId IdType="doi">10.1159/000315513</ArticleId><ArticleId IdType="pii">000315513</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20685009</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia.</ArticleTitle><Pagination><StartPage>791</StartPage><EndPage>803</EndPage><MedlinePgn>791-803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2010.06.011</ELocationID><Abstract><AbstractText>Genetic association studies investigating the association between genes of serotonergic and dopaminergic systems and behavioral and psychological symptoms in dementia (BPSD) are contradictory. We have utilized 1008 probable Alzheimer's disease (AD) patients from the UK and used the 12-item Neuropsychiatric Inventory. We applied a multiple indicators-multiple causes (MIMIC) approach to investigate the effect of 11 polymorphisms on the 4 behavioral subphenotypes "psychosis", "moods", "agitation", and "behavioural dyscontrol". Significant associations were observed between the serotonin transporter gene (SERT) polymorphism STin2 and "psychosis"; the dopamine transporter gene (DAT) 3' variable number tandem repeats (VNTR) and "agitation"; and the dopamine receptor 4 (DRD4) VNTR and "moods" factors. Direct associations were identified between the dopamine receptor 3 (DRD3) BalI polymorphism and depression; the dopamine receptor 1 (DRD1) and dopamine transporter gene 3' VNTR polymorphisms and aberrant motor behavior; the DRD4 VNTR and sleep disturbances; and the SERT gene VNTR 5HTTLPR and apathy items. Significant interactions observed between polymorphisms suggested epistatic effects and interactions between polymorphisms and medications highlighted potential treatment response. This multiple indicators multiple causes (MIMIC) model efficiently captured the complexity of the interrelations between genetic variation, behavioral symptoms, and clinical variables.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2012 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, London, UK. petroula.proitsi@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Suzanne J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Belinda M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Iyegbe</LastName><ForeName>Conrad</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>John F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018598" MajorTopicYN="N">Minisatellite Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20685009</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.06.011</ArticleId><ArticleId IdType="pii">S0197-4580(10)00276-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20684745</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-764X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Expert opinion on drug safety</Title><ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.</ArticleTitle><Pagination><StartPage>35</StartPage><EndPage>43</EndPage><MedlinePgn>35-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14740338.2010.506711</ELocationID><Abstract><AbstractText Label="IMPORTANCE OF THE FIELD" NlmCategory="BACKGROUND">Many people with Alzheimer's disease (AD) and other dementias are prescribed atypical antipsychotics for behavioral and psychiatric symptoms such as aggression and psychosis. Recent evidence has highlighted safety concerns regarding antipsychotics in these individuals.</AbstractText><AbstractText Label="AREAS COVERED IN THIS REVIEW" NlmCategory="METHODS">We summarize the evidence pertaining to efficacy and safety from short-term randomized controlled trials (up to 12 weeks), key findings from case-register studies and more detailed discussion of longer term outcome studies, including longer term mortality risk of antipsychotics in AD.</AbstractText><AbstractText Label="WHAT THE READER WILL GAIN" NlmCategory="RESULTS">The review aims to provide a balanced and up to date overview of the efficacy and safety concerns related to atypical antipsychotics in people with AD, in particular providing a detailed overview of mortality risk, and a personal interpretation of the implications and recommendations for the way forward.</AbstractText><AbstractText Label="TAKE HOME MESSAGE" NlmCategory="CONCLUSIONS">Atypical antipsychotics confer modest benefits for short-term (up to 12 weeks) treatment of aggression and psychosis in AD. These benefits have to be balanced against the risk of serious adverse events including 1.5 - 1.8-fold increased mortality. The benefits are less clear-cut with longer term prescribing, but the mortality risk remains significantly elevated. Pharmacogenetics may provide an opportunity to more effectively focus prescribing in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballard</LastName><ForeName>Clive</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wolfson Centre for Age-Related Diseases, Wolfson Wing, King's College London, Guy's Campus, Hodgkin Building, London, UK. Clive.ballard@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creese</LastName><ForeName>Byron</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Drug Saf</MedlineTA><NlmUniqueID>101163027</NlmUniqueID><ISSNLinking>1474-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20684745</ArticleId><ArticleId IdType="doi">10.1517/14740338.2010.506711</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20667296</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>7</Issue><PubDate><Year>2010</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Memantine-related psychotic symptoms in a patient with bipolar disorder.</ArticleTitle><Pagination><StartPage>957</StartPage><MedlinePgn>957</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.09l05802gry</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canan</LastName><ForeName>Fatih</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ataoglu</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20667296</ArticleId><ArticleId IdType="doi">10.4088/JCP.09l05802gry</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20625270</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial.</ArticleTitle><Pagination><StartPage>360</StartPage><EndPage>364</EndPage><MedlinePgn>360-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0b013e3181e6a4d7</ELocationID><Abstract><AbstractText>Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and 66 with AD hospitalized for behavioral disturbance were treated under randomized, double-blind conditions with citalopram or risperidone for up to 12 weeks. Neuropsychiatric symptoms were assessed with the nursing home version of the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression of Change (CGIC). Side effects were measured using the UKU Side Effect Rating Scale. A significantly higher proportion of participants with DLB (68%) than with AD (50%) discontinued the study prematurely. Discontinuation rates were comparable in DLB participants treated with citalopram (71%) or risperidone (65%). However, participants with DLB randomized to risperidone experienced a higher overall burden of side effects. Scores on the NPI and the CGIC worsened in DLB participants and improved in those with AD. Most patients with behavioral disturbances or psychosis associated with DLB tolerate citalopram or risperidone poorly and do not seem to benefit from either medication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Culo</LastName><ForeName>Sandi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>*Department of Psychiatry, University of British Columbia, Vancouver &#x2020;Department of Psychiatry, Centre for Addiction and Mental Health, and University of Toronto &#x2225;Rotman Institute, Baycrest, Toronto, Canada &#x2021;Departments of Psychiatry, Western Psychiatric Institute and Clinic &#xa7;Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Jules</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mazumdar</LastName><ForeName>Sati</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Blakesley</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Patricia R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00073658</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>M01RR0056</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59666</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH65416</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH69430</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20625270</ArticleId><ArticleId IdType="doi">10.1097/WAD.0b013e3181e6a4d7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20605008</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0948-6259</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater</Title><ISOAbbreviation>Neuropsychiatr</ISOAbbreviation></Journal><ArticleTitle>[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].</ArticleTitle><Pagination><StartPage>125</StartPage><EndPage>131</EndPage><MedlinePgn>125-31</MedlinePgn></Pagination><Abstract><AbstractText>We conducted an open, 16-week study on the efficacy of memantine on behavioral disturbances and psychotic symptoms in moderate to moderately severe Alzheimer s disease in daily routine. Fifty-three patients of 20 outpatient centers in Austria were recruited. The Neuropsychiatric Inventory (NPI) was defined as main outcome measure. After 16 weeks the total NPI score improved by 4,6 points (p&lt;0.01). The caregiver distress score was also significantly reduced. The most pronounced improvements were seen in the NPI components depression (-24,6%), aberrant motor behavior (-16,9%), agitation/agression, fear, apathy, disinhibition and disturbances in appetite and eating behavior (-11,3%, each). Our naturalistic study is in line with the results of controlled trials in moderate and severe Alzheimer dementia stages. Controlled clinical trials which have behavioral disturbances and psychotic symptoms as primary endpoint are needed to define the true potential of memantine in mild dementia stages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Reinhold</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe4;tsklinik f&#xfc;r Neurologie, Medizinische Universit&#xe4;t Graz. reinhold.schmidt@meduni-graz.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumhackl</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Berek</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Br&#xfc;cke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kapeller</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lechner</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rainer</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>St&#xf6;gerer</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Memantin in der Behandlung von Verhaltensauff&#xe4;lligkeiten und psychotischen Symptomen bei moderater bis mittelschwerer Alzheimer-Demenz: Eine naturalistische Studie im ambulanten Bereich in Osterreich.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Neuropsychiatr</MedlineTA><NlmUniqueID>9440588</NlmUniqueID><ISSNLinking>0948-6259</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20605008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20601646</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2011</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0891-9887</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of geriatric psychiatry and neurology</Title><ISOAbbreviation>J Geriatr Psychiatry Neurol</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in a population-based sample of 85-year-old individuals with dementia.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>8</EndPage><MedlinePgn>3-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0891988710373596</ELocationID><Abstract><AbstractText>Psychotic symptoms are common in elderly persons with dementia. These symptoms affect a person's ability to function in daily life and put strain on the caregiver. Most studies focus on psychotic symptoms in clinical samples with Alzheimer disease (AD). Thus, their prevalence and relation with dementia subtype and severity in very old populations is unclear. We assessed a representative sample of 85-year-old individuals living in Gothenburg, Sweden (n = 494) using neuropsychiatric examinations, key informant interviews, and medical record reviews; 147 had dementia. Dementia and its severity were diagnosed in accordance with Diagnostic and Statistical Manual of Mental Disorders (Third Edition, Revision [DSM-III-R]) criteria. Alzheimer disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria was diagnosed in 64 persons and vascular dementia (VaD) according to Erkinjuntti criteria was observed in 69. Fourteen had dementia due to other causes. Psychotic symptoms were classified according to DSM-III-R. The prevalence of psychotic symptoms in this very old population was 36% among AD cases compared to 54% in VaD cases (P = .04). Proportions with psychotic symptoms increased with increasing dementia severity in individuals with AD. No such association could be shown in those with VaD. This finding of a high proportion of psychotic symptoms also in individuals with mild severity of VaD should alert health professionals to evaluate dementia in very old patients who present with hallucinations or delusions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostling</LastName><ForeName>Svante</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Sahlgrenska Academy at Gothenburg University, Institute of Clinical Neuroscience and Physiology, Sahlgrenska University Hospital, Sweden. svante.ostling@neuro.gu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gustafson</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>B&#xf6;rjesson-Hanson</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Waern</LastName><ForeName>Margda</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Geriatr Psychiatry Neurol</MedlineTA><NlmUniqueID>8805645</NlmUniqueID><ISSNLinking>0891-9887</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20601646</ArticleId><ArticleId IdType="doi">10.1177/0891988710373596</ArticleId><ArticleId IdType="pii">0891988710373596</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20573053</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Category verbal fluency predicted changes in behavioral and psychological symptoms of dementia in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>408</StartPage><EndPage>414</EndPage><MedlinePgn>408-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1440-1819.2010.02107.x</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Alzheimer's disease (AD) is characterized by cognitive symptoms and behavioral symptoms, and their association is inconsistent. The aim of this study was to investigate the relationship between cognitive function and the changes in behavioral and psychological symptoms of dementia (BPSD) in patients with AD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 101 patients with probable AD were enrolled (57 women and 44 men, mean age 77.6 +/- 7.7 years). The Category Verbal Fluency Test (CVFT), the Mini-Mental State Examination (MMSE), the Constructional Praxis Test, the Delayed Word Recall Test, the Clinical Dementia Rating Scale, and the Neuropsychiatry Inventory (NPI) were administered at baseline. The NPI was reassessed with a median follow-up duration of 10 months (range 6-18 months). The change in the NPI scores was defined as the end-point score of the NPI minus the initial one. The associations between the changes in NPI total score, its four subdomains (hyperactivity, psychosis, affection, and apathy), and cognitive function were examined using multivariate linear models. The results were adjusted for confounders including demographics, baseline NPI, and duration of follow up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean MMSE was 18.6 +/- 5.6, the CVFT score was 7.1 +/- 3.9, and the NPI score was 10.9 +/- 13.8. Regression analyses found that the CVFT score (beta = -0.32, P = 0.004) was significantly associated with the change in NPI score, but not the MMSE, the Delayed Word Recall score, or the Constructional Praxis score. The CVFT score was significantly associated with changes in the psychosis subdomain (beta = -0.34, P = 0.001), but not the other subdomains.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study showed that CVFT was predictive of the changes in behavior disturbance in patients with AD, particularly in the psychosis domain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chia-Fen</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuu-Jiun</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fuh</LastName><ForeName>Jong-Ling</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014705" MajorTopicYN="Y">Verbal Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20573053</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2010.02107.x</ArticleId><ArticleId IdType="pii">PCN2107</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20562743</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2010</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Social behaviour vs. psychiatric features of frontotemporal dementia - Clinical report of two cases.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>182</EndPage><MedlinePgn>179-82</MedlinePgn></Pagination><Abstract><AbstractText>Behavioural disturbances are prominent in frontotemporal dementia (FTD), a focal, non-Alzheimer type of dementia. Although most patients with FTD present with socially inappropriate behaviour, compulsive-like acts, poor insight and disinhibition, the presence of psychiatric features including delusions, hallucinations, and paranoia can lead to a misclassification of FTD as psychiatric disorder. In the absence of cognitive deficits non-experts fail to recognize these social changes as dementia symptoms. We report two individuals who met current clinical criteria for behavioural or frontal variant FTD (bv-FTD), with the aim of distinguishing between psychotic symptoms and the often bizarre personality and behaviour change found in FTD. Also we review the literature on the noncognitive neuropsyhiatric manifestation of this disorder. Clinical findings presented, and a literature review, indicate that psychotic symptoms are rare in FTD. Better awareness of behavioural symptoms in clinical practice is necessary in order to avoid misdiagnosis of FTD as psychiatric disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lisci&#x107;</LastName><ForeName>Rajka Marija</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Institute for Medical Research and Occupational Health, 10001 Zagreb, Croatia. rliscic@imi.hr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogoj</LastName><ForeName>Ales</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017524" MajorTopicYN="N" Type="Geographic">Slovenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012920" MajorTopicYN="N">Social Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20562743</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">20559265</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>110</Volume><Issue>5 Suppl 1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>38</EndPage><MedlinePgn>33-8</MedlinePgn></Pagination><Abstract><AbstractText>To assess efficacy and safety of 4-month therapy with rivastigmine in Alzheimer's disease (AD) and to evaluate the burden of caregivers to these patients, 25 AD patients have been studied. Rivastigmine was prescribed internally and 22 patients were assigned to additional antipsychotic therapy at the admission to the hospital. The treatment duration was 16 weeks (12 weeks in the hospital and 4 weeks after the discharge). The study revealed that rivastigmine improved cognitive functions and led to the reduction of psychotic and behavioral disorders in AD patients at the moderate stage of the disease. The inclusion of rivastigmine in the complex treatment of AD patients resulted in the significant reduction in doses of necessary psychotropic drugs and in the complete withdrawal of all antipsychotic drugs in some patients. It should be specifically emphasized that the treatment with rivastigmine of patients with moderate AD and behavioral disorders led to the significant (up to 30%) reduction of the time spent for caregiving, the decrease of burden and the health improvement of caregivers that increase quality of life of both the patient and the family.</AbstractText></Abstract><Language>rus</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="Y">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20559265</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20555138</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Are the behavioral symptoms of Alzheimer's disease directly associated with neurodegeneration?</ArticleTitle><Pagination><StartPage>627</StartPage><EndPage>639</EndPage><MedlinePgn>627-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-100048</ELocationID><Abstract><AbstractText>Behavioral and psychological symptoms of dementia (BPSD) are commonly observed over the course of Alzheimer's disease (AD). However, it is unclear whether BPSD are part of AD neuropathology or rather represent a psychological reaction to cognitive disabilities. Using voxel-based-morphometry (VBM), we aimed to clarify this issue by investigating patients with AD at different clinical stages. Twenty-seven patients with AD (12 early [ADe] and 15 moderate [ADm]), 19 with amnestic mild cognitive impairment (a-MCI), and 23 healthy controls underwent MRI scanning at 3T. Assessment of BPSD was done in each patient using the Neuropsychiatric Inventory-12 (NPI-12). VBM was used to investigate changes in grey matter (GM) atrophy across groups, and associations between regional GM volumes and occurrence and severity of BPSD in patients. Mood disorders, anxiety, and agitation were present in both a-MCI and AD, while psychotic symptoms were observed mainly in AD. As expected, VBM showed only limited areas of GM atrophy in a-MCI patients, with a progressive extension in ADe and ADm patients (PFWE-corrected-values &lt; 0.05). Disinhibition was strongly associated with GM volume in bilateral cingulate and right middle frontal gyri, while delusions were associated with GM volume in right hippocampus (PFWE-corrected-values &lt; 0.05). This study confirms that BPSD are present since the earliest AD stages. Interesting associations were found in regions traditionally implicated by AD neuropathology. This suggests that BPSD are likely to represent clinical features of AD and should be regarded for their diagnostic and prognostic value.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroimaging Laboratory, Santa Lucia Foundation, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perri</LastName><ForeName>Roberta</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cercignani</LastName><ForeName>Mara</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Span&#xf2;</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fadda</LastName><ForeName>Lucia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Camillo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Carlesimo</LastName><ForeName>Giovanni A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Caltagirone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bozzali</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20555138</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-100048</ArticleId><ArticleId IdType="pii">B26408H43327PR02</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20537736</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2011</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6976</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Archives of gerontology and geriatrics</Title><ISOAbbreviation>Arch Gerontol Geriatr</ISOAbbreviation></Journal><ArticleTitle>Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD).</ArticleTitle><Pagination><StartPage>258</StartPage><EndPage>263</EndPage><MedlinePgn>258-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.archger.2010.04.015</ELocationID><Abstract><AbstractText>This study aimed to estimate the prevalence and explore the multidimensional complexity of the neuropsychiatric syndromes of AD. Neuropsychiatric symptoms and syndromes of 216 subjects with probable and possible AD diagnosed by NINCDS-ADRDA criteria were evaluated by the Korean version of behavior rating scale for dementia (BRSD-K). The prevalence rate of six neuropsychiatric syndromes (depressive symptoms, inertia, vegetative symptoms, irritability/aggression, behavioral dysregulation, psychotic symptoms) and comorbid neuropsychiatric syndromes were calculated according to the Clinical Dementia Rating scale. To investigate the relationship among neuropsychiatric syndromes, logistic regression analyses were performed. About 95% of patients with AD had one or more neuropsychiatric symptoms and syndromes during the past month. Among the neuropsychiatric syndromes, irritability/aggression (76.2%) was the most frequent, followed by apathy (72.3%) and depressive symptoms (68.0%). About 90% of the subjects had one or more comorbid neuropsychiatric syndromes. The mean numbers of comorbid neuropsychiatric syndromes were significantly varied according to the severity of disease (p&lt;0.05). Depressive symptoms were significantly associated with vegetative symptoms and irritability/aggression (p&lt;0.05). Inertia and psychotic symptoms were significantly associated with vegetative symptoms and behavioral dysregulation, respectively (p&lt;0.05). This study demonstrated that neuropsychiatric syndromes of AD were highly prevalent and involved complex relationships among them.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Jong Chul</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Yongin, Kyunggi-do 449-769, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Young</ForeName><Initials>DY</Initials></Author><Author ValidYN="Y"><LastName>Jhoo</LastName><ForeName>Jin Hyeong</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ki Woong</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Choo</LastName><ForeName>Il Han</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Jong Inn</ForeName><Initials>JI</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Arch Gerontol Geriatr</MedlineTA><NlmUniqueID>8214379</NlmUniqueID><ISSNLinking>0167-4943</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057565" MajorTopicYN="N">Apathy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018458" MajorTopicYN="N">Persistent Vegetative State</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20537736</ArticleId><ArticleId IdType="doi">10.1016/j.archger.2010.04.015</ArticleId><ArticleId IdType="pii">S0167-4943(10)00116-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20523051</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Validity and reliability of the Persian language version of the neuropsychiatry unit cognitive assessment tool.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>522</EndPage><MedlinePgn>516-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000313981</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Only a limited number of cognitive screening tools are available for the Persian-speaking population, and we sought to translate and validate the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG), a multidimensional cognitive screening tool.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used multiple language specialists to translate and then back-translate the NUCOG, and administered the Persian language NUCOG and Mini-Mental State Examination (MMSE) to 184 individuals: 60 controls and 124 patients, 33 of whom had dementia, 30 non-dementing neurological disorders and 61 a psychiatric illness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The NUCOG outperformed the MMSE in differentiating the patient groups and controls. The 'profile' across the 5 NUCOG domains differentiated dementia subgroups such as senile dementia of the Alzheimer type (SDAT), frontotemporal dementia and mild cognitive impairment (MCI). Psychiatric patients with psychosis and posttraumatic stress disorder were more impaired than patients with affective disorders. The NUCOG reliably differentiated controls from patients with MCI (at 86.5/100, sensitivity of 83.3% and specificity of 87.5%) and SDAT (at 75/100, sensitivity and specificity of 100%) patients from controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The Persian language NUCOG appears to perform strongly in an unselected population, reliably differentiating patients with dementia from controls, and detecting cognitive impairment in a range of clinical disorders.</AbstractText><CopyrightInformation>Copyright 2010 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barekatain</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walterfang</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Behdad</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tavakkoli</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mahvari</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Maracy</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Velakoulis</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003943" MajorTopicYN="Y">Diagnostic Techniques, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014177" MajorTopicYN="N">Translations</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20523051</ArticleId><ArticleId IdType="doi">10.1159/000313981</ArticleId><ArticleId IdType="pii">000313981</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20514637</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2010</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1576-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Psychological and behavioural symptoms as factors of progression to Alzheimer-type dementia in mild cognitive impairment].</ArticleTitle><Pagination><StartPage>653</StartPage><EndPage>660</EndPage><MedlinePgn>653-60</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Mild cognitive impairment (MCI) is a cognitive disturbance in which intensity is not enough to be classified as dementia and does not affect significantly the functioning or activities of daily living. The MCI has a progression rate to Alzheimer-type dementia (ATD) related to different factors.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the association between the presence of psychological and behavioural symptoms (PBS) with progression to ATD en MCI subjects.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We evaluated 318 patients with MCI assessed in a Dementia Unit of Catalonia between 1998 to 2002 who were followed five years after the MCI diagnosis. We determined the PBS presence, those classified as affective, behavioural and psychotic symptoms. We also assessed sociodemographic aspects and the ApoE genotype.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age was 74 +/- 7.87 years-old, 56.7% presented PBS, with affective (53%), behavioural (32.2%) and psychotic symptoms (14.8%). In the study, 32.1% progressed to ATD. We found association between the presence of PBS and the progression to ATD (OR = 2.77; 95% CI = 1.66-4.63), specifically with behavioural and psychotic symptoms. The ApoE epsilon4 allele showed association with the progression to ATD (OR = 1.81; 95% CI = 1.11-2.94). The logistic regression model showed a significant association between the PBS and the epsilon4 allele with the progression to ATD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The PBS presence in MCI patients is associated with ATD progression with or without ApoE epsilon4 allele.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reyes-Figueroa</LastName><ForeName>Julio C&#xe9;sar</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Hospital Psiqui&#xe0;tric Universitari Institut Pere Mata, ISPV, Universitat Rovira i Virgili Reus, Tarragona, Espa&#xf1;a. reyesj@peremata.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosich-Estrag&#xf3;</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bordas-Buera</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gaviria-G&#xf3;mez</LastName><ForeName>Ana Milena</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Vilella-Cuadrada</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Labad-Alqu&#xe9;zar</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>S&#xed;ntomas psicol&#xf3;gicos y conductuales como factores de progresi&#xf3;n a demencia tipo Alzheimer en el deterioro cognitivo leve.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20514637</ArticleId><ArticleId IdType="pii">rn2009714</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20496284</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3843</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Neurologia i neurochirurgia polska</Title><ISOAbbreviation>Neurol Neurochir Pol</ISOAbbreviation></Journal><ArticleTitle>The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>147</EndPage><MedlinePgn>139-47</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to determine whether dementia with Lewy bodies (DLB) progres-ses more rapidly than Alzheimer disease (AD) and to compare survival after dementia onset and mortality in both dementia groups.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">A medical records analysis of AD (n = 183) and DLB (n = 51) patients was performed to determine age at onset of symptoms, the date of first presentation to the psychiatric services, dementia severity at diagnosis (MMSE score), and mean disease duration before diagnosis. Categorical data regarding vascular risk factors were collected. Projected decline rate (MMSE/year), survival rate after the diagnosis of dementia, mean survival time after diagnosis and mortality rate were calculated and compared between DLB and AD groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The comparison of clinical and demographic parameters revealed no significant differences between groups, apart from a more pronounced decline rate in the DLB group. Diabetes, and to a lesser extent hypertension, influenced survival in AD, but not in DLB subjects. Overall, however, the difference in mortality rates and survival time between DLB and AD subjects cannot be attributed to the presence of any vascular risk factor analysed. DLB, independently of the presence of vascular risk factors, seems to be a more aggressive disorder than AD, when mortality and survival time are taken into account.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">More rapid progression of cognitive decline and shorter duration of dementia were found in DLB in this naturalistic study. The findings may have important implications for the management and treatment of DLB and should be confirmed in prospective studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Magierski</LastName><ForeName>Rados&#x142;aw</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland. r.magierski@csk.umed.lodz.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz M</ForeName><Initials>TM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Neurol Neurochir Pol</MedlineTA><NlmUniqueID>0101265</NlmUniqueID><ISSNLinking>0028-3843</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20496284</ArticleId><ArticleId IdType="doi">10.1016/s0028-3843(14)60005-0</ArticleId><ArticleId IdType="pii">S0028-3843(14)60005-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20441786</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5118</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Progress in neurobiology</Title><ISOAbbreviation>Prog Neurobiol</ISOAbbreviation></Journal><ArticleTitle>The putative neurodegenerative links between depression and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>362</StartPage><EndPage>375</EndPage><MedlinePgn>362-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pneurobio.2010.04.005</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the leading neurodegenerative cause of dementia in the elderly. Thus far, there is no curative treatment for this devastating condition, thereby creating significant social and medical burdens. AD is characterized by progressive cognitive decline along with various neuropsychiatric symptoms, including depression and psychosis. Depression is a common psychiatric disorder affecting individuals across the life span. Although the "monoamine hypothesis" of depression has long been proposed, the pathologies and mechanisms for depressive disorders remain only partially understood. Pharmacotherapies targeting the monoaminergic pathways have been the mainstay in treating depression. Additional therapeutic approaches focusing other pathological mechanisms of depression are currently being explored. Interestingly, a number of proposed mechanisms for depression appear to be similar to those implicated in neurodegenerative diseases, including AD. For example, diminishing neurotrophic factors and neuroinflammation observed in depression are found to be associated with the development of AD. This article first provides a concise review of AD and depression, then discusses the putative links between the two neuropsychiatric conditions.</AbstractText><CopyrightInformation>(c) 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wuwongse</LastName><ForeName>Suthicha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, LKS Faculty of Medicine, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Raymond Chuen-Chung</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Andrew C K</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neurobiol</MedlineTA><NlmUniqueID>0370121</NlmUniqueID><ISSNLinking>0301-0082</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>232</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20441786</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2010.04.005</ArticleId><ArticleId IdType="pii">S0301-0082(10)00095-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20438444</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6638</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Medicinal chemistry (Shariqah (United Arab Emirates))</Title><ISOAbbreviation>Med Chem</ISOAbbreviation></Journal><ArticleTitle>Dimethyl-carbamic acid 2,3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine-1-Carbonyl)-phenyl ester: a novel multi-target therapeutic approach to neuroprotection.</ArticleTitle><Pagination><StartPage>123</StartPage><EndPage>140</EndPage><MedlinePgn>123-40</MedlinePgn></Pagination><Abstract><AbstractText>We report herein the synthesis and biological evaluation of dimethyl-carbamic acid 2,3-bis-dimethylcarbamoyloxy-6-(4-ethyl-piperazine-1-carbonyl)-phenyl ester (SP-04), a new drug candidate that is designed to offer a multi-target therapeutic neuroprotective approach as a treatment for Alzheimer's disease (AD). SP-04 inhibits acetylcholinesterase (AchE) activity both in vitro and in vivo, and induces a dose-dependent increase in Ach levels. SP-04 releases the metabolite 4-(4-ethyl-piperazin-1-yl)-1-(2,3,4-trihydroxy-phenyl)-butan-1-one (SP-04m). Both SP-04 and SP-04m are s1-receptor antagonists supporting their interest in relieving symptoms related to psychosis, a non-cognitive condition often associated with AD. SP-04m displays important antioxidant properties and both SP-04 and SP-04m offers neuroprotection against Ab&#xf031;42 toxicity in various neuronal cell lines. In addition, both SP-04 and SP-04m protect neuronal cells and rat brain mitochondria exposed to various mitochondrial respiratory chain complex toxins. Taken together these data suggest that the SP-04 multi-targeting approach might offer a novel therapeutic strategy for the treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lecanu</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Research Institute of the McGill University, Health Centre and the Departments of Medicine, Biochemistry and Pharmacology &amp; Therapeutics, McGill University, 1650 Cedar Avenue, C10-148, Montreal, Quebec H3G 1A4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tillement</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McCourty</LastName><ForeName>Althea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rammouz</LastName><ForeName>Georges</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Wenguo</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Greeson</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Vassilios</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R41AG024684</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Med Chem</MedlineTA><NlmUniqueID>101240303</NlmUniqueID><ISSNLinking>1573-4064</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558225">4-(4-ethyl-piperazin-1-yl)-1-(2,3,4-trihydroxyphenyl)butan-1-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058851">GPI-Linked Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558224">dimethyl-carbamic acid 2,3-bis-dimethylcarbamoyloxy-6-(4-ethylpiperazine-1-carbonyl)phenyl ester</NameOfSubstance></Chemical><Chemical><RegistryNumber>632XD903SP</RegistryNumber><NameOfSubstance UI="D005707">Gallic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="D000110">Acetylcholinesterase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.7</RegistryNumber><NameOfSubstance UI="C548246">Ache protein, rat</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000110" MajorTopicYN="N">Acetylcholinesterase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058851" MajorTopicYN="N">GPI-Linked Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005707" MajorTopicYN="N">Gallic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016716" MajorTopicYN="N">PC12 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="N">Receptors, sigma</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097605" MajorTopicYN="N">Sigma-1 Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20438444</ArticleId><ArticleId IdType="doi">10.2174/1573406411006030123</ArticleId><ArticleId IdType="pii">MC-Abs-037</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20420490</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Combination treatments in Alzheimer's disease: risks and benefits.</ArticleTitle><Pagination><StartPage>693</StartPage><EndPage>702</EndPage><MedlinePgn>693-702</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1586/ern.10.43</ELocationID><Abstract><AbstractText>Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to boost the clinical effects by adding drugs with different modes of action, or by adding a compound that is not neurotransmitter-based and not directly symptomatic, which may result in achieving disease progression modification. Recent studies with add-on therapies in Alzheimer's disease, apart from expanding our clinical knowledge, have also provided some new insights to guide future studies and therapeutic approaches. One such lesson is the critical necessity for precise characterization of subjects recruited to the studies, preferably with the use of biomarkers. Currently, even the best studied combination (memantine with a cholinesterase inhibitor) still requires further detailed trials to elucidate its usefulness at different disease stages, in patients with comorbidities, with or without the use of other concomitant medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sobow</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Czechoslowacka 8/10, Lodz, Poland. tomasz.sobow@umed.lodz.pl</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014815">Vitamins</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>82</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20420490</ArticleId><ArticleId IdType="doi">10.1586/ern.10.43</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20373664</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1294-8322</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Dialogues in clinical neuroscience</Title><ISOAbbreviation>Dialogues Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Epigenetic approaches to psychiatric disorders.</ArticleTitle><Pagination><StartPage>25</StartPage><EndPage>35</EndPage><MedlinePgn>25-35</MedlinePgn></Pagination><Abstract><AbstractText>Psychiatric diseases place a tremendous burden on affected individuals, their caregivers, and the health care system. Although evidence exists for a strong inherited component to many of these conditions, dedicated efforts to identify DNA sequence-based causes have not been exceptionally productive, and very few pharmacologic treatment options are clinically available. Many features of psychiatric diseases are consistent with an epigenetic dysregulation, such as discordance of monozygotic twins, late age of onset, parent-of-origin and sex effects, and fluctuating disease course. In recent years, experimental technologies have significantly advanced, permitting in-depth studies of the epigenome and its role in maintenance of normal genomic functions, as well as disease etiopathogenesis. Here, we present an epigenetic explanation for many characteristics of psychiatric disease, review the current literature on the epigenetic mechanisms involved in major psychosis, Alzheimer's disease, and autism spectrum disorders, and describe some future directions in the field of psychiatric epigenomics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ptak</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Krembil Family Epigenetics Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petronis</LastName><ForeName>Arturas</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH074127</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH088413</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dialogues Clin Neurosci</MedlineTA><NlmUniqueID>101238198</NlmUniqueID><ISSNLinking>1294-8322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las enfermedades psiqui&#xe1;tricas determinan un enorme costo para los individuos afectados, sus cuidadores y el sistema de atenci&#xf3;n de salud. Aunque existe evidencia de un fuerte componente hereditario para muchas de estas condiciones, los esfuerzos dedicados a identificar las causas en base a las secuencias de ADN no han resultado especialmente productivos y son muy pocas las opciones de tratamientos farmacol&#xf3;gicos que est&#xe1;n cl&#xed;nicamente disponibles. Muchas caracter&#xed;sticas de las enfermedades psiqui&#xe1;tricas son concordantes con una falta de regulaci&#xf3;n epigen&#xe9;tica, como la discordancia de los gemelos monocig&#xf3;ticos, la edad tard&#xed;a de aparici&#xf3;n, los efectos del sexo y de los padres biol&#xf3;gicos y el curso fluctuante de la enfermedad. Recientemente las tecnolog&#xed;as experimentales han avanzado de manera significativa, permitiendo estudios a fondo del epigenoma y de su papel en el mantenimiento de las funciones gen&#xf3;micas normales, como tambi&#xe9;n en la etiopatogenia de las enfermedades. En este art&#xed;culo se presenta una explicaci&#xf3;n epigen&#xe9;tica para muchas caracter&#xed;sticas de la enfermedad psiqui&#xe1;trica, se revisa la literatura actual acerca de los mecanismos epigen&#xe9;ticos involucrados en las principales psicosis, la Enfermedad de Alzheimer, y los trastornos del espectro aut&#xed;stico, y se describen algunas l&#xed;neas a futuro en el campo de la epigen&#xf3;mica psiqui&#xe1;trica.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="fre"><AbstractText>Les maladies psychiatriques p&#xe8;sent consid&#xe9;rablement sur les individus atteints, leurs soignants et sur le syst&#xe8;me de sant&#xe9;. M&#xea;me s'il existe des arguments pour une forte h&#xe9;ritabilit&#xe9; de beaucoup de ces troubles, les efforts port&#xe9;s sur l'identification des causes li&#xe9;es &#xe0; une s&#xe9;quence ADN n'ont pas &#xe9;t&#xe9; tr&#xe8;s productifs et tr&#xe8;s peu de traitements pharmacologiques sont disponibles. De nombreuses caract&#xe9;ristiques des maladies psychiatriques concordent avec une dysr&#xe9;gulation &#xe9;pig&#xe9;n&#xe9;tique, comme une discordance entre jumeaux monozygotes, un d&#xe9;but tardif, des effets li&#xe9;s au sexe et aux origines parentales et une &#xe9;volution fluctuante de la maladie. Ces derni&#xe8;res ann&#xe9;es, des avanc&#xe9;es significatives des technologies exp&#xe9;rimentales ont permis d'&#xe9;tudier en profondeur l'&#xe9;pig&#xe9;nome et son r&#xf4;le dans le maintien des fonctions g&#xe9;nomiques normales comme dans l'&#xe9;tiopathogen&#xe8;se de la maladie. Nous pr&#xe9;sentons dans cet article une explication &#xe9;pig&#xe9;n&#xe9;tique pour de nombreuses caract&#xe9;ristiques des maladies psychiatriques, nous analysons la litt&#xe9;rature actuelle sur les m&#xe9;canismes &#xe9;pig&#xe9;n&#xe9;tiques impliqu&#xe9;s dans les psychoses majeures, la maladie d'Alzheimer et les troubles autistiques et nous donnons quelques perspectives dans le domaine de l'&#xe9;pig&#xe9;nomique psychiatrique.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20373664</ArticleId><ArticleId IdType="pmc">PMC3181944</ArticleId><ArticleId IdType="doi">10.31887/DCNS.2010.12.1/cptak</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Henikoff S, Matzke MA. Exploring and explaining epigenetic effects. Trends Genet. 1997;13:293&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">9260513</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220929</ArticleId></ArticleIdList></Reference><Reference><Citation>Riggs AD, Xiong Z, Wang L, LeBon JM. Methylation dynamics, epigenetic fidelity and X chromosome structure. Novartis Found Symp. 1998;214:214&#x2013;25 discussion 25-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9601020</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards EJ. Inherited epigenetic variation--revisiting soft inheritance. Nat Rev Genet. 2006;7:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminsky ZA, Tang T, Wang SC, et al. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet. 2009;41:240&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">19151718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaenisch R, Bird A. Epigenetic regulation of gene expression how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(suppl):245&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">12610534</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey CA, Sargent DF, Luger K, Maeder AW, Richmond TJ. Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution. J Mol Biol. 2002;319:1097&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">12079350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263819</ArticleId><ArticleId IdType="pubmed">19372393</ArticleId></ArticleIdList></Reference><Reference><Citation>Margueron R, Trojer P, Reinberg D. The key to development interpreting the histone code? Curr Opin Genet Dev. 2005;15:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15797199</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">12724214</ArticleId></ArticleIdList></Reference><Reference><Citation>Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol. 2007;8:307&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">17342184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson TB, Chen T. LSD1 demethylates histone and non-histone proteins. Epigenetics. 2009;4:129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19395867</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss D, Plomin R, Hetherington EM. Genetics and psychiatry: an unheralded window on the environment. Am J Psychiatry. 1991;148:283&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">1992831</ArticleId></ArticleIdList></Reference><Reference><Citation>Petronis A, Gottesman II, Kan P, et al. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull. 2003;29:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12908672</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102:10604&#x2013;10609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1174919</ArticleId><ArticleId IdType="pubmed">16009939</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry. 1997;154:1641&#x2013;1647.</Citation><ArticleIdList><ArticleId IdType="pubmed">9396940</ArticleId></ArticleIdList></Reference><Reference><Citation>Auger AP, Jessen HM. Corepressors, nuclear receptors, and epigenetic factors on DNA a tail of repression. Psychoneuroendocrinology. 2009;34 (suppl 1):S39&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3133443</ArticleId><ArticleId IdType="pubmed">19545950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. Ann Med. 2006;38:530&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pubmed">17438668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara K, Xu HD, Mori N, et al. Anticipation and imprinting in schizophrenia. Biol Psychiatry. 1997;42:760&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">9347124</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Avramopoulos D, Fallin D. Evidence for parent of origin effect in late-onset Alzheimer disease. Am J Med Genet. 2002;114:679&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb JA, Barnby G, Bonora E, et al. Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. J Med Genet. 2005;42:132&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735992</ArticleId><ArticleId IdType="pubmed">15689451</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze TG, Chen YS, Badner JA, et al. Additional, physically ordered markers increase linkage signal for bipolar disorder on chromosome 18q22. Biol Psychiatry. 2003;53:239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">12559657</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlow DP. Gametic imprinting in mammals. Science. 1995;270:1610&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pubmed">7502071</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaval K, Wagschal A, Feil R. Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. Bioessays. 2006;28:453&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">16615080</ArticleId></ArticleIdList></Reference><Reference><Citation>Petronis A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry. 2004;55:965&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">15121478</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland JE, Costa M. Epigenetics and the environment. Ann NY Acad Sci. 2003;983:151&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">12724220</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, Sweatt JD. Epigenetic mechanisms: a common theme in vertebrate and invertebrate memory formation. Cell Mol Life Sci. 2006;63:1009&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11136205</ArticleId><ArticleId IdType="pubmed">16596331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin FD, Roth TL, Sweatt JD. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J Neurosci. 2008;28:10576&#x2013;10586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312036</ArticleId><ArticleId IdType="pubmed">18923034</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, van Groen T, Kadish I, Tollefsbol TO. DNA methylation impacts on learning and memory in aging. Neurobiol Aging. 2009;30:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656583</ArticleId><ArticleId IdType="pubmed">17850924</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando V. Polycomb, epigenomes, and control of cell identity. Cell. 2003;112:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">12628181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Levenson JM, Korsmeyer S, Sweatt JD, Schumacher A. Developmental regulation of Eed complex composition governs a switch in global histone modification in brain. J Biol Chem. 2007;282:9962&#x2013;9972.</Citation><ArticleIdList><ArticleId IdType="pubmed">17259173</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, O'Riordan KJ, Brown KD, et al. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem. 2004;279:40545&#x2013;40559.</Citation><ArticleIdList><ArticleId IdType="pubmed">15273246</ArticleId></ArticleIdList></Reference><Reference><Citation>Levenson JM, Roth TL, Lubin FD, et al. Evidence that DNA (cytosine5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem. 2006;281:15763&#x2013;15773.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606618</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh SH, Lin CH, Gean PW. Acetylation of nuclear factor-kappaB in rat amygdala improves long-term but not short-term retention of fear memory. Mol Pharmacol. 2004;65:1286&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivleva E, Thaker G, Tamminga CA. Comparing genes and phenomenology in the major psychoses schizophrenia and bipolar 1 disorder. Schizophr Bull. 2008;34:734&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632452</ArticleId><ArticleId IdType="pubmed">18515820</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 1995;346:477&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">7637483</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet. 2005;42:193&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736023</ArticleId><ArticleId IdType="pubmed">15744031</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock N, Jones I. Genetics of bipolar disorder. J Med Genet. 1999;36:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762980</ArticleId><ArticleId IdType="pubmed">10465107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertelsen A, Gottesman II. Schizoaffective psychoses: genetical clues to classification. Am J Med Genet. 1995;60:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">7485238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardno AG, Gottesman II. Twin studies of schizophrenia: from bowand-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000;97:12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">10813800</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome. Hum Genet. 2009;126:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19521722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82:696&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427301</ArticleId><ArticleId IdType="pubmed">18319075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta DS, McCullumsmith RE, Beneyto M, et al. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse. 2005;57:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15945063</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastwood SL, Harrison PJ. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res. 2005;73:159&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653259</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, MeadorWoodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res. 2005;75:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15820321</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyaoka T, Seno H, Ishino H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr Res. 1999;38:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10427605</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA. 2005;102:9341&#x2013;9346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1166626</ArticleId><ArticleId IdType="pubmed">15961543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tochigi M, Iwamoto K, Bundo M, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry. 2008;63:530&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">17870056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock WM, Cardon K, Bustillo J, Roberts RC, Perrone-Bizzozero NI. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry. 2008;165:1594&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923069</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav. 2002;77:501&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">12526990</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003;23:6315&#x2013;63126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740534</ArticleId><ArticleId IdType="pubmed">12867516</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HS, Matevossian A, Whittle C, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27:11254&#x2013;11262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673022</ArticleId><ArticleId IdType="pubmed">17942719</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma RP, Grayson DR, Gavin DP. Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res. 2008;98:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2254186</ArticleId><ArticleId IdType="pubmed">17961987</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS One. 2007;2:e809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950080</ArticleId><ArticleId IdType="pubmed">17726539</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S, Ruehl MG, Bliven E, et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry. 2005;62:829&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">16061760</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldic M, Caruncho HJ, Liu WS, et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci U S A. 2004;101:348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314188</ArticleId><ArticleId IdType="pubmed">14684836</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldic M, Kadriu B, Maloku E, et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res. 2007;91:51&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876737</ArticleId><ArticleId IdType="pubmed">17270400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhubi A, Veldic M, Puri NV, et al. An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res. 2009;111:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031301</ArticleId><ArticleId IdType="pubmed">19386473</ArticleId></ArticleIdList></Reference><Reference><Citation>Satta R, Maloku E, Zhubi A, et al. Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci U S A. 2008;105:16356&#x2013;16361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570996</ArticleId><ArticleId IdType="pubmed">18852456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lising-Enriquez K, George TP. Treatment of comorbid tobacco use in people with serious mental illness. J Psychiatry Neurosci. 2009;34:E1&#x2013;E2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674967</ArticleId><ArticleId IdType="pubmed">19448844</ArticleId></ArticleIdList></Reference><Reference><Citation>McGowan PO, Kato T. Epigenetics in mood disorders. Environ Health Prev Med. 2008;13:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698240</ArticleId><ArticleId IdType="pubmed">19568875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuratomi G, Iwamoto K, Bundo M, et al. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol Psychiatry. 2008;13:429&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">17471289</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer J, Johannssen K, Freitag CM, et al. Rare variants of the gene encoding the potassium chloride co-transporter 3 are associated with bipolar disorder. Int J Neuropsychopharmacol. 2005;8:495&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098236</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser D, Ekawardhani S, Kumsta R, et al. Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009;34:458&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536702</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyanik G, Elcioglu N, Penzien J, et al. Novel truncating and missense mutations of the KCC3 gene associated with Andermann syndrome. Neurology. 2006;66:1044&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennvik K, Fastbom J, Blomberg M, et al. Levels of alpha-and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 2000;278:169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">10653020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer's diseaseadvising relatives. Br J Psychiatry. 2001;178:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136203</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano S, Gonzalez J, Marcos A, Matias-Guiu J. [Genetics and Alzheimer's disease]. Neurologia. 2009;24:83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">19322684</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunblatt E. Commonalities in the genetics of Alzheimer's disease and Parkinson's disease. Expert Rev Neurother. 2008;8:1865&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">19086884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Avramopoulos D, Perry RT, et al. Further evidence of a maternal parent-of-origin effect on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586169</ArticleId><ArticleId IdType="pubmed">16741936</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinoy DC, Das R, Weidman JR, Jirtle RL. Metastable epialleles, imprinting, and the fetal origins of adult diseases. Pediatr Res. 2007;61:30R&#x2013;37R.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413847</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegmund KD, Connor CM, Campan M, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One. 2007;2:e895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1964879</ArticleId><ArticleId IdType="pubmed">17878930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyaux D, Decaestecker C, Heizmann CW, et al. S100 proteins in Corpora amylacea from normal human brain. Brain Res. 2000;867:280&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in lateonset Alzheimer's disease. PLoS One. 2008;3:e2698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2444024</ArticleId><ArticleId IdType="pubmed">18628954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornsson HT, Sigurdsson MI, Fallin MD, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA. 2008;299:2877&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581898</ArticleId><ArticleId IdType="pubmed">18577732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollati V, Schwartz J, Wright R, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev. 2009;130:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956267</ArticleId><ArticleId IdType="pubmed">19150625</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumbier E, Domes G, Herpertz-Dahlmann B, Herpertz SC. [Autism and autistic disorders: Historical and current aspects]. Nervenarzt. 2010;81:55&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">19597797</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallmayer J, Glasson EJ, Bower C, et al. On the twin risk in autism. Am J Hum Genet. 2002;71:941&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378547</ArticleId><ArticleId IdType="pubmed">12297988</ArticleId></ArticleIdList></Reference><Reference><Citation>Piggot J, Shirinyan D, Shemmassian S, Vazirian S, Alarcon M. Neural systems approaches to the neurogenetics of autism spectrum disorders. Neuroscience. 2009;164:247&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">19482063</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespi B. Genomic imprinting in the development and evolution of psychotic spectrum conditions. Biol Rev Camb Philos Soc. 2008;83:441&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">18783362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusufzai TM, Wolffe AP. Functional consequences of Rett syndrome mutations on human MeCP2. Nucleic Acids Res. 2000;28:4172&#x2013;4179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC113135</ArticleId><ArticleId IdType="pubmed">11058114</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JI, Hong EP, Castle JC, et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci U S A. 2005;102:17551&#x2013;17558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266160</ArticleId><ArticleId IdType="pubmed">16251272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriaucionis S, Bird A. DNA methylation and Rett syndrome. Hum Mol Genet. 2003;12 Spec No 2:R221&#x2013;R227.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928486</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001;27:322&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242117</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins AL, Levenson JM, Vilaythong AP, et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet. 2004;13:2679&#x2013;2689.</Citation><ArticleIdList><ArticleId IdType="pubmed">15351775</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazian M, Young J, Yuva-Paylor L, et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. 2002;35:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160743</ArticleId></ArticleIdList></Reference><Reference><Citation>Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci. 2009;29:5051&#x2013;5061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3436907</ArticleId><ArticleId IdType="pubmed">19386901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics. 2006;1:e1&#x2013;e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866172</ArticleId><ArticleId IdType="pubmed">17486179</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan RP, Patzel KA, Martin M, et al. MECP2 promoter methylation and X chromosome inactivation in autism. Autism Res. 2008;1:169&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614877</ArticleId><ArticleId IdType="pubmed">19132145</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan AM, Liang X, Luo Y, et al. The loss of methyl-CpG binding protein 1 leads to autism-like behavioral deficits. Hum Mol Genet. 2008;17:2047&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700628</ArticleId><ArticleId IdType="pubmed">18385101</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegbola A, Gao H, Sommer S, Browning M. A novel mutation in JARID1C/SMCX in a patient with autism spectrum disorder (ASD). Am J Med Genet A. 2008;146A:505&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">18203167</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran LK, Newschaffer CJ, Lee LC, et al. Behaviors associated with fever in children with autism spectrum disorders. Pediatrics. 2007;120:e1386&#x2013;e1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">18055656</ArticleId></ArticleIdList></Reference><Reference><Citation>Plagge A, Isles AR, Gordon E, et al. Imprinted Nesp55 influences behavioral reactivity to novel environments. Mol Cell Biol. 2005;25:3019&#x2013;3026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069615</ArticleId><ArticleId IdType="pubmed">15798190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehler MF, Purpura DP. Autism, fever, epigenetics and the locus coeruleus. Brain Res Rev. 2009;59:388&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668953</ArticleId><ArticleId IdType="pubmed">19059284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundakovic M, Chen Y, Costa E, Grayson DR. DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol. 2007;71:644&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065238</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash PK, Orsi SA, Moore AN. Histone deactylase inhibition combined with behavioral therapy enhances learning and memory following traumatic brain injury. Neuroscience. 2009;213:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4217276</ArticleId><ArticleId IdType="pubmed">19531374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003;100:2041&#x2013;2046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149955</ArticleId><ArticleId IdType="pubmed">12576549</ArticleId></ArticleIdList></Reference><Reference><Citation>Camelo S, Iglesias AH, Hwang D, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;164:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15885809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PS, Peng GS, Li G, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry. 2006;11:1116&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">16969367</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagtas AS, Edens ER, Gilbert KM. Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4(+) T cells. Int Immunopharmacol. 2009;9:1289&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">19664724</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley B, D'Annibale MA, Suh K, et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci. 2008;28:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577229</ArticleId><ArticleId IdType="pubmed">18171934</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008;118:296&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">18798830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Exp Rev Neurother. 2007;7:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajatovic M, Coconcea N, Ignacio RV, et al. Adjunct extended-release valproate semisodium in late life schizophrenia. Int J Geriatr Psychiatry. 2008;23:142&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">17582828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajduk PJ, Greer J. A decade of fragment-based drug designs: trategic advances and lessons learned. Nat Rev Drug Discov. 2007:6211&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">17290284</ArticleId></ArticleIdList></Reference><Reference><Citation>Strausberg RL, Schreiber SL. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science. 2003;300:294&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">12690189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25:473&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">17289593</ArticleId></ArticleIdList></Reference><Reference><Citation>Waggoner D. Mechanisms of disease: epigenesis. Semin Pediatr Neurol. 2007;14:7&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">17331879</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushparaj PN, Melendez AJ. Short interfering RNA (siRNA) as a novel therapeutic. Clin Exp Pharmacol Physiol. 2006;33:504&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">16700886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein E, Allis CD. RNA meets chromatin. Genes Dev. 2005;19:1635&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamieson AC, Miller JC, Pabo CO. Drug discovery with engineered zincfinger proteins. Nat Rev Drug Discov. 2003;2:361&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12750739</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu GL, Bestor TH. Cytosine methylation targetted to pre-determined sequences. Nat Genet. 1997;17:376&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">9398832</ArticleId></ArticleIdList></Reference><Reference><Citation>Roelfsema JH, White SJ, Ariyurek Y, et al. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet. 2005;76:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1199295</ArticleId><ArticleId IdType="pubmed">15706485</ArticleId></ArticleIdList></Reference><Reference><Citation>Philibert RA, Gunter TD, Beach SR, Brody GH, Madan A. MAOA methylation is associated with nicotine and alcohol dependence in women. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:565&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685146</ArticleId><ArticleId IdType="pubmed">18454435</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonsch D, Lenz B, Fiszer R, et al. Lowered DNA methyltransferase (DNMT3b) mRNA expression is associated with genomic DNA hypermethylation in patients with chronic alcoholism . J Neural Transm. 2006;113:1 299&#x2013;1304.</Citation><ArticleIdList><ArticleId IdType="pubmed">16463117</ArticleId></ArticleIdList></Reference><Reference><Citation>Stack EC, Del Signore SJ, Luthi-Carter R, et al. Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet. 2007;16:1164&#x2013;1175.</Citation><ArticleIdList><ArticleId IdType="pubmed">17403718</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren ST. The Epigenetics of Fragile X Syndrome. Cell Stem Cell. 2007;1:488&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">18938744</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling E, El Chartouni C, Rehli M. Allele-specific DNA methylation in mouse strains is mainly determined by cis-acting sequences. Genome Res. 2009;19:2028&#x2013;2035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775599</ArticleId><ArticleId IdType="pubmed">19687144</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20297855</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1934</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.</ArticleTitle><Pagination><StartPage>303</StartPage><EndPage>317</EndPage><MedlinePgn>303-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2165/11530260-000000000-00000</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive deficits have been described in patients with schizophrenia from the first descriptions of dementia praecox to current concepts of cognitive dysmetria. Nevertheless, little is known about how to deal with them. In Alzheimer disease, cholinergic deficit is found and cholinesterase inhibitors have been used to delay the progression of memory and cognitive dysfunction. Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate cognitive and clinical effects of adjunctive cholinesterase inhibitors in patients with schizophrenia and schizoaffective disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a literature search on PubMed and EMBASE (up to December 2008) for articles that investigated adjunctive cholinesterase inhibitors in patients with schizophrenia. The terms 'schizophrenia', 'acetylcholinesterase inhibitors', 'rivastigmine', 'donepezil', 'galantamine' and 'cognitive deficit' were searched with restriction for English language and without a year limit. All articles that presented original data from randomized, double-blind, placebo-controlled trials with donepezil, rivastigmine or galantamine in patients with schizophrenia or schizoaffective disorder were included in the meta-analysis. Studies were excluded for the following reasons: (i) case study/letter/correspondence/review; (ii) animal study; (iii) molecular/genetic investigation; and (iv) inclusion of patients with schizophrenia and co-morbid dementia. Few appropriate data for meta-analysis were found because of the large heterogeneity of the assessment instruments used. Nevertheless, effects of cholinesterase inhibitors in some cognitive domains (executive function, memory and language), psychopathology (using the Positive and Negative Syndrome Scale) and extrapyramidal symptoms could be analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Six open-label and 24 double-blind studies were found. In five open-label studies there was an improvement in memory, attention and executive functions. Thirteen double-blind studies (four with rivastigmine, six with donepezil and three with galantamine) contributed to the meta-analysis. Significant improvement was found in this analysis for memory and the Trail Making test part A.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The reviewed studies suggest that specific cognitive deficits (memory, and the motor speed and attention part of executive function) of patients with schizophrenia and schizoaffective disorder are responsive to rivastigmine, donepezil and galantamine as adjunctive therapy. Confirmatory studies are needed to determine the clinical utility of this treatment strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ribeiz</LastName><ForeName>Salma R I</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Faculty of Medicine, University of S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil. salma.ribeiz@.usp.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassitt</LastName><ForeName>D&#xe9;bora P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Arrais</LastName><ForeName>Jony A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Avila</LastName><ForeName>Renata</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Steffens</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Bottino</LastName><ForeName>C&#xe1;ssio M C</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20297855</ArticleId><ArticleId IdType="doi">10.2165/11530260-000000000-00000</ArticleId><ArticleId IdType="pii">3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Neuropsychopharmacol. 2004 Jun;7(2):117-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14741060</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurocase. 2003 Jun;9(3):274-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12925933</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2003 Jan 1;59(1):29-33</Citation><ArticleIdList><ArticleId IdType="pubmed">12413639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(10):1083-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12476323</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Sep;181(2):358-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15778880</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Dec;150(12):1856-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8238642</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 1997 Feb;7(2):89-97</Citation><ArticleIdList><ArticleId IdType="pubmed">23338128</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jan;157(1):4-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10618007</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2006 Dec;21(8):548-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16797936</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 Nov;31(6):369-76</Citation><ArticleIdList><ArticleId IdType="pubmed">17136214</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1995;9 Suppl 2:43-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8534423</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Med Res Opin. 2007 Mar;23(3):575-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17355738</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Jul;85(1-3):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16797163</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Mar 1;51(5):349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">11904128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2005 Aug;25(4):311-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16012272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1999 Apr 30;868:620-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10414343</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Jun;180(1):177-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15654502</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2004 Nov;19(6):319-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15486516</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1979 Aug;36(9):927-34</Citation><ArticleIdList><ArticleId IdType="pubmed">37813</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Psychogeriatr. 2006 Sep;18(3):429-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16478570</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2007 May-Jun;30(3):169-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17545751</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1998;24(3):325-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9718627</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Mar;153(3):321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8610818</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2003 Nov-Dec;26(6):317-21</Citation><ArticleIdList><ArticleId IdType="pubmed">14646612</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2007 Jan-Feb;30(1):3-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17272964</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 May;194(5):439-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19407274</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurocase. 2001;7(2):105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11320158</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 May;33(6):1217-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17625502</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drug Rev. 2002 Summer;8(2):159-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12177686</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Jun;154(6):861-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9167518</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 17;325(3):976-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15541385</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47</Citation><ArticleIdList><ArticleId IdType="pubmed">10071091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Apr 21;70(5):717-29</Citation><ArticleIdList><ArticleId IdType="pubmed">19389335</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2004 Jul;19(5):343-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15252826</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2006 Oct;9(5):603-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16202177</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Jun;63(6):630-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16754836</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 1998 May-Jun;32(5-6):413-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9676739</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Med. 1987;17(2):193-200</Citation><ArticleIdList><ArticleId IdType="pubmed">3610485</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2007 Jul-Aug;30(4):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">17762319</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jul;30(5):934-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16580765</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jan;165(1):82-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17986678</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2004 Jun;174(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15205878</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Neuroanat. 2001 Jul;22(1-2):53-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11470554</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Neuropsychiatry. 2007 Sep;12(5):412-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17690999</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2005;130(4):997-1012</Citation><ArticleIdList><ArticleId IdType="pubmed">15652996</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1998 Mar;18(3):175-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9471115</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1998;24(2):203-18</Citation><ArticleIdList><ArticleId IdType="pubmed">9613621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2007 Jun;21(4):421-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17092979</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Aug;103(1-3):326-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18571377</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2007 Mar;22(2):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17293705</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Jul;93(1-3):131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17391930</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2003 Aug;23 (4):400-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12920417</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 May;55(5):433-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9596046</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Nov;155(11):1536-43</Citation><ArticleIdList><ArticleId IdType="pubmed">9812114</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2005 May-Jun;28(3):139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15965314</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2000 Oct;23 (4):351-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10989262</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Jul 1;38(1):22-33</Citation><ArticleIdList><ArticleId IdType="pubmed">7548469</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Jul;102(1-3):88-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18325740</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 1995 Jan;114(2):454-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7881744</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jan 15;29(2):545-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16181792</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Jun 27;54(12):2261-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10881250</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2003 Jan-Feb;26(1):12-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12567159</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Sep 15;60(6):530-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16806095</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 2005 Jul-Aug;28(4):179-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16062097</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Feb 2;293(5):596-608</Citation><ArticleIdList><ArticleId IdType="pubmed">15687315</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2004 Jul-Aug;12(4):358-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15249273</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1997 Sep;12 Suppl 4:S29-36</Citation><ArticleIdList><ArticleId IdType="pubmed">9352344</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jan 8;289(2):210-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12517232</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20205140</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2010</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1576-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>50 Suppl 2</Volume><PubDate><Year>2010</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Revista de neurologia</Title><ISOAbbreviation>Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>[Cognitive and neuropsychiatric disorders in Parkinson's disease].</ArticleTitle><Pagination><StartPage>S33</StartPage><EndPage>S39</EndPage><MedlinePgn>S33-9</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In Parkinson's disease there are patients with isolated and multiple cognitive impairment, and their cognitive performance ranges from normal to an advanced degree of dementia. Most patients present an executive deficit, either in isolation or combined with other cognitive disorders, which is considered to be the most characteristic aspect of the disease, and 30-40% of those affected will end up with a clinically-defined dementia.</AbstractText><AbstractText Label="DEVELOPMENT" NlmCategory="METHODS">The presence of a mild cognitive disorder in patients with Parkinson means that the risk of dementia appearing at some time during the development of the disease is high. The dementia associated with Parkinson's disease is specifically related with neuropsychiatric signs and symptoms, which may have three possible explanations: disorders affecting the mesolimbic pathways, diffuse limbic and cortical compromise, or associated Alzheimer-type phenomenology. Psychotic episodes tend to present more often in patients with dopaminergic treatment and the clinical spectrum of Parkinson-related psychosis covers visual illusions, visual-audio-olfactory hallucinations, delirium and severe paranoid hallucinatory psychosis. All the antiparkinsonian drugs can give rise to hallucinations and psychosis, but the dopamine agonists are the ones with the greatest capacity to do so.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In managing these problems, it is crucial for prevention as well as diagnosis and treatment to be carried out as soon as they are detected. Doses of antiparkinsonian drugs must be reduced, although this is not usually enough, and so it will be necessary to associate atypical antipsychotics, which act mainly on 5-HT receptors and, in most cases, do not produce D2 blockage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Constenla</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro Hospitalario POVISA, Pontevedra, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabo-L&#xf3;pez</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Bellas-Lamas</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cebri&#xe1;n</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Trastornos cognitivos y neuropsiqui&#xe1;tricos en la enfermedad de Parkinson.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Neurol</MedlineTA><NlmUniqueID>7706841</NlmUniqueID><ISSNLinking>0210-0010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>72</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20205140</ArticleId><ArticleId IdType="pii">rn2009737</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20220586</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Diagnostic correlates of Alzheimer dementia in a U.S. Nationwide inpatient sample.</ArticleTitle><Pagination><StartPage>821</StartPage><EndPage>829</EndPage><MedlinePgn>821-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181ca3a13</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Alzheimer dementia (ALZ-D) is among the most frequent diseases in the elderly. Several somatic and psychiatric disorders have been suggested to be related to this diagnosis. The aim of this analysis of a large and representative U.S. nationwide inpatient sample (NIS) was to identify diagnostic correlates of ALZ-D in subjects aged 60 years and older.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Of the total sample of 800,457 inpatient subjects ( approximately 2% of all inpatients in 2004), 315,244 individuals were 60 years or older. Of these, 9,572 (3.03%) received a diagnosis of ALZ-D, whereas 33,367 (10.59%) were diagnosed with osteoarthritis (OA) and served as a comparison group. Comparisons of potential somatic and psychiatric diagnostic correlates were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As determined by both univariate comparison and multivariate logistic regression analysis, after controlling for age and gender, subjects with ALZ-D (versus OA) had an overall higher rate of diagnoses of diseases of the vascular system (stroke: odds ratio 1.69; 95% confidence interval: 1.25-2.30) and psychotic and affective disorders (bipolar: 2.78 [1.26-6.12]; schizoaffective: 3.06 [2.10-4.47]). Increasing age and male gender were positively associated with the diagnosis of ALZ-D.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Many somatic diagnoses related to ALZ-D were confirmed by these analyses of the NIS. However, psychotic and affective disorders were identified to be equally significant correlates of ALZ-D, even in the presence of all other disorders. Prospective and longitudinal data are needed to investigate potential causal and temporal relationships between ALZ-D with somatic and psychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Preuss</LastName><ForeName>Ulrich W</ForeName><Initials>UW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychotherapy and Psychosomatics, University of Halle-Wittenberg, Germany. ulrich.preuss@medizin.uni-halle.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watzke</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="Y">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003628" MajorTopicYN="N">Database Management Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="Y">Vascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20220586</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181ca3a13</ArticleId><ArticleId IdType="pii">S1064-7481(12)60354-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20220583</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Syndromic association of behavioral and psychological symptoms of dementia in Alzheimer disease and patient classification.</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>432</EndPage><MedlinePgn>421-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181c6532f</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To identify patient groups with Alzheimer disease (AD) according to the presence of psychological and behavioral syndromes and to determine the clinical differences among these groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cross-sectional and observational study of 491 patients with probable AD whom were administered the Neuropsychiatric Inventory (NPI) at the baseline visit and reevaluated after 12 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Principal component analysis (PCA) of baseline NPI data revealed three factors, including a psychosis factor (delusions, hallucinations, and aberrant motor behavior), a depressive factor (depression, anxiety, irritability, agitation, and apathy) and a hypomanic factor (euphoria and disinhibition). Cluster analysis of factor scores indicated the presence of three patient groups: one group was characterized by low scores in factors, a second group including patients with high scores in the depressive factor, and a third group that included patients with high scores in the three factors. The PCA of the NPI scores carried out after 1 year showed the persistence of the three factors. The cluster analysis of their factor scores also showed the presence of the same three patient groups but with a few differences in certain symptoms. A higher frequency of personal psychiatric history but no family history was observed in the cluster with depressive symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Three neuropsychiatric syndromes have been identified, which have made it possible to classify patients with AD in three distinct large groups. A temporal stability is evidenced among the group with low symptoms. Patients with high scores in depressive factor or in three factors showed greater temporal instability. Certain differences among the groups suggest that different physiopathogenic mechanisms may be involved in neuropsychiatric syndromes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vilalta-Franch</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory and Dementia Unit, University of Girona, Spain. uvamid@ias.scs.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Pousa</LastName><ForeName>Secundino</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Turon-Estrada</LastName><ForeName>Antoni</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lozano-Gallego</LastName><ForeName>Manoli</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hern&#xe0;ndez-Ferr&#xe0;ndiz</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pericot-Nierga</LastName><ForeName>Imma</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Garre-Olmo</LastName><ForeName>Josep</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20220583</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181c6532f</ArticleId><ArticleId IdType="pii">S1064-7481(12)60208-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20219155</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-5111</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The international journal of neuropsychopharmacology</Title><ISOAbbreviation>Int J Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.</ArticleTitle><Pagination><StartPage>1343</StartPage><EndPage>1354</EndPage><MedlinePgn>1343-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1461145710000222</ELocationID><Abstract><AbstractText>Galantamine, a drug used to treat Alzheimer's disease, inhibits acetylcholinesterase (AChE) and allosterically modulates nicotinic acetylcholine receptors (nAChRs) resulting in stimulation of catecholamine neurotransmission. In this study, we investigated whether galantamine exerts cognitive-improving effects through the allosteric modulation of nAChRs in an animal model of methamphetamine (Meth) psychosis. The mice treated with Meth (1 mg/kg.d) for 7 d showed memory impairment in a novel object recognition test. Galantamine (3 mg/kg) ameliorated the memory impairment, and it increased the extracellular dopamine release in the prefrontal cortex (PFC) of Meth-treated mice. Donepezil, an AChE inhibitor (1 mg/kg) increased the extracellular ACh release in the PFC, whereas it had no effect on the memory impairment in Meth-treated mice. The nAChR antagonist, mecamylamine, and dopamine D1 receptor antagonist, SCH 23390, blocked the ameliorating effect of galantamine on Meth-induced memory impairment, whereas the muscarinic AChR antagonist, scopolamine, had no effect. The effects of galantamine on extracellular dopamine release were also antagonized by mecamylamine. Galantamine attenuated the defect of the novelty-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2). The ameliorating effect of galantamine on recognition memory in Meth-treated mice was negated by microinjection of an ERK inhibitor, PD98059, into the PFC. These results suggest that the ameliorating effect of galantamine on Meth-induced memory impairment is associated with indirect activation of dopamine D1 receptor-ERK1/2 following augmentation with dopaminergic neurotransmission in the PFC through the allosteric activation of nAChRs. Galantamine could be a useful therapeutic agent for treating cognitive deficits in schizophrenia/Meth psychosis, as well as Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Yukihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, Graduate School of Pharmaceutical Science, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouri</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Waki</LastName><ForeName>Yukari</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shin-Nosuke</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Yoshimi</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kiyofumi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ozaki</LastName><ForeName>Norio</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dayong</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Nabeshima</LastName><ForeName>Toshitaka</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neuropsychopharmacol</MedlineTA><NlmUniqueID>9815893</NlmUniqueID><ISSNLinking>1461-1457</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>44RAL3456C</RegistryNumber><NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8SSC91326P</RegistryNumber><NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="C535150">MAPK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9YNS0M02X</RegistryNumber><NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000109" MajorTopicYN="N">Acetylcholine</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008694" MajorTopicYN="N">Methamphetamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20219155</ArticleId><ArticleId IdType="doi">10.1017/S1461145710000222</ArticleId><ArticleId IdType="pii">S1461145710000222</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20214847</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>53</EndPage><MedlinePgn>44-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610210000244</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study is to identify factors that predict nursing home placement among community-dwelling Alzheimer's disease (AD) patients with psychosis and/or agitation in a randomized clinical trial (ClinicalTrials.gov number, NCT00015548).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">418 participants with AD enrolled in the Clinical Antipsychotic Trial of Intervention Effectiveness - AD (CATIE-AD) trial of anti-psychotic medications and having no evidence of nursing home use at baseline were followed at 9 months post-random assignment using data provided by caregiver proxy. &#x3c7;2 tests, t-tests and Cox proportional hazard modeling were used to examine the baseline correlates of nursing home use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of outpatients with no prior nursing home use, 15% were placed in a nursing home in the 9 months following baseline, with the average time to placement being 122 days. Bivariate analyses indicate that those with prior outpatient mental health use at study entry were more likely to be admitted; so too were those with worse physical functioning - i.e. lower scores on the AD Cooperative Study Activities of Daily Living Scale (ADCS-ADL), lower utility scores on the Health Utility Index (HUI)-III, and worse cognition on the Mini-mental State Examination. Controlling for other factors, non-Hispanic white race (hazard ratio [HR] = 2.16) and prior mental health use (HR = 1.87) increased the likelihood of admission. Those with higher ADCS-ADL scores were less likely to be placed (HR = 0.97).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Factors leading to nursing home entry among psychotic/agitated AD patients are similar to the general population, though high incidence of nursing home entry highlights the importance of accounting for such utilization in health economic studies of AD outcomes. It also highlights the importance of using information on ADLs and other characteristics to develop profiles identifying those at greater or lesser risk of nursing home entry and, in so doing, inform population planning associated with AD and identification of those patients and caregivers who might benefit most from interventions to prevent eventual placement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Edward Alan</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Gerontology and Gerontology Institute, McCormack Graduate School of Policy Studies, University of Massachusetts Boston, Boston, MA 02125, USA. edward.miller@umb.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Rosenheck</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00015548</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142-26A16897</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037561</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 MH9001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009735" MajorTopicYN="N">Nursing Homes</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="Y">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20214847</ArticleId><ArticleId IdType="mid">NIHMS235431</ArticleId><ArticleId IdType="pmc">PMC3951873</ArticleId><ArticleId IdType="doi">10.1017/S1041610210000244</ArticleId><ArticleId IdType="pii">S1041610210000244</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AD2000 Collaborate Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. The Lancet. 2004;363:2105&#x2013;2115.</Citation><ArticleIdList><ArticleId IdType="pubmed">15220031</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer's Association . Alzheimer's Disease Facts and Figures. Alzheimer's Association; Chicago, Illinois: 2009.</Citation></Reference><Reference><Citation>Anderson R. Revisiting the behavior model and access to care: Does it matter? Journal of Health and Social Behavior. 1995;36:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">7738325</ArticleId></ArticleIdList></Reference><Reference><Citation>Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns. Journal of Gerontology. 1984;39:194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">6699375</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaum CS, Ofstedal MB, Liang J. Low cognitive performance, comorbid disease, and task-specific disability: Findings from a nationally representative survey. Journal of Gerontology: Medical Sciences. 2002;57A:M523&#x2013;M531.</Citation><ArticleIdList><ArticleId IdType="pubmed">12145367</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle NG. Deficiency citations for mental health care in nursing homes. Administration and Policy in Mental Health. 2002;29:157&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939750</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan DC, Kasper JD, Black BS, Rabins PV. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. Journal of Gerontology: Medical Sciences. 2003;58A:548&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12807927</ArticleId></ArticleIdList></Reference><Reference><Citation>Colenda CC, Streim J, Greene JA, Meyers N, Beckwith E, Rabins P. The impact of OBRA '87 on psychiatric services in nursing homes: Joint testimony of the American Psychiatric Association and American Association for Geriatric Psychiatry. American Journal of Geriatric Psychiatry. 1999;7:12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">9919316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Marin DB, Kane R, Patrick D, Raskind MA, Puder KL. The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer's disease. International Journal Geriatric Psychiatry. 1997;12:978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395929</ArticleId></ArticleIdList></Reference><Reference><Citation>Feeny D, et al. Multiattribute and single attribute utility functions for the Health Utilities Index Mark 3 system. Med Care. 2002;40:113&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">11802084</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, et al. An inventory to assess Activities of Daily Living for clinical trials in Alzheimer's disease. Alzheimer Disease and Associated Disorders. 1997;22:S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler JE, Duyal S, Anderson KA. Predicting nursing home admission in the U.S.: A meta-analysis. BMC Geriatrics. 2007;7:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914346</ArticleId><ArticleId IdType="pubmed">17578574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler GE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia. Medical Care. 2009;47:191&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">19169120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Bienias JL, Wilson RS, Benett DA, Beck TL, Evans DA. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychological Medicine. 2004;34:1129&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">15554582</ArticleId></ArticleIdList></Reference><Reference><Citation>Green C. Modeling disease progression in Alzheimer's disease: A review of modeling methods used for cost-effectiveness analyses. Pharmacoeconomics. 2007;25:735&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">17803333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert R, Dubois MF, Wolfson C, Chambers L, Cohen C. Factors associated with long-term institutionalization of older people with dementia: Data from the Canadian study of health and aging. Journal of Gerontology: Medical Sciences. 2001;56A:M693&#x2013;M699.</Citation><ArticleIdList><ArticleId IdType="pubmed">11682577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: Prevalence estimates from the 2000 census. Archives of Neurology. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotoum HT, Thomas SK, Lin SJ, Lane R, Bullock R. Predicting time to nursing home placement based on activities of daily living scores&#x2014;a modeling analysis using data on Alzheimer's diseae patients receiving rigastigmine or donepezil. Journal of Medical Economics. 2009;12:98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19492974</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M. Nursing home placement is related to dementia progression. Neurology. 1999;52:714&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078715</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D, et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neuroloy. 1996;47:166&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710072</ArticleId></ArticleIdList></Reference><Reference><Citation>Loewenstein DA, et al. Caregivers&#x2019; judgments of the functional abilities of the Alzheimer's disease patient: A comparison of proxy reports and objective measures. Journal of Gerontology, Series B. 2001;2:P78&#x2013;P84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245361</ArticleId></ArticleIdList></Reference><Reference><Citation>Magaziner J, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: Diagnosis by expert panel. The Gerontologist. 2000;40:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">11131083</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EA, Allen SM, Mor V. Navigating the Labyrinth of long-term care: Shoring up informal caregiving in a home- and community-based world. Journal of Aging and Social Policy. 2009;21(1):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">19197605</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EA, Rosenheck RA. Risk of nursing home admission in association with mental illness nationally in the Department of Veterans Affairs. Medical Care. 2006;44:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">16565635</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EA, Weissert WG. Predicting elderly people's risk for nursing home placement, hospitalization, functional impairment, and mortality: A synthesis. Medical Care Research and Review. 2000;57:259&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">10981186</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EA, Weissert WG. Incidence of four adverse outcomes in the elderly population: Implications for home care policy and research. Home Health Care Services Quarterly. 2001;20:17&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12068965</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Inspector General . Younger Nursing Facility Residents with Mental Illness: Preadmission Screening and Resident Review (PASRR) Implementation and Oversight. U.S. Department of Health and Human Services; Rockville, MD: 2001.</Citation></Reference><Reference><Citation>Orry MG, Hoffman RR, Yee JL, Tennstedt S, Schulz R. Prevalence and impact of caregiving: A detailed comparison between dementia and nondementia caregivers. The Gerontologist. 39:177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">10224714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Kasper JD, Kleinman L, Black BS. Concepts and methods in the development of the ADRQL: An instrument for assessing health-related quality of life in persons with Alzheimer's disease. Journal of Mental Health and Aging. 1999;5:33&#x2013;48.</Citation></Reference><Reference><Citation>Reichman WE, et al. Psychiatric consultation in the nursing home: A survey of six states. American Journal of Geriatric Psychiatry. 1998;6:320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">9793580</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea DG, Russo PA, Smyer MA. Use of mental health services by persons with a mental illness in nursing facilities: Initial impacts of OBRA 87. Journal of Aging and Health. 2000;12:560&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">11503732</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenheck RA, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer Disease. Archives of General Psychiatry. 2007;64:1259&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17984395</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: Clinical characteristics and history. Journal of Psychiatric Research. 2004;38:105&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, Kokmen E, O'Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. Journal of the American Geriatrics Society Society. 2000;48:519&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811545</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, O'Brien PC, Ivnik RJ, Kokemen E, Tangalos EG. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology. 2001;57:1467&#x2013;1473.</Citation><ArticleIdList><ArticleId IdType="pubmed">11673591</ArticleId></ArticleIdList></Reference><Reference><Citation>Spruytte N, Van Audenhove C, Lammertyn F. Predictors of institutionalization of cognitively-impaired elderly cared for by their relatives. International Journal Geriatric Psychiatry. 2001;16:1119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748770</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, et al. Predicting time to nursing home care and death in individuals with Alzheimer Disease. Journal of the American Medical Association. 1997;277:806&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052710</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DH, Sloan F. How much do persons with Alzheimer's disease cost Medicare? Journal of the American Geriatrics Society. 2000;48:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">10855599</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissert WG, Hirth RA, Chernew ME, Diwan S, Kim J. Case management: Effects of improved risk and value information. The Gerontologist. 2003;43:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">14704377</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissert WG, Miller EA. Balancing resources and risk: Selecting home care clients in Florida's CARES program. Home Health Care Services Quarterly. 2001;18:63&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">11216439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. Journal of the American Medical Association. 2002;287:2090&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20189499</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-8194</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Disease-a-month : DM</Title><ISOAbbreviation>Dis Mon</ISOAbbreviation></Journal><ArticleTitle>Hypertension and cognitive function in the elderly.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>147</EndPage><MedlinePgn>106-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.disamonth.2009.12.007</ELocationID><Abstract><AbstractText>Alzheimer's disease is the most prevalent and common form of cognitive impairment, ie, dementia, in the elderly followed in second place by vascular dementia due to the microangiopathy associated with poorly-controlled hypertension. Besides blood pressure elevation, advancing age is the strongest risk factor for dementia. Deterioration of intellectual function and cognitive skills that leads to the elderly patient becoming more and more dependent in his, her, activities of daily living, ie, bathing, dressing, feeding self, locomotion, and personal hygiene. It has been known and demonstrated for many years that lowering of blood pressure from a previous hypertensive point can result in stroke prevention yet lowering of blood pressure does not prevent the microangiopathy that leads to white matter demyelinization which when combined with the clinical cognitive deterioration is compatible with a diagnosis of vascular dementia. It is known from many large studies, ie, SHEP, SCOPE, and HOPE, that lowering of blood pressure gradually will not and should not worsen the cognitive impairment. However, if the pressure is uncontrolled a stroke which might consequently occur would further worsen their cognitive derangement. So an attempt at slow reduction of blood pressure since cerebral autoregulation is slower as age increases is in the patient's best interest. It is also important to stress that control of blood glucose can also be seen as an attempt to prevent vascular dementia from uncontrolled hyperglycemia. Vascular dementia is not considered one of the reversible causes of dementia. Reversible causes of cognitive impairment are over medication with centrally acting drugs such as sedatives, hypnotics, antidepressants, and antipsychotics, electrolyte imbalance such as hyponatremia, azotemia, chronic liver disease, and poor controlled chronic congestive heart failure. Criteria for the clinical diagnosis of vascular dementia include cognitive decline in regards to preceding functionally higher level characterized by alterations in memory and in two or more superior cortical functions that include orientation, attention, verbal linguistic capacities, visual spacial skills, calculation, executive functioning, motor control, abstraction and judgment. Patients with disturbances of consciousness, delirium (acute confusional states), psychosis, serious aphasia, or sensory-motor alterations that preclude proper execution of neuro-psychological testing are also considered to have probably vascular dementia. Furthermore, these are ten of the other essential cerebral or systematic pathologies present that would be able to produce a dementia syndrome.</AbstractText><CopyrightInformation>Copyright 2010 (c). Published by Mosby, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cherubini</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gerontology and Geriatrics, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowenthal</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Paran</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Leonard S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Senin</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Mon</MedlineTA><NlmUniqueID>0370657</NlmUniqueID><ISSNLinking>0011-5029</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049292" MajorTopicYN="N">Leukoaraiosis</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>178</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20189499</ArticleId><ArticleId IdType="doi">10.1016/j.disamonth.2009.12.007</ArticleId><ArticleId IdType="pii">S0011-5029(09)00155-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20185150</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Evidence of association of KIBRA genotype with episodic memory in families of psychotic patients and controls.</ArticleTitle><Pagination><StartPage>795</StartPage><EndPage>798</EndPage><MedlinePgn>795-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2010.01.012</ELocationID><Abstract><AbstractText>The first genome-wide association study of human memory identified an association between a common T/C polymorphism of the KIBRA gene (rs17070145) and episodic memory performance in normal individuals; subsequent studies have implicated the same polymorphism in Alzheimer's disease. Since impaired neurocognitive performance, including memory, may be both a core feature of schizophrenia and a candidate endophenotype, we attempted to replicate this association in a total sample of 544 subjects (including patients with psychosis, their unaffected relatives as well as normal individuals). In the combined sample there was a significant association between the KIBRA T allele and better performance in the single principle component of the memory measures, which included immediate and delayed logical and visual memory from the Wechsler Memory Scale (p=0.019). In the unaffected individuals (patients' relatives and healthy controls) we observed an association of KIBRA with immediate and delayed logical memory (p=0.020 and 0.025, respectively), while in patients with psychosis with delayed visual memory (p=0.05). This study replicates the association between the KIBRA gene and episodic memory and suggests a possibly differential effect of the polymorphism in psychotic and non-psychotic individuals.</AbstractText><CopyrightInformation>Copyright (c) 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vassos</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Department of Psychological Medicine and Psychiatry and NIHR Biomedical Research Centre, London, UK. evangelos.vassos@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bramon</LastName><ForeName>Elvira</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Picchioni</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walshe</LastName><ForeName>Muriel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Filbey</LastName><ForeName>Francesca M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Kravariti</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Colm</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Robin M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Collier</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Toulopoulou</LastName><ForeName>Timothea</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0901310</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PDA/02/06/016</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RR03655</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513637">WWC1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20185150</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2010.01.012</ArticleId><ArticleId IdType="pii">S0022-3956(10)00021-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20182055</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2010</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>No association between neuregulin 1 and psychotic symptoms in Alzheimer's disease patients.</ArticleTitle><Pagination><StartPage>561</StartPage><EndPage>567</EndPage><MedlinePgn>561-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-1405</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) patients commonly suffer from behavioral and psychological symptoms of dementia (BPSD). Variants within the neuregulin-1 (NRG1) gene have been investigated both in early onset psychiatric disorders, such as schizophrenia and recently in AD patients with psychosis. In this study, we analyzed NRG1 variants in AD patients with and without psychosis. Our large cohort of 399 probable AD patients had longitudinal information on the BPSD, which was used to dichotomize patients into whether they had ever suffered from psychotic symptoms within the study period. The NRG1 single nucleotide polymorphisms rs3924999, rs35753505 (SNP8NRG221533) and the microsatellites 478B14-848 and 420M9-1395 were investigated for association with psychosis using genotype, allele, and haplotype analyses. No associations were found between any of these variants or haplotypic combinations with delusions, hallucinations, psychosis, or elation/mania in our cohort. Positive associations with polymorphisms and haplotype combinations of NRG1 have been reported in psychiatric disorders. One previous study found an association with psychosis in AD, with a SNP outside the haplotype block first reported for association with schizophrenia. We found no association with any of these variants in our cohort. Further investigations of this region on chromosome 8 are clearly required, with replication in different large longitudinal cohorts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Middle</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Molecular Psychiatry Group, Institute of Biomedical Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>Antonia L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Handoko</LastName><ForeName>Herlina</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Sayeed</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holder</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lendon</LastName><ForeName>Corinne L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094131">NRG1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018895" MajorTopicYN="N">Microsatellite Repeats</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20182055</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-1405</ArticleId><ArticleId IdType="pii">J70635L478012352</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20164571</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>20 Suppl 1</Volume><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Caffeine, mental health, and psychiatric disorders.</ArticleTitle><Pagination><StartPage>S239</StartPage><EndPage>S248</EndPage><MedlinePgn>S239-48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-1378</ELocationID><Abstract><AbstractText>Caffeine intake is so common that its pharmacological effects on the mind are undervalued. Since it is so readily available, individuals can adjust their own dose, time of administration and dose intervals of caffeine, according to the perceived benefits and side effects of each dose. This review focuses on human studies of caffeine in subjects with and without psychiatric disorders. Besides the possibility of mild drug dependence, caffeine may bring benefits that contribute to its widespread use. These benefits seem to be related to adaptation of mental energy to the context by increasing alertness, attention, and cognitive function (more evident in longer or more difficult tasks or situations of low arousal) and by elevating mood. Accordingly, moderate caffeine intake (&lt; 6 cups/day) has been associated with less depressive symptoms, fewer cognitive failures, and lower risk of suicide. However, its putative therapeutic effects on depression and ADHD have been insufficiently studied. Conversely, in rare cases high doses of caffeine can induce psychotic and manic symptoms, and more commonly, anxiety. Patients with panic disorder and performance social anxiety disorder seem to be particularly sensitive to the anxiogenic effects of caffeine, whereas preliminary data suggests that it may be effective for some patients with obsessive compulsive disorder (OCD). The threshold for the anxiogenic effect of caffeine is influenced by a polymorphism of the A2A receptor. In summary, caffeine can be regarded as a pharmacological tool to increase energy and effortful behavior in daily activities. More populational (cross-sectional and prospective) and experimental studies are necessary to establish the role of caffeine intake in psychiatric disorders, especially its putative efficacy on depressive mood and cognitive/attentional disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lara</LastName><ForeName>Diogo R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Faculdade de Bioci&#xea;ncias, PUCRS, Porto Alegre, Brazil. drlara@pucrs.br</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043705">Receptor, Adenosine A2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G6A5W338E</RegistryNumber><NameOfSubstance UI="D002110">Caffeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002110" MajorTopicYN="N">Caffeine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008606" MajorTopicYN="N">Mental Processes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043705" MajorTopicYN="N">Receptor, Adenosine A2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>126</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20164571</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-1378</ArticleId><ArticleId IdType="pii">54X2N5075X170P62</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20157235</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Genetics of psychosis in Alzheimer's disease: a review.</ArticleTitle><Pagination><StartPage>761</StartPage><EndPage>780</EndPage><MedlinePgn>761-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2010-1274</ELocationID><Abstract><AbstractText>In and of itself, late-onset Alzheimer's disease (AD) can be a devastating illness. However, a sub-group of AD patients develop psychosis as the disease progresses. These patients have an added burden of greater cognitive impairment, higher rates of institutionalization, and higher mortality than AD patients without psychosis. While the etiopathogenesis such as psychosis in AD (AD+P) is not known, mounting evidence accrued over the past ten years indicates that AD+P represents a distinct phenotype with a genetic basis. Elucidating the genetic mechanism of AD+P is crucial if better pharmaceutical treatments are to be developed for these patients. The goal of this review is to summarize what is currently known regarding the genetic basis of psychosis in AD. Specific attention is given to familial aggregation and heritability, linkage to chromosomal loci, and associations of candidate genes of APOE and the monoamine neurotransmitter system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeMichele-Sweet</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-03</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-210020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094131">NRG1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Alzheimers Dis. 2010;20(4):1263</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20157235</ArticleId><ArticleId IdType="mid">NIHMS191543</ArticleId><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="doi">10.3233/JAD-2010-1274</ArticleId><ArticleId IdType="pii">R22877580842M378</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K. Candidate gene for the chromosome 1 familial Alzheimer&#x2019;s disease locus. Science. 1995;269:973&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer&#x2019;s dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983.</Citation><ArticleIdList><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJSDE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y, Rogaeva E, Wakutani Y, Farrer L, St George-Hyslop P, Mayeux R. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol. 2007;64:501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639214</ArticleId><ArticleId IdType="pubmed">17420311</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van BC, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008;29:769&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Myers AJ, Pearson JV, Craig DW, Hu-Lince D, Coon KD, Zismann VL, Beach T, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Huentelman MJ, Joshipura K, Walker D, Heward CB, Ravid R, Rogers J, Papassotiropoulos A, Hardy J, Reiman EM, Stephan DA. Sorl1 as an Alzheimer&#x2019;s disease predisposition gene? Neurodegener Dis. 2008;5:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17975299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y, Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. Am J Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EH, Drevets WC, Burke WJ. Nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol. 1988;1:17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">3266997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Finkel SI. Psychosis of Alzheimer&#x2019;s disease and related dementias. Am J Geriatr Psychiatry. 2000;8:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, DeKosky ST, Sweet RA. Prediction of Psychosis Onset in Alzheimer Disease: The Role of Cognitive Impairment, Depressive Symptoms, and Further Evidence for Psychosis Subtypes. Am J Geriatr Psychiatry. 2006;14:352&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference><Reference><Citation>Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL, DeKosky ST, Sweet RA. The relationship of excess cognitive impairment in MCI and early Alzheimer&#x2019;s disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009;21:78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678562</ArticleId><ArticleId IdType="pubmed">18814807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and associated factors in Alzheimer&#x2019;s disease. J Neuropsychiatry. 1991;3:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley DW, Wilson RS, Beckett LA, Evans DA. Psychotic symptoms and physically aggressive behavior in Alzheimer&#x2019;s disease. J Am Geriatr Soc. 1997;45:1074&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, Kastango KB, DeKosky ST. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer&#x2019;s disease. Int Psychogeriatr. 2001;13:401&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">12003247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, MacMillan A, Ketchel P, DeKosky ST. Assessing the impact of neuropsychiatric symptoms in Alzheimer&#x2019;s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248:333&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">7087127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999;56:1266&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">10520944</ArticleId></ArticleIdList></Reference><Reference><Citation>Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol. 1996;9:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">8873875</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Diaz C, Levy M, Binetti G, Litvan I., I Neuropsychiatric Syndromes in Neurodegenerative Disease: Frequency and Signficance. Semin Clin Neuropsychiatry. 1996;1:241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Steinberg M, Rosenblatt A, Baker A, Lyketsos CG. Delusions and hallucinations in Alzheimer&#x2019;s disease: Prevalence and clinical correlates. Int J Geriatr Psychiatry. 2000;15:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Krueger KR, Kamenetsky JM, Tang Y, Gilley DW, Bennett DA, Evans DA. Hallucinations and mortality in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:984&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry. 2004;65(Suppl 11):11&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhana N, Spencer CM. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging. 2000;16:451&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">10939309</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2004;19:115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758577</ArticleId></ArticleIdList></Reference><Reference><Citation>Streim JE, McQuade R, Stock E, Goyvaerts H, Breder C, Iwamoto T, Yamamoto Y. Aripiprazole for the treatment of institutionalized patients with psychosis of Alzheimer&#x2019;s dementia. J Am Geriatr Soc. 2004;52:S15&#x2013;S15.</Citation></Reference><Reference><Citation>Jeste DV, De Deyn P, Carson W, Marcus R, McQuade RD, Schneider L, Mintzer J. Aripiprazole in dementia of the Alzheimer&#x2019;s type. J Am Geriatr Soc. 2003;51:S226&#x2013;S226.</Citation></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry. 2004;161:1113&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169702</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004;5:129&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15008183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J. 2004;170:1395&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395813</ArticleId><ArticleId IdType="pubmed">15111472</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J. 2002;167:1269&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC134141</ArticleId><ArticleId IdType="pubmed">12451085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8:383&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunstall N, Owen MJ, Williams J, Rice F, Carty S, Lillystone S, Fraser L, Kehoe P, Neill D, Rudrasingham V, Sham P, Lovestone S. Familial influence on variation in age of onset and behavioural phenotype in Alzheimer&#x2019;s disease. Br J Psychiatry. 2000;176:156&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10755053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58:907&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, O&#x2019;Donovan MC, Sims R, Powell J, Lovestone S, Myers A, Devrieze FW, Hardy J, Goate A, Owen M, Williams J. Increased familial risk and genomewide significant linkage for Alzheimer&#x2019;s disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Linkage analysis of Alzheimer disease with psychosis. Neurology. 2002;59:118&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">12105318</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60:132&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">16442083</ArticleId></ArticleIdList></Reference><Reference><Citation>Go RC, Perry RT, Wiener H, Bassett SS, Blacker D, Devlin B, Sweet RA. Neuregulin-1 polymorphism in late onset Alzheimer&#x2019;s disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet. 2005;139B:28&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082692</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramopoulos D, Fallin MD, Bassett SS. Linkage to chromosome 14q in Alzheimer&#x2019;s disease (AD) patients without psychotic symptoms. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389761</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Massey H, Lamb H, Morris C. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1997;63:273b&#x2013;273b.</Citation><ArticleIdList><ArticleId IdType="pubmed">9285479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R, Rodriguez B, Carrera C, Caamano J, Beyer K, Lao JI, Sellers MA. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol. 1996;18:693&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">9121226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JB, Wang PN, Chen WT, Liu CY, Hong CJ, Lin KN, Liu TY, Chi CW, Liu HC. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology. 2004;63:1105&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452311</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabryelewicz T, Religa D, Styczynska M, Peplonska B, Pfeffer A, Wasiak B, Luczywek E, Golebiowski M, Androsiuk W, Czyzewski K, Przekop I, Barcikowska M. Behavioural pathology in Alzheimer&#x2019;s disease with special reference to apolipoprotein E genotype. Dement Geriatr Cogn Disord. 2002;14:208&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411763</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood DG, Barker WW, Ownby RL, St.George-Hyslop PH, Duara R. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer&#x2019;s disease. Am J Geriatr Psychiatry. 1999;7:119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, Ikejiri Y, Imamura T, Shimomura T, Ikeda M, Hashimoto M, Yamashita H. Factors associated with psychotic symptoms in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 1998;64:648&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170086</ArticleId><ArticleId IdType="pubmed">9598682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirono N, Mori E, Yasuda M, Imamura T, Shimomura T, Hashimoto M, Tanimukai S, Kazui H, Yamashita H. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 1999;11:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9990558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Moskvina V, Dowzell K, Moore PJ, Foy C, Archer N, Lynch A, Lovestone S, Brayne C, Rubinsztein DC, Lawlor B, Gill M, Owen MJ, Williams J. Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer&#x2019;s disease. J Am Geriatr Soc. 2006;54:1348&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16970641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtovirta M, Soininen H, Helisalmi S, Mannerman A, Helkala EL, Hartikainen P, Hannimen T, Ryynanen M, Rickkinen PJ. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer&#x2019;s disease: Relation to apolipoprotein E polymorphism. Neurology. 1996;46:413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614504</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy ML, Cummings J, Fairbanks LA, Sultzer DL, Small GW. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer&#x2019;s disease. Biol Psychiatry. 1999;45:422&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">10071711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E &#x3b5;4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer&#x2019;s disease. Neurology. 1997;49:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">9305342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Baker L, Warren A, Steele C, Brandt J, Steinberg M, Kopunek S, Baker A. Depression, delusions, and hallucinations in Alzheimer&#x2019;s disease: no relationship to apolipoprotein E genotype. The Journal of Neuropsychiatry and Clinical Neurosciences. 1997;9:64&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9017530</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, Bentham P, Lendon CL. The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2007;78:123&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077651</ArticleId><ArticleId IdType="pubmed">16980336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran G, Marder K, Tang M, Schofield PW, Chun MR, Devanand DP, Stern Y, Mayeux R. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer&#x2019;s disease. Neurology. 1996;47:256&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710089</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, Devanand DP, Marder K, Bell K, Ciappa A, Tycko B, Stern Y. Association between the APOE genotype and psychopathologic symptoms in Alzheimer&#x2019;s disease. Neurology. 2002;58:1182&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3029097</ArticleId><ArticleId IdType="pubmed">11971084</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Caltagirone C. Delusion symptoms are associated with ApoE epsilon4 allelic variant at the early stage of Alzheimer&#x2019;s disease with late onset. Eur J Neurol. 2006;13:176&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490049</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Kamboh MI, Wisniewski SR, Lopez OL, Klunk WE, Kaufer DI, DeKosky ST. Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer&#x2019;s disease. J Geriatr Psychiatry Neurol. 2002;15:24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11936240</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Staekenborg S, Pijnenburg YA, Gillissen F, Romkes R, Kok A, Bouwman FH, Scheltens P. Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Disord. 2007;23:42&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17077632</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Vega GRRC, Honig LS, Collum CM, Crumpacker D, Rosenburg RN. Apolipoprotein E&#x3b5;4, other risk factors, and course of Alzheimer&#x2019;s disease. Biol Psychiatry. 1999;45:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer&#x2019;s disease. Neuropsychopharmacology. 2007;32:171&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">16841077</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF., III Serotonin in aging, late-life depression, and Alzheimer&#x2019;s disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">9571651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross AJ. Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann N Y Acad Sci. 1990;600:405&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">1701291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, Sims NR, Smith CC, Spillane JA, Esiri MM, Neary D, Snowdon JS, Wilcock GK, Davison AN. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer&#x2019;s disease. J Neurochem. 1983;41:266&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">6306169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng AV, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, Edwardson JA, Perry RH, Perry EK. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J Neurol Sci. 1991;106:50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">1779239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejani-Butt SM, Yang J, Pawlyk AC. Altered serotonin transporter sites in Alzheimer&#x2019;s disease raphe and hippocampus. Neuroreport. 1995;6:1207&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7662909</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JT, Peacock ML, Rodriguez LC, Fink JK. An Mspi Polymorphism in the Hyman Serotonin Receptor Gene (Htr2) - Detection by Dgge and Rflp Analysis. Hum Mol Genetics. 1993;2:338&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">7684645</ArticleId></ArticleIdList></Reference><Reference><Citation>Polesskaya O, Sokolov B. Differential Expression of the &#x201c;C&#x201d; and &#x201c;T&#x201d; Alleles of the 5-HTR2A Receptor Gene in the Temporal Cortex of Normal Individuals and Schizophrenics. J Neurosci Res. 2002;67:812&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">11891796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, Ortenzi L, Petruzzi C, Serio A, Marcon G, Sorbi S. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer&#x2019;s disease. Biol Psychiatry. 2001;50:472&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566166</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, Murri L. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): Association studies with psychosis in Alzheimer disease. Genetic Testing. 2003;7:309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15000807</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Arranz MJ, Powell JF, Collier D, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer&#x2019;s disease. Hum Mol Genetics. 1998;7:1507&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700207</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61:1249&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15313842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam LC, Tang NL, Ma SL, Zhang W, Chiu HF. 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Int J Geriatr Psychiatry. 2004;19:523&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Kodavali C, Weamer EA, Miyahara S, Lopez OL, Nimgaonkar VL, DeKosky ST, Sweet RA. Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818007</ArticleId><ArticleId IdType="pubmed">17525976</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Donnelly C, Hart D, Carson R, Passmore P. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer&#x2019;s disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:126&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">16967466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Harris J, Pritchard CW, Coates J, Haque S, Holder R, Bentham P, Lendon CL. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer&#x2019;s disease. Neurobiol Aging. 2008;29:341&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">17098333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C) Genomics. 1995;27:274&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">7557992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region. Science. 1996;274:1527&#x2013;1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">8929413</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, Stober G, Li T, Heils A, Catalano M, DiBella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Muller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1996;1:453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154246</ArticleId></ArticleIdList></Reference><Reference><Citation>Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621&#x2013;2624.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha TM, Cho DM, Park SW, Joo MJ, Lee BJ, Kong BG, Kim JM, Yoon JS, Kim YH. Evaluating associations between 5-HTTLPR polymorphism and Alzheimer&#x2019;s disease for Korean patients. Dement Geriatr Cogn Disord. 2005;20:31&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">15832033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24:201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer&#x2019;s disease. J Alzheimers Dis. 2007;12:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057558</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Agosti C, Costanzi C, Archetti S, Franzoni S, Caltagirone C, Di Luca M, Caimi L, Padovani A. Genetic correlates of behavioral endophenotypes in Alzheimer disease: Role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol Aging. 2006;11:1595&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, Riederer P. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994;95:157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">7865169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, Smith CA. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet. 1996;347:731&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">8602004</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P. Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 1992;7:261&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">1362057</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams J, Spurlock G, Holmans P, Mant R, Murphy K, Jones L, Cardno A, Asherson P, Blackwood D, Muir W, Meszaros K, Aschauer H, Mallet J, Laurent C, Pekkarinen P, Seppala J, Stefanis CN, Papadimitriou GN, Macciardi F, Verga M, Pato C, Azevedo H, Crocq MA, Gurling H, Kalsi G, Curtis D, McGuffin P, Owen MJ. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Mol Psychiatry. 1998;3:141&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">9577838</ArticleId></ArticleIdList></Reference><Reference><Citation>Talkowski ME, Mansour H, Chowdari KV, Wood J, Butler A, Varma PG, Prasad S, Semwal P, Bhatia T, Deshpande S, Devlin B, Thelma BK, Nimgaonkar V. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry. 2006;60:570&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer&#x2019;s disease. Arch Neurol. 1998;55:1335&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779662</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, Lovestone S. Psychosis and aggression in Alzheimer&#x2019;s disease: the effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry. 2001;71:777&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737623</ArticleId><ArticleId IdType="pubmed">11723200</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, Carson R, McIlroy SP, Passmore AP. Psychotic symptoms in Alzheimer&#x2019;s disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neurosci Lett. 2004;368:33&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord. 2008;26:257&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">18841010</ArticleId></ArticleIdList></Reference><Reference><Citation>Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H, Chowdari KV, Milanova V, Wood J, McClain L, Prasad K, Shirts B, Zhang J, O&#x2019;Donovan MC, Owen MJ, Devlin B, Nimgaonkar VL. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet. 2008;17:747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777405</ArticleId><ArticleId IdType="pubmed">18045777</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">13575440</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2. Genomics. 1992;12:822&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">1572656</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, Patanjali SR, Weissman SM, Anyane-Yeboa K, Warburton D, Scambler P, Shprintzen R, Kucherlapati R, Morrow BE. Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am J Hum Genet. 1997;61:620&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1715959</ArticleId><ArticleId IdType="pubmed">9326327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genetics. 1996;67:468&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8886163</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56:940&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">10530637</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams HJ, Owen MJ, O&#x2019;Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull. 2007;33:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2526139</ArticleId><ArticleId IdType="pubmed">17412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Devlin B, Pollock BG, Sukonick DL, Kastango KB, Bacanu S-A, Chowdari KV, DeKosky ST, Ferrell RE. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol Psychiatry. 2005;10:1026&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027741</ArticleId></ArticleIdList></Reference><Reference><Citation>Shifman S, Bronstein MSM, Pisante-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Beckmann JS, Yakir B, Risch N, Zak NB, Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002;71:1296&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378567</ArticleId><ArticleId IdType="pubmed">12402217</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Grassi M, Costanzi C, Zanetti M, Archetti S, Franzoni S, Caimi L, Padovani A. Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol Aging. 2007;28:1231&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pubmed">16837108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006;314:1930&#x2013;1933.</Citation><ArticleIdList><ArticleId IdType="pubmed">17185601</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997;94:587&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19557</ArticleId><ArticleId IdType="pubmed">9012828</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA, Tsuang MT, Farone SV, Malaspina D, Svrakic DM, Sanders A, Gejman P. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7) Am J Med Genet. 2001;105:20&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11424985</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson R, Craig D, Hart D, Todd S, McGuinness B, Johnston JA, O&#x2019;Neill FA, Ritchie CW, Passmore AP. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer&#x2019;s disease. Neuromolecular Med. 2008;10:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">18696274</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. The interleukin 1beta gene promoter polymorphism (&#x2212;511) acts as a risk factor for psychosis in Alzheimer&#x2019;s dementia. Ann Neurol. 2004;56:121&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15236409</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR, Bird TD. Familial aggregation of psychotic symptoms in Huntington&#x2019;s disease. Am J Psychiatry. 2000;157:1955&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">11097960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird TD, Wijsman EM, NOchlin D, Leehey M, Sumi SM, Payami H, Poorkaj P, Nemens E, Rafkind M, Schellenberg GD. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology. 1997;48:950&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109883</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi G, Williamson J, Massoud F, Anderson K, Stern Y, Devanand DP, Mayeux R. A comparison of family history of psychiatric disorders among patients with early- and late-onset Alzheimer&#x2019;s disease. J Neuropsychiatry Clin Neurosci. 2004;16:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">14990760</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin B, Roeder K, Bacanu SA. Unbiased methods for population-based association studies. Genet Epidemiol. 2001;21:273&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">11754464</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin J, Kaiser J. Genome-wide association. Closing the net on common disease genes. Science. 2007;316:820&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">17495150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20147454</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>Pt 4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study.</ArticleTitle><Pagination><StartPage>1155</StartPage><EndPage>1162</EndPage><MedlinePgn>1155-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awq001</ELocationID><Abstract><AbstractText>Determining the genetic architecture of late onset Alzheimer's disease remains an important research objective. One approach to the identification of novel genetic variants contributing to the disease is the classification of biologically meaningful subgroups within the larger late-onset Alzheimer's disease phenotype. The occurrence of psychotic symptoms in patients with late-onset Alzheimer's disease may identify one such group. We attempted to establish methods for the reliable assessment of psychotic symptoms in a large, geographically dispersed collection of families, multiply affected with late onset Alzheimer's disease, who were participants in the larger National Institute on Aging Late Onset Alzheimer's Disease Family Study; and to characterize the correlates and familial aggregation of psychosis within this cohort. We found that reliable assessments of psychotic symptoms during in-person or phone interviews were readily implemented. The presence of psychosis in late onset Alzheimer's disease was significantly associated with degree of cognitive impairment, and significantly, albeit modestly, correlated with the severity of other behavioural symptoms. Psychosis significantly aggregated within late onset Alzheimer's disease families suggesting that it may identify a genetically determined subgroup. Future studies should examine the linkage and association of psychosis with genetic variation within these families.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Biomedical Science Tower, Rm W-1645, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA. sweetra@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>National Institute on Aging Late-Onset Alzheimer's Disease Family Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50AG165574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854-14</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016579</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016582</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027342</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-04</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG13854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG02219</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-210020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136-28</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854-15</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054561" MajorTopicYN="Y">National Institute on Aging (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowal</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>farrer</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santana</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmechel</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaskel</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horner</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreiner</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prentice</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blacker</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuntz</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norgaard</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kistler</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haddow</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beeri</LastName><ForeName>Michal Schnaider</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Joy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lally</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne-Murphy</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Holli</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Jeen-Soo</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arends</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toland</LastName><ForeName>Usha</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markesberry</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brickhouse</LastName><ForeName>Alise</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarty Wood</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varpetian</LastName><ForeName>Arousiak</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rumbaugh</LastName><ForeName>Malia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levitch</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>Betsy</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coats</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20147454</ArticleId><ArticleId IdType="pmc">PMC2912688</ArticleId><ArticleId IdType="doi">10.1093/brain/awq001</ArticleId><ArticleId IdType="pii">awq001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in AlzQheimer disease. Am J Geriatr Psychiatry. 2005;13:624&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassiony MM, Rosenblatt A, Baker A, Steinberg M, Steele CD, Sheppard J, et al. The relationship between delusions and depression in Alzheimer's; disease. Int J Geriatr Psychiatry. 2002;17:549&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van BC, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat. 2008;29:769&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407551</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer Disease: a review. J Alzheimers Dis. 2009 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942073</ArticleId><ArticleId IdType="pubmed">20157235</ArticleId></ArticleIdList></Reference><Reference><Citation>Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">2912509</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2009 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's; disease. Nature. 1991;349:704&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's; disease. Nat Genet. 2009;41:1088&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Hamshere ML, Holmans PA, O'D;onovan MC, Sims R, Powell J, et al. Increased familial risk and genomewide significant linkage for Alzheimer's; disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:841&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1997;140:566&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's; disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc. 1998;46:210&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9475452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">11001602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, et al. A full genome scan for late onset Alzheimer's; disease. Hum Mol Genetics. 1999;8:237&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Yamamoto M, Morihara T, Akatsu H, Kudo T, Kamino K, et al. SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci Lett. 2009;461:177&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19539718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Teipel SJ, et al. Association of SORL1 gene variants with Alzheimer's; disease. Brain Res. 2009;1264:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19368828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's; disease. Nat Genet. 2009;41:1094&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R. Analyses of the National Institute on Aging Late-Onset Alzheimer's; Disease Family Study: implication of additional loci. Arch Neurol. 2008;65:1518&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694670</ArticleId><ArticleId IdType="pubmed">19001172</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's; disease locus. Science. 1995;269:973&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">7638622</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Rowland C, Catanese J, Morris J, Lovestone S, O'D;onovan MC, et al. SORL1 variants and risk of late-onset Alzheimer's; disease. Neurobiol Dis. 2008;29:293&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323581</ArticleId><ArticleId IdType="pubmed">17949987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's; disease. J Neuropsychiatry Clin Neurosci. 2003;15:346&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard J, Steinberg G, Tschanz J, Norton MC, Steffens DC, et al. Neuropsychiatric disturbance in Alzheimer's; disease clusters into three groups; the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack JL, Patterson MB, Tariot PN. Behavior Rating Scale for Dementia: development of test scales and presentation of data for 555 individuals with Alzheimer's; disease. J Geriatr Psychiatry Neurol. 1999;12:211&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616870</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's; disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's; disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, et al. Identification of novel genes in late-onset Alzheimer's; disease. Exp Gerontol. 2000;35:1343&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113612</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's; disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005;162:2022&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's; disease. Nature. 1995;375:754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003;8:383&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002;58:907&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EK, Lee J, Chen CP, Teo YY, Zhao Y, Lee WL. SORL1 haplotypes modulate risk of Alzheimer's; disease in Chinese. Neurobiol Aging. 2009;30:1048&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunstall N, Owen MJ, Williams J, Rice F, Carty S, Lillystone S, et al. Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's; disease. Br J Psychiatry. 2000;176:156&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">10755053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkosz PA, Miyahara S, Lopez OL, DeKosky ST, Sweet RA. Prediction of psychosis onset in Alzheimer disease: the role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry. 2006;14:352&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">16582044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20130406</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9824</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2010</Year></PubDate></JournalIssue><Title>Dementia and geriatric cognitive disorders</Title><ISOAbbreviation>Dement Geriatr Cogn Disord</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms in korean patients with Alzheimer's disease: exploratory factor analysis and confirmatory factor analysis of the neuropsychiatric inventory.</ArticleTitle><Pagination><StartPage>82</StartPage><EndPage>87</EndPage><MedlinePgn>82-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000264629</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">We designed this study to examine subsyndromes in Korean patients with Alzheimer's disease (AD) using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Initial participants were 778 AD patients recruited from the Clinical Research Center for Dementia of South Korea and assessed via the Korean Neuropsychiatric Inventory. Those with &gt; or =1 neuropsychiatric symptom were randomly divided into groups. Principal axis factoring with oblimin rotation was used to analyze group 1 inventory results, and maximum likelihood estimation extraction with Bollen-Stine bootstrapping was used for group 2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results of the EFA showed the presence of 4 subsyndromes: hyperactivity, affect, psychosis and apathy/vegetative symptom. The CFA results indicated this model was the best-fitting model for explaining these subsyndromes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our model showed the best fit and identified 4 subsyndromes. This study might contribute to a clearer understanding of the neuropsychiatric symptoms in AD.</AbstractText><CopyrightInformation>2010 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyo Shin</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Clinical Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Inn Sook</ForeName><Initials>IS</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji Hae</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doh Kwan</ForeName><Initials>DK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dement Geriatr Cogn Disord</MedlineTA><NlmUniqueID>9705200</NlmUniqueID><ISSNLinking>1420-8008</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006948" MajorTopicYN="N">Hyperkinesis</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20130406</ArticleId><ArticleId IdType="doi">10.1159/000264629</ArticleId><ArticleId IdType="pii">000264629</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20129320</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2010</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Subtypes of depression among patients with Alzheimer's disease and other dementias.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>69</EndPage><MedlinePgn>63-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2009.04.1232</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We compared the prevalence of subtypes of depression in patients with Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the Integrated Healthcare Information Services database, we conducted an analysis of subtypes of depression (major depressive disorder, depressive disorder not otherwise specified, dysthymic disorder; depressive psychosis, and adjustment disorder depressive) among patients with AD, VaD, and UD. Six thousand four hundred and forty patients aged 60 years or older with dementia (2947 with AD, 725 with VaD, and 2768 with UD) were identified from January 1 to December 31, 2001. Both subtypes of depression and dementia subgroups were diagnosed using criteria from the International Classification of Diseases, 9th version.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall prevalence of depressive disorders was 27.41%. The prevalence of depressive disorders was significantly higher in VaD (44.14%) and UD (32.48%) patients compared with AD (18.53%, P &lt; .0001) patients. The AD patients had the lowest prevalence of all subtypes of depression. The VaD patients, compared with both AD and UD (P &lt; .005), had a significantly higher prevalence of: 1) depressive disorder not otherwise specified, 2) major depressive disorder, and 3) dysthymic disorder. Adjustment disorder with depressive symptoms was more common in the UD subgroup, whereas the rate of depressive psychosis was similar in all dementia subgroups</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study supports the view that depressive disorders are more prevalent in VaD compared with UD and AD, and provides indicators to the clinician for further evaluation of depression in dementia subgroups.</AbstractText><CopyrightInformation>2010 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castilla-Puentes</LastName><ForeName>Ruby C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, USA. Ruby_Castilla@med.unc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habeych</LastName><ForeName>Miguel E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20129320</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2009.04.1232</ArticleId><ArticleId IdType="pii">S1552-5260(09)00107-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20102130</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2010</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0279-3695</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of psychosocial nursing and mental health services</Title><ISOAbbreviation>J Psychosoc Nurs Ment Health Serv</ISOAbbreviation></Journal><ArticleTitle>A comparison of multisensory and traditional interventions on inpatient psychiatry and geriatric neuropsychiatry units.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>31</EndPage><MedlinePgn>24-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3928/02793695-20091204-03</ELocationID><Abstract><AbstractText>Sensory rooms and the use of multisensory interventions are becoming popular in inpatient psychiatry. The empirical data supporting their use are limited, and there is only anecdotal evidence indicating effectiveness in psychiatric populations. The specific aims of this observational pilot study were to determine whether multisensory-based therapies were effective in managing psychiatric symptoms and to evaluate how these interventions compared to traditional ones used in the milieu. The study found that multisensory interventions were as effective as traditional ones in managing symptoms, and participants' Brief Psychiatric Rating Scale scores significantly improved following both kinds of intervention. Medication administration did not affect symptom reduction. This article explores how multisensory interventions offer choice in symptom management. Education regarding multisensory strategies should become integral to inpatient and outpatient group programs, in that additional symptom management strategies can only be an asset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Massachusetts, MA, USA. Margaret_Knight@uml.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adkison</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kovach</LastName><ForeName>Joan Stack</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychosoc Nurs Ment Health Serv</MedlineTA><NlmUniqueID>8200911</NlmUniqueID><ISSNLinking>0279-3695</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009730" MajorTopicYN="N">Nursing Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="Y">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011567" MajorTopicYN="Y">Psychiatric Department, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026421" MajorTopicYN="N">Sensory Art Therapies</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20102130</ArticleId><ArticleId IdType="doi">10.3928/02793695-20091204-03</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20075646</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.</ArticleTitle><Pagination><StartPage>40</StartPage><EndPage>43</EndPage><MedlinePgn>40-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0b013e3181ca0c59</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Behavioral disturbances are determining factors in handling patients with Alzheimer dementia. The current pharmacotherapy for behavioral symptoms associated with dementia is not satisfactory. Our goal was to compare a new anticonvulsant, topiramate, with a usually used medication, risperidone, for controlling behavioral disturbances of patients with Alzheimer dementia.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Elderly patients with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of Alzheimer disease and significant behavioral disturbances were randomized to receive, for a period of 8 weeks, a flexible dose of either topiramate (25-50 mg/d) or risperidone (0.5-2 mg/d). Outcome measures were the Cohen-Mansfield Agitation Inventory, Neuropsychiatry Inventory parts 1 and 2, and the Clinical Global Impression.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Forty-eight patients were randomized to treatment with either topiramate or risperidone, and 41 patients (21 of 25 in topiramate group and 20 of 23 in risperidone group) completed the trial. Both groups showed significant improvement in all outcome measures without important difference (Neuropsychiatry Inventory total score P &lt; 0.531, Z = 0.62; Cohen-Mansfield Agitation Inventory P &lt; 0.927, Z = 0.09; Clinical Global Impression, P &lt; 0.654, Z = 0.48). There were no significant changes in the cognitive status of patients (assessed by Mini-Mental Status Examination) taking topiramate or risperidone during the trial.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with a low dose of topiramate (25-50 mg/d) demonstrated a comparable efficacy with risperidone in controlling behavioral disturbances of patients with Alzheimer dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mowla</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Persian Gulf Bioscience Research Center, Bushehr University of Medical Sciences, Bushehr, Iran. mowlaar@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pani</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0H73WJJ391</RegistryNumber><NameOfSubstance UI="D000077236">Topiramate</NameOfSubstance></Chemical><Chemical><RegistryNumber>30237-26-4</RegistryNumber><NameOfSubstance UI="D005632">Fructose</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005632" MajorTopicYN="N">Fructose</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077236" MajorTopicYN="N">Topiramate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20075646</ArticleId><ArticleId IdType="doi">10.1097/JCP.0b013e3181ca0c59</ArticleId><ArticleId IdType="pii">00004714-201002000-00007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20054753</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3843</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>Neurologia i neurochirurgia polska</Title><ISOAbbreviation>Neurol Neurochir Pol</ISOAbbreviation></Journal><ArticleTitle>Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?</ArticleTitle><Pagination><StartPage>507</StartPage><EndPage>516</EndPage><MedlinePgn>507-16</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Cholinesterase inhibitors (ChEI) are currently the mainstream symptomatic treatment of patients with Alzheimer's disease (AD). To this end, the response to the treatment with ChEI is clinically difficult to predict. Several demographic, clinical and biological variables have been proposed as pre-treatment predictors of long-term therapy efficacy. The aim of the study was to confirm our initial observations of the significance of a change in plasma levels of beta-amyloid (Abeta) peptides after initial treat-ment with rivastigmine for predicting clinical response to ChEI.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Fifty-four carefully selected subjects (37 females) satisfying criteria for mild (n = 25) or moderate (n = 29) AD were included in the study. Rivastigmine was prescribed at the initial dose of 3 mg/day b.i.d.; the dose was escalated to the maximum tolerated one in at least 4-week intervals. The response to treatment was assessed using the ADAS-Cog and CDR scales. Whole blood samples were collected twice: before the first rivastigmine dose and at the 2nd week on active treatment. Levels of Abeta(1-40) and Abeta(1-42) were measured in plasma using a commercially available ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We confirmed that higher initial disease severity (higher ADAS-Cog scores) and the increase in the con-centration of plasma Abeta(1-42) peptide following 2 weeks of treatment with an initial dose of rivastigmine increased the chance of a clinically meaningful response to ChEI therapy in AD patients after 2 years of follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A change in plasma Abeta(1-42) level might constitute a novel biochemical predictor of long-term rivastigmine treatment efficacy in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sob&#xf3;w</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, ul. Czechos&#x142;owacka 8/10, 92-216 &#x141;&#xf3;d&#x17a;, Poland. tmsobow@csk.umed.lodz.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#x142;oszewska</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Flirski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Liberski</LastName><ForeName>Pawe&#x142;</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Neurol Neurochir Pol</MedlineTA><NlmUniqueID>0101265</NlmUniqueID><ISSNLinking>0028-3843</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20054753</ArticleId><ArticleId IdType="pii">13879</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20021448</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1874-4702</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Current molecular pharmacology</Title><ISOAbbreviation>Curr Mol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine.</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>82</EndPage><MedlinePgn>77-82</MedlinePgn></Pagination><Abstract><AbstractText>Behavioural symptoms are a significant problem in Alzheimer's disease (AD). Symptoms including agitation/aggression and psychosis reduce patient quality of life, significantly increase caregiver burden, and often trigger nursing home placement. Underlying changes in the serotonergic, noradrenergic and cholinergic systems have been linked to some behavioural problems, however, the use of antipsychotics in this population has been associated with significant safety concerns. A role for the glutamate system in schizophrenia, as well as in anxiety and depression, has been suggested, and evidence is emerging for a role for dysfunctional glutamate neurotransmission (via N-methyl-D-aspartate (NMDA) receptors) in certain behavioural changes in dementia. For example, the NMDA receptor antagonist, memantine has been shown to improve cognition, function (activities of daily living, ADLs) and, more recently, agitation/aggression, and delusions in AD patients. To date, little information is available regarding the neurochemical basis of agitation/aggression. However, the frontal and cingulate cortices--specifically, the formation of neurofibrillary tangles in glutamatergic pyramidal neurones of these areas--are proposed as regional substrates of these behaviours. Given that memantine displays a favourable tolerability profile, it is relevant to investigate the underlying mechanism linking memantine with the behavioural elements of AD. One hypothesis proposes that memantine corrects dysfunctional glutamatergic neurotransmission in the frontal and cingulate cortices, thereby normalising pathways responsible for causing agitation. An alternative hypothesis is based on the observation that increased tangle formation is associated with agitation, and on recent studies where memantine has been shown to reduce tau phosphorylation via glycogen synthase kinase (GSK)-3 or activation of protein phosphatase (PP)-2A, which might subsequently lead to reduced agitation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>P T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>King's College London, Wolfson Centre for Age-Related Diseases, London, UK. paul.francis@kcl.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Mol Pharmacol</MedlineTA><NlmUniqueID>101467997</NlmUniqueID><ISSNLinking>1874-4672</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20021448</ArticleId><ArticleId IdType="doi">10.2174/1874467210902010077</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20009237</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-8908</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>953</StartPage><EndPage>960</EndPage><MedlinePgn>953-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2009-1194</ELocationID><Abstract><AbstractText>The occurrence of neuropsychiatric symptoms in patients with Alzheimer's disease hampers the clinical management and exacerbates the burden for caregivers. To what extent psychotic symptoms are genetically determined and which are the genes involved has to be established. We tested the hypothesis that the occurrence of delusions and hallucinations in AD is associated with variations in the G72/DAOA gene, which is supposed to play a key role in the glutamate pathway regulated through the NMDA receptors. A panel of single nucleotide polymorphisms were genotyped in a cohort of 185 Alzheimer's disease patients. The analysis demonstrated a nominally significant association (p&lt; 0.05) with one single nucleotide polymorphism (rs2153674). In addition, multivariate regression showed that the rs2153674 genotype accounts for up to 15% of the variance in delusions severity, as assessed by using the Neuropsychiatric Inventory. If the results from the present study will be replicated, the glutamate hypothesis could be invoked to explain the occurrence of psychosis in neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Maria</LastName><ForeName>Emilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Genova, Italy. emilio.dimaria@unige.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonvicini</LastName><ForeName>Cristian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bonomini</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alberici</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zanetti</LastName><ForeName>Orazio</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Gennarelli</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475071">DAOA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20009237</ArticleId><ArticleId IdType="doi">10.3233/JAD-2009-1194</ArticleId><ArticleId IdType="pii">030T8786H273421Q</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19996874</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2009</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1543-3641</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology</Title><ISOAbbreviation>Cogn Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Behavioral dimensions and acetylcholinesterase inhibitor-related effect in Alzheimer disease over time: a latent trajectory modeling.</ArticleTitle><Pagination><StartPage>222</StartPage><EndPage>228</EndPage><MedlinePgn>222-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WNN.0b013e3181bf2e5d</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate whether treatment with acetylcholinesterase inhibitors (AChEIs) exerts a favorable effect on the behavioral dimensions in Alzheimer disease (AD) over time.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two hundred AD patients entered the study and underwent clinical and neuropsychologic examination. Neuropsychiatry Inventory (NPI) total scores and 4 behavioral factor scores, termed "psychosis," "moods," "apathy," and "frontal" were also evaluated. Of this large sample, 107 completed the 6-month follow-up and 83 were followed through for 1 year. Latent Trajectory Modeling analysis was applied, which allows for the estimation of a developmental trajectory over time for each case in the sample adjusting for confounders. These trajectories can be modeled to better understand individual differences in rates of change of behavioral dimensions and the relationship with AChEIs dose therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The behavioral phenotypes and NPI total scores were differently expressed, the most prevalent being the mood and the less prevalent being frontal endophenotype over time. The development relationship between the baseline and trend levels of behavioral phenotypes, or NPI total scores and the differences of AChEIs, adjusting for disease severity, concurrent drugs, and demographic data did not "travel together" through time, that is, the correlations of individual trajectories could be estimated equal to zeros.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data confirm that behavioral dimensions are variably represented in AD and change over time. However, AChEIs could not influence the behavioral disturbance pattern, both measured as total behavioral abnormality burden or as behavioral defined clusters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center for Aging Brain and Dementia, University of Brescia, Italy. bborroni@inwind.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Costanzi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cogn Behav Neurol</MedlineTA><NlmUniqueID>101167278</NlmUniqueID><ISSNLinking>1543-3633</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19996874</ArticleId><ArticleId IdType="doi">10.1097/WNN.0b013e3181bf2e5d</ArticleId><ArticleId IdType="pii">00146965-200912000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19910886</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The circadian rest-activity cycle in Korsakoff psychosis.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>41</EndPage><MedlinePgn>33-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181b0467a</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Alzheimer disease (AD) has been associated with diminished function of the biological clock in the suprachiasmatic nuclei (SCN) and pronounced circadian sleep-wake cycle disturbances. Few studies have investigated other dementia etiologies. Because alcohol acts on the SCN and modifies circadian rhythms in animal studies, Korsakoff psychosis (KP) may also be associated with circadian rhythm abnormalities. This pilot study investigated the rest-activity cycle of KP to see whether there were sleep-wake cycle disturbances similar to those that the authors had observed in patients with AD.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Cross-sectional observational study in a single academic medical center. PARTICIPANTS, MEASUREMENTS: The authors investigated the circadian rest-activity cycle of six moderately demented patients with KP who wore an activity/lux monitor for 10-26 days and compared these patterns with those of six home-living healthy individuals of the same age group. In addition, rest-activity cycle data from previous studies of patients with AD were examined.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">None.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rest-activity cycle of KP was remarkably well entrained, without the marked circadian and sleep disturbances found in patients with AD on the same ward. KP had a &gt;2 hour earlier bedtime and rest onset than healthy subjects and a 30-minute earlier wake-up time, resulting in longer nocturnal rest duration. The major difference was a greatly diminished daytime activity level and extremely low light exposure.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A stably entrained, although low-amplitude and phase-advanced rest-activity cycle may reflect the different neuropathology of demented patients with KP compared with patients with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wirz-Justice</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Chronobiology, Psychiatric Hospital of University Basel, Basel, Switzerland. anna.wirz-justice@unibas.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Carmen M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Gasio</LastName><ForeName>Paola Fontana</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Cajochen</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Savaskan</LastName><ForeName>Egemen</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020915" MajorTopicYN="N">Korsakoff Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008029" MajorTopicYN="N">Lighting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="Y">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="Y">Rest</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020178" MajorTopicYN="N">Sleep Disorders, Circadian Rhythm</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19910886</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181b0467a</ArticleId><ArticleId IdType="pii">S1064-7481(12)60270-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19910872</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis.</ArticleTitle><Pagination><StartPage>839</StartPage><EndPage>846</EndPage><MedlinePgn>839-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e3181ab8c3f</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors attempted to understand the role of two serotonin system genes, HTR2A and SLC6A4, on psychosis associated with Alzheimer dementia (AD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Relevant published studies were assessed, and their data were meta-analyzed to determine pooled odds ratios (ORs) that were assessed for heterogeneity. Additional robustness checks were performed to assess for publication bias and any undue influence from a single study. Finally, the number of studies required to invalidate positive findings was determined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The C allele of HTR2A emerged as a significant risk factor for psychosis, with an allelic OR of 2.191 that increased to 5.143 for the homozygous CC genotype. The SLC6A4 polymorphism was not reliably associated with either psychosis or delusions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The strong and robust positive association that was noted between the C allele of HTR2A and psychosis suggests that the HTR2A T102C polymorphism is a significant risk factor for psychosis of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>Seethalakshmi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>TS Srinivasan Centre for Clinical Neurosciences, The Institute for Neurological Sciences, Taramani, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatt</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19910872</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e3181ab8c3f</ArticleId><ArticleId IdType="pii">00019442-200910000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19846683</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-2731</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><MedlineDate>2009 Dec-2010 Jan</MedlineDate></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>The effect of multisensory stimulation on persons residing in an extended care facility.</ArticleTitle><Pagination><StartPage>450</StartPage><EndPage>455</EndPage><MedlinePgn>450-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1533317509350153</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Non-pharmacological interventions, such as multisensory stimulation environments (MSSE), have demonstrated the ability to reduce inappropriate behavior among individuals with Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we compared the incidences of problematic behavior among individuals with Alzheimer's disease residing in a long-term care facility who were and were not exposed to an MSSE. Retrospective data were obtained using the Psychotic Behavior Assessment Record (PBAR), mandated by Medicare to be used when antipsychotic medications are administered. Psychotic Behavior Assessment Record data were collected using the first and sixth month of admission for residents after appropriate consent was secured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Documented disruptive behavior included pacing, exit-seeking activities, hitting, yelling, and aggressive talking. The use of the MSSE resulted in a decrease in the number of incidences of disruptive behavior, but not the behaviors present.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of MSSE, as a non-pharmacological intervention, demonstrates the ability to decrease the number of incidences of disruptive or problematic behavior. The use of these interventions, where feasible, should be considered prior to the use of pharmacological methods.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ward-Smith</LastName><ForeName>Peggy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Missouri, Kansas City, Missouri, USA. wardsmithp@umkc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llanque</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019341" MajorTopicYN="Y">Aromatherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004779" MajorTopicYN="N">Environment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007374" MajorTopicYN="N">Interior Design and Furnishings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009147" MajorTopicYN="Y">Music Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012064" MajorTopicYN="Y">Relaxation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012866" MajorTopicYN="Y">Skilled Nursing Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19846683</ArticleId><ArticleId IdType="pmc">PMC10846236</ArticleId><ArticleId IdType="doi">10.1177/1533317509350153</ArticleId><ArticleId IdType="pii">1533317509350153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Alzheimer&#x2019;s Association. Alzheimer&#x2019;s Disease Facts and Figures; 2009. http://www.alz.org/national/documents/reportalzfactsfigures2009.pdf. Accessed March 29, 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">19426951</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc . 1986;34(10):722-727.</Citation><ArticleIdList><ArticleId IdType="pubmed">3760436</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weert JC , van Dulmen AM, Spreeuwenberg PM, Ribbe MW, Bensing JM Behavioral mood effects of Snoezelen integrated into 24-hour dementia care. J Am Geriatr Soc. 2005;53(1):24-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15667372</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips CD, Spry KM, Sloane PD, Hawes C. Use of physical restraints and psychotropic medications in Alzheimer special care units in nursing homes. Am J Public Health. 2000;90(1):92-96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1446122</ArticleId><ArticleId IdType="pubmed">10630143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Gauthier S., Cumming JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-255.</Citation><ArticleIdList><ArticleId IdType="pubmed">19488082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovach CR Sensoristasis and imbalance in persons with dementia. J Nurs Scholarsh. 2000;32(4):379-384.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140202</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck C., Frank L., Chumbler NR, et al. Correlates of disruptive behavior in severely cognitively-impaired nursing home residents. Gerontologist. 1998. ;38(2): 189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">9573663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Agitated behavior and cognitive functioning in nursing home resident. Clinical Gerontologist. 1988;7(3):11-22.</Citation></Reference><Reference><Citation>Hall GR, Buckwalter KC Progressively lowered stress threshold: a conceptual model for care of adults with Alzheimer&#x2019;s disease. Arch Psychiatr Nurs. 1987; 1(6):399-406.</Citation><ArticleIdList><ArticleId IdType="pubmed">3426250</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N. , Brandt J., Blacker D., et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007;64(12):1755-1761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690610</ArticleId><ArticleId IdType="pubmed">18071039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdner LA Effects of individualized versus classis &#x2018;&#x2018;relaxation&#x2019;&#x2019; music on the frequency of agitation in elderly persons with Alzheimer&#x2019;s disease and related disorders. Int Psychogeriatr. 2000;12(1):49-65.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798453</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns I., Cox H., Plant H. Leisure or therapeutics? Snoezelen and the care of older persons with dementia . Int J Nurs Pract. 2000;6(3):118-126.</Citation><ArticleIdList><ArticleId IdType="pubmed">11249409</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G., Johnston K., Katona C., Paton J., Lyketsos CG and the Old Age Task Force of the World Federation of Biological Psychiatry. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996-2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavet J. Multisensory environments. Snoezelen-your questions answered. Commun Living. 1994;7(3):26.</Citation></Reference><Reference><Citation>Hogg J., Cavet J., Lambe L., Smeddle M. The use of &#x2018;Snoezelen&#x2019; as multisensory stimulation with people with intellectual disabilities: a review of the research. Res Dev Disabil. 2001;22(5):353-372.</Citation><ArticleIdList><ArticleId IdType="pubmed">11580163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball J., Haight BK Creating a multisensory environment for dementia: the goals of a Snoezelen room. J Gerontol Nurs. 2005;31(10):4-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16262085</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley-Doucet CK Use of multisensory environment in the home for people with dementia. J Gerontol Nurs. 2009;35(5):42-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">19476192</ArticleId></ArticleIdList></Reference><Reference><Citation>Milev RV, Kellar T., McLean M., et al. Multisensory stimulation for elderly with dementia: a 24-week single-blind randomized controlled pilot study. Am J Alzheimers Dis Other Demen. 2008;23(4):372-376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10697329</ArticleId><ArticleId IdType="pubmed">18453647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancioni GE , Cuvo AJ, O&#x2019;Reilly MF Snoezelen: an overview of research with people with developmental disabilities and dementia. Disabil Res. 2002;24(4):175-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">11926258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Jjcc, Lai Ccky. Snoezelen for dementia. Cochrane Database Syst Rev. 2002;(4):CD003152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9002239</ArticleId><ArticleId IdType="pubmed">12519587</ArticleId></ArticleIdList></Reference><Reference><Citation>
American Association of Multi Sensory Environments. Position paper; 2009. http://www.aamse.us/research.php . Accessed July 7, 2009.</Citation></Reference><Reference><Citation>Hutchison R. Sensory Environments. Chesterfield: Whittington Hall Hospital; 1994.</Citation></Reference><Reference><Citation>Reisberg B. Diagnostic criteria in dementia: a comparison of current criteria, research challenges, and implications for DSM-V. J Geriatr Psychiatry Neurol. 2006; 19(3):137-146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19781112</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Trajectories of cognitive decline in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>290</EndPage><MedlinePgn>281-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610209991001</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Late-onset Alzheimer disease (LOAD) is a clinically heterogeneous complex disease defined by progressively disabling cognitive impairment. Psychotic symptoms which affect approximately one-half of LOAD subjects have been associated with more rapid cognitive decline. However, the variety of cognitive trajectories in LOAD, and their correlates, have not been well defined. We therefore used latent class modeling to characterize trajectories of cognitive and behavioral decline in a cohort of AD subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">201 Caucasian subjects with possible or probable Alzheimer's disease (AD) were evaluated for cognitive and psychotic symptoms at regular intervals for up to 13.5 years. Cognitive symptoms were evaluated serially with the Mini-mental State Examination (MMSE), and psychotic symptoms were rated using the CERAD behavioral rating scale (CBRS). Analyses undertaken were latent class mixture models of quadratic trajectories including a random intercept with initial MMSE score, age, gender, education, and APOE 4 count modeled as concomitant variables. In a secondary analysis, psychosis status was also included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">AD subjects showed six trajectories with significantly different courses and rates of cognitive decline. The concomitant variables included in the best latent class trajectory model were initial MMSE and age. Greater burden of psychotic symptoms increased the probability of following a trajectory of more rapid cognitive decline in all age and initial MMSE groups. APOE 4 was not associated with any trajectory.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Trajectory modeling of longitudinal cognitive and behavioral data may provide enhanced resolution of phenotypic variation in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilkosz</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seltman</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Devlin</LastName><ForeName>Bernie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Weamer</LastName><ForeName>Elise A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224-03</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133-210020</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>CONFLICT OF INTEREST DECLARATION</b>. Sources of Financial Support: Supported in part by research grants AG027224 and AG005133 from the National Institute of Aging. Information about Financial Relationships: The authors do not have a financial relationship with any organization that might have vested interest in the conduct and reporting of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19781112</ArticleId><ArticleId IdType="mid">NIHMS175370</ArticleId><ArticleId IdType="pmc">PMC2834298</ArticleId><ArticleId IdType="doi">10.1017/S1041610209991001</ArticleId><ArticleId IdType="pii">S1041610209991001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of psychosis in Alzheimer disease. American Journal of Geriatric Psychiatry. 2005;13:624&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009739</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Gender, cognitive decline, and risk of AD in older persons. Neurology. 2003;60:1777&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796530</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Archives of Neurology. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram K, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic Meta-Analysis of Alzheimer Disease Genetic Association Studies: The AlzGene Database. Nature Genetics. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology. 2003;60:1077&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682309</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer&#x2019;s disease. Neurology. 1998;51:149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674794</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran PJ, Willoughby MT. Implications of latent trajectory models for the study of developmental psychopathology. Development and Psychopathology. 2003;15:581&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">14582933</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge HH, Du Y, Saxton JA, Ganguli M. Cognitive domains and trajectories of functional independence in nondemented elderly persons. Journals of Gerontology Series A Biological Sciences and Medical Sciences. 2006;61:1330&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1808540</ArticleId><ArticleId IdType="pubmed">17234830</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruen B, Leisch F. FlexMix Version 2: finite mixtures with concomitant variables and varying and constant parameters. Journal of Statistical Software. 2008;28:1&#x2013;35.</Citation></Reference><Reference><Citation>Healy DG. Case-control studies in the genomic era: a clinician&#x2019;s guide. Lancet Neurology. 2006;5:701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">16857576</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgeson VS, Snyder P, Seltman H. Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change. Health Psychology. 2004;23:3&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">14756598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Increased familial risk and genomewide significant linkage for Alzheimer&#x2019;s disease with psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2007;144B(7):841&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">17492769</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmans P, et al. Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer&#x2019;s disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2005;135B:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15729734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Archives of Neurology. 2005;62:454&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767511</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociological Methods &amp; Research. 2001;29:374&#x2013;393.</Citation></Reference><Reference><Citation>Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesteral levels in normoglycemic and diabetic subjects in biethnic population from the San Luis Valley, Colorado. Atherosclerosis. 1995;112:145&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">7772075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiman T, et al. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer&#x2019;s disease: retrospective and prospective analysis. Dementia and Geriatric Cognitive Disorders. 2006;22:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699282</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisch E. FlexMix: A General Framework for Finite Mixture Models and Latent Class Regression in R. Journal of Statistical Software. 2004;11:1&#x2013;18.</Citation></Reference><Reference><Citation>Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N. Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566948</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann UM, Mohr E, Gearing M, Chase TN. Heterogeneity in Alzheimer&#x2019;s disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. Journal of Neurology, Neurosurgery and Psychiatry. 1992;55:956&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1015199</ArticleId><ArticleId IdType="pubmed">1431960</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65:1888&#x2013;1893.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380608</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">8909416</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hara R, Sommer B, Way N, Kraemer HC, Taylor J, Murphy G. Slower speed-of-processing of cognitive tasks is associated with presence of the apolipoprotein epsilon4 allele. Journal of Psychiatric Research. 2008;42:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17250852</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2007.</Citation></Reference><Reference><Citation>Rasmusson DX, Carson KA, Brookmeyer R, Kawas C, Brandt J. Predicting rate of cognitive decline in probable Alzheimer&#x2019;s disease. Brain and Cognition. 1996;31:133&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: a review of 55 studies published from 1990 to 2003. American Journal of Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall DR, Palmer R, Chiodo LK, Polk MJ. Normal rates of cognitive change in successful aging: the freedom house study. Journal of the International Neuropsychological Society. 2005;11:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16519269</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Archives of Neurology. 2005;62:1601&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3028538</ArticleId><ArticleId IdType="pubmed">16216946</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz G. Estimating the Dimension of a Model. Annals of Statistics. 1978;6:461&#x2013;464.</Citation></Reference><Reference><Citation>Tariot PN, et al. The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease. American Journal of Psychiatry. 1995;152:1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">7653692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyas SL, et al. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. American Journal of Epidemiology. 2007;165:1231&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516202</ArticleId><ArticleId IdType="pubmed">17431012</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19764601</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0370-8179</ISSN><JournalIssue CitedMedium="Print"><Volume>137</Volume><Issue>7-8</Issue><PubDate><Year>2009</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Srpski arhiv za celokupno lekarstvo</Title><ISOAbbreviation>Srp Arh Celok Lek</ISOAbbreviation></Journal><ArticleTitle>[Mild cognitive impairment].</ArticleTitle><Pagination><StartPage>434</StartPage><EndPage>439</EndPage><MedlinePgn>434-9</MedlinePgn></Pagination><Abstract><AbstractText>Mild cognitive impairment (MCI) is a syndrome that spans the area between normal ageing and dementia. It is classified into amnestic and non-amnestic types, both with two subtypes: single domain and multiple domains. Prevalence of MCI depends on criteria and population and can vary from 0.1 to 42% persons of older age. In contrast to dementia, cognitive deterioration is less severe and activities of daily living are preserved. Most impaired higher cognitive functions in MCI are memory, executive functions, language, visuospatial functions, attention etc. Also there are depression, apathy or psychomotor agitation, and signs of psychosis. Aetiology of MCI is multiple, mostly neurodegenerative, vascular, psychiatric, internistic, neurological, traumatic and iatrogenic. Persons with amnestic MCI are at a higher risk of converting to Alzheimer's disease, while those with a single non-memory domain are at risk of developing frontotemporal dementia. Some MCI patients also progress to other dementia types, vascular among others. In contrast, some patients have a stationary course, some improve, while others even normalize. Every suspicion of MCI warrants a detailed clinical exploration to discover underlying aetiology, laboratory analyses, neuroimaging methods and some cases require a detailed neuropsychological assessment. At the present time there is no efficacious therapy for cognitive decline in MCI or the one that could postpone conversion to dementia. The treatment of curable causes, application of preventive measures and risk factor control are reasonable measures in the absence of specific therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pavlovi&#x107;</LastName><ForeName>Dragan M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Pavlovi&#x107;</LastName><ForeName>Aleksandra M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>srp</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Blago kognitivno oste&#x107;enje.</VernacularTitle></Article><MedlineJournalInfo><Country>Serbia</Country><MedlineTA>Srp Arh Celok Lek</MedlineTA><NlmUniqueID>0027440</NlmUniqueID><ISSNLinking>0370-8179</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>47</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19764601</ArticleId><ArticleId IdType="doi">10.2298/sarh0908434p</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19748376</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Is late-onset schizophrenia related to neurodegenerative processes? A review of literature].</ArticleTitle><Pagination><StartPage>386</StartPage><EndPage>393</EndPage><MedlinePgn>386-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2008.06.008</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Since 1943 when, for the first time, M. Bleuler used the term late-onset schizophrenia (LOS) to refer to diagnostic groups gathering some clinical features of schizophrenia, but with onset after the age of 40, opinions on this entity are divided. The main question is whether LOS and schizophrenia, with onset in early adulthood (early-onset schizophrenia EOS), have the same etiopathogeny. This discussion became more complex with the introduction, in 2000, of a new entity, the "very-late-onset schizophrenia-like psychosis" (VLOSP), which took the place of "late paraphrenia" and grouped together schizophrenia, delusional disorders and paranoid psychosis with age of onset after 60 years. Neuropathological processes underlying these entities have not beed determined. In particular, neurodegenerative processes could be explored.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A literature review between 1 January 1995 and 30 April 2008, based on a research on PubMed with the terms "late-onset schizophrenia", "paraphrenia", "late paraphrenia", "VLOSP", and "late psychosis", takes stock of the various studies and hypotheses which have investigated the link between LOS/VLOSP and neurodegenerative processes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical approach: there is no greater family history of dementia disorders in LOS/VLOSP than in the general population. Neuropsychological pattern between LOS and Alzheimer's disease (AD) seems different, with more impairment in delayed recall in AD, and in short-term memory in LOS. Some longitudinal studies, however, have argued that a part of patients with LOS would develop dementia at 10 years. These patients would have a later onset of disorders (&gt; 60 years). Anatomopathological approach: anatomopathological studies show that LOS is not consecutive to AD, and might be related to a restricted limbic tauopathy. Neuroimaging approach: Magnetic Resonance Imaging (MRI) morphological neuroimaging studies show little differences between LOS and EOS. The thalamus volume was significantly smaller, and cortical atrophy was more important in LOS. MRI neuroimaging studies regarding white matter hyperintensities (WMH), which are considered as a macroscopic manifestation of cerebrovascular disease (CD), show inconsistent results. Positive results are observed with LOS subjects with later onset of disease. In addition, WMH were not located on cerebral tracts, which are implicated in EOS, but were periventricular.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">It is notable that the studies conducted do not differentiate between LOS and VLOSP, since these two groups of patients are generally mixed. Furthermore, an attempt to analyse the data has to take into account only the studies which have included subjects with strict criteria of schizophrenia, independently of the disorders' age of onset. In addition, we found no study comparing LOS and Lewy Bodies Dementia, which is however an important differential diagnosis. The two main hypotheses tested appear to be: (1): is LOS a prodrome of AD? (2): is LOS consecutive to CD? This review permits a partial answer to these questions. First, LOS as a prodrome of AD seems very unlikely, considering anatomopathological studies. However, it is possible that subjects with later age of onset of the disease develop dementia at 10 years. Second, CD seems not to be altered by the cerebral tracts which are implicated in EOS. A hypothesis could be that the tracts implicated in LOS and EOS differ. This might explain the differences found in clinical (less formal thought disorders and negative symptoms in LOS compared with EOS) and electroencephalographical studies (no reduction of P300's amplitude in LOS, which has however been proposed as trait marker of schizophrenia in EOS) between LOS and EOS. These tracts could be related to a limbic tauopathy found in anatomopathological studies. More vulnerable subjects would develop LOS with ageing. Other subjects would develop LOS secondary to CD. This could explain the later age of onset of the disease in these subjects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagodka</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service du Pr Pringuey, clinique de psychiatrie et de psychologie m&#xe9;dicale-Abbaye de Saint-Pons, CHU Pasteur, Nice, France. aurelielagodka@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>La schizophr&#xe9;nie tardive est-elle secondaire &#xe0; des processus neurod&#xe9;g&#xe9;n&#xe9;ratifs? Une revue de la litt&#xe9;rature.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748376</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2008.06.008</ArticleId><ArticleId IdType="pii">S0013-7006(08)00158-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19748373</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Depression and frontal dysfunction: risks for the elderly?].</ArticleTitle><Pagination><StartPage>361</StartPage><EndPage>369</EndPage><MedlinePgn>361-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2008.03.012</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frontal lobe syndromes include reduced activity, particularly a diminution of spontaneous activity, lack of drive, inability to plan ahead, and induce a lack of concern. These last points constitute the executive dysfunction syndrome. That executive dysfunction could be the core defect in patients with geriatric or vascular depression, and might be related to frontal-subcortical circuit dysfunction. Sometimes frontal lobe syndromes are associated with restless, aimless, uncoordinated behavior or even disinhibition, increasing the risks of falls and of malnutrition. Some authors have distinguished between lesions of the lateral frontal cortex, most closely linked to the motor structures of the brain, which lead to disturbances of movement and action with perseveration and inertia, and lesions of the orbital and medial areas, interlinked with limbic and reticular systems, damage to which leads to disinhibition and changes of affect. The medial frontal syndrome is marked by akinesia, associated with gait disturbances, and loss of autonomy. For these reasons, it has been proposed that a subtype of depression, "depression-executive dysfunction syndrome" could occur in late life. This assertion was based on clinical, neuropathological, and neuroimaging findings suggesting that frontostriatal dysfunctions contribute to the development of both depression and executive dysfunction and influence the course of depression. Depressive symptomatology, and especially psychomotor retardation and loss of interest in activities, contributed to disability in depression-executive dysfunction syndrome patients. This study is not restricted to major depression. It examined the relationship of executive impairment to the course of depressive symptoms among a psychogeriatric population with dementia or depression in order to assess the consequences of these pathologies on disabilities of aged persons.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study was carried out in Limoges (France) during 2006 and 2007. Three hundred and twenty one psychogeriatric outpatients were included after their written agreement. They were assessed using different scales for autonomy, cognition, depression, frontal impairment and these results were compared with the risk of fall, a possible loss of autonomy and a proteino-energical malnutrition. The statistical study was made using the Systat 11 software. The following tests were used: Student Test, Chi(2) test, and the Manova test, which was adjusted to the duration of the disease, the caregiver's age, his/her education level, and level of cognitive impairment. The regression method used was the multiple linear regression method as well as a descending step-by-step analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and thirty six males (77.3+/-7.09 years old) and 185 females (80.4+/-6.5 years old) were recruited. Patients mainly presented with Alzheimer's disease (n=123) and 65 presented an associated depression, 25 presented vascular dementia, 30 a Lewy bodies dementia, 27 a fronto-temporal dementia. Twenty-seven presented psychosis and 40 a Mild Cognitive Impairment. A control group was composed of 33 persons presumed without psychogeriatric pathologies. Depression associated with an executive dysfunction syndrome increased loss of autonomy, the risk of fall and of malnutrition, especially in the case of cognitive impairment. The multivariate regression analysis step-by-step shows an increasing risk of fall in the presence of a depression-executive dysfunction syndrome. Motivation is altered when the patient is depressed. In demented patients, depression significantly increases behavioral disorders, social and familial relationships, and instrumental acts of daily life. It precipitates the risks of falls and of malnutrition.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The principal finding of this study is that geriatric depression is characterized by impaired executive functioning. In the present study, depressed patients also had a greater tendency to fall and to suffer from malnutrition. Executive processes are fundamental to the daily functioning of depressed older adults, and dysfunction may lead to a lack of compensatory strategies that would improve the outcomes of late-life depression or of increasing dependency as well. In demented patients, depression triggers loss of motivation and executive dysfunction as well.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Depression and executive dysfunction triggers the loss of autonomy, the risk of fall and of malnutrition in elderly patients. The clinical significance of this study is that the delineation of specific executive in depressed elderly patients may facilitate the development of effective treatment interventions, including treatment for geriatric depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service universitaire de psychog&#xe9;riatrie, centre m&#xe9;moire de ressources et de recherches, centre hospitalier Esquirol, 87025 Limoges, France. philippe.thomas@ch-esquirol-limoges.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hazif Thomas</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Billon</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Peix</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Faugeron</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cl&#xe9;ment</LastName><ForeName>J-P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>D&#xe9;pression et syndrome frontal: quels risques pour la personne &#xe2;g&#xe9;e?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000058" MajorTopicYN="N">Accidental Falls</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011502" MajorTopicYN="N">Protein-Energy Malnutrition</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748373</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2008.03.012</ArticleId><ArticleId IdType="pii">S0013-7006(08)00167-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19735591</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1741-203X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Antidepressant use in Alzheimer's disease patients: results of the REAL.FR cohort.</ArticleTitle><Pagination><StartPage>120</StartPage><EndPage>128</EndPage><MedlinePgn>120-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610209990780</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Psychotropic medication is widely prescribed in clinical practice for the management of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD). However, there have been few pharmaco-epidemiological studies or studies conducted in a natural setting on the real use of antidepressants in AD. The aim of this survey was to assess the prevalence of antidepressant use in AD and to identify the clinical factors associated with antidepressant prescription.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">REAL.FR is a four-year, prospective, multi-center study. Baseline data including demographic characteristics, clinical variables and drug intake were obtained. Depressive symptoms were determined using the Neuropsychiatric Inventory (NPI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 686 AD patients were included. Antidepressant treatment was prescribed for 34.8% of patients. Clinically significant depressive symptoms (NPI &gt;or= 4) were observed in 20.5% of the total population. Although depressed subjects were significantly more likely to be treated with antidepressants than non-depressed subjects (p&lt;0.0001), only 60% of depressed subjects overall were prescribed an antidepressant. In multivariate analysis, clinically significant depressive symptoms were associated with antidepressant prescription although this result was only observed in subjects without a previous history of depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The available data on antidepressant efficacy in BPSD other than depression (in particular, agitation, aggression and, occasionally, psychotic symptoms) do not influence prescription choices. Depressive symptoms may be taken more seriously in the absence of a previous history of depression, leading to increased antidepressant prescription rates in individuals presenting with depression for the first time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arbus</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Paul Sabatier University, Department of Psychiatry and Medical Psychology, Purpan-Casselardit Hospital, Toulouse, France. arbus.c@chu-toulouse.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardette</LastName><ForeName>Virginie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bui</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cantet</LastName><ForeName>Christelle</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Andrieu</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nourhash&#xe9;mi</LastName><ForeName>Fati</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><CollectiveName>REAL.FR Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Vellas</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainfray</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard-Harston</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couturier</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackowiak-Cordoliani</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frigard</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Idiri</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallouj</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeandel</LastName><ForeName>Cl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Touchon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portet</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerouge</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>Ph</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brocker</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertogliati</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forette</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teillet</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lechowski</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belmin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariel-Madjlessi</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verny</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Artaz</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forette</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rigaud</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Latour</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouanny</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belliard</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girtanner</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas-Anterion</LastName></Investigator><Investigator ValidYN="Y"><LastName>Cortes</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillette-Guyonnet</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nourhashemi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ousset</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrieu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantet</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19735591</ArticleId><ArticleId IdType="doi">10.1017/S1041610209990780</ArticleId><ArticleId IdType="pii">S1041610209990780</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19735590</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Comparison of behavioral and psychological symptoms of Alzheimer's disease among institution residents and memory clinic outpatients.</ArticleTitle><Pagination><StartPage>1134</StartPage><EndPage>1141</EndPage><MedlinePgn>1134-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610209990767</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Behavioral and psychological symptoms of dementia (BPSD) cause caregiver distress and earlier institutionalization. We compared the prevalence and characteristics of BPSD between institution residents and memory clinic outpatients with Alzheimer's disease (AD) to test the hypothesis that there is more BPSD among institution residents than among their outpatient counterparts. We assessed BPSD by interviewing the patients' principal caregivers, either family or professionals, using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD). Data from 138 patients with probable AD from the memory clinic and 173 residents with possible AD living in the long-term care facilities were collected. The diagnoses followed the NINCDS-ADRDA criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BPSD profiles of the two groups were similar but not identical. The prevalence of at least one BPSD was high in both groups (community 81.9%, institution 74.9%). Activity disturbance was the most frequently reported BPSD in both groups (community 52.2%, institution 38.7%). Delusions, hallucinations, anxiety and aggressiveness were seen more frequently in memory clinic outpatients. The outpatients also had higher scores of BEHAVE-AD subscales in delusion/paranoid ideation, affective disturbance, and global rating of severity. With the increase of disease severity there were significantly more activity disturbance, psychosis, and aggressiveness in patients with AD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Caregiver factor and institution effect were two possible reasons for the higher prevalence and the greater severity of BPSD in community patients. BPSD caused more distress to family caregivers than the professional caregivers. High levels of psychotropic prescriptions for patients living in the long-term care facilities may also play a role.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ting-Wen</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Taiwan University Hospital, National Taiwan University, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ta-Fu</ForeName><Initials>TF</Initials></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>Ping-Keung</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Mau-Sun</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chi-Cheng</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Ming-Jang</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="Y">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007326" MajorTopicYN="Y">Institutionalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19735590</ArticleId><ArticleId IdType="doi">10.1017/S1041610209990767</ArticleId><ArticleId IdType="pii">S1041610209990767</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19717458</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>36</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations.</ArticleTitle><Pagination><StartPage>15483</StartPage><EndPage>15488</EndPage><MedlinePgn>15483-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0901866106</ELocationID><Abstract><AbstractText>The gene MECP2 is a well-known determinant of brain structure. Mutations in the MECP2 protein cause microencephalopathy and are associated with several neurodevelopmental disorders that affect both brain morphology and cognition. Although mutations in MECP2 result in severe neurological phenotypes, the effect of common variation in this genetic region is unknown. We find that common sequence variations in a region in and around MECP2 show association with structural brain size measures in 2 independent cohorts, a discovery sample from the Thematic Organized Psychosis research group, and a replication sample from the Alzheimer's Disease Neuroimaging Initiative. The most statistically significant replicated association (P &lt; 0.025 in both cohorts) involved the minor allele of SNP rs2239464 with reduced cortical surface area, and the finding was specific to male gender in both populations. Variations in the MECP2 region were associated with cortical surface area but not cortical thickness. Secondary analysis showed that this allele was also associated with reduced surface area in specific cortical regions (cuneus, fusiform gyrus, pars triangularis) in both populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joyner</LastName><ForeName>Alexander H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Scripps Translational Science Institute, 3344 North Torrey Pines Court, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J</LastName><ForeName>Cooper Roddey</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Bloss</LastName><ForeName>Cinnamon S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Bakken</LastName><ForeName>Trygve E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Rimol</LastName><ForeName>Lars M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Agartz</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Topol</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Schork</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54RR02504-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025774</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007752</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG031224-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497392">MECP2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19717458</ArticleId><ArticleId IdType="pmc">PMC2741277</ArticleId><ArticleId IdType="doi">10.1073/pnas.0901866106</ArticleId><ArticleId IdType="pii">0901866106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans PD, et al. Microcephalin, a gene regulating brain size, continues to evolve adaptively in humans. Science. 2005;309:1717&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pubmed">16151009</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekel-Bobrov N, et al. Ongoing adaptive evolution of ASPM, a brain size determinant in Homo sapiens. Science. 2005;309:1720&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">16151010</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans PD, et al. Adaptive evolution of ASPM, a major determinant of cerebral cortical size in humans. Hum Mol Genet. 2004;13:489&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates TC, et al. Recently-derived variants of brain-size genes ASPM, MCPH1, CDK5RAP and BRCA1 not associated with general cognition, reading or language. Intelligence. 2008;36:689&#x2013;693.</Citation></Reference><Reference><Citation>Varnas K, et al. Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. Psychiatr Genet. 2008;18:177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">18628679</ArticleId></ArticleIdList></Reference><Reference><Citation>Belichenko NP, Belichenko PV, Li HH, Mobley WC, Francke U. Comparative study of brain morphology in Mecp2 mutant mouse models of Rett syndrome. J Comp Neurol. 2008;508:184&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">18306326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi HY. MeCP2 dysfunction in humans and mice. J Child Neurol. 2005;20:736&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">16225828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankirawatana P, et al. Early progressive encephalopathy in boys and MECP2 mutations. Neurology. 2006;67:164&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832102</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter JC, et al. Selective cerebral volume reduction in Rett syndrome: A multiple-approach MR imaging study. AJNR. 2008;29:436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403765</ArticleId><ArticleId IdType="pubmed">18065507</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir RE, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508514</ArticleId></ArticleIdList></Reference><Reference><Citation>Loat C, et al. Methyl-CpG-binding protein (MECP2) polymorphisms and vulnerability to autism. Genes Brain Behav. 2008;7(7):754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645848</ArticleId><ArticleId IdType="pubmed">19125863</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazian MD, Zoghbi HY. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol. 2001;14:171&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">11262731</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibayama A, et al. MECP2 structural and 3&#x2032;-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism. Am J Med Genet B Neuropsychiatr Genet. 2004;128B:50&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">15211631</ArticleId></ArticleIdList></Reference><Reference><Citation>Aber KM, et al. Methyl-CpG-binding protein 2 is localized in the postsynaptic compartment: an immunochemical study of subcellular fractions. Neuroscience. 2003;116:77&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12535940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahrour M, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443785</ArticleId><ArticleId IdType="pubmed">18511691</ArticleId></ArticleIdList></Reference><Reference><Citation>LaSalle JM. The Odyssey of MeCP2 and parental imprinting. Epigenetics. 2007;2(1):5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866173</ArticleId><ArticleId IdType="pubmed">17965611</ArticleId></ArticleIdList></Reference><Reference><Citation>Stearns NA, et al. Behavioral and anatomical abnormalities in Mecp2 mutant mice: A model for Rett syndrome. Neuroscience. 2007;146:907&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">17383101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffbuhr K, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology. 2001;56:1486&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schule B, Armstrong DD, Vogel H, Oviedo A, Francke U. Severe congenital encephalopathy caused by MECP2 null mutations in males: Central hypoxia and reduced neuronal dendritic structure. Clin Genet. 2008;74:116&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">18477000</ArticleId></ArticleIdList></Reference><Reference><Citation>Belichenko PV, Hagberg B, Dahlstrom A. Morphological study of neocortical areas in Rett syndrome. Acta Neuropathol. 1997;93:50&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9006657</ArticleId></ArticleIdList></Reference><Reference><Citation>Courchesne E. Brain development in autism: Early overgrowth followed by premature arrest of growth. Ment Retard Dev Disabil Res Rev. 2004;10:106&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15362165</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>De Fosse L, et al. Language-association cortex asymmetry in autism and specific language impairment. Ann Neurol. 2004;56:757&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">15478219</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics. 2006;1(4):e1&#x2013;e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866172</ArticleId><ArticleId IdType="pubmed">17486179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinhans NM, et al. Abnormal functional connectivity in autism spectrum disorders during face processing. Brain. 2008;131:1000&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">18234695</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinehart NJ, et al. Gait function in newly diagnosed children with autism: Cerebellar and basal ganglia related motor disorder. Dev Med Child Neurol. 2006;48:819&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">16978461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake SL, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003;55:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890927</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Francke U. Identification of cis-regulatory elements for MECP2 expression. Hum Mol Genet. 2006;15:1769&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">16613900</ArticleId></ArticleIdList></Reference><Reference><Citation>International Hapmap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880871</ArticleId><ArticleId IdType="pubmed">16255080</ArticleId></ArticleIdList></Reference><Reference><Citation>Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human genome. PLoS Biol. 2006;4(3):e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382018</ArticleId><ArticleId IdType="pubmed">16494531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ET, Kodama G, Baldi P, Moyzis RK. Global landscape of recent inferred Darwinian selection for Homo sapiens. Proc Natl Acad Sci USA. 2006;103:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317879</ArticleId><ArticleId IdType="pubmed">16371466</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer KS, et al. Mutation analysis of the coding sequence of the MECP2 gene in infantile autism. Human Genet. 2002;111:305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo-Menendez F, et al. Absence of MeCP2 mutations in patients from the South Carolina autism project. Am J Med Genet B Neuropsychiatr Genet. 2003;117B:97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">12555243</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutinho AM, et al. MECP2 coding sequence and 3&#x2032;UTR variation in 172 unrelated autistic patients. Am J Med Genet B Neuropsychiatr Genet. 2007;144B:475&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17427193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurian JR, Forbes-Lorman RM, Auger AP. Sex difference in mecp2 expression during a critical period of rat brain development. Epigenetics. 2007;2(3):173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965589</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontious A, Kowalczyk T, Englund C, Hevner RF. Role of intermediate progenitor cells in cerebral cortex development. Dev Neurosci. 2008;30:24&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">18075251</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser T, et al. PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. Nat Genet. 1994;7:463&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">7951315</ArticleId></ArticleIdList></Reference><Reference><Citation>Baala L, et al. Homozygous silencing of T-box transcription factor EOMES leads to microcephaly with polymicrogyria and corpus callosum agenesis. Nat Genet. 2007;39:454&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 2002;297:365&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuida K, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 1998;94:325&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708735</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung BP, et al. The expression of methyl CpG binding factor MeCP2 correlates with cellular differentiation in the developing rat brain and in cultured cells. J Neurobiol. 2003;55:86&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12605461</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19715553</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5828</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease.</ArticleTitle><Pagination><StartPage>158</StartPage><EndPage>164</EndPage><MedlinePgn>158-64</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline including loss of memory, orientation and reasoning. However, a relevant aspect of AD is the presence of a variety of behavioural and psychological symptoms in dementia (BPSD), beyond the well-known progressive cognitive impairment. Approximately 50% to 80% of patients diagnosed with AD present behavioural or psychiatric disturbances such as psychosis, depression, agitation, disinhibition, aggression, hyperactivity, and socially intrusive behaviours. These symptoms may be burdensome for physicians and caregivers and lead to earlier institutionalization and increased social and economic costs. In this view, recent literature has considered the likely genetic component of BPSD in AD, defining different clusters. Several studies have investigated whether the main recognised genetic risk factor for late-onset AD, namely the apolipoprotein E (APOE) gene, is associated with BPSD, with conflicting results. The involvement of dopamine- or serotonin-related pathways and associated genetic variabilities has been demonstrated as being interesting candidates for the neuropsychiatry manifestations of dementia. Moreover, genetic variations of neurotrophins, such as brain-derived neurotrophic factor (BDNF), have been related to depression susceptibility in AD. In the present review, we summarise the current literature on genetic risk factors to BPSD susceptibility in AD and discuss future possible treatment strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Brain Aging and Neurodegenerative Disorders, Department of Neurology, University of Brescia, Italy. bborroni@inwind.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costanzi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015306">Biogenic Monoamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015306" MajorTopicYN="N">Biogenic Monoamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>81</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19715553</ArticleId><ArticleId IdType="doi">10.2174/156720510790691173</ArticleId><ArticleId IdType="pii">CAR-10</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19681559</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0098-9134</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of gerontological nursing</Title><ISOAbbreviation>J Gerontol Nurs</ISOAbbreviation></Journal><ArticleTitle>Psychotic events in Alzheimer's disease: application of the PLST model.</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>29</EndPage><MedlinePgn>20-7; quiz 28-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3928/00989134-20090706-05</ELocationID><Abstract><AbstractText>This article focuses on a review of the literature related to the known prevalence of psychotic events in individuals with Alzheimer's disease and associated aggressive, violent behavior toward family caregivers. It also describes the impact of behavioral disturbances on family caregivers and how use of the Progressively Lowered Stress Threshold model and nonpharmacological interventions cited in the literature can help manage these behaviors. Geriatric nurses armed with this information will be better prepared to provide caregivers with much-needed education to better understand psychotic events, as well as strategies to cope with associated behaviors.</AbstractText><CopyrightInformation>Copyright 2009, SLACK Incorporated.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lindsey</LastName><ForeName>Pamela L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>llinois State University Mennonite College of Nursing, Campus Box 5810, Normal, IL 61790, USA. pllinds@ilstu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckwalter</LastName><ForeName>Kathleen C</ForeName><Initials>KC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NR003979</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NR003979-15</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR03234</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gerontol Nurs</MedlineTA><NlmUniqueID>7510258</NlmUniqueID><ISSNLinking>0098-9134</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004509" MajorTopicYN="N">Education, Nursing, Continuing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="Y">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19681559</ArticleId><ArticleId IdType="mid">NIHMS288795</ArticleId><ArticleId IdType="pmc">PMC3135972</ArticleId><ArticleId IdType="doi">10.3928/00989134-20090706-05</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer A. About a peculiar disease of the cerebral cortex. In: Jarvik L, Greenson H, editors. Alzheimer Disease and Associated Disorders. 1. Vol. 1. 1987. pp. 7&#x2013;8. Original work published 1907.</Citation><ArticleIdList><ArticleId IdType="pubmed">3331112</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association  Alzheimer&#x2019;s disease facts and figures 2007. 2007 Retrieved October 1, 2008, from  http://www.alz.org/national/documents/Report_2007FactsAndFigures.pdf.</Citation></Reference><Reference><Citation>Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer&#x2019;s disease: Review of the brain decade. Psychosomatics. 2003;44:388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">12954913</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd MA. Psychiatric nursing: Contemporary practice. 4th ed. Lippincott Williams &amp;Wilkins; Philadelphia: 2008.</Citation></Reference><Reference><Citation>Buckwalter KC. Are you really my nurse, or are you a snake sheriff? Journal of Gerontological Nursing. 1993;19(6):45&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">8099596</ArticleId></ArticleIdList></Reference><Reference><Citation>Chico GF. Targeting behavior problems in Alzheimer&#x2019;s disease. Emergency Medicine. 2005;37(7):9&#x2013;12.</Citation></Reference><Reference><Citation>Cohen-Mansfield J. Nonpharmacological interventions for persons with dementia. Alzheimer&#x2019;s Care Quarterly. 2005;6:129&#x2013;145.</Citation></Reference><Reference><Citation>Fischer C, Bozanovic R, Atkins JH, Rourke SB. Treatment of delusions in Alzheimer&#x2019;s disease&#x2014;Response to pharmacotherapy. Dementia and Geriatric Cognitive Disorders. 2006;22:260&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">16902281</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer C, Bozanovic-Sosic R, Norris M. Review of delusions in dementia. American Journal of Alzheimer&#x2019;s Disease and Other Dementias. 2004;19:19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833946</ArticleId><ArticleId IdType="pubmed">15002340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdner LA, Buckwalter KC, Hall GR. Temporal patterning of agitation and stressors associated with agitation: Case profiles to illustrate the progressively lowered stress threshold model. Journal of the American Psychiatric Nurses Association. 2005;11:215&#x2013;222.</Citation></Reference><Reference><Citation>Hall GR. Testing the PLST model with community-based caregivers. Dissertation Abstracts International. 1999;60:577&#x2013;B. Doctoral dissertation, The University of Iowa, 1998.</Citation></Reference><Reference><Citation>Hall GR, Buckwalter KC. Progressively lowered stress threshold: A conceptual model for care of adults with Alzheimer&#x2019;s disease. Archives of Psychiatric Nursing. 1987;1:399&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">3426250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeste DV, Meeks TW, Kim DS, Zubenko GS. Research agenda for DSM-V: Diagnostic categories and criteria for neuropsychiatric syndromes in dementia. Journal of Geriatric Psychiatry and Neurology. 2006;19:160&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">16880358</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary D, Jyringi D, Sedler M. Childhood conduct problems, stages of Alzheimer&#x2019;s disease, and physical aggression against caregivers. International Journal of Geriatric Psychiatry. 2005;20:401&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer&#x2019;s disease: A review of 55 studies published from 1990 to 2003. American Journal of Psychiatry. 2005;162:2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">16263838</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Buckwalter K. Behaviors associated with dementia. American Journal of Nursing. 2005;105(7):40&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15995392</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Gerdner LA, Hall GR, Buckwalter KC. History, development, and future of the progressively lowered stress threshold: A conceptual model for dementia care. Journal of the American Geriatrics Society. 2004;52:1755&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450057</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Hall GR, Gerdner L, Buckwalter KC. Application of the progressively lowered stress threshold model across the continuum of care. Nursing Clinics of North America. 2006;41:57&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16492454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19672237</PMID><DateCompleted><Year>2009</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>7</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Galantamine (reminyl) in the treatment of severe Alzheimer's disease].</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>61</EndPage><MedlinePgn>57-61</MedlinePgn></Pagination><Abstract><AbstractText>Twenty-five patients with Alzheimer's disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the antipsychotic therapy. Reminyl had a positive effect on cognitive functions and psychotic symptoms of dementia, in particular delusions, aggression and irritability, apathy, aberrant motor behavior, eating and sleep disorders. The therapeutic reduction of these disorders resulted in the distinct reduction of physical and mental burden on the caregivers. The therapeutic effects of reminyl and its good tolerability allow to recommend this drug for treatment of severe stages of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gavrilova</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Kolykhanov</LastName><ForeName>I V</ForeName><Initials>IV</Initials></Author><Author ValidYN="Y"><LastName>Kalyn</LastName><ForeName>Ia B</ForeName><Initials>IaB</Initials></Author><Author ValidYN="Y"><LastName>Selezneva</LastName><ForeName>N D</ForeName><Initials>ND</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0D3Q044KCA</RegistryNumber><NameOfSubstance UI="D005702">Galantamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005702" MajorTopicYN="N">Galantamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19672237</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19619073</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7607</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Expert opinion on drug metabolism &amp; toxicology</Title><ISOAbbreviation>Expert Opin Drug Metab Toxicol</ISOAbbreviation></Journal><ArticleTitle>Rivastigmine in Parkinson's disease dementia.</ArticleTitle><Pagination><StartPage>941</StartPage><EndPage>955</EndPage><MedlinePgn>941-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/17425250903105420</ELocationID><Abstract><AbstractText>Parkinson's disease has now evolved beyond what was considered to be a traditional motor disorder. It is being increasingly recognized that non-motor symptoms such as cognitive impairment, frank dementia, psychosis, depression, autonomic dysfunction and sleep disturbances are just as integral to the disease spectrum. The cholinergic system has been proposed to play a pivotal role in cognitive dysfunction. Based on interpretation of clinical studies in patients with Alzheimer's, cholinesterase inhibitors have also been studied for dementia associated with Parkinson's disease. Most of these include large and small placebo-controlled studies and several pilot studies have indicated that cholinesterase inhibitors have a favorable effect on cognition, psychiatric symptoms and global function in Parkinson's disease dementia. A large randomized placebo-controlled clinical trial showed that rivastigmine had moderate improvement in dementia associated with Parkinson's disease. The magnitude of effects in terms of scores for the cognitive subscale of the Alzheimer's disease assessment scale and Alzheimer's disease cooperative study-clinicians global impression of change were similar to those observed among patients with Alzheimer's disease who were treated with cholinesterase inhibitors. A transdermal patch which gradually releases rivastigmine over the application period is now available for use in mild to moderate dementia associated with Parkinson's disease and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chitnis</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UT Southwestern Medical Center-Neurology, 5323 Harry Hines Blvd, Dallas, Texas 75390-9036, USA. shilpa.chitnis@utsouthwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Jayaraman</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Drug Metab Toxicol</MedlineTA><NlmUniqueID>101228422</NlmUniqueID><ISSNLinking>1742-5255</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048448">Phenylcarbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>PKI06M3IW0</RegistryNumber><NameOfSubstance UI="D000068836">Rivastigmine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010275" MajorTopicYN="N">Parasympathetic Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048448" MajorTopicYN="N">Phenylcarbamates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068836" MajorTopicYN="N">Rivastigmine</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>70</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19619073</ArticleId><ArticleId IdType="doi">10.1517/17425250903105420</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19618379</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2010</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>APOE epsilon-4 allele and cytokine production in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>338</StartPage><EndPage>344</EndPage><MedlinePgn>338-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2344</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The APOE epsilon-4 allele has consistently emerged as a susceptibility factor for Alzheimer's disease (AD). Pro-inflammatory cytokines are detectable at abnormal levels in AD, and are thought to play a pathophysiological role. Animal studies have shown dose-dependent correlations between the number of APOE epsilon-4 alleles and the levels of pro-inflammatory cytokines. The aims of this study were to investigate the influence of APOE genotypes on TNF-alpha, IL-6, and IL-1beta secreted by peripheral blood mononuclear cells (PBMC) from human patients with AD and to analyze the correlation between cytokine production and AD clinical features.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Outpatients with AD (n = 40) were clinically evaluated for cognitive decline (MMSE) and psychiatric symptoms (Cornell Scale for Depression in Dementia; Neuropsychiatric Inventory) and genotyped for APOE variants. PBMCs were isolated from the donors and used to assess spontaneous and PMA-stimulated secretion of TNF-alpha, IL-6, and IL-1beta. Cytokine production was determined by immuno-enzymatic assays (ELISA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In comparison with their counterparts without APOE4, patients with at least one copy of the APOE epsilon-4 allele showed higher spontaneous (p = 0.037) and PMA-induced (p = 0.039) production of IL-1beta after controlling for clinical variables. Significant correlations were reported between NPI scores (psychotic symptoms) and IL-6 production.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These preliminary findings suggest the involvement of inflammatory response in the pathogenic effect of the APOE epsilon-4 allele in AD, although their replication in larger samples is mandatory. The modest correlations between pro-inflammatory cytokines released at peripheral level and AD features emphasizes the need for further research to elucidate the role of neuroinflammation in pathophysiology of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olgiati</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Politis</LastName><ForeName>Antonis</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Malitas</LastName><ForeName>Petros</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Albani</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dusi</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Polito</LastName><ForeName>Letizia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>De Mauro</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zisaki</LastName><ForeName>Aikaterini</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Piperi</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stamouli</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mailis</LastName><ForeName>Antonis</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Batelli</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Forloni</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>De Ronchi</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kalofoutis</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Liappas</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19618379</ArticleId><ArticleId IdType="doi">10.1002/gps.2344</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19594762</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.</ArticleTitle><Pagination><StartPage>1301</StartPage><EndPage>1317</EndPage><MedlinePgn>1301-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1476-5381.2009.00304.x</ELocationID><Abstract><AbstractText>N-methyl-D-aspartate receptors (NMDARs) are ion channels gated by glutamate, the major excitatory neurotransmitter in the mammalian central nervous system (CNS). They are widespread in the CNS and are involved in numerous physiological and pathological processes including synaptic plasticity, chronic pain and psychosis. Aberrant NMDAR activity also plays an important role in the neuronal loss associated with ischaemic insults and major degenerative disorders including Parkinson's and Alzheimer's disease. Agents that target and alter NMDAR function may, thus, have therapeutic benefit. Interestingly, NMDARs are endowed with multiple extracellular regulatory sites that recognize ions or small molecule ligands, some of which are likely to regulate receptor function in vivo. These allosteric sites, which differ from agonist-binding and channel-permeation sites, provide means to modulate, either positively or negatively, NMDAR activity. The present review focuses on allosteric modulation of NMDARs containing the NR2B subunit. Indeed, the NR2B subunit confers a particularly rich pharmacology with distinct recognition sites for exogenous and endogenous allosteric ligands. Moreover, NR2B-containing receptors, compared with other NMDAR subtypes, appear to contribute preferentially to pathological processes linked to overexcitation of glutamatergic pathways. The actions of extracellular H+, Mg2+, Zn2+, of polyamines and neurosteroids, and of the synthetic compounds ifenprodil and derivatives ('prodils') are presented. Particular emphasis is put upon the structural determinants and molecular mechanisms that underlie the effects exerted by these agents. A better understanding of how NR2B-containing NMDARs (and NMDARs in general) operate and how they can be modulated should help define new strategies to counteract the deleterious effects of dysregulated NMDAR activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mony</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de Neurobiologie, Ecole Normale Sup&#xe9;rieure, CNRS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kew</LastName><ForeName>James N C</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Gunthorpe</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Paoletti</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011073">Polyamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>I38ZP9992A</RegistryNumber><NameOfSubstance UI="D008274">Magnesium</NameOfSubstance></Chemical><Chemical><RegistryNumber>J41CSQ7QDS</RegistryNumber><NameOfSubstance UI="D015032">Zinc</NameOfSubstance></Chemical><Chemical><RegistryNumber>R8OE3P6O5S</RegistryNumber><NameOfSubstance UI="C010739">ifenprodil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000495" MajorTopicYN="N">Allosteric Site</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008274" MajorTopicYN="N">Magnesium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011073" MajorTopicYN="N">Polyamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015032" MajorTopicYN="N">Zinc</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19594762</ArticleId><ArticleId IdType="pmc">PMC2765303</ArticleId><ArticleId IdType="doi">10.1111/j.1476-5381.2009.00304.x</ArticleId><ArticleId IdType="pii">BPH304</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N. Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol. 1994;347:150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">7798379</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanine A, Bourson A, B&#xfc;ttelmann B, Gill R, Heitz M-P, Mutel V, et al. 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2003;13:3155&#x2013;3159.</Citation><ArticleIdList><ArticleId IdType="pubmed">12951084</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers GV, Goldstein LB, Hall D, Lesko LM. Aptiganel hydrochloride in acute ischemic stroke &#x2013; a randomized controlled trial. JAMA. 2001;286:2673&#x2013;2682.</Citation><ArticleIdList><ArticleId IdType="pubmed">11730442</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts IL, Nadassy K, Wodak SJ. Analysis of zinc binding sites in protein crystal structures. Protein Sci. 1998;7:1700&#x2013;1716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2144076</ArticleId><ArticleId IdType="pubmed">10082367</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander S, Mathie A, Peters J. Guide to receptors and channels (GRAC) 3rd edn (2008 revision) Br J Pharmacol. 2008;153(Suppl. 2):S1&#x2013;S209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2275471</ArticleId><ArticleId IdType="pubmed">18347570</ArticleId></ArticleIdList></Reference><Reference><Citation>Araneda RC, Lan JY, Zheng X, Zukin RS, Bennett MV. Spermine and arcaine block and permeate N-methyl-D-aspartate receptor channels. Biophys J. 1999;76:2899&#x2013;2911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1300262</ArticleId><ArticleId IdType="pubmed">10354418</ArticleId></ArticleIdList></Reference><Reference><Citation>Banke TG, Dravid SM, Traynelis SF. Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J Neurosci. 2005;25:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725198</ArticleId><ArticleId IdType="pubmed">15634765</ArticleId></ArticleIdList></Reference><Reference><Citation>Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci. 2005;6:565&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959466</ArticleId></ArticleIdList></Reference><Reference><Citation>Benveniste M, Mayer ML. Multiple effects of spermine on N-methyl-D-aspartic acid receptor responses of rat cultured hippocampal neurones. J Physiol. 1993;464:131&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1175378</ArticleId><ArticleId IdType="pubmed">8229795</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686270</ArticleId></ArticleIdList></Reference><Reference><Citation>Borza I, Bozo E, Barta-Szalai G, Kiss C, Tarkanyi G, Demeter A, et al. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007;50:901&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">17290978</ArticleId></ArticleIdList></Reference><Reference><Citation>Borza I, Domany G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem. 2006;6:687&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">16719809</ArticleId></ArticleIdList></Reference><Reference><Citation>Borza I, Kolok S, Gere A, Nagy J, Fodor L, Galgoczy K, et al. Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2006;16:4638&#x2013;4640.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowlby MR. Pregnenolone sulfate potentiation of N-methyl-D-aspartate receptor channels in hippocampal-neurons. Mol Pharmacol. 1993;43:813&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">7684817</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology. 1999;38:611&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">10340299</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce SRRC, Wheeldon A, Rupniak NM, Hill RG. Antinociceptive activity of the NMDA NR2B receptor subtype selective antagonist CP-101,606 in a new rat visceral pain assay. IASP Meeting San Diego. Abstract ID: 848&#x2013;P118.</Citation></Reference><Reference><Citation>B&#xfc;ttelmann B, Alanine A, Bourson A, Gill R, Heitz M-P, Mutel V, et al. 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2003;13:829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">12617901</ArticleId></ArticleIdList></Reference><Reference><Citation>Carron C, Jullien A, Bucher B. Synthesis and pharmacological properties of a series of 2-piperidino alkanol derivatives. Arzneimittelforschung. 1971;21:1992&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pubmed">4400568</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter C, Benavides J, Legendre P, Vincent JD, Noel F, Thuret F, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther. 1988;247:1222&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">2849669</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang HR, Kuo CC. The activation gate and gating mechanism of the NMDA receptor. J Neurosci. 2008;28:1546&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671534</ArticleId><ArticleId IdType="pubmed">18272676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaperon F, Muller W, Auberson YP, Tricklebank MD, Neijt HC. Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol. 2003;14:477&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501261</ArticleId></ArticleIdList></Reference><Reference><Citation>Chazot PL. The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem. 2004;11:389&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">14965239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Lu TJ, Chen XJ, Zhou Y, Chen Q, Feng XY, et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke. 2008;39:3042&#x2013;3048.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688011</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Moshaver A, Raymond LA. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol Pharmacol. 1997;51:1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">9187268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, Decosta DL, et al. 1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol &#x2013; a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem. 1995;38:3138&#x2013;3145.</Citation><ArticleIdList><ArticleId IdType="pubmed">7636876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenard BL, Menniti FS. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des. 1999;5:381&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol. 2007;21:259&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">17591654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci. 2001;22:636&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">11730974</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YB, Lipton SA. Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor. Neuron. 1999;23:171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">10402203</ArticleId></ArticleIdList></Reference><Reference><Citation>Claiborne CF, McCauley JA, Libby BE, Curtis NR, Diggle HJ, Kulagowski JJ, et al. Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2003;13:697&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cull-Candy SG, Leszkiewicz DN. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE. 2004;2004:re16.</Citation><ArticleIdList><ArticleId IdType="pubmed">15494561</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis NR, Diggle HJ, Kulagowski JJ, London C, Grimwood S, Hutson PH, et al. Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2003;13:693&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">12639560</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16:515&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391748</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10049997</ArticleId></ArticleIdList></Reference><Reference><Citation>von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, Kohr G, Seeburg PH, et al. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology. 2007;53:10&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570444</ArticleId></ArticleIdList></Reference><Reference><Citation>von Engelhardt J, Doganci B, Jensen V, Hvalby O, Gongrich C, Taylor A, et al. Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron. 2008;60:846&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">19081379</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkas S, Horvath C, Galgoczy L, Felmerai E, Karsai E, Saghhy K, et al. RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Society for Neuroscience Meeting. Program # 382.8.</Citation></Reference><Reference><Citation>Farrant M, Feldmeyer D, Takahashi T, Cullcandy SG. NMDA-receptor channel diversity in the developing cerebellum. Nature. 1994;368:335&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907398</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayyazuddin A, Villarroel A, Le Goff A, Lerma J, Neyton J. Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors. Neuron. 2000;25:683&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774735</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther. 1997;283:1285&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pubmed">9400004</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa H, Gouaux E. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. Embo J. 2003;22:2873&#x2013;2885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162155</ArticleId><ArticleId IdType="pubmed">12805203</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. Nature. 2005;438:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16281028</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MJ, Huang H, Pritchett DB, Lynch DR. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 1996;271:9603&#x2013;9611.</Citation><ArticleIdList><ArticleId IdType="pubmed">8621635</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielen M, Le Goff A, Stroebel D, Johnson JW, Neyton J, Paoletti P. Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition. Neuron. 2008;57:80&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679256</ArticleId><ArticleId IdType="pubmed">18184566</ArticleId></ArticleIdList></Reference><Reference><Citation>Giffard RG, Monyer H, Christine CW, Choi DW. Acidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures. Brain Res. 1990;506:339&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">1967968</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP, et al. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002;302:940&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">12183650</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol. 2006;6:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16376149</ArticleId></ArticleIdList></Reference><Reference><Citation>Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH. The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur J Pharmacol. 2003;476:193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">12969766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">16767099</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Tomitori H, Mizuno S, Higashi K, Full C, Fukiwake T, et al. Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-d-aspartate receptor. J Neurochem. 2008;107:1566&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690642</ArticleId><ArticleId IdType="pubmed">19014388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003;26:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">12536131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatton CJ, Paoletti P. Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron. 2005;46:261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15848804</ArticleId></ArticleIdList></Reference><Reference><Citation>Herin GA, Aizenman E. Amino terminal domain regulation of NMDA receptor function. Eur J Pharmacol. 2004;500:101&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464024</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA. Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl) 2005;179:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">15759152</ArticleId></ArticleIdList></Reference><Reference><Citation>Horak M, Vlcek K, Chodounska H, Vyklicky L. Subtype-dependence of N-methyl-D-aspartate receptor modulation by pregnenolone sulfate. Neuroscience. 2006;137:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16257494</ArticleId></ArticleIdList></Reference><Reference><Citation>Horak M, Vlcek K, Petrovic M, Chodounska H, Vyklicky L. Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors. J Neurosci. 2004;24:10318&#x2013;10325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730288</ArticleId><ArticleId IdType="pubmed">15548645</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath C. 3rd World Cong. Barcelona: World Inst. Pain; 2004. September 21&#x2013;25.</Citation></Reference><Reference><Citation>Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature. 2006;444:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">17108970</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggins DJ, Grant GH. The function of the amino terminal domain in NMDA receptor modulation. J Mol Graph Model. 2005;23:381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15670959</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang MK, Mierke DF, Russek SJ, Farb DH. A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. Proc Natl Acad Sci USA. 2004;101:8198&#x2013;8203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419580</ArticleId><ArticleId IdType="pubmed">15150412</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry. 2008;63:6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashiwagi K, Fukuchi J, Chao J, Igarashi K, Williams K. An aspartate residue in the extracellular loop of the N-methyl-D-aspartate receptor controls sensitivity to spermine and protons. Mol Pharmacol. 1996;49:1131&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649353</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashiwagi K, Pahk AJ, Masuko T, Igarashi K, Williams K. Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits. Mol Pharmacol. 1997;52:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">9380034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp JA, Kew JNC, Gill R. NMDA receptor antagonists and their potential as neuroprotective agents. In: Jonas P, Monyer H, editors. Handbook of Experimental Pharmacology Volume 141. Ionotropic Glutamate Receptors in the CNS. Berlin: Springer; 1999. pp. 495&#x2013;527.</Citation></Reference><Reference><Citation>Kew JN, Kemp JA. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol. 1998;512(1):17&#x2013;28. Pt.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2231188</ArticleId><ArticleId IdType="pubmed">9729614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew JN, Trube G, Kemp JA. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol. 1996;497(3):761&#x2013;772. Pt.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160972</ArticleId><ArticleId IdType="pubmed">9003561</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss L, Cheng G, Bednar B, Bednar RA, Bennett PB, Kane SA, et al. In vitro characterization of novel NR2B selective NMDA receptor antagonists. Neurochem Int. 2005;46:453&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">15769547</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 2006;326:439&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862427</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005;179:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">15309376</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. 2000;355:1949&#x2013;1954.</Citation><ArticleIdList><ArticleId IdType="pubmed">10859040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerma J. Spermine regulates N-methyl-D-aspartate receptor desensitization. Neuron. 1992;8:343&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">1531415</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging. 2003;24:1113&#x2013;1121.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643383</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007;27:2846&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672582</ArticleId><ArticleId IdType="pubmed">17360906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez de Armentia M, Sah P. Development and subunit composition of synaptic NMDA receptors in the amygdale: NR2B synapses in the adult central amygdala. J Neurosci. 2003;23:6876&#x2013;6883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740716</ArticleId><ArticleId IdType="pubmed">12890782</ArticleId></ArticleIdList></Reference><Reference><Citation>Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004;187:86&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081591</ArticleId></ArticleIdList></Reference><Reference><Citation>Low CM, Lyuboslavsky P, French A, Le P, Wyatte K, Thiel WH, et al. Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol Pharmacol. 2003;63:1212&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12761330</ArticleId></ArticleIdList></Reference><Reference><Citation>Low CM, Zheng F, Lyuboslavsky P, Traynelis SF. Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc Natl Acad Sci USA. 2000;97:11062&#x2013;11067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27148</ArticleId><ArticleId IdType="pubmed">10984504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu WY, Xiong ZG, Orser BA, MacDonald JF. Multiple sites of action of neomycin, Mg2+ and spermine on the NMDA receptors of rat hippocampal CA1 pyramidal neurones. J Physiol. 1998;512(1):29&#x2013;46. Pt.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2231176</ArticleId><ArticleId IdType="pubmed">9729615</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Wang Y, Yasuda RP, Dunah AW, Wolfe BB. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B) Mol Pharmacol. 1997;51:79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">9016349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QP, Hargreaves RJ. Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience. 2000;101:699&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">11113318</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley JA. NR2B subtype-selective NMDA receptor antagonists. 3rd Anglo-Swedish Medicinal Chemistry Symposium. Are, Sweden.</Citation></Reference><Reference><Citation>McCauley JA, Bednar RA, Bednar B, Butcher JW, Claiborne CF, Claremon DA, et al. NR2B subtype-selective NMDA receptor antagonists. Abstracts &#x2013; 236th ACS National Meeting. Philadelphia, PA, August 17&#x2013;21, 2008.</Citation></Reference><Reference><Citation>McGurk JF, Bennett MV, Zukin RS. Polyamines potentiate responses of N-methyl-D-aspartate receptors expressed in xenopus oocytes. Proc Natl Acad Sci USA. 1990;87:9971&#x2013;9974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55296</ArticleId><ArticleId IdType="pubmed">1702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeng S, Zarate CA., Jr The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep. 2007;9:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">18221626</ArticleId></ArticleIdList></Reference><Reference><Citation>Makani S, Chesler M. Endogenous alkaline transients boost postsynaptic NMDA receptor responses in hippocampal CA1 pyramidal neurons. J Neurosci. 2007;27:7438&#x2013;7446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672609</ArticleId><ArticleId IdType="pubmed">17626204</ArticleId></ArticleIdList></Reference><Reference><Citation>Malayev A, Gibbs TT, Farb DH. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br J Pharmacol. 2002;135:901&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1573207</ArticleId><ArticleId IdType="pubmed">11861317</ArticleId></ArticleIdList></Reference><Reference><Citation>Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, et al. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J Pharmacol Exp Ther. 2003;307:897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">14534359</ArticleId></ArticleIdList></Reference><Reference><Citation>Martel MA, Wyllie DJ, Hardingham GE. In developing hippocampal neurons, NR2B-containing N-methyl-d-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience. 2009;158:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635533</ArticleId><ArticleId IdType="pubmed">18378405</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuko T, Kashiwagi K, Kuno T, Nguyen ND, Pahk AJ, Fukuchi J, et al. A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol Pharmacol. 1999;55:957&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">10347236</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer ML. Glutamate receptors at atomic resolution. Nature. 2006;440:456&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">16554805</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchant RE, Bullock MR, Carmack CA, Shah AK, Wilner KD, Ko G, et al. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N Y Acad Sci. 1999;890:42&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10668412</ArticleId></ArticleIdList></Reference><Reference><Citation>Montastruc JL, Rascol O, Senard JM, Rascol A. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992;55:630&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC489186</ArticleId><ArticleId IdType="pubmed">1386383</ArticleId></ArticleIdList></Reference><Reference><Citation>Mony L, Krzaczkowski L, Leonetti M, Goff AL, Alarcon K, Neyton J, et al. Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mol Pharmacol. 2009;75:60&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923063</ArticleId></ArticleIdList></Reference><Reference><Citation>Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994;12:529&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">7512349</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. J Neurosurg. 1999;91:737&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">10541229</ArticleId></ArticleIdList></Reference><Reference><Citation>Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci. 1998;1:659&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196581</ArticleId></ArticleIdList></Reference><Reference><Citation>Neyton J, Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006;26:1331&#x2013;1333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675501</ArticleId><ArticleId IdType="pubmed">16452656</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng FM, Geballe MT, Snyder JP, Traynelis SF, Low CM. Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies. Mol Brain. 2008;1:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2603005</ArticleId><ArticleId IdType="pubmed">19017396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng FM, Soh W, Geballe MT, Low CM. Improving solubility of NR2B amino-terminal domain of N-methyl-d-aspartate receptor expressed in Escherichia coli. Biochem Biophys Res Commun. 2007;362:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">17706601</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson KL, Mansbach RS, Menniti FS, Balster RL. The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. Behav Pharmacol. 2007;18:731&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">17989511</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikam SS, Meltzer LT. NR2B selective NMDA receptor antagonists. Curr Pharm Des. 2002;8:845&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">11945135</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord. 2008;23:1860&#x2013;1866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390310</ArticleId><ArticleId IdType="pubmed">18759356</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hara PJ, Sheppard PO, Thogersen H, Venezia D, Haldeman BA, McGrane V, et al. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding-proteins. Neuron. 1993;11:41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8338667</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahk AJ, Williams K. Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett. 1997;225:29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9143010</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Ascher P, Neyton J. High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci. 1997;17:5711&#x2013;5725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573217</ArticleId><ArticleId IdType="pubmed">9221770</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088105</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Neyton J, Ascher P. Glycine-independent and subunit-specific potentiation of NMDA responses by extracellular Mg2+ Neuron. 1995;15:1109&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">7576654</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Perin-Dureau F, Fayyazuddin A, Goff AL, Callebaut I, Neyton J. Molecular organization of a zinc binding N-terminal modulatory domain in a NMDA receptor subunit. Neuron. 2000;28:911&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">11163276</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Vergnano AM, Barbour B, Casado M. Zinc at glutamatergic synapses. Neuroscience. 2009;158:126&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">18353558</ArticleId></ArticleIdList></Reference><Reference><Citation>Park-Chung M, Wu FS, Purdy RH, Malayev AA, Gibbs TT, Farb DH. Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids. Mol Pharmacol. 1997;52:1113&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">9396781</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkchung MJ, Wu FS, Farb DH. 3-alpha-hydroxy-5-beta-pregnan-20-one sulfate &#x2013; a negative modulator of the NMDA-induced current in cultured neurons. Mol Pharmacol. 1994;46:146&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">7520124</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system &#x2013; too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904591</ArticleId></ArticleIdList></Reference><Reference><Citation>Perin-Dureau F, Rachline J, Neyton J, Paoletti P. Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci. 2002;22:5955&#x2013;5965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757916</ArticleId><ArticleId IdType="pubmed">12122058</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovic M, Sedlacek M, Horak M, Chodounska H, Vyklicky L. 20-oxo-5 beta-pregnan-3 alpha-yl sulfate is a use-dependent NMDA receptor inhibitor. J Neurosci. 2005;25:8439&#x2013;8450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725663</ArticleId><ArticleId IdType="pubmed">16162926</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro PS, Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci. 2008;9:423&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">18464791</ArticleId></ArticleIdList></Reference><Reference><Citation>Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">19011431</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachline J, Perin-Dureau F, Goff AL, Neyton J, Paoletti P. The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci. 2005;25:308&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725474</ArticleId><ArticleId IdType="pubmed">15647474</ArticleId></ArticleIdList></Reference><Reference><Citation>Robel P, Baulieu EE. Neurosteroids biosynthesis and function. Trends Endocrinol Metab. 1994;5:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18407181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock DM, MacDonald RL. Spermine and related polyamines produce a voltage-dependent reduction of N-methyl-D-aspartate receptor single-channel conductance. Mol Pharmacol. 1992;42:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">1378923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rock DM, Macdonald RL. Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol. 1995;35:463&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">7598503</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumbaugh G, Prybylowski K, Wang JF, Vicini S. Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. J Neurophysiol. 2000;83:1300&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">10712457</ArticleId></ArticleIdList></Reference><Reference><Citation>Saltarelli MD, Weaver JJ, Hsu C, Bednar MM. Randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of CP-101,606 (traxoprodil), an NR2B-selective N-methyl D-aspartate receptor antagonist, in subjects with acute ischemic stroke. Stroke. 2004;35:241&#x2013;241.</Citation></Reference><Reference><Citation>Sang CN, Weaver JJ, Jinga L, Wouden J, Saltarelli MD. The NR2B subunit-selective NMDA receptor antagonist CP-101,606 reduces pain intensity in patients with central and peripheral neuropathic pain. Society for Neuroscience. Meeting. Program # 814.9.</Citation></Reference><Reference><Citation>Scimemi A, Fine A, Kullmann DM, Rusakov DA. NR2B-containing receptors mediate cross talk among hippocampal synapses. J Neurosci. 2004;24:4767&#x2013;4777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3379686</ArticleId><ArticleId IdType="pubmed">15152037</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver RA, Traynelis SF, Cull-Candy SG. Rapid-time-course miniature and evoked excitatory currents at cerebellar synapses in situ. Nature. 1992;355:163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370344</ArticleId></ArticleIdList></Reference><Reference><Citation>Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163:239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">10785463</ArticleId></ArticleIdList></Reference><Reference><Citation>Suetake-Koga S, Shimazaki T, Takamori K, Chaki S, Kanuma K, Sekiguchi Y, et al. In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol Biochem Behav. 2006;84:134&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">16764916</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E. Mechanism of glutamate receptor desensitization. Nature. 2002;417:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12015593</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P, et al. Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem. 2008;51:5506&#x2013;5521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142473</ArticleId><ArticleId IdType="pubmed">18800760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamiz AP, Cai SX, Zhou Z-L, Yuen P-W, Shelkun RM, Whittemore ER, et al. Structure-activity relationship of N(Phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists. J Med Chem. 1999;42:3412&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464027</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 2005;12:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">15470478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang CM, Dichter M, Morad M. Modulation of the N-methyl-D-aspartate channel by extracellular H+ Proc Natl Acad Sci USA. 1990;87:6445&#x2013;6449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54551</ArticleId><ArticleId IdType="pubmed">1696732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS, et al. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol. 1997;122:809&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565002</ArticleId><ArticleId IdType="pubmed">9384494</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL. Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci. 1998;18:6163&#x2013;6175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793196</ArticleId><ArticleId IdType="pubmed">9698310</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynelis SF, Cull-Candy SG. Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature. 1990;345:347&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">1692970</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science. 1995;268:873&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">7754371</ArticleId></ArticleIdList></Reference><Reference><Citation>Trube G, Ehrhard P, Malherbe P, Huber G. The selectivity of Ro25-6981 for NMDA receptor subtypes expressed in Xenopus oocytes. Soc Neurosci Abstr. 1996;22:693&#x2013;694.</Citation></Reference><Reference><Citation>Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;76:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15927795</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt K, Mellor J, Tong G, Nicoll R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron. 2000;26:187&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798403</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyklicky L, Jr, Vlachova V, Krusek J. The effect of external pH changes on responses to excitatory amino acids in mouse hippocampal neurones. J Physiol. 1990;430:497&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1181750</ArticleId><ArticleId IdType="pubmed">1707970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LY, MacDonald JF. Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J Physiol. 1995;486:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1156498</ArticleId><ArticleId IdType="pubmed">7562646</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Inoue Y, Sakimura K, Mishina M. Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport. 1992;3:1138&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">1493227</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Inoue Y, Sakimura K, Mishina M. Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J Comp Neurol. 1993;338:377&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">8113446</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Mishina M, Inoue Y. Distinct spatiotemporal distributions of the N-methyl-D-aspartate receptor channel subunit mRNAs in the mouse cervical cord. J Comp Neurol. 1994;345:314&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">7929904</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CE, Land MB, Purdy RH, Richards KG, Gibbs TT, Farb DH. Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca2+ accumulation and cell death. J Pharm Exp Ther. 2000;293:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">10869372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, et al. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci. 2001;4:164&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">11175877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian. rats. Neuropharm. 2004;47:184&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15223297</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor-selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993;44:851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">7901753</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K. Mechanisms influencing stimulatory effects of spermine at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol. 1994a;46:161&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8058050</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K. Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine. Mol Pharmacol. 1994b;46:531&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">7935335</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K, Kashiwagi K, Fukuchi J, Igarashi K. An acidic amino acid in the N-methyl-D-aspartate receptor that is important for spermine stimulation. Mol Pharmacol. 1995;48:1087&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">8848009</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K, Zappia AM, Pritchett DB, Shen YM, Molinoff PB. Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol Pharmacol. 1994;45:803&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">8190097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AW, Medhurst SJ, Dixon CI, Bontoft NC, Winyard LA, Brackenborough KT, et al. An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. Eur J Pain. 2006;10:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">16199187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong E, Ng FM, Yu CY, Lim P, Lim LH, Traynelis SF, et al. Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor. Protein Sci. 2005;14:2275&#x2013;2283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253471</ArticleId><ArticleId IdType="pubmed">16131656</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo TUW, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res. 2008;1218:267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665281</ArticleId><ArticleId IdType="pubmed">18534564</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodhall G, Evans DI, Cunningham MO, Jones RS. NR2B-containing NMDA autoreceptors at synapses on entorhinal cortical neurons. J Neurophysiol. 2001;86:1644&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pubmed">11600627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu FS, Gibbs TT, Farb DH. Pregnenolone sulfate &#x2013; a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol. 1991;40:333&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">1654510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA, Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">16390905</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002;33:849&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zheng X, Paupard MC, Wang AP, Santchi L, Friedman LK, et al. Spermine potentiation of recombinant N-methyl-D-aspartate receptors is affected by subunit composition. Proc Natl Acad Sci USA. 1994;91:10883&#x2013;10887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45130</ArticleId><ArticleId IdType="pubmed">7971977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Baudry M. Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci. 2006;26:2956&#x2013;2963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673978</ArticleId><ArticleId IdType="pubmed">16540573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19589191</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>The Environmental Cleanliness and Clutter Scale (ECCS).</ArticleTitle><Pagination><StartPage>1041</StartPage><EndPage>1050</EndPage><MedlinePgn>1041-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1041610209990135</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Development of a scale to rate the degree and various aspects of uncleanliness will facilitate description and research in cases of severe domestic squalor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Discussion with representatives of relevant agencies led to selection of various aspects of domestic uncleanliness and clutter to be assessed when describing cases of squalor. Rooms and areas with varying functions (toilet, kitchen, bedroom, etc.) were all to be rated, along with other indicators of squalor (e.g. odor, vermin). Trial use and further discussion resulted in reduction to ten items, each rated on a four-point scale, with succinct descriptions of anchor-points. Two experienced psychogeriatricians then used this new Environmental Cleanliness and Clutter Scale (ECCS) to rate independently 55 dwellings which had been reported by Aged Care staff as cluttered or unclean, and also rated overall degree of squalor. Reliability and indications of validity were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The inter-rater reliability for the ten items was considered satisfactory (kappa 0.48, varying from 0.31 to 0.58). Cronbach's alpha for the new scale was 0.94, demonstrating high internal consistency. Each author's ratings of degree of squalor (none to severe) matched well with the other's ratings on the scale; a score of &gt;12 usually indicated moderate or severe squalor.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ECCS proved reliable and useful in rating cases where elderly people were living in severe domestic squalor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Graeme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sydney South West Area Health Service, Concord Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snowdon</LastName><ForeName>John</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003153" MajorTopicYN="N">Community Health Services</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004282" MajorTopicYN="N">Documentation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017408" MajorTopicYN="N">Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016852" MajorTopicYN="N">Housing for the Elderly</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006920" MajorTopicYN="N">Hygiene</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033183" MajorTopicYN="N">Interdisciplinary Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009517" MajorTopicYN="N" Type="Geographic">New South Wales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="Y">Social Environment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19589191</ArticleId><ArticleId IdType="doi">10.1017/S1041610209990135</ArticleId><ArticleId IdType="pii">S1041610209990135</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19577545</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2968</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Biochemical pharmacology</Title><ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation></Journal><ArticleTitle>A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.</ArticleTitle><Pagination><StartPage>852</StartPage><EndPage>862</EndPage><MedlinePgn>852-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2009.06.102</ELocationID><Abstract><AbstractText>In monkeys proficient in the performance of a computer-assisted delayed response task, administration of sub-sedative doses of ketamine significantly impaired task performance after the 2mg/kg dose, producing a decrease in accuracies across all four delay intervals. Ketamine elicited occasional and inconsistent increases in task latencies. But in general processing speed was not dramatically affected by the test dose. Pretreatment with the alpha7 nicotinic receptor agonist GTS-21 (DMXB-A) [3-[(3E)-3-[(2,4-dimethoxyphenyl) methylidene]-5,6-dihydro-4H-pyridin-2-yl]pyridine] produced a dose-dependent attenuation of ketamine-induced decreases in task accuracies. In fact, the best dose of GTS-21 completely reversed the effects of ketamine. The nicotine metabolite cotinine is a cognitive-enhancer, and active in models predictive of antipsychotic activity. Pretreatment with cotinine did not reverse the task deficits produced by ketamine, and selection of a best dose was necessary to show the activity of cotinine. However, the best dose of cotinine, like GTS-21, completely reversed the ketamine-induced task deficits. Task accuracies were increased relative to their non-ketamine baselines during sessions run 24h later. The cotinine-ketamine order of administration was reversed to provide a more clinically relevant model, and cotinine post-treatment regimen produced a clear reversal of the ketamine-induced task deficits. The protracted task improvement also was still evident. The DMTS task impairment induced by ketamine was capable of being completely reversed by two compounds that are known to improve working memory and cognition. The model could provide a means of late stage preclinical evaluation of new compounds that address the cognitive impairment associated with major psychotic disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buccafusco</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Alzheimer's Research Center, Medical College of Georgia, Augusta, GA 30912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terry</LastName><ForeName>Alvin V</ForeName><Initials>AV</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG029617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029617-02</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biochem Pharmacol</MedlineTA><NlmUniqueID>0101032</NlmUniqueID><ISSNLinking>0006-2952</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001597">Benzylidene Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006213">Hallucinogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8S399XDN2K</RegistryNumber><NameOfSubstance UI="C088936">3-(2,4-dimethoxybenzylidene)anabaseine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K5161X06LL</RegistryNumber><NameOfSubstance UI="D003367">Cotinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001597" MajorTopicYN="N">Benzylidene Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003367" MajorTopicYN="N">Cotinine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006213" MajorTopicYN="N">Hallucinogens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="N">Ketamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008254" MajorTopicYN="N">Macaca nemestrina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018722" MajorTopicYN="N">Nicotinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19577545</ArticleId><ArticleId IdType="mid">NIHMS130083</ArticleId><ArticleId IdType="pmc">PMC2728139</ArticleId><ArticleId IdType="doi">10.1016/j.bcp.2009.06.102</ArticleId><ArticleId IdType="pii">S0006-2952(09)00498-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreasen NC. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev. 2000;31:106&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">10719138</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber MA, Marder SR. Better pharmacotherapy for schizophrenia: what does the future hold? Curr Psychiat Reports. 2008;10:352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">18627675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172:1703&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1150265</ArticleId><ArticleId IdType="pubmed">15967975</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiat. 2005;10:79&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289815</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychologist. 2005;60:229&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">15796677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophrenia Res. 2005;74:15&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">15694750</ArticleId></ArticleIdList></Reference><Reference><Citation>Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuro-Psychopharmacol Biological Psychiatry. 2005;29:219&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">15694228</ArticleId></ArticleIdList></Reference><Reference><Citation>Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology. 2009;202:259&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">18766331</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiat. 1998;155:1080&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">9699697</ArticleId></ArticleIdList></Reference><Reference><Citation>Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">10755673</ArticleId></ArticleIdList></Reference><Reference><Citation>Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology. 2004;174:111&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15205882</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarter M, Martinez V, Kozak R. A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology. 2009;202:237&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719245</ArticleId><ArticleId IdType="pubmed">18618100</ArticleId></ArticleIdList></Reference><Reference><Citation>Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiat. 2006;63:630&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">16754836</ArticleId></ArticleIdList></Reference><Reference><Citation>Papke RL, Dwoskin LP, Crooks PA. The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery. J Neurochem. 2007;101:160&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">17241116</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehara S, Hikichi H, Satow A, Okuda S, Ohta H. Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia. Pharmacol Biochem Behav. 2008;91:140&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18651995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobascher A, Winterer G. The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry. 2008;41 Suppl 1:S51&#x2013;S59.</Citation><ArticleIdList><ArticleId IdType="pubmed">18756421</ArticleId></ArticleIdList></Reference><Reference><Citation>Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology. 2008;199:89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078257</ArticleId><ArticleId IdType="pubmed">18548234</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, de Fiebre CM. 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res. 1997;12(768):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">9369300</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliott RL, Holladay MW, Hui Y-H, Jackson WJ, Kim DJB, Marsh KC, O&#x2019;Neill A, Prendergast MA, Ryther KB, Sullivan JP, Arneric SP. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21. In vitro and in vivo. Pharmacol Biochem Behav. 1997;57:231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">9164577</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology. 2004;174:54&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15205879</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR. Initial Phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiat. 2008;165:931&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746983</ArticleId><ArticleId IdType="pubmed">18381905</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RC, Warner-Cohen J, Matute M, Butler E, Kelly E, Vaidhyanathaswamy S, Khan A. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology. 2006;31:637&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160711</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry AV, Jr, Hernandez CM, Hohnadel EJ, Bouchard KP, Buccafusco JJ. Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 2005;11:229&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741756</ArticleId><ArticleId IdType="pubmed">16389292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman S. "Ketamine: review of its pharmacology and its use in pediatric anesthesia". Anesth Prog. 1999;46:10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148883</ArticleId><ArticleId IdType="pubmed">10551055</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastwood SL, Harrison PJ. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophrenia Res. 2005;73:159&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">15653259</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz RD, Andreasen NC, Daoud SZ, Conley R, Roberts R, Bustillo J, Perrone-Bizzozero NI. Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia. Am J Psychiat. 2006;163:1829&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012697</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti C, Battaglia G, Molinaro G, Riozzi B, Pittaluga A, Corsi M, Mugnaini M, Nicoletti F, Bruno V. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci. 2007;27:8297&#x2013;8308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673047</ArticleId><ArticleId IdType="pubmed">17670976</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P. Glutamate and dopamine components in schizophrenia. J Psychiat Neurosci. 2009;34:143&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647567</ArticleId><ArticleId IdType="pubmed">19270765</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci. 2008;29:600&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744993</ArticleId><ArticleId IdType="pubmed">19158287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hevers W, Hadley SH, L&#xfc;ddens H, Amin J. Ketamine, but not phencyclidine, selectively modulates cerebellar GABAA receptors containing &#x3b1;6 and &#x3b4; subunits. J Neurosci. 2008;28:5383&#x2013;5393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670651</ArticleId><ArticleId IdType="pubmed">18480294</ArticleId></ArticleIdList></Reference><Reference><Citation>Imre G, Fokkema DS, Den Boer JA, Ter Horst GJ. Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull. 2006;69:338&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564431</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology. 2006;188:408&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">17006715</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrobak JJ, Hinman JR, Sabolek HR. Revealing past memories: proactive interference and ketamine-induced memory deficits. J Neurosci. 2008;28:4512&#x2013;4520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670951</ArticleId><ArticleId IdType="pubmed">18434529</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccafusco JJ. Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. J Alzheimer's Dis. 2008;15:709&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz CK, Novak MA. Environmental enrichment for nonhuman primates: theory and application. Ilar J. 2005;46:178&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15775027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995;77:355&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;nder G, Hippius H, Carlsson A. The &#x2018;atypicality&#x2019; of antipsychotics: a concept re-examined and re-defined. Nature Rev Drug Discov. 2009;8:197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">19214197</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwoskin LP, Teng L, Buxton ST, Crooks PA. (S)-(&#x2212;)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther. 1999;288:905&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027825</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccafusco JJ, Shuster LC, Terry AV., Jr Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine. Neurosci Letts. 2007;413:68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17157984</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Leary K, Parameswaran N, McIntosh JM, Quik M. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J Pharmacol Exp Ther. 2008;325:646&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3134143</ArticleId><ArticleId IdType="pubmed">18305015</ArticleId></ArticleIdList></Reference><Reference><Citation>Paule MG, Bushnell PJ, Maurissen JPJ, Wenger GR, Buccafusco JJ, Chelonis JJ, Elliott R. Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol. 1998;20:493&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">9761587</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccafusco JJ, Terry AV, Jr, Webster SJ, Martin DM, Hohnadel EJ, Bouchard KA, Warner SE. The scopolamine-reversal paradigm in rats and monkeys: The importance of computer-assisted operant conditioning memory tasks for screening drug candidates. Psychopharmacology. 2008;199:481&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">17657478</ArticleId></ArticleIdList></Reference><Reference><Citation>Olincy A, Stevens KE. Treating schizophrenia symptoms with an &#x3b1;7 nicotinic agonist, from mice to men. Biochem Pharmacol. 2007;15(74):1192&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2134979</ArticleId><ArticleId IdType="pubmed">17714692</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccafusco JJ, Letchworth SR, Bencherif M, Lippillo PM. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacological Sci. 2005;26:352&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">15946748</ArticleId></ArticleIdList></Reference><Reference><Citation>Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, Enzell CR. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur J Clin Pharmacol. 1990;38:281&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">2340848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatsukami DK, Grillo M, Pentel PR, Oncken C, Bliss R. Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol Biochemd Behav. 1997;57:643&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">9258989</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooks PA, Dwoskin LP. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol. 1997;54:743&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353128</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig KE, Callaway E, Halliday R, Naylor H, Benowitz N. Effects of cotinine on information processing in nonsmokers. Psychopharmacology. 1998;135:127&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9497017</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19566770</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study.</ArticleTitle><Pagination><StartPage>374</StartPage><EndPage>384</EndPage><MedlinePgn>374-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1440-1819.2009.01955.x</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To examine the effect of neuropsychiatric symptoms on longitudinal changes in the quality of life (QOL) of patients with Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">First, we investigated whether neuropsychiatric symptoms at baseline predict changes in the QOL of AD patients over time. Then we examined the associations between changes in neuropsychiatric symptoms and changes in QOL. QOL was assessed using the Japanese version of the Quality of Life-Alzheimer Disease (QOL-AD) scale and other clinical instruments [the Mini-Mental State Examination, The Neuropsychiatry Inventory (NPI)] at baseline and again two years later in 96 AD patients among 140 AD patients at baseline. We performed a multiple regression analysis of the baseline QOL-AD score, NPI score (mood, psychosis, and euphoria factor), Mini-Mental State Examination score, and other clinical instrument variables (e.g. Activities-of-Daily-Living scores) to determine their contribution to the change in QOL-AD score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While the total QOL-AD score based on the patients' responses did not change significantly, the total QOL-AD score derived from the caregivers' responses declined. Both the Activities-of-Daily-Living score and the mood factor of the NPI score predicted the change in the QOL-AD score as assessed by the caregivers' responses. In addition, there was a significant correlation between the changes in two factors of the NPI, i.e. the mood and psychosis factor, and the changes in the QOL-AD score based on the caregivers' responses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The presence of specific neuropsychiatric symptoms (mood and psychosis symptoms) was associated with changes in the QOL of AD patients during the follow-up period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tatsumi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakaaki</LastName><ForeName>Shutaro</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Katsuyoshi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shinagawa</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Norio</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Junko</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mimura</LastName><ForeName>Masaru</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Toshiaki A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005059" MajorTopicYN="Y">Euphoria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19566770</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2009.01955.x</ArticleId><ArticleId IdType="pii">PCN1955</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19559160</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-7162</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of medicine</Title><ISOAbbreviation>Am J Med</ISOAbbreviation></Journal><ArticleTitle>Pharmacological management of psychosis in elderly patients with parkinsonism.</ArticleTitle><Pagination><StartPage>614</StartPage><EndPage>622</EndPage><MedlinePgn>614-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2009.01.025</ELocationID><Abstract><AbstractText>Parkinsonism is a characteristic feature of Parkinson's disease and dementia with Lewy bodies and is commonly seen in Alzheimer's disease. Psychosis commonly appears during the course of these illnesses. Treatment of parkinsonism with antiparkinsonian medications constitutes an additional risk factor for the appearance or worsening of psychosis. Conversely, treatment of psychosis with antipsychotic drugs in patients with parkinsonism might worsen the underlying movement disorder, especially in the elderly. In this article, we review parkinsonian conditions in the elderly and offer guidelines to assess and manage comorbid psychosis. We focus on the pharmacologic management of psychosis with atypical antipsychotic medications and briefly review the role of acetylcholinesterase inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hasnain</LastName><ForeName>Mehrul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Regional Integrated Health Authority, Sir Thomas Roddick Hospital, Stephenville, Newfoundland, Canada. mehrul_hasnain@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieweg</LastName><ForeName>W Victor R</ForeName><Initials>WV</Initials></Author><Author ValidYN="Y"><LastName>Baron</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Beatty-Brooks</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Antony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pandurangi</LastName><ForeName>Anand K</ForeName><Initials>AK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med</MedlineTA><NlmUniqueID>0267200</NlmUniqueID><ISSNLinking>0002-9343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Med. 2010 Apr;123(4):e19; author reply e21. doi: 10.1016/j.amjmed.2009.09.027</RefSource><PMID Version="1">20362738</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>89</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19559160</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2009.01.025</ArticleId><ArticleId IdType="pii">S0002-9343(09)00166-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19552610</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-764X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert opinion on drug safety</Title><ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?</ArticleTitle><Pagination><StartPage>549</StartPage><EndPage>557</EndPage><MedlinePgn>549-57</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14740330903099636</ELocationID><Abstract><AbstractText>Psychosis in Alzheimer's disease is common and troublesome. The impact on the quality of life of both patients and caregivers is high and drug treatments raise concern in terms of both efficacy and safety. Therefore, identifying the risk factors that play an important role in the onset of psychosis is mandatory for the prevention of this clinical condition. From a biological point of view, drugs with anticholinergic properties are a reasonable cause of psychosis. Demented patients have been found to use a disproportionate amount of drugs with anticholinergic properties. On the other hand, new evidence suggests that the cholinergic system may be implicated not only with the onset of cognitive impairment, but even in the genesis of psychosis symptoms. This review focuses on biological and clinical data which suggest that anti-cholinergic drugs should be regarded as a potential risk factor for psychosis in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cancelli</LastName><ForeName>Iacopo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Santa Maria della Misericordia University Hospital, Department of Neurology, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltrame</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>D'Anna</LastName><ForeName>Lucio</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gigli</LastName><ForeName>Gian Luigi</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Mariarosaria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Drug Saf</MedlineTA><NlmUniqueID>101163027</NlmUniqueID><ISSNLinking>1474-0338</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018680">Cholinergic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018680" MajorTopicYN="N">Cholinergic Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055139" MajorTopicYN="N">Sensory Gating</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>65</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19552610</ArticleId><ArticleId IdType="doi">10.1517/14740330903099636</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19533585</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-4421</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))</Title><ISOAbbreviation>Gesundheitswesen</ISOAbbreviation></Journal><ArticleTitle>[The amount of professional nursing care in a gerontopsychiatric hospital--comparison of the system of the psychiatry personnel act and the long-term care insurance].</ArticleTitle><Pagination><StartPage>233</StartPage><EndPage>239</EndPage><MedlinePgn>233-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0029-1215566</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hospital-based gerontopsychiatric wards are located at an important interface within the healthcare system. If home caring needs continue in inpatient settings nursing resources have to be allocated. The amount of work of professional care in a gerontopsychiatric hospital can be calculated by different systems: the system of the long-term care insurance (SGB XI) and the system of the Psychiatry Personnel Act (PsychPV). The aim of the study was to compare both systems regarding their calculation of allocated nursing resources.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A comprehensive survey over six months was accomplished in an inpatient department for gerontopsychiatric patients with special wards for dementia, psychosis and depression in older people. Data from the long-term care insurance (SGB XI) and the system of the Psychiatry Personnel Act (PsychPV) were calculated and contrasted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">209 datasets could be included (69.7% of all admitted patients). The long-term care insurance system calculated more needed resources than the Psychiatry Personnel Act, especially for people with dementia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Since both systems calculate extremely diverging results, more research is needed to develop valid systems for the measurement and the requirement of nursing resources in gerontopsychiatric hospitals.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart, New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noelle</LastName><ForeName>D R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Evangelisches Krankenhaus Bielefeld, Klinik f&#xfc;r Psychiatrie und Psychotherapie Bethel. Ruediger.Noelle@evkb.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Behrens</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Driessen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Der Arbeitsaufwand professioneller Pflege in der station&#xe4;ren Gerontopsychiatrie--Vergleichende Ressourcenbemessung nach der Logik von Psychiatriepersonalverordnung (PsychPV) und Pflegeversicherung.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Gesundheitswesen</MedlineTA><NlmUniqueID>9204210</NlmUniqueID><ISSNLinking>0941-3790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="N">Health Services Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="Y">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007353" MajorTopicYN="Y">Insurance, Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009741" MajorTopicYN="Y">Nursing Staff, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040841" MajorTopicYN="Y">Resource Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016526" MajorTopicYN="N">Workload</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19533585</ArticleId><ArticleId IdType="doi">10.1055/s-0029-1215566</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19477230</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7972</ISSN><JournalIssue CitedMedium="Internet"><Volume>461</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Evidence that variation in the oligodendrocyte lineage transcription factor 2 (OLIG2) gene is associated with psychosis in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>54</StartPage><EndPage>59</EndPage><MedlinePgn>54-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neulet.2009.05.051</ELocationID><Abstract><AbstractText>Psychotic symptoms are common in individuals with Alzheimer's disease (AD), and define a phenotype associated with more rapid cognitive and functional decline. Evidence suggests that psychotic symptoms may be influenced by genetic factors, and recent studies in schizophrenia, bipolar affective disorder (BPAD) and Alzheimer's disease with psychosis (AD+P) suggest that psychosis susceptibility or modifier genes may act across diseases. We hypothesised that oligodendrocyte lineage transcription factor 2 (OLIG2), a regulator of white matter development and a candidate gene for schizophrenia, may also be associated with psychotic symptoms in AD. We genotyped 11 SNPs in OLIG2 previously tested for association with schizophrenia [L. Georgieva, V. Moskvina, T. Peirce, N. Norton, N.J. Bray, L. Jones, P. Holmans, S. Macgregor, S. Zammit, J. Wilkinson, H. Williams, I. Nikolov, N. Williams, D. Ivanov, K.L. Davis, V. Haroutunian, J.D. Buxbaum, N. Craddock, G. Kirov, M.J. Owen, M.C. O'Donovan, Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia, Proc. Natl. Acad. Sci. U.S.A. 103 (33) (2006) 12469-12474] and tested these for association with AD and AD+P. Significant evidence for association of psychotic symptoms within cases was identified for two SNPs, rs762237 (allelic P=0.002, OR=1.42, corrected P=0.019) and rs2834072 (allelic P=0.004, OR=1.41, corrected P=0.05).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Cardiff University School of Medicine, Heath Park, Cardiff CF144XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Moskvina</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Dowzell</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>064354</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0300429</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C405708">OLIG2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076104">Oligodendrocyte Transcription Factor 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051792" MajorTopicYN="N">Basic Helix-Loop-Helix Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076104" MajorTopicYN="N">Oligodendrocyte Transcription Factor 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19477230</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2009.05.051</ArticleId><ArticleId IdType="pii">S0304-3940(09)00700-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19433976</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-3686</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>American journal of therapeutics</Title><ISOAbbreviation>Am J Ther</ISOAbbreviation></Journal><ArticleTitle>Etiology and risk factors for developing orthostatic hypotension.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>91</EndPage><MedlinePgn>86-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MJT.0b013e3181a2b1bb</ELocationID><Abstract><AbstractText>Orthostatic hypotension (OH) is regarded as a decrease primarily in systolic blood pressure on changing position from supine to erect. Based on clinical criteria, it is characterized by a decrease in systolic pressure of 20 mmHg and diastolic pressure of 10 mmHg within 1 to 3 minutes of standing after being supine. It is most prevalent in, although not limited to, the elderly population and is characterized by a variety of problems, including diminished cognition and disturbed emotion along with gate problems, falls, and brain and cardiovascular difficulties. Although often seen as an age-related condition, occurrence of OH is also associated with a number of autonomic nervous system neurodegenerative disorders. Medications may play a direct role in the risk of triggering OH; these drugs include, but are not limited to, agents used in the treatment of hypertension, myocardial ischemia, psychosis and schizophrenia, depression, Alzheimer and Parkinson disease as well as a vaccine approved for the prevention of cervical cancer. Most of these agents increase the risk for triggering OH through varying vasodilative mechanisms or through sympathetic nervous system interruption; for other drugs, no mechanism of action has been identified. These factors should be considered when diagnosing OH and when prescribing remedies for both patients with OH and those without OH; medication's contributions to the severity and/or risk of developing OH could limit their use. However, their effects could be attenuated or even eliminated by modifying drug dosages.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosnaim</LastName><ForeName>Aron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Pharmacology, College of Health Professions at Rosalind Franklin University, North Chicago, IL 60064, USA. Aron.Mosnaim@rosalindfranklin.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abiola</LastName><ForeName>Rasheed</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Marion E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Perlmuter</LastName><ForeName>Lawrence C</ForeName><Initials>LC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ther</MedlineTA><NlmUniqueID>9441347</NlmUniqueID><ISSNLinking>1075-2765</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="Y">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007024" MajorTopicYN="N">Hypotension, Orthostatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013564" MajorTopicYN="N">Sympathetic Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>37</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19433976</ArticleId><ArticleId IdType="doi">10.1097/MJT.0b013e3181a2b1bb</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19422762</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.</ArticleTitle><Pagination><StartPage>915</StartPage><EndPage>918</EndPage><MedlinePgn>915-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.08m04828</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To ascertain the impact of treatment with citalopram on irritability, apathy, delusions, and hallucinations in nondepressed behaviorally disturbed Alzheimer's disease (AD) patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This was a retrospective analysis of data from the 36-week Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease in which patients with probable AD (diagnosed according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association [NINCDS/ADRDA]) were treated in a naturalistic manner. Scores were compared on the irritability, apathy, delusions, and hallucinations subscales of the Neuropsychiatric Inventory. The trial was conducted between April 2001 and November 2004.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 421 patients enrolled, 44 were started on placebo and were later randomly assigned to citalopram treatment. There were data available for 34 subjects who took placebo for at least 14 days. In this group, there was a 60% reduction in irritability and apathy scores, no effect on scores for delusions, and a clinically insignificant drop in scores for hallucinations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of citalopram was associated with greatly reduced irritability without sedation in a group of behaviorally disturbed patients with AD.</AbstractText><CopyrightInformation>Copyright 2009 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Siddique</LastName><ForeName>Haroon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390-9129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hynan</LastName><ForeName>Linda S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron F</ForeName><Initials>MF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300-15</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19422762</ArticleId><ArticleId IdType="mid">NIHMS321867</ArticleId><ArticleId IdType="pmc">PMC3236068</ArticleId><ArticleId IdType="doi">10.4088/JCP.08m04828</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008;165:429&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176893</ArticleId><ArticleId IdType="pubmed">18346997</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg AS, Coleman M. Depressed 5-hydroxyindole associated with hyperactive and aggressive behavior. Arch Gen Psychiatry. 1976;33:331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">1259523</ArticleId></ArticleIdList></Reference><Reference><Citation>Coccaro EF, Kavoussi RJ. Fluoxteine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54:1081&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">9400343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Yates PO. Neurotransmitter deficits in Alzheimer&#x2019;s disease and in other dementing disorders. Hum Neurobiol. 1986;5:147&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">2876973</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer&#x2019;s disease: neurofibrillary tangles and loss of large neurons. Ann Neurol. 1985;17:573&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">4026228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckern&#xe4;s SA, Nordberg A, et al. Biochemical changes in dementia disorders of the Alzheimer&#x2019;s type (AD/SDAT) Neurobiol Aging. 1983;4:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">6200784</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multi-center study. Br J Psychiatry. 1990;157:894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1705151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH. An open pilot study of citalopram for behavioral disturbances of dementia. Am J Geriatr Psychiatry. 1997;5:70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">11870012</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi D, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Huber KA. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846102</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel S, Mintzer JA. Randomized placebo controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestation of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">14716694</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer&#x2019;s disease: phenomenology and treatment. J Clin Psychoatry. 1987;48:9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome. J Psychiatr Pract. 2004;10:196&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">15330228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D. Serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry. 2007;6:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820592</ArticleId><ArticleId IdType="pubmed">17313684</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsaio JK, Ismail MS, Lebowitz BD, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer&#x2019;s disease. N Engl J Med. 2006;355:1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck AT. Depression Inventory. The Psychological Corporation; San Antonio, TX: 1987.</Citation></Reference><Reference><Citation>Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in Alzheimer&#x2019;s disease: a randomized placebo controlled clinical trial. Neurology. 2000;55:1271&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Tractenberg RE, Gamst A, Teri L, Masterman D, Thal L. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Curr Alz Res. 2004;1:323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371726</ArticleId><ArticleId IdType="pubmed">15975061</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Grossberg GT, Jarvik L, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008 May 13;:e1&#x2013;e10. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674239</ArticleId><ArticleId IdType="pubmed">18494535</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19414887</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2694-233X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Health affairs (Project Hope)</Title><ISOAbbreviation>Health Aff (Millwood)</ISOAbbreviation></Journal><ArticleTitle>Improving mental health treatments through comparative effectiveness research.</ArticleTitle><Pagination><StartPage>783</StartPage><EndPage>791</EndPage><MedlinePgn>783-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1377/hlthaff.28.3.783</ELocationID><Abstract><AbstractText>There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental illnesses receive appropriate care. Because of a general lack of information on the relative effectiveness of different treatments, payers are uncertain about the value of current spending, which in turn may deter new investments to reduce unmet need. We use several recent comparative effectiveness trials to illustrate the potential value of such research for improving practice and policy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health (NIMH) in Bethesda, Maryland, USA. wangphi@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulbricht</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Schoenbaum</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Aff (Millwood)</MedlineTA><NlmUniqueID>8303128</NlmUniqueID><ISSNLinking>0278-2715</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="Y">Health Policy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019458" MajorTopicYN="N">Insurance Coverage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007356" MajorTopicYN="N">Insurance, Pharmaceutical Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19414887</ArticleId><ArticleId IdType="doi">10.1377/hlthaff.28.3.783</ArticleId><ArticleId IdType="pii">28/3/783</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19386383</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD).</ArticleTitle><Pagination><StartPage>434</StartPage><EndPage>442</EndPage><MedlinePgn>434-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2009.03.005</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Although there is evidence for distinct behavioural sub-phenotypes in Alzheimer's disease (AD), their inter-relationships and the effect of clinical variables on their expression have been little investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We have analysed a sample of 1850 probable AD patients from the UK and Greece with 10 item Neuropsychiatric Inventory (NPI) data. We applied a Multiple Indicators Multiple Causes (MIMIC) approach to investigate the effect of MMSE, disease duration, gender, age and age of onset on the structure of a four-factor model consisting of "psychosis", "moods", "agitation" and "behavioural dyscontrol".</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Specific clinical variables predicted the expression of individual factors. When the inter-relationship of factors is modelled, some previously significant associations are lost. For example, lower MMSE scores predict psychosis, agitation and behavioural dyscontrol factors, but psychosis and mood predict the agitation factor. Taking these associations into account MMSE scores did not predict agitation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The complexity of the inter-relations between symptoms, factors and clinical variables is efficiently captured by this MIMIC model.</AbstractText><CopyrightInformation>Copyright &#xa9; 2009 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK. petroula.proitsi@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lupton</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Daniilidou</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hollingworth</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Archer</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Foy</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stylios</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>McGuinness</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lawlor</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rubinsztein</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Passmore</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>064354</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19386383</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.03.005</ArticleId><ArticleId IdType="pii">S0197-4580(09)00101-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19372744</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1933-6926</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Cell adhesion &amp; migration</Title><ISOAbbreviation>Cell Adh Migr</ISOAbbreviation></Journal><ArticleTitle>Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>137</EndPage><MedlinePgn>129-37</MedlinePgn></Pagination><Abstract><AbstractText>Antipsychotic drugs are divided into two groups: typical and atypical. Recent clinical studies show atypical antipsychotics have advantages over typical antipsychotics in a wide variety of neuropsychiatric conditions, in terms of greater efficacy for positive and negative symptoms, beneficial effects on cognitive functioning, and fewer extra pyramidal side effects in treating schizophrenia. As such, atypical antipsychotics may be effective in the treatment of depressive symptoms associated with psychotic and mood disorders, posttraumatic stress disorder and psychosis in Alzheimer disease. In this paper, we describe the effects and potential neurochemical mechanisms of action of atypical antipsychotics in several animal models showing memory impairments and/or non-cognitive behavioral changes. The data provide new insights into the mechanisms of action of atypical antipsychotics that may broaden their clinical applications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jue</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Xijing Hospital, The Fouth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Jiming</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Qing-Rong</ForeName><Initials>QR</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin-Min</ForeName><Initials>XM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Adh Migr</MedlineTA><NlmUniqueID>101469464</NlmUniqueID><ISSNLinking>1933-6918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="Y">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19372744</ArticleId><ArticleId IdType="pmc">PMC2675159</ArticleId><ArticleId IdType="doi">10.4161/cam.3.1.7401</ArticleId><ArticleId IdType="pii">7401</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002;53:239&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738537</ArticleId></ArticleIdList></Reference><Reference><Citation>Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1407745</ArticleId><ArticleId IdType="pubmed">11291531</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley CM, Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: An overview of pivotal clinical trials. J Clin Psychiatry. 1997;58:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9265910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudinal study. Schizophr Res. 2001;48:17&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">11278151</ArticleId></ArticleIdList></Reference><Reference><Citation>Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: Neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy. 2004;24:1759&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585443</ArticleId></ArticleIdList></Reference><Reference><Citation>Brugue E, Vieta E. Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008;23:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090502</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhusoodanan S, Shah P, Brenner R, Gupta S. Pharmacological treatment of the psychosis of alzheimer's disease: What is the best approach? CNS Drugs. 2007;21:101&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">17284093</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al. Effects of olanzapine, quetiapine and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">17606658</ArticleId></ArticleIdList></Reference><Reference><Citation>Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in parkinson's disease. Mov Disord. 2004;19:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">14743357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AH, Van Tol HH. Schizophrenia: From phenomenology to neurobiology. Neurosci Biobehav Rev. 2003;27:269&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989565</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156:876&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">10360126</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods BT, Yurgelun-Todd D, Benes FM, Frankenburg FR, Pope HG, Jr, McSparren J. Progressive ventricular enlargement in schizophrenia: Comparison to bipolar affective disorder and correlation with clinical course. Biol Psychiatry. 1990;27:341&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">2302441</ArticleId></ArticleIdList></Reference><Reference><Citation>Waddington JL, O'Callaghan E, Buckley P, Larkin C, Redmond O, Stack J, et al. The age dependencies of MRI abnormalities in schizophrenia suggest early ventricular enlargement but later prominence of cortical atrophy. Schizophr Res. 1991;5:188&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1760387</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 1997;74:129&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">9255858</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Trojanowski JQ. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol. 1996;92:217&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">8870823</ArticleId></ArticleIdList></Reference><Reference><Citation>Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">8610818</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD. Comprehensive clinical psychology. In: Bellack AS, Hersen M, editors. Schizophrenia and related disorders in late life. Amsterdam: Elsevier; 1998. pp. 74&#x2013;86.</Citation></Reference><Reference><Citation>He J, Xu H, Yang Y, Zhang X, Li XM. Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of bcl-2 decrease in rats. Brain Res. 2004;1018:186&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15276877</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Yang Y, Yu Y, Li X, Li XM. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav Brain Res. 2006;172:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16712969</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Xu H, Yang Y, Zhang X, Li XM. Chronic administration of quetiapine alleviates the anxiety-like behavioural changes induced by a neurotoxic regimen of dl-amphetamine in rats. Behav Brain Res. 2005;160:178&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15836913</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res. 2006;168:236&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16360889</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005;1063:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16271709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res. 2002;69:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111809</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci. 2003;17:1563&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12752374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res. 2003;73:364&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12868070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Mousseau DD, Richardson JS, Dyck LE, Li XM. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25&#x2013;35) by modulating bax and bcl-X(l/s) expression and localization. J Neurosci Res. 2003;74:942&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pubmed">14648600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancela LM, Basso AM, Martijena ID, Capriles NR, Molina VA. A dopaminergic mechanism is involved in the &#x2018;anxiogenic-like&#x2019; response induced by chronic amphetamine treatment: A behavioral and neurochemical study. Brain Res. 2001;909:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">11478934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapin IP. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharmacol Biochem Behav. 1993;44:241&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HQ, Burden PM, Christie MJ, Johnston GA. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: A comparison with amphetamine. Pharmacol Biochem Behav. 1999;62:403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">10080230</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon P, Panissaud C, Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol Biochem Behav. 1993;45:685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">8101381</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berl) 1995;118:316&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">7617825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987;92:180&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">3110839</ArticleId></ArticleIdList></Reference><Reference><Citation>Abekawa T, Ohmori T, Koyama T. Tolerance to the neurotoxic effect of methamphetamine in rats behaviorally sensitized to methamphetamine or amphetamine. Brain Res. 1997;767:34&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9365013</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisch AJ, Marshall JF. Methamphetamine neurotoxicity: Dissociation of striatal dopamine terminal damage from parietal cortical cell body injury. Synapse. 1998;30:433&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">9826235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellison G, Eison MS, Huberman HS, Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science. 1978;201:276&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">26975</ArticleId></ArticleIdList></Reference><Reference><Citation>Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis&#x2014;preliminary observations. Biol Psychiatry. 1970;2:95&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">5459137</ArticleId></ArticleIdList></Reference><Reference><Citation>Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatr Res. 1974;11:13&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">4461784</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9028746</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">7527327</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanic JA, Wasielewski JA, Carl KL, Holloway FA. Attenuation of the amphetamine discriminative cue in rats with the atypical antipsychotic olanzapine. Pharmacol Biochem Behav. 2002;72:767&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush CR, Stoops WW, Hays LR, Glaser PE, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther. 2003;306:195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">12676890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1408069</ArticleId><ArticleId IdType="pubmed">10740989</ArticleId></ArticleIdList></Reference><Reference><Citation>Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">11132243</ArticleId></ArticleIdList></Reference><Reference><Citation>Briley M, Chopin P, Moret C. Effect of serotonergic lesion on &#x201c;anxious&#x201d; behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology (Berl) 1990;101:187&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">2140904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tye NC, Everitt BJ, Iversen SD. 5-hydroxytryptamine and punishment. Nature. 1977;268:741&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">895875</ArticleId></ArticleIdList></Reference><Reference><Citation>Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology. 1979;18:689&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">492489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 2004;1010:81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">15126120</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C, Xu H, Li XM. Post-stress changes in BDNF and bcl-2 immunoreactivities in hippocampal neurons: Effect of chronic administration of olanzapine. Brain Res. 2004;1025:194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464760</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Qing H, Lu W, Keegan D, Richardson JS, Chlan-Fourney J, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett. 2002;321:65&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">11872258</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers DS, Sonsalla PK. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther. 1995;275:1104&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">8531070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, Jr, et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther. 1994;268:1571&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">8138969</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel GM, Seiden LS. Role of hypothermia in the mechanism of protection against serotonergic toxicity I. experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther. 1995;272:860&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">7531765</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DB, O'Callaghan JP. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther. 1994;270:752&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">8071868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt CJ, Black CK, Abbate GM, Taylor VL. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">1980848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan KC, Lin YF, Yu FC, Lin CS, Chu P. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc. 1998;97:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">9747062</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Dell SJ, Weihmuller FB, Marshall JF. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 1991;564:256&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">1810626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior and stimulated dopamine release in the rat. J Neurosci. 1999;19:9141&#x2013;9148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782759</ArticleId><ArticleId IdType="pubmed">10516332</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001;36:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11516769</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000;9:222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">11000918</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisagno V, Ferguson D, Luine VN. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res. 2002;940:95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020880</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder N, O'Dell SJ, Marshall JF. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse. 2003;49:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayanthi S, Deng X, Bordelon M, McCoy MT, Cadet JL. Methamphetamine causes differential regulation of pro-death and anti-death bcl-2 genes in the mouse neocortex. FASEB J. 2001;15:1745&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481222</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadet JL, Ordonez SV, Ordonez JV. Methamphetamine induces apoptosis in immortalized neural cells: Protection by the proto-oncogene, bcl-2. Synapse. 1997;25:176&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">9021898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kita T, Wagner GC, Nakashima T. Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption. J Pharmacol Sci. 2003;92:178&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890883</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard S, Bottino C, Brooke S, Cheng E, Giffard RG, Sapolsky R. Neuroprotective effects of bcl-2 overexpression in hippocampal cultures: Interactions with pathways of oxidative damage. J Neurochem. 2002;83:914&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res. 2005;81:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15948179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowyer JF, Tank AW, Newport GD, Slikker W, Jr, Ali SF, Holson RR. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther. 1992;260:817&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">1346646</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumura M, Cappon GD, Pu C, Broening HW, Vorhees CV. A single dose model of methamphetamine-induced neurotoxicity in rats: Effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 1998;806:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9739098</ArticleId></ArticleIdList></Reference><Reference><Citation>Javitt DC. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry. 1987;9:12&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">2820854</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) 2004;175:310&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15024550</ArticleId></ArticleIdList></Reference><Reference><Citation>Handelmann GE, Contreras PC, O'Donohue TL. Selective memory impairment by phencyclidine in rats. Eur J Pharmacol. 1987;140:69&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">3622624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesner RP, Dakis M, Bolland BL. Phencyclidine disrupts long- but not short-term memory within a spatial learning task. Psychopharmacology (Berl) 1993;111:85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870938</ArticleId></ArticleIdList></Reference><Reference><Citation>Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 1997;752:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9106435</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">2660263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, et al. Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience. 1994;62:1079&#x2013;1092.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell IJ, Cooper AJ, Griffiths MR, Barber DJ. Phencyclidine and corticosteroids induce apoptosis of a subpopulation of striatal neurons: A neural substrate for psychosis? Neuroscience. 1998;84:489&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: Implications for schizophrenia. Neuroscience. 2001;107:535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">11720778</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JM, Cory S. The bcl-2 protein family: Arbiters of cell survival. Science. 1998;281:1322&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">9735050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Kaufmann JA, Sanchez-Ross MG, Johnson KM. Mechanisms of N-methyl-D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons. J Pharmacol Exp Ther. 2000;294:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10871324</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya DN, Yeterian EH. Proposed neural circuitry for spatial memory in the primate brain. Neuropsychologia. 1984;22:109&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">6374496</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland RJ, Whishaw IQ, Kolb B. Contributions of cingulate cortex to two forms of spatial learning and memory. J Neurosci. 1988;8:1863&#x2013;1872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569344</ArticleId><ArticleId IdType="pubmed">3385478</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths MR, Cooper AJ, Barber DJ, Mitchell IJ. Pharmacological mechanisms mediating phencyclidine-induced apoptosis of striatopallidal neurons: The roles of glutamate, dopamine, acetylcholine and corticosteroids. Brain Res. 2000;855:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">10650124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertel P, Mathe JM, Nomikos GG, Iurlo M, Mathe AA, Svensson TH. Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav Brain Res. 1995;72:103&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">8788863</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Wozniak DF, et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry. 1993;34:119&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">8373932</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW, Farber NB. Efficacy of clozapine compared with other antipsychotics in preventing NMDA-antagonist neurotoxicity. J Clin Psychiatry. 1994;55:43&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">7961572</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 2002;47:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11873706</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res. 2003;71:127&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">12478621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, et al. Calyculin A and okadaic acid: Inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 1989;159:871&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">2539153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen P, Holmes CF, Tsukitani Y. Okadaic acid: A new probe for the study of cellular regulation. Trends Biochem Sci. 1990;15:98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">2158158</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnoli CM, Kharlamov E, Atabay C, Uz T, Manev H. Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8 and H-9. J Mol Neurosci. 1996;7:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835783</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam AM, Bol JG, Binnekade R, van Muiswinkel FL. Acute or chronic administration of okadaic acid to rats induces brain damage rather than alzheimer-like neuropathology. Neuroscience. 1998;85:1333&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9681967</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Yamada K, Zou LB, Nabeshima T. Spatial memory deficit and neurodegeneration induced by the direct injection of okadaic acid into the hippocampus in rats. J Neural Transm. 2001;108:1435&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11810406</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Phosphorylation of tau, abetaformation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol Aging. 1998;19:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562497</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience. 1995;69:691&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Bennett P, Sedman GL, NG KT. The impairment of long-term memory formation by the phosphatase inhibitor okadaic acid. Brain Res Bull. 1995;36:557&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">7757489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Q, Lin ZQ, Wang XC, Chen J, Wang Q, Gong CX, et al. Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience. 2004;126:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207345</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Yang Y, Xu H, Zhang X, Li XM. Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology. 2005;30:1511&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">15886720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweatt JD. Hippocampal function in cognition. Psychopharmacology (Berl) 2004;174:99&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">15205881</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado MC, Bachevalier J. Selective neurotoxic damage to the hippocampal formation impairs performance of the transverse patterning and location memory tasks in rhesus macaques. Hippocampus. 2005;15:118&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15390158</ArticleId></ArticleIdList></Reference><Reference><Citation>Benito A, Lerga A, Silva M, Leon J, Fernandez-Luna JL. Apoptosis of human myeloid leukemia cells induced by an inhibitor of protein phosphatases (okadaic acid) is prevented by bcl-2 and bcl-X(L) Leukemia. 1997;11:940&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">9204972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabado AG, Leira F, Vieytes MR, Vieites JM, Botana LM. Cytoskeletal disruption is the key factor that triggers apoptosis in okadaic acid-treated neuroblastoma cells. Arch Toxicol. 2004;78:74&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">14652712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuydens R, Dispersyn G, Van Den Keiboom G, de Jong M, Connors R, Ramaekers F, et al. Bcl-2 protects against apoptosis-related microtubule alterations in neuronal cells. Apoptosis. 2000;5:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11227490</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem. 1998;273:13245&#x2013;13254.</Citation><ArticleIdList><ArticleId IdType="pubmed">9582369</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XM, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res. 1999;56:72&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10213477</ArticleId></ArticleIdList></Reference><Reference><Citation>Matias WG, Traore A, Bonini M, Sanni A, Creppy EE. Oxygen reactive radicals production in cell culture by okadaic acid and their implication in protein synthesis inhibition. Hum Exp Toxicol. 1999;18:634&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">10557016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">11850147</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology. 2002;26:583&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz AF. Uncommon neurodegenerative causes of dementia. Int Psychogeriatr. 2005;17:35&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16240482</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn JA, LePeillet E, Netto CA, Hodges H, Gray JA, Meldrum BS. Global ischaemia: Hippocampal pathology and spatial deficits in the water maze. Behav Brain Res. 1994;62:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">7917032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemerinski E, Levine SR. Neuropsychiatric disorders following vascular brain injury. Mt Sinai J Med. 2006;73:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">17195887</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry. 2004;161:1090&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">15169698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokura H, Robinson RG. Long-term cognitive impairment associated with caudate stroke. Stroke. 1997;28:970&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">9158635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradvik B, Sonesson B, Holtas S. Spatial impairment following right hemisphere transient ischaemic attacks in patients without carotid artery stenosis. Acta Neurol Scand. 1989;80:411&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">2589007</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke: Results of a longitudinal study. Stroke. 2002;33:2254&#x2013;2260.</Citation><ArticleIdList><ArticleId IdType="pubmed">12215596</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmond DW, Moroney JT, Sano M, Stern Y. Mortality in patients with dementia after ischemic stroke. Neurology. 2002;59:537&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196645</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ. Neuronal cell death in nervous system development, disease and injury (review) Int J Mol Med. 2001;7:455&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">11295106</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo D, Campisi A, Curro M, Li Volti G, Vanella A, Ientile R. Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases. Amino Acids. 2004;27:373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15365907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RE, Lee JM, Zipfel GJ, Wozniak DF. Characterizing learning deficits and hippocampal neuron loss following transient global cerebral ischemia in rats. Brain Res. 2005;1043:48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">15862517</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaspers RM, Block F, Heim C, Sontag KH. Spatial learning is affected by transient occlusion of common carotid arteries (2VO): Comparison of behavioural and histopathological changes after &#x2018;2VO&#x2019; and &#x2018;four-vessel-occlusion&#x2019; in rats. Neurosci Lett. 1990;117:149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2290611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B, Bi X, He J, Zhang Y, Thakur S, Xu H, et al. Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice. Life Sci. 2007;81:353&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">17631910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B, He J, Xu H, Zhang Y, Bi X, Thakur S, et al. Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res. 2007;182:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568696</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B, Wang DY, Xing DM, Ding Y, Wang RF, Lei F, et al. The antidepressant effect of ethanol extract of radix puerariae in mice exposed to cerebral ischemia reperfusion. Pharmacol Biochem Behav. 2004;78:319&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryer JB, Starkstein SE, Votypka V, Parikh RM, Price TR, Robinson RG. Reduction of CSF monoamine metabolites in poststroke depression: A preliminary report. J Neuropsychiatry Clin Neurosci. 1992;4:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">1384852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayberg HS, Parikh RM, Morris PL, Robinson RG. Spontaneous remission of post-stroke depression and temporal changes in cortical S2-serotonin receptors. J Neuropsychiatry Clin Neurosci. 1991;3:80&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">7580180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol. 1996;40:346&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797524</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor levels in never medicated first episode psychotic patients and medicated chronic schizophrenic patients. Schizophr Res. 2003;60:117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591576</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. NeuroReport. 2004;15:2109&#x2013;2112.</Citation><ArticleIdList><ArticleId IdType="pubmed">15486491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruckheimer EM, Cho SH, Sarkiss M, Herrmann J, McDonnell TJ. The bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol. 1998;62:75&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">9755641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">15809403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci. 2005;28:223&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">16022595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004;56:570&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15476686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakade CG, Mahadik SP, Waller JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res. 2002;69:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111817</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy NS, Wang S, Jiang L, Kang J, Benraiss A, Harrison-Restelli C, et al. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med. 2000;6:271&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">10700228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: Facts and hypotheses. Rev Neurosci. 2007;18:93&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">17593874</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton SS, Duman RS. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs. 2007;21:715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17696572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19235789</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2009</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1020</StartPage><EndPage>1025</EndPage><MedlinePgn>1020-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.2214</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Alzheimer's disease (AD) patients commonly suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to the development of BPSD in AD has been supported. Polymorphisms within dopamine receptors DRD1, DRD2, DRD3 and DRD4 have previously been investigated in a few interesting studies that are reviewed here and extended using our patient cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our large cohort of 395 probable AD patients had longitudinal information on the BPSD (Neuropsychiatric Inventory), which was used to dichotomise patients into whether they had ever suffered from a given symptom within the study period, or not. These measures were related to the DRD1 (A-48G), DRD2 (ser311cys; C-ins/del), DRD3 (ser9gly) and DRD4 (VNTR) genotype and allele frequencies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Associations were revealed between DRD3 and elation, and between DRD4 with agitation/aggression and with depression; however, these findings do not remain significant after correction for multiple testing. No associations were found with the other genetic variants and these symptoms and no associations were observed between any of the polymorphic variants examined and delusions, hallucinations, psychosis and aberrant motor behaviour.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data, in combination with a review of the literature, reveal a potential role for the VNTR variant of DRD4 in the development of depression in AD patients. The findings presented here need to be replicated in large, well characterised longitudinal cohorts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>Antonia L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Molecular Psychiatry Group, Population Studies and Human Genetics, G Floor CBCRC Building, Queensland Institute of Medical Research, Herston, Brisbane, 4006, Australia. Antonia.Pritchard@qimr.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratcliffe</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Sorour</LastName><ForeName>Eman</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Sayeed</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holder</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bentham</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lendon</LastName><ForeName>Corinne L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19235789</ArticleId><ArticleId IdType="doi">10.1002/gps.2214</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19222984</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A roadmap to key pharmacologic principles in using antipsychotics in the treatment of older patients.</ArticleTitle><Pagination><StartPage>131</StartPage><EndPage>138</EndPage><MedlinePgn>131-8</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ej701bm5055ah4cj</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Clin Psychiatry. 2009 Mar;70(3):434</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19222984</ArticleId><ArticleId IdType="doi">10.4088/jcp.5055ah4cj</ArticleId><ArticleId IdType="pii">ej701bm5055ah4cj</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19222143</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>6</Issue><PubDate><MedlineDate>2008 Dec-2009 Jan</MedlineDate></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>Alcohol dementia and thermal dysregulation: a case report and review of the literature.</ArticleTitle><Pagination><StartPage>563</StartPage><EndPage>570</EndPage><MedlinePgn>563-70</MedlinePgn></Pagination><Abstract><AbstractText>Wernicke's encephalopathy and Korsakoff's psychosis in alcoholics are thought to be due to thiamine deficiency. When the process goes untreated, patients may develop alcohol-induced persisting dementia. We review the literature on thermal dysregulation and the place of thiamine treatment in Wernicke's encephalopathy, Korsakoff's psychosis, and alcohol-induced persisting dementia. We describe a patient with alcohol-induced persisting dementia who showed thermal dysregulation which responded to parenteral but not oral thiamine. Subsequently, he developed aspiration pneumonia with associated fever reaction and expired. We describe the neuroimaging findings--diffuse cortical atrophy, ventricular dilatation, atrophy of the corpus callosum, hypothalamus, and medulla, and a probable arachnoid cyst in the left temporal tip. We conclude that thermal dysregulation was likely related to dysfunction of temperature regulatory brain centers, that thermal dysregulation was stabilized with parenteral but not oral thiamine, and that parenteral thiamine may have a role even in chronic cases of alcohol-induced persisting dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanev</LastName><ForeName>Kaloyan S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>University of Connecticut Health Center, Farmington, Connecticut, USA. ktanev@uchc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roether</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12001-76-2</RegistryNumber><NameOfSubstance UI="D014803">Vitamin B Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>X66NSO3N35</RegistryNumber><NameOfSubstance UI="D013831">Thiamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001833" MajorTopicYN="N">Body Temperature Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013831" MajorTopicYN="N">Thiamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013832" MajorTopicYN="N">Thiamine Deficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014803" MajorTopicYN="N">Vitamin B Complex</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19222143</ArticleId><ArticleId IdType="pmc">PMC10846218</ArticleId><ArticleId IdType="doi">10.1177/1533317508323479</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nakada T., Knight RT Alcohol and the central nervous system. Med Clin North Am . 1984;68:121-130.</Citation><ArticleIdList><ArticleId IdType="pubmed">6318000</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmel PW Vegetative dysfunctions of the hypothalamus. Acta Neurochir (Wien). 1985;75:113-121.</Citation><ArticleIdList><ArticleId IdType="pubmed">3993447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranson WW Regulation of body temperature. Res Publ Assoc Res Nerv Ment Dis. 1949;20:342-299.</Citation></Reference><Reference><Citation>Domenighetti G., Stricker H. Syndrome de detresse respiratoire et hypotermie au cours d une encephalopathy de Wernicke. Schweiz med Wschr . 1985;115:1764-1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">4089574</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearsley JH, Musso AF Hypothermia and coma in the Wernicke-Korsakoff syndrome. Med J Aust. 1980; 2:504-546.</Citation><ArticleIdList><ArticleId IdType="pubmed">7207347</ArticleId></ArticleIdList></Reference><Reference><Citation>
Charness ME
Overview of the chronic neurologic complications of alcohol. UptoDate Online 13.2. Available at: www.uptodate.com. Updated September 17, 2003.</Citation></Reference><Reference><Citation>Diamond PT, Diamond MT Thermoregulatory behavior in Alzheimer's disease. J Am Geriatr Soc. 1991;39:532-536.</Citation><ArticleIdList><ArticleId IdType="pubmed">2022805</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson D., Omar SJ, Quach M., Yesavage JA, Tinklenberg J. Oral temperature changes and cognitive decline in Alzheimer patients: a possible association. J Am Geriatr Soc. 1994;42:1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">7963215</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton JM, Kirkpatrick J., Rosenberg RN Hypothermia and persisting capacity to develop fever. Arch Neurol. 1977;34:498-504.</Citation><ArticleIdList><ArticleId IdType="pubmed">889484</ArticleId></ArticleIdList></Reference><Reference><Citation>Haak HR, van Hilten JJ, Roos RA, Meinders AE Functional hypothalamic derangement in a case of Wernicke's encephalopathy . Neth J Med. 1990;36:291-296.</Citation><ArticleIdList><ArticleId IdType="pubmed">2395497</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar A., Aruffo C., Rodriguez-Carbajal J. Wernicke's encephalopathy. A case report with neurophysiologic and CT-scan studies. Acta Vitaminol Enzymol. 1983;5:125-131.</Citation><ArticleIdList><ArticleId IdType="pubmed">6869152</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulant JA Hypothalamic neurons. Mechanisms of sensitivity to temperature. Ann N Y Acad Sci. 1998; 856:108-115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima K. Central mechanisms for thermoregulation in a hot environment. Ind Health. 2006;44:359-367.</Citation><ArticleIdList><ArticleId IdType="pubmed">16922179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancinelli R., Ceccanti M., Guiducci MS, et al. Simultaneous liquid chromatographic assessment of thiamine, thiamine monophosphate and thiamine diphosphate in human erythrocytes: a study on alcoholics. J of Chromatography B. 2003;789:355-363.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742126</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus R., Coulston A. Water-soluble vitamins, In: Goodman and Gilman's Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001:1753-1756.</Citation></Reference><Reference><Citation>Thomson AD, Marshall EJ The natural history and pathophysiology of Wernicke's encephalopathy and Korsakoff's psychosis. Alcohol Alcohol. 2006;41:151-158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16384871</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker H., Frank O., Zetterman RK, Rajan KS, ten Hove W., Leevy CM Inability of chronic alcoholics with liver disease to use food as a source of folates, thiamin and vitamin B6. Am J Clin Nutr. 1975;28:1377-1380.</Citation><ArticleIdList><ArticleId IdType="pubmed">802999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastaldi G. , Casirola D., Ferrari G., Rindi G. Effect of chronic ethanol administration on thiamine transport in microvillous vesicles of rat small intestine. Alcohol Alcohol. 1989;24:83-89.</Citation><ArticleIdList><ArticleId IdType="pubmed">2719773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroth G., Wichmann W., Valavanis A. Blood-brain barrier disruption in acute Wernicke encephalopathy: MR findings . J Comput Assist Tomogr. 1991;15:1059-1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">1939760</ArticleId></ArticleIdList></Reference><Reference><Citation>Calingasan NY, Baker H., Sheu K., Gibson GE Blood-brain barrier abnormalities in vulnerable brain regions during thiamine deficiency. Exp Neurol. 1995;134:64-72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7672039</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterworth RF, Kril JJ, Harper CG Thiamine-dependent enzyme changes in the brains of alcoholics: relationship to the Wernicke-Korsakoff syndrome. Alcohol Clin Exp Res. 1993;17:1084-1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">8279670</ArticleId></ArticleIdList></Reference><Reference><Citation>Desjardins P., Butterworth RF Role of mitochondrial dysfunction and oxidative stress in the pathogenesis of selective neuronal loss in Wernicke's encephalopathy . Mol Neurobiol. 2005;31:17-25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953809</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe SF, El Hadj D. Phenytoin ameliorates the memory deficit induced in the young chick by ethanol toxicity in association with thiamine deficiency. Pharmacol Biochem Behav. 2002;71:215-221.</Citation><ArticleIdList><ArticleId IdType="pubmed">11812525</ArticleId></ArticleIdList></Reference><Reference><Citation>Vortmeyer AO , Colmant HJ Differentiation between brain lesions in experimental thiamine deficiency. Virchows Arch A Pathol Anat Histopathol . 1988;414:61-67.</Citation><ArticleIdList><ArticleId IdType="pubmed">3144804</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC , Johnston MV, Hess KM, Griffin JW, Price DL Model of Wernicke's encephalopathy. Arch Neurol. 1981;38:350-354.</Citation><ArticleIdList><ArticleId IdType="pubmed">7236062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen B., Larsson C., Wiren J., Hallgren J. Hypothermia and infection in Wernicke's encephalopathy. Acta Med Scand. 1984;215:185-187.</Citation><ArticleIdList><ArticleId IdType="pubmed">6702497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann MW, Degos JD Hypothermia in Wernicke's encephalopathy. Rev Neurol. 1987;143:684-686.</Citation><ArticleIdList><ArticleId IdType="pubmed">3423584</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19201489</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-6147</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Trends in pharmacological sciences</Title><ISOAbbreviation>Trends Pharmacol Sci</ISOAbbreviation></Journal><ArticleTitle>Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.</ArticleTitle><Pagination><StartPage>148</StartPage><EndPage>155</EndPage><MedlinePgn>148-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tips.2008.12.002</ELocationID><Abstract><AbstractText>Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease (AD) and other disorders involving impaired cognitive function. More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms associated with schizophrenia and other central nervous system (CNS) disorders. Efforts to develop mAChR subtype-selective agonists have been hampered by difficulty in achieving high selectivity for individual mAChR subtypes important for CNS function (M(1) and M(4)) and adverse effects due to activation of peripheral mAChRs (especially M(2) and M(3)). Major advances have now been achieved in the discovery of allosteric agonists and positive allosteric modulators of M(1) and M(4) that show greater selectivity for individual mAChR subtypes than do previous mAChR agonists. Early studies indicate that these allosteric mAChR activators have properties needed for optimization as potential clinical candidates and have robust effects in animal models that predict efficacy in the treatment of AD, schizophrenia and related disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conn</LastName><ForeName>P Jeffrey</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt Medical Center, Nashville, TN 37232, USA. jeff.conn@vanderbilt.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Carrie K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Lindsley</LastName><ForeName>Craig W</ForeName><Initials>CW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH073676</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073676-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MH084659-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MH084659</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH082867-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH082867</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Pharmacol Sci</MedlineTA><NlmUniqueID>7906158</NlmUniqueID><ISSNLinking>0165-6147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002491">Central Nervous System Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018721">Muscarinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043643">Receptor, Muscarinic M1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043588">Receptor, Muscarinic M4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002491" MajorTopicYN="N">Central Nervous System Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018721" MajorTopicYN="Y">Muscarinic Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018727" MajorTopicYN="Y">Muscarinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043643" MajorTopicYN="N">Receptor, Muscarinic M1</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043588" MajorTopicYN="N">Receptor, Muscarinic M4</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict-of-interest statement</b>. P.J.C. has received compensation over the past two years as a consultant from: Merck and Co., Johnson and Johnson, Hoffman La Roche, GlaxoSmithKline, Lundbeck Research USA, Epix Pharmaceuticals, Invitrogen Life Technologies, Evotec Inc., Addex Pharmaceuticals, Michael J. Fox Foundation, Seaside Therapeutics, Cephalon Inc., AstraZeneca USA, NeurOp Inc., Forest Research Institute, LEK Consulting, The Frankel Group, Prestwick Chemical Co., Millipore Corp., Genentech, IMS Health, Primary Insight and Otsuka. P.J.C. has received honoraria as a speaker from: University of Toronto, American Society for Bone and Mineral Research, University of Alabama Birmingham, University of Michigan, Southern Research Inst., Harvard Medical School and the University of North Carolina. P.J.C. receives research support that includes salary support from the National Institutes of Health, Michael J. Fox Foundation, Seaside Therapeutics and Vanderbilt University.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19201489</ArticleId><ArticleId IdType="mid">NIHMS212903</ArticleId><ArticleId IdType="pmc">PMC2907736</ArticleId><ArticleId IdType="doi">10.1016/j.tips.2008.12.002</ArticleId><ArticleId IdType="pii">S0165-6147(09)00013-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown TA, Zador AM. Hippocampus. In: Shepherd GM, editor. The Synaptic Organization of the Brain. Oxford University Press; 1990. pp. 346&#x2013;388.</Citation></Reference><Reference><Citation>Cooper J, et al. The Biochemical Basis of Neuropharmacology. Oxford University Press; 1996.</Citation></Reference><Reference><Citation>Hasselmo ME. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 2006;16:710&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659740</ArticleId><ArticleId IdType="pubmed">17011181</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani A, et al. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30:545&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904652</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer&#x2019;s disease - the pivotal role of brain M1 receptors. Neurodegener. Dis. 2008;5:237&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">18322400</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead CJ, et al. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 2008;117:232&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18082893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bymaster FP, et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci. 2003;17:1403&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">12713643</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzenschlager R, et al. Anticholinergics for symptomatic management of Parkinson&#x2019;s disease. Cochrane Database Syst. Rev. 2003 CD003735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728160</ArticleId><ArticleId IdType="pubmed">12804486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wess J, et al. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 2007;6:721&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">17762886</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, Albright CF. Therapeutic strategies for Alzheimer&#x2019;s disease. Mol. Neurobiol. 2008;37:171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">18581273</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder CC, et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 2000;43:4333&#x2013;4353.</Citation><ArticleIdList><ArticleId IdType="pubmed">11087557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008;28:10422&#x2013;10433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577155</ArticleId><ArticleId IdType="pubmed">18842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Conn PJ, et al. Allosteric modulators of GPCRs as a novel approach for treatment of CNS disorders. Nat. Rev. Drug Discov. 2009;8:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907734</ArticleId><ArticleId IdType="pubmed">19116626</ArticleId></ArticleIdList></Reference><Reference><Citation>May LT, et al. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007;47:1&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17009927</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakubik J, et al. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997;52:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzafame A, Christopoulos A. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors. J. Pharmacol.Exp. Ther. 2004;308:830&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">14617684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazareno S, et al. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 2004;65:257&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">14722259</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazareno S, et al. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol. Pharmacol. 1998;53:573&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">9495826</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzi AB, et al. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol. Pharmacol. 2001;59:30&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11125021</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding TA, et al. Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol. Pharmacol. 2002;61:1297&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sur C, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 2003;100:13674&#x2013;13679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263872</ArticleId><ArticleId IdType="pubmed">14595031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CK, et al. TBPB is a highly selective M1 allosteric muscarinic receptor agonist in vitro and produces robust antypsychotic-like effects in vivo. Neuropsychopharmacology. 2006;31:S117.</Citation></Reference><Reference><Citation>Kinney GG. Muscarinic receptor activiation for the treatment of schizophrenia. Neuropsychopharmacology. 2006;31:S26.</Citation></Reference><Reference><Citation>Langmead CJ, et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 2008;154:1104&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2451039</ArticleId><ArticleId IdType="pubmed">18454168</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas RL, et al. G protein coupling and signaling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J. Pharmacol. Exp. Ther. 2008;327:365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">18664591</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">16504943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebon G, et al.  Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 2008  http://molpharm.aspetjournals.org 10.1124/mol.108.050963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684897</ArticleId><ArticleId IdType="pubmed">19001633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 2008;73:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges TM, et al. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I. Exploration of alternative benzyl and privileged structure moieties. Bioorg. Med. Chem. Lett. 2008;18:5439&#x2013;5443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177598</ArticleId><ArticleId IdType="pubmed">18805692</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RN, et al. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part II. Amides, sulfonamides and ureas: the effect of capping the distal basic piperidine nitrogen. Bioorg. Med. Chem. Lett. 2008;18:5444&#x2013;5449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177607</ArticleId><ArticleId IdType="pubmed">18829311</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlo J, et al.  Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol.   http://molpharm.aspetjournals.org 10.1124/ mol.108.052886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684909</ArticleId><ArticleId IdType="pubmed">19047481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray W, et al. Allosteric potentiation of the M1 muscarinic receptor provides unprecedented selectivity and a novel therapeutic strategy for the treamtent of alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4 Suppl. 1:T761.</Citation></Reference><Reference><Citation>Wittmann M, et al. In vivo pharmacodynamic effects of BQCA, a novel selective allosteric M1 receptor modulator. Alzheimers Dement. 2008;4 Suppl. 1:T770.</Citation></Reference><Reference><Citation>Bodick NC, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 1997;54:465&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">9109749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodick NC, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1997;11 Suppl. 4:S16&#x2013;S22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9339268</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr. Opin. Neurol. 2002;15:445&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson&#x2019;s disease: a case series. Curr. Med. Res. Opin. 2002;18:258&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12240787</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H. Treating Alzheimer&#x2019;s disease with cholinesterase inhibitors: what have we learned so far? Int. Psychogeriatr. 2002;14 Suppl. 1:3&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12636177</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossberg GT. The ABC of Alzheimer&#x2019;s disease: behavioral symptoms and their treatment. Int. Psychogeriatr. 2002;14 Suppl. 1:27&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">12636179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer&#x2019;s disease. Dement. Geriatr. Cogn. Disord. 1998;9 Suppl. 2:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9718229</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza NR, et al. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9:159&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741650</ArticleId><ArticleId IdType="pubmed">12847557</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int. J. Clin. Pract. 2002 Suppl:20&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139365</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar A, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry. 2008;165:1033&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593778</ArticleId></ArticleIdList></Reference><Reference><Citation>Anagnostaras SG, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 2003;6:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12483218</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder CC, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 2001;68:2605&#x2013;2613.</Citation><ArticleIdList><ArticleId IdType="pubmed">11392633</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber DJ, et al. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2001;98:15312&#x2013;15317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65026</ArticleId><ArticleId IdType="pubmed">11752469</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl d-aspartate receptor. Curr. Drug Target. CNS Neurol. Disord. 2002;1:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769631</ArticleId></ArticleIdList></Reference><Reference><Citation>Messer WS., Jr Cholinergic agonists and the treatment of Alzheimer&#x2019;s disease. Curr. Top. Med. Chem. 2002;2:353&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966459</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa T, et al. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 2001;21:5239&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762828</ArticleId><ArticleId IdType="pubmed">11438599</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirey JK, et al. An allosteric potentiator of M4 mA ChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008;4:42&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18059262</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady A, et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotion behavior in rats. J. Pharmacol. Exp. Ther. 2008;327:941&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745822</ArticleId><ArticleId IdType="pubmed">18772318</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan WY, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2008;105:10978&#x2013;10983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495016</ArticleId><ArticleId IdType="pubmed">18678919</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien JA, et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) Mol. Pharmacol. 2003;64:731&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12920211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, et al. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg. Med. Chem. Lett. 2008;18:4098&#x2013;4101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2533619</ArticleId><ArticleId IdType="pubmed">18550372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19199877</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5828</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current Alzheimer research</Title><ISOAbbreviation>Curr Alzheimer Res</ISOAbbreviation></Journal><ArticleTitle>Planum temporale analysis via a new volumetric method in autoptic brains of demented and psychotic patients.</ArticleTitle><Pagination><StartPage>69</StartPage><EndPage>76</EndPage><MedlinePgn>69-76</MedlinePgn></Pagination><Abstract><AbstractText>Investigations of alterations in brain asymmetry often focus on the planum temporale of patients with schizophrenia. Data also suggest changes in laterality of demented patients associated with a more marked impairment of the left hemisphere. Our study was performed on autoptic brain tissue of 84 patients, out of which there were 25 non-demented non-psychotic controls, 50 demented patients (34 Alzheimer disease, 9 multi - infarct dementia and 7 mixed-type dementia patients) and 9 people with schizophrenia. The plana temporalia were evaluated via a new volumetric method using dental resin matter. Areas, cortical thickness and volumes of the right and left planum temporale were evaluated without normalization to brain weight in 60 patients and with normalization in 24 people. In controls, a mild right/left laterality of areas, cortical thickness and volumes was found. Moreover, in control women the areas of the left planum temporale were smaller than those observed in control men. The shifts to left/right laterality of areas and volumes were found in all demented groups. In the more numerous Alzheimer group, the change in laterality of an area was associated with a mild decrease on the right and a mild increase on the left side. In contrast, marked but only bilateral area shrinkage as well as reduced cortical thickness and brain volumes were observed in schizophrenic patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zach</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Preclinical Studies, Faculty of Health and Social Studies, South Bohemian University, Czech Republic. zach.petr@post.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristofikov&#xe1;</LastName><ForeName>Zdena</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Mrz&#xed;lkov&#xe1;</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Majer</LastName><ForeName>Emerich</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Selinger</LastName><ForeName>Pavel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Spaniel</LastName><ForeName>Filip</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>R&#xed;pov&#xe1;</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kenney</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Alzheimer Res</MedlineTA><NlmUniqueID>101208441</NlmUniqueID><ISSNLinking>1567-2050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012117">Resins, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000886" MajorTopicYN="N">Anthropometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001303" MajorTopicYN="N">Auditory Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010336" MajorTopicYN="N">Pathology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012117" MajorTopicYN="N">Resins, Synthetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19199877</ArticleId><ArticleId IdType="doi">10.2174/156720509787313907</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19196745</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>338</Volume><PubDate><Year>2009</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Alzheimer's disease.</ArticleTitle><Pagination><StartPage>b158</StartPage><MedlinePgn>b158</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.b158</ELocationID><ELocationID EIdType="pii" ValidYN="Y">338/feb05_1/b158</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Alistair</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Manchester Psychiatry Research Group, Manchester M13 9PL. alistair.burns@manchester.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iliffe</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018690">Excitatory Amino Acid Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>BMJ. 2009 Apr 1. doi: 10.1136/bmj.b1349</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000647" MajorTopicYN="N">Amnesia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018690" MajorTopicYN="N">Excitatory Amino Acid Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008487" MajorTopicYN="N">Medical History Taking</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>24</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19196745</ArticleId><ArticleId IdType="doi">10.1136/bmj.b158</ArticleId><ArticleId IdType="pii">338/feb05_1/b158</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19188291</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>166</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychosis in the elderly.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>150</EndPage><MedlinePgn>146-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2008.08020294</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kyomen</LastName><ForeName>Helen H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>McLean Hospital, 115 Mill St., Belmont, MA 02478, USA. helen_kyomen@hms.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitfield</LastName><ForeName>Theodore H</ForeName><Initials>TH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003511">Cyclohexanols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>7D7RX5A8MO</RegistryNumber><NameOfSubstance UI="D000069470">Venlafaxine Hydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003511" MajorTopicYN="N">Cyclohexanols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069470" MajorTopicYN="N">Venlafaxine Hydrochloride</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19188291</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2008.08020294</ArticleId><ArticleId IdType="pii">166/2/146</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">19187697</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2009</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole for psychosis and agitation in Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>4</EndPage><MedlinePgn>3-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ownby</LastName><ForeName>Raymond L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31. doi: 10.1097/JGP.0b013e3181557b47</RefSource><PMID Version="1">17974864</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19187697</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19182457</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1660-4431</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Frontiers of neurology and neuroscience</Title><ISOAbbreviation>Front Neurol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Clinical investigations in primary care.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000197897</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive neurodegenerative disorder that represents the most common form of dementia. The most prominent feature of AD is the decline in cognitive function, with an early impairment of episodic memory. The memory deficit of an AD patient is characterized by the amnestic syndrome of the medial temporal type. As the disease progresses, the condition often manifests in language disorders, visuospatial deficits and executive dysfunctions. Patients often have neuropsychiatric disturbances, as apathy and psychotic symptoms. Loss of autonomy follows cognitive impairment. The clinical diagnosis of AD is based on a complete medical examination with a neuropsychological evaluation. The FCSRT (free and cued selective reminding test) is recommended for the identification of the amnestic syndrome of the medial temporal type, which is defined by: (1) a very poor free recall and (2) a decreased total recall due to an insufficient effect of cueing. The neuropsychological tests should also assess other cognitive functions that may be perturbed in AD, such as executive functions, praxis, visuospatial capacities and language. Neuroimaging and biological exams (genetics, biomarkers) are of great utility in the evaluation. Other medical, neurological, or psychiatric disorders which could account for the impairment in memory and related symptoms must be always investigated.</AbstractText><CopyrightInformation>Copyright (c) 2009 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Leonardo Cruz</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Celine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol Neurosci</MedlineTA><NlmUniqueID>101274949</NlmUniqueID><ISSNLinking>0300-5186</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="Y">Primary Health Care</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>29</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19182457</ArticleId><ArticleId IdType="doi">10.1159/000197897</ArticleId><ArticleId IdType="pii">000197897</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19158433</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1387-2877</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Journal of Alzheimer's disease : JAD</Title><ISOAbbreviation>J Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>180</EndPage><MedlinePgn>173-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JAD-2009-0950</ELocationID><Abstract><AbstractText>The occurrence of psychotic symptoms is common in Alzheimer's disease (AD), configuring a possibly distinguished clinical entity defined "Psychosis in Alzheimer's Disease" (AD-P). In order to investigate demographic clinical and biological variables potentially associated to the occurrence of AD-P, 148 AD patients were selected. Mini-Mental State Examination (MMSE), Activities of Daily Living (ADL), and Instrumental Activities of Daily Living (IADL) scores, socio-economic status and 5-HTTLPR and APOE gene polymorphisms were determined for each subject. AD-P patients were significantly more frequent carriers of the long (L) allele of 5-HTTLPR. The percentage of AD-P increased with the number of copies of the L-allele: 13% among S homozygote; 36% among heterozygotes; 51% among L-homozygotes. No difference resulted between AD-P and non-psychotic AD (AD-NP) in the distribution of the epsilon4 allele of APOE. The risk of AD-P was increased in L/L homozygous (OR = 7.25, p = 0.003) and, to a lesser extent, in heterozygous (OR = 3.91; p = 0.018). Backward logistic regression analysis showed that the risk for AD-P was increased in older subjects (OR = 1.07; p = 0.018) while an increase of MMSE score was protective (OR = 0.90; p = 0.004). The occurrence of AD-P resulted significantly related to age at examination, cognitive status, and to the presence of the 5-HTTLPR L-allele.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quaranta</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizzarro</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Camillo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vita</LastName><ForeName>Maria Gabriella</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Seripa</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sebastiani</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Mecocci</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Masullo</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Alzheimers Dis</MedlineTA><NlmUniqueID>9814863</NlmUniqueID><ISSNLinking>1387-2877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493230">SLC6A4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050486">Serotonin Plasma Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004493" MajorTopicYN="N">Education</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009790" MajorTopicYN="N">Occupations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050486" MajorTopicYN="N">Serotonin Plasma Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19158433</ArticleId><ArticleId IdType="doi">10.3233/JAD-2009-0950</ArticleId><ArticleId IdType="pii">PR573K5407161706</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19146909</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Chronic underactivity of medial frontal cortical beta2-containing nicotinic receptors increases clozapine-induced working memory impairment in female rats.</ArticleTitle><Pagination><StartPage>296</StartPage><EndPage>302</EndPage><MedlinePgn>296-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2008.12.003</ELocationID><Abstract><AbstractText>Nicotinic receptor decreases in the frontal cortex and hippocampus are important mediators of cognitive impairment in both schizophrenia and Alzheimer's disease. Drug treatments for these diseases should take into account the impacts of compromised brain function on drug response. This study investigated the impact of compromised nicotinic receptor activity in the frontal cortex in rats on memory function. Since both Alzheimer's disease and schizophrenia can involve psychosis, antipsychotic drugs are often given. The impacts of antipsychotic drugs on cognitive function have been found to be quite variable. It is the hypothesis of this and previous studies that the cognitive effects of antispychotic drugs on cognitive function depend on the integrity of brain systems involved in cognition. Previously in studies of the hippocampus, we found that chronic inhibition of beta2-containing nicotinic receptors with dihydro-beta-erythrodine (DHbetaE) impaired working memory and that this effect was attenuated by the antipsychotic drug clozapine. In contrast, chronic hippocampal alpha7 nicotinic receptor blockade with methyllycaconitine (MLA) potentiated the clozapine-induced memory impairment which is seen in rats without compromised nicotinic receptor activity. The current study determined medial frontal cortical alpha7 and beta2-containing nicotinic receptor involvement in memory and the interactions with antipsychotic drug therapy with clozapine. Chronic DHbetaE and MLA infusion effects and interactions with systemic clozapine were assessed in female rats tested for memory on the radial-arm maze. Antipsychotic drug interactions with chronic systemic nicotine were investigated because nicotinic procognitive treatment has been proposed. The same local infusion DHbetaE dose that impaired memory with hippocampal infusion did not impair memory when infused in the medial frontal cortex. Frontal DHbetaE infusion potentiated clozapine-induced memory impairment, whereas previously the memory impairment caused by hippocampal DHbetaE infusion was attenuated by clozapine. Frontal cortical MLA infusions at a dose that previously was found to potentiate the clozapine-induced memory impairment with hippocampal infusion had no significant effect when infused into the medial frontal cortex. The location and subtype of nicotinic receptor underactivity are critical determinates for clozapine effects on memory. Patients with hippocampal beta2-containing nicotinic receptor loss may be well treated with clozapine therapy, while those with frontal cortical beta2-containing receptor loss may have a potentiated memory impairment caused by clozapine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA. edlevin@duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Abigail</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Brotherton</LastName><ForeName>Terrell</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Qazi</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Berez</LastName><ForeName>Chantal</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Montalvo-Ortiz</LastName><ForeName>Janitza</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Kasey</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>N Channelle</ForeName><Initials>NC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH064494</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH064494-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH64494</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579165">Chrna7 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018733">Nicotinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C403531">nicotinic receptor alpha4beta2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C419363">nicotinic receptor beta2</NameOfSubstance></Chemical><Chemical><RegistryNumber>21019-30-7</RegistryNumber><NameOfSubstance UI="C054634">methyllycaconitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>23255-54-1</RegistryNumber><NameOfSubstance UI="D004079">Dihydro-beta-Erythroidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X8YN71D5WC</RegistryNumber><NameOfSubstance UI="D000157">Aconitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000157" MajorTopicYN="N">Aconitine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004079" MajorTopicYN="N">Dihydro-beta-Erythroidine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008845" MajorTopicYN="N">Microinjections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018733" MajorTopicYN="N">Nicotinic Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064569" MajorTopicYN="N">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19146909</ArticleId><ArticleId IdType="mid">NIHMS102913</ArticleId><ArticleId IdType="pmc">PMC2684503</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2008.12.003</ArticleId><ArticleId IdType="pii">S0278-5846(08)00372-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Addy N, Levin ED. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology. 2002;27:534&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377390</ArticleId></ArticleIdList></Reference><Reference><Citation>Addy NA, Pocivavsek A, Levin ED. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology. 2005;30:1121&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15688087</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkondon M, Albuquerque EX. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current. Journal of Pharmacology &amp; Experimental Therapeutics. 1995;274:771&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543571</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkondon M, Pereira ER, Wonnacott S, Albuquerque EX. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. Molecular Pharmacology. 1992;41:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">1569927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur D, Levin ED. Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: Impacts on memory and nicotine response. Psychopharmacology. 2002;160:140&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875631</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley AD, Bressi S, Della Sala S, Logie R, S H. The decline of working memory in Alzheimer's disease. A longitudinal study. Brain. 1991:2521&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pubmed">1782529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancroft A, Levin ED. Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. Neuropharmacology. 2000;39:2770&#x2013;2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">11044746</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Walker JA, Olton DS. Neuroanatomical bases of spatial memory. Brain Research. 1980;200:307&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7417818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettany JH, Levin ED. Ventral hippocampal alpha7 nicotinic receptors and chronic nicotine effects on memory. Pharmacology, Biochemistry and Behavior. 2001;70:467&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796146</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan WK, Wong PT, Sheu FS. Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology. 2007;52:1641&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482650</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong GR. Autism, amnesia, hippocampus, and learning. Neurosci Biobehav Rev. 1992;16:63&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">1553107</ArticleId></ArticleIdList></Reference><Reference><Citation>Durany N, Zochling R, Boissl KW, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Deckert J, Riederer P. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neuroscience Letters. 2000;287:109&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854724</ArticleId></ArticleIdList></Reference><Reference><Citation>Granon S, Poucet B, Thinus-Blanc C, Changeux JP, Vidal C. Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing. Psychopharmacology. 1995;119:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">7659760</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of nicotinic receptor alpha 7 subunit in the frontal cortex from schizophrenic brain. Neuroreport. 1999;10:1779&#x2013;1782.</Citation><ArticleIdList><ArticleId IdType="pubmed">10501574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry. 1986;143:993&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">3487983</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo I, Medina JH, Bianchin M, Walz R, Zanatta MS, Da Silva RC, Bueno e Silva M, Ruschel AC, Paczko N. Memory processing by the limbic system: role of specific neurotransmitter systems. Behav Brain Res. 1993;58:91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellar KJ, Wonnacott S. Nicotinic cholinergic receptors in Alzheimer's disease. In: Wonnacott S, Russell MAH, Stolerman IP, editors. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioral Aspects. Oxford University Press; Oxford: 1990. pp. 341&#x2013;373.</Citation></Reference><Reference><Citation>Kendziorra K, Meyer P, Wolf H, Barthel H, Hesse S, Seese A, Sorger D, Patt M, Gertz HJ, Sabri O. Cerebral nicotinic acetylcholine receptors (nAChRs) in patients with Alzheimer's disease (AD) assessed with 2-F18-A85380 (2-FA) PET &#x2013; Correlations to dementia severity. The Journal of Nuclear Medicine. 2006;47(Supplement 1):8P.</Citation></Reference><Reference><Citation>Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochemical Research. 1998;23:787&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566619</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Archives of General Psychiatry. 2002;59:1085&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470124</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ED, Bradley A, Addy N, Sigurani N. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience. 2002;109:757&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927157</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: Behavioral characterization, pharmacological specification and anatomic localization. Psychopharmacology. 2006;184:523&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">16220335</ArticleId></ArticleIdList></Reference><Reference><Citation>London ED, Ball MJ, Waller SB. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's disease. Neurochemistry Research. 1989;14:745&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">2812250</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology. 2004;174:54&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15205879</ArticleId></ArticleIdList></Reference><Reference><Citation>Miech RA, Breitner JCS, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology. 2002;58:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">11805246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihailescu S, Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Archives of Medical Research. 2000;31:131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10880717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A, Levin ED. Dorsal hippocampal &#x3b1;7 and &#x3b1;4&#x3b2;2 nicotinic receptors and memory. Brain Research. 2006;1081:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16556437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Yamamoto T, Watanabe S. Blockade of hippocampal nicotinic receptors impairs working memory but not reference memory in rats. Pharmacol Biochem Behav. 1993;45:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8516378</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino LJ, Pellegrino AS, Cushman AJ. A Stereotaxic Atlas of the Rat Brain. 2nd. Plenum Press, Plenum Press; 1979.</Citation></Reference><Reference><Citation>Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiat. 1987;50:806&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1032095</ArticleId><ArticleId IdType="pubmed">2956364</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocivavsek A, Icenogle L, Levin ED. Hippocampal alpha7 and alpha4beta2 nicotinic receptors and clozapine effects on memory. Psychopharmacology. 2006;188:596&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847383</ArticleId><ArticleId IdType="pubmed">16715255</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezvani AH, Caldwell DP, Levin ED. Nicotine-antipsychotic drug interactions and attentional performance. European Journal of Pharmacology. 2004;486:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">14975706</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezvani AH, Caldwell DP, Levin ED. Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry. 2006;30:190&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">16310917</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezvani AH, Kholdebarin E, Dawson E, Levin ED. Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. International Journal of Neuropsychopharmacology in press 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">17295931</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezvani AH, Levin ED. Nicotine-antipsychotic drug interactions and attentional performance in female rats. European Journal of Pharmacology. 2004;486:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">14975706</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;der H, Giacobini E, Struble RG, Zilles K, Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's Disease. Neurobiol Aging. 1991;12:259&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">1876232</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry. 2002;47:27&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">11873706</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppe G, Brandt CA, Staedt JH. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs and Aging. 1999;14:41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10069407</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollefson GD. Cognitive function in schizophrenic patients. Journal of Clinical Psychiatry. 1996;57 11:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8941169</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19129546</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1533-3175</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Season>Apr-May</Season></PubDate></JournalIssue><Title>American journal of Alzheimer's disease and other dementias</Title><ISOAbbreviation>Am J Alzheimers Dis Other Demen</ISOAbbreviation></Journal><ArticleTitle>An itemized approach to assessing behavioral and psychological symptoms in dementia.</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>168</EndPage><MedlinePgn>163-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1533317508329480</ELocationID><Abstract><AbstractText>In an effort to obtain more detailed clinical information regarding behavioral and psychology symptoms in dementia, we submitted an existing, comprehensive measure of behavioral and psychology symptoms in dementia (Neuropsychiatric Inventory) to an alternate itemized scoring system. One hundred twenty-four caregivers of patients with dementia (mean Mini-Mental State Examination=22.6) rated the frequency of individual symptoms across all domains of the measure. Internal reliability and factor structures for all domains were analyzed to assess the stability of this scoring approach. Internal consistency alphas for each domain ranged from .57 to .91. Alpha reliability for the total inventory was .96. Results indicate an itemized approach to assessing behavioral and psychological symptoms in dementia among patients with mild-to-moderate dementia can be reliable, has the power to capture multiple features of neuropsychiatric symptoms, and can produce a rich neurobehavioral profile adding valuable information to the diagnosis and treatment of these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychology, Drexel University, Philadelphia, Pennsylvania 19104, USA. jlg37@drexel.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Kara S</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Libon</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Alzheimers Dis Other Demen</MedlineTA><NlmUniqueID>101082834</NlmUniqueID><ISSNLinking>1533-3175</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19129546</ArticleId><ArticleId IdType="pmc">PMC10846199</ArticleId><ArticleId IdType="doi">10.1177/1533317508329480</ArticleId><ArticleId IdType="pii">1533317508329480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finkel SI, Costa e Silva G., Cohen G., Miller S., Sartorious N. Behavioral and psychological symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psycho-geriatr. 1996;8:497-500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154615</ArticleId></ArticleIdList></Reference><Reference><Citation>Assal F., Cummings JL Neuropsychiatric symptoms in the dementias. Curr Opin Neurol . 2002;15:445-450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151841</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B., Borenstein J., Salob SP, Ferris SH, Franssen E., Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48:9-15.</Citation><ArticleIdList><ArticleId IdType="pubmed">3553166</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart DJ, Craig D., Compton SA, et al. A retrospective study of the behavioral and psychological symptoms of mid to late phase Alzheimer's disease. Int J Geriatr Psychiatry . 2003;18:1037-1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">14618556</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele C., Rovner B., Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990;147:1049-1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375439</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo JL, Schmidt KS, Libon DJ Behavioral and pschological symptoms, neurocognitive performance, and functional independence in mild dementia. Dementia. 2008. ; 7:397-413.</Citation></Reference><Reference><Citation>Tekin S., Fairbanks LA, O'Connor S., Rosenberg S., Cummings JL Activities of daily living in Alzheimer's disease. Am J Geriatr Psychiatry. 2001;9:81-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11156757</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC Scale for the assessment of negative symptoms (SANS). Br J Psychiatry. 1989;155:53-58.</Citation><ArticleIdList><ArticleId IdType="pubmed">2695141</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg DP Detection of Psychiatric Illness by Questionnaire. London: : Oxford University Press; 1972.</Citation></Reference><Reference><Citation>Grace J., Malloy P. Frontal Lobe Personality Scale (FLOPS). Providence, R: Brown University; 1992.</Citation></Reference><Reference><Citation>Cummings JL , Mega M., Gray K., Rosenberg-Thompson S., Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:10S-16S.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153155</ArticleId></ArticleIdList></Reference><Reference><Citation>Iverson GL, Hopp GA, DeWolfe K., Solomons K. Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. Int J Geriatr Psychiatry. 2002;17:438-443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL , Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry. 1993. ;33:536-541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513039</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G., Drachman D., Folstein MF, Katzman R., Price DS, Standlan EM Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984. ;34:939-944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Victoroff JI, Margolin D., Jagust W., Shankle R., Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42:473-480.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549205</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF , Folstein SE, McHugh PR ``Mini-mental State.'' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1972;12: 189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Uher R., Treasure J. Brain lesions and eating disorders. J Neurol Neurosurg Psychiatry . 2005;76:852-857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739667</ArticleId><ArticleId IdType="pubmed">15897510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL , Petry S., Dian L., Shapira J., Hill MA Organic personality disorder in dementia: An inventory approach. J Neuropsychiatry Clin Neurosci. 1990;2:261-267.</Citation><ArticleIdList><ArticleId IdType="pubmed">2136084</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn FG, Cummings JL, Gornbein J. Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci. 1991;3:364-370.</Citation><ArticleIdList><ArticleId IdType="pubmed">1821254</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Ready RE, Stout JC, et al. Neurobehaviors and psychotic symptoms in Alzheimer's disease . J Int Neuropsychol Soc. 2000;6:815-820.</Citation><ArticleIdList><ArticleId IdType="pubmed">11105471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bathgate D. , Snowden JS, Varma A., Blackshaw A., Neary D. Behavior in frontotelmporal dementia, Alzheimer's disease, and vascular dementia. Acta Neurol Scand. 2001;103:367-378.</Citation><ArticleIdList><ArticleId IdType="pubmed">11421849</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P., de Vugt ME, Lousberg R., et al. Behavioral problems in dementia: A factor analysis of the Neuropsychiatric Inventory. Dement Geriatr Cogn Disord. 2003. ;15: 99-105.</Citation><ArticleIdList><ArticleId IdType="pubmed">12566599</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Rozzini L., Gozzetti A., et al. Behavioral syndromes in Alzheimer's disease: Description and correlates. Dement Geriatr Cogn Disord. 1999. ;10:130-138.</Citation><ArticleIdList><ArticleId IdType="pubmed">10026387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">21204335</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK5228</ArticleId></ArticleIdList><Book><Publisher><PublisherName>CRC Press/Taylor &amp; Francis</PublisherName><PublisherLocation>Boca Raton (FL)</PublisherLocation></Publisher><BookTitle book="frbehav">Methods of Behavior Analysis in Neuroscience</BookTitle><PubDate><Year>2009</Year></PubDate><AuthorList Type="editors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Buccafusco</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Medical College of Georgia, Augusta</Affiliation></AffiliationInfo></Author></AuthorList><Edition>2nd</Edition><CollectionTitle book="frontcollect">Frontiers in Neuroscience</CollectionTitle><Isbn>9781420052343</Isbn></Book><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>With contributions from more than 40 field specialists, Methods of Behavior Analysis in Neuroscience reflects six years of updates to its first bestselling edition and elucidates new behavioral approaches that are quickly becoming field standards. This second edition features new material on the relevance of transgenic mouse models for Alzheimer's disease, behavioral methods for assessing the cognitive impairment associated with major psychotic disorders, the revival of the scopolamine reversal model for assessing the clinical relevance of new AD drugs, and new approaches to assessing the cognitive impairment in aged mice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2009, Taylor &amp; Francis Group, LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="frbehav" part="dedication.s1">Dedication</SectionTitle></Section><Section><SectionTitle book="frbehav" part="seriespreface.s1">Series Preface</SectionTitle></Section><Section><SectionTitle book="frbehav" part="preface.s1">Preface</SectionTitle></Section><Section><SectionTitle book="frbehav" part="theeditor.s1">The Editor</SectionTitle></Section><Section><SectionTitle book="frbehav" part="contributors.s1">Contributors</SectionTitle></Section><Section><LocationLabel Type="chapter">1</LocationLabel><SectionTitle book="frbehav" part="ch1">Transgenic Mouse Models of Alzheimer&#x2019;s Disease: Behavioral Testing and Considerations</SectionTitle></Section><Section><LocationLabel Type="chapter">2</LocationLabel><SectionTitle book="frbehav" part="ch2">Cued and Contextual Fear Conditioning for Rodents</SectionTitle></Section><Section><LocationLabel Type="chapter">3</LocationLabel><SectionTitle book="frbehav" part="ch3">Drug Discrimination</SectionTitle></Section><Section><LocationLabel Type="chapter">4</LocationLabel><SectionTitle book="frbehav" part="ch4">Conditioned Place Preference</SectionTitle></Section><Section><LocationLabel Type="chapter">5</LocationLabel><SectionTitle book="frbehav" part="ch5">Anxiety-Related Behaviors in Mice</SectionTitle></Section><Section><LocationLabel Type="chapter">6</LocationLabel><SectionTitle book="frbehav" part="ch6">Behavioral Assessment of Antidepressant Activity in Rodents</SectionTitle></Section><Section><LocationLabel Type="chapter">7</LocationLabel><SectionTitle book="frbehav" part="ch7">Assessing Attention in Rodents</SectionTitle></Section><Section><LocationLabel Type="chapter">8</LocationLabel><SectionTitle book="frbehav" part="ch8">The Behavioral Assessment of Sensorimotor Processes in the Mouse: Acoustic Startle, Sensory Gating, Locomotor Activity, Rotarod, and Beam Walking</SectionTitle></Section><Section><LocationLabel Type="chapter">9</LocationLabel><SectionTitle book="frbehav" part="ch9">Intravenous Drug Self-Administration in Nonhuman Primates</SectionTitle></Section><Section><LocationLabel Type="chapter">10</LocationLabel><SectionTitle book="frbehav" part="ch10">Contextually Induced Drug Seeking During Protracted Abstinence in Rats</SectionTitle></Section><Section><LocationLabel Type="chapter">11</LocationLabel><SectionTitle book="frbehav" part="ch11">Operant Analysis of Fronto-striatal Function in Rodents</SectionTitle></Section><Section><LocationLabel Type="chapter">12</LocationLabel><SectionTitle book="frbehav" part="ch12">Working Memory Delayed Response Tasks in Monkeys</SectionTitle></Section><Section><LocationLabel Type="chapter">13</LocationLabel><SectionTitle book="frbehav" part="ch13">Spatial Navigation (Water Maze) Tasks</SectionTitle></Section><Section><LocationLabel Type="chapter">14</LocationLabel><SectionTitle book="frbehav" part="ch14">Water Maze Tasks in Mice: Special Reference to Alzheimer&#x2019;s Transgenic Mice</SectionTitle></Section><Section><LocationLabel Type="chapter">15</LocationLabel><SectionTitle book="frbehav" part="ch15">Behavioral Neuroscience of Zebrafish</SectionTitle></Section><Section><LocationLabel Type="chapter">16</LocationLabel><SectionTitle book="frbehav" part="ch16"><i>Caenorhabditis elegans</i> Model for Initial Screening and Mechanistic Evaluation of Potential New Drugs for Aging and Alzheimer&#x2019;s Disease</SectionTitle></Section><Section><LocationLabel Type="chapter">17</LocationLabel><SectionTitle book="frbehav" part="ch17">The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs</SectionTitle></Section></Sections></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21204335</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19051578</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0279-3695</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>11</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of psychosocial nursing and mental health services</Title><ISOAbbreviation>J Psychosoc Nurs Ment Health Serv</ISOAbbreviation></Journal><ArticleTitle>Psychosis in late life: emerging issues.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>52</EndPage><MedlinePgn>45-52</MedlinePgn></Pagination><Abstract><AbstractText>Psychotic symptoms in older individuals may be more common than was previously thought. Most kinds of psychosis that occur in younger people can be seen in older patients. However, there are important clinical differences between early-onset and late-onset psychosis. Conditions in which psychotic symptoms may occur in older adults include chronic illnesses such as dementia, schizophrenia, and delusional disorder, and acute transient disorders such as delirium and substance-induced psychosis. In this article, we focus on psychosis in chronic disorders in older individuals and discuss presentation and treatment of psychosis in patients with early-onset schizophrenia who have lived into old age, late-onset schizophrenia, very late-onset schizophrenia-like psychosis, delusional disorder, and Alzheimer's disease and other dementias.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Roy R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Montgomery VA Medical Center, Jackson, MS 39216, USA. roy.reeves@med.va.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brister</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychosoc Nurs Ment Health Serv</MedlineTA><NlmUniqueID>8200911</NlmUniqueID><ISSNLinking>0279-3695</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19051578</ArticleId><ArticleId IdType="doi">10.3928/02793695-20081101-09</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>